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This book focuses on the different aspects of ophthalmology - the medical science 
of diagnosis and treatment of eye disorders. Ophthalmology is divided into various 
clinical subspecialties, such as cornea, cataract, glaucoma, uveitis, retina, neuro-
ophthalmology, pediatric ophthalmology, oncology, pathology, and oculoplastics. 
This book incorporates new developments as well as future perspectives in 
ophthalmology and is a balanced product between covering a wide range of diseases 
and expedited publication. It is intended to be the appetizer for other books to follow. 
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This book covers selected topics in ophthalmology, providing a glimpse into the 
advancements in different aspects of the field. It is not aimed to cover the whole field 
of ophthalmology, and hopefully, more topics will be covered in future books. The 
book is intended for the general ophthalmologists, sub-specialists, researchers, 
residents, and fellows. It covers both basic and clinical concepts of ophthalmology. 
Each author incorporated his/her own perspectives on each topic adding his/her won 
theories, future trends, and research. Therefore, the book should enable researchers 
and clinicians to adopt new ideas for further basic research and clinical practice. 
This book, arranged in a systematic approach, discusses first the general aspects of 
ophthalmology (surgery), and then disorders affecting different structures of the eye 
from the cornea and ocular surface backwards to the retina and the structures 
surrounding the globe. It is a product of a balance between the expedited publishing 
process and encompassing broad aspects of the field. 
This book is a result of multi-national ophthalmologists from around the globe, with a 
common desire to take care of patients. Some of the authors have been involved for 
many years within this field, some are just at their beginning. Some authors are 
researches, others are clinicians. Some are world leaders, others will be. I hope that our 
readers will be as much a wide variety as our authors are. 
The book is accessible online to allow free access to as many readers as possible, and is 
also available on print for those who do not have online access, or are interested in 
having their own hard copy. This will definitely contribute to the worldwide 
distribution of the knowledge on ophthalmology between researchers and clinicians. 
I would like to acknowledge each and every one of the contributors for their excellent 
work on each chapter. Each one of them devoted time and effort to write a chapter, 
contributing to the success of this book and the advancement of ophthalmology. I would 
thank Ms. Martina Durovic and Mr. Jan Hyrat, the book Publishing Process Managers 
for their expert assistance in all the issues concerning this book, to Ms. Ana Nikolic, the 
Head of Editorial Consultants for her useful assistance, and for all for choosing me to be 
the editor of the book. My gratitude to the technical editors for arranging the book in a 
uniform format and for the publisher InTech, for undertaking this mission. Lastly, 
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X Preface 
 
I hope that this book will be part of a series of books in all the sub-specialties of 
ophthalmology, and that it will be an example for global collaboration, not only 
between physicians, but also between everyone for the betterment of the humankind. I 
wish you, the reader, an enjoyable journey throughout ophthalmology and I hope that 
you will find the book interesting. 
 
Shimon Rumelt, MD, MPA 
Department of Ophthalmology, 
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Lasers in Ophthalmology 
Magdalena Zdybel, Barbara Pilawa and Anna Krzeszewska-Zaręba 
Medical University of Silesia in Katowice 
Poland 
1. Introduction   
Lasers emit electromagnetic waves of characteristic properties and energies (Gilmour, 2002; 
Krzeszewska & Zdybel, 2010; Podbielska et al., 2004; Sieroń et al., 1994; Ziętek, 2009). These 
specific features are used in the modern ophthalmology (Dick et al., 2010; Evans & 
Abrahamse, 2009; Gilmour, 2002; Schmidt-Erfurth, 2010; Seitz & Langenbucher, 2000; Soong 
& Malta, 2009). In this work we described theoretic problems of lasers as the quantum 
systems, the propagation of laser radiation, the lasers parameters and ranges of them. The 
historical data about laser apparatus and their applications are cited. The biophysical effects 
caused by laser radiation  in biological structures during therapy are mentioned.  
The applications of lasers in ophthalmology are widely taking to account. We described 
widely the two laser applications in ophthalmology which are connected with paramagnetic 
species and singlet oxygen. We chose these subjects, because of our experimental experience 
in spectroscopic studies of paramagnetic centers (Beberok et al., 2010; Buszman et al., 2003, 
2005a, 2005b, 2006; Chodurek et al., 2003; Domagała et al., 2008; Latocha et al., 2004, 2005, 
2006; Matuszczyk et al., 2004; Najder-Kozdrowska et al., 2009, 2010; Pilawa et al., 2002, 
2003a, 2003b, 2005a, 2008c; Zdybel et al., 2009, 2010) and singlet oxygen O2 with zero spin 
(Bartłomiejczyk et al., 2008; Latocha et al., 2008; Pilawa et al., 2005b, 2006, 2008a, 2008b). In 
this work the view of the information in scientific papers is done.  
2. Lasers as the quantum systems – Basic theory  
2.1 Energy levels 
The quantum theory describes the energy levels of atoms and molecules (Glinkowski & 
Pokora, 1993; Sieroń et al., 1994; Ziętek, 2009). Electrons may move only between these 
levels, and these transitions are accompanied by emission or absorption of energy by the 
optical system. The emitted or the absorbed energies reveal the values related to the 
distances between the energy levels. The system will not absorb the energy, when the 
energy is lower or higher than the value of the energetic band between the levels. Energy 
levels of the optical active medium play an important role in laser irradiation. The energy 
levels of the materials used in laser construction determine the energy necessary to their 
excitation and the energy of emitted electromagnetic waves is dependent on these levels. 
The energy (E) of the electromagnetic waves produced by lasers is presented according to 
the formulas (Bartosz, 2006; Hatfield, 1976; Hewitt, 2001; Jaroszyk, 2008; Ziętek, 2009): 
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 E = hν (1) 
 E = hc/λ (2) 
where h is the Planck constant (h = 6,626 x 10-34 Js), c is the speed of the waves  
(c = 299 792 458 m/s), ν is the frequency of electromagnetic waves in Hertz, λ is the 
wavelength in meters. The frequency and wavelength determine the color of laser radiation.  
The emitted energy is fitted to the biological structures treated by the individual lasers, so 
the reason of the majority of lasers used in ophthalmology is understandable. Summing up, 
the lasers produce electromagnetic waves with the given energy correspond to the energy 
levels of their optical systems, and it interact on the specific tissues or cells.  
2.2 Optical pumping  
Condition of absolute emission of radiation by laser is the previous excitation of its active 
optical system e.g. molecules formed in this system (Glinkowski & Pokora, 1993; Sieroń et 
al., 1994; Ziętek, 2009). This excitation is called the optical pumping. Excitation of molecules 
in laser may be done by electromagnetic waves emitted by lamps, by heating or by energy of 
electrical field (Podbielska et al., 2004; Sieroń et al., 1994).  
2.3 Inversion of electron location on the energy levels  
As the result of the optical pumping of the quantum molecular system, higher amount of 
electrons are located on the levels of the higher energy than those of the lower energy 
(Glinkowski & Pokora, 1993; Podbielska et al., 2004; Sieroń et al., 1994; Ziętek, 2009). The 
continuous propagation of energy to the system of electrons in molecules causes that the 
electrons upon absorption of this energy moves to the higher energy levels. Afterwards they 
return to the lower energy states via relaxation processes. The time of electron-lattice 
relaxation processes depends on the molecular structure of the optical system in lasers. 
Electron-lattice relaxation is the transition of the electrons from the excited energy levels to 
the ground energy levels via magnetic interactions with diamagnetic lattice molecules 
(Stankowski & Hilczer, 2005; Wertz & Bolton, 1986). The long time of interactions of 
electrons with the lattice causes the mentioned above inversion. The pumped electrons stay 
on the higher energetic level and the former irradiation of the molecular system in laser do 
not pump electrons to the higher levels, because of their absence in the lower energy levels 
(Ziętek, 2009). The inversion of electrons location on levels is useful to the former effective 
stimulation emission of radiation in laser apparatus (Glinkowski & Pokora, 1993). 
2.4 Stimulated emission of radiation  
The name of the LASER apparatus comes from the roles of its work as the “Light 
Amplification of Stimulated Emission of Radiation” (Maiman, 1960). Two types of emission 
of electromagnetic waves, the spontaneous and stimulated emissions, are known (Bartosz, 
2006; Hatfield, 1976; Hewitt, 2001; Jaroszyk, 2008; Krzeszewska & Zdybel, 2010; Morrish, 
1970; Sieroń et al., 1994). Spontaneous emission is the ordinary effect of energy loosening by 
the excited electrons at the non defined moment. Spontaneous emission is the result of the 
principle that the optimal state of the system is the state with the lowest energy (Glinkowski 
& Pokora, 1993; Jóźwiak & Bartosz, 2008; Sieroń et al., 1994; Ziętek, 2009). The stimulated 
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emission is the most important effect to produce laser irradiation. The scheme of stimulated 
emission of radiation is shown in Figure 1, which was prepared according to the definition 
of this effect presented in (Sieroń et al., 1994). The stimulated emission of radiation is the 
controlled effect of energy loosening by the electrons. Before the proper effect of stimulated 
emission the electron is excited, for example by pumped photons, to the higher energy level. 
After this the stimulated photon is emitted to the system and at this moment two photons of 
the same energy are emitted. The energy of the individual emitted photon is equal to the 
difference between energy of the excited and ground state energy levels. The amplification 
of the energy of radiation is the effect of emission of these two photons after absorption of 
one exciting photon by electron. The radiation comes from stimulated emission consist of 
photons of the same energy so of the same frequency. It means that laser produce 
monochromatic electromagnetic waves. Monochromatic electromagnetic waves are the same 
frequency waves (Ziętek, 2009). 
 
Fig. 1. The scheme of the stimulated emission of radiation prepared according to its 
definition in (Sieroń et al., 1994).  
The exemplary way of the electrons between the three energy levels during laser action is 
described in work of Sieroń et al. (Sieroń et al., 1994). The main energy levels of electrons are 
the ground, non-stabile excited, and the quasi-stabile levels, respectively. Electrons are 
pumped by photons to the non-stabile level with the highest energy in this quantum system. 
Energy of the pumped photons is equal difference between energy of the non-stabile level 
and the ground level. Afterwards the electrons without radiation come to the quasi-stabile 
energy level located lower than the non-stabile level. During the optical pumping there is an 
increase in number of electrons on quasi-stabile level. At the moment dependent on the type 
of laser the effect of inversion of distribution of electrons in the energy levels occurs. The 
higher number of electrons stays on the quasi-stabile level than on the ground level with the 
lowest energy. The pumping is stopped then and the stimulating photons are sent to the 
electrons system. At the same time, at the moment of interactions of electrons with 
stimulated photons the stimulated emission appears. All the electrons located on the quasi-
stabile energy level come to the ground energy level. The photons connected with the 
transition and the stimulated photons are irradiated. The emitted electromagnetic waves 
have properties of laser radiation, which are described in the next part of this chapter. 
 
Advances in Ophthalmology 
 
4 
 E = hν (1) 
 E = hc/λ (2) 
where h is the Planck constant (h = 6,626 x 10-34 Js), c is the speed of the waves  
(c = 299 792 458 m/s), ν is the frequency of electromagnetic waves in Hertz, λ is the 
wavelength in meters. The frequency and wavelength determine the color of laser radiation.  
The emitted energy is fitted to the biological structures treated by the individual lasers, so 
the reason of the majority of lasers used in ophthalmology is understandable. Summing up, 
the lasers produce electromagnetic waves with the given energy correspond to the energy 
levels of their optical systems, and it interact on the specific tissues or cells.  
2.2 Optical pumping  
Condition of absolute emission of radiation by laser is the previous excitation of its active 
optical system e.g. molecules formed in this system (Glinkowski & Pokora, 1993; Sieroń et 
al., 1994; Ziętek, 2009). This excitation is called the optical pumping. Excitation of molecules 
in laser may be done by electromagnetic waves emitted by lamps, by heating or by energy of 
electrical field (Podbielska et al., 2004; Sieroń et al., 1994).  
2.3 Inversion of electron location on the energy levels  
As the result of the optical pumping of the quantum molecular system, higher amount of 
electrons are located on the levels of the higher energy than those of the lower energy 
(Glinkowski & Pokora, 1993; Podbielska et al., 2004; Sieroń et al., 1994; Ziętek, 2009). The 
continuous propagation of energy to the system of electrons in molecules causes that the 
electrons upon absorption of this energy moves to the higher energy levels. Afterwards they 
return to the lower energy states via relaxation processes. The time of electron-lattice 
relaxation processes depends on the molecular structure of the optical system in lasers. 
Electron-lattice relaxation is the transition of the electrons from the excited energy levels to 
the ground energy levels via magnetic interactions with diamagnetic lattice molecules 
(Stankowski & Hilczer, 2005; Wertz & Bolton, 1986). The long time of interactions of 
electrons with the lattice causes the mentioned above inversion. The pumped electrons stay 
on the higher energetic level and the former irradiation of the molecular system in laser do 
not pump electrons to the higher levels, because of their absence in the lower energy levels 
(Ziętek, 2009). The inversion of electrons location on levels is useful to the former effective 
stimulation emission of radiation in laser apparatus (Glinkowski & Pokora, 1993). 
2.4 Stimulated emission of radiation  
The name of the LASER apparatus comes from the roles of its work as the “Light 
Amplification of Stimulated Emission of Radiation” (Maiman, 1960). Two types of emission 
of electromagnetic waves, the spontaneous and stimulated emissions, are known (Bartosz, 
2006; Hatfield, 1976; Hewitt, 2001; Jaroszyk, 2008; Krzeszewska & Zdybel, 2010; Morrish, 
1970; Sieroń et al., 1994). Spontaneous emission is the ordinary effect of energy loosening by 
the excited electrons at the non defined moment. Spontaneous emission is the result of the 
principle that the optimal state of the system is the state with the lowest energy (Glinkowski 
& Pokora, 1993; Jóźwiak & Bartosz, 2008; Sieroń et al., 1994; Ziętek, 2009). The stimulated 
 
Lasers in Ophthalmology 
 
5 
emission is the most important effect to produce laser irradiation. The scheme of stimulated 
emission of radiation is shown in Figure 1, which was prepared according to the definition 
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of the energy of radiation is the effect of emission of these two photons after absorption of 
one exciting photon by electron. The radiation comes from stimulated emission consist of 
photons of the same energy so of the same frequency. It means that laser produce 
monochromatic electromagnetic waves. Monochromatic electromagnetic waves are the same 
frequency waves (Ziętek, 2009). 
 
Fig. 1. The scheme of the stimulated emission of radiation prepared according to its 
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The exemplary way of the electrons between the three energy levels during laser action is 
described in work of Sieroń et al. (Sieroń et al., 1994). The main energy levels of electrons are 
the ground, non-stabile excited, and the quasi-stabile levels, respectively. Electrons are 
pumped by photons to the non-stabile level with the highest energy in this quantum system. 
Energy of the pumped photons is equal difference between energy of the non-stabile level 
and the ground level. Afterwards the electrons without radiation come to the quasi-stabile 
energy level located lower than the non-stabile level. During the optical pumping there is an 
increase in number of electrons on quasi-stabile level. At the moment dependent on the type 
of laser the effect of inversion of distribution of electrons in the energy levels occurs. The 
higher number of electrons stays on the quasi-stabile level than on the ground level with the 
lowest energy. The pumping is stopped then and the stimulating photons are sent to the 
electrons system. At the same time, at the moment of interactions of electrons with 
stimulated photons the stimulated emission appears. All the electrons located on the quasi-
stabile energy level come to the ground energy level. The photons connected with the 
transition and the stimulated photons are irradiated. The emitted electromagnetic waves 
have properties of laser radiation, which are described in the next part of this chapter. 
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3. The properties of laser radiation  
Laser radiation as electromagnetic waves differs from the light emitted by the ordinary lamp 
(Hewitt, 2001). The white light emitted from bulb is superposition of electromagnetic waves 
with frequencies and wavelengths corresponding to the background colors: red, orange, 
yellow, green, blue, and violet. The frequencies of the waves increase in the previously 
given order, and the wavelengths decreases in this manner. The summing of these 
electromagnetic waves of different colors gives the effect of white light. The component 
waves in the white light are not coherent. Coherent waves are the waves with the same 
phase shift (Ziętek, 2009). The component electromagnetic waves in the beam of white light 




Fig. 2. The electromagnetic waves emitted by: the ordinary lamp produced the white light 
(a), the source of the monochromatic light (b), and laser (c). The scheme is prepared 
according to (Hewitt, 2001).  
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The monochromatic light from the lamp consists of electromagnetic waves of the same 
frequencies and the same wavelengths (Hewitt, 2001). The waves are not coherent. The 
electromagnetic waves in the beam of monochromatic light reveal different phases. The 
monochromatic and incoherent waves are presented in Figure 2b, which was prepared 
according to (Hewitt, 2001). The fine examples of monochromatic light are the red waves 
emitted by SOLLUX lamp (Hewitt, 2001).  
Lasers produce monochromatic electromagnetic waves (Glinkowski & Pokora, 1993; Hewitt, 
2001; Sieroń et al., 1994; Ziętek, 2009). The properties of laser radiation distinguish it from 
the ordinary white or monochromatic light (Figure 2c) (Hewitt, 2001). The laser waves are 
monochromatic and coherent. Contrary to white light, laser radiation is monochromatic and 
in the same phase.  
Laser radiation differs from electromagnetic waves sending by the therapeutic BIOPTRON 
lamps (Straburzyńska-Lupa & Straburzyński, 2004). The BIOPTRON lamp produces 
electromagnetic waves of the same frequency, but they are incoherent (Figure 3) 
(Straburzyńska-Lupa & Straburzyński, 2004). The maxima and minima of energy appear on 
the area of the tissue exposed to coherent laser irradiation. The homogeneous distribution of 
energy on irradiated area is characteristic for BIOPTRON light.  
 
Fig. 3. The electromagnetic waves emitted by BIOPTRON lamps. Prepared according to 
(Straburzyńska-Lupa & Straburzyński, 2004). 
Laser electromagnetic waves in the environment propagate as perpendicular electric and 
magnetic fields (Hewitt, 2001). The ranges of wavelength of electromagnetic waves emitted 
by lasers are showed on figure 4. The values of the wavelengths are cited from (Gilmour, 
2002; Ziętek, 2009). The biophysical and biological effects on tissues depend on the energy 
and the wavelengths of electromagnetic waves (Gilmour, 2002; Jaroszyk, 2008).  
There are three basic effects of lasers on biological tissues:  photochemical (photoablation 
and photoradiation), thermal (photocoagulation and photovaporation), and ionizing 
(photodisruption) (L’Esperance, 1983; Podbielska et al., 2004). The photochemical effects are 
the result of absorption of energy of laser radiation by molecules in tissues without their 
destruction. During photoablation the absorption of laser energy causes the increase of 
temperature of the tissues. Practically the photoablation is caused by the short laser pulses 
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of high energy. Photoradiation is the effect which appears after the transition of the excited 
by laser molecules in tissues to the ground or the lower energy levels with accompanied 
radiation of electromagnetic waves. These electromagnetic waves may be responsible for 
biostimulation effects and tissue temperature rise. Thermal effects interact mainly by the 
increase of temperature of the tissues after laser irradiation. Photocoagulation causes the 
increase of temperature in tissues up to 80-90°C via absorption of the laser energy.  
   
   
   
 
Fig. 4. The ranges of length of electromagnetic waves emitted by lasers. The values of the 
wavelengths (λ) are cited from (Gilmour, 2002; Ziętek, 2009).  
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The photocoagulation closes blood and lymphatic vessels, and causes of the necrosis of 
tissues. Photocoagulation denatures proteins and inactivates enzymes. The laser irradiation 
of high energy which causes the increase of temperature of the tissues up to 100-300°C is 
called as the photovaporation. The using of lasers with the high energy of pulse lead to 
photodisruption effects via ionization in tissues. The ionization is accompanied by the 
formation of shock waves. The photodisruption effects play an important role in the 
microsurgery of the front part of the eye. 
UV-C and UV-B waves cause increase of pigmentation, burns and photokeratitis (Ziętek, 
2009). UV-A waves cause burns, photosensitizing reactions, intensification of dark pigment 
production, and cataract (Ziętek, 2009). The visible light may destruct retina, lead to burn, 
and photosensitizing reaction. IR-A and IR-B waves may be responsible for burns and the 
others thermal destruction of epithelium and cataract. IR-B and IR-C waves may destruct 
cornea (Ziętek, 2009).  
4. History of lasers application in ophthalmology 
The history of lasers is connected with the basic theory of quantum radiation presented by 
Albert Einstein in 1916 (Wróblewski, 2006). This theory defines and characterizes 
spontaneous and stimulated emission of radiation by atoms. The method of optical 
pumping of atoms was discovered by Alfred Kastler and Jean Brossel in 1949 (Wróblewski, 
2006) and in 1966 Kastler received the Nobel Prize. The inversion of electron localization on 
energy levels and the effect of stimulated emission of radiation were practically discovered 
by Edward Purcell and Robert Pound in 1950 (Wróblewski, 2006). In 1960 Theodore Harold 
Maiman constructed the ruby laser (Al2O3:Cr3+) emitting light of 694 nm, which is still used 
in ophthalmology (Seitz & Langenbucher, 2000; Wróblewski, 2006; Ziętek, 2009). In Poland 
the first ruby laser was constructed by Zbigniew Puziewicz group from Military University 
of Technology in 1963 (Podbielska et al., 2004). The following types of lasers: helium-neon 
(He-Ne) (1150 nm), semiconducting, carbon dioxide (CO2) (10600 nm), argon (476.5 nm, 
488.0 nm, 514.5 nm), hydrogen (H2) (102.5-123.9 nm), excimer (172 nm), and gallium nitride 
(GaN) (365 nm), were built in 1961, 1962, 1963, 1964, 1970, 1974, 1991, respectively (Ziętek, 
2009). The krypton (647.1 nm, 568.2 nm, 530.8 nm) and neodymium: yttrium-aluminum-
garnet (Nd:YAG) (1064 nm) lasers were introduced to clinical applications in 1972 and 1980, 
respectively (L’Esperance, 1983). 
The ruby (694 nm) laser is used in the therapy of the following ocular structural defects: retinal 
tears, peripheral pigmentary degeneration and lattice degeneration of the retina (L’Esperance, 
1983). Argon laser is used in the structural defects of the retina and choroid (L’Esperance, 
1983). Krypton (647.1 nm) laser is mainly used in outer retinal structural diseases (L’Esperance, 
1983). Krypton red laser photocoagulation is exemplary performed in retinal hemorrhagic 
diseases, retinal edematous diseases, pigment epithelial abnormalities (L’Esperance, 1983). 
Carbon dioxide laser is applied in operations with the high blood loss (L’Esperance, 1983). 
In 1940 light was used in ophthalmology to coagulation of the retina by Gerd Meyer-
Schwickerath (Seitz & Langenbucher, 2000). In Poland the first ruby (694 nm) laser 
coagulator to ophthalmology was constructed in 1965 (Podbielska et al., 2004). In 1961 
Campbell applied confocal laser system to retinal coagulation. In 1971 argon laser was by 
the first used in eye surgery (Seitz & Langenbucher, 2000). In 1977 Nd:YAG (1064 nm) laser 
was used to microexplosion by Franz Fankhauser and Daniele Aron-Rosa. The history of 
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lasers in ophthalmology is broadly described in the paper of Berthold Seitz (Seitz & 
Langenbucher, 2000). 
5. Types of lasers using in ophthalmology 
The group of lasers used in ophthalmology produces coherent electromagnetic radiation of 
different wavelengths (Dick et al., 2010; Evans & Abrahamse, 2009; Gilmour, 2002; Schmidt-
Erfurth, 2010; Seitz & Langenbucher, 2000; Sieroń et al., 1994; Soong & Malta, 2009). Optical 
systems of ophthalmologic lasers are: CO2, excimer, argon, tunable dye, Nd:YAG (Gilmour, 
2002). Optical systems of excimer lasers contain molecules of dimmers of noble gases as 
argon fluoride (ArF), krypton fluoride (KrF) and xenon fluoride (XeF) (Ziętek, 2009). 
The therapeutic effects as photocoagulation, photoablation, ablation via plasma, interact on 
eye structures. Photocoagulation is performed by the following lasers: blue-green (488-514 
nm) and green (514 nm), argon, krypton red (647 nm), diode infrared (810 nm), Nd:YAG 
infrared (1064 nm) (Gilmour, 2002). Photoablation is carried on by lasers: excimer ultraviolet 
(193 nm), holmium: yttrium-aluminum-garnet (Ho:YAG) infrared (2060 nm), erbium: 
yttrium-aluminum-garnet (Er:YAG) infrared (2940 nm), and CO2 infrared (10,600 nm). 
Ablation by plasma is done by pulsed infrared neodymium: yttrium lithium fluoride 
Nd:YLF (1053 nm) laser (Gilmour, 2002).  
6. Parameters of lasers radiation using in ophthalmology 
The power of laser is the energy emitted by laser during one second (L’Esperance, 1983; 
Sieroń et al., 1994). The lasers of low (4-5 mW), medium (6-500 mW), and high (above 500 
mW) powers are used in medicine (Sieroń et al., 1994). The examples of lasers of low, 
medium and high powers are ruby, Nd:YAG, semiconducting (Podbielska et al., 2004; 
Ziętek, 2009). The lasers of low powers are called the soft lasers, and lasers which emit 
electromagnetic wave of high power are called hard lasers. The classification of lasers 
correspond to their irradiated power are shown in Figure 5 (Glinkowski & Pokora, 1993; 
Sieroń et al., 1994). 
 
Fig. 5. Classification of lasers corresponds to power of radiation. The values of 
electromagnetic powers are sited from (Glinkowski & Pokora, 1993; Sieroń et al., 1994).  
 
Lasers in Ophthalmology 
 
11 
The biophysical effects in biological systems under laser irradiation are described by Sieroń 
et al. (Podbielska et al., 2004; Sieroń et al., 1994). Photochemical, thermal and acoustic effects 
appear during laser radiation propagation in biological samples. Photochemical reactions 
mainly exist in melanin biopolymers, enzymes,  photosensitizers, and hemoglobin, which 
strongly absorb its energy. Thermal effects take place not only in the irradiated units, but 
they are also observed in the neighboring structures, because of thermal conductivity of the 
tissues. The lasers of the highest power cause heating, strong electric field, microplasma 
formation, increase of pressure, and as the result acoustic effects appear in the tissues.  
The soft lasers with the low energy emitted to tissues during one second are used to 
biostimulation effects (Podbielska et al., 2004; Sieroń et al., 1994). The soft ruby lasers with 
low energy may be used to biostimulation (Podbielska et al., 2004). The light initiates and 
increases biochemical reactions. Lasers of medium power are applied in photodynamic 
therapy. Hard lasers are used to destruction of tissues mainly via thermal effects (Sieroń et 
al., 1994). Non-thermal effect of photo-destruction occurs in the irradiated structures, when 
the laser of high power interacts with biological system during the very short time 
(Podbielska et al., 2004; Sieroń et al., 1994). Free radicals may be produced by lasers of the 
three mentioned above ranges of power. 
The power dose, time, methods, and pulse frequency should be taken to account during 
planning the laser therapy (Podbielska et al., 2004; Sieroń et al., 1994; Ziętek, 2009). The 
power, density of power, and density of energy should be correlated to the application of 
laser. Density of laser power I [W/m2] is the power related to one square meter of the 
irradiated area. Density of laser energy H [J/m2] is the power related to one square meter of 
the irradiated area (Podbielska et al., 2004; Sieroń et al., 1994; Ziętek, 2009). 
7. Application of lasers in ophthalmology 
The large amount of laser applications in ophthalmology is known. In that kind of medicine 
the excimer, argon, krypton, Er:YAG, Nd:YAG  and semiconductor lasers are usually used 
(Dick et al., 2010; Evans & Abrahamse, 2009; Gilmour, 2002; Schmidt-Erfurth, 2010; Seitz & 
Langenbucher, 2000; Soong & Malta, 2009). The use of lasers in ophthalmology comes down 
to coagulate, cut and leads to photoablation. Laser radiation can reach the eyeball and focus 
on the retina and other locations within the eye without surgical intervention. The most 
common disease which are treated with laser light are glaucoma, cataract, retinal 
detachment, diabetic retinopathy (Fankhauser & Kwasniewska, 2003; Gilmour, 2002).  
Glaucoma  is an eye disease in which the optic nerve suffers damage (Chung & Guan, 2006; 
Eckert, 2010; Herdener & Pache, 2007; Hoffmann & Schulze, 2009; Juzych et al., 2004; 
Kanamori et al., 2006; Keicher & Stoffelns, 2010; Ngoi et al., 2005; Preußner et al., 2010; 
Schlote et al., 2008; Wilmsmeyer et al., 2006). It causes permanently decay of vision and if it 
is untreated it progresses to complete blindness. Glaucoma is often associated with 
increased pressure of the eye fluid (Gilmour, 2002). The cases in which there is constantly 
raise of intraocular pressure without any associated optic nerve damage are called ocular 
hypertension. In that case there is no glaucoma damage. The cases in which there is normal 
or low ocular pressure with typical for glaucoma visual field are called normal or low 
tension glaucoma. However, raised intraocular pressure is still the most significant risk 
factor for glaucoma progression. The permanent damage of the optic nerve and blindness 
are the effects of untreated glaucoma (Chung & Guan, 2006; Eckert, 2010; Herdener & Pache, 
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2007; Hoffmann & Schulze, 2009). There are two main categories of glaucoma - open or 
closed angle. First of them progresses much slower than the other and in this case patient 
can have any notice of vision lose. In the closed angle glaucoma, the symptoms of disease 
can appear rapidly (Chung & Guan, 2006). Gradual loss of vision occurs with open angle 
and chronic angle-closure glaucoma and with acute angle-closure glaucoma. That is why 
that kind of disorder it is recognized when the disease is quite advanced. In glaucoma once 
lost visual field cannot be recovered. There is about two percent chance of glaucoma 
progression in people with a family history of this eye disease. Both laser surgeries and 
conventional surgeries are performed to treat glaucoma. Selective laser trabeculoplasty 
(SLT) is one of the newest, efficient methods for the treatment of open angle glaucoma, 
pseudoexfoliative glaucoma and pigmentary glaucoma. In that kind of treatment Q switch 
Nd:YAG laser with a wavelength of 532 nm is usually used (Eckert, 2010; Gilmour, 2002). 
This laser affects on the cells of the trabecular meshwork but it does not cause any 
destruction or coagulation. The second method of laser treatment in glaucoma is argon laser 
trabeculoplasty (ALT). That method is focused on drainage correction of fluid from the eye. 
As a result the intraocular pressure is lower (Wilmsmeyer et al., 2006). In open angle 
glaucoma the drainage site of the eye does not function normally. In that disorder the iris is 
encircled by the trabecular meshwork of an eye. The increase of pressure is the result of 
difficult in drainage. In ALT therapy an argon laser beam is directed at the trabecular 
meshwork. As the effect the trabecular meshwork drain fluid more effectively (Eckert, 2010; 
Wilmsmeyer et al., 2006). Nd:YAG and argon lasers are used in iridotomy (L’Esperance, 
1983). Argon lasers may be used in iridoplasty (L’Esperance, 1983). 
Laser therapy is used in cataract too (Baratz et al., 2001; Çinal et al., 2007; Gilbert, 2011; Hille 
et al., 2001; Kanellopoulos & Group, 2001; Mahdavi, 2011; Shammas & Shammas, 2007; 
Verge´s & Llevat, 2003). The cataract is a disease that develops in the crystalline lens of an 
eye. It can block the passage of light and causes problems from slight to complete opacity. In     
age-related cataract the power of the lens may be increased, causing near-sightedness called 
myopia. The opacification of the lens may also reduce the perception of blue colors. Cataract 
typically progresses slowly and causes vision loss (Gilmour, 2002). That kind of disease 
potentially induces blinding if it is untreated. Cataract usually affects both eyes, but in most 
cases one eye is affected earlier than the other. A senile cataract which occurs in the elderly 
is characterized by an initial opacity and subsequent edema of the lens. One of the most 
popular cataract treatments nowadays is laser surgery, which uses light to dissolving 
cataract. The most popular method of cataract surgery is phacoemulsification. In that kind 
of treatment nucleus is cracking or chopping into smaller pieces. This fragmentation makes 
emulsification easier. Emulsification of the lens using the Er:YAG laser is  very effective for 
performing small incision cataract surgery in eyes with soft and medium nuclei. The small 
ablation zones which are created during treatment can help prevent damage to surrounding 
ocular structures. The Er:YAG technique causes low ablation energy and does not result in 
thermal injury (Duran & Zato, 2001). Another method involves the removal of almost the 
entire natural lens while the elastic lens capsule is left intact to allow implantation of an 
intraocular lens. It is called conventional extracapsular cataract extraction (ECCE). That kind 
of treatment may be indicated for patients with very hard cataracts or other situations in 
which phacoemulsification is problematic. Increasingly to remove the pupillary membranes 
developed after ECCE is used Nd:YAG laser (Kozobolis et al., 1997). Intracapsular cataract 
extraction (ICCE) is rarely performed kind of cataract surgery, because of high rate of 
complications. It involves the removal of the lens and the surrounding lens capsule in one 
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piece. After lens removal, an artificial plastic lens - implant is placed (Gilbert, 2011; 
Kanellopoulos & Group, 2001). 
Lasers are also used in medical operations in the field of refractive eye surgery (Gilmour, 
2002; Glinkowski & Pokora, 1993; Kim et al., 2011). The main aim of that kind of treatment is 
to achieve the correct relationship between the length of the eyeball and the power of its 
optical centers. This is possible by modifying the other shell knobs and intraocular tissues. 
Refractive surgery can eliminate the necessary of use the contact lenses or glass 
(Krzeszewska & Zdybel, 2010).  
At the beginning of the development of refractive eye surgery procedures used  CO2 lasers 
(Glinkowski & Pokora, 1993; Kim et al., 2011). However, because of emerging adverse 
effects they were abandoned. Currently pulsed excimer laser emitting a beam with a 
wavelength of 193 nm is used during surgeries. The pulses from the beam which is 
transmitted last from 10 ns to 20 ns. This laser radiation penetrates the cornea to a depth of 1 
µm leading to photoablation of the tissue (Krzeszewska & Zdybel, 2010). This is the most 
common refractive method nowadays. Excimer laser ablation is done under a partial-
thickness lamellar corneal flap. While refractive surgery is becoming more affordable and 
safe, it may not be recommended for everybody. Patients that have medical conditions such 
as glaucoma, diabetes uncontrolled cardiovascular disease, autoimmune disease, pregnant 
women or people with certain eye disease are not good candidates for refractive surgery 
(Kim et al., 2011). Although the risk of complications is decreasing compared to the early 
days of refractive surgery, there is still a small chance for serious problems. It may appear 
vision problems such as double-vision, ghosting, halos, starbursts and dry-eye syndrome. 
Refractive surgery is used in myopia, hyperopia and astigmatism treatment (Gilmour, 2002; 
Seitz & Langenbucher, 2000).  
Myopia is an eyes disease with a refractive defect (Gilmour, 2002). In that kind of disorder 
while accommodation relaxes, the collimated light produces image focus in front of retina. In 
other words it is a condition of the eye where the light that comes in does not directly focus on 
the retina. Because of that the image that one sees is out of focus when looking at a distant 
object but comes into focus when looking at a close object (Seitz & Langenbucher, 2000).  
Hyperopia is a vision defect caused by an imperfection of an eye causing difficulty focusing 
on near objects and in extreme cases causing a sufferer to be unable to focus on objects at 
any distance. In that kind of disease power of the cornea and lens is insufficient and the 
image appears blurred (Gilmour, 2002).  
Astigmatism is the visual defect, which is the result of an inability of the cornea to properly 
focus an image onto the retina. As the effect the image is blurred (Seitz & Langenbucher, 2000).  
Laser subephithelial keratomileusis (LASEK) and laser in-situ keratomileusis (LASIK) 
processes are very common in laser surgery (Gilbert, 2011; Hille et al., 2001; Kanellopoulos 
& Group, 2001; Verge´s & Llevat, 2003). In LASEK which is the laser epithelial 
keratomileusis, the cornea's surface layer is treated with alcohol and peeled back to reshape 
the layer underneath. LASIK prevents most problems of postoperative pain, slow 
rehabilitation and corneal haze (Kanellopoulos & Group, 2001; Shammas & Shammas, 2007). 
Lasers are also very useful tools in the management of malignant and benign intraocular 
lesions, nowadays. One of the most popular methods for small melanomas treatment is 
transpupillary thermotherepy (TTT) using 810 nm infrared laser. That kind of treatment can 
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be used in medium and large melanomas as combination therapy with other treatment 
modalities (Gilmour, 2002). 
The important application of lasers in the modern ophthalmology is their use in 
photodynamic therapy (PDT) (Podbielska et al., 2004). Photodynamic therapy was recently 
used to treat wet age-related macular degeneration (AMD). That kind of therapy was used 
for monitory of cases in AMD (Gilmour, 2002; Nakata et al., 2011). Now PDT is used in 
polypoidal choroidal vasculopathy (Akaza et al., 2007; Nakata et al., 2011; Podbielska et al., 
2004). In PDT lasers with the medium range of electromagnetic radiation power are used 
(Podbielska et al., 2004). The molecules of photosensitizers and their excitation by laser play 
the most important role in this method. Laser radiation of the proper energy excites the 
photosensitizer molecules, which come to the next excited energy level, and after it comes to 
the lower energy level via sending the energy to the eye structures. The scheme of the 
processes in photodynamic therapy is presented in Figure 6. This scheme was prepared 
according to the work (Podbielska et al., 2004). 
These optical processes form reactive free radicals and oxygen molecules O2 in the singlet 
state in eye (Fig. 6) (Podbielska et al., 2004). Free radicals and oxygen molecules damage the 
pathologically changed structures in eye. Free radicals are the paramagnetic molecules 
containing unpaired electrons and the short lifetime characterize them, because of free 
radicals interactions with both dia- and paramagnetic molecules in tissues. Mainly the 
reactive oxygen species are formed upon laser irradiation during photodynamic therapy, 
especially hydroxyl radicals (OH) and superoxide radical anion (O2.) (Podbielska et al., 
2004). Single oxygen molecules are diamagnetic, but this oxygen form is higher reactive than 
paramagnetic oxygen molecules in the ground state, because of the most molecules in the 
environment are diamagnetic, so the reactions between the similar units go easier (Bartosz, 
2006; Podbielska et al., 2004).  
Free radicals and singlet oxygen in the physiology are not expected, but their formation in 
the pathological state of organism during photodynamic therapy is the most important 
effect (Bartosz, 2006; Jóźwiak & Bartosz, 2008; Podbielska et al., 2004). Free radicals and 
singlet oxygen damage the pathologically changed tissue. The condition of laser irradiation 
should be fitted to the conditions of the highest formation of free radicals and singlet 
oxygen.  
Free radicals (S = 1/2) may be directly detected by electron paramagnetic resonance (EPR) 
spectroscopy (Eaton et al., 1998; Jóźwiak & Bartosz, 2008; Kęcki, 1999; Kirmse & Stach, 1994; 
Morrish, 1970; Stankowski & Hilczer, 2005; Symons, 1987; Wertz & Bolton, 1986). Electron 
paramagnetic resonance effect is characteristic for unpaired electrons located in magnetic 
field of magnetic induction B (Stankowski & Hilczer, 2005; Symons, 1987; Wertz & Bolton, 
1986). The electromagnet and the cavity of EPR spectrometer is presented in Figure 7. The 
Zeeman splitting of energy levels occurs in magnetic field. The spin magnetic moments 
orientations - parallel and anti-parallel to magnetic field are responsible for Zeeman Effect. 
Zeeman Effect is the effect of splitting of energy levels of unpaired electrons in the magnetic 
field as the result of parallel or non parallel electron magnetic moments orientations in this 
field (Stankowski & Hilczer, 2005; Wertz & Bolton, 1986). The quantization of magnetic 
moments of unpaired electrons with spin S in magnetic field results from the 2S + 1  
(S, S-1, …, -S) possible values of magnetic spin quantum number MS. Energy of these states 
is given by the following formula (Stankowski & Hilczer, 2005; Wertz & Bolton, 1986): 
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 E(MS) = g μB B MS (3) 
where: E – energy, MS – magnetic spin number, g – spectroscopic factor, μB –  Bohr 
magneton, B – induction of magnetic field. 
 
 
Fig. 6. Photodynamic therapy processes. Prepared according to (Podbielska et al., 2004). 
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Unpaired electrons are excited to the higher energy levels in magnetic field by microwaves 
(Stankowski & Hilczer, 2005; Symons, 1987; Wertz & Bolton, 1986). The energy of 
microwaves (hν) must be fitted to the distances between energy levels (ΔE) of unpaired 
electrons (Stankowski & Hilczer, 2005; Wertz & Bolton, 1986):  
 hν = ΔE = g μB B (4) 
where ν is the frequency of microwaves.  
The frequency of microwave from the basic X-band is 9.3 GHz. The equation (4) is called the 
electron paramagnetic resonance equation. The absorbed energy by unpaired electrons is 
presented in EPR spectroscopy as the resonance spectrum. The EPR spectra inform about 
the type and number of paramagnetic centers in the sample. The individual paramagnetic 
centers give EPR signals in characteristic magnetic field. The amplitude and integral 
intensity of EPR lines increase with the increasing of paramagnetic centers concentration in 
the sample. Multi-component EPR spectra as the superposition of several lines are measured 
for the samples with complex paramagnetic centers system consisting of different types of 





Fig. 7. The resonance cavity and electromagnet of EPR spectrometer. 
Free radicals formation during laser irradiation of tumor cells with photosensitizers was 
studied by us earlier (Latocha et al., 2004, 2005, 2006). The observation of the changes of the 
amount of free radicals in eye structures irradiated by lasers is proposed in this work. The 
optimal conditions of PDT in ophthalmology may be search by EPR spectroscopy as the 
conditions with the highest free radical formation. Similar application was discussed by us 
for PDT of different tumor cells (Latocha et al., 2004, 2005, 2006). 
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The optimal conditions of photodynamic therapy are also accompanied by the highest 
formation of singlet oxygen. Singled oxygen as the diamagnetic molecule may be measured 
by EPR spectroscopy only by the use of oximetric probes. Oximetric probe is the 
paramagnetic sample which EPR spectrum strongly changes under changes of the 
concentration of singlet oxygen in its environment. Our previous results indicates that coal 
multi-ring aromatic samples may be used as the oximetric probes (Bartłomiejczyk et al., 
2008; Latocha et al., 2008; Pilawa et al., 2005b, 2006, 2008a, 2008b). The coal oximetric probes 
were synthesized by Helena Wachowska group from Institute of Chemistry of Adam 
Mickiewicz University in Poznań (Poland). Scheme of the idea of application of EPR method 
and coal oximetric probe is shown in Figure 8. Coal paramagnetic probe contains chemical 
structures with unpaired electrons with the high probability of interactions with oxygen 
molecule O2. Before laser irradiation paramagnetic molecules in the ground triplet state with 
spin of 1 mainly exist in the environment of the oximetric probe. Paramagnetic oxygen 
quenches EPR lines of coal probe. After laser irradiation the amount of paramagnetic 
oxygen molecules decreases, so the amplitudes of the EPR lines of coal probe increase. 
Under laser irradiation the paramagnetic oxygen molecules become diamagnetic, so the 
increase of the EPR line of coal probe is proportional to the singlet oxygen formation 
(Bartłomiejczyk et al., 2008; Latocha et al., 2008; Pilawa et al., 2005b, 2006, 2008a, 2008b). 
Such methods may be proposed in ophthalmology.  
 
 
Fig. 8. Potential coal oximetric probe and the changes of its EPR line with increasing of 
singlet oxygen concentration in the environment. 
Lasers in ophthalmology is used to the damage the eye structures via conducting of the 
energy from melanin biopolymer to them (Gilmour, 2002). Mainly eumelanins with the 
chemical structure presented in Figure 9 exist in eye (Bilińska et al., 2002; Pasenkiewicz-
Gierula, 1990; Sarna, 1981; Zdybel, 2008).  
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Unpaired electrons are excited to the higher energy levels in magnetic field by microwaves 
(Stankowski & Hilczer, 2005; Symons, 1987; Wertz & Bolton, 1986). The energy of 
microwaves (hν) must be fitted to the distances between energy levels (ΔE) of unpaired 
electrons (Stankowski & Hilczer, 2005; Wertz & Bolton, 1986):  
 hν = ΔE = g μB B (4) 
where ν is the frequency of microwaves.  
The frequency of microwave from the basic X-band is 9.3 GHz. The equation (4) is called the 
electron paramagnetic resonance equation. The absorbed energy by unpaired electrons is 
presented in EPR spectroscopy as the resonance spectrum. The EPR spectra inform about 
the type and number of paramagnetic centers in the sample. The individual paramagnetic 
centers give EPR signals in characteristic magnetic field. The amplitude and integral 
intensity of EPR lines increase with the increasing of paramagnetic centers concentration in 
the sample. Multi-component EPR spectra as the superposition of several lines are measured 
for the samples with complex paramagnetic centers system consisting of different types of 





Fig. 7. The resonance cavity and electromagnet of EPR spectrometer. 
Free radicals formation during laser irradiation of tumor cells with photosensitizers was 
studied by us earlier (Latocha et al., 2004, 2005, 2006). The observation of the changes of the 
amount of free radicals in eye structures irradiated by lasers is proposed in this work. The 
optimal conditions of PDT in ophthalmology may be search by EPR spectroscopy as the 
conditions with the highest free radical formation. Similar application was discussed by us 
for PDT of different tumor cells (Latocha et al., 2004, 2005, 2006). 
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The optimal conditions of photodynamic therapy are also accompanied by the highest 
formation of singlet oxygen. Singled oxygen as the diamagnetic molecule may be measured 
by EPR spectroscopy only by the use of oximetric probes. Oximetric probe is the 
paramagnetic sample which EPR spectrum strongly changes under changes of the 
concentration of singlet oxygen in its environment. Our previous results indicates that coal 
multi-ring aromatic samples may be used as the oximetric probes (Bartłomiejczyk et al., 
2008; Latocha et al., 2008; Pilawa et al., 2005b, 2006, 2008a, 2008b). The coal oximetric probes 
were synthesized by Helena Wachowska group from Institute of Chemistry of Adam 
Mickiewicz University in Poznań (Poland). Scheme of the idea of application of EPR method 
and coal oximetric probe is shown in Figure 8. Coal paramagnetic probe contains chemical 
structures with unpaired electrons with the high probability of interactions with oxygen 
molecule O2. Before laser irradiation paramagnetic molecules in the ground triplet state with 
spin of 1 mainly exist in the environment of the oximetric probe. Paramagnetic oxygen 
quenches EPR lines of coal probe. After laser irradiation the amount of paramagnetic 
oxygen molecules decreases, so the amplitudes of the EPR lines of coal probe increase. 
Under laser irradiation the paramagnetic oxygen molecules become diamagnetic, so the 
increase of the EPR line of coal probe is proportional to the singlet oxygen formation 
(Bartłomiejczyk et al., 2008; Latocha et al., 2008; Pilawa et al., 2005b, 2006, 2008a, 2008b). 
Such methods may be proposed in ophthalmology.  
 
 
Fig. 8. Potential coal oximetric probe and the changes of its EPR line with increasing of 
singlet oxygen concentration in the environment. 
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Fig. 9. The chemical structure of eumelanin polymer (Wakamatsu & Ito, 2002). 
Melanins are the paramagnetic polymers with o-semiquinone free radicals with spin of 1/2 
and biradicals with spin of 1 incorporated in their structure (Kozdrowska, 2006; Najder-
Kozdrowska et al., 2009, 2010; Pilawa et al., 2004; Sarna, 1981; Zdybel, 2008). o-Semiquinone 
free radicals structure is presented in Figure 10 (Kozdrowska, 2006; Pasenkiewicz-Gierula, 
1990; Sarna, 1981). Our earlier EPR studies of human retinal pigment epithelium 
melanosomes from young and old donors pointed out that the amount of free radicals 
depend on the age and method of irradiation (Bilińska et al., 2002). It seems that free radical 
reactions in melanin of eye influences on therapeutic effect of laser irradiation. This problem 
is the interesting proposition of the future electron paramagnetic resonance studies of free 













Fig. 10. o-Semiquinone free radicals (a) (Pasenkiewicz-Gierula, 1990; Sarna, 1981) and 
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The second types of paramagnetic centers – biradicals in melanin were discovered in the last 
years (Kozdrowska, 2006; Najder-Kozdrowska et al., 2009, 2010; Pilawa et al., 2004; Zdybel, 
2008). It is possible that biradicals of melanin could play the role in interactions of laser 
radiation with eye structures.  
The free radicals and biradicals may be differentiated and detected by electron 
paramagnetic resonance spectroscopy (Kozdrowska, 2006; Najder-Kozdrowska et al., 2009, 
2010; Pilawa et al., 2004; Zdybel, 2008). Integral intensities of EPR lines of free radicals and 
biradicals change differently with the increasing of the measuring temperature (Fig. 11) 
(Hatfield, 1976). Such dependences were obtained for melanin paramagnetic centers differ 
in spins (S: 1/2 and 1) (Hatfield, 1976; Kozdrowska, 2006; Najder-Kozdrowska et al., 2009, 
2010; Pilawa et al., 2004; Zdybel, 2008).  
 
 
Fig. 11. Changes of integral intensity of EPR lines of free radicals (S = 1/2) and biradicals  
(S = 1) with the measuring temperature according to functions in (Hatfield, 1976). 
The following theoretical functions for free radicals and biradicals in melanin were used 
(Hatfield, 1976; Kozdrowska, 2006; Zdybel, 2008): 
 IT = C    for S = ½ (5) 
 IT =  D/(3 + exp(J/kT))    for S = 1 (6) 
where: I – integral intensity of EPR lines, T – temperature, S – spin, k – Boltzmann constant, 
C, D, J – coefficients in the equations. 
The electron paramagnetic resonance spectroscopy could be very useful in modern 
ophthalmology. EPR is the physical method of examination of paramagnetic species which 
does not damage the sample. The conditions of the laser therapy may be spectroscopically 
found and the reactions in the eye structures may be tested.  
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1. Introduction 
Given the small dimensions of the human eye, ocular surgery demands the ability to both 
visualize and precisely manipulate delicate tissue within a microscopic space. Microsurgical 
technological advancements have rapidly changed the way in which ophthalmic 
microsurgery is performed and have provided for greater surgical efficiency and improved 
functional outcomes.  
A thorough understanding of normal ocular anatomy is critical to define pathologic 
anatomic conditions, to delineate surgical goals, and to develop and utilize surgical tools to 
optimize patient outcomes. The anatomy of the eye and orbit can be broadly categorized as 
extraocular structures (including the eyelids, lacrimal gland, canalicular system, 
conjunctiva, and extraocular muscles) and intraocular structures, located within the globe of 
the eye. Intraocular structures are further grouped based on their location in the anterior or 
posterior segments of the eye (figure 1). The anterior segment consists of (from anterior to 
posterior): the cornea, anterior chamber, iris, and crystalline lens. The crystalline lens is 
suspended in place by hundreds of zonular fibers, which extend from the ciliary body to a 
thin capsule surrounding the lens. Contraction of the ciliary body changes the tension of the 
zonular fibers on the lens, allowing the lens to change its shape and focusing power. The 
cornea and lens are of particular importance as a majority of ophthalmic surgical 
interventions are performed on these structures, such as corneal transplantation, refractive 
corneal surgery, and cataract extraction.  
The posterior segment of the eye consists of the vitreous humor (a clear gelatinous substance 
composed primarily of water, type II collagen, and hyaluronic acid), the neurosensory 
retina, the retinal pigment epithelium (which promotes the function and viability of the 
neurosensory retina), and the choroid (a vascular layer interposed between the retinal 
pigment epithelium and the sclera). The neurosensory retina is a highly organized extension 
of the central nervous system composed of photoreceptors and multiple layers of 
interconnected neurons. These neurons ultimately synapse on ganglion cells, whose axons 
coalesce into the optic nerve. Posterior segment ophthalmic surgery generally involves 
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conjunctiva, and extraocular muscles) and intraocular structures, located within the globe of 
the eye. Intraocular structures are further grouped based on their location in the anterior or 
posterior segments of the eye (figure 1). The anterior segment consists of (from anterior to 
posterior): the cornea, anterior chamber, iris, and crystalline lens. The crystalline lens is 
suspended in place by hundreds of zonular fibers, which extend from the ciliary body to a 
thin capsule surrounding the lens. Contraction of the ciliary body changes the tension of the 
zonular fibers on the lens, allowing the lens to change its shape and focusing power. The 
cornea and lens are of particular importance as a majority of ophthalmic surgical 
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The posterior segment of the eye consists of the vitreous humor (a clear gelatinous substance 
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retina, the retinal pigment epithelium (which promotes the function and viability of the 
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coalesce into the optic nerve. Posterior segment ophthalmic surgery generally involves 
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removal of the vitreous humor to: 1) relieve traction of the vitreous on the retina, 2) remove 
visually-significant opacities within the vitreous, or 3) to gain access to the retina or sub-
retinal space for further surgical manipulation.  
The origins of ophthalmic surgery date back as far as the sixth century B.C. when ancient 
Indian surgeons used curved needle-like instruments to dislodge a cataract, a technique 
termed “couching”. Further contributions by Greek, Middle Eastern and European 
physicians provided detailed functional knowledge of the eye and intraocular structures.  
Development of the surgical microscope further revolutionized ophthalmic 
microsurgery. Although initially little more that a binocular telescope worn by the 
surgeon, the modern ophthalmic microscope provides a well-lit binocular stereoscopic 
view with a high-level optical clarity (figure 2). Foot pedal controls allow the surgeon to 
adjust magnification (approximately 10-30x), illumination intensity, x-y axis movement 
and level of focus. Furthermore, both contact and non-contact lens based systems are 
now employed to provide a wide-angle stereoscopic view of the posterior segment. 
Indeed, the ophthalmic microscope has enabled precise visualization of both anterior 
and posterior segment structures making modern ophthalmic microsurgery possible. 
Two such ophthalmic surgeries, cataract extraction and pars plana vitrectomy, are 
described below in detail.   
1.1 Cataract extraction 
1.1.1 Technique overview 
Over two million cataract extractions are performed yearly in the United States making it 
the most common ophthalmic surgery, and among the most frequently performed surgeries 
in any field.  A “cataract” refers to a focal or diffuse opacification of the crystalline lens, a 
structure that is normally optically clear and measures approximately 10mm wide and 6mm 
deep. Opacities within the lens limit the normal focusing ability of the lens resulting in 
blurred vision. Although cataract formation is most commonly an age-related process, 
cataracts may form at any age due to a number of different etiologies including medications, 
systemic metabolic disease, and ocular trauma. Although many methods have been 
developed to remove cataracts, the most common technique employed in modern 
ophthalmic microsurgery is “phacoemulsification”. 
Standard phacoemulsification for cataract extraction typically begins with the creation of a 2.2 
to 3 mm tunnel or wound in the peripheral cornea to gain access to the anterior chamber. The 
anterior chamber is stabilized during intraocular manipulation with an ophthalmic viscoelastic 
device (a clear, removable, gel-like substance composed primarily of water and hyaluronic 
acid). A circular opening is then created in the anterior face of the lens capsule, termed a 
“continuous curvilinear capsulorrhexis”. With the lens contents now accessible, the tip of a 
handpiece connected to a phacoemulsification machine is placed within the anterior chamber. 
This handpiece performs three functions: 1) administration of ultrasonic energy to fracture the 
lens material into small pieces; 2) aspiration to remove the small lens particles; 3) irrigation of a 
saline-like solution to maintain the volume of the anterior chamber (Figure 3).  
Once the lens material is successfully removed, a clear artificial lens is typically placed 
within the intact capsule of the lens. Although early intraocular lenses were composed of 
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rigid polymethylmethacrylate (PMMA) requiring enlargement of the corneal wound for 
intraocular placement, modern intraocular lenses are composed of silicone or acrylic, both of 
which are biologically inert and can be folded and placed into the eye through a small 
corneal incision. 
2. Principles of phacoemulsification 
The fluid dynamics of phacoemulsification require constant fluid irrigation into the anterior 
chamber to maintain normal depth while lens material is aspirated. Due to the small volume 
of the anterior chamber, fluid circulation during phacoemulsification is critical to ensure 
efficient removal of the cataract while preventing complications due to anterior chamber 
collapse. Indeed, if outflow, or aspiration through the handpiece is allowed to exceed 
inflow, or irrigation, even for a fraction of a second, anterior chamber instability may result 
in unintended damage to intraocular tissue. 
The formula that governs fluid flow during phacoemulsification surgery is Poiseuille’s law:  
 Q =  P π r 4 / 8 ηL, 
where Q is flow rate,  P is the pressure gradient, r is the radius of instrument tip, η is fluid 
viscosity, and L is length of the tubing. Given that the viscosity of the fluid and length of the 
tube are constant, flow is essentially proportional to the change in pressure and radius of the 
tubing.  
In the case of phacoemulsification surgery,  P is the pressure gradient between the infusion 
pressure and the vacuum driving aspiration. The source of fluid inflow is a bottle of 
balanced salt solution, the height of which can be adjusted relative to the patient’s eye to 
control infusion pressure. Fluid outflow is dependent on the vacuum level generated by the 
machine. The surgeon can control both the infusion pressure and vacuum or aspiration. 
3. Phacoemulsificaiton instruments 
The primary tool of phacoemulsification is the handpiece (figure 4). The tip of this tool 
delivers ultrasonic energy to break up the lens, aspirate fluid and lens material, and provide 
inflow of fluid to the anterior chamber. The handpiece is connected to a machine that 
regulates the aspiration pressure, the infusion pressure, and the intensity of the ultrasonic 
energy delivered by the handpiece. The design of the handpiece tip varies with respect to 
the angle and size of the lumen. Steeper tip bevels (less angled) provide better cutting ability 
into dense lens nuclear material whereas flatter tip bevels provide a larger surface area for 
improved aspiration of large lens fragments. 
Modern phacoemulsification machines also employ foot pedal controls with at least three 
positions that allow the surgeon to control the fluidics of phacoemulsification. The first 
position typically provides irrigation only, which cools the handpiece and keeps the anterior 
chamber formed. The second position, in addition to irrigating, engages the aspiration mode 
at a constant or variable rate, depending on the settings selected by the surgeon. In the third 
position, ultrasound energy is delivered in addition to irrigation and aspiration. Many other 
microsurgical instruments are also utilized in conjunction with the phacoemulsification 
probe to facilitate manipulation of the lens material and to improve the efficiency of cataract 
extraction. 
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“continuous curvilinear capsulorrhexis”. With the lens contents now accessible, the tip of a 
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This handpiece performs three functions: 1) administration of ultrasonic energy to fracture the 
lens material into small pieces; 2) aspiration to remove the small lens particles; 3) irrigation of a 
saline-like solution to maintain the volume of the anterior chamber (Figure 3).  
Once the lens material is successfully removed, a clear artificial lens is typically placed 
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rigid polymethylmethacrylate (PMMA) requiring enlargement of the corneal wound for 
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which are biologically inert and can be folded and placed into the eye through a small 
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efficient removal of the cataract while preventing complications due to anterior chamber 
collapse. Indeed, if outflow, or aspiration through the handpiece is allowed to exceed 
inflow, or irrigation, even for a fraction of a second, anterior chamber instability may result 
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where Q is flow rate,  P is the pressure gradient, r is the radius of instrument tip, η is fluid 
viscosity, and L is length of the tubing. Given that the viscosity of the fluid and length of the 
tube are constant, flow is essentially proportional to the change in pressure and radius of the 
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pressure and the vacuum driving aspiration. The source of fluid inflow is a bottle of 
balanced salt solution, the height of which can be adjusted relative to the patient’s eye to 
control infusion pressure. Fluid outflow is dependent on the vacuum level generated by the 
machine. The surgeon can control both the infusion pressure and vacuum or aspiration. 
3. Phacoemulsificaiton instruments 
The primary tool of phacoemulsification is the handpiece (figure 4). The tip of this tool 
delivers ultrasonic energy to break up the lens, aspirate fluid and lens material, and provide 
inflow of fluid to the anterior chamber. The handpiece is connected to a machine that 
regulates the aspiration pressure, the infusion pressure, and the intensity of the ultrasonic 
energy delivered by the handpiece. The design of the handpiece tip varies with respect to 
the angle and size of the lumen. Steeper tip bevels (less angled) provide better cutting ability 
into dense lens nuclear material whereas flatter tip bevels provide a larger surface area for 
improved aspiration of large lens fragments. 
Modern phacoemulsification machines also employ foot pedal controls with at least three 
positions that allow the surgeon to control the fluidics of phacoemulsification. The first 
position typically provides irrigation only, which cools the handpiece and keeps the anterior 
chamber formed. The second position, in addition to irrigating, engages the aspiration mode 
at a constant or variable rate, depending on the settings selected by the surgeon. In the third 
position, ultrasound energy is delivered in addition to irrigation and aspiration. Many other 
microsurgical instruments are also utilized in conjunction with the phacoemulsification 
probe to facilitate manipulation of the lens material and to improve the efficiency of cataract 
extraction. 
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Ultrasonic power for phacoemulsification is generated by applying a time-varying electric 
field across a piezoelectric crystal in the phacoemulsification handpiece. The oscillating 
crystal deforms in response to the electric field, resulting in the conversion of electrical to 
mechanical energy. Oscillation of the tip occurs at a preset frequency that varies from 27 
kHz to 60 kHz. The amplitude of the movement, or stroke length, ranges from 50 µm to 100 
µm and is modulated when the phacoemulsification power is changed. As the tip retracts, a 
vacuum is created resulting in the formation of “cavitation bubbles”. When the bubbles 
implode, they release heat and shock waves that fracture the lens material. 
Phacoemulsification power can also be modulated by varying the duty cycle; the period of 
time when the phacoemulsification power is being delivered. Varying the duty cycle allows 
for efficient administration of phacoemulsification energy to promote fracturing of lens 
material while minimizing excess heat and energy that may damage the cornea or other 
intraocular structures.  
4. Phacoemulsification systems 
While there are a variety of phacoemulsification machine manufacturers and configurations, 
they all generate the required vacuum and aspiration based on one of two pump types: 
Venturi and peristaltic. 
A peristaltic system (figure 5) utilizes a series of rollers to displace fluid, producing flow in a 
compressible tube that is wound tightly around a rotating wheel. As the wheel turns, a 
segment of fluid trapped between two rollers is moved, resulting in more fluid being drawn 
into the tubing. Therefore, the flow rate is directly proportional to the speed of the rotary 
mechanism. Significant vacuum is generated only when the tip is occluded. The surgeon 
sets a desired flow rate and vacuum limit. The flow rate determines how rapidly the 
vacuum builds up when the handpiece tip is occluded and flow is restricted.   
The Venturi pump (figure 6) utilizes the Venturi effect to create vacuum. The Venturi effect 
refers to the creation of vacuum secondary to the flow of a fluid (typically nitrogen or air in 
a phacoemulsification machine) over an opening. Thus, a Venturi pump allows a given 
vacuum level to be generated immediately, without occlusion of the phacoemulsification tip 
as is required in the peristaltic system. As such, flow cannot be directly modulated and is 
dependent on the vacuum level generated. The Venturi system provides the surgeon with 
near instantaneous vacuum levels and potentially higher flow rates.  
5. Femtosecond laser technology and the future of phacoemulsification 
In the near future, a new application of an existing technology may alter the way in which 
cataract surgery is performed. The femtosecond laser is a device that emits coherent optical 
pulses with a wavelength of 800nm and duration on the order of 10-15 seconds. It has been 
used extensively in ophthalmology due to its ability to alter delicate tissue in a precise and 
predictable way. In addition to its precision, the femtosecond laser can cut tissue with 
practically no heat development. Clinical trials utilizing the femtosecond laser to perform 
the incisional steps of cataract surgery, including cornea wound creation, capsulorrhexis 
creation, and disassembly of the lens are currently ongoing. Future applications of this laser 
may allow many steps of phacoemulsification to be automated, thus minimizing risk and 
error while increasing surgical efficiency.  
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5.1 Vitreoretinal surgery 
5.1.1 Basic techniques 
Vitreoretinal surgery, in its modern form, is a minimally invasive technique similar  
to laparoscopic surgery whereby small entry ports or trocars are placed on the surface of 
the eye to gain surgical access to intraocular structures. A variety of instruments 
including surgical manipulators, illuminating probes, laser probes, and infusing and 
aspirating devices can be placed through the trocars for a variety of surgical procedures. 
The trocars are placed at a safe anatomic entry point, the pars plana, located within a 
narrow band around the eye 3 to 4 mm posterior to the corneoscleral junction. This space 
lies just posterior to the highly vascularized ciliary body but anterior to the retina. Placing 
trocars too far anteriorly or posteriorly can lead to significant complications and surgical 
failure.  
The vitreous body, a clear gelatinous structure located between the crystalline lens and the 
retina, occupies approximately 80% of the volume of the human eye. It is mainly composed 
of water (99%), collagen fibrils (type II collagen), and hyaluronic acid. The vitreous gel is 
integral in the pathogenesis of many posterior segment diseases. For example, in diabetic 
retinopathy, bleeding into the vitreous cavity can severely reduce visual acuity since dense 
hemorrhages can become loculated within the vitreous body. In some instances where the 
hemorrhage does not dissipate on its own, vitrectomy is necessary to remove the vitreous 
and blood.  The vitreous body is adherent to a number of structures in the posterior segment 
including tight adhesions over the optic disc, the macula, retinal blood vessels and the ora 
serrata (a band which straddles the anterior retina and the pars plana where the vitreous 
and retina are anatomically fused and cannot be surgically separated). Thus, vitreous 
removal must be performed in a precise and controlled fashion to minimize excessive 
traction of the retina, which may result in complications such as retinal tears and 
detachment. Although the vitreous plays an important role in ocular development in utero, 
removal of the vitreous in the adult eye has no deleterious effects on the health of the retina. 
Once vitrectomy is performed, the vitreous cavity is typically replaced by the surgeon with 
balanced salt solution, which is eventually replaced by the eye with aqueous humor. 
Therefore, the vitreous body does not reform once it is removed.  
5.2 Principles of vitreoretinal surgery 
Surgery within the posterior segment of the eye is bound by the same principles as anterior 
segment surgery: the volume of the eye must be maintained as material is removed. Adding 
complexity to vitreoretinal surgery is the difficulty in visualization of the posterior segment 
during intraocular surgical maneuvers. External illumination is generally inadequate to 
visualize the retina and, despite advances in modern lens systems, the surgeon’s view of the 
retinal periphery can be limited while operating near the posterior pole.  
The first pars plana vitrectomy was performed by Robert Machemer in 1970 using a 17-
gauge (1.42 mm diameter) one-port system that combined an infusion cannula and vitreous 
cutter in one handpiece. Since that time, numerous innovations have improved the 
efficiency and outcomes of this procedure and led to the development of the modern 3-port 
20-gauge pars plana vitrectomy. In this procedure, three 20-gauge sclerotomies are created 
within the pars plana. One sclerotomy is used to anchor a cannula that infuses balanced salt 
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removal must be performed in a precise and controlled fashion to minimize excessive 
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retinal periphery can be limited while operating near the posterior pole.  
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solution into the posterior cavity while the vitrectomy is performed, thus maintaining 
intraocular pressure. The remaining ports are used for the vitrectomy probe and a light 
probe to remove the vitreous and illuminate intraocular structures respectively. Following 
removal of the vitreous, the sclerotomy can be used to introduce other instruments such as 
intraocular forceps and laser probes to further manipulate and treat the retina (figure 7). 
Visualization during pars plana vitrectomy is performed using the operating microscope in 
conjunction with a contact lens (which can be held by the assistant or sewn onto the eye at 
the corneoscleral junction) or a non-contact lens viewing system. Direct contact visualization 
systems allow for greater field of view and enhanced three-dimensional perception. Non-
contact lens viewing systems are easier to use and do not require an assistant or additional 
surgical maneuvers to anchor the lens to the ocular surface, but sacrifice some field of view 
and three-dimensional perception.  
5.3 Vitrectomy instruments 
The basic tools of pars plana vitrectomy are a vitreous cutter, illuminating device, laser 
probe, various tissue manipulators such as micro-forceps for delicate intraocular work, and 
an infusion cannula to maintain intraocular pressure. The workhorse of pars plana 
vitrectomy is the vitreous cutter, whose basic function is to remove the vitreous in a 
controlled fashion. Because the vitreous is a semi-solid structure with adhesions to the 
retina, simple aspiration of the vitreous results in excess traction on the retina. To minimize 
such traction, the vitrectomy probe is designed with both an aspiration port and a cutting 
mechanism to aspirate a small volume of vitreous into the handpiece and to cut and remove 
it. High cut speeds allow for incremental removal of small amounts of vitreous while 
minimizing tractional forces of the vitreous on the retina. Lower cut speeds result in 
removal of larger volumes of vitreous, thereby increasing the rate at which vitreous is 
removed. Most modern high-speed (600-5000 cuts per minute) vitrectomy probes are 
pneumatically driven with a side-cutting guillotine port near the tip of the instrument 
(figure 8).  
Most vitrectomy machines are equipped with a built-in light source employing either yellow 
or white light from a halogen or metal-halide light source. The light probe, a fiberoptic cable 
encased in a plastic handpiece, is connected to the light source and can function as a 
separate instrument or, in some cases, can be combined with the infusion cannula to 
simultaneously illuminate and irrigate the posterior segment. A recent innovation has been 
the introduction of a xenon light source, which can provide bright illumination through a 
narrow probe. This has facilitated the performance of smaller gauge surgery and eliminated 
light wavelengths under 400 nm that can be phototoxic to the retina.  
Many surgical instruments have been developed to facilitate surgical procedures on the 
macula. The macula is located at the center of the posterior pole of the retina and has the 
highest concentration of photoreceptors. It is responsible for fine central visual acuity 
needed for such tasks as reading, driving and other activities of daily living. Pars plana 
vitrectomy may be required to treat a variety of macular diseases including epiretinal 
membranes, macular holes, vitreo-macular traction, and hemorrhagic age-related macular 
degeneration. Instruments used to manipulate and treat the macula include a variety of 
micro-forceps (e.g. end-grasping and pick forceps), scissors, needles and cannulas.  
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The intraocular laser probe allows for minimally invasive and precise ablation of retinal 
tissues and is used in a wide variety of surgical procedures. Similar to the light probe, the 
“endolaser” probe is also a fiber-optic cable encased in a plastic handpiece. The intensity of 
the laser ablation is controlled by the surgeon by modulating the power and duration of the 
laser as well as by altering the distance of the probe tip to the retina. Intraocular laser is 
typically employed for two key purposes: 1) to treat retinal tears by creating a fibrous scar 
between the retina and the underlying choroid thus preventing fluid in the eye from 
collecting underneath the retina; and 2) to ablate non-perfused or ischemic retinal tissue (as 
in diabetic retinopathy and other occlusive retinal vascular diseases) to decrease the 
pathologic production of growth factors that result in retinal neovascularization, intraocular 
hemorrhage and retinal edema.  
5.4 Vitrectomy systems 
Vitrectomy machines, similar to phacoemulsification machines, are complex devices that 
drive the vitreous probe cutter, provide irrigation at an adjustable level to control 
intraocular pressure, aspirate and remove intraocular material, and provide a light source 
for intraocular illumination. Many of these functions are controlled via foot pedal by the 
surgeon, similar to the previously-described phacoemulsification machine.  
Two major types of systems are used to drive the vitrectomy probe cutter: electric guillotine 
and pneumatic guillotine. The electric guillotine employs an electric drive motor with a 
sinusoidal transmission, translating the rotary motion of an electric motor shaft to the linear 
guillotine motion of the cutter tip. The profile of motion of the guillotine remains constant as 
the cut rate is altered. That is to say, the duty cycle, or ratio of time the cutter port is open or 
closed, remains constant regardless of the cut rate.  
The second type of handpiece, which is pneumatically driven, uses pulses of air or gas to 
close the cutter tip. The pneumatically-driven guillotine is attached to a diaphragm. When a 
pulse of air is delivered, the diaphragm and guillotine extend, closing the cutter tip and 
completing a cut.  The guillotine then retracts to its original position either through a spring 
mechanism or through a “dual drive” system where an additional pulse of air pushes the 
guillotine back, thus opening the cutter tip. In the spring mechanism, as the cut rate is 
increased, the duration of open time per cut decreases, while the closed time remains 
constant (decreasing the duty-cycle). The “dual drive” system allows for improved duty 
cycle compared with the spring mechanism, but the duty cycle still decreases at high cut 
rates.  
6. Current directions 
Recent advances in vitreous surgery have resulted in the development of smaller 
instruments: the 23- and 25-gauge transconjunctival suture-less vitrectomy systems (figure 
9). A standard 20-gauge (0.9 mm diameter) vitrectomy requires removal of the conjunctiva 
and sutures to close the sclerotomies used to access the posterior segment. 23-gauge (0.6 mm 
diameter) and 25-gauge (0.5 mm diameter) entry wounds, when constructed properly, are 
small enough to self-seal and thus can be placed through the conjunctiva and sclera without 
the need for closing sutures. To allow for easy entry and exit of surgical instruments during 
vitrectomy and to align the entry holes in the conjunctiva and sclera, a 23- or 25-gauge trocar 
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solution into the posterior cavity while the vitrectomy is performed, thus maintaining 
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The intraocular laser probe allows for minimally invasive and precise ablation of retinal 
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sinusoidal transmission, translating the rotary motion of an electric motor shaft to the linear 
guillotine motion of the cutter tip. The profile of motion of the guillotine remains constant as 
the cut rate is altered. That is to say, the duty cycle, or ratio of time the cutter port is open or 
closed, remains constant regardless of the cut rate.  
The second type of handpiece, which is pneumatically driven, uses pulses of air or gas to 
close the cutter tip. The pneumatically-driven guillotine is attached to a diaphragm. When a 
pulse of air is delivered, the diaphragm and guillotine extend, closing the cutter tip and 
completing a cut.  The guillotine then retracts to its original position either through a spring 
mechanism or through a “dual drive” system where an additional pulse of air pushes the 
guillotine back, thus opening the cutter tip. In the spring mechanism, as the cut rate is 
increased, the duration of open time per cut decreases, while the closed time remains 
constant (decreasing the duty-cycle). The “dual drive” system allows for improved duty 
cycle compared with the spring mechanism, but the duty cycle still decreases at high cut 
rates.  
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Recent advances in vitreous surgery have resulted in the development of smaller 
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9). A standard 20-gauge (0.9 mm diameter) vitrectomy requires removal of the conjunctiva 
and sutures to close the sclerotomies used to access the posterior segment. 23-gauge (0.6 mm 
diameter) and 25-gauge (0.5 mm diameter) entry wounds, when constructed properly, are 
small enough to self-seal and thus can be placed through the conjunctiva and sclera without 
the need for closing sutures. To allow for easy entry and exit of surgical instruments during 
vitrectomy and to align the entry holes in the conjunctiva and sclera, a 23- or 25-gauge trocar 
 
Advances in Ophthalmology 
 
32
is placed at the site of the desired sclerotomy. The trocar consists of two components: a 
polyimide cannula and a polymer hub. The polyimide cannula maintains the 
transconjunctival and transcleral tunnel through which surgical instruments are passed. The 
polyimide cannula material provides both strength and flexibility, allowing the cannula wall 
to be thin while avoiding collapse or buckling. The polymer hub is the part of the trocar 
visible on the surface of the eye and prevents the trocar from sliding into the vitreous cavity. 
The hub has a central hole that is continuous with the cannula, allowing for instruments to 
be inserted into the vitreous cavity.   
Many surgeons believe the potential advantages of smaller gauge, suture-less techniques 
include shortened operative time and faster patient recovery. However, the reduction in 
port diameter results in reduced flow rates compared with 20-gauge cutters, and therefore, 
smaller-gauge surgery may require more time to remove the same amount of vitreous or 
may be inadequate to remove dense or highly organized vitreous. Other concerns with 
suture-less techniques include the increased risk of post-operative hypotony and infection if 
the sclerotomies are not constructed properly.   
7. The future of ophthalmic surgery – Robot-assisted microsurgery? 
With recent innovations in engineering and the demands for increasingly precise and 
efficient ophthalmic microsurgery, the next major advancement in ophthalmic surgery may 
be the integration of mechanization and robotics into ophthalmic microsurgical techniques. 
The potential benefits of robotic surgery in ocular surgery include increased precision, 
reduction of human error, task automation and the capacity for remote surgery. 
Guerrouad and Vidal described one of the first ocular robotic systems in 1989. Named the 
“Stereotaxical Microtelemanipulator” (SMOS), it provided relatively good range of motion 
for basic surgical tasks but the technology was too premature at that time to raise tangible 
interest for further development. In the 1990s, Steve Charles and researchers at 
Northwestern University demonstrated the use of robotic platforms for ophthalmic surgery 
with precise position measurement and fine incremental motion but these prototypes were 
limited by the complexity of its software control and the need for increased robotic 
responsiveness to human controls. 
Presently, the Food and Drug Administration has approved the da Vinci Surgical System 
(Intuitive Surgical, Sunnyvale, CA), which has become the most commonly employed robotic 
platform in human surgery (figure 10). Although it has been used in the fields of general 
surgery, urology, gynecology and cardiac surgery, its use in ophthalmic surgery is in its early 
phases. Preliminary studies have demonstrated good robot arm responsiveness to human 
controls for external and intraocular surgical tasks. However, the remote center of motion 
(pivot point) and limited range of motion of the robot arm make intraocular manoeuvrability 
difficult with excessive distortion of the globe of the eye. Furthermore, while the visualization 
system of the da Vinci system is adequate for extraocular and some anterior segment surgical 
procedures, posterior segment surgery is hampered by a limited field of view. Finally, the 
surgical instruments of the da Vinci instruments are not well-suited to ophthalmic 
microsurgery due to their bulkiness. Recent studies have better defined the range of motion 
required for robot-assisted ophthalmic surgery and further refinements to the robot surgery 
platform are underway to make this technology a tangible option in the near future. 
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Ocular robotic surgery poses a myriad of unique challenges and the application of this 
technology will undoubtedly require many stages of evolution. Further work will be 
required to continue to integrate traditional surgical techniques with new devices to bring 
the advantages of robotics to the field of ophthalmology.  
8. Conclusion 
Ophthalmic microsurgery has rapidly evolved in recent history as advances in medical 
device technology have led to the development of numerous minimally invasive procedures 
for the treatment of ocular diseases.  The multi-disciplinary integration of technology and 
knowledge from the fields of biomaterials, optics, lasers, ultrasonics and pneumatics have 
helped to refine the surgical tools available to ophthalmic surgeons, increasing their 
efficiency and surgical outcomes. As life expectancy and the prevalence of various systemic 
diseases continue to rise, so too will the burden of ocular disease. Further advances to better 
address these demands will undoubtedly lead to novel surgical techniques and devices, 
expanding the role of ophthalmic surgery to undiscovered heights.  
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surgical instruments of the da Vinci instruments are not well-suited to ophthalmic 
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Ocular robotic surgery poses a myriad of unique challenges and the application of this 
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required to continue to integrate traditional surgical techniques with new devices to bring 
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knowledge from the fields of biomaterials, optics, lasers, ultrasonics and pneumatics have 
helped to refine the surgical tools available to ophthalmic surgeons, increasing their 
efficiency and surgical outcomes. As life expectancy and the prevalence of various systemic 
diseases continue to rise, so too will the burden of ocular disease. Further advances to better 
address these demands will undoubtedly lead to novel surgical techniques and devices, 
expanding the role of ophthalmic surgery to undiscovered heights.  
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1. Introduction 
The first member of transient receptor potential (TRP) channel superfamily was discovered 
in photoreceptors of Drosophila over 30 years ago.1 Since then this protein superfamily has 
been extensively characterized based on exponential increases in the number of publications 
related to TRP channels. With 28 TRP homologous genes identified in mammals, TRP 
channels have been detected in both neural and non-neural tissues. 
In humans, 27 different TRP genes are classified into two groups and six different subfamilies 
based on their amino acid homology and phenotypes associated with mutant genes. The genes 
of TRP channel in Group 1 and Group 2 are only distantly related. The Group 1 of TRP genes 
are comprised of TRPC (canonical), TRPM (melastatin), TRPV (vanilloid) channel subfamilies, 
with TRPA (ankyrin) being more recently assigned to this group.2 Such categorization is based 
on their resemblance to the amino acid sequence of the Drosophila TRP channel. The 
nomenclature of TRP channel genes in Group 2 is based on the human phenotypes generated 
by the mutation of the founding genes of each subfamily, including polycystic kinase disease 
(PKD) and mucolipidosis type IV (MCOLN, mucolipin). Their encoded proteins have also 
been referred to as TRPP (polycystin) and TRPML (mucolipin), respectively (Figure 1). 
The TRP superfamily is evolutionally conserved from nematodes to mammals.3 The 
common features of TRP channels are six putative transmembrane spanning domains and a 
cation-permeable pore formed by a short hydrophobic region between transmembrane 
domains 5 and 6. They are configured as homo- or hetero-tetramers to form non-selective 
cation channels (Figure 2). Their permeability ratios to Ca2+/Na+ vary significantly among 
individual members. TRPV5 and TRPV6 channels exhibit a Ca2+/Na+ permeability ratio of 
greater than 100, indicating high Ca2+ selectivity.4 In contrast, TRPM4 and TRPM5 channels 
are impermeable to Ca2+ but are selective for monovalent cations (Na+, K+).5, 6 Such intra-
family variability is unique to the TRP channel superfamily whereas most other ion channel 
families have little difference in ionic permeability within a family.7  
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Fig. 1. Human TRP channel superfamily dendrogram. Random proteins bound to the 
plasma membrane (i.e., EGF receptor, EGFR), endoplasmic reticulum (i.e., calreticulin 
precursor, CP), mitochondria (thioredoxin reductase, TR), cytosolic protein (i.e., mitogen-
activated protein kinase 1, MAPK1) and nuclear membrane (i.e., inner nuclear membrane 
protein, INMP) are shown to illustrate that PKD and MCOLN are evolutionarily related to 
TRP channels or are the results of convergent evolution. The dendrogram shows that PKD 
and MCOLN belong to the TRP channel superfamily, since random genes extend from 
branches distinct from the TRP channel superfamily.8 
TRP channel subfamilies in Group 1 share substantial sequence homology in the 
transmembrane domain 6. What divides each subfamily is differences in their intracellular 
domains. TRPC, TRPV and TRPA channels contain ankyrin repeats near the intracellular N-
terminal domain, whereas the TRPC and TRPM channels subfamilies possess proline-rich 
‘TRP domain’ in the region of the C-terminal near the putative transmembrane segment. 
TRPM6 and TRPM7 channels have a protein kinase domain in the C-terminal.  
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The TRPC subfamily consists of seven genes (TRPC1–7) in mammals, but TRPC2 channel is 
a pseudogene in humans. TRPC channels are widely expressed in multiple systems. TRPC4, 
TRPC5, TRPC6 and TRPC7 channels are identified in the various ocular tissues of 
mammals.9-12 The TRPM channel subfamily comprises eight genes (TRPM 1–8), of which 
three encode channel-like proteins and five non-channel proteins. TRPM1 channels are 
expressed in retinas and TRPM8 channels in corneas.13, 14 The TRPV channels subfamily 
contains six members (TRPV1–6). TRPV1, TRPV2, TRPV3 and TRPV4 channels are 
expressed in the cornea whereas TRPV1, TRPV2, TRPV5 and TRPV6 channels are expressed 
in the retina.15-20 The TRPA channel subfamily has only one member, TRPA1.  
 
 
Fig. 2. Domain structure of the TRP channel superfamily. There are five TRP channel 
subfamilies in Group 1 (TRPN, no mechanoreceptor potential C channels are expressed in 
mammals) (a) and two TRP channel subfamilies in Group 2 (b). All subfamilies contain a six-
transmembrane domain unit with a cation-permeable pore between domains 5 and 6. Four 
of such units are assembled as a homo- or hetero-tetramer to form a TRP channel. Domain 
indications: ankyrin repeats (A), coiled-coil domain (cc), protein kinase domain (TRPM6 and 
TRPM7 channels only), cation-permeable pore (P), transmembrane (TM) domain, cation-
permeable (+++), TRP channels domain (TRPC and TRPM channels only), large extracellular 
loop between transmembrane domains 1 and 2 (TRPP and TRPML channels only). Adapted 
with permission from Venkatachalam and Montell.21 
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TRPP and TRPML channel subfamilies belong to Group 2. They contain limited sequence 
homology to TRP channels in Group 1, although such resemblance to classical TRP channels 
is still larger than those of random genes (e.g., EGFR, INMP) (Figure 1). TRPP channel 
proteins share 25 percent amino acid sequence homology to TRPC3 and TRPC6 channels 
over a region including transmembrane domains 4 and 5 and the hydrophobic pore loop 
between domains 5 and 6. TRPML channel proteins consist of three small proteins 
compared with other TRP channel proteins. Homology of their amino acid sequence with 
TRPC channels proteins is restricted to the region spanning transmembrane domains 4 to 6 
(amino acids 331 to 521). TRP channels in Group 2 have a unique large extracellular loop 
between their first and second transmembrane domains. They are named as TRP channels 
based on the six transmembrane domains that they contain and function as cation-
permeable channels. 
The activation mechanisms of TRP channels are unique in that there are a diverse host of 
stimuli that can activate TRP channels and exhibit sharp differences in stimulatory modes 
even within each TRP channel subfamily. TRP channels were initially recognized as sensory 
mechanisms to a variety of stimuli, ranging from light, temperature, osmotic pressure, 
smell, taste, mechanical stress and acidity. There is also increasing awareness of their roles 
in mediating wound healing, inflammation, apoptosis and excretion. These channels are 
sensitive to intracellular and extracellular messengers, as well as declines in the calcium 
content of intracellular calcium stores (ICS).  
Their activation following conformation changes modulates Ca2+/Na+ cell permeability 
ratios, which is dependent on TRP channel subunit composition. Transient increases in 
intracellular calcium concentration trigger intracellular activation of mediators including: 1) 
phospholipase C (PLC) by coupled GTP-binding protein, leading to stimulation of store-
operated Ca2+ channels; 2) transactivation of EGF tyrosine receptors through MMP-
mediated HB-EGF shedding.4, 10, 16 The physiological significance of TRP channel expression 
is indicated by the finding that TRP channel mutations are linked to human diseases.22 
There is compelling evidence that the TRP channel superfamily plays a critical role in ocular 
homeostasis and pathogenesis. Functional importances of TRP isotypes expressed in 
different ocular tissues are multi-faceted. Their activation is essential for retaining corneal 
deturgescence and clarity, mediating aqueous humor outflow through trabecular meshwork 
and ciliary body as well as inducing light sensation in retina. Mutation of TRP channels is 
associated with ocular pathological phenotypes either due to loss of its homeostatic role or 
over-activation of its function. The realization of the importance of TRP channel has 
prompted much research effort to investigate novel strategies for regulating TRP channels 
function in a number of ocular diseases.  
2. Roles of TRP channels in corneal sensation and wound healing 
Continuous renewal of corneal epithelial layer is essential to maintain corneal transparency. 
The intact epithelium not only offers a smooth and clear optical surface, but also provides 
corneal barrier function. This property protects the underlying stroma from swelling and 
pathogenic invasion. Should such protection become compromised by ocular surface 
diseases, outcomes can range from mild symptoms, such as irritation, photophobia, to 
severe consequences including corneal opacity, ulceration and even perforation. TRP 
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channel functions have been indicated to associate with maintaining corneal sensation and 
integrity. Corneas express ample collection of TRP channel isotypes in various mammalians. 
There are TRPC1, TRPC3, TRPC4, TRPC6 and TRPC7 as well as TRPV1–4 channels in the 
corneal epithelium, TRPV1-4 in the corneal endothelium, TRPV1, TRPA1, and TRPM8 in the 
corneal nerves.10, 15-17, 23, 24, 25-27 These channels are involved in corneal regenerative, 
protective and sensory mechanisms. 
TRPC4 channels protein is localized in plasma membranes of cultured human corneal 
epithelial cells (HCEC) and mediate epidermal growth factor (EGF)-promoted epithelial 
proliferation. They are activated by EGF-induced depletion of ICS content in the 
endoplasmic reticulum. This depletion occurs as a consequence of stimulation of PLC 
activity which results in increases in inositol 1,4,5-trisphosphate (IP3) formation. This 
response leads to declines in ICS content and activation of TRPC4 store operated channel 
(SOC) function. Its activation induces intracellular Ca2+ influx leading to stimulation of 
downstream signalling cascades. They include the mitogen activated protein kinase (MAPK) 
cascade composed of ERK, JNK and p38 casettes as well as protein kinase A (PKA), protein 
kinase C (PKC), JAK/STAT and PI3-K/AKT/GSK-3. All of their activations contribute to 
the control of increases in cell survival and proliferation elicited by EGF. The importance of 
TRPC4 channels activation to mediate EGF-induced mitogenic responses is indicated by the 
finding that knockdown of its gene expression in HCEC eliminated the mitogenic response 
to EGF.10  
TRPV1 channel expression was first identified on the ophthalmic branch of the trigeminal 
nerve. More recently, the functional expression of this channel was also identified in the 
corneal epithelial and endothelial layers. A hallmark of its activity is that the vanilloid 
compounds (such as capsaicin isolated from hot chilli pepper), hyperosmolarity, acidity (pH 
below 6) and high temperatures (above 43°C) stimulate TRPV1 channels. In the mouse 
corneal epithelium, severe chemical injury to corneal epithelium induces TRPV1 channel 
activation leading to dysregulated inflammation, scarring and loss of corneal transparency. 
On the other hand, its activation stimulates in HCEC proliferation and migration through 
EGF receptor (EGFR) transactivation.28 The involvement of TRPV1 channel activation in 
inducing these diverse responses is indicated by the finding that in homozygous TRPV1 
knockout mice the wound healing response to an alkali burn does not result in losses of 
corneal transparency. Similarly, TRPV1 channel activation in some types of dry eye disease 
resulting from exposure to hyperosmolar tears may account for chronic inflammation since 
TRPV1 channels activation caused by exposure to a hyperosmolar challenge induced large 
increases in a host of proinflammatory cytokines (e.g., IL-6, IL-8, TNFα and IL-1β) and 
chemoattractants (e.g., MCP-1) in HCEC. On the other hand, pre-exposure to a selective 
TRPV1 channel antagonist obviated all of these responses, suggesting that TRPV1 channels 
are potential drug target for the treatment of dry eye syndrome because suppression of its 
activation may reduce ocular surface inflammation.16, 23 
In contrast with TRPV1, its cohort, TRPV4 channel reacts to a different spectrum of stresses. 
Unlike TRPV1, which is thought to only be activated by a hyperosmolar stress, TRPV4 
channels may instead be an osmosensor for a hypoosmolar challenge.17 Such a stress is 
encountered by the cornea during exposure to fresh water (e.g., swimming, bathing, use of 
some eye drops). This hypotonic exposure results initially in corneal epithelial swelling due 
to obligatory water influx in order to reach equilibration between the cell interior and 
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surface tears. However, excessive swelling can lead to cell lysis. To counter the initial 
swelling, corneal epithelial cells mediate regulatory volume decrease (RVD) behavior by 
stimulating volume-sensitive potassium and chloride channels as well as potassium-
chloride co-transporter (KCC) activity to restore isotonic cell volume through osmotically 
coupled net fluid efflux. 
TRPV1–4 channel isoforms also serve as thermosensors over defined temperature ranges in 
the corneal epithelium. In addition, TRPV3 channel activation, either by temperatures above 
33°C or by its selective agonist, carvacrol, not only contributes to thermosensation, but also 
accelerates epithelial wound recovery by enhancing cell survival, proliferation and 
migration.15, 29 TRPV1–3 and TRPC4 channels are also expressed in corneal endothelial 
cells.9, 30 TRPV1–3 channels are sensitive to temperatures from 25 to 40°C, similar to their 
epithelial counterparts.  
TRP channels play an important role in mediating corneal sensations. The cornea has the 
highest sensory nerve density of any tissue in the body. The corneal sensory nerves originate 
from the ophthalmic branch of the trigeminal ganglion and are responsible for eliciting 
nociception to thermal, chemical and mechanical stimuli.31 TRPV1 channels colocalize with 
substance P (SP) and calcitonin-gene-related peptide (CGRP) in the ophthalmic branch of the 
trigeminal nerve indicating their role in eliciting nociceptive perception. This realization makes 
TRPV1 channel tenable as a potential drug target for treating neurotrophic keratopathy.31, 32 
Additionally, the TRPM8 channel contributes to corneal cold sensation and basal tear secretion 
required to maintain corneal surface hydration.14, 33  
Taken together, these studies on the corneal epithelial, endothelial cells and corneal nerves 
indicate that functional expression of TRP channels are essential for maintaining corneal 
transparency and eliciting adaptive responses to stresses. This indicates the importance of 
further studies on TRP channel regulation since such insight may lead to novel strategies for 
treating corneal diseases and better management of ocular surface inflammatory pain.  
3. Roles of TRP channels in glaucoma 
Some members of the TRPC and TRPV channel subfamilies are expressed in trabecular 
meshwork, ciliary muscle and retinal ganglion cells.34, 35 Their roles have been associated 
with regulating intraocular pressure through modulation of aqueous humor flows and 
ganglion cell survival. The trabecular meshwork contains contractile elements whose 
tension modulation changes fluid drainage rate from the anterior chamber into the Canal of 
Schlemm. The contractile state of trabecular meshwork is governed by tension imparted 
from the ciliary muscle and possibly trabecular meshwork itself.35, 36 The trabecular 
meshwork and the ciliary muscle act as functional antagonists. Such opposition is evident 
since ciliary muscle contraction leads to relaxation of the trabecular meshwork with 
subsequent increases in fluid outflow whereas trabecular meshwork contraction has the 
opposite effect.35 Malfunction of trabecular meshwork and ciliary muscle contractility often 
leads to ocular hypertension and glaucoma.37 Their contractile states are modulated by 
changes in intracellular Ca2+ concentration and Ca2+ channel activity. Specifically, increases 
in cytoplasmic Ca2+ resulting from the stimulation of TRP channels enhance contractility. 
Other types of Ca2+ channels that regulate intracellular Ca2+concentration include L-type 
voltage-gated Ca2+ channels, receptor operated Ca2+ channels and store-operated calcium 
 
Transient Receptor Potential (TRP) Channels in the Eye 
 
41 
entry (SOCE) pathways. In bovine trabecular meshwork cells, TRPC1 and TRPC4 channels 
are implicated in the formation of heteromeric SOCE channels which contribute to rises in 
cytoplasmic Ca2+ store and therefore trabecular meshwork contractility during exposure to 
bradykinin or endothelin-1.4  
Similarly TRPC1, TRPC3, TRPC4 and TRPC6 channels are also present in ciliary muscle 
cells. The ciliary muscle is densely innervated by parasympathetic nerves that stimulate 
muscle contraction through acetylcholine-mediated muscarinic receptor stimulation on 
neighboring muscle cells. Such activation leads to a surge in intracellular Ca2+ concentration 
resulting in membrane voltage depolarization via  receptor-operated non-selective cation 
channels. TRPC1, TRPC3, TRPC4 and TRPV6 channels are considered as potential 
candidates for such channels as they are co-localized with muscarinic receptor type 3 in 
ciliary muscle fibres.38, 39  
Modulation of TRPC channel activity in turn alters aqueous humor outflow and therefore 
intraocular pressure through changes in trabecular meshwork contractility. The dual 
localization of TRPC channels on ciliary muscles and trabecular meshwork cells suggests 
that strategies targeted towards their selective modulation may prove to be advantageous in 
providing better control of intraocular pressure in patients with ocular hypertension or 
glaucoma. Such an outcome is possible once there is definitive identification of the TRP 
channels subtypes on each of these tissues. At this point, it may be possible to maximize 
fluid outflow rates by selectively decreasing trabecular meshwork resistance through a 
decrease in its contractile state. Accordingly, additional studies are needed to map the TRP 
channels subtypes and characterize their mechanisms of regulation in the ciliary muscle and 
trabecular meshwork. 
Chronic intraocular hypertension is a risk factor which in some cases can induce glaucoma due 
to damage to retinal ganglion cells. Such damage can result from either increased hydrostatic 
pressure, declines in retrograde neutrophin flow, ischemic or oxidative stress. Irreversible loss 
of retinal ganglion cells leads to gradual and often insidious vision impairment and possible 
blindness. Elevated intraocular pressures can activate TRP channels in retinal ganglion cells. 
TRP channel sensitivity to hydrostatic pressure has been described in  the bladder, lungs and 
skin.40-42 Sappington et al. showed in vitro that exposure of retinal ganglion cells to elevated 
hydrostatic pressure induced transient rises of intracellular Ca2+ accumulation due to TRPV1 
channel activation. This effect promoted apoptosis of retinal ganglion cells whereas 
suppression of TRPV1 channel activation protected retinal ganglion cells from pressure-
induced death.34 Recently, similar stresses were identified to stimulate TRPV4 channel and 
induce apoptosis in retinal ganglion cells.43 The increased levels of cytoplasmic Ca2+ are the 
underlying mechanism leading to retinal ganglion cells apoptosis.44 Ca2+-dependent 
calcineurin and calpain are a phosphatase and a protease, respectively, that trigger apoptosis 
signalling. Both of them induce cytochrome c release from mitochondria and trigger pro-
apoptotic signalling. In contrast, the TRPV1 channel in the retinal microglia appears to have a 
retinoprotective effect. Retina microglia cells are essential to neuronal homeostasis and 
provide innate immunity for retina to defend against pathogenic infiltration. Exposure of 
microglia to chronic stress is associated with various neurodegenerative diseases, including 
retinal dystrophies. TRPV1 channel activation in the cultured retinal microglia cells by 
hydrostatic pressure induces increases in IL-6 and TNF-α release through transient rises in 
intracellular Ca2+ levels. Rises in IL-6 suppress pro-apoptotic signalling pathways and cell 
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TRP channel sensitivity to hydrostatic pressure has been described in  the bladder, lungs and 
skin.40-42 Sappington et al. showed in vitro that exposure of retinal ganglion cells to elevated 
hydrostatic pressure induced transient rises of intracellular Ca2+ accumulation due to TRPV1 
channel activation. This effect promoted apoptosis of retinal ganglion cells whereas 
suppression of TRPV1 channel activation protected retinal ganglion cells from pressure-
induced death.34 Recently, similar stresses were identified to stimulate TRPV4 channel and 
induce apoptosis in retinal ganglion cells.43 The increased levels of cytoplasmic Ca2+ are the 
underlying mechanism leading to retinal ganglion cells apoptosis.44 Ca2+-dependent 
calcineurin and calpain are a phosphatase and a protease, respectively, that trigger apoptosis 
signalling. Both of them induce cytochrome c release from mitochondria and trigger pro-
apoptotic signalling. In contrast, the TRPV1 channel in the retinal microglia appears to have a 
retinoprotective effect. Retina microglia cells are essential to neuronal homeostasis and 
provide innate immunity for retina to defend against pathogenic infiltration. Exposure of 
microglia to chronic stress is associated with various neurodegenerative diseases, including 
retinal dystrophies. TRPV1 channel activation in the cultured retinal microglia cells by 
hydrostatic pressure induces increases in IL-6 and TNF-α release through transient rises in 
intracellular Ca2+ levels. Rises in IL-6 suppress pro-apoptotic signalling pathways and cell 
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death.45 Therefore, provided strategies can be devised to selectively induce increases in 
microglial TRPV1 channels expression, TRPV1 channels may be a potential drug target in 
managing pressure-induced retinal ganglion cell loss in glaucoma. 
4. Possible roles of TRP channels in cataract development 
Maintenance of intracellular Ca2+ levels is imperative to crystalline lens clarity.46 Lenses 
with cortical cataracts have intracellular Ca2+ levels that are above those in the physiological 
range.47 Accordingly, a better understanding of the mechanisms mediating control of lens 
intracellular Ca2+ levels is pertinent for identifying economical and novel drug strategies to 
preserve lens transparency or slow cataract progression. 
As previously described, store-operated calcium entry (SOCE) channels are composed of 
TRP subunits and are heterogeneously expressed in the lens epithelial cells. Epithelial 
cells in the lens equatorial region have higher SOCE expression than that in the central 
anterior region. This difference is attributable to the fact that the size of the intracellular 
calcium storage is larger in the equatorial than the central anterior epithelial cells.48 The 
higher intracellular Ca2+ load in the equatorial epithelium is required for its more rapid 
proliferative rate than other parts of the lens epithelium. However, the equatorial 
epithelium is more susceptible to damage that can induce cortical cataracts since the 
development of such cataracts is associated with Ca2+ overload in the lens epithelial cells. 
The identity of the TRP channels isoforms constituting SOCE channels is elusive since 
drugs that modulate SOCE channels activity have poor selectivity for each of the different 
TRP subunits in the TRPV and TRPC channel subfamilies. For example, the inhibitory 
effects of lanthanum are used as a criterion to distinguish between SOCE and TRPC 
channel involvement in the development of cataract. At lower concentrations (i.e., in the 
nanomolar range), lanthanum inhibits SOCE channels, whereas at higher concentrations it 
blocks TRPC-containing channels.49, 50 However, this approach is problematic because a 
cut-off between lanthanum concentration ranges having the inhibitory effect on either 
SOCE or TRPC channel is poorly defined. Another complication is that, in the micromolar 
range, Ca2+ influx is potentiated through TRPC4- and TRPC5-containing pathways. 
Nevertheless, the current understanding is that SOCE channels are the major pathway for 
Ca2+ influx in the lens. Better insight into the specific involvement of TRP channels 
dysfunction in cataractogenesis will be clarified once either more selective Ca2+ channel 
modulators become available or genetic approaches are employed to selectively modulate 
levels of TRP channel isoform expression.  
5. Roles of TRP channels in retinopathy 
TRP channels are abundantly expressed in the entire retinal layer including the retinal 
pigment epithelium (RPE), photoreceptors, retinal ganglion cells, Müller cells, and 
microglia. Initially, TRP channel-mediated phototransduction was identified in Drosophila 
and 13 of the known 28 homologues of the mutant insect channels were next identified in 
the mammalian retina.51 For example, the TRPC channels in mammals are most closely 
related to the Drosophila TRP channels. The difference is that in mammals the six TRPC 
subfamily genes (i.e., trpc 1, 3–7) encode seven proteins (TRPC1–7 channels), since TRPC2 is 
a pseudogene. 
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In Drosophila retinal photoreceptors, TRPC channels lead to photoexcitation. Light 
absorption converts rhodopsin to active metarhodopsin, which activates PLC. PLC 
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to IP3 and diacylglycerol (DAG). 
DAG can be degraded to release polyunsaturated fatty acids and protons. TRPC channel 
activation occurs as a consequence of phosphoinositide depletion and acidification 
resulting from PLC-induced PIP2 hydrolysis and proton release associated with IP3 
formation.34 TRPC channel activation by phosphoinositide metabolites suggests that these 
channels are part of the light-sensing mechanism for Drosophila, but their role in humans 
is still unclear.  
TRP channel dysfunction has been implicated in mammalian retinopathy. Mutation of 
TRPM1 channels in ON bipolar cells has been linked to autosomal-recessive congenital 
stationary night blindness (CSNB), a heterogeneous group of retinal disorders characterized 
by non-progressive impaired night vision and variable decreased visual acuity.52 On the 
other hand, Wang et al. reported that TRPC6 channel activation has a neuroprotective effect 
on retinal ischemia-reperfusion (IR) injury in the rat.53 Following IR, the expression of 
TRPC6 channels decreases in retinal ganglion cells. Activation of TRPC6 channels before IR 
reduces retinal ganglion cell losses whereas suppression of TRPC6 channels has an opposite 
effect. Such protection by TRPC6 channels of retinal ganglion cells is dependent on brain-
derived neurotrophic factor (BDNF) signalling.  
The RPE layer has essential roles in sustaining normal retinal function. It regulates the 
hydration and ionic composition of the subretinal space, as well as rod outer segment 
function. RPE also secretes cytokines that are essential for retinal health. TRPV5 and TRPV6 
expressions were identified in vitro in the human RPE, implicating that these two most 
calcium-selective channels of the TRP channel superfamily contribute to the regulation of 
the subretinal space calcium composition accompanying light/dark transitions.19 TRPV2 
channels were shown in another study to control RPE release of vascular endothelial growth 
factor (VEGF). Insulin-like growth factor-1 (IGF-1) is a TRPV2 channel activator that 
selectively induces the intracellular Ca2+ transients required for inducing VEGF release. 
Control of this response is needed to reduce retinal neovascularization, since wet age-
related macular degeneration (AMD) is decreased or stabilized by treatment with anti-VEGF 
antibodies. These results suggest that reducing TRPV2 channels activity may provide 
another option for managing wet AMD.54 
6. Summary 
TRP channels are involved in ocular sensory and cellular functions. In mammals, TRP 
channel subunit proteins are encoded by 27 genes and are classified into two groups and six 
different subfamilies, based on differences in amino acid sequence homology. Group 1 and 
Group 2 of TRP channels are only remotely related, but share similar cation channel-forming 
structures of six transmembrane domains. Their cation selectivity and activation 
mechanisms are very diverse and depend on individual TRP channel. TRP channel 
activation induces a host of responses to variations in ambient temperature, pressure, 
osmolarity and pH. In addition, their activation by injury induces inflammation, 
neovascularization, pain and cell death, as well as wound healing. There is emerging 
interest in characterizing their roles in inducing ocular surface disease, glaucoma, cataracts 
and retinopathy. Such efforts could lead to the identification of novel drug targets for 
improving management of many ocular diseases. 
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death.45 Therefore, provided strategies can be devised to selectively induce increases in 
microglial TRPV1 channels expression, TRPV1 channels may be a potential drug target in 
managing pressure-induced retinal ganglion cell loss in glaucoma. 
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Maintenance of intracellular Ca2+ levels is imperative to crystalline lens clarity.46 Lenses 
with cortical cataracts have intracellular Ca2+ levels that are above those in the physiological 
range.47 Accordingly, a better understanding of the mechanisms mediating control of lens 
intracellular Ca2+ levels is pertinent for identifying economical and novel drug strategies to 
preserve lens transparency or slow cataract progression. 
As previously described, store-operated calcium entry (SOCE) channels are composed of 
TRP subunits and are heterogeneously expressed in the lens epithelial cells. Epithelial 
cells in the lens equatorial region have higher SOCE expression than that in the central 
anterior region. This difference is attributable to the fact that the size of the intracellular 
calcium storage is larger in the equatorial than the central anterior epithelial cells.48 The 
higher intracellular Ca2+ load in the equatorial epithelium is required for its more rapid 
proliferative rate than other parts of the lens epithelium. However, the equatorial 
epithelium is more susceptible to damage that can induce cortical cataracts since the 
development of such cataracts is associated with Ca2+ overload in the lens epithelial cells. 
The identity of the TRP channels isoforms constituting SOCE channels is elusive since 
drugs that modulate SOCE channels activity have poor selectivity for each of the different 
TRP subunits in the TRPV and TRPC channel subfamilies. For example, the inhibitory 
effects of lanthanum are used as a criterion to distinguish between SOCE and TRPC 
channel involvement in the development of cataract. At lower concentrations (i.e., in the 
nanomolar range), lanthanum inhibits SOCE channels, whereas at higher concentrations it 
blocks TRPC-containing channels.49, 50 However, this approach is problematic because a 
cut-off between lanthanum concentration ranges having the inhibitory effect on either 
SOCE or TRPC channel is poorly defined. Another complication is that, in the micromolar 
range, Ca2+ influx is potentiated through TRPC4- and TRPC5-containing pathways. 
Nevertheless, the current understanding is that SOCE channels are the major pathway for 
Ca2+ influx in the lens. Better insight into the specific involvement of TRP channels 
dysfunction in cataractogenesis will be clarified once either more selective Ca2+ channel 
modulators become available or genetic approaches are employed to selectively modulate 
levels of TRP channel isoform expression.  
5. Roles of TRP channels in retinopathy 
TRP channels are abundantly expressed in the entire retinal layer including the retinal 
pigment epithelium (RPE), photoreceptors, retinal ganglion cells, Müller cells, and 
microglia. Initially, TRP channel-mediated phototransduction was identified in Drosophila 
and 13 of the known 28 homologues of the mutant insect channels were next identified in 
the mammalian retina.51 For example, the TRPC channels in mammals are most closely 
related to the Drosophila TRP channels. The difference is that in mammals the six TRPC 
subfamily genes (i.e., trpc 1, 3–7) encode seven proteins (TRPC1–7 channels), since TRPC2 is 
a pseudogene. 
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In Drosophila retinal photoreceptors, TRPC channels lead to photoexcitation. Light 
absorption converts rhodopsin to active metarhodopsin, which activates PLC. PLC 
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to IP3 and diacylglycerol (DAG). 
DAG can be degraded to release polyunsaturated fatty acids and protons. TRPC channel 
activation occurs as a consequence of phosphoinositide depletion and acidification 
resulting from PLC-induced PIP2 hydrolysis and proton release associated with IP3 
formation.34 TRPC channel activation by phosphoinositide metabolites suggests that these 
channels are part of the light-sensing mechanism for Drosophila, but their role in humans 
is still unclear.  
TRP channel dysfunction has been implicated in mammalian retinopathy. Mutation of 
TRPM1 channels in ON bipolar cells has been linked to autosomal-recessive congenital 
stationary night blindness (CSNB), a heterogeneous group of retinal disorders characterized 
by non-progressive impaired night vision and variable decreased visual acuity.52 On the 
other hand, Wang et al. reported that TRPC6 channel activation has a neuroprotective effect 
on retinal ischemia-reperfusion (IR) injury in the rat.53 Following IR, the expression of 
TRPC6 channels decreases in retinal ganglion cells. Activation of TRPC6 channels before IR 
reduces retinal ganglion cell losses whereas suppression of TRPC6 channels has an opposite 
effect. Such protection by TRPC6 channels of retinal ganglion cells is dependent on brain-
derived neurotrophic factor (BDNF) signalling.  
The RPE layer has essential roles in sustaining normal retinal function. It regulates the 
hydration and ionic composition of the subretinal space, as well as rod outer segment 
function. RPE also secretes cytokines that are essential for retinal health. TRPV5 and TRPV6 
expressions were identified in vitro in the human RPE, implicating that these two most 
calcium-selective channels of the TRP channel superfamily contribute to the regulation of 
the subretinal space calcium composition accompanying light/dark transitions.19 TRPV2 
channels were shown in another study to control RPE release of vascular endothelial growth 
factor (VEGF). Insulin-like growth factor-1 (IGF-1) is a TRPV2 channel activator that 
selectively induces the intracellular Ca2+ transients required for inducing VEGF release. 
Control of this response is needed to reduce retinal neovascularization, since wet age-
related macular degeneration (AMD) is decreased or stabilized by treatment with anti-VEGF 
antibodies. These results suggest that reducing TRPV2 channels activity may provide 
another option for managing wet AMD.54 
6. Summary 
TRP channels are involved in ocular sensory and cellular functions. In mammals, TRP 
channel subunit proteins are encoded by 27 genes and are classified into two groups and six 
different subfamilies, based on differences in amino acid sequence homology. Group 1 and 
Group 2 of TRP channels are only remotely related, but share similar cation channel-forming 
structures of six transmembrane domains. Their cation selectivity and activation 
mechanisms are very diverse and depend on individual TRP channel. TRP channel 
activation induces a host of responses to variations in ambient temperature, pressure, 
osmolarity and pH. In addition, their activation by injury induces inflammation, 
neovascularization, pain and cell death, as well as wound healing. There is emerging 
interest in characterizing their roles in inducing ocular surface disease, glaucoma, cataracts 
and retinopathy. Such efforts could lead to the identification of novel drug targets for 
improving management of many ocular diseases. 
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The mucosa, a mucus-secreting membrane, is linings of surface and cavities that are exposed 
to the external environment and internal organs. The mucosal immune system has a unique 
anatomy and physiology, which provides protection to an organism's various mucous 
membranes from invasion by potentially pathogenic microbes. It provides three main 
functions: protecting the mucus membrane against infection, preventing the uptake of 
antigens, microorganisms, and other foreign materials, and moderating the organism's 
immune response to that material. The mucosal epithelium forms the initial interface 
between the environment and host, and functions not only as a barrier but also as a sensor 
providing bidirectional communication with other resident mucosal lymphoid cells with the 
capacity to respond to pathogenic microbes and other injurious agents.  
It has become increasingly clear that epithelial cells play important roles not only in host 
defense and inflammation, but also in regulation of immune responses. The mammalian 
immune system is comprised of two branches, the innate immune system and the adaptive 
immune system, that work in tandem to provide resistance to infection. The innate immune 
cells, represented primarily by monocytes, macrophages, dendritic cells and granulocytes, 
are the first line of host defense and are responsible for immediate recognition and control 
of microbial invasion. In contrast, the adaptive immune system, represented by B and T 
lymphocytes, has a delayed response, which is characterized by clonal expansion of cells 
that bind to a highly specific antigen and have immunological memory [1]. Substantial new 
evidence now indicates that epithelial cells are central participants, as initiators, mediators 
and regulators, in the innate and adaptive immune responses, as well as in the transition 
from innate immunity to adaptive immunity.    
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This new concept has been recently generated from studies mainly in skin and airway 
epithelial cells. In addition to its function as a physical barrier, human skin has been shown 
to be an important immune organ displaying various defense mechanisms, which can be 
divided into three major functional compartments: natural epithelial defense, innate 
immunity and antigen-elicited adaptive immunity [2-4]. Airway epithelial cells have been 
recognized to be at the interface of innate and adaptive immunity [5-7]. Airway epithelial 
cells produce antimicrobial host defense molecules and proinflammatory cytokines and 
chemokines in response to microbial pathogens. Recruitment of immune cells, including 
dendritic cells, T cells and B cells into the proximity of epithelium results in the 
enhancement of adaptive immunity through interactions with epithelial cells. Epithelial cells 
are also responsible for mucus production in both protective immune responses and allergic 
airway inflammatory diseases. The crucial roles of epithelial cells in the innate and adaptive 
immune responses for host defense have also been recognized in other epithelia, including 
gastrointestinal mucosa [8-10] and ocular surface [11-13]. This chapter is focused on recent 
advances of this new concept that mucosal epithelium plays a central role in initiating and 
regulating innate and adaptive immune responses in ocular inflammatory diseases, based 
on literature review and our new findings. These novel breakthroughs in mucosal 
immunology would facilitate new therapeutic strategies for treating ocular inflammatory 
diseases. 
2. Toll-like receptors and ocular mucosal innate immunity  
The innate immune response relies on evolutionarily ancient germline-encoded receptors, 
the pattern recognition receptors (PRRs) [14], which recognize highly conserved microbial 
structures (Table 1). PRRs recognize microbial components, known as pathogen-associated 
molecular patterns. A breakthrough in the understanding of the ability of innate immune 
system to rapidly recognize pathogens occurred with the discovery of the Toll-like receptors 
(TLRs), which is the most important family among the PRRs. At least 10 human TLRs have 
been identified to date. Each TLR has unique ligand specificity. In general, TLRs 1, 2, 4, 5 
and 6 present on the cell plasma membrane and respond to a variety of components of 
bacteria and fungi (Table 1); and TLRs 3, 7, 8 and 9 mainly present on endosomal 
membranes inside cells and recognize viral nucleic acids [12]. Among 4 types of 
transmembrane proteins structurally, TLRs are single-pass type I transmembrane proteins 
with leucine rich repeats in the extracellular domain for ligand recognition, and a Toll/IL-1 
receptor (TIR) domain in the cytoplasmic portion for intracellular signaling [12, 15-17]. TLRs 
are expressed on immune cells that are most likely to first encounter microbes, such as 
neutrophils, monocytes, macrophages, and dendritic cells [15]. Ligand recognition by TLRs 
facilitates the dimerisation of TLRs that triggers the activation of signaling pathways, which 
originates from the cytoplasmic TIR domain, and culminates in the activation of the nuclear 
transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), 
which leads to the expression of pro-inflammatory molecules, such as TNF-α, IL-1β, IL-6 
[16, 18-20]. In addition to innate immune cells, an array of TLRs is expressed by epithelial 
cells at interfaces between host and environment including that of the skin [2, 21], 
respiratory tract [5, 6], gastrointestinal tract [9], and ocular surface [12, 13]. Strategic 
expression of TLRs at such host/environment interfaces appears to play an important role in 
the first line of defense against microbial invasion at these sites.  
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TLR  Microbial components Ligands used for study 
TLR1/TLR2 Triacylated lipopeptide (LP) Pam3CSK4 (1-100 μg/ml) 
TLR2*    Bacterial lipoprotein  
 Peptidoglycan peptidoglycan-BS (1-50 μg/ml) 
 lipoteichoic acid LTA-SA (0.1-10 μg/ml) 
 Zymosan (fungi) Zymosan (1-100 μg/ml) 
TLR3  Double stranded RNA (viruses dsRNA) Poly I:C (5-50 μg/ml) 
TLR4  LPS (Gram negative bacteria) LPS (1-50 μg/ml) 
 Bacterial HSP60  
 Respiratory syncytial virus coat protein  
TLR5  Flagellin (flagellated bacteria) Flagellin-ST (1-25 μg/ml) 
TLR6/TLR2 Diacylated lipopeptides FSL-1 (0.1-10 μg/ml) 
TLR7 Imidazoquinolone antiviral drug Imiquimod (R837, 1-50 μg/ml ) 
TLR8 Single stranded RNA (viruses ssRNA) ssRNA40 (0.1-10 μg/ml) 
 Imidazoquinolone antiviral drug  
TLR9  Unmethylated CpG motifs of bacterial DNA C-CpG-ODN (1-50 μg/ml) 
TLR10  Unknown  
* TLR2 forms heterodimers with TLR1 and TLR6: TLR1 associates with TLR2 to recognize tri-acyl 
lipopeptides; TLR6/TLR2 heterodimer recognizes diacyl lipopeptides. 
Table 1. Human Toll-like receptors (TLRs) and their microbial ligands 
Ocular mucosal epithelial cells have been identified to express an array of functional TLRs 
[12, 13]. The production of pro-inflammatory cytokines, chemokines and antimicrobial 
peptides is stimulated via TLR2 by corneal epithelial cells exposed to yeast zymosan [22] 
and peptidoglycan of Staphylococcus aureus [23]. This pathway may have a role in the 
pathogenesis of Gram positive bacterial keratitis. Signaling through TLR9 appears 
important in P. aeruginosa keratitis, and silencing TLR9 signaling reduces inflammation, but 
likely contributes to decreased bacterial killing in the cornea [24]. Stimulation of TLR3 can 
induce the expression of proinflammatory cytokines, chemokines and antiviral genes that 
help to defend the cornea against viral infection [25, 26]. However, the distinctive role of 
ligand-stimulated TLR signaling in epithelium on regulation of innate and adaptive 
immunity remains to be elucidated. 
3. Ocular epithelial cytokine TSLP links innate and adaptive immunity via Th2 
inflammatory responses  
Compelling evidence has been recently provided that thymic stromal lymphopoietin (TSLP) 
represents a key initiator of allergic inflammation at the interface of epithelial and dendritic 
cells, and TSLP may have a determinant role in the initiation and maintenance of the allergic 
immune response in atopic dermatitis and asthma [27-31]. Skin-derived TSLP was found to 
trigger progression from epidermal-barrier defects to asthma, the atopic march, in mice  
[31, 32].  
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TSLP is a 140-amino acid IL-7-like 4-helix bundle cytokine that was first isolated from a 
murine thymic stromal cell line and shown to support B-cell development in the absence of 
IL-7 [33]. Mouse and human TSLP share a poor homology of 43% amino acid identity. The 
human TSLP gene is localized in chromosome 5q22, not far from the gene cluster encoding 
for all the Th2 cytokines, IL-4, IL-5 and IL-13 [34]. The TSLP receptor (TSLPR) complex 
consists of a TSLP binding chain and the IL-7 receptor α chain (IL-7Rα). Like TSLP, human 
and mouse TSLPR share approximately 40% amino acid identity. By interacting with the 
heterodimeric receptor TSLPR/IL-7Rα, TSLP appears to initiate phosphorylation  of signal 
transducer and activator of transcription (STAT) 3 and STAT-5 [27, 35]. 
It was demonstrated that epithelial cell-derived TSLP could strongly activate human 
myeloid dendritic cells to mature dendritic cells that produce OX40 ligand (OX40L) in the 
absence of IL-12 to induce an inflammatory Th2 response characterized by high level of pro-
inflammatory cytokine TNF-α with low level of anti-inflammatory cytokine IL-10, distinct 
from the regulatory Th2 responses characterized by low TNF-α and high IL-10 production 
[27, 28]. This suggests that TSLP represents a key initiator of allergic inflammation at the 
interface of epithelial cells and dendritic cells. TSLP was also demonstrated to direct the 
innate phase of allergic immune responses through activating mast cells. Therefore, TSLP 
and OX40L may represent important targets for intervention in the initiation of allergic 
inflammatory responses.  
Epithelial cells appear to be the major potential producer of TSLP in both mice and humans, 
although fibroblasts, smooth muscle cells, and mast cells all have the potential to produce 
TSLP [35, 36]. The expression of TSLP by epithelial cells has been recently shown to be 
stimulated by microbial ligands, inflammatory and Th2 cytokines [37-39]. Using ocular 
mucosal epithelium as a model, Li and associates [40] have evaluated the expression and 
production of TSLP by primary human corneal epithelial cells in response to 11 extracted or 
synthetic microbial components that are ligands of TLRs 1-9 (Table 1). As shown in Figure 1A, 
TSLP expression and production were found to be largely induced by the ligands to TLRs 3, 5 
and 6, which were polyinosinic-polycytidylic acid (polyI:C), flagellin and FSL-1, respectively, 
representing viral dsRNA and the bacterial components flagellin and lipopeptides. PolyI:C 
and flagellin, the major TSLP inducers, stimulated TSLP production to 67- and 19-fold, 
respectively. The TSLP mRNA reached the peak levels rapidly in 4 hours in response to these 
ligands. The specificity of this response was confirmed when respective antibody against TLR3 
or TLR5 significantly blocked TSLP expression induced by polyI:C and flagellin, respectively. 
The pattern of TLR-dependant TSLP induction indicates that human corneal epithelial cells are 
able to rapidly initiate an innate immune response to virus or bacteria through TLR-mediated 
pathways. TSLP was also moderately induced by pro-inflammatory cytokines at both mRNA 
and protein levels. TNF-α or IL-1β induced a concentration dependent increase in the TSLP 
mRNA and protein, but their stimulatory effects were much weaker than that of polyI:C and 
flagellin, which stimulated TSLP protein production over 15- and 4-fold higher, respectively, 
than TNF-α. These data suggest that TSLP induction is mainly through a TLR-dependant 
innate immune response to microbes in human ocular epithelium.  
IL-4 and IL-13, the major cytokines secreted by Th2 cells, not only moderately induced TSLP 
mRNA and protein, but also strongly synergized with microbial ligands, such as polyI:C, or 
pro-inflammatory cytokine TNF-α to promote TSLP expression and production  (Figure 1B). 
This synergized induction of TSLP was further confirmed in an ex vivo experiment model 
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using fresh human corneal epithelial tissues (Figure 1C). These findings demonstrate that 
adaptive immunity-derived Th2 cytokines are capable of amplifying the TSLP expression 
and production by the corneal epithelium, which in turn has the capability of priming Th2 
cell differentiation through dendritic cell activation [27, 28]. These findings suggest that 
blocking TSLP could be a novel strategy for treatment of allergic diseases or other TSLP-
driven conditions. 
 
Fig. 1. TLR-mediated induction of TSLP by microbial ligands, TNF-α and Th2 cytokines.  
A. TSLP induction in HCECs. The confluent primary HCECs were incubated with 50µg/ml 
polyI:C or 10µg/ml of Pam3CSK4, peptidoglycan (PGN), LTA, Zymosan, LPS, flagellin,  
FSL-1, R837, single stranded RNA (ssRNA40) or C-CpG-ODN for 4 hours for TSLP mRNA 
expression by RT-qPCR, or for 48 hours for TSLP protein in the culture supernatants by ELISA; 
B. TSLP induction in an ex vivo model of human corneal tissues. A fresh corneoscleral tissue 
was cut into 4 equal size pieces. Each quarter of corneal tissue was placed into a well of 8-
chamber slides in 150 µl of serum-free SHEM medium without or with polyI:C (50 µg/ml) or 
TNF-α (20 ng/ml) in the presence of IL-4 or IL-13 (100 ng/ml) for 24 hours. The culture 
supernatants were used for TSLP ELISA. Results shown are mean ± SD of 3 independent 
experiments. * p < 0.05; ** p < 0.01; *** P < 0.001. C. The corneal tissues were prepared for 
cryosections for TSLP immunohistochemical staining with isotype IgG as negative control. 
Although the recognition of different ligands by specific TLRs leads to activation of an 
intracellular signaling cascade in a myeloid differentiation primary response gene 88 
(MyD88)-dependent or independent fashion, all TLRs share NF-κB signal transduction 
pathways for activation of the transcription factors [20]. TNF-α is also well known to 
promote activation of the NF-κB signaling pathway [41]. TSLP induction has been observed 
through NF-κB activation in airway epithelial cells [30] and synovial fibroblasts [42]. As 
evaluated by Western blot analysis and immunofluorescent staining, NF-κB was found to be 
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TSLP [35, 36]. The expression of TSLP by epithelial cells has been recently shown to be 
stimulated by microbial ligands, inflammatory and Th2 cytokines [37-39]. Using ocular 
mucosal epithelium as a model, Li and associates [40] have evaluated the expression and 
production of TSLP by primary human corneal epithelial cells in response to 11 extracted or 
synthetic microbial components that are ligands of TLRs 1-9 (Table 1). As shown in Figure 1A, 
TSLP expression and production were found to be largely induced by the ligands to TLRs 3, 5 
and 6, which were polyinosinic-polycytidylic acid (polyI:C), flagellin and FSL-1, respectively, 
representing viral dsRNA and the bacterial components flagellin and lipopeptides. PolyI:C 
and flagellin, the major TSLP inducers, stimulated TSLP production to 67- and 19-fold, 
respectively. The TSLP mRNA reached the peak levels rapidly in 4 hours in response to these 
ligands. The specificity of this response was confirmed when respective antibody against TLR3 
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The pattern of TLR-dependant TSLP induction indicates that human corneal epithelial cells are 
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pathways. TSLP was also moderately induced by pro-inflammatory cytokines at both mRNA 
and protein levels. TNF-α or IL-1β induced a concentration dependent increase in the TSLP 
mRNA and protein, but their stimulatory effects were much weaker than that of polyI:C and 
flagellin, which stimulated TSLP protein production over 15- and 4-fold higher, respectively, 
than TNF-α. These data suggest that TSLP induction is mainly through a TLR-dependant 
innate immune response to microbes in human ocular epithelium.  
IL-4 and IL-13, the major cytokines secreted by Th2 cells, not only moderately induced TSLP 
mRNA and protein, but also strongly synergized with microbial ligands, such as polyI:C, or 
pro-inflammatory cytokine TNF-α to promote TSLP expression and production  (Figure 1B). 
This synergized induction of TSLP was further confirmed in an ex vivo experiment model 
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using fresh human corneal epithelial tissues (Figure 1C). These findings demonstrate that 
adaptive immunity-derived Th2 cytokines are capable of amplifying the TSLP expression 
and production by the corneal epithelium, which in turn has the capability of priming Th2 
cell differentiation through dendritic cell activation [27, 28]. These findings suggest that 
blocking TSLP could be a novel strategy for treatment of allergic diseases or other TSLP-
driven conditions. 
 
Fig. 1. TLR-mediated induction of TSLP by microbial ligands, TNF-α and Th2 cytokines.  
A. TSLP induction in HCECs. The confluent primary HCECs were incubated with 50µg/ml 
polyI:C or 10µg/ml of Pam3CSK4, peptidoglycan (PGN), LTA, Zymosan, LPS, flagellin,  
FSL-1, R837, single stranded RNA (ssRNA40) or C-CpG-ODN for 4 hours for TSLP mRNA 
expression by RT-qPCR, or for 48 hours for TSLP protein in the culture supernatants by ELISA; 
B. TSLP induction in an ex vivo model of human corneal tissues. A fresh corneoscleral tissue 
was cut into 4 equal size pieces. Each quarter of corneal tissue was placed into a well of 8-
chamber slides in 150 µl of serum-free SHEM medium without or with polyI:C (50 µg/ml) or 
TNF-α (20 ng/ml) in the presence of IL-4 or IL-13 (100 ng/ml) for 24 hours. The culture 
supernatants were used for TSLP ELISA. Results shown are mean ± SD of 3 independent 
experiments. * p < 0.05; ** p < 0.01; *** P < 0.001. C. The corneal tissues were prepared for 
cryosections for TSLP immunohistochemical staining with isotype IgG as negative control. 
Although the recognition of different ligands by specific TLRs leads to activation of an 
intracellular signaling cascade in a myeloid differentiation primary response gene 88 
(MyD88)-dependent or independent fashion, all TLRs share NF-κB signal transduction 
pathways for activation of the transcription factors [20]. TNF-α is also well known to 
promote activation of the NF-κB signaling pathway [41]. TSLP induction has been observed 
through NF-κB activation in airway epithelial cells [30] and synovial fibroblasts [42]. As 
evaluated by Western blot analysis and immunofluorescent staining, NF-κB was found to be 
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dramatically activated in corneal epithelial cells exposed to polyI:C, flagellin or TNF-α for 4 
hours. This activation was evidenced by nuclear translocation of p65 protein, one of the two 
proteins in NF-κB heterodimer. This p65 nuclear translocation and TSLP induction, 
stimulated by polyI:C, flagellin or TNF-α were markedly blocked by TLR3, TLR5 or TNF-α 
specific antibody, respectively, and also by quinazoline, a NF-κB activation inhibitor [40]. 
These findings confirm that TSLP is mainly induced by microbial components, 
proinflammatory cytokines and Th2 cytokines in human corneal epithelial cells via TLR and 
NF-κB signaling pathways, suggesting that epithelium-derived TSLP links the innate and 
adaptive immune responses, 
4. TSLP/OX40L/OX40 signaling initiates Th2-dominant allergic conjunctivitis 
Allergic diseases like seasonal allergy, asthma, atopic dermatitis, affect up to 20-30% of the 
population in industrialized countries, and up to 50% of these individuals reporting ocular 
allergic manifestations [43-45]. The incidence of allergies has increased steadily over the past 
30 years. Th2-dominant hypersensitivity is a major contributor to allergic inflammatory 
diseases, but the underlining mechanism for initiation of this adaptive immune disorder by 
mucosal epithelia remains a relative mystery. The molecular triggers for Th2 allergic 
inflammation were not clear until studies identified a novel epithelium-derived pro-allergic 
cytokine TSLP, which activates myeloid dendritic cells (DCs) to produce OX40 ligand 
(OX40L) that triggers a Th2 inflammatory response. TSLP has been identified as a key 
initiator in the development of human allergic disease [31, 46, 47], including asthma, atopic 
dermatitis and allergic conjunctivitis, a triad of common atopic IgE-dependent allergic 
diseases [48]. The direct link between TSLP expression and the pathogenesis of atopic 
dermatitis and asthma in vivo has been demonstrated [29]. TSLP was found to be highly 
expressed by keratinocytes in skin lesions of atopic dermatitis and was associated with 
dendritic cell activation in situ [49]. Evidence associating TSLP with human asthma has also 
been reported [29, 32]. Patients suffering from one member of the triad often show 
symptoms of one or both of the other members, suggesting a common genetic or initiating 
element in these diseases [31]. 
Using a well characterized murine model of experimental allergic conjunctivitis (EAC) 
induced by short ragweed (SRW) pollen [50, 51], Li and colleagues observed that the 
repeated topical challenges with ragweed pollen allergen generated typical signs of allergic 
conjunctivitis in the pollen-sensitized BALB/c mice, which developed lid edema, 
conjunctival redness, chemosis, and tearing, as well as frequent scratching of the eye lids 
[52]. They found that TSLP mRNA expression was significantly upregulated in the corneal 
and conjunctival epithelia from mice sensitized and challenged with pollen when compared 
with phosphate buffered saline (PBS) alone and untreated normal controls. 
Immunohistochemical staining confirmed an increase in TSLP production in the eyes 
challenged with SRW pollen. As shown in Figure 2A, the corneal and conjunctival epithelia 
in EAC BALB/c mice displayed much stronger TSLP staining throughout the entire 
epithelium, especially the superficial epithelial layers of the conjunctiva, than the PBS-
treated control. These data indicate the stimulated TSLP mRNA expression and protein 
production by ocular surface epithelia in the SRW-induced EAC murine model. 
The accumulation of CD11c positive (CD11c+) dendritic cells on the ocular surface was 
detected in this EAC model by reverse transcription and quantitative real-time polymerase  
 




Fig. 2. The stimulated production of TSLP signaling proteins and Th2-dominant 
inflammation in SRW-induced EAC model requires TLR4 and MyD88. Top panel: The 
representative images showing immunohistochemical staining of epithelial TSLP, markers 
for dendritic (CD11c) and T cells (CD4), and Th2 cytokines (IL-4, IL-5 and IL-13) on cornea 
and conjunctiva (Conj) of wild type and Tlr4 deficient BALB/c mice challenged by SRW 
pollen, with PBS-treated mice as controls (A), and of C57BL/6 based wild type MyD88+/+ 
and knockout MyD88-/- mice challenged by SRW pollen, with PBS-treated mice as controls 
(C). Bottom panel: The representative images showing immunofluorescent staining of TSLP 
activated signals, TSLPR, OX40L and OX40 on cervical lymph nodes (CLN) of wild type and 
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dramatically activated in corneal epithelial cells exposed to polyI:C, flagellin or TNF-α for 4 
hours. This activation was evidenced by nuclear translocation of p65 protein, one of the two 
proteins in NF-κB heterodimer. This p65 nuclear translocation and TSLP induction, 
stimulated by polyI:C, flagellin or TNF-α were markedly blocked by TLR3, TLR5 or TNF-α 
specific antibody, respectively, and also by quinazoline, a NF-κB activation inhibitor [40]. 
These findings confirm that TSLP is mainly induced by microbial components, 
proinflammatory cytokines and Th2 cytokines in human corneal epithelial cells via TLR and 
NF-κB signaling pathways, suggesting that epithelium-derived TSLP links the innate and 
adaptive immune responses, 
4. TSLP/OX40L/OX40 signaling initiates Th2-dominant allergic conjunctivitis 
Allergic diseases like seasonal allergy, asthma, atopic dermatitis, affect up to 20-30% of the 
population in industrialized countries, and up to 50% of these individuals reporting ocular 
allergic manifestations [43-45]. The incidence of allergies has increased steadily over the past 
30 years. Th2-dominant hypersensitivity is a major contributor to allergic inflammatory 
diseases, but the underlining mechanism for initiation of this adaptive immune disorder by 
mucosal epithelia remains a relative mystery. The molecular triggers for Th2 allergic 
inflammation were not clear until studies identified a novel epithelium-derived pro-allergic 
cytokine TSLP, which activates myeloid dendritic cells (DCs) to produce OX40 ligand 
(OX40L) that triggers a Th2 inflammatory response. TSLP has been identified as a key 
initiator in the development of human allergic disease [31, 46, 47], including asthma, atopic 
dermatitis and allergic conjunctivitis, a triad of common atopic IgE-dependent allergic 
diseases [48]. The direct link between TSLP expression and the pathogenesis of atopic 
dermatitis and asthma in vivo has been demonstrated [29]. TSLP was found to be highly 
expressed by keratinocytes in skin lesions of atopic dermatitis and was associated with 
dendritic cell activation in situ [49]. Evidence associating TSLP with human asthma has also 
been reported [29, 32]. Patients suffering from one member of the triad often show 
symptoms of one or both of the other members, suggesting a common genetic or initiating 
element in these diseases [31]. 
Using a well characterized murine model of experimental allergic conjunctivitis (EAC) 
induced by short ragweed (SRW) pollen [50, 51], Li and colleagues observed that the 
repeated topical challenges with ragweed pollen allergen generated typical signs of allergic 
conjunctivitis in the pollen-sensitized BALB/c mice, which developed lid edema, 
conjunctival redness, chemosis, and tearing, as well as frequent scratching of the eye lids 
[52]. They found that TSLP mRNA expression was significantly upregulated in the corneal 
and conjunctival epithelia from mice sensitized and challenged with pollen when compared 
with phosphate buffered saline (PBS) alone and untreated normal controls. 
Immunohistochemical staining confirmed an increase in TSLP production in the eyes 
challenged with SRW pollen. As shown in Figure 2A, the corneal and conjunctival epithelia 
in EAC BALB/c mice displayed much stronger TSLP staining throughout the entire 
epithelium, especially the superficial epithelial layers of the conjunctiva, than the PBS-
treated control. These data indicate the stimulated TSLP mRNA expression and protein 
production by ocular surface epithelia in the SRW-induced EAC murine model. 
The accumulation of CD11c positive (CD11c+) dendritic cells on the ocular surface was 
detected in this EAC model by reverse transcription and quantitative real-time polymerase  
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inflammation in SRW-induced EAC model requires TLR4 and MyD88. Top panel: The 
representative images showing immunohistochemical staining of epithelial TSLP, markers 
for dendritic (CD11c) and T cells (CD4), and Th2 cytokines (IL-4, IL-5 and IL-13) on cornea 
and conjunctiva (Conj) of wild type and Tlr4 deficient BALB/c mice challenged by SRW 
pollen, with PBS-treated mice as controls (A), and of C57BL/6 based wild type MyD88+/+ 
and knockout MyD88-/- mice challenged by SRW pollen, with PBS-treated mice as controls 
(C). Bottom panel: The representative images showing immunofluorescent staining of TSLP 
activated signals, TSLPR, OX40L and OX40 on cervical lymph nodes (CLN) of wild type and 
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Tlr4 deficient BALB/c mice challenged by SRW pollen with PBS-treated mice as controls (B), 
and of C57BL/6 based wild type MyD88+/+ and knockout MyD88-/- mice challenged by SRW 
pollen, with PBS-treated mice as controls (D). Bar: 20µm; Arrows: red or red brown positive 
staining signals. 
chain reaction (RT-qPCR) and immunostaining. The increased mRNA levels of CD11c, 
TSLPR and OX40L were observed in ocular surface, especially in conjunctival tissues, where 
their transcripts increased to 4-10 fold, respectively (P< 0.05 or <0.01), from SRW pollen-
challenged mice, compared with PBS controls. The large amount of CD11c+ dendritic cells 
was accumulated in the ocular surface of the pollen challenged eyes, primarily in the stroma 
subjacent to the conjunctival epithelia, in EAC mice, but not in the control mice treated with 
PBS (Figure 2A). These results suggest that ocular surface was infiltrated with TSLP 
activated dendritic cells that express TSLPR and produce OX40L in the EAC mice. 
Th2-dominant inflammatory response was clearly observed on ocular surface in the mice 
challenged by pollen. The infiltration of T lymphocytes was evidenced by the increased CD4 
mRNA expression and a markedly increased number of CD4 immunopositive (CD4+) cells 
in the ocular surface, especially in the conjunctiva, of EAC mice (Figure 2A), when 
compared with PBS control mice. These CD4+ T cells appear to be Th2 lineage because the 
transcripts of three key Th2 cytokines, IL-4, IL-5 and IL-13, were all found to be expressed at 
significantly higher levels in corneal and conjunctival tissues from the EAC mice than the 
PBS controls. Immunostaining data confirmed that the IL-4, IL-5 and IL-13-producing Th2 
cells were largely infiltrated in conjunctival stroma (Figure 2A).  
To confirm the TSLP signaling in SRW pollen-induced EAC mice, the ocular surface 
draining cervical lymph nodes (CLN) were collected for evaluation (Figure 3A). Compared 
with PBS controls, the mRNA levels of TSLPR and OX40L were significantly stimulated to 
7.5 and 4.1 fold respectively (both P<0.01) while CD11c expression only slightly increased in 
CLN from EAC mice, indicating CD11c+ DCs were markedly activated by ocular surface 
epithelia-derived TSLP. The mRNA levels of OX40 (3.4 fold, P<0.05) and Th2 cytokines, IL-4, 
IL-5 and IL-13 (13.2, 12.8 and 5.5 fold, respectively, all P<0.01), significantly increased while 
CD4 expression was not changed in the CLN from EAC mice, indicating naive CD4+ T cells 
were largely differentiated to Th2 cells that might be primed by OX40L produced by TSLP 
activated dendritic cells [28]. The increased TSLPR+, OX40L+ and OX40+ cells in the draining 
CLN of the pollen challenged EAC mice were further confirmed by immunofluorescent 
staining that showed dramatically increased immunoreactivity of these 3 signaling proteins 
at cell membrane and cytoplasm in CLN (Figure 2B). All these results demonstrate that 
TSLP/OX40L/OX40 signaling plays a critical role in the development of Th2-dominant 
allergic inflammation in pollen induced EAC model in BALB/c mice, suggesting that TSLP 
signaling molecules could be novel therapeutic targets to treat allergic inflammatory 
disease. 
5. Cutting edge breakthrough: Short ragweed pollen triggers ocular allergic 
inflammation through TLR4-dependent innate immune response 
Although there have been numerous studies on the development of allergen-induced 
inflammation, the mechanisms leading to resolution of allergic inflammation remain poorly 
understood. This represents an important knowledge gap and potential challenge because 
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failure to resolve allergen driven inflammation potentially leads to recurrent or chronic allergic 
diseases. Pollen, a ubiquitous allergen, affects a large population of allergic patients. Pollen is 
the trigger of seasonal rhinitis, conjunctivitis and asthma, as well as an exacerbating factor of 
atopic dermatitis. However, the underlying molecular mechanism by which pollen induces 
Th2-dominant allergic inflammation via epithelial innate immunity pathways is largely 
unknown. Substantial evidence now indicates that epithelial cells are central participants in 
innate and adaptive immune responses [4, 5, 7]. Based on the observation that we and other 
groups have made [40, 53, 54] that TSLP is mainly induced via TLR mediated innate response 
in epithelia exposed to microbial products, we hypothesized that pollen, such as Ambrosia 
artemisiifolia short ragweed (SRW), the most widespread plant in North America, may serve 
as a functional TLR4 agonist that induces production of a proallergic cytokine TSLP via innate 
immune response to trigger Th2-dominant allergic inflammation. To uncover the novel 
phenomenon and molecular signaling pathways involved in pollen induced allergic 
inflammation, a comprehensive set of experiments has been conducted using a well-
characterized murine model of allergic conjunctivitis induced by SRW pollen in BALB/c, TLR4 
deficient and MyD88 knockout mice, as well as a murine topical ocular surface challenge 
model and a culture model of primary human corneal epithelial cells exposed to an aqueous 
extract of defatted SRW pollen. 
TLR-mediated TSLP induction has been recognized [39, 53, 54]. We have demonstrated that 
TSLP was largely induced by specific TLR ligands in human corneal epithelial cells [40]. 
MyD88 is a universal adapter protein necessary for response to all TLRs except TLR3 [55, 
56]. Tlr4-deficient (Tlr4-d, C.C3-Tlr4Lps-d/J) and MyD88 knockout (MyD88-/-) mice have 
been used to identify TLR4 mediated signaling [57, 58]. To explore whether SRW pollen 
stimulates TSLP through TLR4-dependent innate response, we sensitized and topically 
challenged the wild-type BALB/c, Tlr4-d (Jackson Laboratory, Bar Harbor, ME) and MyD88-
/- mice (gifts from Dr. Shizuo Akira, Research Institute for Microbial Disease, Osaka 
University, Japan) with SRW pollen. 
Compared with wild-type BALB/c mice, the ocular allergic signs, stimulated 
TSLP/OX40L/OX40 signaling and Th2-dominant inflammatory response by ocular mucosa, 
especially conjunctival tissues, were dramatically reduced or eliminated in BALB/c based 
Tlr4-d mice. As shown in Figure 3A, the mRNA levels of TSLP, OX40L, OX40 and Th2 
cytokines (IL-4, IL-5 and IL-13) were significantly stimulated in cornea, conjunctiva and 
draining CLN from wild-type BALB/c, but not in those from Tlr4-d mice. The 
immunostaining results confirmed that SRW pollen did not stimulate TSLP and its 
downstream molecules or a Th2 response in ocular mucosal tissues (Figure. 2A) and 
draining CLN (Figure. 2B) of Tlr4-d mice. These findings suggest that TLR4-dependent 
TSLP signaling was involved in the SRW pollen induced allergic inflammation. 
The SRW topical challenges triggered the typical allergic signs and scratching behavior in 
wild type MyD88+/+ mice, although less severe than BALB/c mice. The expression of TSLP 
and its signaling molecules, TSLPR, OX40L and OX40, as well as Th2 cytokines IL-4, IL-5 
and IL-13 was significantly stimulated in the cornea, conjunctiva and CLN from SRW 
challenged wild type MyD88+/+ mice at both mRNA (Figure. 3B) and protein levels (Figure 
2C, 2D). Clinical allergic signs and stimulated production of TSLP signaling molecules 
(TSLPR, OX40L and OX40) and Th2 cytokines (IL-4, IL-5 and IL-13) were dramatically 
reduced or eliminated in SRW challenged MyD88-/- mice as evaluated by RT-qPCR (Figure 
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Tlr4 deficient BALB/c mice challenged by SRW pollen with PBS-treated mice as controls (B), 
and of C57BL/6 based wild type MyD88+/+ and knockout MyD88-/- mice challenged by SRW 
pollen, with PBS-treated mice as controls (D). Bar: 20µm; Arrows: red or red brown positive 
staining signals. 
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challenged mice, compared with PBS controls. The large amount of CD11c+ dendritic cells 
was accumulated in the ocular surface of the pollen challenged eyes, primarily in the stroma 
subjacent to the conjunctival epithelia, in EAC mice, but not in the control mice treated with 
PBS (Figure 2A). These results suggest that ocular surface was infiltrated with TSLP 
activated dendritic cells that express TSLPR and produce OX40L in the EAC mice. 
Th2-dominant inflammatory response was clearly observed on ocular surface in the mice 
challenged by pollen. The infiltration of T lymphocytes was evidenced by the increased CD4 
mRNA expression and a markedly increased number of CD4 immunopositive (CD4+) cells 
in the ocular surface, especially in the conjunctiva, of EAC mice (Figure 2A), when 
compared with PBS control mice. These CD4+ T cells appear to be Th2 lineage because the 
transcripts of three key Th2 cytokines, IL-4, IL-5 and IL-13, were all found to be expressed at 
significantly higher levels in corneal and conjunctival tissues from the EAC mice than the 
PBS controls. Immunostaining data confirmed that the IL-4, IL-5 and IL-13-producing Th2 
cells were largely infiltrated in conjunctival stroma (Figure 2A).  
To confirm the TSLP signaling in SRW pollen-induced EAC mice, the ocular surface 
draining cervical lymph nodes (CLN) were collected for evaluation (Figure 3A). Compared 
with PBS controls, the mRNA levels of TSLPR and OX40L were significantly stimulated to 
7.5 and 4.1 fold respectively (both P<0.01) while CD11c expression only slightly increased in 
CLN from EAC mice, indicating CD11c+ DCs were markedly activated by ocular surface 
epithelia-derived TSLP. The mRNA levels of OX40 (3.4 fold, P<0.05) and Th2 cytokines, IL-4, 
IL-5 and IL-13 (13.2, 12.8 and 5.5 fold, respectively, all P<0.01), significantly increased while 
CD4 expression was not changed in the CLN from EAC mice, indicating naive CD4+ T cells 
were largely differentiated to Th2 cells that might be primed by OX40L produced by TSLP 
activated dendritic cells [28]. The increased TSLPR+, OX40L+ and OX40+ cells in the draining 
CLN of the pollen challenged EAC mice were further confirmed by immunofluorescent 
staining that showed dramatically increased immunoreactivity of these 3 signaling proteins 
at cell membrane and cytoplasm in CLN (Figure 2B). All these results demonstrate that 
TSLP/OX40L/OX40 signaling plays a critical role in the development of Th2-dominant 
allergic inflammation in pollen induced EAC model in BALB/c mice, suggesting that TSLP 
signaling molecules could be novel therapeutic targets to treat allergic inflammatory 
disease. 
5. Cutting edge breakthrough: Short ragweed pollen triggers ocular allergic 
inflammation through TLR4-dependent innate immune response 
Although there have been numerous studies on the development of allergen-induced 
inflammation, the mechanisms leading to resolution of allergic inflammation remain poorly 
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failure to resolve allergen driven inflammation potentially leads to recurrent or chronic allergic 
diseases. Pollen, a ubiquitous allergen, affects a large population of allergic patients. Pollen is 
the trigger of seasonal rhinitis, conjunctivitis and asthma, as well as an exacerbating factor of 
atopic dermatitis. However, the underlying molecular mechanism by which pollen induces 
Th2-dominant allergic inflammation via epithelial innate immunity pathways is largely 
unknown. Substantial evidence now indicates that epithelial cells are central participants in 
innate and adaptive immune responses [4, 5, 7]. Based on the observation that we and other 
groups have made [40, 53, 54] that TSLP is mainly induced via TLR mediated innate response 
in epithelia exposed to microbial products, we hypothesized that pollen, such as Ambrosia 
artemisiifolia short ragweed (SRW), the most widespread plant in North America, may serve 
as a functional TLR4 agonist that induces production of a proallergic cytokine TSLP via innate 
immune response to trigger Th2-dominant allergic inflammation. To uncover the novel 
phenomenon and molecular signaling pathways involved in pollen induced allergic 
inflammation, a comprehensive set of experiments has been conducted using a well-
characterized murine model of allergic conjunctivitis induced by SRW pollen in BALB/c, TLR4 
deficient and MyD88 knockout mice, as well as a murine topical ocular surface challenge 
model and a culture model of primary human corneal epithelial cells exposed to an aqueous 
extract of defatted SRW pollen. 
TLR-mediated TSLP induction has been recognized [39, 53, 54]. We have demonstrated that 
TSLP was largely induced by specific TLR ligands in human corneal epithelial cells [40]. 
MyD88 is a universal adapter protein necessary for response to all TLRs except TLR3 [55, 
56]. Tlr4-deficient (Tlr4-d, C.C3-Tlr4Lps-d/J) and MyD88 knockout (MyD88-/-) mice have 
been used to identify TLR4 mediated signaling [57, 58]. To explore whether SRW pollen 
stimulates TSLP through TLR4-dependent innate response, we sensitized and topically 
challenged the wild-type BALB/c, Tlr4-d (Jackson Laboratory, Bar Harbor, ME) and MyD88-
/- mice (gifts from Dr. Shizuo Akira, Research Institute for Microbial Disease, Osaka 
University, Japan) with SRW pollen. 
Compared with wild-type BALB/c mice, the ocular allergic signs, stimulated 
TSLP/OX40L/OX40 signaling and Th2-dominant inflammatory response by ocular mucosa, 
especially conjunctival tissues, were dramatically reduced or eliminated in BALB/c based 
Tlr4-d mice. As shown in Figure 3A, the mRNA levels of TSLP, OX40L, OX40 and Th2 
cytokines (IL-4, IL-5 and IL-13) were significantly stimulated in cornea, conjunctiva and 
draining CLN from wild-type BALB/c, but not in those from Tlr4-d mice. The 
immunostaining results confirmed that SRW pollen did not stimulate TSLP and its 
downstream molecules or a Th2 response in ocular mucosal tissues (Figure. 2A) and 
draining CLN (Figure. 2B) of Tlr4-d mice. These findings suggest that TLR4-dependent 
TSLP signaling was involved in the SRW pollen induced allergic inflammation. 
The SRW topical challenges triggered the typical allergic signs and scratching behavior in 
wild type MyD88+/+ mice, although less severe than BALB/c mice. The expression of TSLP 
and its signaling molecules, TSLPR, OX40L and OX40, as well as Th2 cytokines IL-4, IL-5 
and IL-13 was significantly stimulated in the cornea, conjunctiva and CLN from SRW 
challenged wild type MyD88+/+ mice at both mRNA (Figure. 3B) and protein levels (Figure 
2C, 2D). Clinical allergic signs and stimulated production of TSLP signaling molecules 
(TSLPR, OX40L and OX40) and Th2 cytokines (IL-4, IL-5 and IL-13) were dramatically 
reduced or eliminated in SRW challenged MyD88-/- mice as evaluated by RT-qPCR (Figure 
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3B) and immunostaining (Figure 2C, 2D). These findings suggest that MyD88 pathway is 
involved in the TLR4-dependent TSLP signaling induced by SRW pollen. 
 
 
Fig. 3. The stimulated expression of TSLP signaling molecules and Th2 cytokines in SRW-
induced EAC model requires TLR4 and MyD88. The mRNA expression of proallergic 
cytokine TSLP, its downstream signals in dendritic (TSLPR, OX40L, & CD11c) and T cells 
(OX40 & CD4), as well as Th2 cytokines (IL-4, IL-5 and IL-13) by corneal epithelium, 
conjunctiva and cervical lymph nodes in wild type and Tlr4 deficient BALB/c mice 
sensitized and topically challenged by SRW with PBS-treated mice as controls (A), and in 
C57BL/6 based wild type MyD88+/+ and knockout MyD88-/- mice, sensitized and topically 
challenged by SRW pollen, with PBS-treated mice as controls (B). The mRNA levels are 
presented as relative fold in EAC mice over the controls, which were evaluated by RT and 
real-time qPCR using TaqMan gene expression assay system with GAPDH as an internal 
control. Results shown are the Mean ± SD of four independent experiments. *P<0.05, 
**P<0.01; n=4, compared with PBS controls; P<0.05, P<0.01, n=4, compared with wild 
type mice. 
To confirm that SRW pollen directly stimulates TSLP production by ocular mucosal 
epithelia through TLR4-dependent innate immunity pathway, we created a topical 
challenge murine model using an aqueous extract of defatted SRW pollen (SRWe) at 
150µg/5µl/eye for 4-24 hours. TSLP mRNA was induced as early as 4 hours and reached 
peak levels at 8 hours, and TSLP protein levels increased in 24 hours in ocular epithelia 
exposed to SRWe. As shown in Figure 4 A & B, SRWe significantly stimulated TSLP mRNA 
by 2 fold in corneal and conjunctival epithelia (Both P<0.05), and its protein levels by 3.2 
fold (from 150.2±37.6 pg/mg cellular protein to 480.00±89.6 pg/mg) in cornea epithelia and 
2.2 fold (from 128.6±29.8 pg/mg to 281.6±19.3 pg/mg) in conjunctiva in BALB/c mice when 
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compared with untreated or PBS-treated controls. The SRWe-stimulated TSLP were 
significantly decreased at both mRNA and protein levels by TLR4 blocker, a rat anti-mouse 
TLR4 antibody, but not by its isotype rat IgG2a.  
The SRWe topical challenge did not increase TSLP mRNA (Figure 4C) and protein levels 
(Figure 4D) in corneal and conjunctival epithelia of Tlr4-d mice. Similarly, a TLR4 agonist 
lipopolysaccharides (LPS, 5µg/5µl/eye) stimulated TSLP production by corneal and 
conjunctival epithelia in BALB/c mice, but not in Tlr4-d mice. Furthermore, we applied this 
topical challenge model to MyD88 knockout mice and their wild type controls. SRWe  
 
Fig. 4. Aqueous extract of defatted SRW pollen (SRWe) induces TSLP expression and 
production by murine ocular surface epithelia through TLR4- and MyD88-dependent innate 
immunity pathway. A, B. BALB/c mice were topically instilled with SRWe at 
150µg/5µl/eye for 6 or 24 hours for TSLP mRNA (A) or protein (B) respectively, without or 
with pre-instilled rat anti-mouse TLR4 antibody (1µg/5µl/eye) or its isotype rat IgG2a. 
Untreated (UT) and PBS-treated mice were used as controls. Corneal epithelium and 
conjunctiva were harvested for TSLP mRNA and protein by RT-qPCR and ELISA 
respectively. C, D. TSLP mRNA (C) and protein (D) induction by topically challenged SRWe 
or LPS (5µg/5µl/eye) in wild type and Tlr4-d BALB/C mice, with untreated or PBS-treated 
mice as controls. E, F. TSLP mRNA (E) and protein (F) induction by topically challenged 
SRWe or LPS in wild type MyD88+/+ and knockout MyD88-/- mice, with untreated or PBS-
treated mice as controls. Results shown are the Mean ± SD of four independent experiments. 
*P<0.05, **P<0.01; n=4, compared with PBS controls. 
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3B) and immunostaining (Figure 2C, 2D). These findings suggest that MyD88 pathway is 
involved in the TLR4-dependent TSLP signaling induced by SRW pollen. 
 
 
Fig. 3. The stimulated expression of TSLP signaling molecules and Th2 cytokines in SRW-
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control. Results shown are the Mean ± SD of four independent experiments. *P<0.05, 
**P<0.01; n=4, compared with PBS controls; P<0.05, P<0.01, n=4, compared with wild 
type mice. 
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by 2 fold in corneal and conjunctival epithelia (Both P<0.05), and its protein levels by 3.2 
fold (from 150.2±37.6 pg/mg cellular protein to 480.00±89.6 pg/mg) in cornea epithelia and 
2.2 fold (from 128.6±29.8 pg/mg to 281.6±19.3 pg/mg) in conjunctiva in BALB/c mice when 
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compared with untreated or PBS-treated controls. The SRWe-stimulated TSLP were 
significantly decreased at both mRNA and protein levels by TLR4 blocker, a rat anti-mouse 
TLR4 antibody, but not by its isotype rat IgG2a.  
The SRWe topical challenge did not increase TSLP mRNA (Figure 4C) and protein levels 
(Figure 4D) in corneal and conjunctival epithelia of Tlr4-d mice. Similarly, a TLR4 agonist 
lipopolysaccharides (LPS, 5µg/5µl/eye) stimulated TSLP production by corneal and 
conjunctival epithelia in BALB/c mice, but not in Tlr4-d mice. Furthermore, we applied this 
topical challenge model to MyD88 knockout mice and their wild type controls. SRWe  
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production by murine ocular surface epithelia through TLR4- and MyD88-dependent innate 
immunity pathway. A, B. BALB/c mice were topically instilled with SRWe at 
150µg/5µl/eye for 6 or 24 hours for TSLP mRNA (A) or protein (B) respectively, without or 
with pre-instilled rat anti-mouse TLR4 antibody (1µg/5µl/eye) or its isotype rat IgG2a. 
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promoted TSLP production by ocular epithelia at both mRNA (Figure 4E) and protein levels 
(Figure 4F) only in MyD88+/+ mice, but not in MyD88-/- mice, a similar pattern to that 
observed following LPS topical challenge. Taken together, these data demonstrated that 
SRWe directly stimulates TSLP production by ocular mucosal epithelia via a TLR4-
dependent innate pathway. 
To explore whether this phenomenon occurs in humans, we investigated TSLP expression in 
human corneal epithelium. TSLP mRNA was upregulated at 4 hours and its protein was 
detected at 24 hours in human corneal epithelial cells (HCECs) exposed to SRWe, which is 
consistent with our previous report [40]. TSLP induction at mRNA (Figure 5A) and protein 
levels (Figure 5B) was concentration-dependently stimulated by SRWe in primary HCECs. 
TSLP protein was barely detectable (4.83±1.60 pg/ml) in the supernatant of normal HCEC 
cultures. SRWe at 10µg/ml increased the TSLP protein to 48.92±4.23 pg/ml (P<0.01), the 
levels comparable to that stimulated by 10ng/ml of TNF-α in HCECs [40]. The SRWe 
(10µg/ml)-stimulated TSLP mRNA was significantly blocked by pre-incubation of cells with 
10µg/ml of neutralizing monoclonal antibody against human TLR4, but not by its isotype 
mouse IgG2a k (Figure 5C). Furthermore, SRWe stimulated TSLP expression was also 
significantly inhibited by quinazoline, a NF-κB Activation Inhibitor (Figure 5C). These 
findings were confirmed by detection of increased TSLP protein levels as shown in Figure 
5D. These data demonstrate that SRW induces TSLP production in human corneal epithelial 
cells through TLR4 and NF-κB innate signaling pathways. 
 
Fig. 5. SRWe induces TSLP expression and production by human corneal epithelial cells 
(HCECs) through TLR4 and NF-κB signaling pathways. A, B. Confluent cultures of primary 
HCECs were treated with 0.1 to 50 µg/ml of SRWe for 4 hours for TSLP mRNA or 48 hours 
for TSLP protein in the supernatants. C, D. HCECs were pre-incubated with mouse TLR4 
antibody (10µg/ml), isotype mouse IgG2a k, or NF-κB activation inhibitor quinazoline 
(NFkB-I, 10µM) for 1 hour before adding 10µg/ml SRWe for 4 hours for TSLP mRNA or 48 
hours for TSLP protein in the supernatants. Results shown are the Mean ± SD of four 
independent experiments. *P<0.05, **P<0.01; n=4. 
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Traditionally, TLRs recognize conserved microbial components as ligands or agonists. Recent 
studies have revealed that TLR4 recognizes a wider variety of ligands than previous thought. 
In addition to its first identified ligand, bacterial LPS, TLR4 was found to recognize certain 
viral proteins such as the F protein from respiratory syncytial virus and mouse mammary 
tumor virus. Not limited to pathogen-associated molecular patterns (PAMP), TLR4 responds 
to human endogenous structural proteins derived from tissue injury or during inflammation, 
the damage-associated molecular patterns (DAMP), such as type III repeat extra domain A of 
fibronectin, oligosaccharides of hyaluronic acid, human heat-shock protein Hsp60 and Hsp70 
(see review [59]). A few reports have revealed the potential for protein extracts from plants 
and herbs to activate TLR4, such as taxol, an antitumor agent derived from the Yew plant [60], 
and aqueous extract of Rhodiola imbricata rhizome, a medicinal plant [61]. 
In conclusion, we have for the first time uncovered a novel phenomenon and a unknown 
mechanism that short ragweed pollen, serving as a functional TLR4 agonist, induces 
TSLP/OX40L/OX40 signaling to trigger Th2-dominant allergic inflammation via TLR4-
dependent innate immunity pathways [62]. These novel findings shed light on the 
understanding of innate mucosal epithelial immunity involved in allergic inflammation, and 
may create new therapeutic targets to cure allergic disease. 
6. Epithelium-derived interleukin 33 initiates allergic inflammation 
The IL-1 receptor family has several members, including the classical IL-1 receptor (IL-1R) 
and the IL-18 receptor (IL-18R). In 1989, one member of the family, ST2, a protein encoded 
by IL-1 receptor-like 1 (IL-1RL1) gene, was identified as an orphan receptor [63]. 
Investigation into the function of ST2 revealed its participation in inflammatory processes, 
particularly regarding mast cells, type 2 CD4+ T helper cells and the production of Th2-
associated cytokines. In fact, ST2 was characterized as a specific cellular marker that 
differentiated Th2 from Th1 T cells. Clinical and experimental observations led to the 
association of ST2 with disease entities such as asthma, pulmonary fibrosis, rheumatoid 
arthritis, collagen vascular diseases and septic shock [64]. In 2005, the discovery of IL‑33 as a 
ST2 ligand provided new insights into ST2 signaling [65]. By binding to ST2 receptor, IL-33 
can activate Th2 cells and mast cells to secrete the proinflammatory and Th2 cytokines and 
chemokines that lead to severe pathological changes in mucosal organs [66]. 
IL-33 is produced mainly by epithelial and endothelial cells, fibroblast, and others [66-68]. 
IL-33 expression has been found to be up-regulated by stimulation with inflammatory 
cytokines, TNF-α and IL-1β [69]. However, the expression and regulation of IL-33 by 
mucosal surface epithelia has not been well elucidated. Using fresh donor corneal tissues 
and primary HCECs, we recently observed that IL-33 is mainly expressed by epithelium and 
largely induced by microbial products through TLR and NF-κB signaling pathways [70]. 
The findings suggest that the mucosal epithelial cell-derived cytokine IL-33 may play an 
important role in allergic inflammatory diseases through innate immune responses. 
As shown in Figure 6A, IL-33 expression and production were largely induced by polyI:C, 
lipopolysaccharides (LPS), flagellin, FSL-1 and R837, the ligands for TLR3, -4, -5, -6 and -7, 
representing viral dsRNA and the bacterial components flagellin and lipopeptides, 
respectively. PolyI:C and flagellin were major IL-33 inducers, stimulating IL-33 production 
by 7- and 4-fold, respectively, with the peak mRNA levels at 8 hours by HCECs. The IL-33 
induction by these 2 ligands was further confirmed using an ex vivo donor corneal tissue 
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promoted TSLP production by ocular epithelia at both mRNA (Figure 4E) and protein levels 
(Figure 4F) only in MyD88+/+ mice, but not in MyD88-/- mice, a similar pattern to that 
observed following LPS topical challenge. Taken together, these data demonstrated that 
SRWe directly stimulates TSLP production by ocular mucosal epithelia via a TLR4-
dependent innate pathway. 
To explore whether this phenomenon occurs in humans, we investigated TSLP expression in 
human corneal epithelium. TSLP mRNA was upregulated at 4 hours and its protein was 
detected at 24 hours in human corneal epithelial cells (HCECs) exposed to SRWe, which is 
consistent with our previous report [40]. TSLP induction at mRNA (Figure 5A) and protein 
levels (Figure 5B) was concentration-dependently stimulated by SRWe in primary HCECs. 
TSLP protein was barely detectable (4.83±1.60 pg/ml) in the supernatant of normal HCEC 
cultures. SRWe at 10µg/ml increased the TSLP protein to 48.92±4.23 pg/ml (P<0.01), the 
levels comparable to that stimulated by 10ng/ml of TNF-α in HCECs [40]. The SRWe 
(10µg/ml)-stimulated TSLP mRNA was significantly blocked by pre-incubation of cells with 
10µg/ml of neutralizing monoclonal antibody against human TLR4, but not by its isotype 
mouse IgG2a k (Figure 5C). Furthermore, SRWe stimulated TSLP expression was also 
significantly inhibited by quinazoline, a NF-κB Activation Inhibitor (Figure 5C). These 
findings were confirmed by detection of increased TSLP protein levels as shown in Figure 
5D. These data demonstrate that SRW induces TSLP production in human corneal epithelial 
cells through TLR4 and NF-κB innate signaling pathways. 
 
Fig. 5. SRWe induces TSLP expression and production by human corneal epithelial cells 
(HCECs) through TLR4 and NF-κB signaling pathways. A, B. Confluent cultures of primary 
HCECs were treated with 0.1 to 50 µg/ml of SRWe for 4 hours for TSLP mRNA or 48 hours 
for TSLP protein in the supernatants. C, D. HCECs were pre-incubated with mouse TLR4 
antibody (10µg/ml), isotype mouse IgG2a k, or NF-κB activation inhibitor quinazoline 
(NFkB-I, 10µM) for 1 hour before adding 10µg/ml SRWe for 4 hours for TSLP mRNA or 48 
hours for TSLP protein in the supernatants. Results shown are the Mean ± SD of four 
independent experiments. *P<0.05, **P<0.01; n=4. 
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model (Figure 6B). The specificity of TLR-dependent response by HCECs was also 
confirmed when an antibody against TLR3 or TLR5 significantly inhibited IL-33 expression 
by polyI:C or flagellin respectively (Figure 6C). The pattern of TLR-dependent IL-33 
induction indicates that HCECs are able to rapidly initiate an innate immune response to 
virus or bacteria, and play an important role in allergic inflammatory disease. 
 
Fig. 6. TLR-dependent induction of IL-33 by microbial ligands in human corneal epithelium. 
A. IL-33 mRNA and protein levels induced by primary human corneal epithelial cells 
(HCECs) exposed to 50μg/ml polyI:C or 10μg/ml of Pam3CSK4, peptidoglycan (PGN), 
polyI:C, LPS, flagellin, FSL-1, R-837, ssRNA40 or C-CpG-ODN for 8 or 48 hours, evaluated 
by quantitative real-time PCR or ELISA, respectively. Results shown are the mean ± SD of 
four independent experiments. *P< 0.05; **P < 0.01. B. The immunohistochemical staining 
showing IL-33 induction in an ex vivo human corneal tissues by polyI:C (50μg/ml) or 
flagellin (10μg/ml) for 24 hours with isotype IgG as a negative control. C. TLR and NF-κB 
signaling pathways involved in IL-33 induction by polyI:C or flagellin in HCECs exposed to 
polyI:C (50μg/mL) or flagellin (10μg/mL) in the absence or presence of preincubated rabbit 
TLR3Ab (10μg/mL), TLR5Ab (10μg/mL), BAY11-7082 (10μM) or quinazoline (10μM) for 1 
hour, and Pepinh-MYD (40μM) or Pepinh-TRIF (40μM) for 6 hours. The cultures treated by 
ligands for 8 hours for IL-33 mRNA, or for 48 hours for IL-33 protein by ELISA and by 
Western blot with β-actin as control (D). Results shown are the mean ± SD of four 
independent experiments. *P< 0.05; **P < 0.01. 
IL-33 is an extracellular inflammatory cytokine while it also acts as a nuclear transcription 
factor [71]. It has been shown that IL-33 is mainly localized to the nucleus of endothelial cells 
and bound to chromatin. IL-33 mRNA is primarily translated and synthesized in vivo as a 
30-kDa precursor, a pro-IL-33 protein. As a member of IL-1 super family and like IL-1 and 
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IL-18, pro-IL-33 protein sequence does not have a signal peptide that directs it for secretion 
via the ER–Golgi pathway [66, 72]. Like pro-IL-1β, human pro-IL-33 was reported to be 
cleaved by caspase-1 to generate active form, an 18-kDa fragment (mature IL-33), which is 
sufficient to activate signaling via the IL-33 receptor ST2. Recombinant mature IL-33 has 
been known to induce Th2-associated cytokines and inflammatory cytokines via its receptor, 
ST2 [72, 73]. However, processing of pro-IL-33 in vivo has not been clarified yet. It is not 
clear whether caspase-1 cleavage of pro-IL-33 occurs in vivo and whether, as for IL-1β, this 
cleavage is a prerequisite for IL-33 secretion and bioactivity. 
Our data have showed that no significantly changes of IL-33 protein levels can be detected 
by ELISA in the culture supernatants, other than in cell lysate, of the HCECs. IL-33 protein 
levels significantly increased in the cell lysate, but not in the culture supernatants, of HCECs 
exposed to polyI:C or flagellin for 24-48 hours, when compared with the untreated control. 
However, the stimulated cellular IL-33 protein was released outside the cells into culture 
supernatant after co-incubation with ATP for additional 30 minutes, as evaluated by ELISA 
and Western blot analysis [70]. The finding supports a notion that caspase 1-dependant 
activation may involved in the release and secretion of IL-33 protein since ATP has been 
known to activate caspase-1 through triggering the P2X7 receptor [74]. Further studies are 
necessary to clarify the underlining mechanism.  
As shown in Figure 6C evaluated by RT-qPCR and ELISA, as well as in Figure 6D by 
Western blotting, synthetic dsRNA polyI:C-induced IL-33 mRNA expression and protein 
production were markedly blocked by TLR3 antibody and TIR-domain-containing adaptor 
inducing interferon (TRIF) inhibitory peptide (Pepinh-TRIF), but not by TLR5 antibody or 
MyD88 inhibitory peptide (Pepinh-MYD), while extracted bacterial component flagellin-
induced IL-33 production was dramatically suppressed by TLR5 antibody and Pepinh-
MYD, but not by TLR3 antibody or Pepinh-TRIF, in corneal epithelial cells. The stimulated 
IL-33 induction by polyI:C or flagellin were also significantly blocked by IκB-α inhibitor 
BAY11-7082 or NF-κB activation inhibitor quinazoline. Further study has shown that NF-κB 
was dramatically activated with p65 protein nuclear translocation in corneal epithelial cells 
exposed to polyI:C or flagellin for 4 hours, as evaluated by Western blot analysis and 
immunofluorescent staining. BAY 11 selectively inhibits the phosphorylation and 
degradation of IκB-α, blocked the nuclear translocation of NF-κB p65 protein. NF-κB 
activation inhibitor quinazoline also blocked the p65 nuclear translocation. These findings 
demonstrate a novel phenomenon that a newly defined pro-allergic cytokine IL-33 is largely 
induced by microbial components through TLR and NF-κB signaling pathways in human 
corneal epithelium. This suggests that human ocular mucosal epithelium plays an important 
role in initiating Th2-dominant allergic inflammation via innate immune responses.  
In a clinical study, we have tested conjunctival impression cytology specimens obtained from 8 
patients with active atopic conjunctivitis and 8 normal subjects by RT-qPCR (Figure 7). The 
mRNA levels of TSLP, TSLPR, OX40L, OX40, IL-33 and ST2 were found to be significantly 
elevated in the atopic group compared with the normal control subjects, suggesting a potential 
role of TSLP/TSLPR/OX40L/OX40 and IL-33/ST2 signaling pathways in allergic 
conjunctivitis (Figure 7A). In SRW pollen induced EAC mice, the transcripts and proteins of 
IL-33, ST2, and IL-1 receptor accessory protein (IL1RAP) were also found to be significantly 
increased in the corneal epithelium, conjunctiva and CLN, as evaluated by RT-qPCR (Figure 
7B) and immunostaining (Figure 7C). IL-33, ST2 and TLRs could become novel biomarkers 
and molecular targets for the intervention to treat allergic inflammatory diseases. 
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model (Figure 6B). The specificity of TLR-dependent response by HCECs was also 
confirmed when an antibody against TLR3 or TLR5 significantly inhibited IL-33 expression 
by polyI:C or flagellin respectively (Figure 6C). The pattern of TLR-dependent IL-33 
induction indicates that HCECs are able to rapidly initiate an innate immune response to 
virus or bacteria, and play an important role in allergic inflammatory disease. 
 
Fig. 6. TLR-dependent induction of IL-33 by microbial ligands in human corneal epithelium. 
A. IL-33 mRNA and protein levels induced by primary human corneal epithelial cells 
(HCECs) exposed to 50μg/ml polyI:C or 10μg/ml of Pam3CSK4, peptidoglycan (PGN), 
polyI:C, LPS, flagellin, FSL-1, R-837, ssRNA40 or C-CpG-ODN for 8 or 48 hours, evaluated 
by quantitative real-time PCR or ELISA, respectively. Results shown are the mean ± SD of 
four independent experiments. *P< 0.05; **P < 0.01. B. The immunohistochemical staining 
showing IL-33 induction in an ex vivo human corneal tissues by polyI:C (50μg/ml) or 
flagellin (10μg/ml) for 24 hours with isotype IgG as a negative control. C. TLR and NF-κB 
signaling pathways involved in IL-33 induction by polyI:C or flagellin in HCECs exposed to 
polyI:C (50μg/mL) or flagellin (10μg/mL) in the absence or presence of preincubated rabbit 
TLR3Ab (10μg/mL), TLR5Ab (10μg/mL), BAY11-7082 (10μM) or quinazoline (10μM) for 1 
hour, and Pepinh-MYD (40μM) or Pepinh-TRIF (40μM) for 6 hours. The cultures treated by 
ligands for 8 hours for IL-33 mRNA, or for 48 hours for IL-33 protein by ELISA and by 
Western blot with β-actin as control (D). Results shown are the mean ± SD of four 
independent experiments. *P< 0.05; **P < 0.01. 
IL-33 is an extracellular inflammatory cytokine while it also acts as a nuclear transcription 
factor [71]. It has been shown that IL-33 is mainly localized to the nucleus of endothelial cells 
and bound to chromatin. IL-33 mRNA is primarily translated and synthesized in vivo as a 
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Fig. 7. The role of IL-33 in allergic disease. A. Elevated mRNA levels of TSLP and IL-33 
signaling molecules in conjunctiva of atopic patients compared with normal subjects by RT-
qPCR. * P<0.05, **P<0.01, n=8. B. The mRNA levels of IL-33, ST2 and IL1RAP in corneal 
epithelium (Cornea), conjunctiva (Conj) and cervical lymph nodes (CLN) of in BALB/c mice 
with PBS-treated mice as controls. * P<0.05, n=3. C. Immunostaining images showing the 
stimulated IL-33 in ocular surface of EAC BALB/c mice with untreated mouse control and 
isotype IgG negative control. 
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7. Th17 pathway links innate and adaptive immunity 
Th17 has been recently identified as a new T helper cell subset. CD4+ T helper (Th) cells now 
include three different types based on their cytokine signatures: interferon-γ (IFN-γ)-
secreting Th1, IL-4, -5, and -13-secreting Th2 [75], and IL-17-producing Th17 cells [76]. Th17 
cells have been recognized to be key effector T cells in a variety of human inflammatory and 
autoimmune diseases as well as experimental animal models [77, 78]. The IL-17 family 
includes 6 members (IL17A-F). IL-17A (also known as IL-17) and IL-17F are the founding 
members of the IL-17 cytokine family. The genes encoding IL-17A and IL-17F are localized 
in the same chromosomal region in mice and in humans. But IL-17F has significantly weaker 
biological activity than IL-17A [79, 80]. IL-17E, also known as IL-25, is produced by Th2 cells 
and mast cells. In contrast, IL-17B, IL-17C and IL-17D have not been well investigated [81, 
82]. The receptor for IL-17A (IL-17R or IL-17RA) is a single-pass transmembrane protein of 
approximately 130 kDa. Four additional receptors (IL-17RB-RE) have been identified, but 
are not well characterized. IL-17RC was recently identified to be a receptor for IL-17F [83]. It 
has been reported that Th17 cells also produce IL-22 [84, 85] and CC-chemokine attractant 
ligand 20 (CCL20) [86] in mice and humans. Therefore, distinct from Th1 and Th2 cells, Th17 
cells produce a unique and expanding array of pro-inflammatory cytokines.  
Compelling evidence has demonstrated that the differentiation of Th17 cells from naïve 
CD4+ T cells is initiated by cytokines IL-6 or TGF-β, and expanded by cytokines IL-23, IL-1β 
and IL-21. IL-6 or TGF-β was proposed as a major initiator necessary for Th17 differentiation 
[87-89]. IL-23 was the first cytokine shown to selectively regulate IL-17 expression [90, 91], 
but it might not be required for the initial differentiation of Th17 cells in vivo [92]. Recently, 
IL-1β was found to promote Th17 cell development and proliferation in the presence of 
TGF-β and IL-6 [88]. IL-21, produced by activated T cells and natural killer (NK) cells [93], 
may be required for full commitment of Th17 cells [94, 95]. Hence IL-23, IL-1β and IL-21 
may possibly maintain and expand the differentiated Th17 cells in the presence of IL-6 and 
TGF-β [88]. Furthermore, STAT3 has been found to mediate the initiation of Th17 cell 
differentiation by these inducing cytokines [87]. Activation of STAT3 induces the expression 
of retinoic-acid-receptor-related orphan receptor-α (RORα) and RORγt [96],  two 
transcription factors that promote the Th17-cell-associated gene-expression program, 
leading to the production of IL-17, IL-17F, IL-22 and CCL20. 
Using peripheral CD4+ T cell isolated from mouse spleen and cervical lymph nodes, our 
team evaluated the differential effects of these inducing cytokines in promoting Th17 
differentiation [97]. The results showed that IL-6 and TGF-β1, only minimally induced IL-17 
production at both mRNA and protein levels. In the presence of IL-6 and TGF-β1, IL-23 was 
the strongest stimulator of the Th17 signature cytokines IL-17A and IL-17F, IL-22, and 
chemokine CCL20, as well as STAT3 among the 3 expanding cytokines IL-23, IL-1β and IL-
21. In the 4 cytokine system, IL-1β stimulated much higher levels of IL-17 family cytokines, 
1.5-2 fold greater than IL-21 in the presence of TGF-β1, IL-6 and IL-23. These findings 
suggest that TGF-β1 and IL-6 initiate low level differentiation of Th17 cells; and their 
maintenance and development need other expanding factors, among which IL-23 plays a 
potent role and IL-1β amplifies this expansion further in Th17 differentiation [97].  
A variety of mucosal epithelia have been found to produce Th17 inducing cytokines, 
including TGF-β1, IL-6, IL-23, and IL-1β [98, 99]. IL-1β is a well recognized proinflammatory 
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cytokine produced by mucosal epithelia in response to stress, infection or wounding. In an 
attempt to mimic known stressors of the ocular surface, we measured production of Th17 
inducing cytokines in cultured HCECs in response to hyperosmotic stress, microbial 
components and inflammatory cytokines. 
The ocular surface epithelium is subjected to hyperosmotic stress in dry eye conditions. 
Exposure of human epithelial cells to hyperosmotic stress has been noted to activate 
mitogen-activated protein kinase pathways and stimulate production of pro-inflammatory 
cytokines, such as IL-1β, TNF-α, and IL-8 [100]. We have also observed that TGF-β1, IL-6 
and IL-23 were highly induced in the corneal epithelium in response to hyperosmotic stress.  
We evaluated the expression and production of Th17-inducing cytokines by HCECs in 
response to 9 extracted or synthetic microbial components that are ligands of TLRs 1-9, 
respectively. TGF-β1, IL-6, IL-23, and IL-1β expression and production were found to be 
largely induced by polyI: C, flagellin, and R837, the respective ligands for TLRs3, 5 and 7, 
representing viral or bacterial infections. Among these TLR agonists, polyI:C was the 
strongest stimulator of Th17 inducing cytokines by HCECs.  
Hyperosmotic stress and microbial components also promoted production of pro-
inflammatory cytokines including TNF-α, which plays an important role in ocular surface 
disease [100, 101]. Consequently, TNF-α stimulus was found to markedly induce TGF-β1, 
IL-6, IL-23, and IL-1β. 
Based on our findings that among TLR ligands, polyI:C is the potent stimulator of Th17 
inducing cytokines, and that TNF-α is a representative pro-inflammatory factor, we evaluated 
the Th17 inducing capacity of conditioned media (CM) of HCECs treated with polyI:C and 
TNF-α [97]. It has been observed that Th17 cell differentiation was significantly stimulated in 
CD4+ T cells exposed to the 50% conditioned media of HCECs challenged by polyI:C (CM-
polyI:C) or TNF-α (CM-TNF-α) when compared with media from untreated cultures. 
As shown in Figure 8A-E, the mRNA levels of IL-17A, IL-17F, IL-22, CCL-20 and STAT3 
were significantly higher in CD4+ T cells treated with CM-polyI:C or CM-TNF-α for 4 days 
compared with the control medium or conditioned media of HCEC culture without any 
stressors (CM-Control, all P<0.05, n=3). IL-17 protein levels in the supernatants of CD4+ T 
cells exposed to CM-polyI:C or CM-TNF-α for 4 days (Figure 8F) were also significantly 
higher than the media (both P<0.01, n=3) and CM (P<0.05, n=3) controls. Furthermore, the 
number of IL-17-producing cells differentiated from CD4+ T cells, determined by ELISPOT 
bioassay (Figure 8G, 8H), displayed the same pattern to the induction of IL-17 mRNA and 
protein. The numbers of IL-17-producing cells were stimulated by CM-polyI:C or CM-TNF-
α, to the levels similar to that seen in the 3-cytokine system (TGF-β1+IL-6+IL-23), suggesting 
that cytokines in the conditioned media of HCECs exposed to polyI:C or TNF-α were 
capable to promote Th17 cell expansion to levels induced by IL-6+TGF-β1+IL-23. It suggests 
that the Th17 cells can be indeed promoted by factors produced by corneal epithelium in 
response to a variety of inflammatory stimuli [97].  
8. Th17-mediated inflammation in dry eye 
Dry eye is the second most common problem of patients seeking eye care, and is 
characterized by eye irritation symptoms and blurred vision. The prevalence of dry eye  
 






Fig. 8. Induction of Th17 differentiation of murine CD4+ T cells cultured in RPMI media 
containing 50% conditioned media (CM) of HCECs. A-E. Real-time PCR data showing the 
relative fold of mRNA of Th17 associated cytokines (IL-17A, IL-17F, IL-22, CCL-20) and 
regulator STAT3 in CD4+ T cells incubated for 4 days with 50% of conditioned media of 
HCECs irritated by polyI:C (CM-PolyI:C) or TNF-α (CM-TNF-α) for 48 hrs. F. Luminex 
immunobead assay showing IL-17 concentration in the supernatant of CD4+ T cells receiving 
the same treatment for 4 days. G & H. ELISPOT bioassay showing the spots/3x105 
cells/well, representing the numbers of IL-17-producing T cells, in CD4+ T cells treated with 
CM-PolyI:C, CM-TNF-α, or 3 cytokines (TGF-β1+IL-6+IL-23) for 7 days. Results shown are 
mean ± SD of 3-5 independent experiments. *, P < 0.05; **, P <0.01; ***, P < 0.001 each treated 
groups vs. media control. ^, P < 0.05; ^^, P <0.01; ^^^, P < 0.001 CM-PolyI:C or CM-TNF-α 
groups vs. CM-control group. 
increases with age, 6% at the age of 40, and 15-25% in the population over the age of 65. 
Among dry eye patients, 11% have been estimated to have the systemic autoimmune 
condition Sjögren’s syndrome, a severe and potentially blinding condition. Dry eye is a 
potent stimulus of both innate and adaptive immune systems. At the nexus of the dry eye 
inflammatory/immune response is the dynamic interplay between the ocular surface 
epithelia and bone marrow derived immune cells. On the one hand, the ocular surface 
epithelial cells play a key initiating role in this inflammatory reaction, while on the other 
hand they are targets of cytokines that are produced by activated T cells that are recruited to 
the ocular surface in response to dry eye.  
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Dry eye has been demonstrated to cause inflammation of the ocular surface, evidenced by 
increased levels of inflammatory cytokines (IL-1, IL-6, and TNF-α) in the tear fluid, corneal 
and conjunctival epithelium, and an increased infiltration of dendritic cells and T 
lymphocytes in the conjunctiva [102-105]. Recently, increased levels of IL-17, IL-23 and IL-6 
were found in saliva and salivary glands biopsies obtained from patients with the severe 
autoimmune dry eye condition, Sjögren’s syndrome [106]. The increased matrix 
metalloproteinase (MMP) 9 and disrupted barrier function were observed in human [107] 
and murine dry eye [108]. Recently, our group has found increased expression of Th17 
associated cytokines and IL-17-producing cells in human and experimental murine dry eye 
[108, 109]. Increased expression of Th17 cytokine IL-17A was observed in corneal and 
conjunctival epithelia of the dry eye mice. Since IL-17A is produced by T cells, not by 
epithelial cells, the Th17 reaction of the ocular surface is likely due to CD4+ T cells, which 
have previously been found to infiltrate ocular surface tissues following experimental 
desiccating stress [110, 111]. Antibody neutralization of IL-17 ameliorated experimental dry 
eye-induced corneal epithelial barrier dysfunction and decreased the expression of MMP-3 
and -9 [108]. These findings provide clear evidence that changes in the ocular surface 
environment, such as Th17-inducing cytokines, following desiccating stress are capable of 
inducing Th17 differentiation [112], which plays an important role in dry eye disease. 
Th17 differentiation was also found to be mediated through a dendritic cell-mediated 
pathway. DCs have an important function in Th17 cell differentiation. They are antigen-
presenting cells specialized to activate CD4+ T cells and through their interaction with CD4+ 
T cells to initiate primary immune responses. Furthermore, when primed, certain DCs 
express a high-level of Th17 inducing cytokines, including IL-6, TGF-β, IL-23 and IL-1 [113].  
We found that efficient differentiation of CD4+ T cells to IL-17 producers required the 
combination of ocular surface epithelium from dry eye mice and dendritic cells. CD4+ T cells 
that were co-cultured with ocular epithelial explants from desiccating stress-induced dry 
eye mice and dendritic cells were found to express increased mRNA levels of Th17 
cytokines (IL-17A, IL-17F, IL-22) and chemokine (C-C motif) ligand 20 (CCL20) (Figure 9A), 
as well as to produce and release IL-17A (Figure 9B & 9D), but not Th1 cytokine IFN-γ 
(Figure 9C). Exposure of dendritic cells to conditioned media from ocular surface explants of 
dry eye mice did not sufficiently activate these cells to promote T cell differentiation. The 
possible explanations for these findings include the need for direct contact between these 
cells, more efficient activation of cytokines such as TGF-β1 produced by the ocular surface 
epithelial cells or insufficient concentrations of Th17 inducing factors in the explants 
conditioned media.  
The transcription factor RORγt was identified as a candidate master regulator that drives 
Th17 cell lineage differentiation [96]. Expression of RORγt is induced by TGF-β or IL-6, and 
overexpression of γt was found to promote Th17-cell differentiation when both Th1- and 
Th2-cell differentiations were blocked. In a model of experimental autoimmune 
encephalomyelitis, mice with RORγt-deficient T cells were found to have attenuated 
autoimmune disease and lacked tissue-infiltrating Th17 cells [96]. We found robust up-
regulation (up to 100 fold) of the level of Th17 cell transcription factor-RORγt in T cells co-
cultured with desiccated ocular surface tissues and dendritic cells (Figure 9E). This provides 
further evidence of the potent Th17 prone environment induced by desiccation. 
 




Fig. 9. Th17 differentiation of CD4+ T cells induced by the co-culture with dendritic cells (DCs) 
in the presence of cornea and conjunctival tissues of C57BL/6 mice subjected to desiccating 
stress. A. Real-time PCR data showing the relative mRNA expression (x-fold) of Th17 
cytokines (IL-17A, IL-17F, IL-22, CCL-20) in CD4+ T cells (3x105 cells/ well) co-cultured for 1, 2, 
4 days with DCs (T cell+DC), or with DCs and cornea and conjunctival explants from non-
stressed control mice (T cell+DC+NS) or from mice desiccating stressed for 10-day (T 
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cytokines (IL-17A, IL-17F, IL-22, CCL-20) in CD4+ T cells (3x105 cells/ well) co-cultured for 1, 2, 
4 days with DCs (T cell+DC), or with DCs and cornea and conjunctival explants from non-
stressed control mice (T cell+DC+NS) or from mice desiccating stressed for 10-day (T 
 
Advances in Ophthalmology 
 
70
cell+DC+DS), (n=4). B & C. ELISPOT bioassay showing the numbers of IL-17 or IFN-γ- 
producing cells in these 3 groups. D. IL-17 concentration in the supernatant of CD4+ T cells co-
cultured with DCs for 4 days in absence or presence of corneal and conjunctival explants from 
non-stressed and 10 day desiccating stressed mice. E. Real-time PCR showing the relative 
mRNA expression of RORγt in CD4+ T cells co-cultured for 1, 2, 4 days in 3 conditions. Data 
are presented as mean ± SD of 3 or 4 independent experiments. *P<0.05, **P<0.01, ***P<0.001.  
 
Fig. 10. The inflammatory effects of IL-17 on HCECs. Primary HCECs (5×105 cells/well) 
were treated with recombinant human IL-17A at 10 ng/ml for 4-48 hours with or without 
NF-кB activation inhibitor quinazoline (NFκB-I, 5µM). The pro-inflammatory cytokines 
(TNF-α, IL-1β and IL-6) and chemokine IL-8 were measured by RT-qPCR for mRNA (A) and 
by ELISA or Luminex immunobead assays in culture supernatants (B). Results shown are 
mean ± SD of 4 independent experiments. * P < 0.05, ** P< 0.01. 
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IL-17 producing T cells are distinct from Th1 cells. Analysis of the expression of 
transcription factors showed clearly that IL-17-producing T cells expressed neither GATA-3 
nor T-bet and its target Hlx, which were typically expressed by IFN-γ-producing Th1 cells 
[88]. In the T cells co-cultured with desiccated ocular surface tissues and dendritic cells, we 
observed the lower expression of Th1 associated factors (IL-2, T-bet) and Th2 associated 
factors (IL-4, IL-13, GATA-3). There was no change in production of IFN-γ and IL-12 
transcripts as well as in the number of IFN-γ-producing CD4+T cells in this co-culture 
system. Taken together, these findings indicate that desiccating stress may selectively 
promote the Th17 pathway, a finding that is consistent with the increased level of IL-17 in 
dry eye disease [108].  
IL-17 initiates pro-inflammatory effects by binding to the IL-17 receptor (IL-17R), which is 
expressed by a variety of cell types including epithelial, endothelial, and fibroblastic stromal 
cells [81, 114]. As shown in Figure 10, recombinant human IL-17A (10 ng/ml) significantly 
increased mRNA levels (2-4 fold) of proinflammatory cytokines (TNF-α, IL-1β and IL-6) and 
chemokine IL-8 expressed by HCECs. These stimulatory responses to IL-17A were confirmed 
by 4-7 fold increases at protein levels. The stimulated production of these inflammatory 
cytokines and chemokine was significantly suppressed at both mRNA (all P<0.05, n=4) and 
protein levels (P<0.05 or 0.01) by NF-κB activation inhibitor quinazoline [115], indicating NF-
κB pathway is involved in the inflammatory effect of IL-17 on mucosal epithelium. 
These findings demonstrate that desiccating stress stimulates the expression and production 
of Th17 inducing cytokines by corneal and conjunctival epithelia, and that desiccation 
creates an environment promoting Th17 differentiation through a dendritic cell-mediated 
pathway. We hypothesize that Th17 inducing cytokines produced by the ocular epithelium 
may participate in Th17 differentiation in three ways: (1) activation of immature dendritic 
cells on the ocular surface; (2) direct transfer to the lymph node in lymphatic liquid; or (3) 
direct promotion of differentiated Th17 cells that infiltrate the ocular surface. 
9. Conclusion 
This chapter focused on recent breakthroughs in ocular mucosal immunology, including the 
discoveries of TLR signaling in innate immunity, novel epithelium-derived pro-allergic 
cytokines TSLP and IL-33, and a new Th17 cell population in adaptive immunity. One of 
important breakthroughs is a discovery of a novel mechanism by which short ragweed 
pollen, serving as a functional TLR4 agonist, induces TSLP/OX40L/OX40 signaling to 
trigger Th2-dominant allergic inflammation via TLR4-dependent innate immunity 
pathways. All these advances provide compelling evidence that mucosal epithelium actively 
participate, as initiators, mediators and regulators, in innate and adaptive immune 
responses for host defense, in addition to physical barrier function. These novel signaling 
molecules may be critical for allergic, inflammatory and autoimmune diseases on mucosal 
ocular surface, and may become potential molecular targets for new therapies to treat these 
ocular diseases.  
10. Abbreviations used in this chapter 
CLN: cervical lymph nodes; DAMP: damage-associated molecular patterns; DC: dendritic 
cell; dsRNA: double stranded RNA; EAC: experimental allergic conjunctivitis; HCECs: 
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10. Abbreviations used in this chapter 
CLN: cervical lymph nodes; DAMP: damage-associated molecular patterns; DC: dendritic 
cell; dsRNA: double stranded RNA; EAC: experimental allergic conjunctivitis; HCECs: 
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human corneal epithelial cells; IL: interleukin; MyD88: myeloid differentiation primary 
response gene 88; MyD88-/-: MyD88 knockout mice; LPS: lipopolysaccharide; NF-κB: nuclear 
factor kappa B; PBS: phosphate buffered saline; PGN: peptidoglycan; PAMP: pathogen-
associated molecular patterns; PCR: polymerase chain reaction; polyI:C: polyinosinic-
polycytidylic acid; PRR: pattern recognition receptor; R837: imiquimod; RT-qPCR: reverse 
transcription and quantitative real-time PCR; ROR: retinoic-acid-receptor-related orphan 
receptor; SRW: short ragweed; SRWe: aqueous extract of defatted short ragweed pollen; 
ssRNA: single stranded RNA; TGF-β: transforming growth factor; Th1: T helper cell type 1; 
Th17: T helper cell producing IL-17 family; Th2: T helper cell type 2; TLR: Toll-like receptor; 
Tlr4-d: Tlr4 gene deficient; TRIF: TIR-domain-containing adaptor inducing interferon; TSLP: 
thymic stromal lymphopoietin;  TSLPR: TSLP receptor. 
11. References 
[1] Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat 
Immunol. 2004;5:971-974. 
[2] Meyer T, Stockfleth E, Christophers E. Immune response profiles in human skin. Br J 
Dermatol. 2007;157 Suppl 2:1-7. 
[3] Buchau AS, Gallo RL. Innate immunity and antimicrobial defense systems in psoriasis. 
Clin Dermatol. 2007;25:616-624. 
[4] Wollenberg A, Klein E. Current aspects of innate and adaptive immunity in atopic 
dermatitis. Clin Rev Allergy Immunol. 2007;33:35-44. 
[5] Kato A, Schleimer RP. Beyond inflammation: airway epithelial cells are at the interface of 
innate and adaptive immunity. Curr Opin Immunol. 2007;19:711-720. 
[6] Mayer AK, Dalpke AH. Regulation of local immunity by airway epithelial cells. Arch 
Immunol Ther Exp (Warsz ). 2007;55:353-362. 
[7] Schleimer RP, Kato A, Kern R, Kuperman D, Avila PC. Epithelium: at the interface of 
innate and adaptive immune responses. J Allergy Clin Immunol. 2007;120:1279-1284. 
[8] Muller CA, Autenrieth IB, Peschel A. Innate defenses of the intestinal epithelial barrier. 
Cell Mol Life Sci. 2005;62:1297-1307. 
[9] Ishihara S, Rumi MA, Ortega-Cava CF, Kazumori H, Kadowaki Y, Ishimura N, Kinoshita 
Y. Therapeutic targeting of toll-like receptors in gastrointestinal inflammation. Curr 
Pharm Des. 2006;12:4215-4228. 
[10] Sharma R, Young C, Neu J. Molecular modulation of intestinal epithelial barrier: 
contribution of microbiota. J Biomed Biotechnol. 2010;2010:305879. 
[11] Hazlett LD. Role of innate and adaptive immunity in the pathogenesis of keratitis. Ocul 
Immunol Inflamm. 2005;13:133-138. 
[12] Kumar A, Yu FS. Toll-like receptors and corneal innate immunity. Curr Mol Med. 
2006;6:327-337. 
[13] Chang JH, McCluskey PJ, Wakefield D. Toll-like receptors in ocular immunity and the 
immunopathogenesis of inflammatory eye disease. Br J Ophthalmol. 2006;90:103-
108. 
[14] Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 
2006;124:783-801. 
[15] Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376. 
[16] Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune 
defence. Nat Rev Immunol. 2007;7:179-190. 
[17] Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annu 
Rev Biochem. 2007;76:141-165. 
 
Recent Advances in Mucosal Immunology and Ocular Surface Diseases 
 
73 
[18] Vercammen E, Staal J, Beyaert R. Sensing of viral infection and activation of innate 
immunity by toll-like receptor 3. Clin Microbiol Rev. 2008;21:13-25. 
[19] Liu J, Buckley JM, Redmond HP, Wang JH. ST2 negatively regulates TLR2 signaling, 
but is not required for bacterial lipoprotein-induced tolerance. J Immunol. 
2010;184:5802-5808. 
[20] Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 
2007;13:460-469. 
[21] Miller LS, Modlin RL. Toll-like receptors in the skin. Semin Immunopathol. 2007;29:15-
26. 
[22] Li DQ, Zhou N, Zhang L, Ma P, Pflugfelder SC. Suppressive effects of azithromycin on 
zymosan-induced production of proinflammatory mediators by human corneal 
epithelial cells. Invest Ophthalmol Vis Sci. 2010;51:5623-5629. 
[23] Kumar A, Zhang J, Yu FS. Innate immune response of corneal epithelial cells to 
Staphylococcus aureus infection: role of peptidoglycan in stimulating 
proinflammatory cytokine secretion. Invest Ophthalmol Vis Sci. 2004;45:3513-3522. 
[24] Huang X, Barrett RP, McClellan SA, Hazlett LD. Silencing Toll-like receptor-9 in 
Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci. 2005;46:4209-4216. 
[25] Kumar A, Zhang J, Yu FS. Toll-like receptor 3 agonist poly(I:C)-induced antiviral 
response in human corneal epithelial cells. Immunology. 2006;117:11-21. 
[26] Ueta M, Hamuro J, Kiyono H, Kinoshita S. Triggering of TLR3 by polyI:C in human 
corneal epithelial cells to induce inflammatory cytokines. Biochem Biophys Res 
Commun. 2005;331:285-294. 
[27] Liu YJ. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of 
dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol. 2007;120:238-
244. 
[28] Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt RW, Omori M, Zhou B, 
Ziegler SF. TSLP: an epithelial cell cytokine that regulates T cell differentiation by 
conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193-219. 
[29] Holgate ST. The epithelium takes centre stage in asthma and atopic dermatitis. Trends 
Immunol. 2007;28:248-251. 
[30] Lee HC, Ziegler SF. Inducible expression of the proallergic cytokine thymic stromal 
lymphopoietin in airway epithelial cells is controlled by NFkappaB. Proc Natl Acad 
Sci USA. 2007;104:914-919. 
[31] Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers 
progression from epidermal-barrier defects to asthma. PLoS Biol. 2009;7:e1000067. 
[32] Zhang Z, Hener P, Frossard N, Kato S, Metzger D, Li M, Chambon P. Thymic stromal 
lymphopoietin overproduced by keratinocytes in mouse skin aggravates 
experimental asthma. Proc Natl Acad Sci U S A. 2009;106:1536-1541. 
[33] Sims JE, Williams DE, Morrissey PJ, Garka K, Foxworthe D, Price V, Friend SL, Farr A, 
Bedell MA, Jenkins NA, Copeland NG, Grabstein K, Paxton RJ. Molecular cloning 
and biological characterization of a novel murine lymphoid growth factor. J Exp 
Med. 2000;192:671-680. 
[34] Quentmeier H, Drexler HG, Fleckenstein D, Zaborski M, Armstrong A, Sims JE, Lyman 
SD. Cloning of human thymic stromal lymphopoietin (TSLP) and signaling 
mechanisms leading to proliferation. Leukemia. 2001;15:1286-1292. 
[35] Reche PA, Soumelis V, Gorman DM, Clifford T, Liu M, Travis M, Zurawski SM, 
Johnston J, Liu YJ, Spits H, de Waal MR, Kastelein RA, Bazan JF. Human thymic 
stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol. 
2001;167:336-343. 
 
Advances in Ophthalmology 
 
72
human corneal epithelial cells; IL: interleukin; MyD88: myeloid differentiation primary 
response gene 88; MyD88-/-: MyD88 knockout mice; LPS: lipopolysaccharide; NF-κB: nuclear 
factor kappa B; PBS: phosphate buffered saline; PGN: peptidoglycan; PAMP: pathogen-
associated molecular patterns; PCR: polymerase chain reaction; polyI:C: polyinosinic-
polycytidylic acid; PRR: pattern recognition receptor; R837: imiquimod; RT-qPCR: reverse 
transcription and quantitative real-time PCR; ROR: retinoic-acid-receptor-related orphan 
receptor; SRW: short ragweed; SRWe: aqueous extract of defatted short ragweed pollen; 
ssRNA: single stranded RNA; TGF-β: transforming growth factor; Th1: T helper cell type 1; 
Th17: T helper cell producing IL-17 family; Th2: T helper cell type 2; TLR: Toll-like receptor; 
Tlr4-d: Tlr4 gene deficient; TRIF: TIR-domain-containing adaptor inducing interferon; TSLP: 
thymic stromal lymphopoietin;  TSLPR: TSLP receptor. 
11. References 
[1] Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat 
Immunol. 2004;5:971-974. 
[2] Meyer T, Stockfleth E, Christophers E. Immune response profiles in human skin. Br J 
Dermatol. 2007;157 Suppl 2:1-7. 
[3] Buchau AS, Gallo RL. Innate immunity and antimicrobial defense systems in psoriasis. 
Clin Dermatol. 2007;25:616-624. 
[4] Wollenberg A, Klein E. Current aspects of innate and adaptive immunity in atopic 
dermatitis. Clin Rev Allergy Immunol. 2007;33:35-44. 
[5] Kato A, Schleimer RP. Beyond inflammation: airway epithelial cells are at the interface of 
innate and adaptive immunity. Curr Opin Immunol. 2007;19:711-720. 
[6] Mayer AK, Dalpke AH. Regulation of local immunity by airway epithelial cells. Arch 
Immunol Ther Exp (Warsz ). 2007;55:353-362. 
[7] Schleimer RP, Kato A, Kern R, Kuperman D, Avila PC. Epithelium: at the interface of 
innate and adaptive immune responses. J Allergy Clin Immunol. 2007;120:1279-1284. 
[8] Muller CA, Autenrieth IB, Peschel A. Innate defenses of the intestinal epithelial barrier. 
Cell Mol Life Sci. 2005;62:1297-1307. 
[9] Ishihara S, Rumi MA, Ortega-Cava CF, Kazumori H, Kadowaki Y, Ishimura N, Kinoshita 
Y. Therapeutic targeting of toll-like receptors in gastrointestinal inflammation. Curr 
Pharm Des. 2006;12:4215-4228. 
[10] Sharma R, Young C, Neu J. Molecular modulation of intestinal epithelial barrier: 
contribution of microbiota. J Biomed Biotechnol. 2010;2010:305879. 
[11] Hazlett LD. Role of innate and adaptive immunity in the pathogenesis of keratitis. Ocul 
Immunol Inflamm. 2005;13:133-138. 
[12] Kumar A, Yu FS. Toll-like receptors and corneal innate immunity. Curr Mol Med. 
2006;6:327-337. 
[13] Chang JH, McCluskey PJ, Wakefield D. Toll-like receptors in ocular immunity and the 
immunopathogenesis of inflammatory eye disease. Br J Ophthalmol. 2006;90:103-
108. 
[14] Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 
2006;124:783-801. 
[15] Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376. 
[16] Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune 
defence. Nat Rev Immunol. 2007;7:179-190. 
[17] Gay NJ, Gangloff M. Structure and function of Toll receptors and their ligands. Annu 
Rev Biochem. 2007;76:141-165. 
 
Recent Advances in Mucosal Immunology and Ocular Surface Diseases 
 
73 
[18] Vercammen E, Staal J, Beyaert R. Sensing of viral infection and activation of innate 
immunity by toll-like receptor 3. Clin Microbiol Rev. 2008;21:13-25. 
[19] Liu J, Buckley JM, Redmond HP, Wang JH. ST2 negatively regulates TLR2 signaling, 
but is not required for bacterial lipoprotein-induced tolerance. J Immunol. 
2010;184:5802-5808. 
[20] Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med. 
2007;13:460-469. 
[21] Miller LS, Modlin RL. Toll-like receptors in the skin. Semin Immunopathol. 2007;29:15-
26. 
[22] Li DQ, Zhou N, Zhang L, Ma P, Pflugfelder SC. Suppressive effects of azithromycin on 
zymosan-induced production of proinflammatory mediators by human corneal 
epithelial cells. Invest Ophthalmol Vis Sci. 2010;51:5623-5629. 
[23] Kumar A, Zhang J, Yu FS. Innate immune response of corneal epithelial cells to 
Staphylococcus aureus infection: role of peptidoglycan in stimulating 
proinflammatory cytokine secretion. Invest Ophthalmol Vis Sci. 2004;45:3513-3522. 
[24] Huang X, Barrett RP, McClellan SA, Hazlett LD. Silencing Toll-like receptor-9 in 
Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci. 2005;46:4209-4216. 
[25] Kumar A, Zhang J, Yu FS. Toll-like receptor 3 agonist poly(I:C)-induced antiviral 
response in human corneal epithelial cells. Immunology. 2006;117:11-21. 
[26] Ueta M, Hamuro J, Kiyono H, Kinoshita S. Triggering of TLR3 by polyI:C in human 
corneal epithelial cells to induce inflammatory cytokines. Biochem Biophys Res 
Commun. 2005;331:285-294. 
[27] Liu YJ. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of 
dendritic cell-mediated allergic inflammation. J Allergy Clin Immunol. 2007;120:238-
244. 
[28] Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt RW, Omori M, Zhou B, 
Ziegler SF. TSLP: an epithelial cell cytokine that regulates T cell differentiation by 
conditioning dendritic cell maturation. Annu Rev Immunol. 2007;25:193-219. 
[29] Holgate ST. The epithelium takes centre stage in asthma and atopic dermatitis. Trends 
Immunol. 2007;28:248-251. 
[30] Lee HC, Ziegler SF. Inducible expression of the proallergic cytokine thymic stromal 
lymphopoietin in airway epithelial cells is controlled by NFkappaB. Proc Natl Acad 
Sci USA. 2007;104:914-919. 
[31] Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers 
progression from epidermal-barrier defects to asthma. PLoS Biol. 2009;7:e1000067. 
[32] Zhang Z, Hener P, Frossard N, Kato S, Metzger D, Li M, Chambon P. Thymic stromal 
lymphopoietin overproduced by keratinocytes in mouse skin aggravates 
experimental asthma. Proc Natl Acad Sci U S A. 2009;106:1536-1541. 
[33] Sims JE, Williams DE, Morrissey PJ, Garka K, Foxworthe D, Price V, Friend SL, Farr A, 
Bedell MA, Jenkins NA, Copeland NG, Grabstein K, Paxton RJ. Molecular cloning 
and biological characterization of a novel murine lymphoid growth factor. J Exp 
Med. 2000;192:671-680. 
[34] Quentmeier H, Drexler HG, Fleckenstein D, Zaborski M, Armstrong A, Sims JE, Lyman 
SD. Cloning of human thymic stromal lymphopoietin (TSLP) and signaling 
mechanisms leading to proliferation. Leukemia. 2001;15:1286-1292. 
[35] Reche PA, Soumelis V, Gorman DM, Clifford T, Liu M, Travis M, Zurawski SM, 
Johnston J, Liu YJ, Spits H, de Waal MR, Kastelein RA, Bazan JF. Human thymic 
stromal lymphopoietin preferentially stimulates myeloid cells. J Immunol. 
2001;167:336-343. 
 
Advances in Ophthalmology 
 
74
[36] Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, 
Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, 
McClanahan T, de Waal-Malefyt RR, Bazan F, Kastelein RA, Liu YJ. Human 
epithelial cells trigger dendritic cell mediated allergic inflammation by producing 
TSLP. Nat Immunol. 2002;3:673-680. 
[37] Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, Paquette N, 
Ziegler SF, Sarfati M, Delespesse G. Thymic stromal lymphopoietin is released by 
human epithelial cells in response to microbes, trauma, or inflammation and 
potently activates mast cells. J Exp Med. 2007;204:253-258. 
[38] Bogiatzi SI, Fernandez I, Bichet JC, Marloie-Provost MA, Volpe E, Sastre X, Soumelis V. 
Cutting Edge: Proinflammatory and Th2 cytokines synergize to induce thymic 
stromal lymphopoietin production by human skin keratinocytes. J Immunol. 
2007;178:3373-3377. 
[39] Kato A, Favoreto S Jr, Avila PC, Schleimer RP. TLR3- and Th2 cytokine-dependent 
production of thymic stromal lymphopoietin in human airway epithelial cells. J 
Immunol. 2007;179:1080-1087. 
[40] Ma P, Bian F, Wang Z, Zheng X, Chotikavanich S, Pflugfelder SC, Li DQ. Human 
corneal epithelium-derived thymic stromal lymphopoietin links the innate and 
adaptive immune responses via TLRs and Th2 cytokines. Invest Ophthalmol Vis Sci. 
2009;50:2702-2709. 
[41] Mohan RR, Mohan RR, Kim WJ, Wilson SE. Modulation of TNF-alpha-induced 
apoptosis in corneal fibroblasts by transcription factor NF-kappaB. Invest 
Ophthalmol Vis Sci. 2000;41:1327-1336. 
[42] Ozawa T, Koyama K, Ando T, Ohnuma Y, Hatsushika K, Ohba T, Sugiyama H, 
Hamada Y, Ogawa H, Okumura K, Nakao A. Thymic stromal lymphopoietin 
secretion of synovial fibroblasts is positively and negatively regulated by Toll-like 
receptors/nuclear factor-kappaB pathway and interferon-gamma/dexamethasone. 
Mod Rheumatol. 2007;17:459-463. 
[43] Stern ME, Siemasko KF, Niederkorn JY. The Th1/Th2 paradigm in ocular allergy. Curr 
Opin Allergy Clin Immunol. 2005;5:446-450. 
[44] Niederkorn JY. Immune regulatory mechanisms in allergic conjunctivitis: insights from 
mouse models. Curr Opin Allergy Clin Immunol. 2008;8:472-476. 
[45] Buc M, Dzurilla M, Vrlik M, Bucova M. Immunopathogenesis of bronchial asthma. 
Arch Immunol Ther Exp (Warsz ). 2009;57:331-344. 
[46] Ying S, O'Connor B, Ratoff J, Meng Q, Fang C, Cousins D, Zhang G, Gu S, Gao Z, 
Shamji B, Edwards MJ, Lee TH, Corrigan CJ. Expression and cellular provenance of 
thymic stromal lymphopoietin and chemokines in patients with severe asthma and 
chronic obstructive pulmonary disease. J Immunol. 2008;181:2790-2798. 
[47] Matsuda A, Ebihara N, Yokoi N, Kawasaki S, Tanioka H, Inatomi T, de Waal MR, 
Hamuro J, Kinoshita S, Murakami A. Functional role of thymic stromal 
lymphopoietin in chronic allergic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 
2010;51:151-155. 
[48] Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med. 2001;344:30-37. 
[49] Komine M. Analysis of the mechanism for the development of allergic skin 
inflammation and the application for its treatment:keratinocytes in atopic 
dermatitis - their pathogenic involvement. J Pharmacol Sci. 2009;110:260-264. 
[50] Magone MT, Chan CC, Rizzo LV, Kozhich AT, Whitcup SM. A novel murine model of 
allergic conjunctivitis. Clin Immunol Immunopathol. 1998;87:75-84. 
 
Recent Advances in Mucosal Immunology and Ocular Surface Diseases 
 
75 
[51] Stern ME, Siemasko K, Gao J, Duong A, Beauregard C, Calder V, Niederkorn JY. Role 
of interferon-gamma in a mouse model of allergic conjunctivitis. Invest Ophthalmol 
Vis Sci. 2005;46:3239-3246. 
[52] Zheng X, Ma P, de Paiva CS, Cunningham MA, Hwang CS, Pflugfelder SC, Li DQ. 
TSLP and downstream molecules in experimental mouse allergic conjunctivitis. 
Invest Ophthalmol Vis Sci. 2010;51:3076-3082. 
[53] Le TA, Takai T, Vu AT, Kinoshita H, Chen X, Ikeda S, Ogawa H, Okumura K. Flagellin 
Induces the Expression of Thymic Stromal Lymphopoietin in Human Keratinocytes 
via Toll-Like Receptor 5. Int Arch Allergy Immunol. 2010;155:31-37. 
[54] Kinoshita H, Takai T, Le TA, Kamijo S, Wang XL, Ushio H, Hara M, Kawasaki J, Vu 
AT, Ogawa T, Gunawan H, Ikeda S, Okumura K, Ogawa H. Cytokine milieu 
modulates release of thymic stromal lymphopoietin from human keratinocytes 
stimulated with double-stranded RNA. J Allergy Clin Immunol. 2009;123:179-186. 
[55] Johnson AC, Heinzel FP, Diaconu E, Sun Y, Hise AG, Golenbock D, Lass JH, Pearlman 
E. Activation of toll-like receptor (TLR)2, TLR4, and TLR9 in the mammalian cornea 
induces MyD88-dependent corneal inflammation. Invest Ophthalmol Vis Sci. 
2005;46:589-595. 
[56] Piggott DA, Eisenbarth SC, Xu L, Constant SL, Huleatt JW, Herrick CA, Bottomly K. 
MyD88-dependent induction of allergic Th2 responses to intranasal antigen. J Clin 
Invest. 2005;115:459-467. 
[57] Akira S, Hoshino K, Kaisho T. The role of Toll-like receptors and MyD88 in innate 
immune responses. J Endotoxin Res. 2000;6:383-387. 
[58] Tsuji RF, Hoshino K, Noro Y, Tsuji NM, Kurokawa T, Masuda T, Akira S, Nowak B. 
Suppression of allergic reaction by lambda-carrageenan: toll-like receptor 
4/MyD88-dependent and -independent modulation of immunity. Clin Exp Allergy. 
2003;33:249-258. 
[59] Fasciano S, Li L. Intervention of Toll-like receptor-mediated human innate immunity 
and inflammation by synthetic compounds and naturally occurring products. Curr 
Med Chem. 2006;13:1389-1395. 
[60] Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. Mouse toll-like 
receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction 
by Taxol. J Biol Chem. 2000;275:2251-2254. 
[61] Mishra KP, Ganju L, Chanda S, Karan D, Sawhney RC. Aqueous extract of Rhodiola 
imbricata rhizome stimulates Toll-like receptor 4, granzyme-B and Th1 cytokines in 
vitro. Immunobiology. 2009;214:27-31. 
[62] Li D-Q, Zhang L, Pflugfelder SC, de Paiva CS, Zhang X, Zhao G, Zheng X, Su Z, Qu 
Y. Short ragweed pollen triggers allergic inflammation via TLR4-dependent 
TSLP/OX40L/OX40 signaling pathways. J Allergy Clin. Immunol. 2011;128: 1318-
1325.e2 
[63] Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is 
highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS 
Lett. 1989;258:301-304. 
[64] Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. 
Nat Rev Drug Discov. 2008;7:827-840. 
[65] Eiwegger T, Akdis CA. IL-33 links tissue cells, dendritic cells and Th2 cell development 
in a mouse model of asthma. Eur J Immunol. 2011;41:1535-1538. 
[66] Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, 
Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-
 
Advances in Ophthalmology 
 
74
[36] Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, 
Antonenko S, Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, 
McClanahan T, de Waal-Malefyt RR, Bazan F, Kastelein RA, Liu YJ. Human 
epithelial cells trigger dendritic cell mediated allergic inflammation by producing 
TSLP. Nat Immunol. 2002;3:673-680. 
[37] Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, Paquette N, 
Ziegler SF, Sarfati M, Delespesse G. Thymic stromal lymphopoietin is released by 
human epithelial cells in response to microbes, trauma, or inflammation and 
potently activates mast cells. J Exp Med. 2007;204:253-258. 
[38] Bogiatzi SI, Fernandez I, Bichet JC, Marloie-Provost MA, Volpe E, Sastre X, Soumelis V. 
Cutting Edge: Proinflammatory and Th2 cytokines synergize to induce thymic 
stromal lymphopoietin production by human skin keratinocytes. J Immunol. 
2007;178:3373-3377. 
[39] Kato A, Favoreto S Jr, Avila PC, Schleimer RP. TLR3- and Th2 cytokine-dependent 
production of thymic stromal lymphopoietin in human airway epithelial cells. J 
Immunol. 2007;179:1080-1087. 
[40] Ma P, Bian F, Wang Z, Zheng X, Chotikavanich S, Pflugfelder SC, Li DQ. Human 
corneal epithelium-derived thymic stromal lymphopoietin links the innate and 
adaptive immune responses via TLRs and Th2 cytokines. Invest Ophthalmol Vis Sci. 
2009;50:2702-2709. 
[41] Mohan RR, Mohan RR, Kim WJ, Wilson SE. Modulation of TNF-alpha-induced 
apoptosis in corneal fibroblasts by transcription factor NF-kappaB. Invest 
Ophthalmol Vis Sci. 2000;41:1327-1336. 
[42] Ozawa T, Koyama K, Ando T, Ohnuma Y, Hatsushika K, Ohba T, Sugiyama H, 
Hamada Y, Ogawa H, Okumura K, Nakao A. Thymic stromal lymphopoietin 
secretion of synovial fibroblasts is positively and negatively regulated by Toll-like 
receptors/nuclear factor-kappaB pathway and interferon-gamma/dexamethasone. 
Mod Rheumatol. 2007;17:459-463. 
[43] Stern ME, Siemasko KF, Niederkorn JY. The Th1/Th2 paradigm in ocular allergy. Curr 
Opin Allergy Clin Immunol. 2005;5:446-450. 
[44] Niederkorn JY. Immune regulatory mechanisms in allergic conjunctivitis: insights from 
mouse models. Curr Opin Allergy Clin Immunol. 2008;8:472-476. 
[45] Buc M, Dzurilla M, Vrlik M, Bucova M. Immunopathogenesis of bronchial asthma. 
Arch Immunol Ther Exp (Warsz ). 2009;57:331-344. 
[46] Ying S, O'Connor B, Ratoff J, Meng Q, Fang C, Cousins D, Zhang G, Gu S, Gao Z, 
Shamji B, Edwards MJ, Lee TH, Corrigan CJ. Expression and cellular provenance of 
thymic stromal lymphopoietin and chemokines in patients with severe asthma and 
chronic obstructive pulmonary disease. J Immunol. 2008;181:2790-2798. 
[47] Matsuda A, Ebihara N, Yokoi N, Kawasaki S, Tanioka H, Inatomi T, de Waal MR, 
Hamuro J, Kinoshita S, Murakami A. Functional role of thymic stromal 
lymphopoietin in chronic allergic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 
2010;51:151-155. 
[48] Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med. 2001;344:30-37. 
[49] Komine M. Analysis of the mechanism for the development of allergic skin 
inflammation and the application for its treatment:keratinocytes in atopic 
dermatitis - their pathogenic involvement. J Pharmacol Sci. 2009;110:260-264. 
[50] Magone MT, Chan CC, Rizzo LV, Kozhich AT, Whitcup SM. A novel murine model of 
allergic conjunctivitis. Clin Immunol Immunopathol. 1998;87:75-84. 
 
Recent Advances in Mucosal Immunology and Ocular Surface Diseases 
 
75 
[51] Stern ME, Siemasko K, Gao J, Duong A, Beauregard C, Calder V, Niederkorn JY. Role 
of interferon-gamma in a mouse model of allergic conjunctivitis. Invest Ophthalmol 
Vis Sci. 2005;46:3239-3246. 
[52] Zheng X, Ma P, de Paiva CS, Cunningham MA, Hwang CS, Pflugfelder SC, Li DQ. 
TSLP and downstream molecules in experimental mouse allergic conjunctivitis. 
Invest Ophthalmol Vis Sci. 2010;51:3076-3082. 
[53] Le TA, Takai T, Vu AT, Kinoshita H, Chen X, Ikeda S, Ogawa H, Okumura K. Flagellin 
Induces the Expression of Thymic Stromal Lymphopoietin in Human Keratinocytes 
via Toll-Like Receptor 5. Int Arch Allergy Immunol. 2010;155:31-37. 
[54] Kinoshita H, Takai T, Le TA, Kamijo S, Wang XL, Ushio H, Hara M, Kawasaki J, Vu 
AT, Ogawa T, Gunawan H, Ikeda S, Okumura K, Ogawa H. Cytokine milieu 
modulates release of thymic stromal lymphopoietin from human keratinocytes 
stimulated with double-stranded RNA. J Allergy Clin Immunol. 2009;123:179-186. 
[55] Johnson AC, Heinzel FP, Diaconu E, Sun Y, Hise AG, Golenbock D, Lass JH, Pearlman 
E. Activation of toll-like receptor (TLR)2, TLR4, and TLR9 in the mammalian cornea 
induces MyD88-dependent corneal inflammation. Invest Ophthalmol Vis Sci. 
2005;46:589-595. 
[56] Piggott DA, Eisenbarth SC, Xu L, Constant SL, Huleatt JW, Herrick CA, Bottomly K. 
MyD88-dependent induction of allergic Th2 responses to intranasal antigen. J Clin 
Invest. 2005;115:459-467. 
[57] Akira S, Hoshino K, Kaisho T. The role of Toll-like receptors and MyD88 in innate 
immune responses. J Endotoxin Res. 2000;6:383-387. 
[58] Tsuji RF, Hoshino K, Noro Y, Tsuji NM, Kurokawa T, Masuda T, Akira S, Nowak B. 
Suppression of allergic reaction by lambda-carrageenan: toll-like receptor 
4/MyD88-dependent and -independent modulation of immunity. Clin Exp Allergy. 
2003;33:249-258. 
[59] Fasciano S, Li L. Intervention of Toll-like receptor-mediated human innate immunity 
and inflammation by synthetic compounds and naturally occurring products. Curr 
Med Chem. 2006;13:1389-1395. 
[60] Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M. Mouse toll-like 
receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction 
by Taxol. J Biol Chem. 2000;275:2251-2254. 
[61] Mishra KP, Ganju L, Chanda S, Karan D, Sawhney RC. Aqueous extract of Rhodiola 
imbricata rhizome stimulates Toll-like receptor 4, granzyme-B and Th1 cytokines in 
vitro. Immunobiology. 2009;214:27-31. 
[62] Li D-Q, Zhang L, Pflugfelder SC, de Paiva CS, Zhang X, Zhao G, Zheng X, Su Z, Qu 
Y. Short ragweed pollen triggers allergic inflammation via TLR4-dependent 
TSLP/OX40L/OX40 signaling pathways. J Allergy Clin. Immunol. 2011;128: 1318-
1325.e2 
[63] Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is 
highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS 
Lett. 1989;258:301-304. 
[64] Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. 
Nat Rev Drug Discov. 2008;7:827-840. 
[65] Eiwegger T, Akdis CA. IL-33 links tissue cells, dendritic cells and Th2 cell development 
in a mouse model of asthma. Eur J Immunol. 2011;41:1535-1538. 
[66] Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, 
Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-
 
Advances in Ophthalmology 
 
76
1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T 
helper type 2-associated cytokines. Immunity. 2005;23:479-490. 
[67] Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively 
expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 
'alarmin'? PLoS One. 2008;3:e3331. 
[68] Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation 
and asthma. Clin Exp Allergy. 2009. 
[69] Allam JP, Bieber T, Novak N. Dendritic cells as potential targets for mucosal 
immunotherapy. Curr Opin Allergy Clin Immunol. 2009;9:554-557. 
[70] Zhang L, Lu R, Zhao G, Pflugfelder SC, Li DQ. TLR-mediated induction of pro-allergic 
cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol. 2011;43:1383-
1391. 
[71] Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33 - 
cytokine of dual function or novel alarmin? Trends Immunol. 2009;30:227-233. 
[72] Hayakawa M, Hayakawa H, Matsuyama Y, Tamemoto H, Okazaki H, Tominaga S. 
Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem 
Biophys Res Commun. 2009;387:218-222. 
[73] Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active 
independently of caspase-1 cleavage. J Biol Chem. 2009;284:19420-19426. 
[74] Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S. Toll-like receptor signal 
transduction. Exp Mol Med. 2007;39:421-438. 
[75] Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine 
secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173. 
[76] Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-
producing cells. Nat Rev Immunol. 2006;6:329-333. 
[77] Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura 
Y. IL-17 plays an important role in the development of experimental autoimmune 
encephalomyelitis. J Immunol. 2006;177:566-573. 
[78] Hwang SY, Kim HY. Expression of IL-17 homologs and their receptors in the synovial 
cells of rheumatoid arthritis patients. Mol Cells. 2005;19:180-184. 
[79] Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F 
regulates inflammatory responses. Cell Res. 2007;17:435-440. 
[80] Williams IR. CCR6 and CCL20: partners in intestinal immunity and 
lymphorganogenesis. Ann N Y Acad Sci. 2006;1072:52-61. 
[81] Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 
receptors. Cytokine Growth Factor Rev. 2003;14:155-174. 
[82] Gaffen SL, Kramer JM, Yu JJ, Shen F. The IL-17 cytokine family. Vitam Horm. 
2006;74:255-282. 
[83] Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K, Harder B, Okada S, 
Ostrander CD, Kreindler JL, Aujla SJ, Reardon B, Moore M, Shea P, Schreckhise R, 
Bukowski TR, Presnell S, Guerra-Lewis P, Parrish-Novak J, Ellsworth JL, Jaspers S, 
Lewis KE, Appleby M, Kolls JK, Rixon M, West JW, Gao Z, Levin SD. Identification 
of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol. 
2007;179:5462-5473. 
[84] Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, 
Fouser LA. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and 
cooperatively enhance expression of antimicrobial peptides. J Exp Med. 
2006;203:2271-2279. 
 
Recent Advances in Mucosal Immunology and Ocular Surface Diseases 
 
77 
[85] Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. 
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation 
and acanthosis. Nature. 2007;445:648-651. 
[86] Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi 
T, Nomura T, Ito H, Nakamura T, Sakaguchi N, Sakaguchi S. Preferential 
recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in 
rheumatoid arthritis and its animal model. J Exp Med. 2007;204:2803-2812. 
[87] Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C. 
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J 
Biol Chem. 2007;282:9358-9363. 
[88] Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the 
context of an inflammatory cytokine milieu supports de novo differentiation of IL-
17-producing T cells. Immunity. 2006;24:179-189. 
[89] Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton 
RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces 
development of the T(H)17 lineage. Nature. 2006;441:231-234. 
[90] Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, 
Sedgwick JD, Cua DJ. Divergent pro- and antiinflammatory roles for IL-23 and IL-
12 in joint autoimmune inflammation. J Exp Med. 2003;198:1951-1957. 
[91] Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, 
Littman DR. IL-6 programs T(H)-17 cell differentiation by promoting sequential 
engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967-974. 
[92] Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, 
McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population 
that induces autoimmune inflammation. J Exp Med. 2005;201:233-240. 
[93] Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, 
apoptosis and differentiation. Nat Rev Immunol. 2005;5:688-698. 
[94] Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. IL-21 
initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 
2007;448:484-487. 
[95] Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, 
Watowich SS, Jetten AM, Dong C. Essential autocrine regulation by IL-21 in the 
generation of inflammatory T cells. Nature. 2007;448:480-483. 
[96] Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman 
DR. The orphan nuclear receptor RORgammat directs the differentiation program 
of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121-1133. 
[97] Zheng X, Bian F, Ma P, de Paiva CS, Stern M, Pflugfelder SC, Li DQ. Induction of Th17 
differentiation by corneal epithelial-derived cytokines. J Cell Physiol. 2010;222:95-
102. 
[98] Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol. 
2007;19:377-382. 
[99] Holtta V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G, Salo H, 
Rasanen L, Kolho KL, Farkkila M, Savilahti E, Vaarala O. IL-23/IL-17 immunity as 
a hallmark of Crohn's disease. Inflamm Bowel Dis. 2008;14:1175-1184. 
[100] Li D-Q, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases 
mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress 
in human limbal epithelial cells. Exp Eye Res. 2006;82:588-596. 
[101] Barton K, Monroy DC, Nava A, Pflugfelder SC. Inflammatory cytokines in the tears of 
patients with ocular rosacea. Ophthalmology. 1997;104:1868-1874. 
 
Advances in Ophthalmology 
 
76
1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T 
helper type 2-associated cytokines. Immunity. 2005;23:479-490. 
[67] Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively 
expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 
'alarmin'? PLoS One. 2008;3:e3331. 
[68] Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation 
and asthma. Clin Exp Allergy. 2009. 
[69] Allam JP, Bieber T, Novak N. Dendritic cells as potential targets for mucosal 
immunotherapy. Curr Opin Allergy Clin Immunol. 2009;9:554-557. 
[70] Zhang L, Lu R, Zhao G, Pflugfelder SC, Li DQ. TLR-mediated induction of pro-allergic 
cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol. 2011;43:1383-
1391. 
[71] Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. Interleukin-33 - 
cytokine of dual function or novel alarmin? Trends Immunol. 2009;30:227-233. 
[72] Hayakawa M, Hayakawa H, Matsuyama Y, Tamemoto H, Okazaki H, Tominaga S. 
Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem 
Biophys Res Commun. 2009;387:218-222. 
[73] Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active 
independently of caspase-1 cleavage. J Biol Chem. 2009;284:19420-19426. 
[74] Krishnan J, Selvarajoo K, Tsuchiya M, Lee G, Choi S. Toll-like receptor signal 
transduction. Exp Mol Med. 2007;39:421-438. 
[75] Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine 
secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173. 
[76] Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-
producing cells. Nat Rev Immunol. 2006;6:329-333. 
[77] Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, Kakuta S, Sudo K, Iwakura 
Y. IL-17 plays an important role in the development of experimental autoimmune 
encephalomyelitis. J Immunol. 2006;177:566-573. 
[78] Hwang SY, Kim HY. Expression of IL-17 homologs and their receptors in the synovial 
cells of rheumatoid arthritis patients. Mol Cells. 2005;19:180-184. 
[79] Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F 
regulates inflammatory responses. Cell Res. 2007;17:435-440. 
[80] Williams IR. CCR6 and CCL20: partners in intestinal immunity and 
lymphorganogenesis. Ann N Y Acad Sci. 2006;1072:52-61. 
[81] Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 
receptors. Cytokine Growth Factor Rev. 2003;14:155-174. 
[82] Gaffen SL, Kramer JM, Yu JJ, Shen F. The IL-17 cytokine family. Vitam Horm. 
2006;74:255-282. 
[83] Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K, Harder B, Okada S, 
Ostrander CD, Kreindler JL, Aujla SJ, Reardon B, Moore M, Shea P, Schreckhise R, 
Bukowski TR, Presnell S, Guerra-Lewis P, Parrish-Novak J, Ellsworth JL, Jaspers S, 
Lewis KE, Appleby M, Kolls JK, Rixon M, West JW, Gao Z, Levin SD. Identification 
of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol. 
2007;179:5462-5473. 
[84] Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, 
Fouser LA. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and 
cooperatively enhance expression of antimicrobial peptides. J Exp Med. 
2006;203:2271-2279. 
 
Recent Advances in Mucosal Immunology and Ocular Surface Diseases 
 
77 
[85] Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. 
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation 
and acanthosis. Nature. 2007;445:648-651. 
[86] Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, Yamaguchi 
T, Nomura T, Ito H, Nakamura T, Sakaguchi N, Sakaguchi S. Preferential 
recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in 
rheumatoid arthritis and its animal model. J Exp Med. 2007;204:2803-2812. 
[87] Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C. 
STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J 
Biol Chem. 2007;282:9358-9363. 
[88] Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the 
context of an inflammatory cytokine milieu supports de novo differentiation of IL-
17-producing T cells. Immunity. 2006;24:179-189. 
[89] Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton 
RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces 
development of the T(H)17 lineage. Nature. 2006;441:231-234. 
[90] Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, 
Sedgwick JD, Cua DJ. Divergent pro- and antiinflammatory roles for IL-23 and IL-
12 in joint autoimmune inflammation. J Exp Med. 2003;198:1951-1957. 
[91] Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, 
Littman DR. IL-6 programs T(H)-17 cell differentiation by promoting sequential 
engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007;8:967-974. 
[92] Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, 
McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population 
that induces autoimmune inflammation. J Exp Med. 2005;201:233-240. 
[93] Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, 
apoptosis and differentiation. Nat Rev Immunol. 2005;5:688-698. 
[94] Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. IL-21 
initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 
2007;448:484-487. 
[95] Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, 
Watowich SS, Jetten AM, Dong C. Essential autocrine regulation by IL-21 in the 
generation of inflammatory T cells. Nature. 2007;448:480-483. 
[96] Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman 
DR. The orphan nuclear receptor RORgammat directs the differentiation program 
of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121-1133. 
[97] Zheng X, Bian F, Ma P, de Paiva CS, Stern M, Pflugfelder SC, Li DQ. Induction of Th17 
differentiation by corneal epithelial-derived cytokines. J Cell Physiol. 2010;222:95-
102. 
[98] Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol. 
2007;19:377-382. 
[99] Holtta V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G, Salo H, 
Rasanen L, Kolho KL, Farkkila M, Savilahti E, Vaarala O. IL-23/IL-17 immunity as 
a hallmark of Crohn's disease. Inflamm Bowel Dis. 2008;14:1175-1184. 
[100] Li D-Q, Luo L, Chen Z, Kim HS, Song XJ, Pflugfelder SC. JNK and ERK MAP kinases 
mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress 
in human limbal epithelial cells. Exp Eye Res. 2006;82:588-596. 
[101] Barton K, Monroy DC, Nava A, Pflugfelder SC. Inflammatory cytokines in the tears of 
patients with ocular rosacea. Ophthalmology. 1997;104:1868-1874. 
 
Advances in Ophthalmology 
 
78
[102] Corrales RM, Villarreal A, Farley W, Stern ME, Li DQ, Pflugfelder SC. Strain-related 
cytokine profiles on the murine ocular surface in response to desiccating stress. 
Cornea. 2007;26:579-584. 
[103] Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis BL. Interleukin-6 levels in the 
conjunctival epithelium of patients with dry eye disease treated with cyclosporine 
ophthalmic emulsion. Cornea. 2000;19:492-496. 
[104] Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-
inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients 
with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283-2292. 
[105] Pflugfelder SC, de Paiva CS, Li DQ, Stern ME. Epithelial-immune cell interaction in 
dry eye. Cornea. 2008;27 Suppl 1:S9-11. 
[106] Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of 
interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and 
mice. Arthritis Rheum. 2008;58:734-743. 
[107] Chotikavanich S, de Paiva CS, Li DQ, Chen JJ, Bian F, Farley WJ, Pflugfelder SC. 
Production and Activity of Matrix Metalloproteinase-9 on the Ocular Surface 
Increase in Dysfunctional Tear Syndrome. Invest Ophthalmol Vis Sci. 2009; 50:3203-
3209. 
[108] de Paiva CS, Chotikavanich S, Pangelinan SB, Pitcher JD, III, Fang B, Zheng X, Ma P, 
Farley WJ, Siemasko KF, Niederkorn JY, Stern ME, Li DQ, Pflugfelder SC. IL-17 
disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2:243-
253. 
[109] Chauhan SK, El AJ, Ecoiffier T, Goyal S, Zhang Q, Saban DR, Dana R. Autoimmunity 
in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 
2009;182:1247-1252. 
[110] de Paiva CS, Villarreal AL, Corrales RM, Rahman HT, Chang VY, Farley WJ, Stern ME, 
Niederkorn JY, Li DQ, Pflugfelder SC. Dry eye-induced conjunctival epithelial 
squamous metaplasia is modulated by interferon-gamma. Invest Ophthalmol Vis Sci. 
2007;48:2553-2560. 
[111] Stern ME, Siemasko KF, Gao J, Calonge M, Niederkorn JY, Pflugfelder SC. Evaluation 
of ocular surface inflammation in the presence of dry eye and allergic conjunctival 
disease. Ocul Surf. 2005;3:S161-S164. 
[112] Zheng X, de Paiva CS, Li DQ, Farley WJ, Pflugfelder SC. Desiccating stress promotion 
of Th17 differentiation by ocular surface tissues through a dendritic cell-mediated 
pathway. Invest Ophthalmol Vis Sci. 2010;51:3083-3091. 
[113] Shainheit MG, Smith PM, Bazzone LE, Wang AC, Rutitzky LI, Stadecker MJ. Dendritic 
cell IL-23 and IL-1 production in response to schistosome eggs induces Th17 cells in 
a mouse strain prone to severe immunopathology. J Immunol. 2008;181:8559-8567. 
[114] Molesworth-Kenyon SJ, Yin R, Oakes JE, Lausch RN. IL-17 receptor signaling 
influences virus-induced corneal inflammation. J Leukoc Biol. 2008;83:401-408. 
[115] Bian F, Qi H, Ma P, Zhang L, Yoon KC, Pflugfelder SC, Li DQ. An immunoprotective 
privilege of corneal epithelial stem cells against Th17 inflammatory stress by 
producing glial cell-derived neurotrophic factor. Stem Cells. 2010;28:2172-2181.  
5 
Trafficking of Immune Cells  
in the Cornea and Ocular Surface 
Yureeda Qazi,  
Aslihan Turhan and Pedram Hamrah 
Cornea Service, Massachusetts Eye and Ear Infirmary,  
Department of Ophthalmology, Harvard Medical School 
USA 
1. Introduction 
The role of immuno-inflammatory responses in the cornea and ocular surface has 
continuously been evolving over the past decades and has been becoming the center stage 
for therapeutic approaches for many diseases. In fact, the relevance of inflammation as a 
significant component in the pathophysiology of most acute and chronic forms of corneal 
and ocular surface diseases (e.g., microbial keratitis, allergy, and dry eye syndrome) has 
become evident. Both local and systemic immunomodulation with anti-inflammatory 
agents have been used successfully in improving these conditions or bringing these 
conditions under control. Thus, understanding the cellular and molecular mechanisms by 
which the ocular surface participates in immuno-inflammatory disorders is crucial for a 
more rational clinical approach to treating these diseases. 
There are several unique anatomical and physiological features of the cornea and  
ocular surface as compared to other tissues in the body, which translate into specific 
mechanisms by which they are involved in both inciting and expressing immunity, as 
well as preventing unnecessary inflammation. There are a very large number of immune 
and inflammatory disorders that involve the cornea and ocular surface. Control of 
leukocyte entry and migration within the cornea and ocular surface is thus vital to 
regulate protective and pathological responses. While local control of pathogens is 
dependent on the ability of immune cells to access and operate within these sites, too 
much inflammation can be deleterious and lead to loss of vision. In this chapter, the 
current knowledge on the coordinated migratory events that regulate leukocyte 
trafficking in the cornea and ocular surface are discussed. The aim is to first provide an 
overview of the contribution of resident bone marrow (BM)-derived cells of the cornea 
and ocular surface. Second, the role of infiltrating leucocytes in some of the innate defense 
mechanisms will be discussed. Third, we will provide a summary of the mechanisms that 
dictate immune cell trafficking to the cornea and ocular surface in response to 
inflammation. Finally, we will discuss trafficking mechanisms of antigen presenting cells 
from the cornea and ocular surface to draining lymph nodes where the immune responses 
are initiated. 
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2. Role of leukocytes in disease 
2.1 Overview of resident leukocytes 
The cornea and ocular surface have constant and direct contact with the external world. This 
necessitates a powerful and intrinsic immune surveillance system involved in their natural 
defense. Resident ocular tissue elements together with circulating bone marrow-derived 
cells are important components of this system, delicately balancing defense and tolerance 
under steady sate conditions. The ocular surface consists of three distinct anatomical 
regions: the cornea, limbus, and the conjunctiva. These regions function both in concert and 
independently against microbial, immunogenic and traumatic insults.  
Antigen presenting cells (APCs) and in particular dendritic cells (DCs) orchestrate the 
immune response through their capacity to capture, process and subsequently present 
antigens. APCs serve as the principal immune sentinels to the foreign world. They can be 
divided into ‘professional’ and ‘nonprofessional’ types. While the latter are found among 
nonlymphoid tissues (e.g., vascular endothelial or some tissue epithelial cells), professional 
APC are BM-derived, and form an integral part of the immune system. Professional APCs 
include DCs (including epithelial Langerhans cells; LCs), macrophages, and B cells, 
although DCs are the most potent APCs. Expression of major histocompatibility class II 
(MHC-II) antigens on DCs, whose primary function is to distinguish between self and non-
self, plays an integral role in antigen recognition and presentation. DCs have a dual function 
as key regulators of T cell immunity and tolerance induction to both self and foreign 
antigens. Precursor and progenitor DCs constitutively repopulate normal tissues from the 
bloodstream, and are recruited in elevated numbers to sites of inflammation. A second type 
of DC precursors is constituted by peripheral blood monocytes that are recruited during an 
inflammation.  
DCs originate from bone marrow hematopoietic stem cells. (Traver et al., 2000; Wu et al., 
2001) DC progenitors are not restricted to the BM and can be found in multiple locations. 
These progenitors can differentiate into DC upon challenge in peripheral tissues. Fully 
differentiated DC are found in healthy tissues as immunologically immature cells, being 
able to sample foreign antigens, but not able activate T cells. Although rare in numbers in 
the circulation, one fully mature DC is capable to interact with ten thousand T cells per 
day.(O'Keeffe et al., 2003) DC consist of several distinct populations that can be 
differentiated by surface and intracellular phenotypic markers, immunological function, and 
anatomic location. Irrespective of their phenotype and immunological role, DC exert their 
activity in the eye remote from their place of origin, where they utilize their advanced 
migratory skills for navigation. Currently, factors leading to the development from 
precursor DC to differentiated mature DC are still largely unknown. It has been shown that 
depending on the environmental cues, different forms of DC may be generated.(Naik et al., 
2006) Further, while in lymphoid as well as in some non-lymphoid organs,(Kabashima et al., 
2005; Merad et al., 2002) DC have been shown to proliferate locally, it is yet unclear whether 
resident corneal DC have the same proliferative potential, or are alternatively replenished 
through circulating DC. The diverse functions of DC in immune regulation depend on the 
diversity of DC subsets and lineages and on the functional plasticity of DCs at their 
immature stage.  
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Over the last several decades, the search for corneal APC, largely reliant on their presumed 
and universal MHC-II expression, had led to the dogma that APC are essentially absent in 
the central corneal. This absence of corneal APC was assumed to be a critical component of 
corneal immune privilege. However, this paradigm has now shifted with the demonstration 
of a diverse population of resident APC over the last years.(Hamrah et al., 2003a; Hamrah et 
al., 2003b, c) Dendritic cells, the sentinels of the immune system, were recently discovered to 
reside not only in the peripheral cornea, but also in the centreal cornea (Fig 1).(Hamrah et 
al., 2003c; Hamrah et al., 2002b; Liu et al., 2002) While a large number of DC are MHC class 
II+ in the periphery, a large population of MHC class II-negative immature/precursor DC are 
present both in the central  epithelium and stroma.(Hamrah et al., 2003c; Hamrah et al., 
2002b) Immature DC do neither express major histocompatibility complex (MHC)-II nor 
costimulatory molecules unless they are incited by cytokines. Thus, in contrast to other 
organs, where terminally differentiated populations of resident DC and/or macrophages 
outnumber colonizing precursors, large numbers of DCs within the cornea remain in an 
undifferentiated state.  
 
Fig. 1. Dendritic Cell in central corneal epithelium in CD11c-Yellow fluorescent protein 
(YFP) transgenic mouse 
The constitutive presence of these DCs in the cornea focuses now attention on the cornea as a 
participant in immune and inflammatory responses, rather than the cornea being essentially a 
collagenous tissue that simply responds to the activity of infiltrating cells. Other immune cells 
that populate the cornea and ocular surface are T cells, B cells, macrophages, plasma cells, and 
neutrophils (PMN). Further, macrophages and neutrophils together with natural killer (NK) 
cells, initially constitute the primary innate immune response, while DCs, T cells and B cells 
largely play a role in the secondary, adaptive response.(Janeway C, 2004) While the primary 
innate immune response is non-specific, rapid, and lacks memory, the secondary adaptive 
immune response is slower, but highly specific. Further, T and B cell responses maintain 
immunological memory, such that any following encounters with the same antigen will lead 
to rapid and robust immune responses.  
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2.2 Microbial keratitis 
2.2.1 Herpes simplex virus type-1 (HSV-1)  
HSV-1, is a member of the α-herpesviridae family of double-stranded DNA (dsDNA) 
viruses.(Shukla & Spear, 2001) HSV-1 infections are prevalent both in the developed and 
developing countries with a higher and earlier onset of seroconversion in population groups 
of lower socioeconomic status.(Whitley & Roizman, 2001) 60% to 90% of the global adult 
population is infected with this pathogen, with a remarkably high prevalence of 
approximately 90% in the United States.(Carr et al., 2001; Whitley & Roizman, 2001) The two 
main forms of ocular HSV-1 infections are epithelial keratitis, and immune stromal 
keratitis.(Thomas, J. & Rouse, 1997) In the West, HSV-1 is also the leading cause of blindness 
secondary to recurrent infection, corneal stromal inflammation (herpes stromal keratitis; 
HSK), stromal thinning, neovascularisation and scarring.(Dana, M. R. et al., 2000)  
The ocular surface, through several means, is able retard host invasion by external 
pathogens. The tear film which forms the outermost layer of the ocular surface presents 
the first barrier to viral invasion.(Farris, 1998) Some of the anti-viral factors in the tear film 
include, but are not limited to, tear film proteins such as lysozyme, immunoglobulin A 
(IgA), lactate dehydrogenase (LDH), complement proteins, amylase, peroxidase, as well 
as interferons alpha (IFNα) and beta (IFNβ). (Babu et al., 1995; Chatterjee et al., 1984; Chen 
et al., 1994) Since herpes viruses rely on replication and dissemination in metabolically 
active cells (Schang et al., 1998; Schang et al., 2000), the terminally differentiated outer 
layers of the corneal epithelium act as both a physical and metabolic barrier against viral 
entry. In the event of a breach in the integrity of the corneal epithelium, the virion 
attaches to epithelial cells via interaction of its surface glycoproteins with cognate 
receptors, (Campadelli-Fiume et al., 2007; Shukla et al., 1999; Spear, 2004) leading to either 
attachment, surfing and fusion of the virion envelope to the host cell plasma membrane, 
or, via endocytosis of the nucleocapsid into the host cell cytoplasm. Having intercepted 
the barriers to entry, HSV-1 inhibits its host’s programmed cell death, assembles its 
immune-defying, host-crippling machinery to invade, replicate and infect the cornea, 
nerves and eventually the trigeminal ganglion where the virus maintains lifelong latency, 
leading to recurrent infections and potentially irreversible damage to the corneal 
tissue.(Akhtar & Shukla, 2009; Whitley & Roizman, 2001) Transmission may occur 
through cell lysis and shedding of viral progeny or cell-to-cell spread of the virion. Once 
the host corneal epithelial layers are penetrated, HSV replicates in the corneal epithelial 
cells. Following host infection, the outcome of viral latency or resolution has been shown 
to be dependent on the initial viral load.(Kintner & Brandt, 1995). 
Cytokines are low molecular weight proteins produced by various resident corneal cells 
such as epithelial cells, stromal cells, and APCs.(Torres & Kijlstra, 2001) They are responsible 
for recruiting inflammatory and immune cells via cell-to-cell signalling through autocrine, 
paracrine and endocrine pathways, thus promoting tissue damage.(Balkwill & Burke, 1989) 
As the disease course changes, expression profiles of cytokines follow suit. During the early 
phase of HSK, the cornea expresses interleukin (IL)-1α, interferon (IFN)-γ and IL-2, whereas 
IL-4 is expressed later, indicating that the Th1 T cell response is required for induction of 
HSK. (Babu et al., 1995; Niemialtowski & Rouse, 1992b) (Heiligenhaus et al., 1999) While  
IL-2 may be responsible for incurring destructive effects on the stroma, IL-2 knockout mice 
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are more prone to severe HSV infection, which is ameliorated by providing recombinant IL-
2 treatment, hence indicating that the Th1 T cell response not only plays a role in tissue 
destruction, but also plays a protective role against HSV-1 invasion.(Ghiasi et al., 1999) 
Paradoxically, IFN-γ has also been implicated in the clearance of virus from the cells thus 
reducing latency, (Bouley et al., 1995; Smith et al., 1994) (Hendricks et al., 1991) yet driving 
immunopathogenesis as exemplified by the reduction in HSK severity following 
neutralisation of IFN-γ titres beforehand. (Hendricks et al., 1992b; Niemialtowski & Rouse, 
1992a, b) Among the array of cytokines produced, IL-1 is particularly pertinent to corneal 
melting by induction of LC migration into the cornea thereby priming the tissue for further 
destruction. In order to combat the effects of IL-1, human corneal epithelium and stroma 
constitutively express interleukin-1 receptor antagonist (IL-1 RA), which helps maintain 
corneal immune privilege.(Dana, M. R. et al., 1998; Kennedy et al., 1995) Finally, while 
proinflammatory cytokines contribute to the augmentation of the immune response, 
vascular endothelial growth factor (VEGF) secreted by polymorphonuclear (PMN) cells, and 
local epithelial cells, contributes to corneal neovascularization in HSK.(Lee, S. et al., 2002; 
Zheng, M. et al., 2001)  
Chemokines are specific, small cytokines of 8-10 kDa and can be classified according to their 
structure and function. Structurally, they fall into four families, the two most important of 
which are the CXC (alpha) and CC (beta) families. The CC and CXC chemokines are named 
based on intervening residues between their amino (N)-terminal cysteine amino acids. 
Hence, the CC family of chemokines have two adjacent cysteine amino acids near the N-
terminus without an intervening residue. However, in the CXC family of chemokines, these 
N-terminal cysteine residues are separated by an amino acid “X”, thus their “CXC” 
salutation. Chemokine receptors (CCR) CCR1, CCR2, CCR5, CXC chemokine receptor 
(CXCR) CXCR2 and their ligands (CCL/CXCL) have a well-defined role in HSV. Viral 
replication leads to expression of chemokines such as macrophage inflammatory protein 
(MIP)-1α/CCL3, KC/CXCL1, MIP-1β/CCL4, MIP-2/CXCL2, monocyte chemotactic protein 
(MCP)-1/CCL2 and lymphotactin/XCL1. (Thomas, J. et al., 1998) (Wolpe et al., 1989) Of 
these, MIP-1 α /CCL3 plays the most pivotal role in causing stromal inflammation, possibly 
by recruiting neutrophils and T cells as seen in experimental studies on murine 
corneas.(Tumpey et al., 1998; Wolpe et al., 1988) Furthermore, CXCR3 and its ligands, 
namely, monokine induced by gamma interferon (MIG)/CXCL9, interferon gamma-induced 
protein 10 (IP-10)/CXCL10 and interferon-inducible T-cell alpha chemoattractant (I-TAC)/ 
CXCL11 may also contribute to the development of a protective, anti-viral immune response 
seen in the cornea following HSV-1 infection. (Carr et al., 2008; Wuest & Carr, 2008) These 
chemokines may form potential targets for therapy in HSK.  
It is well established that primary infection with HSV-1 incites both a localized innate 
immune response, and systemic immunity through the adaptive arm of the immune 
cascade. The localized innate immune response involves PMNs, natural killer (NK) cells, 
and macrophages, with the adaptive immune response involving DCs and T cells.(Brandt & 
Salkowski, 1992; Ghiasi et al., 2000; Hendricks & Tumpey, 1990; Meyers-Elliott & Chitjian, 
1981; Niemialtowski & Rouse, 1992a; Pepose, 1991; Tullo et al., 1983; Tumpey et al., 1996) 
Clinically, the collection of these cells is seen as infiltrates in the corneal stroma. Within 48 
hours following infection, PMN cells, which constitute the first line of defense, are recruited 
to the cornea by means of the limbus vasculature, following a multi-step adhesion cascade, 
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2.2 Microbial keratitis 
2.2.1 Herpes simplex virus type-1 (HSV-1)  
HSV-1, is a member of the α-herpesviridae family of double-stranded DNA (dsDNA) 
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immune-defying, host-crippling machinery to invade, replicate and infect the cornea, 
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IL-2 may be responsible for incurring destructive effects on the stroma, IL-2 knockout mice 
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are more prone to severe HSV infection, which is ameliorated by providing recombinant IL-
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including selectins, integrins, and chemokines.(Thomas, J. et al., 1997) A cytokine and 
chemokine response by recruited PMN cells, including tumor necrosis factor (TNF-
α),(Daheshia et al., 1998) then quickly translates into recruitment of other cells to the site of 
infection. Additionally, toll-like receptors (TLRs) expressed on the corneal epithelium and 
stroma, recognise pathogens and their activation leads to generation of both an innate and 
acquired adaptive immune responses. Of particular note are TLRs 3, 4, 7, and 9 which 
mediate an anti-viral response to corneal epithelial infection with HSV-1 (Redfern & 
McDermott) Binding of the pathogen to TLRs causes release of cytokines and chemokines 
which provide alert signals to draw in inflammatory cells such as neutrophils and 
lymphocytes. TLR activation also induces resident corneal APCs to express MHC-II and 
costimulatory molecules thus engaging the acquired immune response.(Hamrah & Dana, 
2007) The anti-viral immune response of TLR7 has been successfully tested in clinical trials 
treating HSV following the success of Imiquimod, an FDA-approved TLR7 agonist used in 
the treatment of infection with the human papilloma virus (HPV).(Miller, R. L. et al., 2008) 
Despite encouraging results of TLR agonist therapy for HSV, one must exercise caution in 
their use since excessive TLR stimulation can lead to an unfavourably strong immune 
response with much damage to bystander cells and tissues of the eye. 
Langerhans cells have been found in abundance near the limbus and are recruited to the site 
of inflammation within a few days in the wake of HSV-1 infection.(Streilein et al., 1979) 
(Asbell & Kamenar, 1987; Hendricks et al., 1992a) There they process the viral antigens for 
presentation to naïve T-helper (Th0) cells in draining lymph nodes. These Th0 cells mature 
into Th1 or Th2 cells depending upon the type of cytokines, prostaglandins and 
costimulatory molecules released by LCs and cells of the innate immune system.(Torres & 
Kijlstra, 2001) The extent of stromal damage in HSK is affected by the density of LCs in the 
cornea.(Asbell & Kamenar, 1987; Hendricks et al., 1992a; Jager et al., 1991; Jager et al., 1992; 
Miller, J. K. et al., 1993) Virally-induced migration or maturation of LCs in the cornea 
precedes the development of HSK. Induction of LC migration into the central cornea before 
HSV-1 infection results in an accelerated and enhanced delayed type hypersensitivity (DTH) 
response to HSV-1 antigens, and an increased severity of HSK. On the contrary, depletion of 
DCs reduces the incidence and severity of HSK, suggesting a role for DCs in the induction 
of a T cell response. These findings have led to the conclusion that HSV-1 infection results in 
de novo migration of LCs from the limbus, which in turn might play a role in the 
immunopathology of HSK through presentation of antigens to T cells in the infected cornea. 
Thus, patients that have a higher density of corneal LCs are likely to get more severe forms 
of HSK, which highlights the role of LCs as a potential therapeutic target in HSK.  
HSK has been studied extensively using mouse models of disease and CD4+ T helper 1 (Th1) 
cells have been purported to be key mediators in the immunopathogenesis of corneal HSV-1 
infection. (Hendricks, 1997; Streilein et al., 1997) In mice depleted of CD4+ cells, HSK 
development and progression was prevented or retarded, whereas depletion of CD8+ cells 
either made no difference or made the severity of HSK worse. (Newell et al., 1989a; Newell 
et al., 1989b) Corticosteroids, which are commonly prescribed in addition to antiviral 
therapy in HSK, work partially via inhibition of CD4+ T-cell response and are thus effective 
in controlling inflammatory damage to the eye. Among other local tissue factors, the kind of 
T-helper response generated is orchestrated by a fine balance between cytokines IL-12 and 
IFN-α, and IL-4 and IL-10, which mature Th0 cells into Th1 or Th2 respectively. (Torres & 
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Kijlstra, 2001) The predominant expression of cytokines IL-2 and IFN- α  in HSK further 
corroborates the role of CD4+ Th1 immune response in HSK pathogenesis.(Hendricks et al., 
1992b; Niemialtowski & Rouse, 1992b) The role of Th2 cells in HSK is far more controversial 
and inconclusive. While some groups state that Th2 cells have negligible involvement in 
HSK, (Niemialtowski & Rouse, 1992a, b) others either ascribe Th2 cells as inducers of HSK, 
(Foster et al., 1993; Jayaraman et al., 1993) or ascribe their role to  convalescent phase of 
HSK.(Jayaraman et al., 1993) There is however one caveat; the kind of response generated is 
also driven by the strain of HSV-1. Corneal infections with the reticuloendotheliosis (RE) 
strain of HSV-1 are predominantly CD4+ driven, whereas the relatively less neuroinvasive 
(KOS) strain recruits and activates CD8+ T cells. (Hendricks & Tumpey, 1990; Newell et al., 
1989a; Russell et al., 1984) T cell mediated delayed type hypersensitivity eventually is critical 
for the elimination of the virus. After this point circulating memory T and B lymphocytes 
continuously scan the cornea. 
The suggested T-cell mediated immune response in HSK, is supported by the fact that 
specific HSV epitopes have been shown to mount an immune response by generation of 
autoreactive T cells. (Zhao et al., 1998) Murine studies of chronic HSK further demonstrated 
that despite clinical signs of active disease and lesions, 10-15 days post viral inoculation, 
viral antigens and messenger RNA (mRNA) were undetectable in the corneas of these 
mice.(Babu et al., 1996) Furthermore, Avery and colleagues performed elegant experiments, 
demonstrating that transfer of autoreactive CD4+ T cells to into athymic mice infected with 
HSV-1, results in the development of HSK.(Avery et al., 1995) However, there is ongoing 
debate regarding the source of antigenic response elicited in HSK. Verjans et al. have shown 
that T cells harvested and cultured from HSK donor corneas failed to show reactivity 
against human corneal antigens.(Verjans et al., 2000) Moreover, human studies to date have 
been inconclusive and it has been hypothesised that a variable clinical spectrum of disease 
in patients with recurrent HSK may either be due to a heterogeneous immune response to 
the HSV epitopes, or, to heterogeneity in the expression of corneal autoantigens in the 
host.(Ellison et al., 2003)  
Based on the ability of HSV-1 to circumvent the immune response and maintain latency, 
along with the complexity of immune players that orchestrate signalling cascades leading to 
a spectrum of disease seen clinically, it is challenging for clinicians to treat HSK effectively. 
Attempts towards immunomodulation of HSK have been made, ranging from induction of 
apoptosis in T cells by amniotic membrane transfer,(Bauer et al., 2009) to suppression of 
chemotaxis and activation of CD4+T cells by targeting chemokine receptors.(Komatsu et al., 
2008; Lee, S. K. et al., 2008). However, with an evolving and deeper understanding of the 
molecular mediators of HSV-1 infection, new molecular targets may provide platforms for 
emerging therapies. 
2.2.2 Pseudomonas keratitis 
One of the most important organisms in the group of bacterial keratitides is the Gram-
negative bacterium Pseudomonas aeruginosa. P. aeruginosa is an opportunistic pathogen, 
which like other microbes, requires a breach in the corneal surface for infection.(Hazlett et 
al., 1978) Such infections are typically seen in individuals who wear contact lenses for 
extended periods of time, and in nosocomial or tropical settings stemming from the ability 
of the bacterium to grow in any niche without much nutritional support.(Hazlett, 2004) 
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Pseudomonal keratitis is highly invasive and can lead to corneal perforation within 24-48 
hours post-infection.(Jones, 1973) Pseudomonal infections of the cornea are marked by 
inflammation and necrosis; there is a suppurative stromal infiltrate, coagulative necrosis, 
epithelial edema, a mucopurulent exudate, and in some cases a paracentral corneal ring 
infiltrate that can be seen in addition to a hypopyon.(Hazlett, 2004) One of the main host 
factors that is the culprit for a stromal meltdown is the massive recruitment of neutrophils, 
which release lysosomal enzymes and oxidative compounds, digesting collagen of the 
stromal extracellular matrix. (Carubelli et al., 1990; Nicas & Iglewski, 1985; Trinkaus-Randall 
et al., 1991; Van Horn et al., 1978; Weiss, 1989) IL-6, one of the cytokines expressed within 24 
hours of P.aeruginosa invasion, may be involved in recruitment of PMNs to the site of 
inflammation by upregulating the expression intercellular adhesion molecule-1 (ICAM-1), a 
key molecule involved in migration of neutrophils.(Cole et al., 1999; Youker et al., 1992) 
Integrin-mediated neutrophil migration is a critical phenomenon that occurs not only within 
the proteoglycan matrix, but also among stromal keratocytes which express adhesion 
molecules.(Burns et al., 2005) 
The rapid spread of infection in the early stages of disease has been attributed in part to a 
delayed response from the responsible TLRs, TLR-2, -4 and -5, which are expressed at a later 
stage in the disease thus leading to a delay in activation of both the innate and adaptive 
arms of the immune response. (Jin et al.) Using a murine model of pseudomonal keratitis, 
Sun and colleagues demonstrated that P.aeruginosa activates expression of TLR-4/5 on 
resident corneal bone marrow-derived macrophages, inducing transcription of chemokines 
and cytokines such as KC/CXCL1, as well as IL-1α and IL-1β. Subsequent recruitment of 
neutrophils into the corneal stroma leads to destruction of P.aeruginosa. The produced IL-1 
has a positive feedback effect by activating the IL-1 receptor in macrophages and other cells 
of the cornea, thus ensuring a sustained response against the bacteria.(Sun et al.) While a 
sustained immune response favours reducing bacterial load, it is also associated with 
bystander local tissue damage from dysregulation of cytokines and chemokines as seen by 
elevated expression of TNF- α , MIP-2/CXCL2, IL-1 but low levels of IL-10.(Zhou et al.) It 
is evident that the role of a prompt and efficient immune response is critical in curtailing the 
spread and severity of pseudomonal keratitis, and eventually in preventing loss of vision. 
However, the caveat to a robust immune response remains the collateral damage incurred to 
surrounding cells and tissues.  
From a therapeutic standpoint, TLRs make interesting molecular targets. Particularly, TLR-9 
is one of the first in its class to be expressed when the cornea is invaded by P. aeruginosa. 
Huang and colleagues used RNA interference (RNAi) to knockdown TLR-9 in mice which 
resulted in decreased corneal opacity, fewer corneal perforations, with decreases in PMNs, 
inductors of the Th1 pathway IFN-γ and IL-12, and mediators of chemotaxis IL-1 β  and 
MIP-2/CXCL2, but higher bacterial titers than controls.(Huang et al., 2005) Further, when 
mice were either depleted of CD4+ T cells or received IFN- γ  neutralising antibodies prior to 
inoculation, they were spared corneal perforation and had a reduced DTH response, 
corroborating the role of a CD4+ T-cell mediated immunopathogenesis of this 
disease.(Kwon & Hazlett, 1997) Cytokines released by CD4+ T cell and LC result in 
infiltration of higher numbers of PMN, eventually leading to increased corneal.(Hazlett et 
al., 2001; Hazlett et al., 2002) While some propose that in order to minimise this collateral 
damage to ocular tissues, therapies should consider directing the immune response from 
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CD4+/Th1 mediated towards a Th2 pathway, (Kijlstra, 1994) others are of the opinion that it 
is the balance between pro-and anti-inflammatory mediators that is of greater significance in 
pseudomonal keratitis. (Hazlett, 2004) (O'Callaghan et al., 1996)  
2.2.3 Fungal keratitis 
Fungal keratitis is a vision-threatening infection and has seen a recent continual rise in 
incidence, with a spike during 2005-2006, following Fusarium contamination of a commercial 
contact lens solution. The three most common risk factors for fungal keratitis are contact 
lens use, trauma and penetrating keratoplasty. (Yildiz et al.) (Iyer et al., 2006) Filamentous 
fungi form the majority of causative organisms with Fusarium (41%), Candida (14%), 
Aspergillus (12%) and Curvularia (12%) being among the top contenders.(Iyer et al., 2006; 
Jurkunas et al., 2009) Fungal infections of the cornea, if not treated immediately and 
managed appropriately, can rapidly lead to corneal ulceration, perforation, corneal 
neovascularisation, loss of vision and possibly, loss of the eye. (Yuan & Wilhelmus, 2009) 
(Thomas, P. A. & Geraldine, 2007) It is thus imperative to understand the molecular 
underpinnings of fungal keratitis, especially the involvement of immune players, for a more 
thorough understanding towards devising novel and efficacious treatment modalities. 
Contact lens wear can compromise the integrity of the corneal epithelium, making it 
susceptible to fungal invasion. It is known that contact lens wear can induce a subclinical 
host immune response with recruitment of LCs into the cornea. (Sankaridurg et al., 2000) 
TLRs on APCs, such as LCs or macrophages, recognize fungi, thereby activating the innate 
and adaptive immune response to clear the infection.(Barton & Medzhitov, 2003; Johnson et 
al., 2005) Hu et al. demonstrated the importance of macrophages through depletion of these 
cells, showing the contribution of macrophages in two different fungal infection models 5 
and 7 days following infection. In this study development of more severe keratomycosis in 
mice depleted of macrophages points the contribution of macrophages in limiting fungal 
disease. (Hu et al., 2009) In vitro studies have shown that inactivated hyphae of Fusarium 
solani upregulate gene expression of TLRs-2, 3, 4 and 6, along with protein expression of 
TLRs 2 and 4 with resultant increases in cytokine expression of IL-6 and IL-8. The 
importance of TLR-4 in modulating the host defense mechanisms to fungi, especially 
Fusarium keratitis, has been demonstrated by several groups. In an experimental model of 
infectious keratitis, it was observed that resolution of Fusarium keratitis involved activation 
of both the innate immune response along with the adaptive arm through TLR-4.(Sun et al.) 
In another murine study, inoculation in knockout models of TLR-4, lead to impaired host 
anti-fungal defense mechanisms, decreased production of CXCL1 with subsequent 
decreased recruitment of neutrophils into the cornea, as well as uncontrolled fungal growth 
and eventually corneal perforation (Tarabishy et al., 2008) On the contrary, hydrocortisone 
treatment in vitro leads to a TLR-mediated increase in resistance to Fusarium solani with a 
concomitant increase in IL-6 expression by human corneal endothelial cells (HCEC).(Jin et 
al., 2007) 
Similarly, in humans, fungal keratitis secondary to Aspergillus and Candida species also rely 
on human corneal TLRs 2 and 4 for hosting an immune response.(Mambula et al., 2002; 
Netea et al., 2002; Netea et al., 2003) TLRs 2 and 4 recognise fungal zymosan and mannan, 
leading to an expected increase in the production of IL-6 and IL-1β when challenged with 
Aspergillus, which is diminished by knocking down these innate receptors, confirming the 
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Pseudomonal keratitis is highly invasive and can lead to corneal perforation within 24-48 
hours post-infection.(Jones, 1973) Pseudomonal infections of the cornea are marked by 
inflammation and necrosis; there is a suppurative stromal infiltrate, coagulative necrosis, 
epithelial edema, a mucopurulent exudate, and in some cases a paracentral corneal ring 
infiltrate that can be seen in addition to a hypopyon.(Hazlett, 2004) One of the main host 
factors that is the culprit for a stromal meltdown is the massive recruitment of neutrophils, 
which release lysosomal enzymes and oxidative compounds, digesting collagen of the 
stromal extracellular matrix. (Carubelli et al., 1990; Nicas & Iglewski, 1985; Trinkaus-Randall 
et al., 1991; Van Horn et al., 1978; Weiss, 1989) IL-6, one of the cytokines expressed within 24 
hours of P.aeruginosa invasion, may be involved in recruitment of PMNs to the site of 
inflammation by upregulating the expression intercellular adhesion molecule-1 (ICAM-1), a 
key molecule involved in migration of neutrophils.(Cole et al., 1999; Youker et al., 1992) 
Integrin-mediated neutrophil migration is a critical phenomenon that occurs not only within 
the proteoglycan matrix, but also among stromal keratocytes which express adhesion 
molecules.(Burns et al., 2005) 
The rapid spread of infection in the early stages of disease has been attributed in part to a 
delayed response from the responsible TLRs, TLR-2, -4 and -5, which are expressed at a later 
stage in the disease thus leading to a delay in activation of both the innate and adaptive 
arms of the immune response. (Jin et al.) Using a murine model of pseudomonal keratitis, 
Sun and colleagues demonstrated that P.aeruginosa activates expression of TLR-4/5 on 
resident corneal bone marrow-derived macrophages, inducing transcription of chemokines 
and cytokines such as KC/CXCL1, as well as IL-1α and IL-1β. Subsequent recruitment of 
neutrophils into the corneal stroma leads to destruction of P.aeruginosa. The produced IL-1 
has a positive feedback effect by activating the IL-1 receptor in macrophages and other cells 
of the cornea, thus ensuring a sustained response against the bacteria.(Sun et al.) While a 
sustained immune response favours reducing bacterial load, it is also associated with 
bystander local tissue damage from dysregulation of cytokines and chemokines as seen by 
elevated expression of TNF- α , MIP-2/CXCL2, IL-1 but low levels of IL-10.(Zhou et al.) It 
is evident that the role of a prompt and efficient immune response is critical in curtailing the 
spread and severity of pseudomonal keratitis, and eventually in preventing loss of vision. 
However, the caveat to a robust immune response remains the collateral damage incurred to 
surrounding cells and tissues.  
From a therapeutic standpoint, TLRs make interesting molecular targets. Particularly, TLR-9 
is one of the first in its class to be expressed when the cornea is invaded by P. aeruginosa. 
Huang and colleagues used RNA interference (RNAi) to knockdown TLR-9 in mice which 
resulted in decreased corneal opacity, fewer corneal perforations, with decreases in PMNs, 
inductors of the Th1 pathway IFN-γ and IL-12, and mediators of chemotaxis IL-1 β  and 
MIP-2/CXCL2, but higher bacterial titers than controls.(Huang et al., 2005) Further, when 
mice were either depleted of CD4+ T cells or received IFN- γ  neutralising antibodies prior to 
inoculation, they were spared corneal perforation and had a reduced DTH response, 
corroborating the role of a CD4+ T-cell mediated immunopathogenesis of this 
disease.(Kwon & Hazlett, 1997) Cytokines released by CD4+ T cell and LC result in 
infiltration of higher numbers of PMN, eventually leading to increased corneal.(Hazlett et 
al., 2001; Hazlett et al., 2002) While some propose that in order to minimise this collateral 
damage to ocular tissues, therapies should consider directing the immune response from 
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CD4+/Th1 mediated towards a Th2 pathway, (Kijlstra, 1994) others are of the opinion that it 
is the balance between pro-and anti-inflammatory mediators that is of greater significance in 
pseudomonal keratitis. (Hazlett, 2004) (O'Callaghan et al., 1996)  
2.2.3 Fungal keratitis 
Fungal keratitis is a vision-threatening infection and has seen a recent continual rise in 
incidence, with a spike during 2005-2006, following Fusarium contamination of a commercial 
contact lens solution. The three most common risk factors for fungal keratitis are contact 
lens use, trauma and penetrating keratoplasty. (Yildiz et al.) (Iyer et al., 2006) Filamentous 
fungi form the majority of causative organisms with Fusarium (41%), Candida (14%), 
Aspergillus (12%) and Curvularia (12%) being among the top contenders.(Iyer et al., 2006; 
Jurkunas et al., 2009) Fungal infections of the cornea, if not treated immediately and 
managed appropriately, can rapidly lead to corneal ulceration, perforation, corneal 
neovascularisation, loss of vision and possibly, loss of the eye. (Yuan & Wilhelmus, 2009) 
(Thomas, P. A. & Geraldine, 2007) It is thus imperative to understand the molecular 
underpinnings of fungal keratitis, especially the involvement of immune players, for a more 
thorough understanding towards devising novel and efficacious treatment modalities. 
Contact lens wear can compromise the integrity of the corneal epithelium, making it 
susceptible to fungal invasion. It is known that contact lens wear can induce a subclinical 
host immune response with recruitment of LCs into the cornea. (Sankaridurg et al., 2000) 
TLRs on APCs, such as LCs or macrophages, recognize fungi, thereby activating the innate 
and adaptive immune response to clear the infection.(Barton & Medzhitov, 2003; Johnson et 
al., 2005) Hu et al. demonstrated the importance of macrophages through depletion of these 
cells, showing the contribution of macrophages in two different fungal infection models 5 
and 7 days following infection. In this study development of more severe keratomycosis in 
mice depleted of macrophages points the contribution of macrophages in limiting fungal 
disease. (Hu et al., 2009) In vitro studies have shown that inactivated hyphae of Fusarium 
solani upregulate gene expression of TLRs-2, 3, 4 and 6, along with protein expression of 
TLRs 2 and 4 with resultant increases in cytokine expression of IL-6 and IL-8. The 
importance of TLR-4 in modulating the host defense mechanisms to fungi, especially 
Fusarium keratitis, has been demonstrated by several groups. In an experimental model of 
infectious keratitis, it was observed that resolution of Fusarium keratitis involved activation 
of both the innate immune response along with the adaptive arm through TLR-4.(Sun et al.) 
In another murine study, inoculation in knockout models of TLR-4, lead to impaired host 
anti-fungal defense mechanisms, decreased production of CXCL1 with subsequent 
decreased recruitment of neutrophils into the cornea, as well as uncontrolled fungal growth 
and eventually corneal perforation (Tarabishy et al., 2008) On the contrary, hydrocortisone 
treatment in vitro leads to a TLR-mediated increase in resistance to Fusarium solani with a 
concomitant increase in IL-6 expression by human corneal endothelial cells (HCEC).(Jin et 
al., 2007) 
Similarly, in humans, fungal keratitis secondary to Aspergillus and Candida species also rely 
on human corneal TLRs 2 and 4 for hosting an immune response.(Mambula et al., 2002; 
Netea et al., 2002; Netea et al., 2003) TLRs 2 and 4 recognise fungal zymosan and mannan, 
leading to an expected increase in the production of IL-6 and IL-1β when challenged with 
Aspergillus, which is diminished by knocking down these innate receptors, confirming the 
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putative role of TLRs 2 and 4 in Aspergillus keratitis.(Guo & Wu, 2009) In a recent study 
from the same group investigated the effect of targeting TLR2 by a small interfering RNA 
(siRNA) construct applied subconjunctively and topically to the cornea, showed that 
suppressing TLR2 expression in the cornea results in a decrease in neutrophil infiltration, 
allowing the cornea to preserve its morphological integrity. Suppressing TLR2 expression 
also caused a decrease in TNF-α, IL-1β, IL-6, IL-12, monocyte chemoattractant protein (MCP-
1)/CCL2 and macrophage inflammatory protein (MIP-2)/CXCL2 expression. 
Immunomodulation by targeting TLR2 might be a treatment approach in fungal keratitis to 
avoid damage to the cornea by an immune response.(Guo et al.) Aspergillus fumigatus also 
induces IL-10 expression, and taken together, these cytokines attract and direct PMNs into 
the cornea, inciting innate immunity.(Redfern & McDermott) Thus, in addition to anti-
fungal therapy, modulating fungus-specific TLR responses and controlling the host’s 
immune response to the patient’s advantage, is an exciting avenue to explore in the field of 
molecular anti-fungal therapy towards quicker resolution of infection with minimal residual 
damage. 
2.2.4 Acanthamoeba keratitis 
Acanthamoeba keratitis (AK) is a resilient, vision-threatening infection of the cornea. 
Acanthamoeba is an ubiquitous protozoa, which is exceptionally difficult to treat. Infection 
with Acanthamoeba either resolves spontaneously, or, as often seen, results in progressive 
infection and eventual corneal melting, suggesting a role of the immune system in its 
pathophysiology. Corneal transplantation is indicated in cases of severe infection, however, 
reinfection can commonly occur due to the presence of Acanthamoeba cysts within the host 
graft bed. Reinfection and recrudescence indicates the absence of memory against this 
parasite, and hence a poor activation of the adaptive arm of the immune response. 
Acanthamoeba species exist freely in the environment and on certain mucosal surfaces of 
healthy individuals.(Alizadeh et al. 1996; Niederkorn et al. 1999) Two of the most critical 
risk factors for AK include contact lens use and corneal trauma.(Niederkorn et al. 1999) 
Trophozoites attach to the surface of the contact lens which are then introduced to the ocular 
surface. Integrity of the host immune machinery predicts the severity of infection and 
incidence of disease as patients with AK have lower tear levels of IgA against Acanthamoeba 
antigens as compared to healthy controls, implicating the role of mucosa-mediated 
immunity in AK. (Alizadeh et al. 2001) The unique resilience of the double-layered cellulose 
wall of Acanthamoeba cysts, which are resistant to extreme temperatures, UV and gamma 
irradiation, underlies the challenges of treating AK. Systemic immunization to Acanthamoeba 
antigens does not confer immunity unlike mucosa-induced immunity. 
Once the trophozoites invade the corneal epithelium through dislodgement of the epithelial 
cells caused by contact-lens induced microabrasions, there is a TLR-4-mediated immune 
response in corneal epithelial cells with release of cytokines IL-8 and TNF-α as shown in rats 
(Ren and Wu 2011). The innate immune response is activated with recruitment of 
neutrophils and macrophages. Macrophages are believed to be pivotal to the resolution of 
AK. They have a chemotactic response to the pathogen, and bear an inherent ability to kill 
the trophozoites in vivo. This phenomenon can be demonstrated by the depletion of 
macrophages in Clodronate treated animals which develop severe, chronic AK. (Stewart et 
al. 1992; van Klink et al. 1996) Although cysts are more difficult to eradicate, macrophages 
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forming the first line of defence in AK may also attack Acanthamoeba cysts by direct 
phagocytosis as seen in vitro (Hurt et al. 2003). Like macrophages, neutrophils also form the 
first-line defence against both Acanthamoeba cysts and trophozoites, but demonstrate a more 
robust and efficient response. They are found in large numbers in corneas with AK, where 
they clear the protozoan using myeloperoxidase-dependent killing. Neutrophils are 
important both in the prevention and resolution of AK.(Hurt et al. 2003; Clarke et al. 2005).  
The most convincing and potent response from the adaptive arm of the immune system is 
the secretion of IgA antibody. IgA antibody promotes neutrophil-mediated killing of 
trophozoites hence preventing adhesion of the trophozoites to the corneal epithelium. 
Furthermore, it shuts down the corneal melt-down plant of the trophozoites by inhibiting 
mannose-induced cytopathic protein 133 (MIP-133)-induced digestion of the corneal 
epithelium and stroma. The role of corticosteroids in the treatment of AK remains 
controversial. This issue arises from the contrary effects of dexamethasone on the eye; on the 
one hand they help in the resolution of AK-associated ocular inflammation, but on the other 
hand, they induce excystment of dormant cysts leading to recrudescence. Thus, targeting 
MIP-133 offers an attractive target in the therapy of AK. Earlier detection of disease by 
visualization of cysts in the cornea using in vivo confocal microscopy (IVCM) may offer an 
advantage in the management of AK.(Kumar et al. 2010) Through a more sensitive approach 
in the detection and consequent treatment of AK, the prognosis may be improved leading to 
fewer cases of corneal melting and associated complications. 
2.3 Corneal transplantation 
Corneal transplantation is the most common form of solid tissue transplantation with 
approximately 45,000 cases being performed annually in the United States alone.(CCTS, 
1992; Niederkorn, 1999; Streilein, 1999) Unlike other solid tissue transplants, corneal 
allotransplants enjoy immune privilege, and neither require standard human leukocyte 
antigen (HLA) matching, nor permanent systemic immunosuppression. First time recipients 
of corneal allografts enjoy a 2-year graft survival rate of greater than 90% if the recipient 
corneal bed is avascular and free of inflammation.(Niederkorn, 1990) Corneal immune 
privilege is attributed to: (a) an avascular corneal bed which prevents recruitment of 
immune cells and leukocytes to the graft site, thus preventing recognition of non-self HLA 
antigens; (b) lack of lymphatic vessels, which eliminates transport and presentation of non-
self HLA antigens and egress of APCs to T cells in draining lymph nodes, thus decreasing 
sensitisation (c) paucity of mature MHC-II+/HLA-DR+ resident corneal dendritic cells, 
including LC, thus decreasing direct presentation of unmatched HLA antigens to T cells; (d) 
constitutive expression of Fas ligand (CD95; FasL), which programs cell death of activated 
Fas+ T cells; (e) local ocular production of immunomodulatory neuropeptides and factors in 
aqueous humour such as transforming growth factor beta (TGF)-β2 and alpha-melanocyte 
stimulating hormone (α -MSH), which inhibits alloantigen-driven T cell activation and 
DTH.(Dana, M. R. et al., 2000; Dua & Azuara-Blanco, 1999; Griffith et al., 1995; Jager et al., 
1995; Niederkorn, 1990; Niederkorn et al., 1989; Streilein, 1993, 1995; Stuart et al., 1997; Thiel 
et al., 2009) 
Neovascularization of the corneal graft greatly increases the rate of rejection.(Alldredge & 
Krachmer, 1981; Maguire et al., 1994) As per guidelines of the Collaborative Corneal 
Transplantation Studies, the recipient cornea is considered “high-risk” if there is stromal 
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putative role of TLRs 2 and 4 in Aspergillus keratitis.(Guo & Wu, 2009) In a recent study 
from the same group investigated the effect of targeting TLR2 by a small interfering RNA 
(siRNA) construct applied subconjunctively and topically to the cornea, showed that 
suppressing TLR2 expression in the cornea results in a decrease in neutrophil infiltration, 
allowing the cornea to preserve its morphological integrity. Suppressing TLR2 expression 
also caused a decrease in TNF-α, IL-1β, IL-6, IL-12, monocyte chemoattractant protein (MCP-
1)/CCL2 and macrophage inflammatory protein (MIP-2)/CXCL2 expression. 
Immunomodulation by targeting TLR2 might be a treatment approach in fungal keratitis to 
avoid damage to the cornea by an immune response.(Guo et al.) Aspergillus fumigatus also 
induces IL-10 expression, and taken together, these cytokines attract and direct PMNs into 
the cornea, inciting innate immunity.(Redfern & McDermott) Thus, in addition to anti-
fungal therapy, modulating fungus-specific TLR responses and controlling the host’s 
immune response to the patient’s advantage, is an exciting avenue to explore in the field of 
molecular anti-fungal therapy towards quicker resolution of infection with minimal residual 
damage. 
2.2.4 Acanthamoeba keratitis 
Acanthamoeba keratitis (AK) is a resilient, vision-threatening infection of the cornea. 
Acanthamoeba is an ubiquitous protozoa, which is exceptionally difficult to treat. Infection 
with Acanthamoeba either resolves spontaneously, or, as often seen, results in progressive 
infection and eventual corneal melting, suggesting a role of the immune system in its 
pathophysiology. Corneal transplantation is indicated in cases of severe infection, however, 
reinfection can commonly occur due to the presence of Acanthamoeba cysts within the host 
graft bed. Reinfection and recrudescence indicates the absence of memory against this 
parasite, and hence a poor activation of the adaptive arm of the immune response. 
Acanthamoeba species exist freely in the environment and on certain mucosal surfaces of 
healthy individuals.(Alizadeh et al. 1996; Niederkorn et al. 1999) Two of the most critical 
risk factors for AK include contact lens use and corneal trauma.(Niederkorn et al. 1999) 
Trophozoites attach to the surface of the contact lens which are then introduced to the ocular 
surface. Integrity of the host immune machinery predicts the severity of infection and 
incidence of disease as patients with AK have lower tear levels of IgA against Acanthamoeba 
antigens as compared to healthy controls, implicating the role of mucosa-mediated 
immunity in AK. (Alizadeh et al. 2001) The unique resilience of the double-layered cellulose 
wall of Acanthamoeba cysts, which are resistant to extreme temperatures, UV and gamma 
irradiation, underlies the challenges of treating AK. Systemic immunization to Acanthamoeba 
antigens does not confer immunity unlike mucosa-induced immunity. 
Once the trophozoites invade the corneal epithelium through dislodgement of the epithelial 
cells caused by contact-lens induced microabrasions, there is a TLR-4-mediated immune 
response in corneal epithelial cells with release of cytokines IL-8 and TNF-α as shown in rats 
(Ren and Wu 2011). The innate immune response is activated with recruitment of 
neutrophils and macrophages. Macrophages are believed to be pivotal to the resolution of 
AK. They have a chemotactic response to the pathogen, and bear an inherent ability to kill 
the trophozoites in vivo. This phenomenon can be demonstrated by the depletion of 
macrophages in Clodronate treated animals which develop severe, chronic AK. (Stewart et 
al. 1992; van Klink et al. 1996) Although cysts are more difficult to eradicate, macrophages 
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forming the first line of defence in AK may also attack Acanthamoeba cysts by direct 
phagocytosis as seen in vitro (Hurt et al. 2003). Like macrophages, neutrophils also form the 
first-line defence against both Acanthamoeba cysts and trophozoites, but demonstrate a more 
robust and efficient response. They are found in large numbers in corneas with AK, where 
they clear the protozoan using myeloperoxidase-dependent killing. Neutrophils are 
important both in the prevention and resolution of AK.(Hurt et al. 2003; Clarke et al. 2005).  
The most convincing and potent response from the adaptive arm of the immune system is 
the secretion of IgA antibody. IgA antibody promotes neutrophil-mediated killing of 
trophozoites hence preventing adhesion of the trophozoites to the corneal epithelium. 
Furthermore, it shuts down the corneal melt-down plant of the trophozoites by inhibiting 
mannose-induced cytopathic protein 133 (MIP-133)-induced digestion of the corneal 
epithelium and stroma. The role of corticosteroids in the treatment of AK remains 
controversial. This issue arises from the contrary effects of dexamethasone on the eye; on the 
one hand they help in the resolution of AK-associated ocular inflammation, but on the other 
hand, they induce excystment of dormant cysts leading to recrudescence. Thus, targeting 
MIP-133 offers an attractive target in the therapy of AK. Earlier detection of disease by 
visualization of cysts in the cornea using in vivo confocal microscopy (IVCM) may offer an 
advantage in the management of AK.(Kumar et al. 2010) Through a more sensitive approach 
in the detection and consequent treatment of AK, the prognosis may be improved leading to 
fewer cases of corneal melting and associated complications. 
2.3 Corneal transplantation 
Corneal transplantation is the most common form of solid tissue transplantation with 
approximately 45,000 cases being performed annually in the United States alone.(CCTS, 
1992; Niederkorn, 1999; Streilein, 1999) Unlike other solid tissue transplants, corneal 
allotransplants enjoy immune privilege, and neither require standard human leukocyte 
antigen (HLA) matching, nor permanent systemic immunosuppression. First time recipients 
of corneal allografts enjoy a 2-year graft survival rate of greater than 90% if the recipient 
corneal bed is avascular and free of inflammation.(Niederkorn, 1990) Corneal immune 
privilege is attributed to: (a) an avascular corneal bed which prevents recruitment of 
immune cells and leukocytes to the graft site, thus preventing recognition of non-self HLA 
antigens; (b) lack of lymphatic vessels, which eliminates transport and presentation of non-
self HLA antigens and egress of APCs to T cells in draining lymph nodes, thus decreasing 
sensitisation (c) paucity of mature MHC-II+/HLA-DR+ resident corneal dendritic cells, 
including LC, thus decreasing direct presentation of unmatched HLA antigens to T cells; (d) 
constitutive expression of Fas ligand (CD95; FasL), which programs cell death of activated 
Fas+ T cells; (e) local ocular production of immunomodulatory neuropeptides and factors in 
aqueous humour such as transforming growth factor beta (TGF)-β2 and alpha-melanocyte 
stimulating hormone (α -MSH), which inhibits alloantigen-driven T cell activation and 
DTH.(Dana, M. R. et al., 2000; Dua & Azuara-Blanco, 1999; Griffith et al., 1995; Jager et al., 
1995; Niederkorn, 1990; Niederkorn et al., 1989; Streilein, 1993, 1995; Stuart et al., 1997; Thiel 
et al., 2009) 
Neovascularization of the corneal graft greatly increases the rate of rejection.(Alldredge & 
Krachmer, 1981; Maguire et al., 1994) As per guidelines of the Collaborative Corneal 
Transplantation Studies, the recipient cornea is considered “high-risk” if there is stromal 
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vascularisation in two or more quadrants preoperatively.(1992) The other factors which lead 
to graft rejection include growth of lymphatic vessels into the cornea, thereby establishing 
drainage to the cervical lymph nodes;(Hamrah et al., 2002a) migration of LCs into the 
cornea; maturation of resident LCs and DCs of the cornea, which can then serve as 
APCs;(Dekaris et al., 1999; Hamrah & Dana, 2007; Hamrah et al., 2002b; Liu et al., 2002) 
increased expression of cytokines IL-1 and TNF- α , which lead to recruitment of 
neutrophils, suppression of anterior chamber-associated immune deviation (ACAID), 
maturation of corneal APCs, upregulation of vascular adhesion molecules, and recruitment 
of  leukocytes.(Dana, M. R. & Streilein, 1996; Dana, R., 2007; Hamrah et al., 2007; Pepose et 
al., 1985; Streilein et al., 1996; Yamagami et al., 1999; Zhu, S. et al., 1999; Zhu, S. N. & Dana, 
1999) 
The process of corneal transplant rejection includes an induction phase, called the “afferent” 
arm, and an expression phase, called the “efferent” arm. In the afferent arm, the host 
becomes sensitized to the donor antigens by APCs (e.g., MHC class II-positive DC, LC, 
macrophages, etc.) that present antigens to T cells in draining lymph nodes. This 
sensitization process involves two different pathways. The direct pathway, which involves 
donor APCs that sensitize the host directly when T cells recognize the donor class II MHC, 
thus generating direct alloreactive T cells, and the indirect pathway, which involves host 
APCs that migrate to the graft, take up donor antigens, process it, migrate to draining 
lymph nodes, and then present their antigens to T cells. Host sensitization to donor antigens 
of corneal grafts occurs through both pathways of sensitization, especially in high-risk 
corneal grafting. Further, the critical role of draining cervical lymph nodes in the process of 
allosensitization has been clearly demonstrated by recent studies. Upon arrival in the lymph 
nodes, APCs upregulate surface expression of co-stimulatory molecules, secrete cytokines, 
leading to activation of T cells. The subsequent efferent phase is then responsible for the 
actual rejection of the graft. This phase consists of the proliferation of alloreactive T cells in 
lymphoid organs, migration of these cells to the cornea, and the development of “memory” 
that can assist the alloimmune response in case of repeated exposure to the same antigens. 
Both CD8+ cytotoxic T lymphocyte (CTL) and CD4+ T helper (Th) cells have been implicated 
in the rejection process. Th1 cells uniquely secrete IL-2, IFN-γ, and lymphotoxin, and have 
the purpose of eradicating offending pathogens by promoting inflammation. Th2 cells 
secrete IL-4 and IL-10, suppress Th1 cells, and promote B cell differentiation, leading to the 
production of antibodies. CD4+ Th1 cells are the primary mediators of the efferent arm and 
act directly as effector cells and not as helper cells in corneal graft rejection. IL-2, secreted by 
these cells, stimulates the activation and proliferation of other T and B cells, whereas IFN-γ 
activates macrophages and induces expression of class II antigens in the donor tissue. The 
role of CD8+ T cells in the rejection of allogeneic corneal grafts remains controversial. While 
CD8+ T cells can contribute to graft rejection, corneal grafts can still be rejected in their 
absence, hence making CD8+ T cells sufficient but not necessary for graft rejection.  
A major factor directing the recruitment of T cells and other leukocytes into grafts are 
chemokines. Surgical trauma induces  release of early cytokines such as TNF-α and IL-1 by 
corneal epithelial cells. These cytokines in turn stimulate the production of early neutrophil- 
and macrophage-attractant chemokines, including MIP-2/CXCL2, MCP-1/CCL2, regulated 
upon activation normal T-cell expressed and secreted protein (RANTES)/CCL5, MIP-
1α/CCL3, MIP-1β/CCL4 and eotaxin/CCL11, especially after high-risk corneal 
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transplantation.(Flynn et al., 2008; Yamagami et al., 2005; Yamagami et al., 2000; Yamagami 
et al., 1999) While early chemokines direct non-antigen-specific leukocytes to the graft, late 
chemokines as stated above produced by the graft and infiltrating leukocytes recruit 
alloantigen-primed T cells into the graft. In addition, recipients of high-risk transplants 
express very high levels of the IP-10/CXCL10 chemokine. Chemokines function together 
with other molecular mediators including integrins and adhesion molecules to direct the 
immune response toward the graft. Therapeutic endeavours seek to inhibit either or both 
arms of the immune response to prolong graft survival. Regulatory T cells (Foxp3+Tregs) 
have been shown to promote graft survival by inhibiting alloimmunity in draining lymph 
nodes as opposed to altering to the effector arm of the immune response.(Chauhan et al., 
2009; Cunnusamy et al.; Tang & Bluestone, 2008)  Measures devised to enhance graft 
survival should essentially revolve around three main goals: (a) to prevent induction of 
alloimmune response, (b) to inhibit or deplete immune effector cells, and, (c) to induce 
tolerance to specific alloantigens.(Niederkorn, 2002)  
2.4 Dry Eye Disease 
Dry eye disease (DED) is one of the most common diagnoses made in ophthalmic practice. 
DED affects millions of people around the world. It is more prevalent in women than men and 
is of inflammatory etiology.(Calonge et al.; 2007b) In epidemiologic studies conducted by 
Schaumberg and colleagues, they found a prevalence of 5.7% in women aged 50 years or 
younger, and 9.8% in women aged 75 years or above.(Schaumberg et al., 2003) Patients usually 
present with ocular irritation and in severe cases, there may be accompanying ocular pain, 
punctate keratopathy and filamentary keratitis.(Pflugfelder, 1998) The definition of DED has 
been modified over the years to integrate evolving concepts of the involvement of tear film 
hyperosmolarity, inflammation of the ocular surface, and the effects of DED on vision. In 2007, 
the International Dry Eye Workshop (DEWS) defined DED as: “a multifactorial disease of the 
tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear 
film instability with potential damage to the ocular surface. It is accompanied by increased 
osmolarity of the tear film and inflammation of the ocular surface.”(DEWS, 2007a)  
Clinically, DED can be categorised into (a) aqueous deficient and, (b) evaporative dry eye. 
(Lemp, 1995) Aqueous deficient DED consists of disorders that affect the lacrimal functional 
unit (LFU). The term “lacrimal functional unit” was coined in 1998 by Stern and group, 
comprising the ocular surface, lacrimal glands, associated innervation, and neuroendocrine 
factors.(Stern et al., 1998; Stern et al., 2004) The clinical diagnosis of DED is made using a 
combination of examination techniques, including Schirmer’s test, tear film osmolarity, and 
fluorescein tear break-up time (fTBUT). A reading of less than 15mm on the Schirmer’s strip 
in conjunction with elevated tear film osmolarity (>315 mOsm) is indicative of decreased 
tear production, hence, suggestive of aqueous-deficient DED. When fTBUT is less than 10 
seconds, there is increased suspicion of evaporative DED. Diseases that lead to aqueous 
deficient dry eye disease include Sjögren’s syndrome and non-Sjögren’s autoimmune 
conditions. Whereas, evaporative dry eye is due to diseases that affect the production, 
quality and distribution of the tear film lipid layer, namely, meibomian gland dysfunction 
(MGD) and chronic blepharitis.(Barabino & Dana, 2007; Calonge et al.) It has been 
demonstrated that regardless of the etiology of dry eye, inflammation of the ocular surface 
and homing of immune cells to the target tissue, are hallmarks of DED. These immuno-
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vascularisation in two or more quadrants preoperatively.(1992) The other factors which lead 
to graft rejection include growth of lymphatic vessels into the cornea, thereby establishing 
drainage to the cervical lymph nodes;(Hamrah et al., 2002a) migration of LCs into the 
cornea; maturation of resident LCs and DCs of the cornea, which can then serve as 
APCs;(Dekaris et al., 1999; Hamrah & Dana, 2007; Hamrah et al., 2002b; Liu et al., 2002) 
increased expression of cytokines IL-1 and TNF- α , which lead to recruitment of 
neutrophils, suppression of anterior chamber-associated immune deviation (ACAID), 
maturation of corneal APCs, upregulation of vascular adhesion molecules, and recruitment 
of  leukocytes.(Dana, M. R. & Streilein, 1996; Dana, R., 2007; Hamrah et al., 2007; Pepose et 
al., 1985; Streilein et al., 1996; Yamagami et al., 1999; Zhu, S. et al., 1999; Zhu, S. N. & Dana, 
1999) 
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arm, and an expression phase, called the “efferent” arm. In the afferent arm, the host 
becomes sensitized to the donor antigens by APCs (e.g., MHC class II-positive DC, LC, 
macrophages, etc.) that present antigens to T cells in draining lymph nodes. This 
sensitization process involves two different pathways. The direct pathway, which involves 
donor APCs that sensitize the host directly when T cells recognize the donor class II MHC, 
thus generating direct alloreactive T cells, and the indirect pathway, which involves host 
APCs that migrate to the graft, take up donor antigens, process it, migrate to draining 
lymph nodes, and then present their antigens to T cells. Host sensitization to donor antigens 
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secrete IL-4 and IL-10, suppress Th1 cells, and promote B cell differentiation, leading to the 
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role of CD8+ T cells in the rejection of allogeneic corneal grafts remains controversial. While 
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corneal epithelial cells. These cytokines in turn stimulate the production of early neutrophil- 
and macrophage-attractant chemokines, including MIP-2/CXCL2, MCP-1/CCL2, regulated 
upon activation normal T-cell expressed and secreted protein (RANTES)/CCL5, MIP-
1α/CCL3, MIP-1β/CCL4 and eotaxin/CCL11, especially after high-risk corneal 
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transplantation.(Flynn et al., 2008; Yamagami et al., 2005; Yamagami et al., 2000; Yamagami 
et al., 1999) While early chemokines direct non-antigen-specific leukocytes to the graft, late 
chemokines as stated above produced by the graft and infiltrating leukocytes recruit 
alloantigen-primed T cells into the graft. In addition, recipients of high-risk transplants 
express very high levels of the IP-10/CXCL10 chemokine. Chemokines function together 
with other molecular mediators including integrins and adhesion molecules to direct the 
immune response toward the graft. Therapeutic endeavours seek to inhibit either or both 
arms of the immune response to prolong graft survival. Regulatory T cells (Foxp3+Tregs) 
have been shown to promote graft survival by inhibiting alloimmunity in draining lymph 
nodes as opposed to altering to the effector arm of the immune response.(Chauhan et al., 
2009; Cunnusamy et al.; Tang & Bluestone, 2008)  Measures devised to enhance graft 
survival should essentially revolve around three main goals: (a) to prevent induction of 
alloimmune response, (b) to inhibit or deplete immune effector cells, and, (c) to induce 
tolerance to specific alloantigens.(Niederkorn, 2002)  
2.4 Dry Eye Disease 
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punctate keratopathy and filamentary keratitis.(Pflugfelder, 1998) The definition of DED has 
been modified over the years to integrate evolving concepts of the involvement of tear film 
hyperosmolarity, inflammation of the ocular surface, and the effects of DED on vision. In 2007, 
the International Dry Eye Workshop (DEWS) defined DED as: “a multifactorial disease of the 
tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear 
film instability with potential damage to the ocular surface. It is accompanied by increased 
osmolarity of the tear film and inflammation of the ocular surface.”(DEWS, 2007a)  
Clinically, DED can be categorised into (a) aqueous deficient and, (b) evaporative dry eye. 
(Lemp, 1995) Aqueous deficient DED consists of disorders that affect the lacrimal functional 
unit (LFU). The term “lacrimal functional unit” was coined in 1998 by Stern and group, 
comprising the ocular surface, lacrimal glands, associated innervation, and neuroendocrine 
factors.(Stern et al., 1998; Stern et al., 2004) The clinical diagnosis of DED is made using a 
combination of examination techniques, including Schirmer’s test, tear film osmolarity, and 
fluorescein tear break-up time (fTBUT). A reading of less than 15mm on the Schirmer’s strip 
in conjunction with elevated tear film osmolarity (>315 mOsm) is indicative of decreased 
tear production, hence, suggestive of aqueous-deficient DED. When fTBUT is less than 10 
seconds, there is increased suspicion of evaporative DED. Diseases that lead to aqueous 
deficient dry eye disease include Sjögren’s syndrome and non-Sjögren’s autoimmune 
conditions. Whereas, evaporative dry eye is due to diseases that affect the production, 
quality and distribution of the tear film lipid layer, namely, meibomian gland dysfunction 
(MGD) and chronic blepharitis.(Barabino & Dana, 2007; Calonge et al.) It has been 
demonstrated that regardless of the etiology of dry eye, inflammation of the ocular surface 
and homing of immune cells to the target tissue, are hallmarks of DED. These immuno-
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inflammatory processes are culprits of corneal and conjunctival damage leading to the 
presenting symptoms.(Barabino & Dana, 2007; Dana, M. R. & Hamrah, 2002) 
Recent evidence suggests a role for chemokines in the pathogenesis of dry eye syndromes. 
Increased RNA levels of IL-8, which is chemotactic for neutrophils, are found in the conjunctival 
epithelium of Sjogren's syndrome patients compared to controls. Furthermore, increased levels 
of select chemokines in the lacrimal glands of nonobese diabetic (NOD) mice, an animal model 
of Sjogren's syndrome, have been detected. NOD mice are a murine model for type-1 insulin-
dependent diabetes with an autoimmune component. They represent a murine model of 
Sjogren’s syndrome based on the similar histopathological picture of sialoadenitis. These mice 
have lymphocytic infiltration of not just the pancreas but also the submandibular and lacrimal 
glands. Both RANTES/CCL5 and IP-10/CXCL10 gene transcripts are detected in lacrimal 
glands at 8 weeks of age increased markedly during the course of active disease, concomitant 
with induction of their receptors CCR1, CCR5 and CXCR3. The examination of lacrimal glands 
indicated that lymphocytes in the inflammatory infiltrates are responsible for the production of 
these chemokines. Moreover, anti-RANTES treatment significantly reduced inflammation in the 
lacrimal glands of these mice. Further, patients with DED have a significant increase in the 
number of ocular surface cells that express CCR5, the receptor for RANTES/CCL5 and MIP-
1β/CCL4. These data suggest that a better understanding of the role of chemokines and 
chemokine receptors in DES could open new doors for development of molecular strategies for 
immune modulation in this common disorder.  
Numerous studies have demonstrated the enhanced expression of pro-inflammatory 
cytokines (e.g., IL-1, IL-6, IL-8, TNF-α ) mRNA and protein by the ocular surface epithelium 
or tear film. The increase of these proinflammatory cytokines can lead to epithelial cell 
proliferation, keratinization, and angiogenesis, and thereby could link ocular surface disease 
with a number of lid margin disorders, such as rosacea, characterized by inflammation. In 
addition, IL-1 may lead to upregulation of matrix proteases, including collagenases, and 
thereby exacerbate stromal pathology as well as alter the paracrine effect of other cytokines 
on resident DCs, macrophages, fibroblasts, and epithelial cells by altering the matrix milieu 
in which these cytokines bind their respective receptors. Corneal epithelial cells respond to 
stress signals by producing cytokine mediators of inflammation such as TNF- α , IL-1β, IL- 8 
and MMPs.(Li et al., 2006; Luo et al., 2004) Subsequently, maturing resident and recruited 
DC carry antigen to the draining lymph nodes to present and activate T cells. T cell-
mediated responses have recently been shown to play a center stage in DED. Th1 cells 
recognize antigenic peptides in association with MHC class II molecules on the surface of 
APC, and release pro-inflammatory cytokines that increase vascular permeability and 
recruit further inflammatory cells to the site of injury. Due to the nonspecific nature of cell 
recruitment employed by CD4+ Th1 cells, inflammation can be severe with damage to 
bystander tissue. More recently, Th 17 associated cytokines and IL 17 producing cells have 
been found in the ocular surface epithelium of dry eye patients and it has been hypothesized 
that epithelial cells subjected to desiccating conditions promote DC to secrete IL-6, IL-23 and 
TGF-β, which in turn induce Th17 cells.(Zheng, X. et al.) 
3. Leukocyte trafficking 
Trafficking signals finely control the movement of distinct subsets of immune cells into and 
out of specific tissues. Leukocyte extravasation from blood to tissue, including that of APC 
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and T cells, usually occurs through a multistep process, involving adhesion molecules and 
chemokines. Because the accumulation of leukocytes in tissues contributes to a wide variety 
of diseases, these 'molecular codes' provide new targets for inhibiting tissue-specific 
inflammation. However, immune cell migration is also critically important for the delivery 
of protective immune responses to tissues. Therefore, the challenge lies in identifying 
trafficking molecules that will specifically inhibit key cell subsets that drive disease 
processes without affecting the migration of leukocytes required for protective immunity.  
Adhesion molecules can be categorized according to their structure or function. Four major 
families are distinguished structurally: the selectins, the sialomucins, the integrins, and the 
Ig superfamily. Leukocyte tethering and rolling, mediated typically by three selectins, L-
selectin, E-selectin and P-selectin, are the first steps in the process of leukocyte binding to 
vascular endothelium. Two selectins, P- and E-selectin, are expressed on activated 
endothelium, whereas L-selectin is found on leukocytes. L-selectin is involved in the 
homing of T cells to lymphoid tissues but is also expressed on other leukocytes, where it 
participates in inflammation. E-selectin is expressed on corneal vascular endothelium, 
whereas P-selectin is expressed on inflamed vascular endothelium and by certain 
leukocytes. P-selectin glycoprotein ligand-1 (PSGL-1) binds all three selectins and is 
expressed on peripheral blood DC.  
In the cornea, studies in both human and animal models of disease have confirmed that cell 
adhesion molecules are closely associated with the development of herpetic keratitis, and 
corneal allograft rejection. P- and E-selectin have been shown to mediate neutrophil 
recruitment to the cornea in studies using P/E-selectin knockout mice. Integrins are found 
on most cell types. Two subfamilies are most important for leukocyte migration: the α4 
(CD49) and the 2 (CD11/CD18) integrins. Four distinct members of 2 integrins exist, three 
of which are expressed by DC. Vascular endothelial ligands for these molecules are 
members of the immunoglobulin superfamily. Leukocyte arrest in venules requires in situ 
activation of at least one of the four main integrins: VLA-4 (binds to VCAM-1), 47 (binds 
to MadCAM-1), Mac-1(binds to ICAM-1) and LFA-1 (binds to ICAM-1 and 2). VCAM-1 has 
been shown to be present on monocytes and vascular endothelial cells during corneal 
inflammation. Arguably the most important ligand for 2 integrins is ICAM-1, which is 
expressed on many cell types and is strongly upregulated upon exposure to inflammatory 
cytokines in the cornea and on limbal endothelial cells, deletion of which has been shown to 
suppress corneal graft rejection.  
Chemokine receptors regulate leukocyte retention within tissues. The migration of 
leukocytes to inflammatory sites depends on a cascade of discrete events mediated, in part, 
by chemokines and their receptors. Numerous chemokines have now been described during 
inflammation, including CCL3/MIP-1, CCL4/MIP-1, and CCL5/RANTES, ligands for 
CCR1 and CCR5; CCL2/MCP-1, a ligand for CCR2; CCL22/MDC and CCL17/TARC, 
ligands for CCR4; CCL20/MIP-3α, the ligand for CCR6; CXCL8/IL-8, a ligand for CXCR1 
and CXCR2; CXCL1/KC, CXCL2/MIP-2, and CXCL5/ENA-78, ligands for CXCR2; CXCL9 
/MIG, CXCL10/IP10 and CXCL11/ITAC, ligands for CXCR3. In addition, constitutively 
expression of CCLs 2-5,CXCL10, and CCL27/CTACK, a ligand for CCR10 have been 
described in the normal cornea. Which of these chemokines is relevant in recruitment, 
retention and egrees of corneal APC, is unclear. Little is known about the constitutive 
recruitment of DC and macrophage precursors into peripheral tissues in the absence of 
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inflammatory processes are culprits of corneal and conjunctival damage leading to the 
presenting symptoms.(Barabino & Dana, 2007; Dana, M. R. & Hamrah, 2002) 
Recent evidence suggests a role for chemokines in the pathogenesis of dry eye syndromes. 
Increased RNA levels of IL-8, which is chemotactic for neutrophils, are found in the conjunctival 
epithelium of Sjogren's syndrome patients compared to controls. Furthermore, increased levels 
of select chemokines in the lacrimal glands of nonobese diabetic (NOD) mice, an animal model 
of Sjogren's syndrome, have been detected. NOD mice are a murine model for type-1 insulin-
dependent diabetes with an autoimmune component. They represent a murine model of 
Sjogren’s syndrome based on the similar histopathological picture of sialoadenitis. These mice 
have lymphocytic infiltration of not just the pancreas but also the submandibular and lacrimal 
glands. Both RANTES/CCL5 and IP-10/CXCL10 gene transcripts are detected in lacrimal 
glands at 8 weeks of age increased markedly during the course of active disease, concomitant 
with induction of their receptors CCR1, CCR5 and CXCR3. The examination of lacrimal glands 
indicated that lymphocytes in the inflammatory infiltrates are responsible for the production of 
these chemokines. Moreover, anti-RANTES treatment significantly reduced inflammation in the 
lacrimal glands of these mice. Further, patients with DED have a significant increase in the 
number of ocular surface cells that express CCR5, the receptor for RANTES/CCL5 and MIP-
1β/CCL4. These data suggest that a better understanding of the role of chemokines and 
chemokine receptors in DES could open new doors for development of molecular strategies for 
immune modulation in this common disorder.  
Numerous studies have demonstrated the enhanced expression of pro-inflammatory 
cytokines (e.g., IL-1, IL-6, IL-8, TNF-α ) mRNA and protein by the ocular surface epithelium 
or tear film. The increase of these proinflammatory cytokines can lead to epithelial cell 
proliferation, keratinization, and angiogenesis, and thereby could link ocular surface disease 
with a number of lid margin disorders, such as rosacea, characterized by inflammation. In 
addition, IL-1 may lead to upregulation of matrix proteases, including collagenases, and 
thereby exacerbate stromal pathology as well as alter the paracrine effect of other cytokines 
on resident DCs, macrophages, fibroblasts, and epithelial cells by altering the matrix milieu 
in which these cytokines bind their respective receptors. Corneal epithelial cells respond to 
stress signals by producing cytokine mediators of inflammation such as TNF- α , IL-1β, IL- 8 
and MMPs.(Li et al., 2006; Luo et al., 2004) Subsequently, maturing resident and recruited 
DC carry antigen to the draining lymph nodes to present and activate T cells. T cell-
mediated responses have recently been shown to play a center stage in DED. Th1 cells 
recognize antigenic peptides in association with MHC class II molecules on the surface of 
APC, and release pro-inflammatory cytokines that increase vascular permeability and 
recruit further inflammatory cells to the site of injury. Due to the nonspecific nature of cell 
recruitment employed by CD4+ Th1 cells, inflammation can be severe with damage to 
bystander tissue. More recently, Th 17 associated cytokines and IL 17 producing cells have 
been found in the ocular surface epithelium of dry eye patients and it has been hypothesized 
that epithelial cells subjected to desiccating conditions promote DC to secrete IL-6, IL-23 and 
TGF-β, which in turn induce Th17 cells.(Zheng, X. et al.) 
3. Leukocyte trafficking 
Trafficking signals finely control the movement of distinct subsets of immune cells into and 
out of specific tissues. Leukocyte extravasation from blood to tissue, including that of APC 
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and T cells, usually occurs through a multistep process, involving adhesion molecules and 
chemokines. Because the accumulation of leukocytes in tissues contributes to a wide variety 
of diseases, these 'molecular codes' provide new targets for inhibiting tissue-specific 
inflammation. However, immune cell migration is also critically important for the delivery 
of protective immune responses to tissues. Therefore, the challenge lies in identifying 
trafficking molecules that will specifically inhibit key cell subsets that drive disease 
processes without affecting the migration of leukocytes required for protective immunity.  
Adhesion molecules can be categorized according to their structure or function. Four major 
families are distinguished structurally: the selectins, the sialomucins, the integrins, and the 
Ig superfamily. Leukocyte tethering and rolling, mediated typically by three selectins, L-
selectin, E-selectin and P-selectin, are the first steps in the process of leukocyte binding to 
vascular endothelium. Two selectins, P- and E-selectin, are expressed on activated 
endothelium, whereas L-selectin is found on leukocytes. L-selectin is involved in the 
homing of T cells to lymphoid tissues but is also expressed on other leukocytes, where it 
participates in inflammation. E-selectin is expressed on corneal vascular endothelium, 
whereas P-selectin is expressed on inflamed vascular endothelium and by certain 
leukocytes. P-selectin glycoprotein ligand-1 (PSGL-1) binds all three selectins and is 
expressed on peripheral blood DC.  
In the cornea, studies in both human and animal models of disease have confirmed that cell 
adhesion molecules are closely associated with the development of herpetic keratitis, and 
corneal allograft rejection. P- and E-selectin have been shown to mediate neutrophil 
recruitment to the cornea in studies using P/E-selectin knockout mice. Integrins are found 
on most cell types. Two subfamilies are most important for leukocyte migration: the α4 
(CD49) and the 2 (CD11/CD18) integrins. Four distinct members of 2 integrins exist, three 
of which are expressed by DC. Vascular endothelial ligands for these molecules are 
members of the immunoglobulin superfamily. Leukocyte arrest in venules requires in situ 
activation of at least one of the four main integrins: VLA-4 (binds to VCAM-1), 47 (binds 
to MadCAM-1), Mac-1(binds to ICAM-1) and LFA-1 (binds to ICAM-1 and 2). VCAM-1 has 
been shown to be present on monocytes and vascular endothelial cells during corneal 
inflammation. Arguably the most important ligand for 2 integrins is ICAM-1, which is 
expressed on many cell types and is strongly upregulated upon exposure to inflammatory 
cytokines in the cornea and on limbal endothelial cells, deletion of which has been shown to 
suppress corneal graft rejection.  
Chemokine receptors regulate leukocyte retention within tissues. The migration of 
leukocytes to inflammatory sites depends on a cascade of discrete events mediated, in part, 
by chemokines and their receptors. Numerous chemokines have now been described during 
inflammation, including CCL3/MIP-1, CCL4/MIP-1, and CCL5/RANTES, ligands for 
CCR1 and CCR5; CCL2/MCP-1, a ligand for CCR2; CCL22/MDC and CCL17/TARC, 
ligands for CCR4; CCL20/MIP-3α, the ligand for CCR6; CXCL8/IL-8, a ligand for CXCR1 
and CXCR2; CXCL1/KC, CXCL2/MIP-2, and CXCL5/ENA-78, ligands for CXCR2; CXCL9 
/MIG, CXCL10/IP10 and CXCL11/ITAC, ligands for CXCR3. In addition, constitutively 
expression of CCLs 2-5,CXCL10, and CCL27/CTACK, a ligand for CCR10 have been 
described in the normal cornea. Which of these chemokines is relevant in recruitment, 
retention and egrees of corneal APC, is unclear. Little is known about the constitutive 
recruitment of DC and macrophage precursors into peripheral tissues in the absence of 
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inflammation. APC function and migratory behavior are related to rapid and coordinated 
switching in chemokine receptor expression by these cells, allowing them to coordinate 
migratory routes and biological function. During inflammation, CCL2, CCL5, and CXCL8 
are produced to attract immature DC that express CXCR4 and CCR4 respectively. In 
addition, these DC are ideally suited for recruitment to inflammatory sites by their 
expression of functional receptors for inflammation-induced chemokines, such as CCR1, 
CCR2, CCR3, CCR5 and CXCR1.  
Inflammatory signals induce resident corneal DCs to undergo maturation. Upon 
maturation, DCs downregulate pattern recognition receptors necessary for surveillance of 
antigens  and upregulate CCR7, a receptor important in the homing of DCs to the lymph 
nodes. Maturing CCR7+ DCs then enter CCL21-expressing lymphatic vessels and travel to 
the draining lymph nodes where CCR7 ligands, namely, CCL19/EBI1 ligand chemokine 
(ELC) and CCL21/secondary lymphoid tissue chemokine (SLC), are produced. In addition, 
after fluorescein isothiocyanate (FITC) painting (dendritic cell migration assay), CXCR4 
inhibition has been shown to impair LC and dermal DC migration to draining LNs, 
indicating that both CCR7 and CXCR4 make independent contributions to the egress of DCs 
from resident tissue to the lymph nodes. DC migration into and along afferent lymphatics 
occurs through a series of steps, including (1) mobilization, (2) detachment, (3) interstitial 
migration, (4) entry into the afferent lymphatics, and (5) transit via lymph. Recent data have 
shown that lymphatic endothelial cells upregulate E-selectin, chemokines (CCL5, CCL20, 
and CXCL5), and adhesion molecules (ICAM-1 and VCAM-1) after cytokine stimulation in 
vitro or in vivo. Once in the draining lymph nodes, antigen-loaded mature DCs activate 
naive T cells, which then proliferate and enter the blood and migrate back to the site of 
inflammation. In the cornea, CCR5 and CX3CR1, but not CCR1 are partially involved in the 
recruitment of MHC-II+ LCs. How the central immature LC or stromal APC populations are 
recruited is not known, although the recently demonstrated constitutive expression of CCR2 
on stromal BM-derived cell subsets, implicates a role for this chemokine. Further, both 
vascular endothelial growth factor (VEGFR)-3 and CCR7 are partially implicated in the 
egress of stromal DCs. APC recruitment to the cornea is likely complex, highly regulated 
and dependent on recruitment signals that are either tissue-specific or inflammation-
induced, or both.  
4. Conclusion 
The cornea and ocular surface are constantly exposed to environmental pollutants and 
irritants, microbes, and other potentially noxious agents. Since from an evolutionary 
standpoint the scope of the host defense mechanisms against these stimuli should be 
narrow, that is to say adequately effective to protect the eye against the potential harm from 
these agents and yet tempered enough not to lead to unwanted damage, the eye has 
developed many mechanisms to effect and regulate its response to environmental 
challenges. Identification of the critical pathways of cell migration to and from the cornea 
will provide new molecular targets for pharmacological intervention in inflammatory, 
infectious, alloimmune and autoimmune diseases and may lead to novel highly specific 
strategies for immunotherapy, through modulation of APC and T cell migration and 
function. Few effective anti-inflammatory drugs have emerged over the last decades in the 
ophthalmic field and an urgent need for new drugs exists, as many inflammatory diseases 
are inadequately responsive to current medications.  
 




Akhtar, J. & Shukla, D. (2009). Viral entry mechanisms: cellular and viral mediators of 
herpes simplex virus entry. FEBS J.  276: 7228-7236. 
Alizadeh, H.,  Niederkorn, J.Y.,  McCulley, J.P.,  in: Pepose, J.S., Holland, G.N.,  Wilhelmus, 
K.R. (Eds.), Ocular Infection and Immunity, Mosby, St. Louis, 1996, pp. 1062e1071. 
Alizadeh H, Apte S, El-Agha MS, Li, L. Hurt, M. Howard, K. Cavanagh, H. D. McCulley, J. 
P. Niederkorn, J.Y. (2001) Tear IgA and serum IgG antibodies against 
Acanthamoeba in patients with Acanthamoeba keratitis. Cornea. 20:622-627. 
Alldredge, O.C. & Krachmer, J.H. (1981). Clinical types of corneal transplant rejection. Their 
manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol.  
99: 599-604. 
Asbell, P.A. & Kamenar, T. (1987). The response of Langerhans cells in the cornea to herpetic 
keratitis. Curr Eye Res.  6: 179-182. 
Avery, A.C., Zhao, Z.S., Rodriguez, A., Bikoff, E.K., Soheilian, M., Foster, C.S., & Cantor, H. 
(1995). Resistance to herpes stromal keratitis conferred by an IgG2a-derived 
peptide. Nature.  376: 431-434. 
Babu, J.S., Kanangat, S., & Rouse, B.T. (1995). T cell cytokine mRNA expression during the 
course of the immunopathologic ocular disease herpetic stromal keratitis. J 
Immunol.  154: 4822-4829. 
Babu, J.S., Thomas, J., Kanangat, S., Morrison, L.A., Knipe, D.M., & Rouse, B.T. (1996). Viral 
replication is required for induction of ocular immunopathology by herpes simplex 
virus. J Virol.  70: 101-107. 
Balkwill, F.R. & Burke, F. (1989). The cytokine network. Immunol Today.  10: 299-304. 
Barabino, S. & Dana, M.R. (2007). Dry eye syndromes. Chem Immunol Allergy.  92: 176-184. 
Barton, G.M. & Medzhitov, R. (2003). Toll-like receptor signaling pathways. Science.  300: 
1524-1525. 
Bauer, D., Wasmuth, S., Hennig, M., Baehler, H., Steuhl, K.P., & Heiligenhaus, A. (2009). 
Amniotic membrane transplantation induces apoptosis in T lymphocytes in murine 
corneas with experimental herpetic stromal keratitis. Invest Ophthalmol Vis Sci.  50: 
3188-3198. 
Bouley, D.M., Kanangat, S., Wire, W., & Rouse, B.T. (1995). Characterization of herpes 
simplex virus type-1 infection and herpetic stromal keratitis development in IFN-
gamma knockout mice. J Immunol.  155: 3964-3971. 
Brandt, C.R. & Salkowski, C.A. (1992). Activation of NK cells in mice following corneal 
infection with herpes simplex virus type-1. Invest Ophthalmol Vis Sci.  33: 113-120. 
Burns, A.R., Li, Z., & Smith, C.W. (2005). Neutrophil migration in the wounded cornea: the 
role of the keratocyte. Ocul Surf.  3: S173-176. 
Calonge, M., Enriquez-de-Salamanca, A., Diebold, Y., Gonzalez-Garcia, M.J., Reinoso, R., 
Herreras, J.M., & Corell, A. (2010). Dry eye disease as an inflammatory disorder. 
Ocul Immunol Inflamm.  18: 244-253. 
Campadelli-Fiume, G., Amasio, M., Avitabile, E., Cerretani, A., Forghieri, C., Gianni, T., & 
Menotti, L. (2007). The multipartite system that mediates entry of herpes simplex 
virus into the cell. Rev Med Virol.  17: 313-326. 
Carr, D.J., Harle, P., & Gebhardt, B.M. (2001). The immune response to ocular herpes 
simplex virus type 1 infection. Exp Biol Med (Maywood).  226: 353-366. 
 
Advances in Ophthalmology 
 
94
inflammation. APC function and migratory behavior are related to rapid and coordinated 
switching in chemokine receptor expression by these cells, allowing them to coordinate 
migratory routes and biological function. During inflammation, CCL2, CCL5, and CXCL8 
are produced to attract immature DC that express CXCR4 and CCR4 respectively. In 
addition, these DC are ideally suited for recruitment to inflammatory sites by their 
expression of functional receptors for inflammation-induced chemokines, such as CCR1, 
CCR2, CCR3, CCR5 and CXCR1.  
Inflammatory signals induce resident corneal DCs to undergo maturation. Upon 
maturation, DCs downregulate pattern recognition receptors necessary for surveillance of 
antigens  and upregulate CCR7, a receptor important in the homing of DCs to the lymph 
nodes. Maturing CCR7+ DCs then enter CCL21-expressing lymphatic vessels and travel to 
the draining lymph nodes where CCR7 ligands, namely, CCL19/EBI1 ligand chemokine 
(ELC) and CCL21/secondary lymphoid tissue chemokine (SLC), are produced. In addition, 
after fluorescein isothiocyanate (FITC) painting (dendritic cell migration assay), CXCR4 
inhibition has been shown to impair LC and dermal DC migration to draining LNs, 
indicating that both CCR7 and CXCR4 make independent contributions to the egress of DCs 
from resident tissue to the lymph nodes. DC migration into and along afferent lymphatics 
occurs through a series of steps, including (1) mobilization, (2) detachment, (3) interstitial 
migration, (4) entry into the afferent lymphatics, and (5) transit via lymph. Recent data have 
shown that lymphatic endothelial cells upregulate E-selectin, chemokines (CCL5, CCL20, 
and CXCL5), and adhesion molecules (ICAM-1 and VCAM-1) after cytokine stimulation in 
vitro or in vivo. Once in the draining lymph nodes, antigen-loaded mature DCs activate 
naive T cells, which then proliferate and enter the blood and migrate back to the site of 
inflammation. In the cornea, CCR5 and CX3CR1, but not CCR1 are partially involved in the 
recruitment of MHC-II+ LCs. How the central immature LC or stromal APC populations are 
recruited is not known, although the recently demonstrated constitutive expression of CCR2 
on stromal BM-derived cell subsets, implicates a role for this chemokine. Further, both 
vascular endothelial growth factor (VEGFR)-3 and CCR7 are partially implicated in the 
egress of stromal DCs. APC recruitment to the cornea is likely complex, highly regulated 
and dependent on recruitment signals that are either tissue-specific or inflammation-
induced, or both.  
4. Conclusion 
The cornea and ocular surface are constantly exposed to environmental pollutants and 
irritants, microbes, and other potentially noxious agents. Since from an evolutionary 
standpoint the scope of the host defense mechanisms against these stimuli should be 
narrow, that is to say adequately effective to protect the eye against the potential harm from 
these agents and yet tempered enough not to lead to unwanted damage, the eye has 
developed many mechanisms to effect and regulate its response to environmental 
challenges. Identification of the critical pathways of cell migration to and from the cornea 
will provide new molecular targets for pharmacological intervention in inflammatory, 
infectious, alloimmune and autoimmune diseases and may lead to novel highly specific 
strategies for immunotherapy, through modulation of APC and T cell migration and 
function. Few effective anti-inflammatory drugs have emerged over the last decades in the 
ophthalmic field and an urgent need for new drugs exists, as many inflammatory diseases 
are inadequately responsive to current medications.  
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1. Introduction 
Keratoconus is an ectatic disease in which the cornea develops a conical shape due to 
thinning of the collagenous corneal stroma. Characteristic morphological features seen on 
slit lamp examination are well described. This overview describes the recent advances in our 
understanding of keratoconic pathology, focussing particularly on the matrix 
metalloproteinase hypothesis of keratoconus disease progression.   
2. The diversity and complexity of keratoconus 
Keratoconus is a corneal ectatic disease where the cornea assumes a conical shape due to 
thinning of the corneal stroma, inducing irregular astigmatism and myopia and leading to 
marked impairment of vision1. Keratoconus typically starts at puberty and progresses until 
the third or fourth decade of life; alternatively it may commence later and arrest at any age. 
This disease is associated with several conditions, particularly those which encourage eye 
rubbing. 
The mechanism of disease progression has long been the subject of intense research; 
however, research is complicated by the large degree of variation in clinical features 
between patients. Forme fruste or sub-clinical forms of the disease, likely contribute to the 
differences in reported incidence are estimated to occur between 50 and 230 per 100,000 of 
the general population1. There are also significant geographical variations. New Zealand, for 
example, has an unusually high prevalence of keratoconus. 50% of corneal transplants 
performed in New Zealand are due to this debilitating disease, compared with 30% in 
Australia2 and 20% in the UK3. 
3. Clinical signs of keratoconus 
The first adequate description of keratoconus, setting it aside from other ectatic conditions, 
was advanced by Nottingham in 1854 in his treatise ‘Practical observations on conical 
cornea: and on the short sight, and other defects of vision connected with it’4. 
In 1943 Berliner5 listed the seven distinct features of keratoconus as classified by Von der 
Heydt and Appelbaum:  
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1. Thinning of the cornea at the apex of the cone 
2. Reflex from the endothelial cup 
3. Striae 
4. Irregular superficial opacities or scars 
5. Ruptures in Descemet’s membrane 
6. Increased visibility of the nerve fibres and  
7. Fleischer’s ring.  
These morphological features became incorporated by Duke-Elder6 into the 1965 text 
‘System of Ophthalmology’, which went on to describe keratoconus as a disease which can 
be recognised by: 
1. A thinning of the cornea at the apex of the cone from one half to one fifth of its normal 
dimensions 
2. An endothelial reflex in the central portion of the cornea at the peak of the cone 
3. Vertical lines in the deeper layers of the stroma 
4. An increased visibility of the nerve fibres which form a network of grey lines 
interspersed with small dots 
5. Fleischer’s ring, a line running round the base of the cone 
6. Ruptures of Descemet’s membrane of characteristic appearance 
7. Ruptures in Bowman’s membrane in advanced cases producing superficial linear scars. 
Rabinowitz1 lists the following clinical signs which may be present individually or in 
combination in moderate to advanced keratoconus: 
‘Stromal thinning (centrally or paracentrally, most commonly inferiorly or 
inferotemporally); conical protrusion; an iron line partially or completely surrounding the 
cone (Fleischer’s ring); and fine vertical lines in the deep stroma and Descemet’s membrane 
(Vogt’s striae)... Other accompanying signs might include epithelial nebulae, anterior 
stromal scars, enlarged corneal nerves and increased intensity of the corneal endothelial 
reflex and subepithelial fibrillary lines.’ 
Since then advances in corneal topographical assessment have greatly aided the diagnosis of 
early disease. Prior to topography, forme fruste keratoconus was harder to recognise as 
patients do not necessarily have symptoms or observable clinical signs in these early stages.  
4. Antero-posterior review of morphological changes in keratoconus  
Pathological and histopathological abnormalities have been documented in every layer of 
the keratoconic cornea and this has previously been reviewed by our laboratory7. The 
following represents a layer by layer summary of keratoconic morphological variations 
reported.   
4.1 Epithelium  
Ex vivo histological analysis of keratoconic corneas has demonstrated significant thinning of 
the central epithelium8. Central epithelial thinning was significantly greater in those corneas 
which also had breaks in the Bowman’s layer, however, the authors thought it likely that 
differences in the integrity of Bowman’s layer could nevertheless be considered to be 
manifestations of the same disease process.  Subsequent studies report thickened epithelia in 
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keratoconus9,10 or else no difference in epithelial thickness between keratoconus and normal 
controls11.   
In vivo confocal microscopy studies of the epithelium demonstrate morphological alterations 
in the area of the keratoconic corneal apex.  Elongated superficial epithelial cells, arranged in 
a whorl-like fashion, can be observed. Near Bowman's membrane highly reflective changes 
and fold-like structures are visible12. These in vivo pathological features may well reflect the 
oedematous disruptions of basal epithelial integrity in keratoconus.  
Apoptotic changes have also been detected in epithelia of keratoconic samples. TUNEL 
positive epithelial cells were confined to the superficial epithelium of normal corneas while 
extending further down in keratoconic corneas9.This is supported by the work which 
reported that intense TUNEL labelling was present in the basal epithelia of fifteen out of 
sixteen keratoconic corneas examined13.  
The keratoconic basement membrane assumes an irregular appearance and breaks in places14. 
It also undergoes a change in composition15,16 that cannot be explained by scarring alone. 
Laminin-1 and laminin-5 staining was shown to be irregular and thickened at defect sites, 
however monoclonal antibodies against the 2 and 2 chains did not react15. Type IV collagen 
1 and 2 reactivity was also only found in the defect regions of keratoconic or scarred 
corneas15. Immunostaining for type VII collagen was patchily localised to the basement 
membrane defects15. Integrin 4 staining which was positive in the basement membrane and 
the lateral and apical cell membranes of the epithelial cells, was found to be discontinuous in 
keratoconic corneas15. It has been suggested that a process similar to wound healing might 
account for such differences in structure. Basement membrane alterations may affect critical 
interactions of the corneal epithelium with the underlying basement membrane, as well as cell-
matrix interactions and matrix organization in the stroma16.  
4.2 Nerve fibres 
Increased visibility of nerve fibres by slit lamp biomicroscopy has been demonstrated in 
keratoconus. Corneal nerves pass between the stroma and epithelium at sites of early 
degradative change17. Keratocytes wrap around the nerves as they pass through an 
otherwise acellular Bowman's layer17. Localised nerve thickenings develop in the epithelium 
and stress epithelial architecture17.  
4.3 Bowman’s layer 
Scanning electron microscopy has found defects and ruptures in Bowman’s layer to varying 
degrees in all keratoconic corneas examined18. Discontinuities in Bowman’s layer are 
sometimes accompanied by distortion of the stroma beneath the defect15 or alternatively, 
direct contact between epithelial and stromal cells19. Rather than being seen throughout the 
affected cornea, such abnormalities of the extracellular matrix are usually confined to 
several loci, suggesting a localised focus of disease progression. 
4.4 Stroma – Collagen lamellae and keratocytes 
The thickness of collagen lamellae in keratoconus is unaltered, but the number of lamellae 
appears to be significantly reduced compared to normal tissue20. There is no difference in 
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interfibrillar spacing between keratoconus and control corneas, conclusively demonstrating 
that stromal thinning in keratoconus is not due to closer packing of the fibrils in the stroma.  
There is some evidence for a progressive loss of lamellae from the stroma, for example, a 
reduction in the volume of proteoglycan along the collagen fibrils has been found in 
keratoconus21. Low angle x-ray scattering has shown that the orientation of collagen fibrils 
within lamellae is also altered in the disease22. It is likely that these changes reflect the 
presence of a degradative process or alternatively, insufficient repair mechanisms. 
Biochemical analyses of stromal matrix components are inconclusive: Critchfield and co-
workers23 described decreased collagen and total protein levels in keratoconic tissue by 
western blotting. Radda et al.24 found a 5% increase in type I collagen in keratoconus; while 
Zimmermann et al.25 found no differences in collagen composition. 
Keratoconus is also associated with changes in keratocyte morphology as well as loss of 
keratocyte density11, 12. Keratocytes may be lost though apoptosis9,13, however, as apoptosis 
was not seen in all keratoconic samples analysed it was proposed that such cells might not 
be detected if at the time of analysis the tissue was in a period of keratoconic remission. An 
alternative explanation suggests that because keratoconus is diagnosed on the basis of 
clinical findings, there may be several diseases with differing pathophysiological 
mechanisms that produce the phenotypic change that is referred to as keratoconus.  
Keratocyte density was lowest in the anterior-most part of the stroma12. Whilst there may be 
a significant decrease in the density of keratocytes in the stroma immediately underneath 
Bowmans’ membrane, the remaining keratocytes are far from quiet. Such keratocytes and 
their pseudopodia are oriented apically towards the overlying epithelium and their 
activated state is reflected by the abundance of rough endoplasmic reticulum within the 
cells26.   
Studies of the peripheral keratoconic cornea also show discrete incursions of fine keratocytic 
processes into Bowman’s membrane10. These processes were often observed in conjunction 
with posterior collapse of epithelial cells into the Bowman’s layer10. 
4.5 Descemet’s membrane 
Ruptures and folds in Descemet’s membrane are common in keratoconus14. The origin of 
these ruptures is unclear as several studies of extracellular matrix proteins have revealed no 
differences in the levels of collagens, laminin, entactin or perlecan between keratoconus and 
normal tissue19,25. The appearance of the defects in Descemet’s membrane may well be 
associated with environmental factors such as eye rubbing and may lead to the development 
of hydrops1. 
4.6 Endothelium 
The endothelium may be normal in keratoconus or may demonstrate intracellular dark 
structures, pleomorphisms or elongation of cells1. Scanning slit confocal microscopy and 
ultrasound biomicroscopy in living patients with keratoconus revealed central detachment 
of Descemet’s membrane and endothelium from the posterior part of the stroma27. Ruptures 
in Descemet’s membrane may directly lead to endothelial cell loss by triggering cell 
membrane perforation, loss of cell contents and edema28. Alternatively apoptosis may 
account for decreased endothelial cell density13. 
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4.7 Evidence from recurrence of keratoconus 
The recurrences of keratoconus in patients after penetrating keratoplasty29 suggest either a 
recurrence of the host disease in the graft or else represent transmission of undiagnosed 
keratoconus from the donor cornea30. Histological examination of corneal buttons from 
patients undergoing repeated penetrating keratoplasty revealed structural changes 
compatible with a diagnosis of keratoconus in all the examined corneas31. Recurrence of 
keratoconus characteristics may be attributed to graft repopulation by the recipient cells, 
ageing of the grafted tissue, or both. However a recent study from our own laboratory failed 
to find evidence of recurrence of keratoconus in patients undergoing regraft surgery32. 
 
Fig. 1. A diverse range of morphological changes have been described in every layer of the 
keratoconic cornea. An antero-posterior section of a keratoconic cornea labelled with CellTracker 
green to highlight cellular morphology and integrin 31 labelling the basal epithelium in red 
helps to summarise characteristic histopathological abnormalities by corneal layer.  
Figure reproduced by permission from Wiley-Blackwells7 
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5. Pathology to pathogenesis 
The diversity of pathologies described for keratoconus are likely to represent temporal 
differences in the progression of the disease, positional differences relative to the apical 
centre of maximum damage and reflect a variety of pathophysiological diseases which make 
up the clinical pigeonhole of keratoconus.  
Matrix metalloproteinases (MMPs) have long been suspected of mediating the pathological 
progression of keratoconus. The cornea is 70% collagen by weight and the reduced collagen 
content of the keratoconic cornea suggests a degraded extracellular matrix23. Extracellular 
matrix breakdown is, however, only a small component of the MMP repertoire of activity.  
Nevertheless, this function is essential for normal remodeling, leading to the constitutive 
expression of MMPs in healthy tissues.  
Various models emphasise the role of MMPs in disease, for example, as mediators of 
connective tissue destruction in arthritis33. Consistent with such an involvement is the MMP 
hypothesis of keratoconus which proposes that MMPs are over-expressed in the disease 
while MMP inhibitors may be down-regulated, shifting the balance towards excessive tissue 
destruction. Over the last decade many studies have set out to measure the levels of MMPs 
and their inhibitors by a variety of techniques yet over-expression of MMPs or presence of 
active forms has not been found consistently34.  
It is important to consider that the relative balance between various MMPs could be more 
significant than absolute concentrations. This is relevant given that MMPs often undergo 
intermolecular interactions with each other to achieve activation from the latent form or to 
target MMP action to a particular site such as the cell surface. Paradoxically, tissue inhibitors of 
matrix metalloproteinases (TIMPs) can associate with pro form MMPs to trigger proteolytic 
activity33. Tissue degradation in thinning disorders, such as keratoconus, also involves the 
expression of inflammatory mediators, including proinflammatory cytokines and cell adhesion 
molecules35, which modulate MMP activity and are themselves modulated by it.  
The MMP family includes more than 25 members that make up five families based on their 
substrate preference: collagenases (MMP-1, MMP-8, and MMP-13), stromelysins (MMP-3, 
MMP-10), matrilysins (MMP-7, MMP-26), gelatinases (MMP-2, MMP-9), membrane type 
MMPs (MPP-14 to MMP-17, MMP-24) and others36. Most are synthesised by resident cells, 
some are brought in by invading leukocytes.  Specific MMPs appear in specific locations 
within the cornea36, likely due to cellular and soluble factors particular to the layer.  
MMP changes have been described in every layer of the cornea in keratoconus. The 
following is a layer by layer summary of MMP changes reported within the last 15 years.  
5.1 Tear film and increased MMP-9 
Tear film composition reflects ocular surface events and tears may therefore be considered a 
vehicle for some of the pathogenic protagonists of keratoconus.  Unfortunately, the cellular 
origin of any such molecules cannot be determined conclusively as both corneal and non-
corneal secretions will be represented in the tear fluid. 
In 2000 the presence of collagen degradation products was reported in the tears of patients 
with keratoconus37. The detected telopeptides were presumed to be of corneal origin but the 
authors conceded that serum and conjunctiva were also potential sources. The conjunctival 
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epithelium is indeed altered in keratoconus. Elevation of lysosomal enzyme levels has been 
found in corneal and conjunctival epithelium38 though such enzymes are mostly involved 
with lipid metabolism, rather than turnover of proteins or connective tissues.  Lipids, 
however, are crucial to the integrity of the tear film and indeed, chronic ocular desiccation 
and aqueous tear deficiency can produce inferior corneal steepening and high astigmatism 
resembling keratoconus39. 
More recently, the levels of interleukin-6 (IL-6), tumour nectosis factor-α (TNF-α), and 
MMP-9 in the tear fluid of keratoconic patients were measured by enzyme linked 
immunoadsorbent assay and were found to be significantly higher than in normal subjects40. 
Increases in the levels of these molecules may be intermittent, but sufficient to provoke 
slowly progressive ectasia40. No significant differences in the concentrations of adhesion 
molecules inter cellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion protein-1 
(VCAM-1) were detected and other proteinases were not measured40. 
In most cases, keratoconus initially affects only one eye and later the ectasia may progress to 
include both eyes. Lema et al. followed up their initial work by measuring the 
concentrations of IL-6, TNF-α and MMP-9 in thirty patients with unilateral keratoconus - 
one eye diagnosed with keratoconus and the other eye having subclinical disease. IL-6 and 
TNF-α levels were found to be raised in both eyes in patients with asymmetric keratoconus, 
however, only TNF-α was significantly higher in the keratoconic eye, with respect to the 
subclinical one.  Increased MMP-9 levels were found in keratoconic eyes only35.   
TNF-α has been shown to upregulate MMP-9 expression in human corneal epithelial cells41 
and such proinflammatory cytokines are present at the ocular surface even in the absence of 
inflammation42. Interestingly, increased concentrations of cytokines are found in tears from 
various ocular allergic disease states43. While atopy is associated with keratoconus44, 
multivariate analysis has shown that the contribution to pathogenesis likely occurs from the 
eye rubbing encouraged by the itch of atopy rather than from chemical mediators associated 
with atopy itself45. 
The keratoconic ocular surface is characterised by a disorder of tear quality, decreased 
corneal sensitivity, conjunctival squamous metaplasia and higher fluorescein and rose 
bengal staining scores, all of which seem to relate to the extent of keratoconus progression46. 
In that respect the ocular surface is not unlike that of dry eye. It has been shown that 
inflammation plays an important role in both of these conditions and MMP-9 is found in the 
tears of both40,47.  
In fact MMP-9 accumulation has been demonstrated in several other disorders with an 
inflammatory basis, for example, in tears of patients with peripheral ulcerative keratitis, 
herpetic keratitis and Sjogren's syndrome48.  
Among the MMPs, MMP-9 is of central importance in cleaving epithelial basement 
membrane components and tight junction proteins that maintain corneal epithelial barrier 
function47. MMP-9 belongs to the gelatinase group of metalloproteinases that degrade 
denatured collagen; native collagens type IV, V, and VII; and elastin47. Expression of MMP-9 
by ocular surface epithelia in normal healthy eyes is low. Indeed, MMP-9 knockout mice 
show significantly less alteration of epithelial barrier function in response to experimental 
desiccating stress than do wild-type mice, an effect  abrogated by topical application of 
MMP-9 to the ocular surface49. 
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5.2 Whole cornea studies and decreased TIMP-1 
Studies have also assessed levels of various degradative enzymes in whole processed 
keratoconic corneas. This research was triggered by observations that cultured human 
dermal fibroblasts exposed to reactive oxygen species go on to upregulate MMP-1 and 
MMP-2 mRNA while downregulating TIMP-2 mRNA50,51. Thus oxidative stress was 
thought to be a contributing factor to the pathogenesis of keratoconus by promoting, 
amongst others, degradative activity.  
Kenney et al. measured RNA levels by semi-quantitative reverse transcription-polymerase 
chain reaction (RT-PCR) and Southern blot.  MMP-1, -2, -7, -9, -14, TIMP-2 and TIMP-3 mRNA 
levels did not differ between normal and keratoconic corneas52. There was, however, a 1.8 fold 
decrease in TIMP-1 mRNA and 2.8 fold decrease in TIMP-1 protein in keratoconus52.  
Decreased TIMP-1 may account for the high gelatinase activity and increased apoptosis of 
keratoconus. It has been proposed that TIMP-1 curtails the activity of MMP-2, the major 
protease of the corneal stroma. Unlike the constitutively expressed TIMP-2, TIMP-1 is an 
inducible inhibitor generally confined to the corneal epithelium53. Its synthesis seems to be 
upregulated in stromal cell cultures from scarred keratoconic corneas53. Apart from its anti-
proteinase role TIMP-1 prevents TIMP-3 mediated stromal cell apoptosis53. Dysequilibrium in 
the TIMP-1/TIMP-3 system can thus, at least partially, account for the keratoconic condition.  
It is likely that changes in MMP and TIMP systems are also present in several other eye 
diseases. For example, diabetic retinopathy corneas contain higher levels of MMP-3 and 
MMP-10 mRNA as measured by RT-PCR compared with keratoconic corneas54. This is 
thought to account for the various basement membrane and extracellular matrix alterations 
in the cornea of diabetic retinopathy.  
5.3 Epithelium and increased MMP-1 
Collier et al. performed peroxidase immunohistochemistry and determined that MMP-14 
(MT1-MMP) was significantly elevated in the epithelium of keratoconic corneas compared 
to eye bank controls, while MMP-2 was not55. This was surprising given that MMP-14 was 
previously shown to activate latent MMP-2 as well as being able to degrade matrix 
molecules directly. MMP-14 forms a tri-molecular complex on the cell surface with MMP-2 
and TIMP-2 in a complex sequence55. The timing of this interaction and concentrations of 
component molecules determine whether the MMP-14 active site is exposed and available 
for MMP-2 activation and matrix degradation55.  
It was also noted that the expression of MMP-14 in control corneas varied considerably from 
virtually none to pronounced levels, raising the possibility that the enzyme is expressed in 
response to any minor inflammatory or other pathological event.  
Subsequent work failed to detect a significant difference in either MMP-2 or MMP-14 between 
keratoconic and normal epithelium56, instead reporting higher levels of MMP-13 in the 
keratoconic epithelium compared to healthy specimens56.  TNF-α and IL-1β increase corneal 
epithelial MMP-13 synthesis57 while MMP-13 has been shown to activate MMP-9 in vitro58. The 
temporal and spatial correlation between MMP-13, MMP-9 and corneal re-epithelialisation 
suggests that MMP-13 plays a role in corneal reepithelialisation after injury59. MMP-13 
activation seems to be much more prominent in bullous keratopathy than keratoconus60.  
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Several studies report increased MMP-1 expression in keratoconus. The epithelia of healthy 
corneas and corneas with post LASIK keratectasia display nearly absent immunolabelling 
for MMP-1, whereas strong labelling occurs in the epithelium and stroma of keratoconic 
specimens56,61,62. MMP-1 is able to degrade many non-collagenous components of the 
extracellular matrix, including fibronectin, laminin, and basement membrane glycoproteins, 
but first and foremost, it cleaves native interstitial collagens types I and III62.  
MMP-1 can be effectively induced by the extracellular matrix metalloproteinase inducer 
(EMMPRIN), which is a member of the immunoglobulin superfamily of adhesion 
molecules62. In keratoconus, EMMPRIN expression was found in all layers of the cornea, 
especially in histopathologically altered areas, however, the distribution of MMP-1 did not 
totally overlap with histologically apparent corneal damage and EMMPRIN expression62. 
This may be because EMMPRIN upregulates other MMPs (MMP-2, MMP-3) in stromal 
fibroblasts. In areas of destruction EMMPRIN-inducible MMPs, other than MMP-1, may be 
participating in the local pathological process.  
MMP-8 seems to be down-regulated in keratoconic epithelium compared to normal 
controls56. MMP-8 plays a paradoxical role in tissues, on the one hand being able to cleave 
collagens despite the presence of TIMPs and on the other controlling the inflammatory load 
in tissues by downregulating the polymorphonuclear (PMN) burden63. Unlike other MMPs 
epithelial MMP-8 is not upregulated by TNF-α and IL-1β57. Such MMPs may contribute to 
the pathogenesis of keratoconus by proteolytic modulation of proinflammatory cytokines or 
chemokines or the generation of apoptotic signals for inflammatory and corneal cells.  
5.4 Stroma 
Despite much research, contradictory reports preclude any conclusive statement on the 
contribution of specific MMPs to histopathological hallmarks found in the keratoconic 
corneal stroma.  
In one study MMP-1, -2 and -13 immunolabelling was noted to be greater in keratoconic 
samples compared to normal controls while no difference in MMP-8 or MMP-14 
immunolabelling was observed56. In another study, keratoconic immunolabelling for MMP-
1, -2 and -3 resembled that of the normal cornea and post LASIK keratectasia61 while 
peroxidase immunohistochemistry performed by Collier’s group showed that MMP-14 was 
significantly elevated in the keratoconic stroma55.  
Stromal tissue layer supernatant showed no significant difference in MMP-2, MMP-9, pro 
MMP-13 and TIMP-1 concentrations between bullous keratopathy and keratoconus60. 
Keratocyte cultures from normal and keratoconic corneas also showed no significant 
changes in mRNA levels for MMP-1, -2, -3, TIMP-1, or TIMP-264. Only TIMP-1 protein was 
decreased, prompting a three-fold increase in the MMP-2/TIMP-1 ratio in keratoconus64.  
Yet stromal cell cultures performed by Smith et al. found MMP-2 to be over-expressed in 
clear keratoconic and scarred keratoconic corneas65. The quantities of TIMP-1 and TIMP-2 in 
normal and clear keratoconic cultures were similar.  Scarred keratoconic cultures over-
expressed TIMP-165. In these cultures the cells remained healthy and the extent of stress 
induced MMP-2 activation was low65. For this reason, in addition to inhibiting MMP 
activity, upregulated TIMP-1 production may be a feature of corneal scar tissue cells that are 
refractory to dying. Alternatively, TIMP-1 may prevent cell death that is conceivably 
initiated by upregulated TIMP-3 production and sequestration in the extracellular matrix65.  
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5.5 Endothelium with Descemet’s  
There are only a few studies assessing MMP changes specific to Descemet’s membrane and 
endothelium. The endothelial monolayer often gets damaged or lost as the result of tissue 
handling making studies technically difficult. It was noted that endothelial cells and 
Descemet’s membrane were pathologically altered in keratoconus and EMMPRIN was 
expressed next to areas of histological damage without, however, any evidence of MMP-1 
expression in the area62. Mackiewicz et al. did not detect a difference in MMP-1, -13 and -14 
between keratoconus and healthy controls but did report more MMP-2 in the endothelium 
and Descemet’s of keratoconus and less MMP-8 in the same layers compared to normal 
controls56. Endothelial tissue supernatant showed no significant difference in MMP-2, MMP-
9, pro MMP-13 and TIMP-1 concentrations between bullous keratopathy and keratoconus60.  
 
Fig. 2. Matrix metalloproteinase (MMP) and tissue inhibitor of matrix metalloproteinase 
(TIMP) changes have been described in every layer of the keratoconic cornea. Again, an 
antero-posterior section of a keratoconic cornea illustrated the MMP and TIMP molecules 
whose expression have been reported as  altered in keratoconus. Green arrows represent 
increased expression, whilst red represents reported decreased expression and blue no 
change. It is evident in several cases that reported expression profiles are cotradictory. 
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6. Conclusion  
MMPs are a group of proteolytic enzymes that are able to degrade the main components of 
the extracellular matrix and corneal membranes. Owing to these activities, MMPs are widely 
assumed to have a central role in the pathogenesis of keratoconus. However, studies have 
shown that MMPs can also handle substrates distinct from extracellular matrix proteins, 
influencing cell processes such as apoptosis. Proteolytic modulation of proinflammatory 
cytokines or chemokines or the generation of apoptotic signals for resident and 
inflammatory cells may prove to be as important in mediating keratoconus progression as 
purported extracellular matrix degradation.  
The involvement of proteases in keratoconus has been the subject of much research; 
however, the exact nature of proteolytic phenomena that contribute to keratoconus 
progression remains unclear. Studies have described upregulation of MMP-1, MMP-2, 
MMP-9, MMP-13 and MMP-14 in keratoconus, yet this has not been seen consistently. Other 
authors report no change in MMP levels or else a downregulation of MMP-8 or TIMP-1. 
Increased activity of other proteinases such as cathepsins66 likely contributes to the 
structural deterioration seen in keratoconus. 
For MMP inhibition or TIMP upregulation to be considered a valid therapeutic target for 
amelioration of the disease process it is important to know exactly which MMPs are 
culpable. However, due to complex inter-molecular interactions between individual 
members of the MMP family, the ratios between various MMPs may turn out to be more 
significant to keratoconus pathogenesis than absolute concentrations of specific MMPs.  The 
ability to measure multiple MMPs in a single corneal specimen is therefore necessary in 
order to understand the interplay of proteinases within the cornea. Tear fluid analysis 
affords the opportunity to investigate keratoconus protagonists in the earlier stages of the 
disease, a significant advantage over end-stage corneal tissue analysis. MMP changes are 
seen in many other corneal diseases, suggesting that MMP activation may be a nonspecific 
response to corneal insult. Indeed, the observed changes in inflammatory mediators or 
MMP levels within the cornea can in fact be epiphenomena of changes in corneal structure35. 
It is also possible that several diseases, with differing pathophysiology produce the 
phenotypic changes that are called keratoconus, accounting for the difference in proteinase 
profiles of examined keratoconic samples.  
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1. Introduction 
1.1 History of corneal refractive surgery 
There is a long history of corneal refractive surgery. Leonardo Da Vinci in 1508 said the 
theory of refractive errors. The first systematic analysis of the nature and results of refractive 
errors came from Francis Cornelius Donders. His classic treatise, “On the anomalies of 
accommodation and refraction of the eye”, outlined the fundamental principles of 
physiological optics. Ironically, in this treatise, Donders railed against surgical attempts to 
correct refractive errors by altering the corneal shape. In 1885 Hjalmar Schiotz performed 
corneal incision to correct astigmatism. Modern refractive surgery extended corneal 
reshaping to treat myopia and astigmatism. Throughout the 1930s and 1940s, Sato published 
several reports, describing his attempts to refine incisional refractive surgery with anterior 
and posterior corneal incisions. The Russian ophthalmologist, Fyodorov later developed a 
systematic process of anterior radial keratotomy and treated thousands of myopic patients 
with greater predictability. Lamellar surgery was first introduced by Jose Barraquer. He 
invented keratoplasty procedures that involved the transplantation of corneal tissue of a 
size different from the host size to alter the curvature of cornea. He also invented a series of 
lamellar procedures and developed a formula that represented the relationship between the 
added corneal thickness and the change in refractive power, later called Barraquer’s law of 
thickness. The transition from incisional to ablative laser refractive surgery arose with the 
development of Excimer laser technology. Excimer lasers use argon fluoride gases to emit 
ultraviolet laser pulses. Taboda and Archibald reported the use of the Excimer laser to 
reshape the corneal epithelium in 1981. In 1983, Trokel and colleagues showed how the 
Excimer laser could be used to ablate bovine corneal stroma. In 1985, Seiler did the first 
Excimer laser treatment in a blind eye. He later did the first Excimer laser astigmatic 
keratotomy. In 1989, McDonald and colleagues did the first photorefractive keratectomy on 
a seeing eye with myopia. Jose Barraquer’s pioneering work, including the use of lamellar 
procedures to subtract corneal stromal tissue and the development of the first 
microkerotomes, set the stage for laser in situ keratomileusis (LASIK) surgery. Ruiz and 
Rowsey modified Barraquer’s technique to perform keratomileusis in situ with a geared 
automated microkeratome. In the early 1990s, Pallikaris and colleagues and Buratto and 
colleagues independently described a technique that combined two existing technologies: 
the microkeratome and the Excimer laser. Pallikaris coined the term LASIK for this new 
technique, which has become a widely used refractive technique worldwide (1). 
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Astigmatism is a unique refractive error that causes reduced visual acuity and produces 
symptoms of glare, monocular diplopia, asthenopia, and distortion. The control and 
correction of astigmatism has been a topic of great interest to cataract, refractive and corneal 
surgeons. 
Corneal refractive surgical techniques that can correct astigmatism are: incisional surgical 
techniques, such as arcuate keratotomy and limbal relaxing incisions; laser-assisted in situ 
keratomileusis (LASIK); and surface ablation techniques, such as photorefractive 
keratectomy (PRK), trans-epithelial PRK (tPRK), laser-assisted subepithelial keratomileusis 
(LASEK),    epi-LASIK and Intralase.  
Arcuate keratotomy is an incisional surgical technique in which arcuate incisions of 
approximately 95% depth are made in the corneal midperipheral 7,0 mm zone placed in the 
steep meridian(s). Arcuate keratotomy was used to correct naturally occuring astigmatism, 
but it is now used primarily to correct postkeratoplasty astigmatism. Limbal relaxing 
incisions are incisions set at approximately 600 µm depth, or 50 µm less than the thinnest 
pachymetry at the limbus, and placed just anterior to the limbus. Limbal relaxing incisions 
are used to manage astigmatism during or after phacoemulsification and intraocular lens 
(IOL) implantation (2). 
LASIK is a lamellar laser refractive surgical technique in which the Excimer laser ablation is 
done under a partial-thickness lamellar corneal flap. The lamellar flap could be made with a 
microkeratome or with a femtosecond laser. The microkeratome uses an oscillating blade to 
cut the flap after immobilization of the cornea with a suction ring. Microkeratomes from 
several companies cut the lamellar flaps with either superior or nasal hinges, and can cut to 
depths of 100–200 µm. A femtosecond laser has been developed that can etch lamellar flaps 
within the cornea stroma at a desired corneal depth. The femtosecond laser provides more 
accuracy in flap thickness than previous methods; the microkeratome cuts can vary widely 
in depth. The ablation might either correct sphere and cylinder error, or is wavefront-
guided. After the ablation has been completed, the stromal bed is irrigated and the corneal 
flap is repositioned (3).  
Surface ablation is a generic term referring to the application of Excimer laser directly on the 
anterior stromal surface. The epithelium is removed in order for the Excimer laser to be 
applied to the stroma. There are several ways in which the epithelium can be separated from 
Bowmans layer. The epithelium can be fashioned as a flap and replaced (as in LASEK and 
epi-LASIK) or removed (as in PRK). Surface ablation techniques are continuously evolving 
in order to achieve better results with faster visual recovery and less pain (4).  
LASIK and PRK are the most commonly used refractive surgical methods worldwide. 
2. Laser in situ keratomileusis (LASIK) 
Laser in situ keratomileusis (LASIK) is the most commonly used refractive surgical method 
worldwide. This method employs two technologies: Excimer laser and microkeratome. 
Excimer (acronym for excited dimer) laser is an ultraviolet gas laser (argon-fluoride, ArF) 
with wavelength of 193 nm, which achieves photoablative effect on tissue of corneal stroma. 
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First, microkeratome cuts through the cornea and make intrastromal flap on hinge. Flap has 
a diameter from 8 to 10 mm and its thickness can be 100-180 μm, but usually 100-130 μm 
(about 15-35% of total corneal thickness). Then the flap is lifted and the corneal stroma 
exposed to the Excimer laser, and stroma is remodeled according to the type of ametropia 
and its values. On the end of Excimer laser the flap is repositioned and for a short time have 
stable position without of need for sutures (5). Postoperative visual rehabilitation is rapid. 
Sixteen hours after LASIK the majority of patients are reaching 97% of the preoperative best 
corrected visual acuity (6). 
 
Fig. 1. Placing of suction ring and microkeratome on the eye (5). 
 
Fig. 2. Flap is created and corneal stroma prepared for Excimer laser ablation (5). 
The American Academy of Ophthalmology (AAO) recommended the indications for LASIK: 
myopia up to - 10 Dsph, hyperopia up to + 4 Dsph, and astigmatism up to 4 Dcyl  (7). 
The contraindications for Excimer laser refractive surgery including LASIK and PRK are 
general and ophthalmic. General are: immunological diseases (autoimmune, collagen 
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vascular, immune deficiency); pregnancy or breast feeding; the tendency to form keloids; 
diabetes; and systemic administration of isotretionin or amiodarone. Ophthalmic are: dry 
eye; neurotrophic keratitis; herpes zoster ophthalmicus / keratitis herpetica; glaucoma; 
ectatic corneal dystrophy (keratoconus, keratoglobus); highly irregular astigmatism; uveitis, 
diabetic retinopathy; progressive retinal disease and previously performed radial 
keratotomy (8). 
The complications of LASIK include: intraoperative and postoperative complications. The 
intraoperative complications or flap related complications (9) are: wrong ablation, flap loss, 
buttonhole flap (hole in the flap), thin flap, brief flap, free cap (flap amputation), corneal 
bleeding, epithelial defects and corneal perforation (very rare). The postoperative 
complications (10) are: infections, dislocation of the flap, flap folding (striae), diffuse 
lamellar keratitis (sands of the Sahara), epithelial ingrowth, corneal ectasia, regression, 
intraflap fluid accumulation and paradoxical hypotony. 
Each candidate for LASIK should be at least 21 years of age and must have a stable 
refractive error in the period of two years. Preoperative evaluation of each candidate 
includes: general and ophthalmic history; autorefractokeratometry; uncorrected visual 
acuity (UCVA) and best corrected visual acuity (BCVA); Schirmer test; review of the eye 
anterior segment on slit-lamp; applanation tonometry; review of the eye fundus in a wide 
pupil; imaging of corneal topography and aberrometry. The following formula to evaluate 
whether a candidate can safely perform LASIK is: 
Central pachymetry – flap thickness - ablation depth = residual stromal thickness of the 
cornea  
As a limit value for residual stromal thickness of the cornea (residual stromal bed) after 
cutting and effects of Excimer laser 300 μm are taken; as a critical value for steep corneal 
meridian (steep K) <39 or > 47 D are taken; as a limit value for elevation of the posterior 
corneal surface 50 μm are taken (5). 
Numerous studies confirm the effectiveness of LASIK for the correction of astigmatism. 
Stojanovic and Nitter evaluated safety, efficacy, predictability, and stability in the treatment 
of myopic astigmatism with LASIK and PRK using the 200 Hz flying-spot technology of the 
Excimer laser. This retrospective study included 110 eyes treated with LASIK and 87 eyes 
treated with PRK that were available for evaluation at 6 and 12 months. The mean 
preoperative spherical equivalent (SE) was −5.35 diopters (D) ± 2.50 (SD) (range −1.13 to 
−11.88 D) in the LASIK eyes and −4.72 ± 2.82 D (range −1.00 to −15.50 D) in the PRK eyes. 
The treated astigmatism was 4.00 D in both groups. None of the eyes lost 2 or more lines of 
best spectacle-corrected visual acuity. Seventy-seven percent of the LASIK eyes and 78% of 
the PRK eyes achieved an uncorrected visual acuity of 20/20 or better; 98% in both groups 
achieved 20/40 or better. In conclusion, Excimer laser was safe, effective, and predictable 
and with LASIK and PRK the results are stable when treating low to moderate myopia and 
astigmatism up to 4.0 D (11). Ditzen et al evaluated safety, predictability, efficacy, and 
stability of LASIK for spherical hyperopia and hyperopia with astigmatism. This 
retrospective study analyzed the results of 23 eyes of 23 patients who had LASIK for 
spherical hyperopia (preoperative astigmatism  <0.75 D) and 44 eyes of 44 patients who had 
LASIK for hyperopia with astigmatism. In group 1 (spherical hyperopia), mean preoperative 
spherical equivalent refraction was +4.88 ± 2.13 D (range +2.13 to +9.63 D); in group 2 
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(hyperopic astigmatism), +4.33 ± 2.15 D (range +0.50 to +9.50 D). One year after LASIK, 
mean spherical equivalent refraction was +0.30 ± 0.90 D (range -0.75 to +2.50 D) in group 1 
and +0.29 ± 1.27 D (range -3.25 to +3.25 D) in group 2. In group 1, no eyes lost two or more 
lines, and one eye (6%) lost one line of best spectacle-corrected visual acuity at 1 year. In 
group 2, one eye (4%) lost one line and one eye (4%) lost more than two lines at 1 year. 
Uncorrected visual acuity of 20/40 or better was achieved in 83% (group 1) vs. 62% (group 
2) at 1 year. In conclusion, LASIK seemed to be safe and effective for hyperopia and 
hyperopia with astigmatism for corrections up to +6.00 D (12). Albarran-Diego et al 
evaluated bitoric LASIK for the correction of mixed astigmatism. This prospective study 
included 28 eyes of 21 patients with mixed astigmatism who had bitoric LASIK. Six months 
after bitoric LASIK, the mean UCVA was 0.70 ± 0.23 (SD). The percentage of eyes with a 
UCVA of 20/40 or better was 78.6% and of 20/20, 21.4%. There was a statistically significant 
increase in the mean BCVA from 0.71 ± 0.19 before surgery to 0.83 ± 0.15 at 6 months. Three 
eyes (10.7%) lost 1 line of BCVA. The mean preoperative astigmatism of −4.04 ± 1.13 
diopters (D) was reduced to −0.67 ± 0.79 D after surgery (13). 
3. Photorefractive keratectomy (PRK) 
Photorefractive keratectomy (PRK) is still a successful method in certain indications and 
now is used worldwide as PRK or as its modification - LASEK and EpiLASIK. All methods 
for its performance require use of Excimer laser (14).  
PRK is superficial ablative method because the Excimer laser thinner and reshapes the 
anterior part of the corneal stroma just below Bowman's membrane. This provides greater 
residual stromal thickness, and thus strengthens the biomechanical strength of the cornea. 
But, ablation of front stroma, especially through a layer of Bowman's membrane, causing 
aggressive response in wound healing, which may result in frequent appearance of 
subepithelial clouding (haze) and scarring compared with LASIK. Recovery after PRK is 
slower and more painful compared with LASIK. One to four days after the intervention 
most of the patients have a transient low-intensity pain. Postoperative visual rehabilitation 
is a little longer and lasts several weeks (1,15). 
Certain situations may favor PRK over LASIK in particular safety issues due to the absence 
of flap related complications in PRK. These situations include: predisposition for contact 
injury (e.g. those involved in martial arts or boxing); anterior basement membrane (BM) 
dystrophy; epithelial sloughing during LASIK in the fellow eye; thin corneas in which the 
residual stromal bed would be less than 250–300 mm; deep set eyes or a small palpebral 
aperture (poor exposure for the microkeratome); previous surgery involving the conjunctiva 
(e.g. glaucoma drainage bleb, scleral buckle); and moderate dry eye before surgery. In 
addition, flat (< 41 D) or steep corneas (> 48 D), with the risk of free, thin, incomplete or 
buttonholed flaps, may be better suited to PRK. It is desirable to avoid suction and 
iatrogenically raising the IOP during LASIK, as in patients with glaucoma or a risk of poor 
optic nerve perfusion, PRK procedure would be preferred (15).  
In PRK the first step is corneal epithelium removing (mechanically with knife-hockey or 
rotating brush; or by chemical abrasion with 20% ethanol), then the corneal stroma is 
exposed to the effects of Excimer laser which thins and reshapes it according to the type of 
ametropia and its values and after that therapeutic soft contact lens is applied for 5 days. 
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The American Academy of Ophthalmology (AAO) recommended the next indications for 
PRK: myopia up to – 8 Dsph, hyperopia up to + 4 Dsph, and astigmatism up to 4 Dcyl (7). 
Large corrections (ablation depth greater than 100 µm) are considered for adjunctive 0,02% 
mitomycin C (MMC) because of the increased risk of postoperative haze and regression (16). 
Complications of PRK include: subepithelial haze, corneal scarring, ectasia and regression. 
Each candidate for PRK should be at least 21 years of age and must have a stable refractive 
error in the period of two years. Preoperative evaluation of each candidate includes: general 
and ophthalmic history; autorefractokeratometry; uncorrected visual acuity (UCVA) and 
best corrected visual acuity (BCVA) in each eye; Schirmer test; examination of the eye 
anterior segment on slit-lamp; applanation tonometry; examination of the eye fundus in a 
wide pupil; imaging of corneal topography and aberrometry. As a limit value for residual 
stromal thickness of the cornea (residual stromal bed) is 300 μm. The critical value for steep 
corneal meridian (steep K) is <39 or > 47 D and the limit value for elevation of the posterior 
corneal surface is 50 μm (5). 
Numerous studies have investigated the effectiveness of PRK in the correction of 
astigmatism. Haw and Manche evaluated the safety and efficacy of PRK for the treatment of 
primary compound myopic astigmatism. Ninety three eyes from 56 patients with a mean 
spherical equivalent of −4.98 ± 1.80 diopters (range, −1.75 to −8.5) underwent 
photoastigmatic refractive keratectomy and were followed for 2 years. Fifty-six eyes (94.9%) 
had an uncorrected visual acuity of 20/40 or greater, whereas 34 eyes (57.6 %) demonstrated 
an uncorrected visual acuity of 20/20 or greater. One eye (1.7%) lost 2 or more lines of best 
spectacle-corrected visual acuity (17). Nagy et al evaluated the results of PRK using 
Gaussian flying spot technology in the treatment of hyperopia and hyperopic astigmatism. 
Two hundred eyes were evaluated with 12-month follow-up. Eyes were divided into four 
groups: group 1 (spherical hyperopia up to +3.50 D and astigmatism less than 1.00 D, n=62); 
group 2 (hyperopia up to +3.50 D and astigmatism of 1.00 D or more, n=44); group 3 
(hyperopia greater than +3.50 D and astigmatism less than 1.00 D, n=56); and group 4 
(hyperopia greater than +3.50 D and astigmatism of 1.00 D or more, n=38). In group 1, 82.2% 
(51/62 eyes) were within ±0.50 D of target refraction; 88.7% (55/62 eyes) had 20/20 or better 
uncorrected visual acuity; 1.6% (1/62 eye) lost two or more lines. In group 2, 68.1% (30/44 
eyes) were within ±0.50 D; 77.2% (34/44 eyes) had 20/20 or better uncorrected visual acuity; 
9.1% (4/44 eyes) lost two or more lines of spectacle-corrected visual acuity. In group 3, 
76.8% (43/56 eyes) were within ±0.50 D; 78.6% (44/56 eyes) had 20/20 or better uncorrected 
visual acuity; 5.4% (3/56 eyes) lost two or more lines of spectacle-corrected visual acuity. In 
group 4, 42% (16/38 eyes) were within ±0.50 D; 60.5% (23/38 eyes) had 20/20 or better 
uncorrected visual acuity; 15.8% (6/38 eyes) lost two or more Snellen lines. In conclusion 
PRK was most safe and effective for low hyperopia (18). 
4. Trans-epithelial photorefractive keratectomy (tPRK) 
In this method, the Еxcimer laser is used to ablate the epithelium in addition to then 
ablating the underlying stroma. The cornea undergoes an epithelial ablation within a fixed 
diameter. The operating room lights are turned off as blue fluorescent light is emitted 
whereas epithelium is ablated. Once the blue fluorescence disappears, this indicates that the 
epithelium has been removed. Accuracy with this method is dependent upon regular 
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epithelial thickness across the diameter treatment zone and also similar epithelial 
thicknesses between different eyes. This technique can produce variable results when laser 
surface enhancement is proposed after previous refractive surgery due to areas of epithelial 
hyperplasia causing variable epithelial thickness (15). 
5. Laser-assisted subepithelial keratomileusis (LASEK) 
LASEK is a surgical procedure that combines certain elements of both LASIK and PRK to 
improve the risk/benefit ratio. Diluted alcohol is used to loosen the epithelial adhesion to 
the corneal stroma. The loosened epithelium is moved aside from the treatment zone as a 
hinged sheet. Laser ablation of the subepithelial stroma is performed before the epithelial 
sheet is returned to its original position. The main rationale for combining elements of 
LASIK and PRK to LASEK is to avoid the flap-related LASIK complications and the slow 
visual recovery and haze risk of PRK. LASEK may avoid several of the inherent 
complications, including free caps, incomplete pass of the microkeratome, flap wrinkles, 
epithelial ingrowth, flap melt, interface debris, corneal ectasia, and diffuse lamellar keratitis, 
after LASIK and postoperative pain, subepithelial haze, and slow visual rehabilitation after 
PRK. Current ophthalmic literature does not provide the specific indications, visual 
outcomes, complications, and limitations of LASEK (19). Bilgihan et al. evaluated the 
efficacy, predictability, and safety of LASEK for treatment of high myopia with astigmatism. 
LASEK was performed in 61 eyes of 36 consecutive patients with myopic spherical 
equivalent refraction of -6.00 to -10.00 D using the Aesculap-Meditec MEL60 Еxcimer laser. 
Ninety-six percent of eyes achieved 20/40 or better uncorrected visual acuity (UCVA) at 1 
month. At 12 months, 64% of eyes achieved 20/20 and 92% achieved 20/40 or better UCVA. 
Two eyes lost 2 lines of best spectacle-corrected visual acuity (BSCVA) at 6 or 12 months. 
Accuracy of correction was ±0.50 D from emmetropia in 82% of eyes, and ±1.00 D in 90% at 
12 months (20). Taneri et al evaluated the visual outcomes and complications in low to 
moderate levels of myopia and astigmatism treated with LASEK. One hundred seventy-one 
eyes of 105 patients were studied. Preoperatively, the mean spherical equivalent was -2.99 
diopters (D) ± 1.43 (SD) and the mean cylinder -0.78 ± 0.73 D. One week postoperatively, 
96% of eyes had a UCVA of 20/40 or better but definitive visual recovery took more than 4 
weeks in some eyes. Approximately 95% of eyes were within ±1.0 D of emmetropia after 4 to 
52 weeks; the remaining 5% did not show major deviations. At 4 to 52 weeks, only 1 eye was 
overcorrected by more than 1.0 D of manifest refraction (21). 
6. Epithelial laser in situ keratomileusis (Epi-LASIK) 
Epi-LASIK has proved to be a suitable procedure, especially in patients with active lifestyles 
or occupations, eyes with thin corneas without ectatic disorders, and patients with moderate 
dry-eye syndrome. In epi-LASIK, an epithelial flap is created with the help of a special 
microkeratome. The epithelial flap is repositioned on the cornea after photoablation. It has 
been postulated that compared with conventional laser-assisted subepithelial keratectomy 
(LASEK), in which an epithelial flap is created after the epithelium is exposed to an alcohol 
solution, cell viability of the epithelial sheet is better in epi-LASIK surgery, in which 
mechanical separation is performed with a microkeratome. The quality of the epithelial 
separation is crucial for the success of the procedure because stromal lacerations or 
remaining islands of basal epithelial cells would reduce the optical quality of the cornea 
after photoablation (22). 
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The American Academy of Ophthalmology (AAO) recommended the next indications for 
PRK: myopia up to – 8 Dsph, hyperopia up to + 4 Dsph, and astigmatism up to 4 Dcyl (7). 
Large corrections (ablation depth greater than 100 µm) are considered for adjunctive 0,02% 
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epithelial thickness across the diameter treatment zone and also similar epithelial 
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Fig. 3. Widely accepted relative differences between PRK, LASEK, epi-LASIK, and LASIK 
(23). 
7. Femtosecond laser in laser in situ keratomileusis 
In the early 1960s, Barraquer introduced the concept of lamellar refractive procedures. In the 
1990s, Pallikaris et al. and Buratto et al. conceived of techniques combining lamellar 
procedures with Еxcimer laser ablation. These advances led to the development of modern 
laser in situ keratomileusis (LASIK) procedures. LASIK has several advantages over PRK 
when performed properly in appropriate eyes. These include faster visual recovery, less 
discomfort after surgery, and milder and more predictable wound healing with less risk for 
corneal stromal opacity (haze). Lamellar corneal flap formation is the critical step in 
successful LASIK surgery. Improper flap formation, including improper flap geometry, 
decentration, irregularity of the cut, and epithelial damage, can lead to myriad LASIK 
complications. Considerable progress has been made over the years in producing safer 
instruments for LASIK flap formation since the Automated Corneal Shaper was adapted to 
LASIK. Thus, more reliable and safer mechanical microkeratomes contributed to the 
explosive growth of refractive surgery over the past 15 years. Despite these advances, 
complications such as incomplete or partial flaps, free flaps, buttonholes, and small irregular 
flaps continue to plague refractive surgeons who perform LASIK with a microkeratome. 
There are also significant limitations to the eyes that can safely have lamellar flap formation 
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performed with a mechanical microkeratome, including corneas that are too steep (likely to 
have buttonhole flaps), too flat (likely to have small diameter flaps), or relatively thin (more 
likely to have low residual stromal bed) (Fig. 4).  
 
Fig. 4. Corneal complications reported with conventional microkeratomes (24). 
The femtosecond laser became available for LASIK flap formation approximately 10 years 
ago. Since the early femtosecond laser models were introduced, considerable progress has 
been made in improving flap geometry and limiting complications of LASIK performed 
with the laser. This has led to increasing popularity of LASIK performed with the 
femtosecond laser, to the point that different sources estimate that 30% to 50% of LASIK 
procedures in the United States in 2008 were performed using a femtosecond laser. Recently, 
new femtosecond laser models were introduced. These include the Femtec (20/10 Perfect 
Vision AG), the Femto LDV (Zeimer Group), the Visu-Max (Carl Zeiss Meditec) and 
commonly used IntraLase 60 kHz femtosecond laser (Abbott Medical Optics, Inc.). All 4 
commercially available femtosecond laser systems use ultrashort pulses of laser and 
produce corneal tissue cutting using a photodisruption process. To create the lamellar flap, 
the IntraLase laser generates pulses of femtosecond laser at a near-infrared (1053 nm) 
wavelength and delivers closely spaced 3 mm spots, which are focused at variable depths to 
photodisrupt stromal tissue. When a high peak power is reached, hot plasma is generated, 
initiating a process of tissue ionization that is commonly called laser-induced optical 
breakdown. The hot plasma expands in shock waves and creates an intrastromal cavitation 
bubble composed primarily of water and carbon dioxide. Multiple cavitation bubbles 
coalesce, and an intrastromal cleavage plane is created. The laser delivers a series of pulses 
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in a specified pattern to create the lamellar intrastromal cut and then extends the cleavage to 
the surface with a side cut to complete the flap (25). Stonecipher et al. reported the refractive 
results after LASIK for high myopia and cylinder at one center with one surgeon comparing 
two laser platforms. A total of 206 eyes of 121 patients were treated for –6.00 to –12.00 
diopters (D) of spherical equivalent refractive error with up to 3.00 D of cylinder. All eyes 
underwent LASIK with the ALLEGRETTO WAVE 200-Hz (n=141) or 400-Hz (n=65) laser 
(Alcon Laboratories Inc). Corneal flaps were created with the IntraLase femtosecond laser 
(Abbott Medical Optics) at an intended thickness of 100 or 110 µm in all cases. At 3- and 6-
month follow-up in the 200-Hz group, 77% (109/141) and 86% (121/141) of eyes, 
respectively, were within ±0.50 D of intended correction. In the 400-Hz group, 98.5% (64/65) 
and 100% (65/65) of eyes were within ±50 D of intended correction at 3 and 6 months 
postoperatively. At 3- and 6-month follow-up, 84% (119/141) and 77% (109/141) of eyes, 
respectively, in the 200-Hz group and 80% (52/65) and 92% (60/65) of eyes, respectively, in 
the 400-Hz group had 20/20 or better uncorrected distance visual acuity. At 6-month follow-
up, refractive predictability and visual acuity were statistically superior in eyes in the 400-
Hz group (chi square, P<.01). No eyes underwent retreatment as a secondary procedure 
during the time of analysis (26). 
8. Refractive laser surgery in children 
The use of Еxcimer laser vision correction in children is controversial because their eyes and 
refractive state continue to change. More studies on the growing eye and the effect of 
Еxcimer laser on the pediatric corneal endothelium are needed before the effect of refractive 
surgery in the pediatric age group can be fully understood (27).  
Traditional methods of correcting and rehabilitating the refractive status of children with 
high myopia, myopic anisometropic amblyopia, hyperopia, hyperopic anisometropic 
amblyopia or significant astigmatism include glasses and contact lenses combined with 
some form of occlusion or optical penalization therapy. However, some children may not 
improve with these traditional forms of treatment because of aniseikonia, compliance issues, 
or both. This is especially true when children have concurrent medical diagnoses such as 
autism, cerebral palsy, developmental delay, Down syndrome, or other associated ocular 
disorders (eg, corneal, retinal, and optic nerve problems). So, in such children traditional 
optical refractive correction is often not successful (28, 29).  
In the past ten years, refractive laser surgery techniques have been shown to be a good last-
resort treatment in children who have failed with traditional treatment approaches. There 
are numerous reports of the successful performance of PRK, LASIK and LASEK in children 
when conventional therapy failed.  
Autrata and Rehurek evaluated the visual and refractive results of multizonal PRK for high 
myopic anisometropia and contact-lens intolerance in children. Twenty-one patients aged 7 
to 15 years with high myopic anisometropia had multizonal PRK in the more myopic eye 
and were retrospectively analyzed. The scanning-slit Nidek EC-5000 Еxcimer laser was 
used. The safety, efficacy, predictability, and stability of the procedure were evaluated. 
Long-term binocular vision outcome was analyzed. All patients completed a 4-year follow-
up. The mean preoperative spherical equivalent (SE) refraction was - 8.93 diopters (D) ± 1.39 
(SD) (range - 6.75 to - 11.75 D) and the mean postoperative SE was – 1.66 ± 0.68 D (range - 
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0.50 to - 2.75 D). The mean preoperative uncorrected visual acuity (UCVA) of 0.034 ± 0.016 
increased to 0.35 ± 0.15 postoperatively. The mean preoperative best spectacle-corrected 
visual acuity (BSCVA) was 0.53 ± 0.19 and changed to 0.64 ± 0.16 postoperatively. No eye 
lost a line of BSCVA; 9 eyes gained 1 line, and 5 eyes gained 2 lines. No eye had + 3 haze. 
There were no significant complications. In conclusion, PRK was safe and effective in 
correcting high myopic anisometropia in children who were contact-lens intolerant (30). 
Yin et al. assessed the efficacy of LASIK in facilitating amblyopia management of children 
from 6 to 14 years old, with high hyperopic and myopic anisometropia. Between 2000 and 
2005, 42 children with high hyperopic anisometropic amblyopia and 32 children with high 
myopic anisometropic amblyopia underwent LASIK to reduce their anisometropia. LASIK 
was performed under topical or general anesthesia. Follow-up ranged from 6 months to 3 
years, the averages of which were 17,45 months in the hyperopic group and 18,31 months in 
myopic group. Hyperopic anisometropia correction ranged from + 3.50 D to + 7.75 D, and 
the mean postoperative anisometropia was +0.56 ± 0.75 D at 3 years. Myopic anisometropia 
correction ranged from -15.75 to - 5.00 D and the mean postoperative anisometropia at 3 
years was - 2.20 ± 1.05 D. The best-corrected visual acuity for distance and reading in the 
myopic group improved from 0.4 ± 0.25 and 0.58 ± 0.27, respectively, before surgery to 0.59 
± 0.28 and 0.96 ± 0.35, respectively, 3 years after surgery. In the hyperopic group, best-
corrected visual acuity for distance and reading improved from 0.23 ± 0.21 and 0.34 ± 0.32, 
respectively, before surgery to 0.53 ± 0.31 and 0.80 ± 0.33, respectively, 3 years after surgery. 
Study shows that LASIK is an alternative method for correcting high hyperopic and myopic 
anisometropia. The proportion of patients who had stereopsis increased from 19.1% 
preoperatively to 46.7% postoperatively in the hyperopic group and from 19% to 89% in the 
myopic group. In conclusion, LASIK reduced high hyperopic and myopic anisometropia in 
children, thus facilitating amblyopia management and improving their visual acuity and 
stereopsis (31). 
Astle et al. assessed the refractive, visual acuity, and binocular results of LASEK for 
anisomyopia, anisohyperopia, and anisoastigmatia in children with various levels of 
amblyopia secondary to the anisometropic causes. Retrospective review was of 53 children 
with anisometropia who had LASEK to correct the refractive difference between eyes. All 
LASEK procedures were performed using general anesthesia. Patients were divided into 3 
groups according to their anisometropia as follows: myopic difference greater than 3.00 
diopters (D), astigmatic difference greater than 1.50 D, and hyperopic difference greater 
than 3.50 D. The children were followed for at least 1 year. The mean age at treatment was 
8.4 years (range 10 months to 16 years). The mean preoperative anisometropic difference 
was 6.98 D in the entire group, 9.48 D in the anisomyopic group, 3.13 D in the 
anisoastigmatic group, and 5.50 D in the anisohyperopic group. One year after LASEK, the 
mean anisometropic difference decreased to 1.81 D, 2.43 D, 0.74 D, and 2.33 D, respectively, 
and 54% of all eyes were within ± 1.00 D of the fellow eye, 68% were within ± 2.00 D, and 
80% were within ± 3.00 D. Preoperative visual acuity and binocular vision could be 
measured in 33 children. Postoperatively, 63.6% of children had an improvement in best 
corrected visual acuity (BCVA) and the remainder had no noted change. No patient had a 
reduction in BCVA or a loss in fusional ability after LASEK. Of the 33 children, 39.4% had 
positive stereopsis preoperatively and 87.9% had positive stereopsis 1 year after LASEK. In 
conclusion, LASEK is an effective surgical alternative to improve visual acuity in 
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anisometropic children unable to tolerate conventional methods of treatment or in whom 
these methods fail (32). 
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1. Introduction 
Visual impairment remains a major public health problem world wide, with an estimated 
161 million people with visual impairment, of whom 37 million are blind.1 Uncorrected or 
inadequately corrected refractive errors have been shown to be a major cause of visual 
impairment in population-based studies2-6. While amblyopia is a significant cause of 
unilateral reduced visual acuity in a population aged 40 years and older.7  
Genetic factors are thought to play a role in development of refractive errors. It has been 
established that myopia clusters within families, and familial high myopia (refraction of -6 
diopter {D} or less) has been linked to long arm regions on chromosomes 7, 12 and 188,9. 
Environmental risk factors have also been associated with refractive errors, myopia or 
hypermetropia. Education10,11 and near-work12 are both strongly associated with increasing 
severity of myopia. 
In different parts of Asia such as in India, the Andhra Pradesh Eye Disease Study shows 
15.2%13 prevalence rate of myopia (spherical equivalent {SE} at least -1.0D). While study in 
a 15,068 Singapore military recruits aged 16 to 25 years, the prevalence rates of myopia 
(SE at least -0.5 D) were much higher with some racial variation, 82.2% in Chinese, 68.8% 
in Indians, and 65.0% in Malays14. Similar high rates of myopia (SE at least -0.25 D; 84%) 
were present in 16 to 18 years old Chinese children in Taiwan15. In Pakistan the 
prevalence rates of myopia, hypermetropia, astigmatism (with SE worse than –0.5 D, 
greater than +0.5D, and greater than 0.75D respectively) was 36.5%, 27.1%, and 37%, 
respectively in adults aged 30 years or more in the National Blindness and Visual 
Impairment Survey.16 
In United states, the Baltimore eye survey17 and Beaver Dam study18 showed the prevalence 
rates of myopia (SE at least -0.5 D) were 28.1% in white adults aged 40 years or more and 
26.2% in adults aged 43 to 84 years respectively. 
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Amblyopia is a frequent cause of unilateral or bilateral blindness. The prevalence of 
amblyopia ranges from 0.73% to 3.06%7 in previous studies. However, the epidemiology of 
amblyopia among this region of Asia is not well described and may be different from other 
because of difference in distribution of refractive error or strabismus.   
AIM: To assess the incidence of refractive error and associated amblyopia among young 
adult. 
2. Methodology 
2.1 Subjects  
This six months study was conducted from June 2008 to November 2008 at tertiary referral 
center Liaquat University Eye Hospital, Hyderabad Sindh, Pakistan. Three thousand four 
hundred fifty two patients were included and examined in out patients department with age 
ranged from 20-40 years. The proportion of men and women was 1:0.54. Both rural and 
urban residents were evaluated. After taking written consent all subjects underwent a 
comprehensive ophthalmic examination, and a standardized form was used to extract the 
data, including the following variables: demographic information, best corrected visual 
acuity, types of refractive error including myopia, hypermetropia, astigmatism and 
amblyopia.   
2.2 Methods 
Monocular visual acuity was determined with current spectacle prescription if any. Pinhole 
acuity was assessed in eyes with presenting visual acuity <20/20. Non-cycloplegic auto-
refraction followed by subjective refinements was performed in all subjects. The best 
corrected visual acuity was recorded. Refraction data was based on subjective refraction. 
Only the right phakic eye of each subject was considered for refractive error evaluation and 
amblyopia evaluated bilaterally.  
Amblyopia was defined as best-corrected visual acuity of 20/40 or worse in the absence of 
any pathological cause. Hypermetropia was defined as a SE greater than +0.5 diopter sphere 
(DS)17-21. Emetropia was defined as a SE between -0.50 and +0.50 DS20.  Myopia was defined 
as a SE worse than -0.50 DS17--21 and a SE or worse than -5.00 DS19 was classified as high 
myopia. Astigmatism correction was prescribed in minus cylinder format, and astigmatism 
was defined as cylindrical error worse than -0.50 diopter cylinder (DC) in any axis. The axis 
of any cylinder component was classified as with the rule (WTR) if the minus cylinder axis 
was within 15o of 180o, against the rule (ATR) for minus cylinder axis within 15o of 90o, or 
oblique (other than WTR or ATR)22.  
3. Results  
Of the 3452 patients, 847 (24.54 %) patients had best corrected visual acuity 20/40 or better 
and remaining 2605 (75.46%) had less than 20/40 due to different anterior and posterior 
segment eye pathologies, or amblyopia.  
Out of the 847 patients 525 (15.20 %) were phakic in right eye, and remaining 322  
(9.32%) were pseudophakic. For refractive error the result was analyzed for only 15.20% 
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phakic ametropic patients. While for amblyopia all patients who met the criteria were 
evaluated.   
There were 341 (64.95% of phakic ametropic patients) male and 184 (35.05%) were female. 
The age range from 20 to 40 years (Table 1), mean age being 26±3.9 years. The mean age of 
men and women was 28±3.9 and 24±6.3 years respectively (statistically significant at 
P<0.001). The mean refractive error was 0.75D.  
Hypermetropia was found in 185 (35.24% of phakic ametropic) patients (Table 1). The mean 
age of hypermetropia was 26.31±4.51 years. Which was not significantly different from that of 
entire population (P=0.5476). There were 121 men (23.04% of total ametropic) and 64 women 
(12.19%). Man had significantly higher prevalence of hypermetropia than women (P<0.001). 
Three hundred and fifteen (60% of phakic ametropic) patients had myopia (Table 1). The 
mean age of myopes was 23.69±3.98 years. Which was significantly lower than the entire 
population (P<0.001). There were 205 (39.05%) men and 110 (20.95%) women. The man had 
a significantly higher prevalence of myopia than did the women (P<0.001) 
Twenty five (4.76%) patients of the study population were high myopes (Table 1). Among 
which 15 patients were males and 10 were females. The mean age among high myopes was 
22. 50±3.25 years. Which was also significantly lower than the entire population (P<0.0002). 
However there was no significant different between the mean age of myopes and high 
myopes (P=0.1632). 
Two hundred and fifteen (25.38 % of phakic ametropic) patients had astigmatism worse 
than –0.5 DC. The males were 134 (62.32%) of total astigmatic patients and remaining were 
females. The man had a significantly higher prevalence of astigmatism than women 
(P<0.001). One hundred and forty two (66.04%) patients had ATR astigmatism, 52 (24.18%) 
had WTR astigmatism and 21 (9.76%) had oblique astigmatism. The prevalence of against 
the rule astigmatism increased significantly with age (P=0.007). 
The incidence of associated unilateral amblyopia was in 19 (3.62%) of phakic ametropic 
patients (Table 2). Ten (52.63%) patients were male and 09 (47.37%) were females. 
Amblyopia was not found to be significantly different by age (p=0.1312) group and gender 
(p=0.1211). Anisometropia was more common in amblyopic cases (41.75%) compared to the 
normal population (5.91%), and 69% of amblyopic eyes had visual acuity worse than 20/60. 
However, two amblyopic patients had strabismus in addition to anisometropia, but the 
prime reason of both conditions was anisometropia. While none of the case of bilateral 
amblyopia were seen in this study. 
 
Age (yrs) 
Hypermetropia Myopia High myopia 
Total (%) 
M F M F M F 
21-25 38             21 48          25 7             4 143  (27.23) 
26-30 29             17 65          27 5             4 147  (28.00) 
31-35 27             10 49          32 0             1 119  (22.68) 
36-40 27             16 43          26 3             1 116  (22.09) 
Total 121           64 205        110 15           10 525   (100) 
Table 1. Age and type of refractive error    
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3. Results  
Of the 3452 patients, 847 (24.54 %) patients had best corrected visual acuity 20/40 or better 
and remaining 2605 (75.46%) had less than 20/40 due to different anterior and posterior 
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phakic ametropic patients. While for amblyopia all patients who met the criteria were 
evaluated.   
There were 341 (64.95% of phakic ametropic patients) male and 184 (35.05%) were female. 
The age range from 20 to 40 years (Table 1), mean age being 26±3.9 years. The mean age of 
men and women was 28±3.9 and 24±6.3 years respectively (statistically significant at 
P<0.001). The mean refractive error was 0.75D.  
Hypermetropia was found in 185 (35.24% of phakic ametropic) patients (Table 1). The mean 
age of hypermetropia was 26.31±4.51 years. Which was not significantly different from that of 
entire population (P=0.5476). There were 121 men (23.04% of total ametropic) and 64 women 
(12.19%). Man had significantly higher prevalence of hypermetropia than women (P<0.001). 
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population (P<0.001). There were 205 (39.05%) men and 110 (20.95%) women. The man had 
a significantly higher prevalence of myopia than did the women (P<0.001) 
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had WTR astigmatism and 21 (9.76%) had oblique astigmatism. The prevalence of against 
the rule astigmatism increased significantly with age (P=0.007). 
The incidence of associated unilateral amblyopia was in 19 (3.62%) of phakic ametropic 
patients (Table 2). Ten (52.63%) patients were male and 09 (47.37%) were females. 
Amblyopia was not found to be significantly different by age (p=0.1312) group and gender 
(p=0.1211). Anisometropia was more common in amblyopic cases (41.75%) compared to the 
normal population (5.91%), and 69% of amblyopic eyes had visual acuity worse than 20/60. 
However, two amblyopic patients had strabismus in addition to anisometropia, but the 
prime reason of both conditions was anisometropia. While none of the case of bilateral 
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Age (yrs) 
Hypermetropia Myopia High myopia 
Total (%) 
M F M F M F 
21-25 38             21 48          25 7             4 143  (27.23) 
26-30 29             17 65          27 5             4 147  (28.00) 
31-35 27             10 49          32 0             1 119  (22.68) 
36-40 27             16 43          26 3             1 116  (22.09) 
Total 121           64 205        110 15           10 525   (100) 
Table 1. Age and type of refractive error    
 




Frequency of amblyopia 
Total ( %) 
Male Female 
21 -25 2                         2 4 (21.04) 
26 -30 3                         2 5 (26.32) 
31 -35 2                         3 5 (26.32) 
36 -40 3                         2 5 (26.32) 
Total 10                        9 19  (100) 
Table 2. Demography of amblyopia 
4. Discussion  
The incidence of hypermetropia in this study was 35.24% of total 525 phakic ametropic 
patients. In contrast to Andhra Paeye disease study (APEDS)13, Barbados eye study20, and 
several other studies17,18 hypermetropia decrease with increasing age in our study 
The incidence of myopia and high myopia in this study was 60% and 4.76% of the phakic 
ametropic patients and decreased with age. The Attebok et al18, Wang et al11, Katz et al17 
reported a significant trends of decreasing myopia with age. However the Chennai 
glaucoma study3, Barbodos20 study reported increase of myopia with age and also have an 
association of nuclear sclerosis with myopia. Saw22, Guggenheim et al23 and Dan et al24 
reported environmental influence such as near work, night lighting and ultraviolet exposure 
may be responsible for ageing of the crystalline lens and associated myopia. In contrast to 
population based studies from Australia18, Singapore19, and Indonesia25, the incidence of 
myopia was more in males than females in our study. 
The incidence of astigmatism in this study was 25.38% and increased significantly with age. 
The same has been reported from Chenni3, Australia18, Singapore19, and Indonesia25. ATR 
astigmatism in this study was predominant that made the 66.04% of the total ametropic 
patients. In relation to the Chennai3 study the incidence of ATR astigmatism significantly 
increased with age and WTR astigmatism decreased with age in our study. Gudmundsdottir 
et al26, Pensyl et al22 and Goss et al28 reported same and the reason for this could be 
increased lid laxity with age causing flattening of vertical corneal meridian thereby 
decreasing WTR astigmatism and increased ATR astigmatism. 
In this study the incidence, of associated amblyopia was 3.62% of phakic ametropic patients, 
which was less than Goel B.S29 study in which amblyopia was reported 5.97%. One thing 
common in both were higher rate of amblyopia in ametropic then general population. In 
contrast to Karki JKD30 study amblyopia was not found significantly different by age and 
gender in this study. 
In conclusion, 15.20% of people had refractive error and 3.62% has the amblyopia. The 
prevalence of myopia was 60% and decreased with age. Hypermetropia was more common 
among men. The prevalence of astigmatism was 25.38%. It was interesting to note that 
against the rule astigmatism in contrast to other studies was observed more often (66.04%) 
in this study. Though the above study represent the regional population of limited age (20-
40 years), but the differences in the pattern of refractive error in this study leads us to 
believe that genetic, racial, environmental and occupational influences may play an 
important role. 
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1. Introduction 
Myopia has been investigated scientifically for over a century but the search for an effective 
remedy has been manifestly unsuccessful. The prevalence of myopia in developed societies 
has now risen to about 30% in USA (Vitale, Sperduto et al. 2009) and up to 70% in some 
Asian centres (Lin, Shih et al. 2004). In addition to the socio-economic burden of providing 
optical corrections for myopia, common myopia limits career choice and increases the risk of 
glaucoma and cataract. High myopia also increases the risk of retinal detachment, chorio-
retinal degeneration and subsequent visual impairment (Saw, Gazzard et al. 2005). Both 
genetic and environmental factors have been implicated in the aetiology of myopia. 
Children with myopic parents have a higher than normal risk of developing myopia (Mutti, 
Mitchell et al. 2002) and twin studies show a higher level of concordance of common myopia 
in monozygotic compared to dizygotic twins (Dirani, Chamberlain et al. 2006). However, the 
rapid rise in myopia prevalence over recent decades argues strongly that changing 
environmental factors also play an important role in the aetiology of myopia. 
In the early 1900s Fuchs asserted ‘The following means are advised to put a stop to the extension of 
myopia in schools. First, the excess of work which many scholars have at present to struggle with 
should be reduced’…. ‘Instruction ought not to begin too early (if possible not before the completion of 
the sixth year) and more time should be allotted to bodily exercise, especially in the open air, than has 
hitherto been the case.’ (Duane 1919). Although the long-held view that myopia primarily 
results from too much near-work is now regarded as an over-simplification, several recent 
studies support Fuchs’s idea that outdoor activity may have an important role in protecting 
against myopia. 
There have been many attempts to inhibit the progression of myopia in children. More 
recently, these have included treatment with antimuscarinic agents such as atropine eye-
drops (Chua, Balakrishnan et al. 2006) and optical devices including multifocal spectacle 
lenses (Gwiazda, Hyman et al. 2003), dual-focus contact lenses (Anstice and Phillips 2011) 
and orthokeratology (Kakita, Hiraoka et al. 2011). However, none of these approaches 
entirely arrests myopia progression in the long term and the vast majority of myopia is 
managed by optical correction alone. Although conventional optical corrections including 
refractive surgery restore acuity, they do not prevent the abnormal enlargement of the 
myopic eye, so children with myopia remain at increased risk of ocular disease later in life. 
In this review we examine evidence from human and animal studies that one aspect of 
outdoor activity, namely exposure to natural light, may reduce the prevalence and 
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progression of myopia. We focus on the timing of light exposure in relation to the circadian 
cycle and on the potential roles of dopamine and melatonin in control of ocular growth and 
refractive development. 
2. Human myopia and light 
2.1 Outdoor activity 
Current epidemiological research, as quantified by validated surveys, supports the idea that 
time spent in outdoor activities has a beneficial effect in reducing myopia prevalence in 
children and young adults (Jones, Sinnott et al. 2007; Rose, Morgan et al. 2008a; Rose, 
Morgan et al. 2008b). Whether the effect derives predominantly from increased natural light 
exposure or increased activity (e.g. sport) or from greater viewing distances outdoors has 
yet to be ascertained. An association between greater physical activity and reduced myopia 
progression has been reported in university students (Jacobsen, Jensen et al. 2008) although 
this association may have been confounded by other factors in the outdoor environment 
where much of the activity took place. Other studies have found an association between 
increased outdoor hours and lower myopia even when time spent playing sport outdoors 
was excluded (Rose, Morgan et al. 2008a). Moreover, indoor sport appears to have no 
beneficial effect (Rose, Morgan et al. 2008a; Dirani, Tong et al. 2009) suggesting that physical 
activity alone cannot account for the effect of outdoor activity. Whether the increased 
viewing distance typically associated with being outdoors has a positive effect in reducing 
myopia is unknown. The idea that time spent outdoors may act beneficially by substituting 
for time spent in near and mid-working distance activities seems not to be the case (Rose, 
Morgan et al. 2008a). In relation to distance viewing outdoors, the accommodative demand 
for viewing beyond about 6 metres is minimal. Indoor environments, particularly in city 
apartments, inevitably restrict viewing distance and typically include low dioptric stimuli 
for accommodation over the peripheral visual field (Charman 2011). However, the most 
obvious difference between spending time outdoors and time indoors is in light exposure. 
The spectral composition of light outdoors includes large amounts of ultraviolet (UV) and 
infrared (IR) in addition to light in the visible spectrum. Indoors, the UV portion of the 
spectrum is largely absent and if incandescent lighting is used the composition of the light is 
often biased towards the red end of the spectrum. Light intensity indoors is rarely more 
than 800 lux, whereas outdoor light intensity is around 50,000 lux on a sunny, blue-sky day 
and is rarely less than 5,000 lux, even when overcast. The cumulative light exposure for one 
hour spent outdoors is thus very much greater than for one hour spent indoors (Backhouse, 
Ng et al. 2011). This increased light exposure during the day is generally believed to be the 
most likely basis for the beneficial effect of outdoor activity in reducing myopia prevalence 
(Rose, Morgan et al. 2008a).  
2.2 Light at night 
Between birth and 2 years of age, the normal eye grows very rapidly, with axial length 
increasing at a rate of about 2 mm/year before slowing to about 0.1 mm/year until the eye 
reaches adult size (Larsen 1971). It has been suggested that environmental influences acting 
in this early period of rapid eye growth may potentially affect refractive development later 
in life. Quinn et al. (Quinn, Shin et al. 1999) investigated the effects of light exposure early in 
life on refractive status later in childhood. Their study, which was based on a questionnaire 
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completed by parents of children aged 2-16 years (median 8 years) on their child’s night-
time light-exposure, reported a strong, dose-dependent association between the prevalence 
of myopia at the time of the study and night-time lighting conditions experienced by the 
children before the age of 2 years. Remarkably, 55% of children who slept with the room 
lights on developed myopia whereas 34% of children who slept with night-lights, and 10% 
of children who slept in darkness, had developed myopia at the time of the study. On the 
statistical strength of their findings, the authors suggested that the absence of a daily period 
of darkness could be a precipitating factor in the later development of myopia. A similar 
study (Czepita, Goslawski et al. 2004) also reported increased prevalence of myopia in 
children who had experienced ambient light at night before the age of 2 years. However, 
several studies in different parts of the world, also based on parental questionnaires, have 
reported no difference in prevalence of myopia in children sleeping in darkness or with 
ambient light at night before the age of 2 years (USA (Gwiazda, Ong et al. 2000; Zadnik, 
Jones et al. 2000), Asia (Saw, Zhang et al. 2002), UK (Guggenheim, Hill et al. 2003)). Both 
studies from the USA found associations between the number of myopic parents in the 
family and nursery lighting experienced by the child before the age of 2 years, suggesting 
that the results obtained by Quinn et al. may have been confounded by the uncontrolled 
effect of parental myopia. However, exposure to light at night may also affect the refractive 
development of young adults. A study of law students (Loman, Quinn et al. 2002) reported 
an association between increased myopia progression during law school with less daily 
exposure to darkness (i.e. more artificial light at night). 
2.3 Season of birth 
Further evidence for the influence of light exposure early in life on later refractive error 
comes from studies on the effect of season of birth (and by implication perinatal 
photoperiod) on adult refractive status. In a study population of 276,911 adolescents born in 
Israel (Mandel, Grotto et al. 2008), moderate and severe myopia prevalence varied by birth 
month, with the summer months (June/July) being associated with a higher myopia 
prevalence than the winter months (December/January). Moreover, increasing photoperiod 
was associated with increasing myopia prevalence in a dose-dependent pattern. Mild 
myopia was not associated with either season of birth or photoperiod. Birth during the 
summer was also found to be significantly associated with high myopia in a UK study 
(McMahon, Zayats et al. 2009) but no association was found between postnatal photoperiod 
and prevalence of myopia in adulthood. Seasonal variations in photoperiod are particularly 
extreme above the Arctic Circle. However, in a study of Finnish military conscripts (Vannas, 
Ying et al. 2003) no associations between myopia prevalence and birth month, global 
irradiance at birth month or daily hours of darkness during the birth month were found, 
although there was a trend towards higher prevalence of myopia among conscripts living 
above the Arctic Circle.  
The human data on light exposure and refractive development suggest that increased day-
time outdoor light exposure is associated with reduced myopia prevalence whereas 
increased night-time exposure to artificial light may be associated with increased myopia 
development – a case of day-light good, night-light bad. The remainder of this review 
examines the underlying processes which could explain why perturbations in the daily 
light-dark cycle may affect eye growth and refractive development. 
 
Advances in Ophthalmology 
 
142 
progression of myopia. We focus on the timing of light exposure in relation to the circadian 
cycle and on the potential roles of dopamine and melatonin in control of ocular growth and 
refractive development. 
2. Human myopia and light 
2.1 Outdoor activity 
Current epidemiological research, as quantified by validated surveys, supports the idea that 
time spent in outdoor activities has a beneficial effect in reducing myopia prevalence in 
children and young adults (Jones, Sinnott et al. 2007; Rose, Morgan et al. 2008a; Rose, 
Morgan et al. 2008b). Whether the effect derives predominantly from increased natural light 
exposure or increased activity (e.g. sport) or from greater viewing distances outdoors has 
yet to be ascertained. An association between greater physical activity and reduced myopia 
progression has been reported in university students (Jacobsen, Jensen et al. 2008) although 
this association may have been confounded by other factors in the outdoor environment 
where much of the activity took place. Other studies have found an association between 
increased outdoor hours and lower myopia even when time spent playing sport outdoors 
was excluded (Rose, Morgan et al. 2008a). Moreover, indoor sport appears to have no 
beneficial effect (Rose, Morgan et al. 2008a; Dirani, Tong et al. 2009) suggesting that physical 
activity alone cannot account for the effect of outdoor activity. Whether the increased 
viewing distance typically associated with being outdoors has a positive effect in reducing 
myopia is unknown. The idea that time spent outdoors may act beneficially by substituting 
for time spent in near and mid-working distance activities seems not to be the case (Rose, 
Morgan et al. 2008a). In relation to distance viewing outdoors, the accommodative demand 
for viewing beyond about 6 metres is minimal. Indoor environments, particularly in city 
apartments, inevitably restrict viewing distance and typically include low dioptric stimuli 
for accommodation over the peripheral visual field (Charman 2011). However, the most 
obvious difference between spending time outdoors and time indoors is in light exposure. 
The spectral composition of light outdoors includes large amounts of ultraviolet (UV) and 
infrared (IR) in addition to light in the visible spectrum. Indoors, the UV portion of the 
spectrum is largely absent and if incandescent lighting is used the composition of the light is 
often biased towards the red end of the spectrum. Light intensity indoors is rarely more 
than 800 lux, whereas outdoor light intensity is around 50,000 lux on a sunny, blue-sky day 
and is rarely less than 5,000 lux, even when overcast. The cumulative light exposure for one 
hour spent outdoors is thus very much greater than for one hour spent indoors (Backhouse, 
Ng et al. 2011). This increased light exposure during the day is generally believed to be the 
most likely basis for the beneficial effect of outdoor activity in reducing myopia prevalence 
(Rose, Morgan et al. 2008a).  
2.2 Light at night 
Between birth and 2 years of age, the normal eye grows very rapidly, with axial length 
increasing at a rate of about 2 mm/year before slowing to about 0.1 mm/year until the eye 
reaches adult size (Larsen 1971). It has been suggested that environmental influences acting 
in this early period of rapid eye growth may potentially affect refractive development later 
in life. Quinn et al. (Quinn, Shin et al. 1999) investigated the effects of light exposure early in 
life on refractive status later in childhood. Their study, which was based on a questionnaire 
 
Myopia, Light and Circadian Rhythms 
 
143 
completed by parents of children aged 2-16 years (median 8 years) on their child’s night-
time light-exposure, reported a strong, dose-dependent association between the prevalence 
of myopia at the time of the study and night-time lighting conditions experienced by the 
children before the age of 2 years. Remarkably, 55% of children who slept with the room 
lights on developed myopia whereas 34% of children who slept with night-lights, and 10% 
of children who slept in darkness, had developed myopia at the time of the study. On the 
statistical strength of their findings, the authors suggested that the absence of a daily period 
of darkness could be a precipitating factor in the later development of myopia. A similar 
study (Czepita, Goslawski et al. 2004) also reported increased prevalence of myopia in 
children who had experienced ambient light at night before the age of 2 years. However, 
several studies in different parts of the world, also based on parental questionnaires, have 
reported no difference in prevalence of myopia in children sleeping in darkness or with 
ambient light at night before the age of 2 years (USA (Gwiazda, Ong et al. 2000; Zadnik, 
Jones et al. 2000), Asia (Saw, Zhang et al. 2002), UK (Guggenheim, Hill et al. 2003)). Both 
studies from the USA found associations between the number of myopic parents in the 
family and nursery lighting experienced by the child before the age of 2 years, suggesting 
that the results obtained by Quinn et al. may have been confounded by the uncontrolled 
effect of parental myopia. However, exposure to light at night may also affect the refractive 
development of young adults. A study of law students (Loman, Quinn et al. 2002) reported 
an association between increased myopia progression during law school with less daily 
exposure to darkness (i.e. more artificial light at night). 
2.3 Season of birth 
Further evidence for the influence of light exposure early in life on later refractive error 
comes from studies on the effect of season of birth (and by implication perinatal 
photoperiod) on adult refractive status. In a study population of 276,911 adolescents born in 
Israel (Mandel, Grotto et al. 2008), moderate and severe myopia prevalence varied by birth 
month, with the summer months (June/July) being associated with a higher myopia 
prevalence than the winter months (December/January). Moreover, increasing photoperiod 
was associated with increasing myopia prevalence in a dose-dependent pattern. Mild 
myopia was not associated with either season of birth or photoperiod. Birth during the 
summer was also found to be significantly associated with high myopia in a UK study 
(McMahon, Zayats et al. 2009) but no association was found between postnatal photoperiod 
and prevalence of myopia in adulthood. Seasonal variations in photoperiod are particularly 
extreme above the Arctic Circle. However, in a study of Finnish military conscripts (Vannas, 
Ying et al. 2003) no associations between myopia prevalence and birth month, global 
irradiance at birth month or daily hours of darkness during the birth month were found, 
although there was a trend towards higher prevalence of myopia among conscripts living 
above the Arctic Circle.  
The human data on light exposure and refractive development suggest that increased day-
time outdoor light exposure is associated with reduced myopia prevalence whereas 
increased night-time exposure to artificial light may be associated with increased myopia 
development – a case of day-light good, night-light bad. The remainder of this review 
examines the underlying processes which could explain why perturbations in the daily 
light-dark cycle may affect eye growth and refractive development. 
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3. Light and animal models of myopia 
Animal studies have shown that a diurnal light:dark photoperiod is required for the normal 
refractive development of the eye in chicks (Li, Troilo et al. 1995; Stone, Lin et al. 1995), tree 
shrews (Norton, Amedo et al. 2006)  and Rhesus monkeys (Smith, Bradley et al. 2001). In 
normal chick eyes there is a diurnal growth rhythm in which greatest eye elongation occurs 
during the day with reduced growth rates at night (Weiss and Schaeffel 1993; Nickla, 
Wildsoet et al. 1998). The choroid also demonstrates a similar diurnal rhythm in which the 
choroid thins during the day and thickens at night (Papastergiou, Schmid et al. 1998). In 
eyes deprived of form vision in order to induce myopia, a phase shift occurs in the 
relationship between the axial length and choroidal rhythms such that peak axial  growth 
occurs earlier than in normal eyes (Nickla, Wildsoet et al. 1998). 
3.1 Effect of constant light 
Rearing chicks under constant light with open eyes produces hyperopia, due to corneal 
flattening resulting in shallow anterior chambers (Li, Troilo et al. 1995; Stone, Lin et al. 
1995). While the anterior chamber becomes shallower, the vitreous chamber lengthens, 
resulting in no net change in axial length at 2 weeks of age. Continued rearing of chicks in 
constant light beyond 2 weeks produces macrophthalmos (Oishi, Lauber et al. 1987). The 
final refractive state may be hyperopic despite the development of significantly deeper 
vitreous chambers (Li, Troilo et al. 1995). In form-deprived eyes, constant light also 
produces hyperopia despite overall longer axial lengths and enlarged vitreous chambers in 
both axial and equatorial directions; (Stone, Lin et al. 1995). 
While rearing chicks under continuous light produces hyperopia, the effect is dependent on 
the level of ambient illumination. Thus, higher light intensities are correlated with higher 
degrees of hyperopia, lower corneal power and increased vitreous chamber depth. Cohen et 
al. (Cohen, Belkin et al. 2008) reported that chicks raised under continuous illumination at 
10,000 lux for 90 days developed a hyperopic mean refraction of +11.97D, while those raised 
under 50 lux resulted in an emmetropic mean refraction of +0.63D. An illumination level of 
500 lux also produced a relatively high hyperopic outcome of +7.90D. While vitreous 
chamber depth was positively correlated with light intensity, overall axial length did not 
vary significantly between groups due to the corneal flattening associated with increasing 
light intensity, resulting in an overall hyperopic refraction at the moderate and high 
illumination levels (Cohen, Belkin et al. 2008).  
Monkeys raised under continuous light conditions (Smith, Bradley et al. 2001) do not exhibit 
the increase in ocular growth typically found in the chick. Rhesus monkeys raised under 
continuous light for 6 months developed hyperopic refractions similar in magnitude to 
animals raised under normal diurnal light cycles. However, the refractions were more variable 
in outcome, with some animals developing axial anisometropia and low myopia (Smith, 
Bradley et al. 2001). The authors cautioned that the animals may have been able to re-establish 
at least a partial diurnal cycle by shielding their eyes during sleep with their arms, although no 
significant difference in behaviour was observed (Smith, Bradley et al. 2001).  
3.2 Effect of constant darkness 
Rearing chicks in complete darkness also produces hyperopia irrespective of whether a 
diffusing goggle is worn (Gottlieb, Fugate-Wentzek et al. 1987). The degree of hyperopia 
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produced is approximately double that of normal chicks by 42 days. In contrast, tree shrews 
placed in continuous darkness eventually exhibit a myopic shift in refraction (Norton, 
Amedo et al. 2006). Although the animals initially stabilise at a low degree of hyperopia 
following 16 days of normal visual experience after eye opening,  a subsequent period of 10 
days of continuous darkness results in vitreous elongation and a myopic refraction (Norton, 
Amedo et al. 2006). While both chicks and tree shrews exhibit ocular growth under constant 
darkness, the significant corneal flattening which produces hyperopia in chicks does not 
occur in the tree shrew. Conversely, raising rhesus monkeys in continuous darkness appears 
to interfere with the emmetropisation process such that they retain their relatively high 
hyperopic neonatal refractions (Guyton, Greene et al. 1989). 
Gottlieb et al. (Gottlieb, Fugate-Wentzek et al. 1987) proposed that two mechanisms may 
combine under dark-rearing in chicks to produce the hyperopic outcome: a visual 
deprivation mechanism which triggers enlargement of the eye, as occurs in form-
deprivation myopia, and a second photoperiod-related mechanism which results in corneal 
flattening. 
A phase advance in the cycle of eye growth is found in chicks raised under constant 
darkness which is associated with an overall increase in axial growth and choroidal thinning 
(Nickla, Wildsoet et al. 2001). As the rhythms in choroidal thinning and axial growth persist 
under constant darkness, they must be circadian in origin, rather than simply diurnal in 
response to external light-dark cycles (Nickla, Wildsoet et al. 2001). Nickla (Nickla 2006) 
provides further evidence for the role of a phase shift in the temporal relationship between 
axial length and choroidal thickness cycles in the control of ocular growth in a study 
comparing recovery from form-deprivation, myopic defocus and hyperopic defocus in 
chicks. It appears that where the treatment requires a decrease in ocular growth (such as 
recovery from form-deprivation) the axial length and choroidal rhythms shift into phase. 
The mechanism by which such a phase shift might influence ocular growth is not certain, 
although it has been proposed that the variation in thickness of the choroid may regulate 
diffusion of a signal molecule from the retina to the sclera, or may act as a mechanical 
scaffolding against the influence of diurnal intra-ocular pressure changes on the sclera 
(Nickla 2006). 
3.3 Diurnal modulation of illumination 
In order to determine the minimum period of darkness within the diurnal light:dark cycle 
that is required for normal eye growth, Li et al. (Li, Howland et al. 2000) investigated the 
effect of various periods of darkness from zero (constant light) to a standard 12:12 h 
light:dark cycle in chicks. They found that at least 4 hours darkness per diurnal cycle 
produced a normal emmetropisation response in the chick (Li, Howland et al. 2000). Further 
investigations demonstrated that the 4 hours of darkness was most effective in blocking the 
effects of excess light exposure when presented in a single period at the same time of day, 
rather than at random times or as multiple periods totalling 4 hours (Li, Howland et al. 
2000). Li et al. (Li, Howland et al. 2000) concluded that this period of darkness may be 
sufficient to entrain the intrinsic circadian clock of the avian retina (Morgan and Boelen 
1996). The requirement for periods of darkness during a diurnal cycle in order to produce 
normal eye growth in chicks has a potential corollary in humans. As noted earlier, the use of 
night lights in children’s bedrooms under the age of 2 years has been associated with the 
development of myopia in later life (Quinn, Shin et al. 1999). 
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Diurnal modulation of ambient illumination rather than the need for periods of total 
darkness may be the significant requirement for normal emmetropisation in chicks. Liu et al. 
(Liu, Pendrak et al. 2004) reared chicks under light:dark, light:dim and constant light cycles 
with the aim of investigating the effect of ambient lighting at night on emmetropisation. The 
irradiance of the light phase was 1500 W/cm2, while the dim phase varied between 0.01 
and 500 W/cm2. The eyes of chicks raised under light:dark and light:dim cycles had 
comparable ocular refractions and dimensions. Conversely, rearing under constant light 
levels from 1 W/cm2 (~0.3 lux) to 1500 W/cm2 (~500 lux) produced the typical shallow 
anterior chamber and hyperopic shift in refraction as found previously in chicks. These 
results imply that the modulation of light levels during a diurnal cycle may be of more 
importance in the maintenance of the normal emmetropisation response than the absolute 
light (or dark) levels. Consequently, the use of light:dim diurnal cycles may be a more 
pertinent paradigm for study as it more closely approximates the typical urban environment 
with artificial lighting at night (Liu, Pendrak et al. 2004). 
3.4 Amplitude modulation of illumination 
Recent animal investigations support the fundamental hypothesis that light exposure is the 
mediator of the antimyopiagenic effect of outdoor activity (Rose, Morgan et al. 2008a). 
Experiments in chicks have shown that exposure to high ambient light levels, either artificial 
or natural, modifies the development of experimental myopia due to either visual form 
deprivation using translucent occluders, or induced defocus using spectacle lenses (Ashby, 
Ohlendorf et al. 2009; Ashby and Schaeffel 2010). While exposure to high illumination levels 
of 15,000 lux for 5 hours per day significantly reduced form-deprivation myopia by around 
60%, in lens-induced myopia the rate of compensation for the induced defocus was 
modified, but not the final degree of refractive error produced (Ashby and Schaeffel 2010). 
The normal emmetropisation process in chicks can also be directly influenced by ambient 
light levels: raising animals under low light levels (50 lux) produced myopic refractive 
outcomes on average, while high light levels (10,000 lux) produced hyperopic refractive 
outcomes (Cohen, Belkin et al. 2011). 
In form-deprivation experiments in chicks, exposure to high artificial light (15,000 lux) 
indoors or natural light (30,000 lux) outdoors for 15 minutes per day with occluders 
removed was sufficient to produce a statistically significant decrease in axial myopia 
beyond that produced by the removal of the occluders under normal laboratory light levels 
(500 lux) (Ashby, Ohlendorf et al. 2009). The antimyopiagenic effect of high illumination 
levels was also demonstrated under constant occluder wear conditions where a significant 
decrease in axial myopia development was also demonstrated in chicks raised under 15,000 
lux for 6 hours per day when compared to animals raised under 50 or 500 lux (Ashby, 
Ohlendorf et al. 2009). As the antimyopiagenic effect occurred during continuous occluder 
wear the authors conclude that the effect cannot be due to a reduction in image blur 
resulting from pupil constriction as these animals did not receive clear form vision at any 
time in the occluded eye. It has been suggested that high ambient illumination levels  may 
affect the diurnal variation in retinal dopamine, which is disrupted in form-deprivation in 
chicks (Weiss and Schaeffel 1993), with the proposal that the chick retina has a graded 
release of dopamine under high illumination levels which results in a retardation of myopia 
development (Ashby, Ohlendorf et al. 2009). The intra-vitreal administration of a dopamine 
antagonist (spiperone) blocked the protective effect of high illumination levels against form-
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deprivation myopia in chicks (Ashby and Schaeffel 2010) further supporting the hypothesis 
that this neurotransmitter is intrinsically involved in the control of the emmetropisation 
mechanism (Ashby and Schaeffel 2010; Mao, Liu et al. 2010; Nickla, Totonelly et al. 2010).  
3.5 Chromaticity and refractive development 
The contribution of the chromatic component of light to refractive development has been 
investigated in a number of animal models including chicks (Rucker and Wallman 2009), 
fish (Kroger and Wagner 1996) and guinea pigs (Long, Chen et al. 2009). Guinea pigs raised 
under long-wavelength light (peak at 760 nm) reportedly develop a significant degree of 
myopia, associated with a significant increase in vitreous chamber depth, over a period of 4 
weeks when compared to animals raised under mixed-wavelength light (unfiltered halogen 
lamps) (Long, Chen et al. 2009). The myopiagenic effect of long-wavelength light was 
reversed by allowing the animals to recover under mixed-wavelength light conditions for 
two weeks, after which there was no significant difference in refraction (Long, Chen et al. 
2009).  
One possible explanation for the effect of wavelength on refractive outcome is based on the 
intrinsic chromatic aberration of the vertebrate eye (Mandelman and Sivak 1983) which 
could provide a sign-of-defocus signal for emmetropisation (Flitcroft 1990) as the long and 
short wavelength components would produce relative hyperopic and myopic defocus of the 
retinal image respectively. For example, in a comparison of the effects of raising guinea pigs 
under equiluminant short wavelength light (430 nm) or middle wavelength light (530 nm), 
Liu et al. (Liu, Qian et al. 2011) demonstrated that after 12 weeks the 530 nm group was less 
hyperopic due to faster vitreous elongation, while the 430 nm group was more hyperopic 
following slower vitreous elongation. The difference in refraction between the groups  (4.50 
D) exceeded the longitudinal chromatic aberration of the guinea pig eye (approximately 1.5 
D) at the selected wavelengths, which was possibly due to additional accommodative effects 
produced by the monochromatic illumination (Seidemann and Schaeffel 2002), or by 
wavelength-dependent alteration of retinal or retinal pigment epithelium growth signals 
(Liu, Qian et al. 2011). 
4. Light and circadian rhythms 
The role of illumination level and the requirement for periodic light:dark cycles during 
normal refractive development points to a role for the intrinsic circadian clock and the 
associated dopamine-melatonin cycle in the control of eye growth (Cahill and Besharse 1995; 
Witkovsky 2004; Iuvone, Tosini et al. 2005). The presumed role of circadian rhythms, which 
persist in constant darkness independent of the diurnal light:dark cycle, is to regulate the 
timing of biological events so as to optimise the metabolic function and energy use of the 
organism (Roenneberg and Foster 1997; Levi and Schibler 2007). 
4.1 The circadian pacemaker 
Although the control of the circadian rhythm is a complex, multivariate process, it has been 
known for some time that light plays a pivotal role (Iuvone, Tosini et al. 2005). The 
underlying circadian rhythm is controlled by a circadian clock, through the expression of 
“clock genes” and their products, and entrainment cues known as zeitgebers (“time givers”) 
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Diurnal modulation of ambient illumination rather than the need for periods of total 
darkness may be the significant requirement for normal emmetropisation in chicks. Liu et al. 
(Liu, Pendrak et al. 2004) reared chicks under light:dark, light:dim and constant light cycles 
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irradiance of the light phase was 1500 W/cm2, while the dim phase varied between 0.01 
and 500 W/cm2. The eyes of chicks raised under light:dark and light:dim cycles had 
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levels from 1 W/cm2 (~0.3 lux) to 1500 W/cm2 (~500 lux) produced the typical shallow 
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levels was also demonstrated under constant occluder wear conditions where a significant 
decrease in axial myopia development was also demonstrated in chicks raised under 15,000 
lux for 6 hours per day when compared to animals raised under 50 or 500 lux (Ashby, 
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affect the diurnal variation in retinal dopamine, which is disrupted in form-deprivation in 
chicks (Weiss and Schaeffel 1993), with the proposal that the chick retina has a graded 
release of dopamine under high illumination levels which results in a retardation of myopia 
development (Ashby, Ohlendorf et al. 2009). The intra-vitreal administration of a dopamine 
antagonist (spiperone) blocked the protective effect of high illumination levels against form-
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organism (Roenneberg and Foster 1997; Levi and Schibler 2007). 
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Although the control of the circadian rhythm is a complex, multivariate process, it has been 
known for some time that light plays a pivotal role (Iuvone, Tosini et al. 2005). The 
underlying circadian rhythm is controlled by a circadian clock, through the expression of 
“clock genes” and their products, and entrainment cues known as zeitgebers (“time givers”) 
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which influence the timing of these rhythms (Roenneberg and Foster 1997; Iuvone, Tosini et 
al. 2005).  The primary, central time keeping clock in the body is the suprachiasmatic 
nucleus (SCN) of the hypothalamus (Roenneberg and Foster 1997). The primary input to the 
SCN is from the retina via the retinohypothalamic tract (RHT) (Simonneaux and Ribelayga 
2003), which makes light the primary zeitgeber for entrainment of the circadian rhythm 
(Roenneberg and Foster 1997). While input via the RHT is not necessary for the generation 
of a circadian rhythm (evidenced by the free running nature of the SCN rhythm), it is 
necessary for the entrainment of the circadian rhythm to the normal light:dark cycle (Inouye 
and Kawamura 1979). 
4.2 The light entrainment pathway 
The traditional view of the photosensitive retinal organisation is of a dual photoreceptor 
system comprising both rods and cones. However, circadian entrainment has been found to 
originate from a small subset of retinal ganglion cells, the intrinsically photosensitive retinal 
ganglion cells (ipRGCs) (Berson, Dunn et al. 2002; Hattar, Liao et al. 2002). The 
photopigment melanopsin, first described in melanophores on frog skin and subsequently 
found in the inner retina of a number of mammals including humans, provides the ipRGCs 
with this photosensitivity (Provencio, Rodriguez et al. 2000; Hattar, Liao et al. 2002). 
Melanopsin has an action spectrum that peaks around 480 nm (Berson, Dunn et al. 2002). 
However, studies in melanopsin-knockout mice showed that melanopsin is not essential for 
light entrainment of the circadian pacemaker, but improves the magnitude of the response 
(Ruby, Brennan et al. 2002).  It transpires that the melanopsin-containing ipRGCs also 
receive input from the traditional rod and cone photoreceptors (Perez-Leon, Warren et al. 
2006). There is a loss of photo-entrainment, but a persistence of pattern vision, in animals 
without functional ipRGCs providing definitive support for the role of the ipRGCs in the 
entrainment of the circadian system by light (Guler, Ecker et al. 2008). The entrainment of 
the circadian system in mammals is thus mediated by the ipRGCs as a balance between 
intrinsic photoreception enabled by melanopsin and input from the traditional retinal 
photoreceptors. In chicks melanopsin is found in both the retina and the pineal gland, 
indicating light can entrain the circadian pacemaker through both retinal (via ipRGCs) and 
direct pineal routes (Torii, Kojima et al. 2007; Neumann, Ziegler et al. 2008). 
The SCN, working as a central master clock, controls the circadian timing of the organism 
through a multisynaptic pathway. The SCN projects to neurones in the paraventricular 
hypothalamic nucleus, which synapse preganglionic sympathetic neurons in the 
intermediolateral cell column, stimulating postganglionic sympathetic neurons in the 
superior cervical ganglion, before finally providing sympathetic input to the pineal gland 
(Larsen, Enquist et al. 1998). The main circadian mediator from the pineal gland is 
melatonin, a hormone first isolated from bovine pineal glands and named for its ability to 
lighten the melanocytes in frog skin (Lerner, Case et al. 1958). Melatonin acts through 
melatonin receptors in a diverse range of tissues, performing a variety of roles in circadian 
entrainment, endocrine functions, cardiovascular responses, the immune system, and ocular 
physiology (Alarma-Estrany and Pintor 2007). 
4.3 Melatonin precursors 
Melatonin (N-acetyl-5-methoxytryptamine) is a circadian hormone produced through a 
pathway involving four precursor intermediaries (Fig. 1.). All of the components necessary 
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for the production of melatonin are active within the pineal gland, which is the main site of 
production (Axelrod 1974; Zawilska, Skene et al. 2009). The first step is the conversion of the 
dietary amino acid tryptophan to 5-hydroxytryptophan by the enzyme tryptophan 
hydroxylase (TPH); the second step involves the conversion of 5-hydroxytryptophan to 
serotonin via the enzyme aromatic L-amino acid decarboxylase (AADC); serotonin is 
converted in the third step to N-acetylserotonin by the enzyme arylalkylamine-N-
acetyltransferase (AANAT); the final step is the O-methylation of N-acetylserotonin to 
melatonin by the enzyme hydroxyindole-O-methyltransferase (HIOMT). The rate limiting 
enzyme in the production of melatonin is widely thought to be AANAT, although recent 
work suggests that HIOMT may be the crucial limiting factor (Liu and Borjigin 2005). The 
precursor components of melatonin synthesis also show inherent circadian rhythms of 
production (Axelrod 1974). The retina is another significant producer of melatonin in some 
animals, providing the basis for a peripheral clock in addition to the central clock of the 
pineal gland (Iuvone, Tosini et al. 2005) 
 
Fig. 1. Melatonin production pathway showing the precursor compounds and the enzymes 
involved. 
4.4 Circadian melatonin rhythms 
In the majority of species studied to date, whether they are diurnally or nocturnally active, 
there is a circadian secretion pattern of melatonin with high levels present at night and low 
levels during the day (Zawilska, Skene et al. 2009). The onset of darkness following a period 
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which influence the timing of these rhythms (Roenneberg and Foster 1997; Iuvone, Tosini et 
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entrainment of the circadian system by light (Guler, Ecker et al. 2008). The entrainment of 
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intrinsic photoreception enabled by melanopsin and input from the traditional retinal 
photoreceptors. In chicks melanopsin is found in both the retina and the pineal gland, 
indicating light can entrain the circadian pacemaker through both retinal (via ipRGCs) and 
direct pineal routes (Torii, Kojima et al. 2007; Neumann, Ziegler et al. 2008). 
The SCN, working as a central master clock, controls the circadian timing of the organism 
through a multisynaptic pathway. The SCN projects to neurones in the paraventricular 
hypothalamic nucleus, which synapse preganglionic sympathetic neurons in the 
intermediolateral cell column, stimulating postganglionic sympathetic neurons in the 
superior cervical ganglion, before finally providing sympathetic input to the pineal gland 
(Larsen, Enquist et al. 1998). The main circadian mediator from the pineal gland is 
melatonin, a hormone first isolated from bovine pineal glands and named for its ability to 
lighten the melanocytes in frog skin (Lerner, Case et al. 1958). Melatonin acts through 
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of light leads to an increase in pineal AANAT and melatonin levels in phase with each other 
(Wilkinson, Arendt et al. 1977). However, there appears to be a refractory period for dark-
induced melatonin rises such that darkness during periods when the organism is expecting 
it to be light does not induce the rise (Binkley, Macbride et al. 1975). Three distinct patterns 
of nocturnal melatonin production have been described in mammals: Type A is uncommon 
and represents a peak in melatonin late in the dark phase (e.g. Syrian hamster and house 
mouse); Type B is most common and shows peak melatonin expression occurring around 
midnight (e.g. rat, guinea pig, and human); and Type C which is also common and shows 
elevated melatonin levels for most of the dark phase (e.g. sheep and cat) (Zawilska, Skene et 
al. 2009). The human melatonin cycle, like that of animals (Tast, Love et al. 2001), can be 
entrained to variations in the light:dark cycle. When the light:dark cycle is phase-shifted by 
12 hours, the human rhythm in melatonin secretion re-entrains to the new dark phase over a 
period of 5 to 7 days (Lynch, Jimerson et al. 1978). 
4.5 Light and melatonin suppression 
Darkness is required for the rise in melatonin, as animals kept in constant light show a 
reduction or complete loss of melatonin synthesis (Perlow, Reppert et al. 1980). However, 
the factor mediating the entrainment of the melatonin rhythm appears to be light exposure. 
Presentation of light during the dark phase, when melatonin levels are elevated, results in a 
rapid suppression of production and a reduction in serum melatonin concentration (e.g. 
(Illnerova, Backstrom et al. 1978; Rollag, O'Callaghan et al. 1978)). Human melatonin 
suppression by light is intensity dependant, with brighter light leading to greater levels of 
melatonin suppression (McIntyre, Norman et al. 1989; Zeitzer, Dijk et al. 2000). Suppression 
to near daytime levels (67% suppression) is achieved with 1000 lux (McIntyre, Norman et al. 
1989), while a half maximal suppression response can be seen between approximately 50 
and 130 lux (Zeitzer, Dijk et al. 2000). This light induced suppression also shows an inverse 
correlation with duration, such that longer durations of light require lower intensities of 
light to induce suppression (Aoki, Yamada et al. 1998). However, independent of light level 
there appears to be an asymptote for melatonin suppression after around 60 minutes of light 
exposure (Figueiro, Rea et al. 2006). Interestingly the melatonin suppression by light appears 
to be sensitised/desensitised by the amount of light received during the day prior, such that 
less light exposure (as experienced during winter months) results in much greater melatonin 
suppression for a given amount of light at night (Smith, Schoen et al. 2004; Higuchi, 
Motohashi et al. 2007).  
The action spectrum for melatonin suppression shows peak effect between 446 and 477 nm 
(Brainard, Hanifin et al. 2001; Thapan, Arendt et al. 2001). The light response of the 
melanopsin containing ipRGCs mirrors that of the melatonin suppression action spectrum, 
indicating that these cells are the likely mediators of the response (Berson, Dunn et al. 2002). 
Circadian photo-entrainment also appears to be mediated by a peak action spectrum 
response from the same blue wavelength portion of the spectrum (Hattar, Lucas et al. 2003). 
These responses are also seen in humans, although a greater response is seen when 
polychromatic light is used instead of monochromatic light at peak melanopsin sensitivity, 
suggesting melanopsin may not be solely responsible and that rod and cone input also play 
a role (Revell and Skene 2007). Despite uncertainty as to the exact cellular input driving the 
circadian entrainment, it is clear that the blue end of the spectrum is important. 
Interestingly, exposure to the blue part of the spectrum also appears to suppress myopia 
development in guinea pigs (e.g. (Liu, Qian et al. 2011; Wang, Zhou et al. 2011)). 
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Wang et al. (Wang, Zhou et al. 2011) raised guinea pigs under blue light (480 nm), green 
light (530 nm) and broadband white light. After 10 days the levels of melatonin in the pineal 
glands were significantly lower in both the blue light and white light groups when 
compared to the green light group. This difference existed in both daytime (10 am) and 
night-time (10 pm) samples. The green-light group were also about 2 D more myopic, had 
greater axial lengths and greater vitreous depths than the other groups. Furthermore the 
green-light group exhibited reduced expression of retinal melanopsin mRNA and reduced 
levels of melanopsin protein. MT1 receptor mRNA expression was higher in both the retina 
and sclera of the green-light group. Overall this study demonstrated a clear link between 
wavelength of illumination, refractive error development and modulation of the melatonin 
pathway in guinea pigs. 
4.6 Light as a zeitgeber 
Light is the primary zeitgeber for the entrainment of the circadian system (Roenneberg and 
Foster 1997). Phase response curves have shown that the timing of light exposure is critical 
to circadian responses to light (Daan and Pittendrigh 1976). When light is presented at the 
beginning of the subjective night there is a phase delay of the subsequent activity-rest cycle, 
while light presented at the end of the subjective night leads to a phase advance. 
Presentation of light during the subjective day has little effect on the phase response curve, 
suggesting the twilight zones of dusk and dawn are the key times for entrainment 
(Roenneberg and Foster 1997). The phase shifting effect of light also affects the timing of the 
dim light melatonin onset (the increase in melatonin levels at night) (Lewy, Sack et al. 1985). 
Bright light in the evening delays dim light melatonin onset while bright light in the 
morning advances it. Bright light presented both in the morning and evening gives an 
intermediate response between delay and advance (Lewy, Sack et al. 1987). Exposure to 
bright light results in immediate melatonin suppression, but longer exposure of greater 
intensity is required to entrain the pacemaker (Hashimoto, Nakamura et al. 1996). However, 
dim light exposure at the appropriate time and for a long enough period has also been 
shown to entrain the circadian system (Zeitzer, Dijk et al. 2000). The importance of the 
timing of the signal for entrainment has a parallel in form-deprivation myopia wherein 
removal of the occluder for 40 minutes in the evening is more effective at reducing the 
induced myopia than if the occluder is removed in the morning (Ohngemach, Feldkaemper 
et al. 2001).  
4.7 Photoperiodism and photoperiodic history 
Photoperiodism, the adaptation of an organism’s physiological functions to changes in 
season, is thought to be determined by both the absolute photoperiod length and by changes 
(either increasing or decreasing) in photoperiod length (Goldman 2001). Three main 
hypotheses to explain the influence of melatonin on this phenomenon exist: the duration, 
coincidence, and amplitude hypotheses. 
The duration hypothesis proposes that the duration of night-time melatonin release is used 
as a signal encoding day length, with a shorter duration melatonin signal indicating long 
day/short night periods and vice versa (Simonneaux and Ribelayga 2003). In 
pinealectomised animals, short duration infusion of melatonin replicates a long day 
reproductive response while long duration infusion replicates a short day response (e.g. 
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of light leads to an increase in pineal AANAT and melatonin levels in phase with each other 
(Wilkinson, Arendt et al. 1977). However, there appears to be a refractory period for dark-
induced melatonin rises such that darkness during periods when the organism is expecting 
it to be light does not induce the rise (Binkley, Macbride et al. 1975). Three distinct patterns 
of nocturnal melatonin production have been described in mammals: Type A is uncommon 
and represents a peak in melatonin late in the dark phase (e.g. Syrian hamster and house 
mouse); Type B is most common and shows peak melatonin expression occurring around 
midnight (e.g. rat, guinea pig, and human); and Type C which is also common and shows 
elevated melatonin levels for most of the dark phase (e.g. sheep and cat) (Zawilska, Skene et 
al. 2009). The human melatonin cycle, like that of animals (Tast, Love et al. 2001), can be 
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12 hours, the human rhythm in melatonin secretion re-entrains to the new dark phase over a 
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to be sensitised/desensitised by the amount of light received during the day prior, such that 
less light exposure (as experienced during winter months) results in much greater melatonin 
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melanopsin containing ipRGCs mirrors that of the melatonin suppression action spectrum, 
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suggesting melanopsin may not be solely responsible and that rod and cone input also play 
a role (Revell and Skene 2007). Despite uncertainty as to the exact cellular input driving the 
circadian entrainment, it is clear that the blue end of the spectrum is important. 
Interestingly, exposure to the blue part of the spectrum also appears to suppress myopia 
development in guinea pigs (e.g. (Liu, Qian et al. 2011; Wang, Zhou et al. 2011)). 
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Wang et al. (Wang, Zhou et al. 2011) raised guinea pigs under blue light (480 nm), green 
light (530 nm) and broadband white light. After 10 days the levels of melatonin in the pineal 
glands were significantly lower in both the blue light and white light groups when 
compared to the green light group. This difference existed in both daytime (10 am) and 
night-time (10 pm) samples. The green-light group were also about 2 D more myopic, had 
greater axial lengths and greater vitreous depths than the other groups. Furthermore the 
green-light group exhibited reduced expression of retinal melanopsin mRNA and reduced 
levels of melanopsin protein. MT1 receptor mRNA expression was higher in both the retina 
and sclera of the green-light group. Overall this study demonstrated a clear link between 
wavelength of illumination, refractive error development and modulation of the melatonin 
pathway in guinea pigs. 
4.6 Light as a zeitgeber 
Light is the primary zeitgeber for the entrainment of the circadian system (Roenneberg and 
Foster 1997). Phase response curves have shown that the timing of light exposure is critical 
to circadian responses to light (Daan and Pittendrigh 1976). When light is presented at the 
beginning of the subjective night there is a phase delay of the subsequent activity-rest cycle, 
while light presented at the end of the subjective night leads to a phase advance. 
Presentation of light during the subjective day has little effect on the phase response curve, 
suggesting the twilight zones of dusk and dawn are the key times for entrainment 
(Roenneberg and Foster 1997). The phase shifting effect of light also affects the timing of the 
dim light melatonin onset (the increase in melatonin levels at night) (Lewy, Sack et al. 1985). 
Bright light in the evening delays dim light melatonin onset while bright light in the 
morning advances it. Bright light presented both in the morning and evening gives an 
intermediate response between delay and advance (Lewy, Sack et al. 1987). Exposure to 
bright light results in immediate melatonin suppression, but longer exposure of greater 
intensity is required to entrain the pacemaker (Hashimoto, Nakamura et al. 1996). However, 
dim light exposure at the appropriate time and for a long enough period has also been 
shown to entrain the circadian system (Zeitzer, Dijk et al. 2000). The importance of the 
timing of the signal for entrainment has a parallel in form-deprivation myopia wherein 
removal of the occluder for 40 minutes in the evening is more effective at reducing the 
induced myopia than if the occluder is removed in the morning (Ohngemach, Feldkaemper 
et al. 2001).  
4.7 Photoperiodism and photoperiodic history 
Photoperiodism, the adaptation of an organism’s physiological functions to changes in 
season, is thought to be determined by both the absolute photoperiod length and by changes 
(either increasing or decreasing) in photoperiod length (Goldman 2001). Three main 
hypotheses to explain the influence of melatonin on this phenomenon exist: the duration, 
coincidence, and amplitude hypotheses. 
The duration hypothesis proposes that the duration of night-time melatonin release is used 
as a signal encoding day length, with a shorter duration melatonin signal indicating long 
day/short night periods and vice versa (Simonneaux and Ribelayga 2003). In 
pinealectomised animals, short duration infusion of melatonin replicates a long day 
reproductive response while long duration infusion replicates a short day response (e.g. 
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(Bittman and Karsch 1984; Maywood, Buttery et al. 1990)). The coincidence hypothesis 
proposes that there is a coincidence between a sensitive period for signal detection and the 
presence of the melatonin signal. Infusion of melatonin at specific circadian time points in 
pinealectomised individuals suggests a critical period of sensitivity either at the onset of the 
dark phase (Gunduz and Stetson 2001), or at a specific time after the initial melatonin rise 
(Pitrosky, Kirsch et al. 1995). More recent work suggests that the coincidence timing effect of 
melatonin acts through clock gene expression oscillations (for review see (Hazlerigg and 
Wagner 2006)). While the amplitude hypothesis, which proposes that the peak amplitude of 
melatonin secretion is the signal for seasonal timing, is often discussed (e.g. (Simonneaux 
and Ribelayga 2003)), very little experimental data exists to back it up. Thus duration and 
timing of circadian signals may be more important than signal amplitude for circadian 
entrainment. 
During periods of intermediate day-length between the winter and summer solstices a 
single day-length signal is insufficient to determine whether the days are becoming longer 
or shorter, so photoperiodic history, based upon the length of the preceding days, is used. 
The photoperiodic history appears to rely on the summation of recent photoperiod 
information over a number of days (Prendergast, Gorman et al. 2000), and the prenatal 
photoperiod actually appears to modify the postnatal day-length threshold which controls 
the maximal rate of development (Shaw and Goldman 1995). The ability of the perinatal 
photoperiodic history to influence future development rates may explain the observed 
season of birth effect in human refractive development (see Section 2.3). 
5. Peripheral clocks 
In addition to the master central circadian clock, peripheral systems and indeed individual 
cells also possess clocks (reviewed by (Balsalobre 2002)). Of these the retina, which also 
provides the main entrainment cue for the central clock, constitutes the most relevant 
peripheral clock for refractive development. The retina is a highly circadian tissue, showing 
rhythms in a variety of functions including visual sensitivity, the electroretinogram 
response, rod outer segment disc shedding, melanopsin mRNA expression, melatonin 
synthesis, and dopamine synthesis (for excellent reviews see (Iuvone, Tosini et al. 2005; 
Tosini, Pozdeyev et al. 2008)).  
5.1 Retinal melatonin 
Melatonin is synthesised in the retina in a circadian manner, independent of the SCN, in 
both non-mammalian (Cahill and Besharse 1992; Thomas, Tigges et al. 1993) and 
mammalian (Tosini and Menaker 1996) vertebrates. The retinal photoreceptors appear to 
be the source of this retinal melatonin production, with AANAT and HIOMT activity 
having been localised mainly to these cells, and only minimal activity in the inner nuclear 
layer and ganglion cells (Guerlotte, Greve et al. 1996; Coon, Del Olmo et al. 2002). 
Moreover, melatonin continues to be produced despite partial or complete destruction of 
the inner retina (Cahill and Besharse 1992; Thomas, Tigges et al. 1993). Human and 
primate retinas appear to be missing activity of the HIOMT enzyme, with expression of 
HIOMT mRNA in such small quantities that it contributes little to the production of 
melatonin (Bernard, Donohue et al. 1995; Coon, Del Olmo et al. 2002). However, labelling 
and activity of HIOMT in human photoreceptors has been demonstrated (Wiechmann and 
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Hollyfield 1987), although this has not been repeated by other groups. It has been 
postulated that N-acetylserotonin might take the place of a local melatonin signal in the 
retina of humans and primates (Iuvone, Tosini et al. 2005), or that the signal is provided 
by circulating melatonin levels (Osol and Schwartz 1984). Interestingly, human RPE and 
ciliary body also synthesise melatonin (Martin, Malina et al. 1992; Zmijewski, Sweatman 
et al. 2009).  
5.2 Central and retinal dopamine rhythms 
Dopamine is a neurotransmitter that has a multitude of roles, such as in learning and 
movement (Witkovsky 2004). Plasma dopamine levels in humans show a circadian rhythm 
in concentration that is phase-shifted relative to melatonin by approximately 180 degrees, 
peaking in the light phase and reaching lowest levels during the dark phase (Sowers and 
Vlachakis 1984). Primates (Perlow, Gordon et al. 1977), rats (Schade, Vick et al. 1995), and 
birds (Kang, Thayananuphat et al. 2007) also show these circadian rhythms in dopamine 
production; high in light, low in dark, and out of phase with melatonin. In pinealectomised 
rats the administration of melatonin suppresses dopamine expression in a dose-dependent 
manner (Khaldy, Leon et al. 2002).  
Dopamine also has many roles in the retina, for example in light adaptation and cell death, 
as well as a potential role in ocular growth (Witkovsky 2004). As in the brain, retinal 
dopamine shows a diurnal rhythm with peak levels during the day and low levels during 
the night in non-human vertebrates (Nowak, Zurawska et al. 1989; Megaw, Boelen et al. 
2006), and in human retinas (Di Paolo, Harnois et al. 1987). The diurnal variation in 
dopamine levels persists in constant darkness in mice, indicating that it has a circadian 
rhythm of release (Doyle, Grace et al. 2002), although others have found no circadian 
rhythm but a light activated fluctuation in retinal dopamine (Melamed, Frucht et al. 1984).  
5.3 Light and dopamine 
Dopamine is released from the perfused retina on exposing it to light (Kramer 1971), and 
light also stimulates retinal dopamine synthesis and turnover (Iuvone, Galli et al. 1978; 
Cohen, Hadjiconstantinou et al. 1983). Moreover, the light-activated rise in dopamine levels 
in the retina is much greater than the rise seen with the underlying circadian rhythm in 
constant darkness (Megaw, Boelen et al. 2006), and the metabolism of dopamine in the light 
is much greater than in the dark (Parkinson and Rando 1983; Megaw, Boelen et al. 2006). 
Furthermore, the intensity of light appears to be important for dopamine release and 
synthesis in the retina, with maximal stimulation and saturation of the response occurring 
between 32 to 80 lux in rats (Proll, Kamp et al. 1982; Brainard and Morgan 1987).  
It transpires that change in light, in the form of flicker, is a more potent stimulus to 
dopamine release than constant light levels. This effect has been shown in several species, 
with increasing release rates seen with increasing stimulus presentation rates, and an 
increase in dopamine release above that seen with constant light alone (Kramer 1971; 
Weiler, Baldridge et al. 1997). Flickering light appears to increase dopamine release two to 
three times that of basal release levels. High frequency flicker at 6 Hz has also been shown 
to inhibit both form-deprivation myopia and lens-induced myopia in the chick (Schwahn 
and Schaeffel 1997). The degree of suppression is correlated with the length of the dark 
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(Bittman and Karsch 1984; Maywood, Buttery et al. 1990)). The coincidence hypothesis 
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Wagner 2006)). While the amplitude hypothesis, which proposes that the peak amplitude of 
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and Ribelayga 2003)), very little experimental data exists to back it up. Thus duration and 
timing of circadian signals may be more important than signal amplitude for circadian 
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single day-length signal is insufficient to determine whether the days are becoming longer 
or shorter, so photoperiodic history, based upon the length of the preceding days, is used. 
The photoperiodic history appears to rely on the summation of recent photoperiod 
information over a number of days (Prendergast, Gorman et al. 2000), and the prenatal 
photoperiod actually appears to modify the postnatal day-length threshold which controls 
the maximal rate of development (Shaw and Goldman 1995). The ability of the perinatal 
photoperiodic history to influence future development rates may explain the observed 
season of birth effect in human refractive development (see Section 2.3). 
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In addition to the master central circadian clock, peripheral systems and indeed individual 
cells also possess clocks (reviewed by (Balsalobre 2002)). Of these the retina, which also 
provides the main entrainment cue for the central clock, constitutes the most relevant 
peripheral clock for refractive development. The retina is a highly circadian tissue, showing 
rhythms in a variety of functions including visual sensitivity, the electroretinogram 
response, rod outer segment disc shedding, melanopsin mRNA expression, melatonin 
synthesis, and dopamine synthesis (for excellent reviews see (Iuvone, Tosini et al. 2005; 
Tosini, Pozdeyev et al. 2008)).  
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Melatonin is synthesised in the retina in a circadian manner, independent of the SCN, in 
both non-mammalian (Cahill and Besharse 1992; Thomas, Tigges et al. 1993) and 
mammalian (Tosini and Menaker 1996) vertebrates. The retinal photoreceptors appear to 
be the source of this retinal melatonin production, with AANAT and HIOMT activity 
having been localised mainly to these cells, and only minimal activity in the inner nuclear 
layer and ganglion cells (Guerlotte, Greve et al. 1996; Coon, Del Olmo et al. 2002). 
Moreover, melatonin continues to be produced despite partial or complete destruction of 
the inner retina (Cahill and Besharse 1992; Thomas, Tigges et al. 1993). Human and 
primate retinas appear to be missing activity of the HIOMT enzyme, with expression of 
HIOMT mRNA in such small quantities that it contributes little to the production of 
melatonin (Bernard, Donohue et al. 1995; Coon, Del Olmo et al. 2002). However, labelling 
and activity of HIOMT in human photoreceptors has been demonstrated (Wiechmann and 
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Hollyfield 1987), although this has not been repeated by other groups. It has been 
postulated that N-acetylserotonin might take the place of a local melatonin signal in the 
retina of humans and primates (Iuvone, Tosini et al. 2005), or that the signal is provided 
by circulating melatonin levels (Osol and Schwartz 1984). Interestingly, human RPE and 
ciliary body also synthesise melatonin (Martin, Malina et al. 1992; Zmijewski, Sweatman 
et al. 2009).  
5.2 Central and retinal dopamine rhythms 
Dopamine is a neurotransmitter that has a multitude of roles, such as in learning and 
movement (Witkovsky 2004). Plasma dopamine levels in humans show a circadian rhythm 
in concentration that is phase-shifted relative to melatonin by approximately 180 degrees, 
peaking in the light phase and reaching lowest levels during the dark phase (Sowers and 
Vlachakis 1984). Primates (Perlow, Gordon et al. 1977), rats (Schade, Vick et al. 1995), and 
birds (Kang, Thayananuphat et al. 2007) also show these circadian rhythms in dopamine 
production; high in light, low in dark, and out of phase with melatonin. In pinealectomised 
rats the administration of melatonin suppresses dopamine expression in a dose-dependent 
manner (Khaldy, Leon et al. 2002).  
Dopamine also has many roles in the retina, for example in light adaptation and cell death, 
as well as a potential role in ocular growth (Witkovsky 2004). As in the brain, retinal 
dopamine shows a diurnal rhythm with peak levels during the day and low levels during 
the night in non-human vertebrates (Nowak, Zurawska et al. 1989; Megaw, Boelen et al. 
2006), and in human retinas (Di Paolo, Harnois et al. 1987). The diurnal variation in 
dopamine levels persists in constant darkness in mice, indicating that it has a circadian 
rhythm of release (Doyle, Grace et al. 2002), although others have found no circadian 
rhythm but a light activated fluctuation in retinal dopamine (Melamed, Frucht et al. 1984).  
5.3 Light and dopamine 
Dopamine is released from the perfused retina on exposing it to light (Kramer 1971), and 
light also stimulates retinal dopamine synthesis and turnover (Iuvone, Galli et al. 1978; 
Cohen, Hadjiconstantinou et al. 1983). Moreover, the light-activated rise in dopamine levels 
in the retina is much greater than the rise seen with the underlying circadian rhythm in 
constant darkness (Megaw, Boelen et al. 2006), and the metabolism of dopamine in the light 
is much greater than in the dark (Parkinson and Rando 1983; Megaw, Boelen et al. 2006). 
Furthermore, the intensity of light appears to be important for dopamine release and 
synthesis in the retina, with maximal stimulation and saturation of the response occurring 
between 32 to 80 lux in rats (Proll, Kamp et al. 1982; Brainard and Morgan 1987).  
It transpires that change in light, in the form of flicker, is a more potent stimulus to 
dopamine release than constant light levels. This effect has been shown in several species, 
with increasing release rates seen with increasing stimulus presentation rates, and an 
increase in dopamine release above that seen with constant light alone (Kramer 1971; 
Weiler, Baldridge et al. 1997). Flickering light appears to increase dopamine release two to 
three times that of basal release levels. High frequency flicker at 6 Hz has also been shown 
to inhibit both form-deprivation myopia and lens-induced myopia in the chick (Schwahn 
and Schaeffel 1997). The degree of suppression is correlated with the length of the dark 
 
Advances in Ophthalmology 
 
154 
phase of the flicker duty cycle (Schwahn and Schaeffel 1997). This may be due to increased 
retinal dopamine levels as 2 hours of exposure to flickering light at 10 Hz was shown to 
restore the rate of dopamine synthesis under form-deprivation conditions in chicks, possibly 
due to increased transcription of the tyrosine hydroxylase gene in dopaminergic amacrine 
cells (Luft, Iuvone et al. 2004).  
5.4 Dopamine and melatonin 
When light is presented during the dark phase there is a rapid suppression of melatonin and 
an increase in dopamine to normal daytime levels (Adachi, Nogi et al. 1998). Interestingly, 
in knockout mice that do not produce melatonin there is a loss of the circadian dopamine 
rhythm when the animals are maintained in constant darkness, but the rhythm is restored 
on administering exogenous melatonin (Doyle, Grace et al. 2002). These results are 
intriguing as they show that in the absence of melatonin a normal dopamine rhythm can be 
maintained by light exposure in a rhythmic light:dark cycle, but that melatonin can, in the 
absence of a light driven zeitgeber, also influence dopamine rhythms. Indeed there is a 
complex interaction between melatonin and dopamine in the retina with mutual inhibitory 
effects between the two compounds. Intra-vitreal injection of dopamine into the eye at night 
suppresses melatonin while the injection of melatonin during the day suppresses dopamine 
(Adachi, Nogi et al. 1998). Melatonin leads to an increase in AANAT activity in the retina 
and a decrease in dopamine levels (Nowak, Zurawska et al. 1989; Nowak, Kazula et al. 
1992), while dopamine inhibits retinal AANAT activity and melatonin release (Iuvone and 
Besharse 1986; Tosini and Dirden 2000).  
As melatonin production has not been demonstrated in the human retina, endogenous 
melatonin released from the pineal gland potentially acts in the retina. Indeed high levels of 
melatonin are found in human retinas, and intraperitoneal injection of melatonin in mice 
leads to an increase in retinal melatonin levels (Osol and Schwartz 1984; Doyle, Grace et al. 
2002). In chicks the pineal gland has been shown to have a significant influence over both 
expression of the dopamine D2-receptor mRNA and dopamine release in the retina 
(Ohngemach, Feldkaemper et al. 2001). Dopamine has also been shown to increase the 
expression of melanopsin mRNA via a D2-receptor pathway in ipRGCs (Sakamoto, Liu et al. 
2005).  
6. Dopamine, melatonin and refractive development 
6.1 Dopamine 
Retinal dopamine levels are reduced during the induction of form-deprivation myopia in 
the chick (Stone, Lin et al. 1989), rhesus monkey (Iuvone, Tigges et al. 1991) and guinea 
pig (Mao, Liu et al. 2010). In the chick, this reduction is due to a decreased rate of 
dopamine synthesis during the light phase of the diurnal light:dark cycle (Stone, Lin et al. 
1989). The use of modified translucent occluders demonstrates that retinal dopamine 
levels inversely correlate with the degree of axial elongation (Stone, Pendrak et al. 2006). 
Retinal dopamine levels exhibit a bidirectional response to retinal blur in chicks, with 
lens-induced myopia decreasing and hyperopia increasing the levels respectively (Guo, 
Sivak et al. 1995) although this effect is not universally reported (Bartmann, Schaeffel et al. 
1994). The increase in retinal dopamine associated with the slowing of axial growth in 
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lens-induced hyperopia parallels recovery from form-deprivation myopia in the chick 
where a similar relationship between dopamine level and axial growth is reported 
(Pendrak, Nguyen et al. 1997).  
The role of dopamine in the control of ocular growth is further supported by the 
demonstration that ocular administration of dopamine agonists  can inhibit the axial growth 
and myopic refractions produced by form-deprivation in chicks (Rohrer, Spira et al. 1993; 
Nickla, Totonelly et al. 2010) and primates (Iuvone, Tigges et al. 1991). Also, extraocular 
administration of the dopamine precursor levodopa by intraperitoneal injection in guinea 
pigs raises retinal dopamine content and reduces the development of myopia during form-
deprivation (Mao, Liu et al. 2010). The relationship between retinal dopamine pathways and 
lens-induced myopia is less certain. At dosages sufficient to suppress form-deprivation 
myopia in chicks, development of lens-induced myopia was not suppressed by intra-vitreal 
injections of 6-hydroxy dopamine, a drug which inhibits dopaminergic pathways (Schaeffel, 
Hagel et al. 1994). Conversely the non-specific dopaminergic agonist apomorphine has been 
shown to block negative lens-induced myopia in other chick studies (Schmid and Wildsoet 
2004; Nickla, Totonelly et al. 2010). 
Investigations using dopamine receptor subtype-specific agonists and antagonists have 
shown that the antimyopiagenic effect of dopamine is primarily mediated by D2 receptors. 
For example, in form-deprivation in chicks, the protective effects of the non-specific 
dopaminergic agonist apomorphine were blocked by the D2 specific antagonist spiperone, 
but not by the D1 specific antagonist SCH-23390 (Rohrer, Spira et al. 1993).  
In lens-induced myopia in chicks, both apomorphine (non-selective) and quinpirole (D2 
specific) agonists prevent the axial elongation and development of myopia associated with 
hyperopic defocus (Nickla, Totonelly et al. 2010). The effect is associated with an initial 
period of choroidal thickening, which is implicated in the inhibition of ocular growth either 
by the action of the choroid as a diffusion barrier to a growth signal or as an additional 
mechanical resistance to the effects of intraocular pressure (Nickla 2006). The D2 antagonist 
spiperone is not as effective in abolishing the protective effect of periodic lens removal as 
has been previously found for the removal of form-depriving diffusers in chicks (McCarthy, 
Megaw et al. 2007). This may suggest a partial role for D1 receptors in the control of ocular 
growth (Nickla, Totonelly et al. 2010). 
6.2 Melatonin 
While experimental evidence supports the role of retinal dopamine in the control of ocular 
growth and in the protective effect of light on myopia development, the role of melatonin, 
with which it is intrinsically linked in a counterphase cycle, is less certain (Cahill and 
Besharse 1995; Witkovsky 2004; Iuvone, Tosini et al. 2005). 
Evidence for the role of an intrinsic melatonin rhythm in the control of eye growth is 
provided by  Li and Howland (Li and Howland 2003) who demonstrated that the use of an 
opaque hood preventing light reaching the pineal gland for 12 hours per day is sufficient to 
significantly reduce the development of constant-light hyperopia in chicks. Covering one 
eye alone with an opaque occluder for 12 hours also partially prevented hyperopia 
development in the fellow eye under constant light conditions. The conclusion was that the 
eyes and pineal gland act as independent photoreceptors able to entrain the melatonin 
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phase of the flicker duty cycle (Schwahn and Schaeffel 1997). This may be due to increased 
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2002). In chicks the pineal gland has been shown to have a significant influence over both 
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2005).  
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Besharse 1995; Witkovsky 2004; Iuvone, Tosini et al. 2005). 
Evidence for the role of an intrinsic melatonin rhythm in the control of eye growth is 
provided by  Li and Howland (Li and Howland 2003) who demonstrated that the use of an 
opaque hood preventing light reaching the pineal gland for 12 hours per day is sufficient to 
significantly reduce the development of constant-light hyperopia in chicks. Covering one 
eye alone with an opaque occluder for 12 hours also partially prevented hyperopia 
development in the fellow eye under constant light conditions. The conclusion was that the 
eyes and pineal gland act as independent photoreceptors able to entrain the melatonin 
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circadian rhythm which is protective against the effects of constant light on eye growth (Li 
and Howland 2003). 
While diurnal retinal melatonin rhythms appear unaffected during form-deprivation 
(Hoffmann and Schaeffel 1996), the intra-vitreal injection of melatonin at relatively high 
doses (1000 g) increases the level of form-deprivation myopia induced in the chick 
(Schaeffel, Bartmann et al. 1995; Hoffmann and Schaeffel 1996). Although retinal melatonin 
content was sampled twice a day (day and night) during monocular occlusion, and an 
expected diurnal variation in melatonin was found, no significant difference was found 
between the occluded and non-occluded eyes (Hoffmann and Schaeffel 1996). While the 
authors concluded that melatonin was not a significant component of the ocular growth 
control mechanism in form-deprivation in chicks a number of factors may have colluded to 
disguise the role of melatonin in form-deprivation myopia. These include the timing of the 
intra-vitreal injection of melatonin (between 2:00-3:00 pm) which may have occurred during 
a refractory period where the system was less sensitive, or that the duration (rather than the 
amplitude) of the nocturnal melatonin pulse may have been altered under form-deprivation 
conditions (see Section 4.7). 
Rada and Wiechmann (Rada and Wiechmann 2006) demonstrated that the intraperitoneal 
injection of melatonin in chick at the beginning of each dark phase of the diurnal light cycle 
during a 5 day period of form-deprivation altered ocular growth patterns in both the form-
deprived and control eyes. In form-deprived eyes, melatonin injection resulted in a 
significant reduction in anterior chamber depth, while vitreous chamber depth only 
exhibited a non-significant trend towards increased growth. The choroidal thickness was 
also significantly reduced in this group when compared to the sham-treatment group. The 
study also demonstrated the presence of melatonin receptors Mel(1A), Mel(1B) and Mel(1C) 
in the cornea, choroid, sclera, and retina of the chick. A diurnal rhythm in the expression of 
these receptors was identified where Mel(1C) expression was highest in the early morning 
around the onset of the light phase, while Mel(1A) and Mel(1B) expression was highest 
around the onset of the dark phase in the evenings. Rada and Wiechmann (Rada and 
Wiechmann 2006) concluded that the presence of melatonin receptors and diurnal rhythms 
of receptor expression, along with the effects of exogenous melatonin, suggests a significant 
role for melatonin in the control of ocular growth, and by extension, in the control of 
refractive development. 
7. Conclusion 
Recent human epidemiological studies propose that light exposure mediates the 
antimyopiagenic effect of outdoor activity. However, light may also have a causative role in 
myopia development when it is presented at an inappropriate time. Animal investigations 
demonstrate that light is a potent modulator of ocular growth and associated rhythms, 
including the interplay between dopamine and melatonin. One question is whether the 
effect of light on refractive development primarily acts through modification of circadian 
rhythms, or through some other intensity or wavelength dependent mechanism. 
If the effect is circadian in origin, is there an optimal period for presenting light in order to 
control ocular growth and prevent myopia?  Both constant light and constant dark disrupt 
ocular growth in animals and result in refractive error development. This can be 
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ameliorated by either pharmacological interventions or controlled light exposure which re-
establish more typical circadian rhythms. Light at night disrupts the normal circadian 
rhythm, rapidly decreasing melatonin and increasing dopamine, which potentially upsets 
the normal balance in ocular growth. As bright light presented in the middle of the day does 
not affect the timing of the circadian rhythm, presentation of a light signal during the 
twilight zones (dawn and dusk) is the most potent circadian zeitgeber. We hypothesise that 
the phase-advancing properties of morning light would be the most effective means of 
regulating the dopamine-melatonin circadian rhythm for the purposes of myopia control. 
If the effect is not circadian in origin, then does the timing of the light signal matter or is it 
the nature of the stimulus (intensity and/or wavelength) that is important?  Time spent 
outdoors leads to a significantly greater light dose than that received indoors, resulting in 
greater melatonin suppression and an increase in retinal dopamine. Additionally, the blue 
light spectral bias of outdoor light preferentially stimulates the melanopsin-containing 
ipRGCs, which would also lead to greater melatonin suppression. Both the intensity and 
wavelength of outdoor light favour increased retinal dopamine levels at the expense of 
melatonin. We hypothesise that it is this bias towards retinal dopamine production when 
outdoors that influences human refractive development, because increased dopamine has 
antimyopiagenic effects in animal experiments. 
While the adage ‘day-light good, night-light bad’ in relation to refractive development is 
appealing, the true relationship between light and myopia is likely to be far more complex, 
with intricate interactions between the circadian cycle and the timing, intensity, and 
wavelength of the light exposure. 
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circadian rhythm which is protective against the effects of constant light on eye growth (Li 
and Howland 2003). 
While diurnal retinal melatonin rhythms appear unaffected during form-deprivation 
(Hoffmann and Schaeffel 1996), the intra-vitreal injection of melatonin at relatively high 
doses (1000 g) increases the level of form-deprivation myopia induced in the chick 
(Schaeffel, Bartmann et al. 1995; Hoffmann and Schaeffel 1996). Although retinal melatonin 
content was sampled twice a day (day and night) during monocular occlusion, and an 
expected diurnal variation in melatonin was found, no significant difference was found 
between the occluded and non-occluded eyes (Hoffmann and Schaeffel 1996). While the 
authors concluded that melatonin was not a significant component of the ocular growth 
control mechanism in form-deprivation in chicks a number of factors may have colluded to 
disguise the role of melatonin in form-deprivation myopia. These include the timing of the 
intra-vitreal injection of melatonin (between 2:00-3:00 pm) which may have occurred during 
a refractory period where the system was less sensitive, or that the duration (rather than the 
amplitude) of the nocturnal melatonin pulse may have been altered under form-deprivation 
conditions (see Section 4.7). 
Rada and Wiechmann (Rada and Wiechmann 2006) demonstrated that the intraperitoneal 
injection of melatonin in chick at the beginning of each dark phase of the diurnal light cycle 
during a 5 day period of form-deprivation altered ocular growth patterns in both the form-
deprived and control eyes. In form-deprived eyes, melatonin injection resulted in a 
significant reduction in anterior chamber depth, while vitreous chamber depth only 
exhibited a non-significant trend towards increased growth. The choroidal thickness was 
also significantly reduced in this group when compared to the sham-treatment group. The 
study also demonstrated the presence of melatonin receptors Mel(1A), Mel(1B) and Mel(1C) 
in the cornea, choroid, sclera, and retina of the chick. A diurnal rhythm in the expression of 
these receptors was identified where Mel(1C) expression was highest in the early morning 
around the onset of the light phase, while Mel(1A) and Mel(1B) expression was highest 
around the onset of the dark phase in the evenings. Rada and Wiechmann (Rada and 
Wiechmann 2006) concluded that the presence of melatonin receptors and diurnal rhythms 
of receptor expression, along with the effects of exogenous melatonin, suggests a significant 
role for melatonin in the control of ocular growth, and by extension, in the control of 
refractive development. 
7. Conclusion 
Recent human epidemiological studies propose that light exposure mediates the 
antimyopiagenic effect of outdoor activity. However, light may also have a causative role in 
myopia development when it is presented at an inappropriate time. Animal investigations 
demonstrate that light is a potent modulator of ocular growth and associated rhythms, 
including the interplay between dopamine and melatonin. One question is whether the 
effect of light on refractive development primarily acts through modification of circadian 
rhythms, or through some other intensity or wavelength dependent mechanism. 
If the effect is circadian in origin, is there an optimal period for presenting light in order to 
control ocular growth and prevent myopia?  Both constant light and constant dark disrupt 
ocular growth in animals and result in refractive error development. This can be 
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ameliorated by either pharmacological interventions or controlled light exposure which re-
establish more typical circadian rhythms. Light at night disrupts the normal circadian 
rhythm, rapidly decreasing melatonin and increasing dopamine, which potentially upsets 
the normal balance in ocular growth. As bright light presented in the middle of the day does 
not affect the timing of the circadian rhythm, presentation of a light signal during the 
twilight zones (dawn and dusk) is the most potent circadian zeitgeber. We hypothesise that 
the phase-advancing properties of morning light would be the most effective means of 
regulating the dopamine-melatonin circadian rhythm for the purposes of myopia control. 
If the effect is not circadian in origin, then does the timing of the light signal matter or is it 
the nature of the stimulus (intensity and/or wavelength) that is important?  Time spent 
outdoors leads to a significantly greater light dose than that received indoors, resulting in 
greater melatonin suppression and an increase in retinal dopamine. Additionally, the blue 
light spectral bias of outdoor light preferentially stimulates the melanopsin-containing 
ipRGCs, which would also lead to greater melatonin suppression. Both the intensity and 
wavelength of outdoor light favour increased retinal dopamine levels at the expense of 
melatonin. We hypothesise that it is this bias towards retinal dopamine production when 
outdoors that influences human refractive development, because increased dopamine has 
antimyopiagenic effects in animal experiments. 
While the adage ‘day-light good, night-light bad’ in relation to refractive development is 
appealing, the true relationship between light and myopia is likely to be far more complex, 
with intricate interactions between the circadian cycle and the timing, intensity, and 
wavelength of the light exposure. 
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1. Introduction 
A perfect point image of an object point is called a stigmatic image. The term „stigmatic“is 
derived from the Greek word stigma, which refers to a sharply pointed stylus (Liesegang et 
al., 2002). Thus, a stigmatic optical system is one able to focus all the light rays from a point 
source onto a single point. However, in most cases, images are not stigmatic. 
In paraxial optics, the focus is stigmatic, and all paraxial rays (those extremely close to the 
optical axis) focus onto a point. With nonparaxial rays, the focus is generally not stigmatic. 
Deviations from stigmatic imaging are called aberrations, and, one of a number of ways to 
classify such aberrations is clinically: into spherical aberrations, regular astigmatism and 
irregular astigmatism.  
Astigmatism is the unequal refraction of the same eye in two different meridians. Unlike the 
basic types of refraction- emetropia, myopia and hyperopia- where all the light rays enter 
one focus (on the retina, behind it, or in front of it), in astigmatism there is no a single focus. 
In basic types of refraction, the cornea is spherical and it refracts equally in all the meridians. 
In astigmatism variations in the curvature of the cornea or lens along different meridians 
prevent the light rays from focusing onto a single point. Corneal refraction depends on the 
corneal curvature. If the cornea is more curved, the power of refraction is higher and vice 
versa. Corneal and lenticular astigmatism can complement or cancel each other. Their 
summation represents the so called “total astigmatism”. 
Due to the lack of a single focus, an astigmatic eye is not able to see clearly without 
correction. Astigmatic patients complain of visual disturbances in both far (in myopia) and 
near vision (in hyperopia), which causes astenopic problems (headache, dizziness, fatigue 
etc). Additionally, regular, symmetric objects might seem to them irregular, and /or 
elongated.  
2. Astigmatism types 
Astigmatism can be regular or irregular.  It can also be divided into myopic, hyperopic and 
mixed/compound astigmatism (where one of the main meridians is hyperopic and the other 
one myopic). 
 
Advances in Ophthalmology 
 
166 
Wilkinson, M., J. Arendt, et al. (1977). "Determination of a dark-induced increase of pineal 
N-acetyl transferase activity and simultaneous radioimmunoassay of melatonin in 
pineal, serum and pituitary tissue of the male rat." J Endocrinol 72(2): 243-244. 
Witkovsky, P. (2004). "Dopamine and retinal function." Doc Ophthalmol 108(1): 17-39. 
Zadnik, K., L. A. Jones, et al. (2000). "Myopia and ambient night-time lighting. CLEERE 
Study Group. Collaborative Longitudinal Evaluation of Ethnicity and Refractive 
Error." Nature 404(6774): 143-144. 
Zawilska, J. B., D. J. Skene, et al. (2009). "Physiology and pharmacology of melatonin in 
relation to biological rhythms." Pharmacol Rep 61(3): 383-410. 
Zeitzer, J. M., D. J. Dijk, et al. (2000). "Sensitivity of the human circadian pacemaker to 
nocturnal light: melatonin phase resetting and suppression." J Physiol 526 Pt 3: 695-
702. 
Zmijewski, M. A., T. W. Sweatman, et al. (2009). "The melatonin-producing system is fully 
functional in retinal pigment epithelium (ARPE-19)." Mol Cell Endocrinol 307(1-2): 
211-216. 
10 
Etiology and Clinical  
Presentation of Astigmatism 
Sanja Masnec Olujić 
Ghethaldus Ophthalmology Policlinics, Zagreb 
Croatia 
1. Introduction 
A perfect point image of an object point is called a stigmatic image. The term „stigmatic“is 
derived from the Greek word stigma, which refers to a sharply pointed stylus (Liesegang et 
al., 2002). Thus, a stigmatic optical system is one able to focus all the light rays from a point 
source onto a single point. However, in most cases, images are not stigmatic. 
In paraxial optics, the focus is stigmatic, and all paraxial rays (those extremely close to the 
optical axis) focus onto a point. With nonparaxial rays, the focus is generally not stigmatic. 
Deviations from stigmatic imaging are called aberrations, and, one of a number of ways to 
classify such aberrations is clinically: into spherical aberrations, regular astigmatism and 
irregular astigmatism.  
Astigmatism is the unequal refraction of the same eye in two different meridians. Unlike the 
basic types of refraction- emetropia, myopia and hyperopia- where all the light rays enter 
one focus (on the retina, behind it, or in front of it), in astigmatism there is no a single focus. 
In basic types of refraction, the cornea is spherical and it refracts equally in all the meridians. 
In astigmatism variations in the curvature of the cornea or lens along different meridians 
prevent the light rays from focusing onto a single point. Corneal refraction depends on the 
corneal curvature. If the cornea is more curved, the power of refraction is higher and vice 
versa. Corneal and lenticular astigmatism can complement or cancel each other. Their 
summation represents the so called “total astigmatism”. 
Due to the lack of a single focus, an astigmatic eye is not able to see clearly without 
correction. Astigmatic patients complain of visual disturbances in both far (in myopia) and 
near vision (in hyperopia), which causes astenopic problems (headache, dizziness, fatigue 
etc). Additionally, regular, symmetric objects might seem to them irregular, and /or 
elongated.  
2. Astigmatism types 
Astigmatism can be regular or irregular.  It can also be divided into myopic, hyperopic and 
mixed/compound astigmatism (where one of the main meridians is hyperopic and the other 
one myopic). 
 
Advances in Ophthalmology 
 
168 
2.1 Regular astigmatism 
In regular astigmatism each meridian refracts regularly and equally, but differently from the 
other meridians. One of the meridians refracts the most and another one the least. Those two 
meridians are called the main meridians, and they are perpendicular to each other. 
In most cases, one of the main meridians is located vertically and the other one horizontally, 
but there can also be oblique, still maintaining the 90° angle to each other. 
In the remaining meridians, located between the both two main meridians, refraction 
changes gradually –increases or decreases (Fig 1). 
 
Fig. 1. With-the-rule astigmatism  of 5.4 D shown on the topographical map of the anterior 
corneal surface , with quantitative information on the corneal curvature, astigmatism and its 
meridians.                   
Vertical meridian, in most of cases, refracts more then the horizontal, most likely due to the 
pressure of eyelids onto the cornea. This type of astigmatism is called with- the- rule 
astigmatism and is more common in children (Mohindra et al., 1978). 
If the horizontal meridian refracts more, this is called against- the- rule astigmatism and is 
more common in older adults. 
The difference in refraction of the two main meridians represents the amount of astigmatism 
and is represented in diopters (D). 
When that difference is no more than 1/2 -3/4 diopters it is a so-called physiological 
astigmatism and a correction is usually not needed, as it does not lead to visual 
deterioration or subjective symptoms. Mostly, it is neutralized by the lenticular astigmatism 
(Parunovic et al., 1995). 
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Astigmatism over ¾ D can lead to visual disturbances and other subjective symptoms, 
because the lenticular astigmatism, which rarely exceeds 1-1.5 D, is not able to compensate 
for the corneal astigmatism. 
Regular type astigmatism is rarely greater than 6-7 D.  
For a better understanding of astigmatism and its correction, the most important optical 
concept is the conoid of Sturm.   
The refractive power, as mentioned above, changes from one meridian to the next, and an 
astigmatic surface cannot bring a pencil of light rays to a point focus. Two focal lines instead 
of a single focus are formed. This complex geometrical envelope of a pencil of light rays 
refracted by a circular spherocylindrical lens is called the conoid of Sturm.  
The conoid of Sturm has two focal lines, each parallel to one of the main meridians of the 
spherocylindrical lens. All the light rays in the pencil pass through each of the focal lines. 
The cross sections of the conoid of Sturm at various points along its length are mostly 
elliptical, including the portion of the conoid external to the two focal lines. At the dioptric 
mean of the two focal lines there is a circular cross section of the conoid of Sturm. This 
circular patch of light rays is called the circle of least confusion, and represents the best overall 
focus for the spherocylindrical lens. The circle of least confusion is the position where all the 
rays would be brought to focus if the lens had a spherical power equal to the average 
spherical power of all the meridians of the spherocylindrical lens (Michaels, 1980). 
This average spherical power of a spherocylindrical lens represents the spherical equivalent 
of the lens, and can be calculated by the following equation:  
Spherical equivalent = sphere + cylinder/2. 
About 50% of infants in their first years of life show astigmatism of over 1D (Bennet et al., 
1989;  Mohindra et al., 1978). 
Some authors have suggested that this high astigmatism helps the infant to bracket the 
position of best focus while it learns to accommodate (Howland et al., 1978). 
In adults, this high incidence of astigmatism is much smaller. Different studies show that 
about 15 % of adults have astigmatism greater than 1D, and only 2 %  of more then 3D 
(Yanoff & Duker, 2004).  
In the leater group, it is most likely that much of the high astigmatism is due to some form 
of intraocular surgery, such as cataract surgery (particularly when extracapsular cataract 
extraction is performed), corneal transplants, corneal lacerations repair,  …etc. 
Regular astigmatism can be congenital and acquired. Congenital astigmatism is usually 
inherited. Acquired astigmatism is mostly against-the rule and as mentioned above, can 
result from various intraocular surgeries.  
Most oftenly, astigmatism is static, but it can also change during the life time. With –the –
rule astigmatism tends to lessen over the years, and the position of the main meridians can 
also slightly change during the lifetime.  
Regular astigmatism is correctable by cylindrical spectacle lenses and contact lenses.  
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In with-the rule astigmatism, a correcting plus cylinder lens should be used at or near the 
90° axis. In against-the rule astigmatism, a correcting plus cylinder lens should be used at or 
near the 180° axis. 
2.2 Irregular astigmatism 
Irregular astigmatism appears when the refraction of light is unequal and irregular in the 
same meridian of the eye. 
That is usually a consequence of pathological changes especially to the cornea (maculae 
centrales corneae, ulcus, pannus, keratoconus etc) or lens (cataract, posterior capsular 
opacification, lens subluxation etc).  
The visual acuity of such an eye is deteriorated and sometimes monocular diplopia or 
poliopia occurs. All eyes have at least a small amount of irregular astigmatism, but the term 
is used clinically only for the stronger irregularities, such as those mentioned above, or 
occurring with keratoconus. 
In the past, irregular astigmatism was not a field of strong interest by clinicians, as it was not 
very common, and was not treatable. It could not be corrected with spectacles, and rigid 
contact lenses could alleviate the problem to some extent only if the irregular astigmatism 
was corneal in origin.   
With the development of keratorefractive surgical procedures, it became increasingly of 
interest, as keratorefractive surgeries may produce visually significant irregular 
astigmatism, or be used to treat it.  
2.2.1 Keratoconus 
Keratoconus (conical cornea) is a condition characterized by a progressive corneal 
steepening, usually inferior to the center of the cornea (Fig. 2.). As a result of a 
noninflammatory thinning of the corneal stroma eventually myopia is induced, together 
with irregular astigmatism, leading to an impairment in the quality of vision. 
Keratoconus is a bilateral, usually asymmetric, noninflammatory corneal ectasia, which 
belongs to a group of corneal shape disorders, together with pellucid marginal corneal 
degeneration and keratoglobus.  
By keratometry keratoconus is classified as:  
1. mild (< 48 D) 
2. moderate (48-54 D) 
3. severe (> 54 D). 
Epidemiology and pathogenesis 
Keratoconus occurs in all ethnic groups with no male or female preponderance. 
Rarely, it can be congenital (Smolin, 1987). 
In majority of the cases, its onset is at puberty and then progresses until the third to fourth 
decade of life, with an incidence of approximately 1 per 2000 in the general population, and 
a prevalence of 54.5 per 100,000 (Hofstetter, 1959; Kennedy et al., 1986). 
 




Fig. 2. Keratoconus (conical cornea) 
In some cases it may also start later in life and progress at any age. 
The etiology of the disease can be divided into three groups:  
1. inherited 
2. sporadic  
3. acquired (secondary or in association to /with other diseases).   
The inheritance of keratoconus is still not defined completely. Before the presence of 
videokeratography it was believed that more than 90 % of cases were sporadic, but recent 
studies revealed evidence that suggests an autosomal dominant pattern of inheritance 
(Gonzales & McDonnell, 1992). 
Corneal thinning appears to result from a loss of structural components in the cornea, but 
why this happens is still not clear.   
Recent biochemical studies of cornea with keratoconus suggest that enzyme abnormalities 
in the corneal epithelium, such as increased expression of proteases and other catabolic 
enzymes (Sawagamuchi et al., 1989) and decreased levels of inhibitors of proteolytic 
enzymes, may play a role in corneal stromal digestion and degradation (Fukuchi et al., 
1994).  
Investigations of corneal α1 proteinase inhibitor and α2 macroglobulin (also proteinase 
inhibitor) support the hypothesis that the degradation process may be aberrant in 
keratoconus (Sawagamuchi et al., 1994) 
Evidence has been provided regarding abnormalities in gene promoters involved in these 
enzyme activities (Maruyama et al., 2001).  
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Other studies have reported abnormalities in corneal collagen and its cross-linking, as a 
potential cause of keratoconus (Bron, 1988).   
Some authors have proposed a role for an IL-1 system in the cornea in the pathogenesis of 
keratoconus. It is suggested that the increased expression of the IL-1 receptor sensitizes the 
keratocytes to IL-1 released from the epithelium or endothelium, causing a loss of 
keratocytes through apoptosis and a decrease in stromal mass over time (Wilson et al., 
1996). 
It is most commonly a single disorder, although much evidence exists that it could be a 
phenotypic expression of many causes, or part of other multisystem or systemic disorders, 
as well as ocular non-corneal disorders (Rabinowitz, 1998, table 1).  
 
Multisystem Disorders Ocular Disorders  
Alagille' s syndrome 
Albers-Schonberg disease 
Angelman syndrome 












Marphan' s syndrome 
Mulvihil-Smith syndrome 
Nail patella syndrome 
Neurocutaneous angiomatosis 
Neurofibromatosis 




Rieger' s syndrome 
Rothmund s syndrome 
Tourette' s disease 
Turner' s syndrome 
Xeroderma pigmentosum 
Congenital hip dysplasia 
False chordae tendineae of left ventricle 
Joint hypermobility 





Anetoderma and bilateral subcapsular cataracts 
Ankyloblepharon 
Bilateral macular coloboma 
Blue sclerae 
Congenital cataracts 
Ectodermal and mesodermal anomalities 
Floppy eyelid syndrome 
Gyrate atrophy 
Iridoschisis 
Lebers congenital amaurosis 
Persistent pupilarry membrane 
Posterior lenticonus 
Retinitis pigmentosa 




Axenfeld' s anomaly 
Avellino' s dystrophy 
Chandler' s syndrome 
Corneal amyloidosis 
Deep filiform corneal dystrophy 
Essential iris atrophy 
Fleck corneal dystrophy 




Pellucid marginal degeneration 
Posterior polymorphous dystrophy 
Terriens marginal degeneration 
Table 1. Diseases associated with keratoconus, as reported by different authors  
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The most common association is with Down syndrome, connective tissue disorders, and 
Leber's congenital amaurosis (Cullen & Butler, 1963; Iwaszkiewicz, 1989). 
Acquired etiologies can be divided into those which are attributed to inflammatory 
conditions, such as vernal conjunctivitis and those secondary to eye rubbing which can also 
release inflammatory mediators, such as Leber's congenital amaurosis and Down syndrome.  
Many authors report a high incidence of mitral valve prolapse (58%) in patients with 
advanced keratoconus, while others report of eye rubbing in systemic atopy and cytokine 
interleukin-1, as a mediator of stromal degradation. Other factors, such as contact lens wear, 
may play a role in the development of the cone (Krachmer et al.,1984; Sharif et al., 1992). 
Also, some studies report 6-8% of cases with positive family history or evidence of familiar 
transmission (Hallerman & Wilson, 1977; Krachmer et al., 1984). 
Ocular manifestations  
Early stages of the disorder may not present any symptoms. Cornea may appear normal on 
slit-lamp examination and there may be no symptoms of the disease. It maya be suspected 
by an ophthalmologist because the patient cannot be refracted to a 20/20 corrected vision. 
There might only be a mild steepening of keratometry mires, inferiorly or centrally. In such 
cases, anterior topography of the central and paracentral cornea will confirm the suspected 
diagnosis (Krachmer et al, 1984). In advanced cases, there can be a significant visual 
disturbance followed by a significant visual loss, but, fortunately, patients with keratoconus 
never become totally blind. Symptoms, as well as clinical signs, are variable and depend on 
the stage of the progression and on the severity of the disease. 
The corneal manifestations include steepening (centrally or paracentrally, most commonly 
inferiorly or inferotemporally), thinning of the corneal apex, conical protrusion, a ring of 
iron deposits partially or completely  accumulating in the epithelium surrounding the cone 
(Fleischer's ring), anterior scars at the level of Bowman's membrane, enlarged corneal nerves, 
increased intensity of the corneal endothelial reflex, and deep vertical lines in stroma and 
Descemet' s membrane,  that disappear momentally  under digital pressure  during slit-
lamp examination (Vogt' s striae). 
The steeping of the cornea leads to clinical signs, which include the V-shaped protrusion of 
the lower eyelid on downgaze due to the ectatic cornea (Munson’s sign, Fig. 3.), sharply 
focused light beam at the nasal limbus, produced by lateral illumination (Rizzuti's sign), and 
a dark reflex using the retroillumination techniques in the area of the cone, when observing 
the cornea with the pupil dilatation (Charleaux' s sign), and an irregular “scissor” reflex on 
retinoscopy. 
Some patients with advanced keratoconus may occasionally experience sudden visual loss 
and pain due to the acute rupture of Descemet's membrane (acute hydrops). In such cases 
the conjunctive may be injected, and diffuse stromal edema appears. These breaks in 
Descemet’s membrane result in acute overhydration and a stromal imbibing of aqueous. The 
overlying corneal epithelium may become edematous. The edema may last for months and, 
after the resolution of redness and relief of pain over time, can be replaced by scarring (and 
the corneal steepness may be reduced).  
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Fig. 3. V-shaped protrusion of the lower eyelid on downgaze due to the ectatic cornea 
(Munson' s sign ) 
Histopathology  
The classic histopathological triad in keratoconus includes the thinning of the corneal 
stroma, breaks in Bowman' s layer and iron deposits in the basal layers of the corneal 
epithelium. Also, every other layer of the cornea can be pathologically affected, depending 
on the stage of the keratoconus. The endothelium is usually not affected, and the Descemet’s 
membrane is rarely affected, other than in cases of acute hydrops.  
Two types of cone morphology may be present. The first one is a „nipple“ type cone, located 
centrally, characterized by small size (5 mm) and steep curvature;  the second one is an 
„oval“ type cone, located inferiorly or inferotemporally, characterized by larger size (5-6 
mm), and an ellipsoid shape (Perry et al., 1980). 
These can be distinguished in most cases on slit-lamp examination, or in the anterior corneal 
topography. 
Diagnosis  
To confirm the diagnosis several devices are available from handheld keratoscopes (placido 
disks), computer-assisted videokeratoscopes to (more recently) computerized 
videokeratography  (Fig.4).   
Computer-assisted topographic modeling systems allow the clinicians to detect subtle and 
minor variations in power distribution of the anterior and posterior corneal surface. The 
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forme fruste, or subclinical keratoconus, recognized by Placido disk-based topography, 
requires caution and is considered a contraindication to refractive surgery. With regard to 
the identification of forme fruste keratoconus, classification programs on corneal 
topographers may assist in differentiating between keratoconus suspects, corneal distortion, 
and even patients having undergone refractive surgery, and normal variations of corneal 
topography.  
 
Fig. 4. Color-coded map of peripheral keratoconus.  Note the inferior steepening 
Rabinowitz has suggested  that the diagnosis of keratoconus can be made when keratometry 
is greater than 47.20 D,  the steepening of the inferior cornea compared with the superior 
cornea is more than 1.2 D, and the skewing of the radial axis of astigmatism is greater then 
21° ( Rabinowitz YS, 1995). 
Differential diagnosis 
The differential diagnosis of keratoconus includes other corneal ectasia disorders, such as 
pellucid marginal corneal degeneration and keratoglobus, and the posttraumatic or post-
surgical (after refractive or cataract surgery) corneal ectasia or protrusion of the cornea after 
corneal ulceration thinning.  
Treatment  
Treatment of keratoconus starts with spectacles in very early stages, for astigmatism and 
myopia, and rigid gas permeable contact lenses in cases of inadequate visual acuity 
correction with spectacles. Contact lenses represent the treatment of choice in 90% of 
patients (Buxton et al., 1984). 
In case of contact lens failure due to a lack of adequate visual acuity, or induced corneal 
abrasion, apical scarring, neovascularization due to hypoxia, poor lens tolerability and 
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discomfort and lens displacement, surgical procedure is indicated. The most frequent 
surgical procedure is penetrating keratoplasty, which refers to the full-thickness 
replacement of diseased corneal tissue with a healthy donor. The main difficulty during 
surgery is suturing to the thin corneal bed. 
Lamellar keratoplasty is also effective, but is not as frequently used as the penetrating 
keratoplasty, due to technical challenges and it being more time consuming. It is a 
procedure in which a partial-thickness graft of donor tissue (donor stroma or sclera) is used 
to provide tectonic stability and /or optical improvement. 
There are generally two types of lamellar keratoplasty:  anterior and posterior. In the 
anterior lamellar keratoplasty, the transplanted tissue does not include corneal endothelium 
and this procedure avoids endothelial rejection. The aim in deep lamellar and posterior 
lamellar keratoplasty is to replace diseased corneal endothelium while keeping the anterior 
corneal surface intact, as well as reducing refractive error and irregular astigmatism. In a 
short amount of time, deep lamellar endothelial keratoplasty (DLEK), Descemet-stripping 
endothelial keratoplasty (DSEK),  Descemet-stripping automated endothelial keratoplasty 
(DSAEK) and Descemet’ s membrane endothelial keratoplasty (DMEK) have become the 
techniques of choice for partial corneal transplant surgeries. 
Descemet’s membrane endothelial keratoplasty (DMEK) and Descemet-stripping automated 
endothelial keratoplasty (DSAEK) are new types of partial-thickness corneal graft 
operations, in which only the innermost corneal layers are replaced. Visual recovery is 
quicker, there is less physical restriction on activities and no related suture problems.  
The results of lamellar techniques are far better than epikeratoplasty which has been 
abandoned due to the suboptimal visual outcomes.  A keratoconic patient has a 10-20% 
chance, over her/his lifetime, of needing a corneal transplant (Smiddy et al., 1988;  Tuft et 
al.,1994). 
Intracorneal ring segments Intacts can be also used in cases without corneal scarring to 
reduce myopia and astigmatism. The purpose of Intacts segment implantation is to defer the 
need for corneal transplantation and restore contact lens tolerance. The placement of Intacts 
generates the response that interrupts the biomechanical disease progression, and a 
biomechanical response that allows visual improvement over six months. The improvement 
in visual acuity and refraction is accomplished by shortening the path length of the portion 
of the collagen lamellae that are central to the segments. The redistribution of corneal 
curvature leads to a redistribution of corneal stress, interrupting the biomechanical cycle of 
the keratoconus progression. 
A relatively new method of treating progressive corneal ectasia is corneal collagen 
crosslinking (CXL). Its clinical use has been rapidly increasing since it was originally 
introduced in 1997 as the first treatment that could improve the biomechanical stability of 
the weakened cornea. This method is based on combined action of the photo-sensitizer 
riboflavin (vitamin B2) and ultraviolet A light, which induce the formation of new covalent 
bonds between the collagen fibers. 
This method has been widely accepted since the first introduction by Spoerl and his co-
workers at Dresden University in Germany, in 1997 (Spörl et al., 1997). 
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The recent advances in diagnostic devices resulted in the detection of more subtle corneal 
changes, suggesting that the sublinical forms are more common than fully developed 
keratoconus. The iatrogenic post-LASIK ectasia is the second most common corneal ectasia. 
It usually appears as a result of refractive surgery performed in predisposed individuals or 
in patients with an undetected early form of keratoconus. Before the introduction of corneal 
collagen crosslinking, the only treatment that could halt the progression of keratoconus in 
most cases was the penetrating keratoplasty.  
Studies which have been conducted so far demonstrated the beneficial effect in halting the 
progression of the diseases, with a very low complication rate (Koller et al., 2009; Tomkins & 
Garzozi, 2008). 
The term „crosslinking“refers to the formation of bonds between natural polymer 
molecules.  
The original crosslinking technique described by Wollensak and co-workers is still being 
used today, with the minor modifications. (Wollensak et al., 2003). 
The photopolymerizing effect is induced by the combined action of riboflavin as a photo-
sensitizer, and long wavelength ultraviolet (UVA) light of 370 nm. This particular 
wavelength was chosen so that riboflavin can achieve a maximal absorption while still 
remaining bellow harmful radiation levels. During the exposure, riboflavin is excited into a 
triplet state, generating the so-called reactive oxygen species which, in turn, induce the 
formation of new covalent bonds (disulphide /s-s) between the amino acids of neighboring 
collagen fibers.  
After the application of a local anesthetic, a lid speculum is inserted and central corneal 
abrasion up to 9.0 mm in diameter is made. According to the protocol of the Institute for 
Refractive and Ophthalmic Surgery in Zürich, Switzerland, 0.1% riboflavin solution 
containing 10 mg of riboflavin-5-phosphate diluted in 10 ml of a 20% dextran solution is 
instilled every 3 minutes, for 30 minutes. After that, central corneal thickness (CCT) is 
measured. For safety reasons, additional riboflavin 0.1% hypoosmotic drops without 
dextran should be applied in corneas whose thickness is less than 400 µm. Otherwise, UVA 
light should not be applied. The cornea is then irradiated for 30 minutes with an UVA 
illumination device.  The device must provide a homogenous UV radiation with irradiance 
of 3 mW/ cm2 at the working distance of 5 cm. During irradiation, the cornea is moistened 
every 3 minutes with the riboflavin 0.1% drops. The total dosage delivered to the cornea in 
that way is 5.4 J/cm2.  At the end, antibiotic ointment is applied and bandage lens inserted to 
facilitate the epithelial healing.  
Beside the standard CXL, as described above (with removal of the epithelium), the 
treatment can also be the transepithelial CXL (without removal of the epithelium). The later 
has less complications, such as death of keratocytes.  Not being invasive, it is very well 
tolerated. 
Indications for cross-linking today are clinical and instrumental progression (refractive, 
topographic, pachimetric, aberrometric) of corneal ectasia disorders such as keratoconus 
and pellucid marginal degeneration in the last 6-12 months, iatrogenic keratectasia after 
refractive lamellar surgery and corneal melting not responding to conventional therapy.  
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every 3 minutes with the riboflavin 0.1% drops. The total dosage delivered to the cornea in 
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and pellucid marginal degeneration in the last 6-12 months, iatrogenic keratectasia after 
refractive lamellar surgery and corneal melting not responding to conventional therapy.  
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Contraindications include corneal thickness of less than 400 µm, central corneal opacity, 
epithelial healing disorders, such as map dot dystrophy and rheumatic disorders, refractive 
keratotomy, previous herpes simplex virus keratitis (UV-A may induce herpes reactivation), 
corneal melting disorders, concurrent infection, severe ocular surface disease, and 
pregnancy. 
In recent years, corneal collagen crosslinking has become a standard treatment for the 
progressive corneal ectasia in numerous centers throughout the world. Additional basic and 
clinical research is necessary in order to establish more precise indications and to 
demonstrate the permanence of the treatment. Despite the evidence in support of the safety 
of new procedure, future studies are necessary to define its limitations and its long-term 
efficacy.  It has the potential to reduce corneal curvature by approximately 1.0-1.5 D. 
Despite the fact that no sight-threatening complications were recorded in the large 
prospective studies, there are some sporadic reports of stromal haze resistant to topical 
steroid treatment (Mazzota et al., 2007), diffuse lamellar keratitis in post-LASIK ectasia, 
herpetic keratitis and iritis (Kymionis et al., 2007), Acanthamoeba keratitis with corneal 
perforation (Rama et al., 2009), and microbial keratitis (Pollhammer & Cursiefen, 2009; 
Zamora & Males, 2009). Other potential  complications include delay in reepithelization, 
sterile infiltrates, potential for induction of herpes simples virus and dendritic ulcer, and 
ocular surface disorders and tear dysfunction (Corkin, 2009).   
The reliable data on the turnover rate of the collagen fibers are still insufficient due to the 
almost complete absence of corneal remodeling (Wollensak & Iomdina., 2009).  
However, data such as the increased resistance to the enzymatic degradation in the 
crosslinked corneas support the theory of the long –lasting effect of the treatment (Spoerl et 
al., 2004). 
2.3 Other corneal ectasias 
Pellucid marginal corneal degeneration 
Pellucid marginal corneal degeneration is a variant of keratoconus, characterized by a 
peripheral band of thinning of the inferior cornea and protrusion  from the 4 to 8 o'clock 
position but a 2 mm uninvolved surface of the cornea between the thinning and the limbus. 
It has also been described in scleroderma (Sii et al., 2004) and in Sjögren syndrome 
(Fernández-Barboza et al., 2009). 
The thickness of the central cornea is usually normal but with marked against-the-rule 
astigmatism. It can nicely be recognized by videokeratography due to the typical 
„butterfly“appearance that represents a large degree of against-the-rule astigmatism 
(Maguire et al., 1987). 
Treatment includes spectacles or contact lenses. Due to the extensive against-the-rule 
astigmatism, the success rate for fitting those patients with the hard contact lens is lesser 
than in patients with keratoconus. In case of inadequately vision corrected patients or in 
case of lens intolerability, large, eccentric penetrating keratoplasty may be considered.   
 




In keratoglobus, in contrast to the localized thinning centrally or paracentrally in 
keratoconus, the entire cornea is thinned out, especially near the limbus, and has a globular 
protrusion (Krachmer et al., 1984). 
It comes in two forms: a congenital or juvenile form and an acquired, adult form. The 
congenital form can be part of Ehlers-Danlos syndrome type Vl, or part of the corneal 
syndrome associated with blue sclera and red hair (Royce et al., 1990).  
The adult form can be associated with blepharitis, vernal keratoconjunctivitis, and orbital 
diseases than cause proptosis (Cameron, 1993). 
It has a recessive pattern of inheritance and is often associated with blue sclerae and other 
systemic features, such as Ehlers-Danlos syndrome and other systemic connective tissue 
abnormalities. These kinds of corneas can be so thinned that they are prone to corneal 
rupture from a minimal trauma.  
It was also described in thyroid orbitopathy (Jacobs et al., 1974), and was acquired in 
pellucid marginal degeneration after extracapsular cataract extraction (Rumelt & Rehany, 
1998).  
Treatment includes protection from trauma, and protective spectacles are strongly 
recommended. Hard contact lenses are contraindicated. Lamellar epikeratoplasty should be 
considered to reinforce thin corneas, and in case of acquired keratoglobus, central 
penetrating keratoplasty may be successful. 
Terrien's marginal corneal degeneration 
Terrien's marginal degeneration is a bilateral, slowly- progressive condition with marginal 
corneal ectasia associated with corneal neovascularisation, lipid deposition along the central 
edge, thinning and opacification. The cause is unknown, but it is likely to be different from 
the causes of most degenerations that occurs with age. It can occur at any age, but most 
frequently in men, 20-40 years old.  Two types have been described. First one is slowly- 
progressive and mostly asymptomatic, and occurs in older population. The second one 
occurs in younger patients, it is more inflammatory in type and may be associated with 
episcleritis and scleritis (Iwamoto et al., 1972).   
Terrien's marginal degeneration initially starts superiorly with peripheral corneal haze, 
gradually vascularizes, and is followed by corneal thinning that starts between the limbus 
and line of lipid deposition. Characteristically, a steeper sloping of the cornea occurs at the 
advancing edge, without the overlying edge like as in Mooren's ulcer (see below).  
The thinning progresses circumferentially, but the overlying epithelium is intact.  
Unlike the Mooren's ulcer, usually there is no pain or inflammation, but occasionally, it may 
present with recurrent painful episodes of inflammation. Perforation may occur, but is rare.  
A pseudopterygium may occur in an oblique axis in some patients. 
Irregular astigmatism is characteristic in the progressive flattening of vertical meridian, and 
the high degree of against-the rule astigmatism.  
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Treatment includes the use of rigid gas-permeable contact lenses. More severe thinning may 
require crescentic, full-thickness or lamellar keratoplasty (Hahn & Kim, 1993).  
Mooren's ulcer 
Mooren’s ulcer is a progressive, crescentic, peripheral corneal ulceration. Two clinical types 
have been documented. One type occurs primarily in the older population, it is typically 
unilateral and more responsive to local therapy. The other is bilateral, painful, progressive 
corneal destruction, mostly in younger individuals, more resistant to systemic 
immunosuppression.  The pathogenesis of  Mooren’s ulcer is unknown but appears to 
involve an autoimmune reaction against a specific target molecule in the stroma, which may 
occur in genetically susceptible individuals (Gottsch et al., 1999). 
It has a characteristic extensive, “overhanging” edge which is absent in Terrien’s disease, 
and progresses with a stromal, yellowish infiltrate at the advancing margin. Over time, 
overlying epithelial defect develops, followed by stromal melting. In the second type, the 
inflammation may affect all the layers of cornea and perilimbal tissue, and perforation can 
occur.  
Patients complain of severe pain, photophobia and tearing.  
In chronic cases, topographical maps show severe irregular astigmatism and peripheral 
steepening as a result of peripheral corneal thinning and scarring. Unlike the other forms of 
peripheral ulcerative keratitis, no clear zone between the ulcer and limbus can be seen.  
Treatment includes local, systemic, and surgical therapy.  Local therapy includes topical 
corticosteroids, followed by conjunctival resection if inflammation is not controlled, as well 
as topical cyclosporine drops. Systemic immunosuppressive treatment of the more 
aggressive bilateral disease has included corticosteroids, cyclosporine and methotrexate 
(Brown & Mondino, 1984; Foster, 1985). 
Other surgical procedures include epikeratoplasty, lamellar keratoplasty, delimiting 
keratotomy, conjunctival flap and patch grafts of periostium.  
2.4 Residual astigmatism (non-corneal astigmatism) 
Corneal astigmatism of more than 2D is present in 5% of general population, while at least 
93% of the population has at least 0.5D of corneal astigmatism. The percentage of residual 
astigmatism is between 10% and 80% (Parunovic et al., 1995). 
Spherical rigid contact lens can correct total astigmatism if the correction of cylinder with 
the spectacles is the same value as the value of corneal astigmatism. In some cases there is a 
difference in value between astigmatism corrected with the spectacles and corneal 
astigmatism. Astigmatism that rises from this difference is called residual astigmatism, and 
does not correlate with the anterior surface of the cornea. Residual astigmatism is in most 
cases lenticular, but can also be derived from a badly fitted contact lens (a decentrated or 
deformed contact lens).  
Lenticular astigmatism may also be caused by lens subluxation, like in Marfan's syndrome 
(Konradsen et al., 2010; Yeung & Weissman, 1997),  changes in lens contour, like in anterior 
and posterior lenticonus in Alport' s syndrome (Al-Mahmood et al., 2010;  Blaise et al., 2003; 
Hentati et al., 2008; Kim et al., 2010), lenticular trauma etc. 
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Residual, lenticular astigmatism is most always against-the-rule astigmatism, rarely more 
than 1D, and usually is masked by correction of total refractive astigmatism. Residual 
astigmatism (RA) is calculated by subtracting the value of corneal astigmatism (CA)  
from the value of astigmatism corrected by the spectacles (SC), according the formula:   
RA = SC - CA. 
Example:  
Keratometry: 43.00 / 43.50 x 90 
Spectacle correction: -2.00 /-1.50 x 180 
Residual astigmatism = (- 1.00 x 180) - (- 0.50 x 180) = - 0.50 x 180 
2.5 Surgically induced astigmatism 
One of the possible complications of cataract surgery (especially extracapsular and 
intracapsular cataract extraction), as well as penetrating keratoplasty, is induced 
astigmatism, which is a major cause of functional disturbance and insufficient uncorrected 
visual acuity. 
The aim of cataract surgery today is rapid visual rehabilitation, the best possible uncorrected 
visual acuity, and minimal postoperative astigmatism. 
The phacoemulsification procedure results in less surgically induced astigmatism than 
extracapsular cataract extraction, in which the incision is much larger.  
Clear corneal incision (CCI) is the most used type of incision in phacoemulsification surgery, 
because it is less time-consuming and doesn't require cauterization or wound suturing. The 
location of the CCI affects the degree of postoperative astigmatism. 
CCI is made deliberately in the steepest meridian if astigmatism is addressed. It can be 
made at superior, oblique or temporal locations. 
Temporal CCI induces regular astigmatism 90 degrees away from the incision (with-the-rule 
astigmatism) thus minimizing the postoperative astigmatism (Cilino et al., 1997; Cravy, 
1991; Hayashi et al., 1994).  It is known to induce the least postoperative astigmatism. Also, 
the smaller the CCI, the lesser the induced astigmatism.  
Oblique scleral tunnel incision predictably reduces astigmatism by simultaneously 
producing corneal flattening and steepening (Simsek et al., 1998). 
Some studies have shown that a small superior CCI induces greater postoperative 
astigmatism than a small supero-oblique CCI, and a small supero-oblique CCI induces 
higher postoperative astigmatism than a small temporal CCI (Mendivil, 1996;  Reiner et al., 
1999; Wirbelauer  et al.,1997). 
Some authors reported that, although temporal CCI is reported to result in the least induced 
astigmatism, locating the incision superotemporally or superonasally may ease surgical 
manipulations during the phacoemulsification cataract surgery for a right-handed surgeon 
who works from the 12 o' clock position relative to the patient (Ermis et al., 2004).  
Performing the procedure from the patient’s temporal side may not be possible with the 
most operating tables, and locating the CCI temporally in left eye may be difficult for a 
right-handed surgeon who sits at the 12 o' clock position.   
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Several groups of authors analyzed refractive astigmatism in patients who have had 
phacoemulsification cataract surgery performed by the oblique clear corneal incision. 
They provided evidence that the supero-oblique clear corneal incision does not induce the 
clinically significant amount of oblique astigmatism (Jacobs et al., 1999; Brian et al., 2001; 
Masnec et al., 2007). 
Also, evidence is provided that the superotemporal or superonasal CCI has minimal effect 
on corneal astigmatism (Masnec et al., 2007). 
Further studies on more patients should provide definitive conclusions about the influence 
of the superotemporal or superonasal clear corneal incision on postoperative astigmatism. 
Many studies investigated the influence of different factors, such as the type of a surgery, 
length of incision and its type (curved, straight, frown), location and width of incision 
(central vs. peripheral-limbal or scleral), presence or absence of a suture and the suturing 
method, on postoperative astigmatism (Azar et al., 1997;  Roman et al., 1998;   Simsek et 
al.,1998;  Wirbelauer  et al.,1997)..   
Any incisions that are made in the cornea have the potential to change the curvature and 
therefore the dioptric power of the cornea in that meridian.  
The location as well as the width of the incision affects the degree of postoperative 
astigmatism. 
Typically, corneal incisions cause flattening at the axis where they are made. The basic 
concepts are:  
 The larger the incisions, the greater the flattening 
The larger the arc length of the corneal incisions, the more effect it has in flattening the 
cornea at that meridian. Due to the coupling effect, arc lengths of more than 90° are 
ineffective. 
 The more central the incisions, the greater the flattening 
Most surgeons prefer performing limbal relaxing incisions (LRIs)  at the periphery of the 
clear cornea. Due to this location, they tend to be more forgiving, heal better, and are less 
likely to cause irregular astigmatism.  But, due to the distance from the central cornea and 
increased thickness of the cornea at the periphery, these incisions have less effect than 
astigmatic keratotomy (AK) incisions, which are more centrally placed. 
 For penetrating incisions, the shorter the tunnel length, the greater the flattening 
Creating an “astigmatically neutral” clear corneal incision during cataract surgery requires 
the incision to have a sufficient tunnel length. This reduces the compromise of the corneal 
structure at the incision site and induces little change in the corneal astigmatism. For 
increasing the astigmatic effect of the corneal incisions, the surgeon can make the tunnel 
length shorter; however, this results in an incision that may be more prone to leaking during 
the postoperative period. Surgeon can also vary the position of the corneal incision so that it 
is placed on the steep axis and, therefore, any induced flattening will help the patient by 
reducing astigmatism. 
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 For nonpenetrating incisions, the deeper the incision, the greater the flattening 
Most nomograms for LRIs call for nonpenetrating incisions that are placed perpendicularly 
to corneal tissue. With incisions that are made at 80% or 90% of the corneal thickness, as 
measured by pachymetry, there is a significant flattening of the corneal astigmatism. As the 
incisions become more shallow, their effect is lesser, and incisions at less than half corneal 
depth have little effect on the corneal curvature and power (Budak et al., 1998; Gills et al., 
2003; Nichamin, 2006;  Thornton, 1994;  Wang et al., 2003).   
3. Conclusion 
Beside the congenital astigmatism which is usually inherited, acquired form of astigmatism 
can be a result of various intraocular surgeries.  
Regular astigmatism is correctable by cylindrical spectacle lenses and contact lenses. In case 
of irregular astigmatism, cylindrical lenses usually do not help and rigid contact lenses may 
be useful. 
That is usually a consequence of pathological changes of cornea, such as keratoconus, or the 
lens.  
In the past, irregular astigmatism was not very interesting for clinicians because it was not 
very common and not treatable. However, with the development of keratorefractive surgical 
procedures, it became increasingly of interest as, in many cases, keratorefractive surgeries 
produce visually significant irregular astigmatism and, at the same time, may also be able to 
treat it.  
Special focus still remains on keratoconus, a disorder characterized by progressive corneal 
steepening due to the loss of structural components in the cornea, but its cause is still 
unclear. It is difficult to treat, and a keratoconic patient has a 10-20% chance, over their 
lifetime, of needing a corneal transplant.  Still, in 90 % of patients contact lenses represent 
the treatment of choice.  
In recent years, corneal collagen crosslinking has become a standard treatment for the 
progressive corneal ectasia in numerous centers throughout the world, because much 
evidence has been provided that it can improve biomechanical stability of the weakened 
cornea. 
Additional basic and clinical research is necessary in order to establish more precise 
indications and to demonstrate the permanence of the treatment. Despite the evidence in 
support of the safety of this new procedure, future studies are necessary to define its 
limitations and its long-term efficacy.   
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1. Introduction 
The eye is an optical system having several optical elements that focus light rays representing 
images onto the retina. Imperfections in the components and materials in the eye may cause 
light rays to deviate from the desired path. These deviations, referred to as optical or 
wavefront aberrations, result in blurred images and decreased visual performance (1). 
Wavefront aberrations are optical imperfections of the eye that prevent light from focusing 
perfectly on the retina, resulting in defects in the visual image. There are two kinds of 
aberrations: 
1. Lower order aberrations (0, 1st and 2nd order) 
2. Higher order aberrations (3rd, 4th, … order) 
Lower order aberrations are another way to describe refractive errors: myopia, hyperopia 
and astigmatism, correctible with glasses, contact lenses or refractive surgery. Lower order 
aberrations is a term used in wavefront technology to describe second-order Zernike 
polynomials. Second-order Zernike terms represent the conventional aberrations defocus 
(myopia, hyperopia and astigmatism). Lower order aberrations make up about 85 per cent 
of all aberrations in the eye. 
Higher order aberrations are optical imperfections which cannot be corrected by any reliable 
means of present technology. All eyes have at least some degree of higher order aberrations. 
These aberrations are now more recognized because technology has been developed to 
diagnose them properly. Wavefront aberrometer is actually used to diagnose and measure 
higher order aberrations. Higher order aberrations is a term used to describe Zernike 
aberrations above second-order. Third-order Zernike terms are coma and trefoil. Fourth-
order Zernike terms include spherical aberration, and so on. Higher order aberrations make 
up about 15 percent of the overall number of aberrations in an eye. 
2. Myopia 
Myopia (nearsightedness, shortsightedness) is a refractive error where parallel light rays 
coming from a distance after refraction through the cornea and lens focus before the retina 
in the vitreous body and mature behind the focus in the state of divergence generate on 
retina wasteful circles (Fig. 1 and 3). Because of this, the image that one sees is out of focus 
when looking at a distant object but comes into focus when looking at a close object. 
Therefore, shortsighted people cannot see clearly at a distance (2).  
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Myopia can be classified by cause, degree, clinical features and age of onset. By cause 
myopia can be: axial myopia, attributed to an increase in eyes axial length (more than 24 
mm), and refractive myopia, attributed to the condition of refractive elements of the eye, like 
curvature myopia (increased curvature of cornea) or index myopia (variation in the index of 
refraction of one or more ocular media, like in nuclear cataract). By degree myopia can be: 
low myopia (−3.0 diopters or less), medium myopia (between −3.0 and −6.0 diopters), and high 
myopia (−6.0 diopters or more). By clinical features myopia can be: simple myopia, 
characterized by the eye being too long for its optical power or optically too powerful for its 
axial length, and degenerative (malignant, pathological, progressive) myopia characterized by 
expressed fundus changes (conus myopicus, staphyloma posticum, degeneratio 
chorioretinae peripherica, maculopathia) and associated with a high refractive error and 
subnormal visual acuity after correction. This form of myopia worsen progressively over 
time and can become complicated with retinal tear and retinal detachment. By age of onset 
myopia can be: congenital myopia, present at birth and persisting through infancy, youth-onset 
myopia (school myopia) with onset between around 5 years of age and physical maturity, early 
adult-onset myopia with onset after physical maturity and up to about 40 years of age, and late 
adult-onset myopia with onset after around 55 years of age due to changes in the nucleus of 
the crystalline lens (2,3,4,5,6).  
 
Fig. 1. Myopia with accommodation relaxed. Parallel light rays from infinity focus to a point 
anterior to the retina, forming a blurred image on the retina (6). 
3. Hyperopia  
Hyperopia (farsightedness, longsightedness) is a refractive error where parallel light rays 
coming from a distance after refraction through the cornea and lens focus behind the retina 
without participation of accommodation (Figs. 2 and 3). Causes of hyperopia are typically 
genetic and involve an eye that is too short or a cornea that is too flat, so that images focus at 
a point behind the retina (2). 
Hyperopia can be classified by: cause, clinical features and accommodative status. By cause 
hyperopia can be: axial hyperopia, attributed to a decrease in eyes axial length (less than 24 
mm), and refractive hyperopia, attributed to the condition of refractive elements of the eye like 
decreased curvature of cornea (cornea plana). By clinical features hyperopia can be: simple, 
pathological (resulting in amblyopia or strabismus), and functional. By accommodative status 
hyperopia can be: total, latent, and manifest. Total hyperopia occurs in state of full paralysis 
of accommodation (after application of cycloplegics) and represents the amount of entire 





accommodation. Manifest hyperopia is the accommodation uncorrected part of hyperopia 
and becoming closer to the total one with age (2,3,4,5,6). 
 
Fig. 2. Hyperopia with accommodation relaxed. Parallel light rays from infinity focus to a 
point posterior to the retina, forming a blurred image on the retina (6). 
 
Fig. 3. Refractive errors (myopia and hyperopia) defined by the position of the secondary 
focal point with respect to the retina, with accommodation fully relaxed. The secondary 
focal point of a myopic eye is the front of the retina inside the vitreous, whereas the focal 
point of a hyperopic eye is behind the retina (7).  
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Astigmatism is a refractive condition in which the eye optical system is incapable of forming 
a point image for a point object. This is because the refracting power of the optical system 
varies from one meridian to another. There are complex optical relationships in astigmatism: 
no focus (as in myopia and hyperopia), but the two focal lines corresponding to main 
meridians. The meridians of greatest and least refraction are defined as main (principal) 
meridians. Astigmatism is caused by the cornea or the crystalline lens. Clinically, most 
astigmatisms are corneal in origin and mainly related to the change in curvature of the 
cornea (3,4).  
There are different types of astigmatism, according to the method of classification (2,3,4,5,6).  
Astigmatism is regular when two main meridians are 90° to each other; it is correctable with 
cylindrical or spherocylindrical lenses. Otherwise, the astigmatism is irregular. Regular 
astigmatism is with-the-rule (direct) when the steepest corneal meridian is close to 90° (±20°) 
and against-the-rule (indirect) when the steepest meridian is close to 180° (±20°). When the 
astigmatism is regular but the main meridians do not lie close to 90° or 180°, it is oblique.  
Astigmatic errors are also described by the location of secondary focal lines relative to the 
retina (with accommodation relaxed). Compound myopic astigmatism occurs when both of 
the main meridians are myopic, pulling the focal lines off the retina into the vitreous. In 
simple myopic astigmatism, one meridian is emmetropic and the other is myopic, one focal 
line is on the retina and the other is pulled into the vitreous. Compound hyperopic 
astigmatism occurs when both of the main meridians are hyperopic, pulling the focal lines 
behind the retina. In simple hyperopic astigmatism, one meridian is emmetropic and the other 
is hyperopic, one focal line is on the retina and the other is pulled behind the retina. Mixed 
astigmatism occurs when one meridian is hyperopic and the other is myopic (Fig. 4).  
Astigmatism can be natural or surgically induced. Natural astigmatism is common, that is, 
around 15% of adult population have astigmatism > 1D and 2% have astigmatism > D. 
Special group of astigmatisms are those surgically induced, postoperative astigmatisms. Any 
surgical intervention in the fibrous mantle of the eye (cornea, sclera) may result in major or 
minor postoperatively acquired astigmatisms. Classic and most common postoperative 
astigmatism occurs after cataract surgery, especially after extra- and intracapsular cataract 
extraction. It is very minimal after phacoemulsification (2). 
As noted, the cornea is usually the source of clinically significant amounts of astigmatism. 
The amount of corneal astigmatism, along with the location of meridians of least and greatest 
refraction, can be easily determined with a keratometer. The vast majority of corneas have 
with-the-rule astigmatism; a small minority of corneas have against-the-rule or oblique 
astigmatism, and a small minority have no astigmatism. As compared to corneal 
astigmatism, internal astigmatism is relatively small in amount, tending to slightly vary from 
one person to another, and is almost always against-the-rule. Main causes of internal 
astigmatism are the toricity of the back surface of the cornea and the tilting of the crystalline 
lens. There is no clinical method of measuring internal astigmatism. Refractive (total) 
astigmatism includes both corneal and internal astigmatism and can be determined with 






Fig. 4. The locations of focal lines with respect to the retina define the type of astigmatism (6). 
5. Higher order aberrations (HOAs) 
Within the past decade, rapid improvement in wavefront-related technologies, including the 
development of sensors for measuring optical properties of the eye in a clinical 
environment, allowed the ophthalmic community to move the wavefront theory of light 
transmission from an academic concept to one being central for better understanding of the 
effect of aberrations on visual performance and the corresponding image-forming properties 
of the eye. Imperfections in the optics of the eye are now measured and expressed as wave 
aberration errors. The wave aberration defines how the phase of light is affected as it passes 
through the eye’s optical system, and is usually defined mathematically by a series of 
Zernike polynomials. Zernike polynomials are used to classify and represent optical 
aberrations because they consist of terms of same form as the types of aberrations observed 
when describing the optical properties of the eye, and can be used reciprocally with no 
misunderstanding. Moreover, the advantage of describing ocular aberrations using the 
normalized Zernike expansion, generally depicted as a pyramid (Figs. 5 and 6), is that the 
value of each mode represents the root mean square (RMS) wavefront error attributable to 
that mode. Coefficients with a higher value identify the modes (aberrations) that have the 
greatest impact on the overall RMS wavefront error in the eye and thus in reducing the 
optical performance of the eye (8). 
The two most important HOAs are coma and spherical aberration. Coma is the distortion in 
image formation occurring when a bundle of light rays enters an optical system not parallel 
to the optic axis. Coma results in off-axis point sources such as stars appearing distorted, 
with a comet-like tail. Spherical aberration is the blurring of an image, occurring when light 
from the margin of a lens or mirror with spherical surface comes to a focus shorter than light 
from the central portion. The changing focal length is caused by deviations in lens or mirror 
surface from a true sphere. 
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Fig. 5. This chart reveals more common shapes of aberrations created when a wavefront of 
light passes through eyes with imperfect vision. A theoretically perfect eye (top) is represented 
by an aberration-free flat plane known, for reference, as piston. (Image: Alcon Inc.) 
HOAs are vision errors more complex than lower-order aberrations. HOAs have relatively 
unfamiliar names such as coma, spherical aberration and trefoil. These types of aberrations 
can produce vision errors such as difficulty seeing at night, glare, halos, blurring, starburst 
patterns or double vision (diplopia). No eye is perfect, which means that all eyes have at 
least some degree of HOAs. These aberrations are now more recognized because technology 
has been developed to diagnose them properly. 
HOAs are measured by aberrometer (wavefront sensor). Aberrometers measure the distortion 
of a light wave as it is altered by passing through the optics of the eye. A plane wave of 
monochromatic light will be distorted by optical imperfections. Wavefront sensors do not 
measure light scatter (from stromal haze or corneal scars), chromatic aberrations or diffraction 
phenomena. Their effects on vision should be assessed by other means. A useful way to think 
of distortions in a wavefront is to think of the path length of parallel rays entering the pupil 
and projecting toward the retina. As light enters the eye from the air, its speed is retarded 
according to the refractive index of the material along its path to the retina. Arrival time is also 
influenced by the traveling distance. These two factors, refractive index and linear path 
variations, are measured with a wavefront sensor. A map can be made to show relevant 
retardation that a plane wave undergoes as it traverses the optics of the eye. Clinicians are now 
used to see this information displayed as Zernike polynomial expansion. In order to parcel the 
wavefront error into individual building blocks, a set of normalized Zernike polynomials is 
best fit to the measured wavefront error. The coefficient of each Zernike term reveals that 






Fig. 6. The Zernike pyramid showing polynomials up to the 10th orders. The 0- to 2nd-order 
terms represent low optical aberrations in the eye, with 2nd-order terms (i.e. defocus and 
astigmatism) having the highest contribution to the overall wavefront aberration in the eye. 
Terms of the 3rd order and higher represent the HOAs. The 3rd- and 4th-order terms are the 
most prevalent HOA in the human eye (8). 
 
Fig. 7. Graphical representation of root mean squared wavefront error (9). 
In the ametropic eye, defocus (i.e. myopia or hyperopia) is by far the largest aberration, 
followed by astigmatism. These are low order terms. The Zernike pyramid is useful (Table 
1). As we follow down the rows from the top, we go from low order to high order. Low 
order encompasses the top three rows’ piston, tilt, tip, and sphere and astigmatism. Row 
three (i.e. sphere and astigmatism) is what we normally measure and prescribe in spectacles. 
The fourth row is called third order aberrations, and it continues from there. Anything 
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beyond lower order is lumped under the term of higher order aberrations (HOAs). As 
observed from the diagram, they have individual names such as coma, and spherical 
aberration. When interpreting data, we need to know whether the wavefront refers to total 
aberrations (9).  
 
 
Table 1. Zernicke pyramid (9). 
In the normal ametropic eye, HOAs are a relatively small component, comprising about 10% 
of eye’s overall aberrations. This varies between individuals. Figure 8a shows a 2-D 
wavefront of a normal ametropic eye with a low amount of HOAs (0.14μm), and Figure 8b 
shows a subtle form fruste keratoconic eye with a larger amount (0.42μm) of HOAs. Both 
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The Irx3 showed the highest repeatability in measuring total ocular aberrations, followed by 
the Keratron, OPD-Scan, and iTrace. The repeatability of corneal aberration measurements 
was highest for the iTrace, followed by the Keratron and OPD-Scan. The OPD-Scan showed 
a lower interobserver variability, compared with the Irx3, Keratron, and iTrace. In 
conclusion, total ocular and corneal aberrations are not comparable when measured with 
different aberrometers. Hartmann-Shack aberrometers showed the best repeatability for 
total ocular aberrations, and iTrace for corneal aberrations (10). 
In our clinic we use WaveLight Analyzer (WaveLight Germany) as aberrometer. Working in 
the same visible spectrum as the human eye, the WaveLight Analyzer is designed  
for wavefront measurements on the basis of the Tscherning principle. In order to perform 
measurements according to the Tscherning principle, an image of regular measurement 
spots is projected onto the retina and captured by a lightsensitive camera. The distortion of 
the light spots on the retina in relation to the reference light bundle is calculated and the 
wavefront error is displayed. Figure 9 shows HOAs in a male aged 32 with myopia on his 
left eye. Wavefront refraction: -6.54/-1.14 ax 72°, coma: 0.16µm, spherical aberration:  
0.02 µm, and pupil diameter: 6.59 mm.  
Can HOAs be corrected? Wavefront technology has been advanced enough only in the last 
few years to produce accurate measurements and diagnoses of HOAs. Some types of new 
wavefront designed glasses, contact lenses, intraocular lens implants and wavefront-guided 
laser vision correction can correct HOAs. 
One of the most powerful clinical applications of aberrometry is wavefront-guided 
refractive surgery. With the development of wavefront analyses, the increase of the HOAs of 
the eye following conventional photorefractive keratectomy (PRK) has been confirmed (11). 
Wavefront-guided refractive surgery is a technique using excimer or other lasers to correct 
not only spherical and cylindrical refractive errors but also HOAs. Seiler et al. reported the 
first application of wavefront-guided laser in situ keratomileusis (LASIK) using a Tscherning 
aberrometer to measure the HOAs (12). McDonald performed almost simultaneously the 
first wavefront-guided LASIK using data obtained from the Hartmann–Shack wavefront 
sensor (13).  
Several excimer laser platforms are available today. Although various terminology has 
been used to label, identify, and differentiate treatment modalities, the most commonly 
used include conventional laser in situ keratomileusis (LASIK); wavefront-guided 
treatments, which customize ablation patterns based on higher- and lower-order 
aberration profiles unique to the eye being treated; and wavefront-optimized treatments, 
which take some eye variables into account but use pre-programmed ablation profiles 
based on population analysis. Wavefront-guided treatments are intended to reduce 
preoperative HOAs, and wavefront-optimized treatments are intended to minimize the 
induction of postoperative HOAs; both modalities minimize significantly postoperative 
HOA changes compared with conventional LASIK treatments. There are some reported 
differences in the outcomes of wavefront-guided and wavefront-optimized platforms; 
however, few studies have directly compared the outcomes of these different 
technologies. The results in these studies are inconsistent, some indicating an advantage 
for wavefront-guided treatments and others finding no significant differences between 











Fig. 9. Wavefront aberrations recorded on WaveLight Analyzer (WaveLight Germany). 
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Fares et al. compared the efficiency, predictability, safety, and induced HOAs between 
wavefront-guided and non-wavefront-guided ablations. Their meta-analysis showed that 
the increase in HOAs in patients who had wavefront-guided LASIK was lesser than in 
those who had non-wavefront-guided LASIK (15).  
We experienced in our clinic that refractive surgical procedures (LASIK and PRK) induce 
HOAs and usually do not reduce visual acuity. Here is a brief overview of a case of 
increasing coma after successful correction of mild myopia using PRK: the patient was a 
male aged 27, and a PRK method was performed on his right eye with myopia. WaveLight 
Allegretto (400 Hz) excimer laser was used. HOAs were measured preoperatively and 
postoperatively on WaveLight Analyzer. Preoperative best spectacle corrected visual acuity 
of the right eye was with - 0.75/-0.25 ax 134° = 1.0, and postoperative uncorrected visual 
acuity was 1.0. Optical zone of 6.5 mm and ablated zone of 9.0 mm were used. Coma was 
increased from 0.02 µm preoperatively to 0.15 µm postoperatively, and sperical aberration 











Fig. 11. Picture of wavefront aberrations postoperatively. 
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1. Introduction 
People with astigmatism have several options available to regain clear vision. They include 
eyeglasses, contact lenses, orthokeratology and refractive surgery procedures. In this 
chapter, we will talk about non-surgical treatment only. 
2. Eyeglasses 
Eyeglasses are a choice for correction for people with regular astigmatism and it doesn’t 
improve vision for irregular astigmatism. They will contain a cylindrical lens prescription 
for the astigmatism in a specific meridian of the lens which designates the axis of the lens 
power. Myopia or hyperopia can be associated to astigmatism. Generally, a single vision 
lens is prescribed so as to provide clear vision at all distances. However, for patients over 
the age of 40 who have presbyopia, a bifocal or progressive addition lens may be needed in 
order to focus effectively for near vision work. 
A wide variety of lens-types and frame designs are now available for patients of all ages. 
Eyeglasses are no longer just a medical device that provides needed vision correction, but 
also a means of enhancing appearance. However, any astigmatism correction numerically 
higher than a cylinder +1.50 or -2.50 should warrant special consideration of lenses and 
frames.(1)  
Some consideration must be made with the intention of obtaining the best adaptation of the 
patient to their eyeglasses. A good frame should be lightweight, strong, fit comfortably and 
suit the wearer’s sense of style. Over-sized lenses or much curved frames need to be avoided 
because they can induce distortion in the periphery of the lens.  Eyeglasses with small 
scaffoldings have a minor possibility of producing alterations in the periphery of the lens. 
The lesser the distance-vertex, the less will be the disparity in the magnification of the image 
as it enters the meridians of the astigmatism. The use of negative cylindrical lenses for this 
sends information to locate the correction of the astigmatism in the posterior part of the lens 
and consequently next to the ocular globe.(2) 
The design of the lens influences the adaptation of the eyeglasses. The lenses of spectacles 
for correcting astigmatism should have a toric or cylindrical surface in order to give a single 
focal point in the retina. The thickness of the lens is not the same across its surface. This 
difference in thickness is increased due to the strength of the astigmatism.(3) 
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Aspheric lenses are not like conventional lenses in that they do not have a spherical front 
curvature but instead have differing degrees of curvature. This allows wearers to see clearly 
whether they are looking directly ahead or to either side. Aspheric lenses can also be 
combined with a high index material so as to produce extremely thin lenses which provide 
the same great vision improvement.(1) 
Lens material is also important. In general, lenses are made from three materials: plastic, 
glass, and polycarbonate.(3) Glass is still used for lenses and it is scratch resistant, but it is 
also heavy and breakable. Polycarbonate and Trivex lenses are designed for high impact 
resistance and are ideal for occupational hazards, children and athletes. They provide the 
best eye protection. Plastic is the most used material for lenses. The ones made of high index 
resin are thin, lightweight, provide good optical quality and do not magnify the eyes as with 
the others. The term ’Index of refraction‘ is used to describe the speed at which light travels 
through a material: a higher index results in thinner lenses. 
The lenses of eye glasses can also be upgraded with scratch protectant, anti-reflective, UV-
protectants, colour tints, or photochromics.  A scratch protectant coating helps the lenses 
become more resistant against most abrasions. A UV coating helps to reduce the amount of 
UV rays that enter the eyes by blocking it through the lens. Anti-reflective lenses diminish 
glare and reflections, and allow people to see your eyes without any problem. They are 
designed to lighten up the tint when in the shade and darken the tint when in direct 
sunlight. Polarised lenses are like sunglasses in that they are tinted with a polarisation filter 
and they block vertical light from placing stress on the eyes. They are good for outdoor 
activities where the sun will be glaring down.(3) 
Doctors should instruct patients about the best glasses for their needs, checking the history 
and the eye exam of each one. The ideal method is to prescribe the spectacles after eyeglass 
trials, giving the patients the opportunity to see how they feel in the situations that are 
common in their everyday life. Often, the physician will try to give the best monocular 
correction at the refractor to their patients; however, when the patient uses the eyeglasses, 
with both eyes open, they will not obtain much comfort and will sometimes feel dizzy and 
get a headache. Ultimately, one needs to take into consideration the binocular vision, the 
differences between the eyes, the interpupillary distance and the pantoscopic angle of the 
scaffolding.(4) (figure 1). 
 
Fig. 1. Pantoscopic angle of glasses.(4) 
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3. Contact lenses 
For some individuals, contact lenses can offer better vision than eyeglasses. They can be 
used for people with regular and irregular astigmatism, such as keratoconus. They may 
provide clearer vision and a wider field of view. However, since contact lenses are worn 
directly on the eyes, they require regular cleaning and care to safeguard eye health(5)  
Contact lenses are the first choice for difficult cases such as corneal ecstasies (e.g. 
keratoconus, keratoglobus and pellucid marginal degeneration). For these cases, there are 
special lenses with a variety of designs. In this current chapter we will focus only on regular 
astigmatisms, since to address this kind of adaptation would require a whole chapter to 
itself. 
Almost everybody has the option of using contact lenses. Before initiating any contact lens 
fitting, it is important to evaluate the patient’s motivation, ocular needs, and ocular and 
medical history. There are four principal indications for contact lens fitting: 1) optical 
indications (myopia, hyperopia, astigmatism and presbyopia); 2) medical indications 
(keratoconus, irregular astigmatism, corneal opacification, anisometropia, unilateral 
aphakia, nystagmus, after refractive surgery or keratoplasty); 3) cosmetic or prosthetic 
indication to hide imperfections of the eye; 4) therapeutic indications for corneal abrasion.(4) 
The contraindications are generally relative, and they will depend upon the criteria of the 
ophthalmologist’s evaluation. Unmotivated patient; poor personal hygiene; inability to 
follow directions of lens maintenance and handling; inability to understand the risks 
associated with contact lens use; allergies that affect the eye; immunosuppressed patients, 
diabetic patients, and alcoholics have a large risk of complications; any effective eye disease 
affecting the cornea, the conjunctiva and lids as, for example, with inflammations, 
infections, dry eye, lagophthalmos and glaucoma; moreover, psychological intolerance can 
be a contraindication for contact lenses use.(4) 
Contact lens can be classified by the nature of the material, by their design or by their 
wearing and replacement schedule, as will seen. A well-made clinical history, along with a 
complete ophthalmological examination and the patient’s needs, determines whether 
contact lenses are appropriate for each patient(5) 
As to the nature of the material of the lens, it can be hard, soft or hybrid. Hard lenses can be 
non-gas permeable or gas permeable. Polymethylmethacrylate (PMMA) is the polymer from 
which hard non-gas permeables are made. The disadvantage with this is a lack of gas 
permeability. The rigid gas permeable lenses (RGP) permit the passage of oxygen and 
carbon dioxide gas but they contain no water. The general categories of gas permeable 
polymers are: cellulose acetate butyrate, pure silicone, silicone acrylate and fluorocarbonate. 
The soft lenses can be hydrogel or silicone hydrogel, both of which have a low water-content 
(less than 50% water) or high water-content (greater than 50% water). The oxygen 
transmissibility of a hydrogel lens is directly related to its water-content. For the silicone 
hydrogel, a higher water-content gives more comfort because it diminishes the roughness of 
the lens.(6) 
There are many designs of lenses. In this chapter, the three basic designs that exist will be 
addressed: spherical (having anterior and posterior spherical surfaces); aspheric (different 
radii of curvature in the centre and periphery, simulating the structure of the cornea); and 
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Aspheric lenses are not like conventional lenses in that they do not have a spherical front 
curvature but instead have differing degrees of curvature. This allows wearers to see clearly 
whether they are looking directly ahead or to either side. Aspheric lenses can also be 
combined with a high index material so as to produce extremely thin lenses which provide 
the same great vision improvement.(1) 
Lens material is also important. In general, lenses are made from three materials: plastic, 
glass, and polycarbonate.(3) Glass is still used for lenses and it is scratch resistant, but it is 
also heavy and breakable. Polycarbonate and Trivex lenses are designed for high impact 
resistance and are ideal for occupational hazards, children and athletes. They provide the 
best eye protection. Plastic is the most used material for lenses. The ones made of high index 
resin are thin, lightweight, provide good optical quality and do not magnify the eyes as with 
the others. The term ’Index of refraction‘ is used to describe the speed at which light travels 
through a material: a higher index results in thinner lenses. 
The lenses of eye glasses can also be upgraded with scratch protectant, anti-reflective, UV-
protectants, colour tints, or photochromics.  A scratch protectant coating helps the lenses 
become more resistant against most abrasions. A UV coating helps to reduce the amount of 
UV rays that enter the eyes by blocking it through the lens. Anti-reflective lenses diminish 
glare and reflections, and allow people to see your eyes without any problem. They are 
designed to lighten up the tint when in the shade and darken the tint when in direct 
sunlight. Polarised lenses are like sunglasses in that they are tinted with a polarisation filter 
and they block vertical light from placing stress on the eyes. They are good for outdoor 
activities where the sun will be glaring down.(3) 
Doctors should instruct patients about the best glasses for their needs, checking the history 
and the eye exam of each one. The ideal method is to prescribe the spectacles after eyeglass 
trials, giving the patients the opportunity to see how they feel in the situations that are 
common in their everyday life. Often, the physician will try to give the best monocular 
correction at the refractor to their patients; however, when the patient uses the eyeglasses, 
with both eyes open, they will not obtain much comfort and will sometimes feel dizzy and 
get a headache. Ultimately, one needs to take into consideration the binocular vision, the 
differences between the eyes, the interpupillary distance and the pantoscopic angle of the 
scaffolding.(4) (figure 1). 
 
Fig. 1. Pantoscopic angle of glasses.(4) 
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3. Contact lenses 
For some individuals, contact lenses can offer better vision than eyeglasses. They can be 
used for people with regular and irregular astigmatism, such as keratoconus. They may 
provide clearer vision and a wider field of view. However, since contact lenses are worn 
directly on the eyes, they require regular cleaning and care to safeguard eye health(5)  
Contact lenses are the first choice for difficult cases such as corneal ecstasies (e.g. 
keratoconus, keratoglobus and pellucid marginal degeneration). For these cases, there are 
special lenses with a variety of designs. In this current chapter we will focus only on regular 
astigmatisms, since to address this kind of adaptation would require a whole chapter to 
itself. 
Almost everybody has the option of using contact lenses. Before initiating any contact lens 
fitting, it is important to evaluate the patient’s motivation, ocular needs, and ocular and 
medical history. There are four principal indications for contact lens fitting: 1) optical 
indications (myopia, hyperopia, astigmatism and presbyopia); 2) medical indications 
(keratoconus, irregular astigmatism, corneal opacification, anisometropia, unilateral 
aphakia, nystagmus, after refractive surgery or keratoplasty); 3) cosmetic or prosthetic 
indication to hide imperfections of the eye; 4) therapeutic indications for corneal abrasion.(4) 
The contraindications are generally relative, and they will depend upon the criteria of the 
ophthalmologist’s evaluation. Unmotivated patient; poor personal hygiene; inability to 
follow directions of lens maintenance and handling; inability to understand the risks 
associated with contact lens use; allergies that affect the eye; immunosuppressed patients, 
diabetic patients, and alcoholics have a large risk of complications; any effective eye disease 
affecting the cornea, the conjunctiva and lids as, for example, with inflammations, 
infections, dry eye, lagophthalmos and glaucoma; moreover, psychological intolerance can 
be a contraindication for contact lenses use.(4) 
Contact lens can be classified by the nature of the material, by their design or by their 
wearing and replacement schedule, as will seen. A well-made clinical history, along with a 
complete ophthalmological examination and the patient’s needs, determines whether 
contact lenses are appropriate for each patient(5) 
As to the nature of the material of the lens, it can be hard, soft or hybrid. Hard lenses can be 
non-gas permeable or gas permeable. Polymethylmethacrylate (PMMA) is the polymer from 
which hard non-gas permeables are made. The disadvantage with this is a lack of gas 
permeability. The rigid gas permeable lenses (RGP) permit the passage of oxygen and 
carbon dioxide gas but they contain no water. The general categories of gas permeable 
polymers are: cellulose acetate butyrate, pure silicone, silicone acrylate and fluorocarbonate. 
The soft lenses can be hydrogel or silicone hydrogel, both of which have a low water-content 
(less than 50% water) or high water-content (greater than 50% water). The oxygen 
transmissibility of a hydrogel lens is directly related to its water-content. For the silicone 
hydrogel, a higher water-content gives more comfort because it diminishes the roughness of 
the lens.(6) 
There are many designs of lenses. In this chapter, the three basic designs that exist will be 
addressed: spherical (having anterior and posterior spherical surfaces); aspheric (different 
radii of curvature in the centre and periphery, simulating the structure of the cornea); and 
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toric (two principal meridians having different radii of curvature; this may be the anterior or 
posterior surfaces of the lenses or both).(6) Other designs, such as multi-curvature, reverse 
curve, progressive and bifocal, are related to other refractive errors besides astigmatism and 
will not be considered here. 
The wearing schedule can be: 1) continuous wear (overnight lenses – utilised both during 
waking and sleeping hours); 2) daily wear (removed daily and not utilised during sleep); 
3) flexible wear (removed daily with sporadic sleepers wearing lenses); 4) occasional wear 
(utilises glasses most of the time and lenses only sometimes, in social activities or 
sports).(5)  
The replacement schedule can be done in three ways: 1) a traditional or conventional way is 
used when the lens must be replaced annually; 2) the planned replacement way which is 
nowadays the most used and where the lens needs to be replaced every 15, 30 or 60 days (as 
defined by the manufacturer’s guidelines); 3) disposable lenses, which are probably are the 
easiest way, because they are immediately discarded after use and do not need 
maintenance.(5)  
Many people ask whether or not RGP lenses are better than hydrogel lenses. The answer to 
this question depends upon vision accuracy, the comfort and satisfaction of the patient and 
corneal health. The adaptation of contact lens is different for each person. Generally, to get 
used to them, the patients need between 1 and 15 days and seem to be easier for those 
wearing hydrogel lenses than for the ones who wear RGP lenses. 
There are many pamphlets to help and teach users how to put on and take off contact lenses, 
as well as how to store them and keep them clean. However, it is necessary to review these 
steps at every follow-up visit to the ophthalmologist. The control of contact lens use needs 
to be done with a specialist every year or else every 6 months, depending on the lens fitting 
and eye condition. 
3.1 Soft contact lenses 
Soft contact lenses conform to the shape of the eye. Spherical soft lenses may not be effective 
in correcting astigmatism;(7) however, toric soft contact lenses can provide a correction for 
regular astigmatism similar to that of eyeglasses. 
A strategy for correcting low degrees of astigmatism with spherical soft lenses is to increase 
the thickness of the lens. Considering that a thicker or stiffer lens may drape less on the 
cornea and mask more astigmatism, thicker lenses associated with a special design can give 
good vision even for irregular astigmatism, such as keratoconus.(5) Another strategy that has 
been described is the use of lenses with low water-content, since it is not so malleable. 
However, a low water-content spherical silicone hydrogel material has been shown to have 
no significant impact on the amount of astigmatism masked.(8) 
Visual acuity with a spherical equivalent refraction remained at tolerable limits with the use 
of spherical contact lenses. Spherical lenses failed to mask corneal toricity during 
topography, while toric lenses caused central neutralisation and a decrease in corneal 
cylinder in low and moderate astigmatic eyes.(9)  
Soft aspheric contact lenses have been recommended for low astigmatic patients because its 
design could decrease the level of spherical aberration that is a distortion in image 
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formation. However, clinical studies have reported that non-toric aspheric soft contact 
lenses did not improve visual acuity significantly when compared to spherical lenses on low 
astigmats. One reason for why these non-toric lenses do not improve visual acuity is that 
aspheric soft contact lenses do not correct astigmatism. Additionally, decentration of 
spherical aberration correction has been shown to induce a coma-like aberration that is 
another distortion in image formation.(9) 
Visual acuity with toric lenses is better than with spherical or aspheric lenses, but initially 
lens quality and stability was a problem. Nowadays, improved lens designs and the 
availability of disposable toric contact lenses have resulted in improved health benefits and 
adaptation(10) Well-fitted hydrogel toric lenses can provide visual acuity and visual 
performance equivalent to that of spherical RGP lenses.(9) 
All the literature agrees that the best way to fit a soft lens is by considering the response to 
the trial lens fitting.  By slit lamp, the physician observes centralisation, the movement of the 
lens and the lens-cornea relationship. After this, over-refraction has to be done.(5) However, 
the fitting without trial lens has proven to be an efficient way to prescribe it. 50% to 80% of 
patients are being fitted successfully with this method for soft toric contact lenses.(11) To fit a 
soft contact lens, keratometry needs to be done. The base curve of the lens should be 
approximately 0.6 to 0.8 mm flatter than the average corneal curvature measurement. The 
lens diameter should be approximately 2.0 mm larger than the horizontal visible iris 
diameter. The dioptric power of the contact lens should consider the total eye refraction and, 
if it is greater than 4.00 D, a table for the correction of the vertex distance should be used.(6) It 






DL= dioptric power of contact lens. 
DA= dioptric power of glasses. 
d= vertex distance (which has an average of 12mm). 
There remains some disagreement as to when to fit soft toric lenses or else spherical lenses. 
In practice, high myopia associated with low astigmatism has good acuity with spherical 
contact lenses; however, low myopes with higher astigmatism had significantly better acuity 
with toric lenses than with the spherical equivalent.(5)  
3.2 Rigid gas permeable lenses 
Rigid gas permeable contact lenses maintain their regular shape while on the cornea, and 
they offer an effective way to compensate for the cornea’s irregular shape and improve the 
vision of persons with astigmatism and other refractive errors. 
Gas permeable (GP) lenses could be very acceptable as a viable option for the correction of 
moderate to severe astigmatism. Patients preferred RGP lenses for visual acuity, especially 
at near and intermediate distances.(12) 
Spherical lenses can compensate for corneal astigmatism up to 3.00 D, although it is known 
that using them on corneas showing more than 2.00 D of toricity may be inappropriate. 
Because of this, it is recommended that spherical fittings should be done where the base 
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toric (two principal meridians having different radii of curvature; this may be the anterior or 
posterior surfaces of the lenses or both).(6) Other designs, such as multi-curvature, reverse 
curve, progressive and bifocal, are related to other refractive errors besides astigmatism and 
will not be considered here. 
The wearing schedule can be: 1) continuous wear (overnight lenses – utilised both during 
waking and sleeping hours); 2) daily wear (removed daily and not utilised during sleep); 
3) flexible wear (removed daily with sporadic sleepers wearing lenses); 4) occasional wear 
(utilises glasses most of the time and lenses only sometimes, in social activities or 
sports).(5)  
The replacement schedule can be done in three ways: 1) a traditional or conventional way is 
used when the lens must be replaced annually; 2) the planned replacement way which is 
nowadays the most used and where the lens needs to be replaced every 15, 30 or 60 days (as 
defined by the manufacturer’s guidelines); 3) disposable lenses, which are probably are the 
easiest way, because they are immediately discarded after use and do not need 
maintenance.(5)  
Many people ask whether or not RGP lenses are better than hydrogel lenses. The answer to 
this question depends upon vision accuracy, the comfort and satisfaction of the patient and 
corneal health. The adaptation of contact lens is different for each person. Generally, to get 
used to them, the patients need between 1 and 15 days and seem to be easier for those 
wearing hydrogel lenses than for the ones who wear RGP lenses. 
There are many pamphlets to help and teach users how to put on and take off contact lenses, 
as well as how to store them and keep them clean. However, it is necessary to review these 
steps at every follow-up visit to the ophthalmologist. The control of contact lens use needs 
to be done with a specialist every year or else every 6 months, depending on the lens fitting 
and eye condition. 
3.1 Soft contact lenses 
Soft contact lenses conform to the shape of the eye. Spherical soft lenses may not be effective 
in correcting astigmatism;(7) however, toric soft contact lenses can provide a correction for 
regular astigmatism similar to that of eyeglasses. 
A strategy for correcting low degrees of astigmatism with spherical soft lenses is to increase 
the thickness of the lens. Considering that a thicker or stiffer lens may drape less on the 
cornea and mask more astigmatism, thicker lenses associated with a special design can give 
good vision even for irregular astigmatism, such as keratoconus.(5) Another strategy that has 
been described is the use of lenses with low water-content, since it is not so malleable. 
However, a low water-content spherical silicone hydrogel material has been shown to have 
no significant impact on the amount of astigmatism masked.(8) 
Visual acuity with a spherical equivalent refraction remained at tolerable limits with the use 
of spherical contact lenses. Spherical lenses failed to mask corneal toricity during 
topography, while toric lenses caused central neutralisation and a decrease in corneal 
cylinder in low and moderate astigmatic eyes.(9)  
Soft aspheric contact lenses have been recommended for low astigmatic patients because its 
design could decrease the level of spherical aberration that is a distortion in image 
 
Non-Surgical Treatment of Astigmatism 209 
formation. However, clinical studies have reported that non-toric aspheric soft contact 
lenses did not improve visual acuity significantly when compared to spherical lenses on low 
astigmats. One reason for why these non-toric lenses do not improve visual acuity is that 
aspheric soft contact lenses do not correct astigmatism. Additionally, decentration of 
spherical aberration correction has been shown to induce a coma-like aberration that is 
another distortion in image formation.(9) 
Visual acuity with toric lenses is better than with spherical or aspheric lenses, but initially 
lens quality and stability was a problem. Nowadays, improved lens designs and the 
availability of disposable toric contact lenses have resulted in improved health benefits and 
adaptation(10) Well-fitted hydrogel toric lenses can provide visual acuity and visual 
performance equivalent to that of spherical RGP lenses.(9) 
All the literature agrees that the best way to fit a soft lens is by considering the response to 
the trial lens fitting.  By slit lamp, the physician observes centralisation, the movement of the 
lens and the lens-cornea relationship. After this, over-refraction has to be done.(5) However, 
the fitting without trial lens has proven to be an efficient way to prescribe it. 50% to 80% of 
patients are being fitted successfully with this method for soft toric contact lenses.(11) To fit a 
soft contact lens, keratometry needs to be done. The base curve of the lens should be 
approximately 0.6 to 0.8 mm flatter than the average corneal curvature measurement. The 
lens diameter should be approximately 2.0 mm larger than the horizontal visible iris 
diameter. The dioptric power of the contact lens should consider the total eye refraction and, 
if it is greater than 4.00 D, a table for the correction of the vertex distance should be used.(6) It 






DL= dioptric power of contact lens. 
DA= dioptric power of glasses. 
d= vertex distance (which has an average of 12mm). 
There remains some disagreement as to when to fit soft toric lenses or else spherical lenses. 
In practice, high myopia associated with low astigmatism has good acuity with spherical 
contact lenses; however, low myopes with higher astigmatism had significantly better acuity 
with toric lenses than with the spherical equivalent.(5)  
3.2 Rigid gas permeable lenses 
Rigid gas permeable contact lenses maintain their regular shape while on the cornea, and 
they offer an effective way to compensate for the cornea’s irregular shape and improve the 
vision of persons with astigmatism and other refractive errors. 
Gas permeable (GP) lenses could be very acceptable as a viable option for the correction of 
moderate to severe astigmatism. Patients preferred RGP lenses for visual acuity, especially 
at near and intermediate distances.(12) 
Spherical lenses can compensate for corneal astigmatism up to 3.00 D, although it is known 
that using them on corneas showing more than 2.00 D of toricity may be inappropriate. 
Because of this, it is recommended that spherical fittings should be done where the base 
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curve of the lens is equal to the cornea’s flattest meridian. The limits of this approach are 
reached on highly toric corneas where the lens may alter the tear film flow, leading to 
peripheral desiccation of the cornea (known as 3–9 o’clock staining). This is why a spherical 
GP lens should be used with extreme caution on a cornea presenting toricity greater than 
2.00 D. At present, it is recommended that reliance should be placed on a topographic map 
of the cornea so as to determine the optimal parameters.(13) 
Many methods can be used to find the base curve. That most frequently used by 
practitioners involves adding 1/3 to 1/4 of the astigmatism measure to K (the flattest 
meridian of the topographic corneal map).(12) The diameter of the lenses is dependent to the 
base curve. A great diameter needs a flatter adaptation (table 1). Another tip is to remember 
is that steeper corneas require lenses with a smaller diameter, and that flatter corneas 
require lenses with a greater diameter (table 2).(5)  
The selected trial lens is placed on the cornea and then, for the evaluation, it is necessary to 
take into account its comfort, position, movement and stability. The slit lamp evaluates the 
relationship between the lens and cornea with fluorescein.  After the fitting is complete, the 




8.6 mm diameter 
lens 
9.2 mm diameter 
lens 
10.2 mm diameter 
lens 
0,00 to 0,50 D 0.25 D STK On K 0.25 D FTK 
0,75 to 1,25 D 0.50 D STK 0,25 D STK On K 
1,50 to 2,00 D 0.75 D STK 0.50 D STK 0.25 D STK 
2,25 to 2,75 D 1.00 D STK 0.75 D STK 0.50 D STK 
3,00 to 3,50 D 1.25 D STK 1.00 D STK 0.75 D STK 
STK = steeper than K / FTK = flatter then K. 
Table 1. Base curve lens determination in dependence of lens diameter and topographic 
corneal cylinder. 
 
Corneal curvature (K) Lens diameter 
38.00 to 42.00 D 9.8 mm or bigger 
42.25 to 44.25 D 9.1 to 9.7 mm 
44.50 to  50.00 D 9.0 mm or smaller 
Table 2. Correlation between corneal curvature flattest meridian of the topographic corneal 
map (K) and contact lens diameter 
Aspheric lenses will always move in the direction of least resistance: this implies that a lens 
that is restricted along the vertical meridian and which is free along the horizontal meridian 
will move freely up and down. Conversely, if there is a restriction along the horizontal 
meridian, the lens will decentre on the nasal or temporal side.(13)  
For those wearing RGP contact lenses, only 18% to 22% wear toric correction, suggesting 
that many practitioners tend to mask astigmatism using spherical equivalence with contact 
lenses. One reason for this behaviour is that toric gas permeable lenses are more complex to 
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fit and have variable results.(13) Some practitioners will consider toric lenses only if the 
patient reports unsatisfactory vision in spherical contact lenses or else when the corneal 
toricity is too great and the fitting has become unstable. Toric lens designs can have different 
radii of curvature on the front surface, back surface or both of what are known as bitoric 
lenses. 
Back-toric design implies that the back surface of the lens is toric and that its front surface is 
spherical. This design is most successful when the corneal toricity represents more than two 
thirds of the refractive astigmatism. Back-toric gas permeable lenses are not designed with 
prism ballasts; their stabilisation is mainly achieved by the correspondence between the 
back curves and the corneal toricity. This type of lens is designed with only 66% corneal 
toricity so as to provide more comfort. However, because of this, the lens will quite certainly 
rotate in the eye. Clinically, this translates as induced astigmatism that can disturb the visual 
outcome where it exceeds 0.75 D.(5)  
Front-toric designs are designed with the astigmatic correction on the front surface of the 
lens, leaving the back surface spherical. They are stabilised with a base-down prism and 
represent the best choice for correcting residual astigmatism, in which the cornea is 
spherical.(5) Residual astigmatism results from causes other than the shape of the anterior 
corneal surface and can refer to astigmatism of the posterior cornea surface, lens, and 
retina. 
A bitoric lens offers both surfaces as toric. The back toric surface curves are designed to be 
aligned with the corneal toricity. Optically speaking, this generates an over-correction of the 
refractive astigmatism. This is why a front toric surface is needed to compensate the power 
of the lens. Bi-toric designs are the most popular toric design in RGP contact lens practice, 
and represent the best choice if corneal toricity is less than or exceeds refractive 
astigmatism.(5) 
For RGP toric lenses, I believe that the most appropriate fitting method is a 4-step approach, 
known as the two-thirds rule, as seen below.(14) 
Step 1. Calculation of corneal toricity: calculate the difference between the two principal 
meridians of the cornea. 
Step 2. Calculation of Base curve 1 (BC-1): the base curve 1 of the lens is determined by 
dividing the corneal toricity (found in Step 1) into two-thirds and then adding it to 
the flattest meridian of the cornea. 
Step 3. Calculation of base curve 2 (BC-2): the base curve 2 of the lens is determined by 
flattening the steepest meridian of the cornea according to Remba’s rule (Table 3). 
Step 4. Calculation of lachrymal lens power and induced astigmatism: this type of 
astigmatism is induced by the relationship of the back surface of the lens to the 
cornea, and can be seen doing the over-refraction. If this value is less than 1.00 D, a 
back-toric design should be ordered because the induced astigmatism is not 
considered to be a contributing factor affecting visual acuity. At this point, a 
spherical equivalence is made in order to determine the final power of the back-
toric lens. However, if the induced astigmatism value exceeds 1.00 D, a bitoric 
design should then be selected because the induced astigmatism should be 
corrected by the addition of the cylinder power to the front-surface of the lens. 
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curve of the lens is equal to the cornea’s flattest meridian. The limits of this approach are 
reached on highly toric corneas where the lens may alter the tear film flow, leading to 
peripheral desiccation of the cornea (known as 3–9 o’clock staining). This is why a spherical 
GP lens should be used with extreme caution on a cornea presenting toricity greater than 
2.00 D. At present, it is recommended that reliance should be placed on a topographic map 
of the cornea so as to determine the optimal parameters.(13) 
Many methods can be used to find the base curve. That most frequently used by 
practitioners involves adding 1/3 to 1/4 of the astigmatism measure to K (the flattest 
meridian of the topographic corneal map).(12) The diameter of the lenses is dependent to the 
base curve. A great diameter needs a flatter adaptation (table 1). Another tip is to remember 
is that steeper corneas require lenses with a smaller diameter, and that flatter corneas 
require lenses with a greater diameter (table 2).(5)  
The selected trial lens is placed on the cornea and then, for the evaluation, it is necessary to 
take into account its comfort, position, movement and stability. The slit lamp evaluates the 
relationship between the lens and cornea with fluorescein.  After the fitting is complete, the 
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9.2 mm diameter 
lens 
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0,00 to 0,50 D 0.25 D STK On K 0.25 D FTK 
0,75 to 1,25 D 0.50 D STK 0,25 D STK On K 
1,50 to 2,00 D 0.75 D STK 0.50 D STK 0.25 D STK 
2,25 to 2,75 D 1.00 D STK 0.75 D STK 0.50 D STK 
3,00 to 3,50 D 1.25 D STK 1.00 D STK 0.75 D STK 
STK = steeper than K / FTK = flatter then K. 
Table 1. Base curve lens determination in dependence of lens diameter and topographic 
corneal cylinder. 
 
Corneal curvature (K) Lens diameter 
38.00 to 42.00 D 9.8 mm or bigger 
42.25 to 44.25 D 9.1 to 9.7 mm 
44.50 to  50.00 D 9.0 mm or smaller 
Table 2. Correlation between corneal curvature flattest meridian of the topographic corneal 
map (K) and contact lens diameter 
Aspheric lenses will always move in the direction of least resistance: this implies that a lens 
that is restricted along the vertical meridian and which is free along the horizontal meridian 
will move freely up and down. Conversely, if there is a restriction along the horizontal 
meridian, the lens will decentre on the nasal or temporal side.(13)  
For those wearing RGP contact lenses, only 18% to 22% wear toric correction, suggesting 
that many practitioners tend to mask astigmatism using spherical equivalence with contact 
lenses. One reason for this behaviour is that toric gas permeable lenses are more complex to 
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fit and have variable results.(13) Some practitioners will consider toric lenses only if the 
patient reports unsatisfactory vision in spherical contact lenses or else when the corneal 
toricity is too great and the fitting has become unstable. Toric lens designs can have different 
radii of curvature on the front surface, back surface or both of what are known as bitoric 
lenses. 
Back-toric design implies that the back surface of the lens is toric and that its front surface is 
spherical. This design is most successful when the corneal toricity represents more than two 
thirds of the refractive astigmatism. Back-toric gas permeable lenses are not designed with 
prism ballasts; their stabilisation is mainly achieved by the correspondence between the 
back curves and the corneal toricity. This type of lens is designed with only 66% corneal 
toricity so as to provide more comfort. However, because of this, the lens will quite certainly 
rotate in the eye. Clinically, this translates as induced astigmatism that can disturb the visual 
outcome where it exceeds 0.75 D.(5)  
Front-toric designs are designed with the astigmatic correction on the front surface of the 
lens, leaving the back surface spherical. They are stabilised with a base-down prism and 
represent the best choice for correcting residual astigmatism, in which the cornea is 
spherical.(5) Residual astigmatism results from causes other than the shape of the anterior 
corneal surface and can refer to astigmatism of the posterior cornea surface, lens, and 
retina. 
A bitoric lens offers both surfaces as toric. The back toric surface curves are designed to be 
aligned with the corneal toricity. Optically speaking, this generates an over-correction of the 
refractive astigmatism. This is why a front toric surface is needed to compensate the power 
of the lens. Bi-toric designs are the most popular toric design in RGP contact lens practice, 
and represent the best choice if corneal toricity is less than or exceeds refractive 
astigmatism.(5) 
For RGP toric lenses, I believe that the most appropriate fitting method is a 4-step approach, 
known as the two-thirds rule, as seen below.(14) 
Step 1. Calculation of corneal toricity: calculate the difference between the two principal 
meridians of the cornea. 
Step 2. Calculation of Base curve 1 (BC-1): the base curve 1 of the lens is determined by 
dividing the corneal toricity (found in Step 1) into two-thirds and then adding it to 
the flattest meridian of the cornea. 
Step 3. Calculation of base curve 2 (BC-2): the base curve 2 of the lens is determined by 
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 Cornea toricity Flattening of the steepest meridian 
2.0 D 0.25 D 
3.0 D 0.50 D 
4.0 D or more 0.75 D 
Table 3. Usable values according to Remba’s rule 
3.3 Orthokeratology 
Orthokeratology (ortho-k) involves the fitting of specially designed rigid contact lenses to 
reshape the cornea so as to temporarily reduce or eliminate refractive error. The contact 
lenses are worn for limited periods, such as overnight, and then removed. Persons with mild 
to moderate myopia and mild astigmatism may be able to temporarily obtain clear vision 
without lenses for most of their daily activities. Ortho-k does not permanently improve 
vision, and if the person stops wearing the retainer lenses, the cornea may return to its 
original condition and vision will be bad again. Ortho-k is a good option for people who 
need RGP contact lenses to improve vision but who cannot wear common lenses for many 
reasons.(5) The main reasons for using this kind of lens are: workers in polluted 
environments or who use chemical products; boxers or water-sports athletes; people who 
feel discomfort with regular lenses and cannot have refractive surgery; people who have 
problems with blinking, dry eye, giant papillary conjunctivitis or nystagmus.  
Ortho-k makes many changes to the shape of the cornea, as can be seen by topography 
maps, wave front measurements and pachymetry. The corneal changes induced by reverse-
geometry – because of the relatively flat-fitting base curve – create a central flattened zone 
called the treatment zone, corresponding approximately to the lens back optic zone. 
Successful ortho-k treatment produces a well-centred regular treatment zone which 
encompasses the pupil diameter, as revealed by inspection of the difference map on the 
corneal topographer’s data display (figure 2).(15)  
The induction of higher-order aberrations with the use of reverse-geometry lenses for 
overnight ortho-k has been reported.(16) The significant increase in spherical aberrations is seen 
by the annular zone of mid-peripheral corneal steepening induced by the reverse-geometry 
lens, and the consequent change in corneal shape from prolate1 towards oblate2 asphericity.(16) 
However, the patients do not complain about these kinds of visual problems.  A higher-order 
aberration is a distortion acquired when light passes through an eye with irregularities. 
Everyone’s eyes have it, but the quantity of it is what determines whether it will affect quality 
of vision, by giving symptoms as glare, halos, starburst effects and ghost images. 
Most of the studies concern ortho-k for myopia of 4.0D and with-the-rule corneal 
astigmatism of less than 1.50D showing rapid results, with most change after the first night 
of lens wear and most stability in refractive change after 4 weeks.(17) However, a few studies 
show good results for irregular astigmatism, such as keratoconus.(15) 
Spherical reverse-geometry lenses can be used on toric corneas in order to reduce 
astigmatism. In a retrospective analysis, Mountford and Pesudovs(18) demonstrated that up 
                                                                 
1 The normal cornea is a prolate surface - steeper in the centre and flatter in the periphery. 
2 The oblate surface is a surface after myopic laser photorefractive keratectomy – flatter in the centre 
and steeper in the periphery. 
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to 50% of corneal astigmatism could be reduced with standard reverse-geometry ortho-k 
lenses, provided that the toricity was with-the-rule and restricted to the central region of the 
cornea. Corneal toricity reaching from limbus to limbus on the topographic map was less 
amenable to modification by ortho-k lenses.  
Toric ortho-k lenses were created for an oval treatment zone and different meridional 
topographic changes, with more corneal flattening in the meridian requiring more myopic 
refractive error correction. Details of corneal topographic changes induced by these different 
ortho-k lens designs over longer periods of wear are yet to be published.(19) 
There is slight regression of effect (about 0.25 to 0.75 D) during the day, and lenses must be 
periodically worn overnight (from every night to every three to four nights) to retain the 
effect. No serious adverse events have been reported from published clinical studies, 
although overnight lens adherence and clinically significant corneal staining in the morning 
after lens removal appear to be relatively common and have caused some clinical concerns 
in some studies.(20) 
Patient satisfaction with overnight ortho-k has been reported as similar to or better than 
other popular modalities of contact lens wear. Unlike refractive surgery, if patients fail to 
achieve a subjectively successful outcome, they can cease lens wear and return to other 
corrective options, such as spectacles or conventional contact lenses. The corneal changes 
induced by overnight ortho-k are fully reversible on cessation of lens wear.(20) 
 
Fig. 2. Topography before and after orthokeratology in a case of irregular astigmatism 
(keratoconus).(15) 
4. Visual stimulation 
Brain plasticity in the visual functions of adults has been shown to improve with repetitive 
practice on specific controlled visual tasks. Through these repetitive practices are initiated 
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practice on specific controlled visual tasks. Through these repetitive practices are initiated 
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neural modifications that lead to an improvement in neuronal efficiency. These neural 
modifications can enhance image quality by compensating for blurred retinal images due to 
optical defocus for all the refract errors.(21) It is indicated by those who have good Snellen 
visual acuity but still have symptoms of ghost images. This commonly happens to people 
with low astigmatism. 
RevitalVision by NeuroVision (NeuroVision Inc., Singapore), based on visual stimulation, 
have developed a computer programme for amblyopia, post lasik (laser assisted in situ 
keratomileusis) and post cataract. However, it can be extended for others refractive errors. 
During training sessions, the user is presented with a series of precise visual tasks consisting 
of Gabor patches with subtle differences in orientation, size and contrast. Through repetitive 
practice, the brain is trained to be more efficient and to improve visual processing by 
improving contrast sensitivity and visual acuity.(22) 
Studies showed mean improvements of visual acuity of about 2.0 LogMar, and the contrast 
sensitivity function also improved at all spatial frequencies. However, the mean refractive 
error remained unchanged after treatment. Follow-up data for up to 12 months post-
treatment showed that the gains were retained.(23) This method has never been proven. The 
effect is probably related to the memory of the patients, and this would be the reason that 
the refractive error remains unchanged. 
Besides this, it requires more evaluation to see the real value of this kind of stimulation for 
the treatment of astigmatism.(21-23) 
5. Advantages and disadvantages for each correcting method 
There are many differences between contact lens and glasses, as can be seen in the chart 
below, but both need an eye doctor’s prescription and periodic evaluation. 
 
Eyeglasses Contact Lenses 
The distance between your eye and the lens 
sometimes creates distortion. 
When worn right on the eye it sometimes can 
blur because of tears. 
Glasses correct only regular astigmatism. Contact lenses can also correct irregular cornea shape that distorts vision. 
Glasses can be inconvenient during games 
and sports. 
Contact lenses are a favourite among 
athletes. 
Poor peripheral vision (visual field) because 
of the frame. Your entire field of view is in focus. 
Eyeglasses can get dirty and decrease vision. Contact lenses can form deposits on the lens and blur the vision acuity. 
Glasses must be sprayed and wiped several 
times a day. 
Contact lenses should be cleaned, disinfected 
and stored properly after each use. 
Periodic need for tightening or other 
adjustment. 
Maintenance and handling of the lens every 
day. 
Sometimes an uncomfortable weight on your 
face and ears. 
Sometimes uncomfortable in the eye as a 
strange body, dry eye or allergy. 
Glasses are fashionable, functional and 
complement your outfit. Cosmetic lens may alter the colour of the eye. 
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Also, there are advantages and disadvantages associated with various types of contact lens, as 
seen below. All of the contact lenses require visits to the ophthalmologist for follow-up care. 
 
Lens Types Advantages Disadvantages 
Soft lenses 
Very short adaptation period. 
More comfortable and more 
difficult to dislodge than RGP 
lenses. 
Maintenance and handling every 
day. Do not last long comparing to 
RGP lenses. Vision may not be as 
sharp as RGP lenses. 
Daily wear 
disposable lenses 
Thinner lenses. Require no 
cleaning. Minimal risk of eye 
infection if the wearing 
instructions are followed. 
Do not correct all vision problems. 
Extended ware 
disposable lenses 
Can usually be worn up to 
several days without removal 
(the wearing period is defined 
by the manufacturer’s 
guidelines). Require no 
cleaning. 
Do not correct all vision problems. 
Increases risk of complication with 
night and day wear. Requires 




Require simplified cleaning 
and disinfection. Good for eye 
health. Available in most 
prescriptions. 
Vision may not be as sharp as RGP 
lenses. Maintenance and handling 
every day. 
Rigid gas permeable 
lenses (RGP) 
Excellent vision. Easier than 
the soft lens for maintenance 
and handling. Correct most 
vision problems. Durable, with 
a relatively long life. 
Require consistent wear to maintain 
good vision. Can slip off the centre 
of the eye more easily than other 
types. Debris can easily get under 
the lenses. Longer period to get 
used to compared to soft lenses. 
Ortoceratologia 
Worn only at times of sleeping. 
Eliminates the use of the lens 
on walking hour. Short 
adaptation period. Comfortable 
to wear. Less friction with the 
lid. Durable, with a long life. 
Correct only low astigmatism and 
low to moderate myopia. Vision 
may not be as sharp as with other 
lenses. 
6. Conclusion 
Individuals with astigmatism have a wide range of options to correct their vision problems 
and, together with an eye exam, the selection of the best treatment that meets vision and 
lifestyle needs must be done. 
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An optical system with astigmatism is one where rays that propagate in two perpendicular 
planes have different foci. If an optical system with astigmatism is used to form an image of a 
cross, the vertical and horizontal lines will be in sharp focus at two different distances. The term 
comes from the Greek α- (a-) meaning "without" and στίγμα (stigma), "a mark, spot, puncture". 
There are two distinct forms of astigmatism. The first is a third-order aberration, which 
occurs for objects (or parts of objects) away from the optical axis. This form of aberration 
occurs even when the optical system is perfectly symmetrical. 
The second form of astigmatism occurs when the optical system is not symmetric about the 
optical axis. This form of astigmatism is extremely important in vision science and eye care, 
since the human eye often exhibits this aberration due to imperfections in the shape of the 
cornea or the lens. 
If an optical system is not axisymmetric, either due to an error in the shape of the optical 
surfaces or due to misalignment of the components, astigmatism can occur even for on-axis 
object points. Ophthalmic astigmatism is a refraction error of the eye in which there is a 
difference in degree of refraction in different meridians. It is typically characterized by an 
aspherical, non-figure of revolution cornea in which the corneal profile slope and refractive 
power in one meridian is less than that of the perpendicular axis. 
Astigmatism causes difficulties in seeing fine detail. In some cases vertical lines and objects 
such as walls may appear to the patient to be leaning over like the Tower of Pisa. 
Astigmatism can be often corrected by glasses with a lens that has different radii of 
curvature in different planes (a cylindrical lens), contact lenses, or refractive surgery. 
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An optical system with astigmatism is one where rays that propagate in two perpendicular 
planes have different foci. If an optical system with astigmatism is used to form an image of a 
cross, the vertical and horizontal lines will be in sharp focus at two different distances. The term 
comes from the Greek α- (a-) meaning "without" and στίγμα (stigma), "a mark, spot, puncture". 
There are two distinct forms of astigmatism. The first is a third-order aberration, which 
occurs for objects (or parts of objects) away from the optical axis. This form of aberration 
occurs even when the optical system is perfectly symmetrical. 
The second form of astigmatism occurs when the optical system is not symmetric about the 
optical axis. This form of astigmatism is extremely important in vision science and eye care, 
since the human eye often exhibits this aberration due to imperfections in the shape of the 
cornea or the lens. 
If an optical system is not axisymmetric, either due to an error in the shape of the optical 
surfaces or due to misalignment of the components, astigmatism can occur even for on-axis 
object points. Ophthalmic astigmatism is a refraction error of the eye in which there is a 
difference in degree of refraction in different meridians. It is typically characterized by an 
aspherical, non-figure of revolution cornea in which the corneal profile slope and refractive 
power in one meridian is less than that of the perpendicular axis. 
Astigmatism causes difficulties in seeing fine detail. In some cases vertical lines and objects 
such as walls may appear to the patient to be leaning over like the Tower of Pisa. 
Astigmatism can be often corrected by glasses with a lens that has different radii of 
curvature in different planes (a cylindrical lens), contact lenses, or refractive surgery. 
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Astigmatism is quite common. Studies have shown that about one in three people suffers 
from it. The prevalence of astigmatism increases with age. Although a person may not 
notice mild astigmatism, higher amounts of astigmatism may cause blurry vision, squinting, 
asthenopia, fatigue, or headaches. 
Astigmatism is an optical defect in which vision is blurred due to the inability of the optics 
of the eye to focus a point object into a sharp focused image on the retina. This may be due 
to an irregular or toric curvature of the cornea or lens. The most of the astigmatism is 
corneal. Astigmatism may also be caused by crystalline lens subluxation, coloboma or 
lenticonus. There are two types of astigmatism: regular and irregular. Irregular astigmatism 
is often caused by a corneal scar or scattering in the crystalline lens. Regular astigmatism 
arising from either the cornea or crystalline lens can be easily corrected. 
The refractive error of the astigmatic eye stems from a difference in degree of curvature 
refraction of the two different meridians (i.e., the eye has different focal points in different 
planes.) For example, the image may be clearly focused on the retina in the horizontal 
(sagittal) plane, but not in the vertical (tangential) plane. Astigmatism causes difficulties in 
seeing fine detail, and in some cases vertical lines (e.g., walls) may appear to the patient to 
be tilted. 
In With-the-rule astigmatism, the eye sees vertical lines more sharply than horizontal lines. 
Against-the-rule astigmatism reverses the situation. Children tend to have With-the-rule 
astigmatism and elderly people tend to have Against-the-rule astigmatism. The prevalence 
of astigmatism increases with age. 
Astigmatism may be corrected with eyeglasses, contact lenses, or refractive surgery. Various 
considerations involving ocular health, refractive status, and lifestyle frequently determine 
whether one option may be better than another. In those with keratoconus, toric contact 
lenses often enable patients to achieve better visual acuities than eyeglasses. Once only 
available in a rigid gas-permeable form, toric lenses are now available also as soft lenses. 
2. Aspheric ablation strategies 
An aspheric lens or asphere is a lens whose surfaces have a profile that is rotationally 
symmetric, but is not a portion of a sphere. The asphere's more complex surface profile can 
reduce or eliminate spherical aberration and also reduce other optical aberrations compared 
to spheric lenses. Aspheric elements are used to reduce aberrations. 
In prescriptions for both farsightedness and nearsightedness, the lens curve flattens toward 
the edge of the asphere. Aspheric ablation strategies for spherical correction are modified by 
means of spherical aberration compensations, whereas aspheric ablation strategies for 
astigmatic correction are modified by means of high-order-asitmgatism aberration 
compensations. 
3. Ocular wavefront (OW) customized ablation strategies 
The treatment plan is developed using OW customised aspheric profiles based on Hartmann-
Shack sensing1. The high-resolution Hartmann-Shack measurements (>800 points for a 7.0-mm 
pupil) referred to the entire eye. Optical errors centered on the line-of-sight are described by the 
Zernike polynomials2 and the coefficients of the Optical Society of America (OSA) standard3. 
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Fig. 1. Principle of the OW measurement. 
3.1 Treatment modality 
Preoperative topography and aberrometry measurements are taken, and visual acuity, and 
mesopic pupil size are measured. To determine the ablation profile of the Custom Ablation 
Manager (CAM), manifest refraction is measured in each eye and crosschecked with 
objective refraction from the SCHWIND Ocular Wavefront Analyzer4. Each eye is planned 
according to the manifest refraction using the CAM Wavefront customised treatments. 
The CAM aspherical profiles were developed with the aim to compensate for the induction 
of aberrations (especially but not only spherical aberration) observed with other types of 
profile definitions5, some of these sources of aberrations are those related to the loss of 
efficiency of the laser ablation for non-normal incidence6,7. Optimization is realized by 
taking into account the loss of efficiency at the periphery of the cornea in relation to the 
center, as there is a tangential effect of the spot in relation to the corneal curvature (K 
(Keratometry) -reading). The software provides K-reading compensation, which considers 
the change in spot geometry and reflection losses of ablation efficiency. 
The base-line for correcting refraction (sphere and cylinder) is aspheric, whereas the high 
order aberrations measured based on Hartmann-Shack sensing of the entire eye are 
combined with manifest refraction. 
Real ablative spot shape (volume) is considered through a self-constructing algorithm. In 
addition, there are a randomized flying-spot ablation pattern, and controls for the local 
repetition rates to minimize the thermal load of the treatment8. 
A central fully corrected ablation zone is used in all eyes with a variable transition size 
automatically provided by the laser related to the planned refractive correction. 
Immediately before the ablation, the laser is calibrated per manufacturer’s instructions and 
the calibration settings are recorded. 
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The CAM software is able to import, visualize, and combine diagnostic data of the eye 
(manifest refraction and ocular wavefront data in this case) into a customised aspherical 
ablation profile to optimize the corneal shape. OW based ablations attempt to reduce the 
wavefront aberration of the entire eye (within Optical Zone, OZ) close to a zero level, 
compensating, as well, for the aberration induction observed with other types of profiles. 
It should be noted that opposing the preoperative wavefront aberration in laser refractive 
surgery constituted only a first approximation of a perfect refractive correction, as tissue 
removal occurs. Considerations such as treatment duration or tissue removal make even 
more difficult to establish a universal optimal profile. Our data suggest that Ocular 
wavefront customized treatments can only be successful, if the pre-existing aberrations are 
greater than the repeatability and the biological noise. In particular, the OW customized 
approach is highly efficient in eyes with greater than 0.25 microns root-mean-square (RMS) 
ocular HOAb, or where individual components of the OW such as coma, trefoil or spherical 
aberration are greater than 0.2 microns RMS. 
4. Corneal wavefront (CW) customized ablation strategies 
The treatment plan is developed using CW customized aspheric profiles based on corneal 
ray tracing (Salmon 19999). Using the Keratron Scout videokeratoscope (Mattioli & Tripoli 
199710) (Optikon 2000 S.p.A, Rome, Italy), the topographical surface and corneal wavefront 
are analyzed (up to the 7th order). Considering a balanced-eye model (Q-Val –0.25) the 
departure of the measured corneal topography from the theoretically optimal corneal 
surface is calculated. Optical errors centered on the line of sight are described by the Zernike 
polynomials (Zernike 193411) and the coefficients of the Optical Society of America (OSA) 
standard (Thibos et al. 200212). 
Ray tracing is a procedure classically performed by applying Snell's law to the corneal 
surface. However, it is much simpler to understand corneal wavefront in terms of optical 
path difference and calculate it by Huygens-Fresnel or ''least time'' Fermat principles 
(Salmon 19999; Guirao & Artal 200013). 
Corneal Wavefront Analyzer
• 28 placido rings
• >80000 analysed points  
Fig. 2. Principle of the dderivation of the CW. 
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In corneal wavefront analysis, the type and size of any optical error on the anterior corneal 
surface are registered, thus allowing a very selective correction. The defects are corrected 
exactly at their origin – the anterior corneal surface. In this context, the precise localization 
of defects is crucial to successfully achieving optimal results in laser surgery. The corneal 
wavefront allows for a very precise diagnosis, thus providing an individual ablation of the 
cornea in order to obtain perfect results. 
Applying this treatment strategy, measurement does not require pupil dilation of the eye, so 
that the treatment zone is not limited by the pupil and accomodation does not influence the 
measuring results. Mention is made that in this way forcing a fixed asphericity quotient (Q) 
on the eyes through the treatment is avoided. Instead, this strategy employs a dynamic 



















where Qexp is the expected/predicted corneal asphericity quotient; R the apical radius of 
curvature of the preoperative cornea; SEqcp the spherical equivalent to be corrected at the 
corneal plane; and n the refractive index of the cornea. 
The expected quotient of asphericity does not incorporate any compensation for the effect of 
postop corneal biomechanics / healing response, and it is rather derived from a pure optical 
model of the cornea. 
Preoperative topography and corneal aberrometry measurements are taken, and visual 
acuity, and mesopic pupil size are measured. Each eye is planned according to the manifest 
refraction using the CAM wavefront customized treatments. Immediately before ablation, 
the laser is calibrated according to the manufacturer’s instructions and the calibration 
settings are recorded. 
When evaluating the outcomes of wavefront customization strategies, wavefront aberration 
analysis is mandatory to be able to determine whether the customization aims could be 
achieved. It has been suggested, as well, that the surface ablation procedures are better suited 
for the wavefront guided ablation as they would avoid the induction of aberrations due to flap 
and interface (Chun et al. 200615; Buzzonetti et al. 200416). Now with the introduction of thin 
and ultrathin planar flaps with femtosecond laser and the newer microkeratomes such as the 
pendular microkeratome, this aspect of the debate will require further research. 
Topography is measured under bright light conditions which might cause pupil constriction 
and also pupil center shift relative to normal photopic levels. Corneal wavefront customized 
treatments can only be successful, if the pre-existing aberrations are greater than the 
repeatability and the biological noise. Considerations such as treatment duration or tissue 
removal make it more difficult to establish a universal optimal profile. 
Furthermore, coupling effects between different high order aberration terms, and between 
HOAs and manifest refraction is still one of the major sources of residual aberrations after 
refractive surgery. This topic has been discussed from a theoretical perspective by Bará et al. 
2006 17 and from a clinical perspective by MacRae 200718 or Buehren et al. 200719. They all 
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found mutually affecting interactions, for example, between defocus and spherical 
aberration, or between 3 order aberrations and low order terms, between spherical 
aberration and coma, or between secondary and primary astigmatisms. 
The accuracy, predictability, and stability of the refractive power change, together with the 
minimal external impact of the CAM ablation profiles on the HOAs, leads to very good 
results in terms of visual quality. In summary, aspheric CW ablation profiles, designed with 
CAM software for the AMARIs laser platform, yield visual, optical, and refractive results 
comparable to those of other wavefront-guided customized techniques for correction of 
myopia and myopic astigmatism. The CW customized approach shows its strength in cases 
where abnormal optical systems are expected. Apart from the risk of minimal additional 
ablation of corneal tissue, systematical wavefront-customized corneal ablation can be 
considered as a safe and beneficial method. 
5. Decision Assistant Wizard 
Our definition of “Customisation” is conceptually different and can be stated as:  “The 
planning of the optimum ablation pattern specifically for each individual eye based on its 
diagnosis and visual demands.”  It is often the case, that the best approach for planning an 
ablation is a sophisticated pattern, which can still be simply described in terms of sphere, 
cylinder, and orientation (axis). The Decision Assistant Wizard, which we present here, is 
based on our experience with the SCHWIND AMARIS laser. While the general principles of 
this Decision-Tree based planning (Fig. 3) can basically be applied to any other laser 
platform offering aspheric and wavefront-guided profiles, some specific aspects concerning 
both diagnosis and treatments may depend on other manufacturers’ specifications.  
We begin by acquiring four corneal topographies (Corneal Wavefront Analyzer, SCHWIND 
eye-tech-solutions GmbH & Co.KG, based on Keratron-Scout, OPTIKON2000, Rome, Italy) 
and derived CW analyses centred on the line-of-sight for each eye of the patient. We extract 
the mean, and discard the less representative one (the one with the poorest similarity to the 
mean). From those remaining three maps, we calculate the mean, and select the most 
representative one (the one with the highest similarity to the mean). 
We continue acquiring, under non pharmacologically dilated pupils, non-cycloplegic 
conditions, and natural dim light conditions (to avoid pharmacologically induced pupil 
shifts20,21), 3 aberrometries (Ocular Wavefront Analyzer, SCHWIND eye-tech-solutions GmbH 
& Co.KG, based on irx3, Imagine Eyes, Orsay, France) and objective refractions for each eye of 
the patient. To minimize the potential accommodative response of the patients, we ask them to 
“see-through-the-target” instead of “looking at the target.”  In this way, patients do not try to 
get a sharp image from the +1.5 D fogged target, since they were instructed to see-through-the-
target. From those aberrometries, we calculate the mean, and select the most representative 
one (the aberrometry map with the highest similarity to the mean). 
We continue assessing subjective refraction based upon non-pharmacologic and non-
cycloplegic conditions, under natural photopic illumination. We use the objective refraction 
analyzed for a sub-pupil of 4 mm diameter, as starting refraction for this step. This is 
particularly useful for determining the magnitude and orientation of the astigmatism. We 
measure manifest refraction, uncorrected and best spectacle-corrected Snellen visual acuity22 
(UCVA and BSCVA, respectively). Further rules that we impose for accurately determining 
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the manifest subjective refractions among equal levels of BSCVA are:  taking the 
measurement with the least negative (the most positive) spherical equivalent (unmasking 
latent hyperopia), if several of them are equal in terms of spherical equivalent, we choose 
the measurement with the least amount of astigmatism (reducing the risk of postoperative 
shifts in the axis of astigmatism). This is particularly useful for determining the magnitude 
and orientation of the internal astigmatism as a difference between the topographic 
astigmatism and the astigmatism of the corneal wavefront analyses compared to the 
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Fig. 3. Decision-Tree applied for selecting the treatment mode (Aspheric aberration neutral, 
Corneal-Wavefront-Guided, or Ocular-Wavefront-Guided). 
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particularly useful for determining the magnitude and orientation of the astigmatism. We 
measure manifest refraction, uncorrected and best spectacle-corrected Snellen visual acuity22 
(UCVA and BSCVA, respectively). Further rules that we impose for accurately determining 
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the manifest subjective refractions among equal levels of BSCVA are:  taking the 
measurement with the least negative (the most positive) spherical equivalent (unmasking 
latent hyperopia), if several of them are equal in terms of spherical equivalent, we choose 
the measurement with the least amount of astigmatism (reducing the risk of postoperative 
shifts in the axis of astigmatism). This is particularly useful for determining the magnitude 
and orientation of the internal astigmatism as a difference between the topographic 
astigmatism and the astigmatism of the corneal wavefront analyses compared to the 





































close to get an 
IOL exchange



























Fig. 3. Decision-Tree applied for selecting the treatment mode (Aspheric aberration neutral, 
Corneal-Wavefront-Guided, or Ocular-Wavefront-Guided). 
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The decision process starts by estimating the global optical impairment resulting from the 
measured wave aberrations. This is done by objectively determining the actual clinical 
relevance of single terms in a Zernike expansion of the wave aberration. In general, for the 
same magnitude of aberration, the optical blur produced by high order aberrations increases 
with increasing radial order and decreases with increasing angular frequencies. Based on 
this, the dioptric equivalent (DEq) was used. 
If the global optical blur for both corneal and ocular wave-aberrations (CWAb and OWAb, 
respectively) are below 0.25 DEq for both eyes, then the treatment to be applied is Aspheric 
aberration neutral. If the global optical blur for any corneal or ocular wave-aberrations is 
between 0.25 DEq and 0.50 DEq for any eye, then we check the BSCVA achieved during the 
manifest refraction. If the BSCVA is better than 20/20 for both eyes, then we ask the patient 
about complaints regarding night vision or, in general, quality of vision. If the patient does 
not report complaints, then the treatment to be applied is Aspheric aberration neutral. 
If the patient reports complaints regarding quality of vision, the BSCVA is worse than 20/20 
for any eye, or the global optical blur for both corneal and ocular wave-aberrations are 
above 0.50 DEq for both eyes, then we compare corneal and ocular wave-aberrations. For 
this, we calculate the differential aberration (CWAb − OWAb, both centred at the line-of-
sight) in terms of the Zernike expansion, and estimate the global optical difference. If this 
global optical difference between corneal and ocular wave-aberrations is below 0.25 DEq for 
both eyes, we consider both corneal and ocular wave-aberrations as equivalent. In this case, 
the treatment to be applied depends on the available diameter of the wavefront maps and 
the scotopic pupil size. If the diameter of the Ocular- or Corneal-WAb map (the one 
providing the largest diameter) is at least as large as the scotopic pupil size (in natural dark 
conditions) reduced in 0.25 mm, then Ocular- or Corneal-Wavefront-guided ablation is 
performed (the one providing the largest diameter), or Aspheric aberration neutral 
otherwise. Usually the size of the Ocular WAb maps is similar to the size of the scotopic 
pupils, whereas Corneal WAb maps are wider (up to 10 mm in diameter). 
If the global optical difference between corneal and ocular wave-aberrations is above 0.25 DEq 
for any eye, we consider internal wave-aberration (IWAb) is relevant, then the treatment to be 
applied is Ocular-Wavefront-guided if the patient is neither in age nor in ophthalmic 
indications close to get an IOL exchange (due to e.g. lenticular opacities), otherwise no laser 
corneal refractive treatment is recommended (since IOL exchange is preferred). 
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If BSCVA > 20/20 
AND no complaints 
about quality or 
night vision 
If (BSCVA < 20/20 OR 
complaints about quality 
or night vision) AND 
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If no lenticular 
problems 
Table 1. Indications chart. 
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There are basically three types of approaches for planning a corneal refractive treatment. 
The first are those that have as their objective the elimination or reduction of the total 
aberrations of the eye. The main criticism to this approach argues that the goal “zero 
aberration” is inconsistent throughout the day due to accommodation, and little lasting, 
since aberrations change with age23,24,25. The second approach is intended to correct all 
corneal aberrations, since corneal aberrations do not change with age26,27. However, this 
concept might also be wrong considering corneal aberrations interact with internal 
aberrations, some of them being cancelled, and producing an aberration pattern of the total 
eye in general different from the aberration pattern of the cornea alone. Therefore, by only 
removing corneal aberration we might worsen the overall aberrations, since the internal 
aberration might not find a corneal aberration for compensation. In case that the corneal 
aberration is of the same sign as the internal aberration, the correction of the corneal 
aberration would be useful, as it would reduce the total aberration of the eye. A third 
approach tries not to induce aberrations. This type of treatment is not as ambitious, but 
much more simple to operate. The goal of the Aberration-FreeTM ablation profile is to 
provide a neutral high-order-aberrations (HOAb) ablation, ie to maintain the same HOAb 
profile both preoperatively with best spectacle correction and postoperatively without 
correction. 
There is evidence of neural adaptation to the baseline wavefront profile. The interaction 
between high-order-aberrations can be beneficial to visual quality regardless of the 
magnitude HOAb. Based on the random nature of the HOAb induction and current 
research, it may be beneficial to maintain the preoperative wavefront profile for a significant 
number of refractive surgery candidates. 
We are not postulating that customized ablation algorithms in any form (ocular-wavefront-
guided, corneal-wavefront-guided, topography-guided) are not be useful. Rather, that 
specific populations with specific demands deserve specific treatment solutions. Aspheric 
treatments aimed at preservation of the preoperative HOAb show their strengths in patients 
with preoperative BSCVA 20/20 or better or in patients where the visual degradation cannot 
be attributable to the presence of clinically relevant HOAb (e.g. lens opacities). 
The corneal wavefront customized approach shows its strength in cases where abnormal 
corneal surfaces are expected. Apart from the risk of additional ablation of corneal tissue, 
wavefront customized corneal ablation can be considered a safe and beneficial method. Our 
experience suggests that wavefront customized treatments can only be successful, if pre-
existing aberrations are greater than repeatability (e.g. repeatability of diagnostic28 and 
treatment devices) and biological noise (e.g. day-to-day variabilities in visual acuity, 
refraction, or aberration in the same subject). 
Furthermore, coupling effects between different high order aberration terms, and between 
HOAb and manifest refraction have been found29,30 for example, between defocus and 
spherical aberration, or between 3rd order aberrations and low order terms, between 
spherical aberration and coma, or between secondary and primary astigmatisms. These 
interactions may provide some relative visual benefits31, but may as well contribute as 
sources of uncertainty in the conversion of wavefront aberration maps to refractive 
prescriptions. Notice that for comparing OWAb and CWAb, the analysis of the IWAb as 
CWAb – OWAb is mandatory since RMS(IWAb) accounts for any deviation (i.e. inductions 
and reductions of the wave-aberration both contribute positively to increase the RMS value). 
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research, it may be beneficial to maintain the preoperative wavefront profile for a significant 
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and reductions of the wave-aberration both contribute positively to increase the RMS value). 
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The Decision Assistant Wizard presented here may theoretically be applied to any other 
laser platform offering aspheric, topography-guided, and wavefront-guided profiles, if 
appropriate analysis functions for CWAb, OWAb, and IWAb are available. Simplified 
versions with limited functionalities are also possible, if, for example, neither CW-analyses 
(i.e. no IWAb) nor topography-guided profiles are available. The desired outcome of non-
wavefront-driven refractive surgery is to balance the effects on the wave-aberration, and, to 
provide normal eyes with perhaps the most natural unaltered quality of vision. While 
Ocular Wavefront treatments have the advantage of being based on Objective Refraction of 
the complete human eye system, whereas Corneal Wavefront treatments have the 
advantage of being independent from accommodation effects or light/pupil conditions; 
Aspheric treatments have the advantage of saving tissue, time and due to their simplicity 
offer better predictability. 
In highly aberrated eyes, manifest refraction may become an art, a sort of guessing around 
the least blurred image. In further studies, systematic deviations from the measured 
manifest refractions, as well as other foreseeable couplings among Zernike coefficients will 
be evaluated. 
6. Minimization of depth and time in laser corneal refractive surgery 
In laser corneal refractive surgery, one always aims to reduce the ablated tissue thickness 
(and, to a minor degree, to reduce the intervention time) because an ectasia of the cornea 
may result from excessive tissue removal. Customized laser corneal refractive surgery on 
aberrated eyes may yield better results than the standard procedure18–21 but generally results 
in higher ablation depth, volume, and time. Therefore, optimizing the customized treatment 
to reduce the ablated thickness while retaining the positive aspects is pertinent.22 
The development of new algorithms or ablation strategies for performing laser corneal 
refractive surgery in a customized form, minimizing the amount of ablated tissue without 
compromising the visual quality, and potentially maximizing visual performance without 
increasing risk factors would be of great value for the refractive surgery community and 
ultimately for the health and safety of patients. The real impact of tissue-saving algorithms 
in customized treatments is controversial. Minimizing the amount of tissue must be done in 
a way that does not compromise the refractive correction or visual performance, and it must 
be safe, reliable, and reproducible. 
In general, for the same amount of equivalent defocus, the optical blur produced by HOAs 
increases with increasing radial order and decreases with increasing angular frequencies. 











  (2) 
where DEqmn  is the dioptric equivalent of the optical blur; n, the radial order of the 
considered Zernike term; m, the angular frequency of the considered Zernike term; δm0, the 
Kronecker delta function of the angular frequency and zero (1 for radially symmetric 
Zernike terms and 0 otherwise); mnC , the weight coefficient of the considered Zernike term; 
and PD, the analysis diameter for the optical blur. 
Treatment Strategies and Clinical  
Outcomes of Aspheric Surgery for Astigmatism Using the SCHWIND Amaris Platform 
 
227 
In such a way, the dioptric equivalent produced by HOAs increases with increasing radial 
order and partly decreases with increasing angular frequencies. This dioptric equivalent 
metric is identical to the power vector notation for the low orders and allows defining a 
general optical blur as a general expression for the one proposed by Thibos et al36: 
  2G DEqmnU    (3) 
where UG is the general optical blur. 
We have expressed each of the Zernike terms as a dioptric equivalent in familiar units to 
help judge the order of magnitude of the effect. Using common clinical limits, the following 
classification is proposed: 
 DEq 0.50 D might be clinically relevantmn    (4) 
 DEq 0.50 D clinically relevantmn    (5) 
This represents the proposed objective determination of the actual clinical relevance of the 
single terms in a Zernike expansion of the wavefront aberration.22 
6.1 Objective minimization of the maximum depth of a customized ablation based on 
the Zernike expansion of the wavefront aberration 
One of the minimization approaches consists of simplifying the profile by selecting a subset 
of Zernike terms that minimizes the necessary ablation depth while respecting the Zernike 
terms considered clinically relevant. The minimize depth (MD+) function analyzes the 
Zernike pyramid as described in the previous section and evaluates the ablation depth of all 
possible free combinations of subsets of Zernike terms while fulfilling several conditions: 
 Only terms of third or higher order can be disabled. 
 Only terms with optical blur dioptric equivalent less than 0.5 D can be disabled. 
 For each subset combination of Zernike terms, the low-order terms are recalculated 
using the automatic refraction balance method. 
From this evaluation, the function selects the subset of Zernike terms that needs the 
minimum amount of maximum depth. 
6.2 Objective minimization of the ablation volume of a customized ablation based on 
the Zernike expansion of the wavefront aberration 
The other minimization approach consists of simplifying the profile by selecting a subset of 
Zernike terms that minimizes the necessary ablation volume while respecting the Zernike 
terms considered clinically relevant. The minimize volume (MV+) function analyzes the 
Zernike pyramid as described in the previous section and evaluates the ablation depth of all 
possible free combinations of subsets of Zernike terms fulfilling several conditions: 
 Only terms of third or higher order can be disabled. 
 Only terms with optical blur dioptric equivalent less than 0.5 D can be disabled. 
 For each subset combination of Zernike terms, the low-order terms are recalculated 
using the automatic refraction balance method. 
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From this evaluation, the function selects the subset of Zernike terms that needs the 
minimum amount of volume for the ablation. Reduced ablation volumes lead to shorter 
treatment times. 
One could use the equivalent defocus applied to each individual Zernike mode to compute 
its clinical relevance. The basis of the equivalent defocus concept is the notion that the 
imaging quality of an eye is determined primarily by wavefront variance, and it does not 
matter which Zernike mode produces that variance. This is only true when the wavefront 
variance is really small and the image quality is measured by the Strehl ratio. Otherwise, the 
relationship between wavefront variance and image quality becomes much more complex. It 
is important to bear in mind that 1 D of ordinary defocus does not necessarily have the same 
effect as 1 D of equivalent defocus because different types of aberrations affect the retinal 
image in different ways. Nevertheless, by expressing RMS error in terms of equivalent 
defocus, the data are put into familiar units that help us judge the order of magnitude of the 
effect. 
Strictly speaking, one cannot consider the clinical relevance of every Zernike term 
independently without demonstrating whether a single Zernike term is alone responsible 
for the loss of visual quality. The visual effect of an aberration does not only depend on that 
specific aberration but also on other possibly present aberrations; for example, the sum of 
small aberrations, previously considered clinically irrelevant, could lead to a clear loss of 
overall optical quality. The idea of approximating a distorted wavefront by means of an 
equivalent dioptric error is much too controversial to be accepted without caution. 
Coupling effects between different HOA terms and between HOAs and manifest refraction 
have been found,44–46 for example, between defocus and spherical aberration, third-order 
aberrations and low-order terms, spherical aberration and coma, or secondary and primary 
astigmatisms. These interactions may provide some relative visual benefits47 but may also 
contribute uncertainty in the conversion of wavefront aberration maps to refractive 
prescriptions.48,49  One could use more sophisticated equations to model the equivalences 
between the optical blur produced by the different Zernike terms, but we have used a 
relatively simple approach driven primarily by the radial order. Different approaches for 
minimizing tissue ablation in refractive surgery have been proposed and extensively 
discussed.22 When to use customized strategies in refractive surgery has been discussed 
previously as well.18–21 
Considering that Zernike terms are either planned to be corrected or left uncorrected, visual 
performance is not compromised because all remaining uncorrected terms are below clinical 
relevance. The proposed approaches are safe, reliable, and reproducible because of the 
objective foundation upon which they are based. It is important to note that the selection of 
the Zernike terms to be included in the correction is not trivial. As mentioned, only Zernike 
terms considered not clinically relevant or of minor clinical relevance can be excluded from 
the correction, but they must not necessarily be excluded. 
Actually, single Zernike terms considered not clinically relevant will only be disabled when 
they represent additional tissue for ablation and will be enabled when they help to save 
tissue. This way, particular cases are represented by the full wavefront correction by 
disabling all nonclinically relevant terms or by disabling all high-order terms. As per design, 
the MD group actually optimizes for minimum ablation depth and shows the largest 
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savings for this aim (−8 ± 4 μm, from −20 to −1 μm), whereas the MV group actually 
optimizes for minimum ablation volume (time) and shows the largest savings for this aim 
(−8 ± 2 seconds, from -26 to -22 seconds). In this context, and as a rule of thumb, MD 
minimization could be used in customized myopic treatments when reducing ablation 
depth is directly related to decreasing the risk of keratectasia, whereas MV minimization 
could be used in long customized treatments when reducing ablation time is directly related 
to better maintenance of homogeneous corneal conditions.  
7. Surgical technique selection 
Excimer laser refractive surgery has evolved full circle. Surface ablations in the form of 
photorefractive keratectomy (PRK) swiftly evolved into intra-stromal procedure of laser in-
situ keratomileusis (LASIK) due to its rapid visual recovery and minimal postoperative 
discomfort. However, with increasing adoption of LASIK grew the concern for post-LASIK 
keratectasia. The last few years have therefore, witnessed a renewed interest in alcohol 
assisted surface ablation procedures to avoid complications of LASIK primarily corneal 
ectasia and flap and interface related problems. 
The decision to perform alcohol assisted LASEK or LASIK is based on preoperative central 
corneal thickness (measured by ultrasonic pachymetry (DGH-550 Pachette 2, DGH 
Technologies, USA)) and calculated depth of ablation. LASEK is performed on all patients 
with central pachymetry less than 500 µm. Eyes with central pachymetry above 500 µm are 
assigned to either LASEK or LASIK techniques, depending on the central pachymetry and 
the depth of ablation. The decision is based on the target of limiting the ablation to the 
anterior one third of the cornea (so as to achieve a residual stromal bed thickness of at least 
2/3rd of pre-operative pachymetry). Patients were tested for LASIK in case they do not meet 
the "2/3" condition they were assigned to the LASEK group. 
For corneal and conjunctival anesthesia, two drops of proparacaine HCl 0.5% (Aurocaine®, 
Aurolab, Madurai, India) are instilled three times before shifting the patient to the operation 
theatre (OT). 
LASIK - Pachymetry is performed before and after flap creation (stromal bed thickness) 
with both the integrated online coherence pachymeter (Heidelberg, Germany) and 
ultrasonic pachymeter. Flap is made using LDV femtosecond laser. Contact lens is applied 
at the end of surgery (Biomedics 55 evolution, Ocular Sciences, Cooper Vision, Hamble, UK) 
in eyes with ‘achieved’ flap thickness less than 110 microns to avoid flap displacements, 
dislocations or striae. 
LASEK - 17% alcohol applied for 30 seconds is used for the creation of epithelial flap. Eight 
or 9 mm diameter epithelial flap is made after incising the corneal epithelium with a 
trephine. Contact lens is applied at the end of surgery in all LASEK patients. 
Postoperative Treatment – For LASIK patients, eye drop Tobradex (Alcon Inc, USA) 3 times 
a day is used for 1 week along with Oasis soft plugs extended duration (6404 Glendora CA) 
and preservative free artificial tear drops during the first three months. A bandage contact 
lens is used during the first night in LASIK patients with flap thickness less than 110µm. For 
LASEK patients, prior to epithelial healing, eye drops lomefloxacin 0.3 % (Okacin) and 
pranoprofen (Ofralar, Alcon Inc, USA) are used along with Oasis soft plugs extended 
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From this evaluation, the function selects the subset of Zernike terms that needs the 
minimum amount of volume for the ablation. Reduced ablation volumes lead to shorter 
treatment times. 
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savings for this aim (−8 ± 4 μm, from −20 to −1 μm), whereas the MV group actually 
optimizes for minimum ablation volume (time) and shows the largest savings for this aim 
(−8 ± 2 seconds, from -26 to -22 seconds). In this context, and as a rule of thumb, MD 
minimization could be used in customized myopic treatments when reducing ablation 
depth is directly related to decreasing the risk of keratectasia, whereas MV minimization 
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with central pachymetry less than 500 µm. Eyes with central pachymetry above 500 µm are 
assigned to either LASEK or LASIK techniques, depending on the central pachymetry and 
the depth of ablation. The decision is based on the target of limiting the ablation to the 
anterior one third of the cornea (so as to achieve a residual stromal bed thickness of at least 
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For corneal and conjunctival anesthesia, two drops of proparacaine HCl 0.5% (Aurocaine®, 
Aurolab, Madurai, India) are instilled three times before shifting the patient to the operation 
theatre (OT). 
LASIK - Pachymetry is performed before and after flap creation (stromal bed thickness) 
with both the integrated online coherence pachymeter (Heidelberg, Germany) and 
ultrasonic pachymeter. Flap is made using LDV femtosecond laser. Contact lens is applied 
at the end of surgery (Biomedics 55 evolution, Ocular Sciences, Cooper Vision, Hamble, UK) 
in eyes with ‘achieved’ flap thickness less than 110 microns to avoid flap displacements, 
dislocations or striae. 
LASEK - 17% alcohol applied for 30 seconds is used for the creation of epithelial flap. Eight 
or 9 mm diameter epithelial flap is made after incising the corneal epithelium with a 
trephine. Contact lens is applied at the end of surgery in all LASEK patients. 
Postoperative Treatment – For LASIK patients, eye drop Tobradex (Alcon Inc, USA) 3 times 
a day is used for 1 week along with Oasis soft plugs extended duration (6404 Glendora CA) 
and preservative free artificial tear drops during the first three months. A bandage contact 
lens is used during the first night in LASIK patients with flap thickness less than 110µm. For 
LASEK patients, prior to epithelial healing, eye drops lomefloxacin 0.3 % (Okacin) and 
pranoprofen (Ofralar, Alcon Inc, USA) are used along with Oasis soft plugs extended 
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duration. Bandage contact lens is applied in all LASEK patients for 5-7 days until complete 
healing of the epithelial defect. After epithelial healing, preservative free artificial tear eye 
drops are given along with efemoline eye drops (Fluoromethalone, Novartis Ophthalmics, 
Switzerland) 3 times a day for 3 months. The steroids are gradually tapered every month to 
once a day in the last month. 
Postoperative follow-up – LASIK patients are followed on first postoperative day, at 1 
month, 3 months, and 1 year. LASEK patients are examined on first postoperative day, at 1 
week, 1 month, 3 months, and 1 year. 
There has been a renewed interest in surface ablation modalities with epithelial 
repositioning like LASEK to overcome some of the flap and ectasia related complications of 
LASIK. Though the rate of visual recovery may be slower in surface ablation thus lacking 
the LASIK ‘wow’ effect, studies have shown that LASEK is an effective modality for surgical 
correction of low to moderate myopia.8-10 However, its utility for correction of high myopia 
is limited.11-13 With introduction of thin and ultrathin flaps using femtosecond laser and 
newer microkeratomes such as the pendular microkeratome, the indications for the 2 
surgical modalities are getting indistinct. Introduction of newer ablation profiles such as 
customized and aspheric ablations has added another aspect to be evaluated. 
It has been suggested that surface ablative procedures may be better suited for customized 
correction though it has not been proven clinically.1,2,14 It has been suggested that the 
creation of corneal flap in LASIK patients can induce further higher order aberrations 
especially coma like aberrations.15 This may be particularly relevant to thinner flaps which 
may have a higher incidence of flap striae. The clinical relevance of these flap induced 
higher order aberrations especially in relation to newer microkeratomes and femtosecond 
laser and the effect of flap thickness require further investigation. 
The aspheric ablation profile is equally successful with both surface ablation as well as 
intrastromal excimer ablation minimizing the change in higher order aberrations. The latest 
development in excimer laser refractive is the thin and the ultrathin flap LASIK. It attempts 
to find the best of both worlds of standard LASIK and surface ablation. Besides pre-existing 
risk factors, low residual stromal bed thickness is the single most important modifiable 
factor that increases the risk of iatrogenic post-LASIK ectasia.38 Thin and ultrathin flap 
LASIK achieves a thicker residual stromal bed and therefore is believed to decrease the risk 
of post-LASIK ectasia. Current study indicates that thin and ultrathin LASIK is safe, 
efficacious, and predictable after short term follow up of 6 months. However, future 
investigations with long-term follow-up are likely to prove if LASIK utilizing thin and 
ultrathin flaps translate into the anticipated decreased risk of post-LASIK ectasia. 
8. 6D Eye-Tracker 
Human eyes have six degrees of freedom to move: X/Y lateral shifts, Z levelling, 
horizontal/vertical rotations, and cyclotorsion (rotations around the optical axis). The 
analysis of these movements has been made since the middle of the 20th century. 
Schwiegerling and Snyder32 measured eye motion in patients having laser in situ 
keratomileusis (LASIK) using a video technique and determine centration and variance of 
the eye position during surgery. They found a standard deviation in the eye movements in 
all eyes larger than 100 µm. Taylor et al.33 determined the accuracy of an eye tracking system 
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designed for laser refractive surgery. The system demonstrated an accuracy of 60 µm for an 
intact cornea and 100 µm for a cornea with a thin flap removed. 
Bueeler et al.34 investigated the lateral alignment accuracy needed in wavefront-guided 
refractive surgery to improve the ocular optics to a desired level in a percentage of normally 
aberrated eyes. To achieve the diffraction limit in 95% of the normal eyes with a 7.0 mm 
pupil, a lateral alignment accuracy of 70 µm or better was required. An accuracy of 200 µm 
was sufficient to reach the same goal with a 3.0 mm pupil. Bueeler and Mrochen35 quantified 
the parallax error associated with localizing corneal positions by tracking the subjacent 
entrance pupil center by means of optical ray-tracing in a schematic model eye. They found 
tracking error can amount to 30% (or more for eye trackers mounted closer than 500 mm to 
the eye) of the detected lateral shift. Thus, if the eye tracker registers a lateral shift of the 
entrance pupil of 200 µm away from the tracking reference axis, the point of interest located 
on the cornea would essentially be 260 µm away from this reference axis. A laser pulse fired 
at that moment would be systematically displaced by 60 µm. 
Measuring rotation when the patient is upright36 to when the refractive treatments are 
performed with the patient supine may lead to ocular cyclotorsion,37,38 resulting in 
mismatching of the applied versus the intended profiles39,40. Recently, some equipment can 
facilitate measurement of and potential compensation for static cyclotorsion occurring when 
the patient moves from upright to the supine position during the procedure41, quantifying 
the cyclorotation occurring between wavefront measurement and laser refractive surgery42 
and compensating for it43,44,45. Further measuring and compensating ocular cyclotorsion 
during refractive treatments with the patient supine may reduce optical “noise” of the 
applied versus the intended profiles46,47,48. 
In recent times, many studies have discussed the methodologies and implications of ocular 
cyclotorsion, but not many papers pay attention to the rolling and axial movements of the 
eye. The more irregular a cornea is, the more important proper eye-tracking. Astigmatism is 
the most common aberration with a vector nature, so usually are the astigmatic problems 
the ones more affected or the ones which benefit the most from advanced eye tracking. 
8.1 Lateral movements during ablation (1st and 2nd dimension) 
AMARIS system includes a pupil-registration module for the eye-tracker subsystem, in 
which, the first pupil image under the AMARIS system obtained with starting the ablation is 
taken as reference and its location referred to the limbus is used for any further eye-tracker 
image in order to determine the pupil centre shift compensation (PCSC). 
8.2 Eye rolling during ablation (3rd and 4th dimension) 
AMARIS system includes a scleral-registration module for the eye-tracker subsystem, in 
which, the first few scleral-tracker images under the AMARIS system obtained with starting 
the ablation are taken as reference (natural rolling) and compared to any further scleral-
tracker image in order to determine the eye rolling (ER). 
8.3 Static cyclotorsion between upright and supine positions (5th dimension) 
AMARIS system includes an eye-registration module for the eye-tracker subsystem, in 
which, the diagnosis image is taken as reference and compared to an eye-tracker image 
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duration. Bandage contact lens is applied in all LASEK patients for 5-7 days until complete 
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Switzerland) 3 times a day for 3 months. The steroids are gradually tapered every month to 
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is limited.11-13 With introduction of thin and ultrathin flaps using femtosecond laser and 
newer microkeratomes such as the pendular microkeratome, the indications for the 2 
surgical modalities are getting indistinct. Introduction of newer ablation profiles such as 
customized and aspheric ablations has added another aspect to be evaluated. 
It has been suggested that surface ablative procedures may be better suited for customized 
correction though it has not been proven clinically.1,2,14 It has been suggested that the 
creation of corneal flap in LASIK patients can induce further higher order aberrations 
especially coma like aberrations.15 This may be particularly relevant to thinner flaps which 
may have a higher incidence of flap striae. The clinical relevance of these flap induced 
higher order aberrations especially in relation to newer microkeratomes and femtosecond 
laser and the effect of flap thickness require further investigation. 
The aspheric ablation profile is equally successful with both surface ablation as well as 
intrastromal excimer ablation minimizing the change in higher order aberrations. The latest 
development in excimer laser refractive is the thin and the ultrathin flap LASIK. It attempts 
to find the best of both worlds of standard LASIK and surface ablation. Besides pre-existing 
risk factors, low residual stromal bed thickness is the single most important modifiable 
factor that increases the risk of iatrogenic post-LASIK ectasia.38 Thin and ultrathin flap 
LASIK achieves a thicker residual stromal bed and therefore is believed to decrease the risk 
of post-LASIK ectasia. Current study indicates that thin and ultrathin LASIK is safe, 
efficacious, and predictable after short term follow up of 6 months. However, future 
investigations with long-term follow-up are likely to prove if LASIK utilizing thin and 
ultrathin flaps translate into the anticipated decreased risk of post-LASIK ectasia. 
8. 6D Eye-Tracker 
Human eyes have six degrees of freedom to move: X/Y lateral shifts, Z levelling, 
horizontal/vertical rotations, and cyclotorsion (rotations around the optical axis). The 
analysis of these movements has been made since the middle of the 20th century. 
Schwiegerling and Snyder32 measured eye motion in patients having laser in situ 
keratomileusis (LASIK) using a video technique and determine centration and variance of 
the eye position during surgery. They found a standard deviation in the eye movements in 
all eyes larger than 100 µm. Taylor et al.33 determined the accuracy of an eye tracking system 
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designed for laser refractive surgery. The system demonstrated an accuracy of 60 µm for an 
intact cornea and 100 µm for a cornea with a thin flap removed. 
Bueeler et al.34 investigated the lateral alignment accuracy needed in wavefront-guided 
refractive surgery to improve the ocular optics to a desired level in a percentage of normally 
aberrated eyes. To achieve the diffraction limit in 95% of the normal eyes with a 7.0 mm 
pupil, a lateral alignment accuracy of 70 µm or better was required. An accuracy of 200 µm 
was sufficient to reach the same goal with a 3.0 mm pupil. Bueeler and Mrochen35 quantified 
the parallax error associated with localizing corneal positions by tracking the subjacent 
entrance pupil center by means of optical ray-tracing in a schematic model eye. They found 
tracking error can amount to 30% (or more for eye trackers mounted closer than 500 mm to 
the eye) of the detected lateral shift. Thus, if the eye tracker registers a lateral shift of the 
entrance pupil of 200 µm away from the tracking reference axis, the point of interest located 
on the cornea would essentially be 260 µm away from this reference axis. A laser pulse fired 
at that moment would be systematically displaced by 60 µm. 
Measuring rotation when the patient is upright36 to when the refractive treatments are 
performed with the patient supine may lead to ocular cyclotorsion,37,38 resulting in 
mismatching of the applied versus the intended profiles39,40. Recently, some equipment can 
facilitate measurement of and potential compensation for static cyclotorsion occurring when 
the patient moves from upright to the supine position during the procedure41, quantifying 
the cyclorotation occurring between wavefront measurement and laser refractive surgery42 
and compensating for it43,44,45. Further measuring and compensating ocular cyclotorsion 
during refractive treatments with the patient supine may reduce optical “noise” of the 
applied versus the intended profiles46,47,48. 
In recent times, many studies have discussed the methodologies and implications of ocular 
cyclotorsion, but not many papers pay attention to the rolling and axial movements of the 
eye. The more irregular a cornea is, the more important proper eye-tracking. Astigmatism is 
the most common aberration with a vector nature, so usually are the astigmatic problems 
the ones more affected or the ones which benefit the most from advanced eye tracking. 
8.1 Lateral movements during ablation (1st and 2nd dimension) 
AMARIS system includes a pupil-registration module for the eye-tracker subsystem, in 
which, the first pupil image under the AMARIS system obtained with starting the ablation is 
taken as reference and its location referred to the limbus is used for any further eye-tracker 
image in order to determine the pupil centre shift compensation (PCSC). 
8.2 Eye rolling during ablation (3rd and 4th dimension) 
AMARIS system includes a scleral-registration module for the eye-tracker subsystem, in 
which, the first few scleral-tracker images under the AMARIS system obtained with starting 
the ablation are taken as reference (natural rolling) and compared to any further scleral-
tracker image in order to determine the eye rolling (ER). 
8.3 Static cyclotorsion between upright and supine positions (5th dimension) 
AMARIS system includes an eye-registration module for the eye-tracker subsystem, in 
which, the diagnosis image is taken as reference and compared to an eye-tracker image 
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under the AMARIS system obtained prior to starting the ablation in order to determine the 
static cyclotorsion component (SCC). 
8.4 Dynamic cyclotorsion during ablation (5th dimension) 
AMARIS system includes an eye-registration module for the eye-tracker subsystem, in 
which, the first eye-tracker image under the AMARIS system obtained with starting the 
ablation is taken as reference and compared to any further eye-tracker image in order to 
determine the dynamic cyclotorsion component (DCC). 
8.5 Axial displacements during ablation (6th dimension) 
AMARIS system includes an scleral-registration module for the eye-tracker subsystem, in 
which, the first few scleral-tracker images under the AMARIS system obtained with starting 
the ablation are taken as reference (natural level) and compared to any further scleral-
tracker image in order to determine the axial displacements (AD). 
 
Fig. 4. Lateral movements (vertical and horizontal displacements) 1st and 2nd dimensions, 
Rolling movements – caused by a tilting of the head or of the eye 3rd and 4th dimensions, 
Rotations around the visual axis - This happens mostly when changing from upright to 
supine position, but also during the treatment 5th dimension, cyclotorsion, Movements 
along the z-axis 6th dimension. All dimensions measured and compensated for static and 
dynamic movements in an active/passive manner. 
The AMARIS TotalTech laser includes compensation for the ocular cyclotorsions occurring 
from upright to supine position (static cyclotorsion from diagnosis to treatment), as well as 
the lateral movements, eye rollings, dynamic cyclotorsions, and displacements along the 
propagation axis occurring during the laser treatment. Further, the differences in pupil size 
and centre for and during the treatment compared to that during diagnosis49 are also 
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compensated for, since the theoretical impact of cyclotorted ablations is smaller than 
decentred ablations or edge effects50 (coma and spherical aberration51). In this way, 
additional lateral displacements52 due to cyclotorsions occurring around any position other 
than the ablation centre are avoided (induced aberrations emanating from lateral 
displacements always increase with decentration53). 
A six dimensional eye-tracker is important since uncompensated pupil movements (lateral 
movements) induce decentrations32 which can be visually manifested as comatic 
aberrations52. Uncompensated rolling movements induce decentrations as well35, which can 
be visually manifested as comatic aberrations52. Uncompensated cyclotorsional movements 
induce aberrations40, whereas uncompensated axial movements induce undercorrections in 
an asymmetrical way. Axial movements produce that the laser spots are no longer in focus 
when they reach the cornea, i.e. ignoring absorption processes in air, for the same energy 
spot diameter is larger reducing the radiant exposure and the ablation depth of the spot. 
Axial movements produce as well that off axis pulses hit the cornea more centrally than 
planned if the eye moves towards the laser system and further peripherally if the eyes 






Fig. 5. A six dimensional eye-tracker is important since uncompensated pupil movements 
(lateral movements) induce decentrations which can be visually manifested as comatic 
aberrations. Uncompensated rolling movements induce decentrations as well, which can be 
visually manifested as comatic aberrations. 
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Fig. 5. A six dimensional eye-tracker is important since uncompensated pupil movements 
(lateral movements) induce decentrations which can be visually manifested as comatic 
aberrations. Uncompensated rolling movements induce decentrations as well, which can be 
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Fig. 6. A six dimensional eye-tracker is important since uncompensated cyclotorsional 
movements induce aberrations, whereas uncompensated axial movements induce 
undercorrections in an asymmetrical way. Axial movements produce that the laser spots are 
no longer in focus when they reach the cornea, i.e. ignoring absorption processes in air, for 
the same energy spot diameter is larger reducing the radiant exposure and the ablation 
depth of the spot. Axial movements produce as well that off axis pulses hit the cornea more 
centrally than planned if the eye moves towards the laser system and further peripherally if 
the eyes moves far from the laser. 
 
Fig. 7. Static cyclotorsion compensation. 
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Fig. 8. Rolling compensation. 
 
 
Fig. 9. Axial movements compensation. 
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In our experience with AMARIS system measuring the pupil displacements, we obtained an 
average of 150 µm. The distribution of the percentage of eyes vs. pupil displacement showed 
3% of eyes had pupil displacements exceeding 1 mm. The ranges for pupil displacements 
over the treatment are relatively mild, but with peaks of up to about 1.5 mm. 
With our system for measuring the rolling movements, we obtained an average value 5°. 
This value is actually the most commonly accepted value for “natural rolling” measured 
as angle alpha54, lambda55, or kappa56. The distribution of the percentage of eyes vs. 
rolling movements showes 3% of eyes had rolling exceeding 8 deg. The ranges for the 
rolling movements over the treatment are relatively mild, but with peaks of up to about 
10 deg. 
With our system for measuring the static cyclotorsional error, we obtained an average 
cyclotorsion of 1°, lower than the observations of Ciccio et al.,57 who reported 4°. The 
distribution of the percentage of eyes vs. cyclotorsional error shows 3% of eyes had 
cyclotorsion exceeding 8 deg. The mean DCC values over the treatment are relatively small, 
but with peaks of up to about 5 deg. Considering that the average cyclotorsion resulting 
from the shift from the upright to the supine position is about ±4 deg,57 it is not enough to 
compensate only for the static cyclotorsion without considering the dynamic cyclotorsion 
during the laser procedure. Finally, the effects of the DCC can be considered as optical 
“noise” of the applied versus the intended profiles.58 
Without eye registration technologies,59,60 considering that maximum cyclotorsion measured 
from the shift from the upright to the supine position does not exceed ±14 deg,57 explains 
why “classical” spherocylindrical corrections in refractive surgery succeed without major 
cyclotorsional considerations. However, only limited amounts of astigmatism can effectively 
be corrected for this cyclotorsional error40. Currently available eye registration technologies, 
providing an accuracy of about 1 deg and measuring static and dynamic cyclotorsion 
components, open a new era in corneal laser refractive surgery, because patients may be 
treated for a wider range of refractive problems with enhanced success ratios. This requires 
high-resolution ablation systems as well.61,62  
With our system for measuring the axial movements, we obtained an average of -300 µm. 
This negative value is fairly low, but means the patients use to push their head back at the 
beginning of the treatment and return smoothly closer to level during treatment. The 
distribution of the percentage of eyes vs. axial movement shows 10% of eyes had axial 
movements exceeding 1 mm. The ranges for axial movements over the treatment are 
relatively mild, but with peaks exceeding 1 mm. 
In our AMARIS experience of over 8000 treated eyes, 91% of treatments result in a 
postoperative cylinder within 0.5 D, and 19% of treatments gain lines of BSCVA compared 
to the preoperative baseline. From the minor induction of aberrations can be inferred that 
mesopic and low-contrast VA have maintained, at least, the best-corrected preoperative 
levels. More clinical data are required before we can state how much improvement can be 
expected from the use of this technology. 
6D Eye-Tracker with AMARIS yields excellent outcomes. Refractions are reduced to 
subclinical values: (mean postoperative defocus -0.12±0.17D and astigmatism 0.15±0.25D) 
with 70% eyes within ±0.25D of emmetropia and 19% eyes gain lines of BSCVA. Rate of 
registration is >90% for Cyclotorsion and >80% for Rolling and Axial movements. Mean 
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Rolling was within ±5° in 52% of the cases, Dynamic Rolling was within ±5° in 66% of the 
cases, Static Cyclotorsion was within ±4° in 69% of the cases, Dynamic Cyclotorsion was 
within ±2° in 72% of the cases, and Z-movement was within ±0.5mm in 69% of the cases. 
6D Eye-Tracker Controls with the SCHWIND AMARIS are safe and very predictable. In 
summary, using SCHWIND AMARIS, six-dimensional movements of the eye can be 
effectively measured and compensated for both static and dynamic conditions during laser 
corneal ablation. 
9. High speed refractive surgery 
The range of repetition rates of the laser systems for refractive surgery currently available in 
the market runs from about 10 Hz to about 1000 Hz (median 250 Hz), with spot size 
diameters ranging from 6.5 mm to about 0.3 mm (median 1 mm), corresponding to 
treatment velocities from about 9 s/D to about 1.7 s/D (mean 5 s/D). If we compare these 
values to the situation at the beginning of the 21st century, a technological quantum leap is 
observed. In 2001, repetition rates of the laser systems for refractive surgery in the market 
ranged from about 10 Hz to about 300 Hz (median 50 Hz), with spot size diameters ranging 
from 6.5 mm to about 0.8 mm (median 2-6 mm), corresponding to treatment velocities from 
about 19 s/D to about 6 s/D (mean 12 s/D). 
To foresee the future trends for these essential values when defining the technological 
capabilities of a system, four driving forces shall be considered: 
 The technological progress of the last 10 years indicating an exponential improvement 
of the technology 
 The non-linear cost-to-benefit ratio for new developments indicating a continued 
improvement of the technology at a slower rate 
 The actual clinical needs for faster or more precise systems indicating a slow-down 
improvement of the technology achieving maturity and stability 
 The limitations imposed by the biological tissue response to the laser interaction (e.g. 
thermal issues, haze development63) 
Considering these effects, we can hypothesize a scenario with repetition rates of the laser 
systems for refractive surgery ranging from about 300 Hz to about 1500 Hz, with spot size 
diameters ranging from 1.5 mm to about 0.2 mm, corresponding to treatment velocities from 
about 4 s/D to about 1.3 s/D. 
However, due to the presence of local frequency controls, the duration of the treatments is 
no longer inversely proportional to the repetition rate. The duration of the treatments is 
inversely proportional to the repetition rate only for slow repetition rates (<180 Hz), and 
stabilizes asymptotically for high repetition rates (>1500 Hz). 
10. Bilateral symmetry 
Human vision is a binocular process. Having two eyes gives binocular summation in which 
the ability to detect faint objects is enhanced. It can give stereopsis in which parallax 
provided by the two eyes' different positions on the head give precise depth perception. 
Such binocular vision is usually accompanied by binocular fusion, in which a single image is 
seen despite each eye is having its own image of any object. 
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In our experience with AMARIS system measuring the pupil displacements, we obtained an 
average of 150 µm. The distribution of the percentage of eyes vs. pupil displacement showed 
3% of eyes had pupil displacements exceeding 1 mm. The ranges for pupil displacements 
over the treatment are relatively mild, but with peaks of up to about 1.5 mm. 
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This value is actually the most commonly accepted value for “natural rolling” measured 
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rolling movements over the treatment are relatively mild, but with peaks of up to about 
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“noise” of the applied versus the intended profiles.58 
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seen despite each eye is having its own image of any object. 
 
Advances in Ophthalmology 
 
238 
Literature suggests that marked anisometropia is uncommon, either in the magnitude of 
sphere or astigmatism, with few notable exceptions concluding that the axis of 
astigmatism does not follow any particular rule (mirror or direct symmetry) across right 
and left eyes. 
Porter et al.64 confirmed in a large population that although the pattern of aberrations varies 
from subject to subject, aberrations, including irregular ones, are correlated in left and right 
eyes of the same subject, indicating that they are not random defects. The Indiana 
Aberration Study by Thibos et al. characterized the aberration structure, and the effects of 
these aberrations on vision, for a reasonably large population of normal, healthy eyes in 
young adults, and verified the hypothesis of bilateral symmetry. 
Wang et al.65 found that anterior corneal wave aberrations varied greatly among subjects, 
but a moderate to high degree of mirror symmetry existed between right and left eyes.  
To our knowledge, very few studies in the literature have addressed the issue of 
symmetry of aberrations between eyes after corneal laser refractive surgery66,67. Jiménez et 
al.66 found that binocular function deteriorates more than monocular function  
after LASIK, and that this deterioration increases as the interocular differences in 
aberrations and corneal shape increase. They found that interocular differences above 0.4 
µm RMS for 5-mm analysis diameter, lead to a decrease of more than 20% in binocular 
summation. 
If binocular symmetry is manifested on virgin human eyes and it is important for 
binocular vision, it shall be interesting to assess whether existing symmetry is maintained 
after treating the cornea for correcting the ametropias using corneal laser refractive 
surgery. Further analysis of bilateral symmetry according to analysis diameter is also of 
interest. The analysis of bilateral symmetry should be related to binocular vision status of 
patients. 
Cuesta et al.68 found that even differences in corneal asphericity might affect the binocular 
visual function by diminishing the binocular contrast-sensitivity function. Arbelaez et al.67 
found that only four of 25 patients showed preoperatively clinically relevant differences 
OS vs. OD larger than 0.25 D, whereas 6-month postoperatively only 2 of 25 patients 
showed clinically relevant differences OS vs. OD larger than 0.25 D. 6-month 
postoperatively three Zernike terms lost significant correlation symmetry OS vs. OD and 4 
Zernike terms gained significant correlation symmetry. However, two of them showed 
borderline correlations. 6-month postoperatively 6 Zernike terms significantly increased 
differences in symmetry OS vs. OD and 4 Zernike terms significantly decreased 
differences in symmetry. However, six of them showed borderline significances of the 
difference. 6-month postoperatively three patients lost significant correlation symmetry 
OS vs. OD and one patient gained significant correlation symmetry. However, two of 
them showed borderline significances of the difference. All these borderline situations 
actually shall be seen as “almost preserved” bilateral symmetry. 
The presented results cannot be extrapolated to patients with symptoms of amblyopia69, 
anisometropia, nystagmus, or aniseikonia70 without further studies. Bilateral symmetry in 
corneal aberrations does not mean any "good or bad" point for binocular vision. We cannot 
evaluate exactly the role of aberrations monocularly (patients with high level of aberrations 
can have an excellent visual acuity and vice-versa); therefore it is more difficult binocularly. 
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The important question in binocular vision is “the role of interocular-differences,” and if 
they can influence significantly binocular performance. Interocular-differences can be minor 
but significant for visual performance. Further studies shall help to determine the impact of 
this on binocular visual performance. 
The more irregular a cornea is, the more important proper bilateral symmetry for adequate 
binocular summation. Astigmatism is the most common aberration with a vector nature, so 
usually are the astigmatic problems the ones more affected or the ones which benefit the 
most from losing or preserving bilateral symmetry. 
11. Correction of high astigmatism 
Because the corneal ablations for refractive surgery treatments induce aberrations (one of 
the most significant side-effects in myopic LASIK is the induction of spherical aberration71, 
which causes halos and reduced contrast sensitivity72), special ablation patterns were 
designed to preserve the preoperative level of high order aberrations73,74,75. For the 
correction of astigmatism many different approaches have been tested, with different 
degrees of success, through the years76,77,78,79,80,81. 
LASIK has been successfully used for low to moderate myopic astigmatism, whether 
LASIK is acceptably efficacious, predictable, and safe in correcting higher myopic 
astigmatism is less documented, specially with regard to the effects of astigmatic 
corrections in HOA’s82. 
The advantage of the Aberration-FreeTM ablation profile is that aims being neutral for HOA, 
leaving the visual print of the patient as it was preoperatively with the best spectacle 
correction. The correction of astigmatism has been approached using several techniques and 
ablation profiles. There are several reports showing good results for compound myopic 
astigmatism using photorefractive keratectomy (PRK) and LASIK, but ablation profiles 
usually cause a hyperopic shift because of a coupling effect in the flattest corneal meridian. 
A likely mechanism of this coupling effect is probably due to epithelial remodeling and 
other effects such as smoothing by the LASIK flap83. In cases of large amounts of 
preoperative astigmatism, deviations from the target refractive outcome are usually 
attribute to “coupling factors”. But, the investigation of the coupling factor remains a rather 
difficult task, because it seems to be dependent on various factors. Individual Excimer laser 
systems may have different coupling factors, cutting the flap could alter the initial 
prescription and also different preoperative corneal curvature (K-reading) may have an 
influence on the coupling factor. 
The most dominant correlations of induced HOAb occurr for C[4,0], and C[6,0] versus 
defocus correction, for C[4,+2] versus cardinal astigmatism correction, and C[4,-2] versus 
oblique astigmatism correction. We evaluated the postoperative clinical outcomes and high 
order aberrations among eyes with astigmatism higher than 2 D that have underwent 
refractive surgery using the SCHWIND AMARIS laser system. SCHWIND CAM 
Aberration-Free Aspheric astigmatic treatments have been performed in all cases. 
At six-month follow-up, 50 eyes with preoperative astigmatism higher than 2 D were 
retrospectively analysed. Ablations performed using the SCHWIND AMARIS flying-spot 
excimer laser system. LASIK flaps were created using Ziemer LDV Femtosecond laser 
system in all cases. 
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Inclusion criteria comprised: 
-  preoperative astigmatism higher than 2 D targeted for emmetropia 
-  BSCVA ≥ 20/25 (logMAR ≤ +0.1) 
-  <0.75 µm RMS-HO for 6-mm diameter 
-  successful completion of 6-month follow-up 
We performed following analyses: 
-  UCVA 
-  BSCVA 
-  manifest subjective refraction (SR) 
-  corneal wavefront up to 7th order at 6-mm diameter without cycloplegia 
50 eyes (100%) completed the 6M follow-up, with an average age at the time of the surgery 
of 28 years (from 17 to 46). 28 eyes were female, and 22 eyes male. 25 patients treated 
bilaterally. Mean preoperative defocus averaged -3.08 D ± 2.32 D (from -7.13 to -1.00), with 
mean astigmatism 3.54 D ± 0.85 D (from 2.00 to 4.75). Mean postoperative defocus averaged 
-0.06 D ± 0.25 D (from -0.75 to +0.75), with mean astigmatism 0.25 D ± 0.26 D (from 0.00 to 
1.25). 92% of the eyes ended up in UCVA 20/20 or better. 38% of the eyes gained at least one 
line of BSCVA (p<.01*). >75% of the eyes within 0.50 D of astigmatism and U-vector, and 








































Fig. 10. Efficacy of the correction of moderate to high astigmatism in an aspheric astigmatic 
setting. 
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Fig. 12. Refractive astigmatic outcome of the correction of moderate to high astigmatism in 
an aspheric astigmatic setting. 
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Fig. 12. Refractive astigmatic outcome of the correction of moderate to high astigmatism in 
an aspheric astigmatic setting. 
 






























Fig. 13. Residual blur of the correction of moderate to high astigmatism in an aspheric 
astigmatic setting. 
A very slight undercorrection in astigmatism was observed (both cardinal and oblique). 
Only 5 HO Zernike terms (out of 30) changed significantly after treatment, whereas 25 HO 
Zernike terms (out of 30) did not change after treatment. 
 
Zernike term 





C[3,-3] -0.14 -0.02 <.0001 
C[4,+2] -0.08 -0.10 <.05 
C[4,+4] +0.03 +0.01 <.05 
C[5,-3] +0.01 -0.01 <.0001 
C[6,0] 0.00 +0.03 <.0001 
HO-RMS +0.47 +0.57 <.0005 
Table 2. Statistically induced Zernike terms. 
For all of them, the variation was well below the clinical relevance. 
50 high-astigmatism treatments were analysed at 6M follow-up. Results were achieved 
without applying additional nomograms (residual sphere about 0 D, residual cyl about -0.25 
D) (>75% within 0.50 D, >90% within 1.0 D). 6-months follow-up time shows the excellent 
performance of the system (48% eyes 20/16 or better UCVA, 98% eyes 20/25 or better 
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UCVA). Aberration-Free astigmatic treatments with SCHWIND AMARIS are safe and very 
predictable (no eye lost >1 line BSCVA, 5 eyes gained >=2 lines BSCVA). 
Scatter: Attempted vs. Achieved Astigmatism      50 eyes








0 1 2 3 4 5





Scatter: Attempted vs. Achieved Cardinal Astigmatism      50 eyes
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Scatter: Attempted vs. Achieved Oblique Astigmatism      50 eyes













-5 -4 -3 -2 -1 0 1 2 3 4 5







Fig. 14. Scattergram of the correction of moderate to high astigmatism in an aspheric 
astigmatic setting. 
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Scatter: Attempted vs. Achieved Astigmatism      50 eyes
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Scatter: Attempted vs. Achieved Oblique Astigmatism      50 eyes
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Fig. 14. Scattergram of the correction of moderate to high astigmatism in an aspheric 
astigmatic setting. 
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From VA, 92% eyes UCVA 20/20 or better and 38% eyes improved their pre-op BSCVA, due 
to the minimum aberrations induction by the AMARIS-CAM profile. Despite large defocus 
and astigmatism magnitudes, minor significant induction of some aberration terms, well 
below clinically relevant magnitudes. The most dominant correlations of induced HOAb 
occurred for: C[4,0] vs. Defocus correction, C[4,+2] vs. Cardinal Astigmatism correction, and 
C[4,-2] vs. Oblique Astigmatism correction. 
Induced aberrations at 6-mm analysis diameter vs. refractive corrections
y = -0,03x - 0,12
R2 = 0,17
y = -0,04x + 0,01
R2 = 0,46





























Fig. 15. Induction of aberrations after the correction of moderate to high astigmatism in an 
aspheric astigmatic setting. 
All ablations were non-wavefront-guided treatments. Despite low aberrations, some 
astigmatisms were not regular. Treatments were centred at the corneal vertex. Despite 
myopic corrections, 40% of the treatments needed an offset >150 µm. 
Laser settings were planned with the manifest astigmatism (magnitude and axis). 
Topographic astigmatism was not considered for the calculations. No nomogram 
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1. Introduction 
Non-inflammatory progressive corneal ectasia and thinning disease are among the most 
common abnormalities that refractive surgeons diagnose. Pellucid Marginal Degeneration 
(PMD) is another ectatic pathology that is rarely detected. PMD is a bilateral, non-
inflammatory, progressive peripheral inferior corneal thinning disorder (1,2). Diagnosis is 
based on the presence of corneal thinning with ectasia characterized by a peripheral band of 
thinning of the inferior cornea with 1 to 2 mm of normal cornea between this area and the 
limbus (2,3). The area of thinning typically is epithelialized, clear, avascular, and without 
lipid deposit. Like keratoconus, PMD is a bilateral progressive disorder although eyes may 
be asymmetrically affected. Topographic examination is very useful to differentiate this 
ectatic disorder. The topographic appearance shows a classical “butterfly” pattern that 
demonstrates large amounts of against-the-rule astigmatism as measured by simulated 
keratometry and inferior thinning. PMD can also be diagnosed by performing a pachymetric 
map of the entire cornea, as well as by elevation corneal maps using placido-ring-based 
videokeratoscopy technology (1).  
The etiology of PMD is not clear, and it is not known whether PMD, keratoconus and 
keratoglobus are distinct diseases or phenotypic variations of the same disorder (4). PMD is 
usually asymptomatic except for progressive deterioration in uncorrected visual acuity 
caused by irregular astigmatism (5). Slit-lamp examination shows a peripheral band of 
thinning with a protrusion (“beer-belly” contour) of the inferior cornea (6,7,8). 
Topographically, this protrusion in the peripheral inferior cornea has high keratometry 
powers, radiating toward the center from the inferior oblique meridians, typically in the 
inferior peripheral cornea. There is an area of flattening in the center of the cornea (5). In 
transmission electron microscopy of the cornea, abnormal fibrous long-spacing (FSL) 
collagen with a periodicity of 100 to 110 nm in PMD is revealed, which contrasts with 60 to 
64 nm found in normal corneas (9). A study reported in 2002 describes associations with 
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vernal keratoconjunctivitis, Marfan's syndrome, ocular hypertension, keratoconus, 
keratoglobus and hydrops (23).  
In the early stages, spectacles and contact lenses are the usual treatment approaches; however, 
in patients who cannot be rehabilitated with these options, a surgical procedure is necessary 
(10). Different surgical options include crescentic wedge resection, crescentic lamellar 
keratoplasty, penetrating keratoplasty, epikeratophakia and thermokeratoplasty. However, all 
these techniques have disadvantages: unpredictability, irreversibility, long period of 
rehabilitation and significant complication rates (11-16). Authors suggest the use of 
intracorneal rings (ICR) in glasses/contact lens-intolerant patients affected by early and 
moderate PMD with against-the-rule astigmatism and inferior peripheral corneal thickness of 
>450 µm (10). Since ICR mechanically lifts the inferior ectasia of PMD, flattens the soft ectatic 
corneal tissue, and decreases asymmetrical astigmatism, visual acuity is expected to improve 
following this procedure (17). Intacs® works on the principle of tissue addition. Peripheral 
distention is directly proportional to the degree of central corneal flattening, and by an arc-
shortening effect it manages to change the shape and power of the central cornea in ectatic 
eyes without weakening the central or the paracentral cornea (17,18). The aspheric shape of the 
natural cornea reduces aberrations and minimizes refractive error fluctuations as the pupil 
changes its size, and therefore reduces visual disturbances such as glare and halos. It is 
important to observe that Intacs® maintains an aspheric cornea. After placement of ring 
segments, central cornea has been shown to maintain a prolate shape because Intacs® flattens 
the peripheral cornea more than the central cornea (19). The major objective of corneal ring 
segment inserts is to reshape the abnormality by neither removing corneal tissue nor touching 
the central cornea (20). Various reports have been published illustrating either the symmetrical 
(inserting two same-size segments) or the asymmetrical (inserting two different size segments) 
Intacs® implantation techniques for the management of PMD. Both these techniques have 
been independently shown to improve UCVA, BSCVA and topographic findings (9,10).  
Intacs® are polymethylmethacrylate crescent-shaped segments with arc length of 150° and 
inner and outer diameters of 6.8 mm and 8.1 mm respectively. The ring segments are 
available in sizes ranging in thickness from 0.25 to 0.45 mm (Table 3). 
2. Patients and methods 
Symmetric ring segments were implanted in ten (10) eyes and asymmetric ring segments 
were implanted in nine (9) eyes. Swanson nomogram was used to calculate segment 
thickness in each eye.  
 
De-Centered Cones (Posterior Float 50% outside the 3 mm optical zone)** 
Spherical Equiv Inferior Intacs® Superior Intacs® 
+1.00 to -2.00 .250 mm .300 mm 
-2.00 to -3.00 .250 mm .350 mm 
-3.00 to -4.00 .300 mm .400 mm* 
-4.00 and -5.00 .300 mm .450 mm* 
-5.00 and higher .350 mm .450 mm* 
**Keratoconus, Pellucid Marginal Degeneration or "Pellucid Like" Nomogram (24)  
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The election of using asymmetric and symmetric ring segments was based on spherical 
equivalent and was randomly chosen. 
Besides the demographic details, key parameters evaluated during the preoperative and 
postoperative examination included: slitlamp microscopy, manifest refraction, spherical 
equivalent (SE), uncorrected visual acuity (UCVA), corneal pachymetry, tonometry, flat and 
steep keratometry readings and topography (Orbscan II). Postoperatively patients were 
evaluated at one month, three months, six months and one year. 
3. Surgical procedure 
Intacs® implantation was performed under topical anesthesia. After the patients were 
prepared through corneal hydration with balanced saline solution and sterile fields, the 
geometric center of the cornea was measured and marked. A radial 2 mm incision was 
performed in the steep corneal meridian with a diamond knife that was calibrated to 85% 
corneal depth. A vacuum centering guide - sloped shelf ring connected to a KV2000 vacuum 
system (Addition Technology® 155 Moffett Park Drive, Suite B-1 Sunnyvale, CA 94089-1330 
U.S.A.) was positioned to stabilize the globe. Clockwise and counterclockwise stromal 
dissectors were introduced into the base of the incision to create stromal tunnels. Intacs® of 
selected thicknesses were placed in the stromal tunnels from each side of the incision. The 
incision site was closed with one interrupted 10-0 nylon suture. Post-operative medication 
included an antibiotic/steroid combination taken every six (6) hours for two (2) weeks. All 
procedures were uneventful and performed by the same surgeon, (LAR).  
4. Statistical analysis 
The two groups were analyzed for any bias with respect to age, size of segments, initial 
values of visual acuity, astigmatism, spherical equivalent, flat and steep keratometry 
readings. Both groups were found to be comparable. 
Our study was descriptive and results were represented as averages and percentages 
(±standard deviations). Confidence intervals were set at 95%. 
Paired t test was used to compare the two groups with respect to changes in the following 
parameters: visual acuity, astigmatism, spherical equivalent, keratometries (flat and steep 
readings). Visual acuity was expressed in log mar (Snellen equivalent). One-way Anova test 
was applied to compare the changes in values throughout time in both the symmetric and 
asymmetric groups. Bonferroni post test was applied in cases where the values were 
statistically significant. Any value of P less than or equal to 0.05 (P >0.05) was considered 
statistically significant. 
5. Results 
Preoperative values in asymmetric group: UCVA 1.00 (log mar); astigmatism: -4.00D; SE: -
2.90D, K (flat) 43.09 D; K (steep) 47.02D. (Table 1) UCVA 0.85 (log mar); astigmatism: -4,50D; 
SE: -2.74D; K (flat) 43.03 D; K (steep) 47.05D. (Table 2)  
Tables 1 and 2 show an improvement in visual acuity, reduction in astigmatism, spherical 
equivalent and decrease in steep and flat keratometry post-op.  
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Mean SE CI 95% Mean SE 95% CI 
Visual Acuity 
(LogMAR) 1.00 0.14 0.67 – 1.33 0.22 0.04 0.13 – 0.30 
Astigmatism -4.00 0.49 -5.13 - -2.88 -2.11 0.39 -5.25 - -0.55 
Spherical 
Equivalent -2.90 1.02 -3.08 - -0.06 -1.57 0.62 -3.08 - -0.06 
Keratometry Flat 43.09 0.49 41.95 – 44.23 40.79 0.63 39.33 – 42.25 
Keratometry Steep 47.02 0.6 45.63 – 48.40 44.51 1.06 42.07 – 46.96 
SE: Standard Error; 95% CI: Confidence Interval of mean 95% (Lower – Upper) 
Table 1. Initial and Final Values for Visual Acuity (LogMAR), Astigmatism, Spherical 
Equivalent and Keratometry (Flat and Steep) in Patients with Diagnosis of Pellucid Marginal 




Mean SE CI 95% Mean SE 95% CI 
Visual Acuity 
(LogMAR) 0.85 0.19 0.42 – 1.28 0.28 0.09 0.09 – 0.48 
Astigmatism -4.50 0.44 -5.5 - -3.5 -3.30 0.54 -4.53 - -2.07 
Spherical 
Equivalent -2.74 1.08 -5.17 - -0.3 -0.58 0.40 -1.49 – 0.33 
Keratometry Flat 43.03 0.27 42.41 – 43.65 42.12 0.50 40.98 – 43.25 
Keratometry 
Steep 47.05 0.79 45.27 – 48.84 45.07 0.48 43.98 – 46.15 
SE: Standard Error; 95% CI: Confidence Interval of mean 95% (Lower – Upper) 
Table 2. Initial and Final Values for Visual Acuity (LogMAR), Astigmatism, Spherical 
Equivalent and Keratometry (Flat and Steep) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion Symmetrical Intacs ® Segments  
The characteristics of the implanted segments were the following: 
Asymmetric segments implanted: 300/250 (3), 450/300 (2), 350/250 (2), 450/250 (2). 
Symmetric segments implanted: 450 (1), 400 (1), 350 (1), 300 (4), 250 (3). 
The asymmetric group had an average age of 29.67  3.42 years, and the symmetric group 
had an average age of 34.5  3.42 years. The study showed a non-significant statistical 
difference between the groups (p=0.357). 
Visual Acuity in the symmetric group was better than the asymmetric group. In order to 
compare the two groups and showed a non-significant statistical difference between the two 
groups (p=0.550). Figure 1 
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Fig. 1. Initial Values of Visual Acuity in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
Spherical equivalent and steep keratometry showed no significant statistical difference in 

















Fig. 2. Initial Values of Astigmatism in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
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Mean SE CI 95% Mean SE 95% CI 
Visual Acuity 
(LogMAR) 0.85 0.19 0.42 – 1.28 0.28 0.09 0.09 – 0.48 
Astigmatism -4.50 0.44 -5.5 - -3.5 -3.30 0.54 -4.53 - -2.07 
Spherical 
Equivalent -2.74 1.08 -5.17 - -0.3 -0.58 0.40 -1.49 – 0.33 
Keratometry Flat 43.03 0.27 42.41 – 43.65 42.12 0.50 40.98 – 43.25 
Keratometry 
Steep 47.05 0.79 45.27 – 48.84 45.07 0.48 43.98 – 46.15 
SE: Standard Error; 95% CI: Confidence Interval of mean 95% (Lower – Upper) 
Table 2. Initial and Final Values for Visual Acuity (LogMAR), Astigmatism, Spherical 
Equivalent and Keratometry (Flat and Steep) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion Symmetrical Intacs ® Segments  
The characteristics of the implanted segments were the following: 
Asymmetric segments implanted: 300/250 (3), 450/300 (2), 350/250 (2), 450/250 (2). 
Symmetric segments implanted: 450 (1), 400 (1), 350 (1), 300 (4), 250 (3). 
The asymmetric group had an average age of 29.67  3.42 years, and the symmetric group 
had an average age of 34.5  3.42 years. The study showed a non-significant statistical 
difference between the groups (p=0.357). 
Visual Acuity in the symmetric group was better than the asymmetric group. In order to 
compare the two groups and showed a non-significant statistical difference between the two 
groups (p=0.550). Figure 1 
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Fig. 1. Initial Values of Visual Acuity in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
Spherical equivalent and steep keratometry showed no significant statistical difference in 

















Fig. 2. Initial Values of Astigmatism in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
 






















Fig. 3. Initial Values of Spherical Equivalent in Patients with Diagnosis of Pellucid Marginal 





























Fig. 4. Variation of Keratometry (Steep) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
After comparing the groups with flat keratometry, a significant statistical difference was 
found (p=0.025). This variation was greater in the asymmetric group. Figure 5 
In Figure 6 and 7 the evolution of visual acuity for the asymmetric and symmetric group can 
be seen. After applying one-way Anova, a significant statistical difference was evidenced 
(p<0.0001 and p=0.0003). We subsequently applied the Bonferroni multiple comparison test  
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Fig. 5. Variation of Keratometry (Flat) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
 
Fig. 6. Time Course of Visual Acuity (LogMAR) in Patients with Diagnosis of Pellucid 
Marginal Degeneration with Insertion of Asymmetrical Intacs ®  
in order to compare each post-operatory time period. No significant statistical differences 
were seen. 
In Figure 8 and 9 the evolution of astigmatism for the asymmetric and symmetric group was 
shown. With the application of one-way Anova, a significant statistical difference was 
observed in asymmetric group (p=0.031) while no significant statistical difference was found 
postoperatively (p =0.074) in symmetric group. The Bonferroni multiple comparison test  
 






















Fig. 3. Initial Values of Spherical Equivalent in Patients with Diagnosis of Pellucid Marginal 





























Fig. 4. Variation of Keratometry (Steep) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
After comparing the groups with flat keratometry, a significant statistical difference was 
found (p=0.025). This variation was greater in the asymmetric group. Figure 5 
In Figure 6 and 7 the evolution of visual acuity for the asymmetric and symmetric group can 
be seen. After applying one-way Anova, a significant statistical difference was evidenced 
(p<0.0001 and p=0.0003). We subsequently applied the Bonferroni multiple comparison test  
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Fig. 5. Variation of Keratometry (Flat) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
 
Fig. 6. Time Course of Visual Acuity (LogMAR) in Patients with Diagnosis of Pellucid 
Marginal Degeneration with Insertion of Asymmetrical Intacs ®  
in order to compare each post-operatory time period. No significant statistical differences 
were seen. 
In Figure 8 and 9 the evolution of astigmatism for the asymmetric and symmetric group was 
shown. With the application of one-way Anova, a significant statistical difference was 
observed in asymmetric group (p=0.031) while no significant statistical difference was found 
postoperatively (p =0.074) in symmetric group. The Bonferroni multiple comparison test  
 




Fig. 7. Time Course of Visual Acuity (LogMAR) in Patients with Diagnosis of Pellucid 
Marginal Degeneration with Insertion of Symmetrical Intacs ®  
 
Fig. 8. Time Course of Astigmatism in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Asymmetrical Intacs ®  
showed no significant statistical difference between initial and one month, and significant 
statistical differences between initial and three months and between initial, six months and 
one year respectively.  
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Fig. 9. Time Course of Astigmatism in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical Intacs ® 
Figures 10 and 11 analyzed the variation of spherical equivalent for the asymmetric and 
symmetric group. After applying one-way Anova, a significant statistical difference was 
observed in both groups (p=0.030; p=0.020). In addition we used the Bonferroni multiple 
comparison test in order to compare each time period and thereby established that the only 
difference was between initial and first month postoperatively in asymmetric group and 
initial with six month and first year in symmetric group. 
In Figure 12 the evolution of flat keratometry in the asymmetric group is graphed. After the 
application of one–way Anova, a significant statistical difference was evidenced (p=0.005). 
We then applied the Bonferroni multiple comparison test in order to compare all the 
postoperative time periods. The difference found was observed in the comparison between 
the initial with three months and the initial with six months. No difference was found upon 
comparing initial with one month, nor when comparing the various time periods after initial 
(one month, three months, and six months) respectively. No significant statistical difference 
was observed in symmetric group (p=0.543) figure 13. 
In Figure 14 the variation in steep keratometry in the asymmetric group was observed. After 
applying one-way Anova, a significant statistical difference was observed (p=0.003). In 
addition we applied the Bonferroni multiple comparison test in order to compare each time 
period, and the only difference found was when comparing initial with one month. 
In Figure 15 we observed the evolution of steep keratometry in the symmetric group. No 
significant statistical difference was found when one–way Anova was applied (p=0.080). 
With respect to the variation in visual acuity (log mar), astigmastism and spherical 
equivcalent, when both groups were compared with the student’s t test, no significant 
statistical difference was found between them (p=0.366; p=0.412; p=0.344 respectively). 
Figure 16, 17 and 18. 
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showed no significant statistical difference between initial and one month, and significant 
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Fig. 9. Time Course of Astigmatism in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical Intacs ® 
Figures 10 and 11 analyzed the variation of spherical equivalent for the asymmetric and 
symmetric group. After applying one-way Anova, a significant statistical difference was 
observed in both groups (p=0.030; p=0.020). In addition we used the Bonferroni multiple 
comparison test in order to compare each time period and thereby established that the only 
difference was between initial and first month postoperatively in asymmetric group and 
initial with six month and first year in symmetric group. 
In Figure 12 the evolution of flat keratometry in the asymmetric group is graphed. After the 
application of one–way Anova, a significant statistical difference was evidenced (p=0.005). 
We then applied the Bonferroni multiple comparison test in order to compare all the 
postoperative time periods. The difference found was observed in the comparison between 
the initial with three months and the initial with six months. No difference was found upon 
comparing initial with one month, nor when comparing the various time periods after initial 
(one month, three months, and six months) respectively. No significant statistical difference 
was observed in symmetric group (p=0.543) figure 13. 
In Figure 14 the variation in steep keratometry in the asymmetric group was observed. After 
applying one-way Anova, a significant statistical difference was observed (p=0.003). In 
addition we applied the Bonferroni multiple comparison test in order to compare each time 
period, and the only difference found was when comparing initial with one month. 
In Figure 15 we observed the evolution of steep keratometry in the symmetric group. No 
significant statistical difference was found when one–way Anova was applied (p=0.080). 
With respect to the variation in visual acuity (log mar), astigmastism and spherical 
equivcalent, when both groups were compared with the student’s t test, no significant 
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Fig. 10. Time Course of Spherical Equivalent in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Asymmetrical Intacs ® 
 
 
Fig. 11. Time Course of Spherical Equivalent in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical Intacs ® 
Comparing Nomograms of Two Symmetric and Two Asymmetric  





Fig. 12. Time Course of Keratometry (Flat) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Asymmetrical Intacs ® 
 
 
Fig. 13. Time Course of Keratometry (Flat) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical Intacs ® 
 





Fig. 10. Time Course of Spherical Equivalent in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Asymmetrical Intacs ® 
 
 
Fig. 11. Time Course of Spherical Equivalent in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical Intacs ® 
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Fig. 12. Time Course of Keratometry (Flat) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Asymmetrical Intacs ® 
 
 
Fig. 13. Time Course of Keratometry (Flat) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical Intacs ® 
 





Fig. 14. Time Course of Keratometry (Steep) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Asymmetrical Intacs ® 
 
 
Fig. 15. Time Course of Keratometry (Steep) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical Intacs ® 
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Fig. 16. Variation of Visual Acuity (LogMAR) in Patients with Diagnosis of Pellucid 


























Fig. 17. Variation of Astigmatism in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
 





Fig. 14. Time Course of Keratometry (Steep) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Asymmetrical Intacs ® 
 
 
Fig. 15. Time Course of Keratometry (Steep) in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical Intacs ® 
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Fig. 16. Variation of Visual Acuity (LogMAR) in Patients with Diagnosis of Pellucid 


























Fig. 17. Variation of Astigmatism in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
 



































Fig. 18. Variation of Spherical Equivalent in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
5.1 Results in asymmetric group 
At the end of follow-up period (one year), mean UCVA was 0.22 log mar, ±0,04 (20/30) (95% 
IC=0.13-0.30). Statistically significant differences were noted throughout the follow-up 
period (p < 0.0001)  
Astigmatism value at final follow-up was -2.11D ±0.39 (95% IC= -5.25 – 0.55). P values at all 
of the postoperative follow-up periods were statistically significant (p=0.001). The 
maximum improvement in astigmatism was at three months postoperative.  
Spherical equivalent mean value was -1.57D ± 0.62 (95% IC=-3.08- 0.06). The changes in 
mean spherical equivalent during the follow-up period were statistically significant 
(p=0.030) with maximum improvement at one month postoperative.  
Keratometry flat meridian was 40.79D±0.63 (95% IC= 39.33- 42.25). All the changes in mean 
readings in flat keratometry were statistically significant (p=0.005). Maximum improvement 
was between three and six months postoperative.  
Keratometry steep meridian was 44.51D±1.06 (95% IC= 42.07 – 46.96). The changes in mean 
readings in steep keratometry were statistically significant (p=0.003) with maximum 
improvement at first month.  
5.2 Results in symmetric group 
Mean UCVA was 0.28 log mar, ±0.09 (20/40) (95% IC=0.09-0.48). Statistically significant 
differences were noted throughout the follow-up period (p < 0.0003)  
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Astigmatism value at final follow-up was -3.30D ±0.54 (95% IC= -4.53 – 2.07). At first year, 
the difference was not statistically significant (p=0.074).  
Spherical equivalent mean values were -0.58D ± 0.40 (95% IC=-1.49 – 0.33). The difference 
was statistically significant (p=0.020) with maximum improvement at six months 
postoperative.  
Keratometry flat meridian value was 42.12D±0.50 (95% IC= 40.98- 43.25). At first year, the 
difference was not statistically significant (p=0.543). 
Keratometry steep meridian was 45.07D±0.48 (95% IC= 43.98 – 46.15). At first year 
postoperative the difference was not statistically significant (p= 0.080).  
5.3 Comparing results of both groups 
Initial visual acuity values were not statistically different between both groups (p=0.550).  
Astigmatism initial values were not statistically significant between both groups. (p=0.456). 
Spherical equivalent values were not statistically significant between both groups (p=0.914). 
Keratometries (flat and steep) meridian initial values were not statistically significant 
between both groups (p=0.905 symmetric group), (p=0.972 asymmetric group).  
UCVA was not statistically significant between the groups (p=0.366). The difference of final 
post-op values in astigmatism for the groups was not statistically significant. (p=0.412). The 
difference of spherical equivalent values at six months post-op between the groups was not 
statistically significant (p=0.344). The difference of keratometry flat values at six months 
post-op between the groups was significant (p=0.025) with a better result in the asymmetric 
group. Keratometry steep values at one year postoperatively in both groups were not 
statistically significant. (p=0.647).  
6. Discussion 
Pellucid marginal degeneration (PMD) is a disease with a complicated prognosis in 
patients who are intolerant to contact lenses (10). Different procedures have been used to 
treat PMD with unpredictable results. Symmetric and asymmetric Intacs® segments are 
relatively new devices that reinforce the cornea through the arc-shortening effect of the 
corneal lamellae that produces flattening of the central cornea. The goal of using Intacs® 
for PMD is to reshape the cornea without removing tissue by lifting the inferior ectasia, 
flattening the soft ectatic corneal tissue and decreasing astigmatism. With this treatment, 
tissue and endothelium is maintained with the benefit that an additive surgical approach 
is used that adds rigidity and reinforces the ectatic cornea, flattening the central area, and 
positioning the optical zone in the center of the pupil. This procedure is also reversible. 
Mularoni et al. proposed a treatment with two asymmetric intracorneal segments in 
patients with intolerance to contact lenses and early and moderate PMD. Results were 
great improvement in UCVA, BSCVA and topographical findings (10). Colin J. and Malet 
F. implanted two symmetric Intacs® segments and followed the progress for two years 
post operatively obtaining favorable results. The findings in this study indicated that 
Intacs® segments are an effective long-term treatment for keratoconus and associated 
ectasia (21). Kymionis et al. reported a case of PMD treated with Intacs® symmetric 
 



































Fig. 18. Variation of Spherical Equivalent in Patients with Diagnosis of Pellucid Marginal 
Degeneration with Insertion of Symmetrical or Asymmetrical Intacs ® Segments  
5.1 Results in asymmetric group 
At the end of follow-up period (one year), mean UCVA was 0.22 log mar, ±0,04 (20/30) (95% 
IC=0.13-0.30). Statistically significant differences were noted throughout the follow-up 
period (p < 0.0001)  
Astigmatism value at final follow-up was -2.11D ±0.39 (95% IC= -5.25 – 0.55). P values at all 
of the postoperative follow-up periods were statistically significant (p=0.001). The 
maximum improvement in astigmatism was at three months postoperative.  
Spherical equivalent mean value was -1.57D ± 0.62 (95% IC=-3.08- 0.06). The changes in 
mean spherical equivalent during the follow-up period were statistically significant 
(p=0.030) with maximum improvement at one month postoperative.  
Keratometry flat meridian was 40.79D±0.63 (95% IC= 39.33- 42.25). All the changes in mean 
readings in flat keratometry were statistically significant (p=0.005). Maximum improvement 
was between three and six months postoperative.  
Keratometry steep meridian was 44.51D±1.06 (95% IC= 42.07 – 46.96). The changes in mean 
readings in steep keratometry were statistically significant (p=0.003) with maximum 
improvement at first month.  
5.2 Results in symmetric group 
Mean UCVA was 0.28 log mar, ±0.09 (20/40) (95% IC=0.09-0.48). Statistically significant 
differences were noted throughout the follow-up period (p < 0.0003)  
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Astigmatism value at final follow-up was -3.30D ±0.54 (95% IC= -4.53 – 2.07). At first year, 
the difference was not statistically significant (p=0.074).  
Spherical equivalent mean values were -0.58D ± 0.40 (95% IC=-1.49 – 0.33). The difference 
was statistically significant (p=0.020) with maximum improvement at six months 
postoperative.  
Keratometry flat meridian value was 42.12D±0.50 (95% IC= 40.98- 43.25). At first year, the 
difference was not statistically significant (p=0.543). 
Keratometry steep meridian was 45.07D±0.48 (95% IC= 43.98 – 46.15). At first year 
postoperative the difference was not statistically significant (p= 0.080).  
5.3 Comparing results of both groups 
Initial visual acuity values were not statistically different between both groups (p=0.550).  
Astigmatism initial values were not statistically significant between both groups. (p=0.456). 
Spherical equivalent values were not statistically significant between both groups (p=0.914). 
Keratometries (flat and steep) meridian initial values were not statistically significant 
between both groups (p=0.905 symmetric group), (p=0.972 asymmetric group).  
UCVA was not statistically significant between the groups (p=0.366). The difference of final 
post-op values in astigmatism for the groups was not statistically significant. (p=0.412). The 
difference of spherical equivalent values at six months post-op between the groups was not 
statistically significant (p=0.344). The difference of keratometry flat values at six months 
post-op between the groups was significant (p=0.025) with a better result in the asymmetric 
group. Keratometry steep values at one year postoperatively in both groups were not 
statistically significant. (p=0.647).  
6. Discussion 
Pellucid marginal degeneration (PMD) is a disease with a complicated prognosis in 
patients who are intolerant to contact lenses (10). Different procedures have been used to 
treat PMD with unpredictable results. Symmetric and asymmetric Intacs® segments are 
relatively new devices that reinforce the cornea through the arc-shortening effect of the 
corneal lamellae that produces flattening of the central cornea. The goal of using Intacs® 
for PMD is to reshape the cornea without removing tissue by lifting the inferior ectasia, 
flattening the soft ectatic corneal tissue and decreasing astigmatism. With this treatment, 
tissue and endothelium is maintained with the benefit that an additive surgical approach 
is used that adds rigidity and reinforces the ectatic cornea, flattening the central area, and 
positioning the optical zone in the center of the pupil. This procedure is also reversible. 
Mularoni et al. proposed a treatment with two asymmetric intracorneal segments in 
patients with intolerance to contact lenses and early and moderate PMD. Results were 
great improvement in UCVA, BSCVA and topographical findings (10). Colin J. and Malet 
F. implanted two symmetric Intacs® segments and followed the progress for two years 
post operatively obtaining favorable results. The findings in this study indicated that 
Intacs® segments are an effective long-term treatment for keratoconus and associated 
ectasia (21). Kymionis et al. reported a case of PMD treated with Intacs® symmetric 
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segments which reported an improvement in corneal topographic pattern. ICR insertion 
can reduce the corneal steepening and astigmatism associated with PMD (9). Rodriguez 
Prats et al. reported a reduction of steepening and astigmatism associated with PMD by 
implanting one inferior segment (17). Sharma M. and Boxer Wachler noted that placement 
of inferior segment Intacs® alone was more suitable than double segments Intacs® 
insertion for peripherally located cones (22). Alió et al found that by implanting either one 
or two segments produced a similar effect in the reduction of the refractive cylinder and 
the keratometric readings (19). Both methods have similar results especially when 
concerning the visual acuity. 
In our study, we compared implanting two segments in an asymmetric group to 
implanting two segments in a symmetric group, with a slightly better result in UCVA in 
the asymmetric group. When we evaluated BCVA, UCVA, spherical equivalent, 
astigmatism and keratometric readings, the differences between preop and postop values 
in all parameters were significantly reduced in both groups with statistically significant 
differences.  
We noted that when analyzing nomograms of the symmetric and asymmetric groups, 
there were no statistically significant differences when comparing the results of both 
procedures. This is mainly due to similar spherical equivalent and showed that both 
nomograms were effective. Both groups tolerated spectacles and contact lenses well after 
the procedures.  
In the asymmetric group we implanted intracorneal segments that were thicker in the 
protrusion area and thinner in the flatter area, taking spherical equivalent into account. This 
could possibly have led to an overcorrection with the implantation of the thicker segment. 
When implanting thicker segments in the thinner protrusion area, great skill was used so as 
not to perforate the cornea or extrude the segment. In the symmetric group we implanted 
two same thickness segments, also dependent on spherical equivalent. In symmetric 
implantations there are more articles available that reported success in keratoconus and 
other ectasias. By implanting thinner segments in the protrusion area, undercorrection was a 
possibility. The advantage of implanting two segments was that corneal prolate is 
maintained. 
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segments which reported an improvement in corneal topographic pattern. ICR insertion 
can reduce the corneal steepening and astigmatism associated with PMD (9). Rodriguez 
Prats et al. reported a reduction of steepening and astigmatism associated with PMD by 
implanting one inferior segment (17). Sharma M. and Boxer Wachler noted that placement 
of inferior segment Intacs® alone was more suitable than double segments Intacs® 
insertion for peripherally located cones (22). Alió et al found that by implanting either one 
or two segments produced a similar effect in the reduction of the refractive cylinder and 
the keratometric readings (19). Both methods have similar results especially when 
concerning the visual acuity. 
In our study, we compared implanting two segments in an asymmetric group to 
implanting two segments in a symmetric group, with a slightly better result in UCVA in 
the asymmetric group. When we evaluated BCVA, UCVA, spherical equivalent, 
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1. Introduction 
Astigmatism can be corrected with: 
1. Glasses and contact lenses 
2. Excimer laser refractive procedures (LASIK, PRK)  
3. Astigmatic keratotomy  
4. Limbal or corneal relaxing and clear corneal incisions  
5. Toric intraocular lens  
 
Fig. 1. Eye with astigmatism. 
The ideal procedure for the correction of astigmatism should provide: precise and accurate 
adjustment, safety, predictable outcome, lasting effect and simplicity with an acceptable price. 
Conventional methods for solving problems such as glasses and/or contact lenses at the 
present time often do not meet the needs of patients. Whether it is the objective or subjective 
reasons for a large number of patients tend to avoid wearing glasses or contact lenses.  
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Fig. 2. The topography of corneal astigmatism. 
Correcting corneal astigmatism during cataract surgery can increase spectacle 
independence. For the patient, this has economic benefits as well as desirable cosmetic and 
practical advantages. Spectacle correction of astigmatism creates meridional magnification, 
which when coupled with the associated back vertex distance produces retinal images that 
are asymmetrically magnified and distorted (1).  
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According to the literature, it is estimated that 15 to 22.2% of patients who are candidates for 
cataract surgery have astigmatism greater than 1.50 D. This indicates that a large number of 
patients still has blurred vision after cataract surgery due to residual astigmatism and 
require operative correction of distance vision glasses or lenses. (2,3). Since the corneal 
limbal relaxing incision often have an unpredictable effect on the postoperative visual 
acuity, and the use of Excimer laser refractive surgery is often not feasible because of it is 
often contraindicated in elderly people, expensive procedure, requires high technological 
equipment and expertise of medical personnel. Toric intraocular lenses are the correction of 
choice for high levels of astigmatism. They promise a predictable method of astigmatic 
correction with minimal impact to the cornea. However, the effectiveness of a toric IOL is 
dependent on its orientation. (1,4)   
2. Surgical aspects of implantation of toric intraocular lenses  
Cataract surgery with implantation of toric intraocular lenses is identical to the normal 
procedure and requires no special training (4). The difference is reflected in the preoperative 
treatment, and in celebration of the cylinder axis, which is adjusted to the patient's eye. Toric 
IOLs need precise positioning to achieve optimal visual results. In accordance with the 
corneal measurements, reference markers on opposite sides of the pupil need to be 
established to demarcate the correct axis for IOL orientation. Eye rotation occurs in a supine 
position and so these markers need to be established pre-operatively. The slit lamp beam 
axis graticule can be dialed to the correct axis or a bespoke eyepiece graticule can be used to 
determine where to place the markers, which can be applied to the cornea or conjunctiva 
using ink or with scratches. Ink should be applied at the last possible minute as it can 
diffuse by 10° or disappear before implantation is complete. As an alternative, a 
Neodymium:Yttrium-Aluminum-Garnet (Nd:YAG)  laser can be used to mark the cornea. It 
has been suggested that this improves the accuracy and definition of the markers. Specific 
toric axis marking instruments exist. One step methods, such as the Devgan Axis Marker 
(Accutome, Pennsylvania, USA) and the Gerten Pendulum Marker (Geuder, Heidelberg, 
Germany)  are used pre-operatively to determine the required axis. They are dependent on a 
vertical head position when applied to the cornea. Two-step methods require marking the 
cornea at the zero and 180 degree positions pre-operatively and then aligning a degree 
gauge with these markings intra-operatively to establish the correct position (1). The iris 
architecture is intricate and full marking is done manually or by using the instrument in a 
sitting position (1,5). Another difference lies in the fact that the shaft of toric IOL to coincide 
with the axis of the cylinder, marked preoperatively. This is achieved by the end of the 
operation during the removal of viscoelastic. There are two main surgical factors that can 
influence IOL rotation. In the early post-operative period careful wound construction is 
essential. Following surgery, the IOP can fluctuate and in 6.3 per cent of patients, it drops to 
below 5 mmHg. It is important to emphasize that it is necessary to remove viscoelastic a 
rotation for maximum stability. Viscoelastic lag could lead to undesirable postoperative 
implant rotation, and therefore should be brought into question and the desired outcome 
(1). 
Consideration of  IOL haptic design is very important when trying to prevent postoperative 
lens rotation. Over time, the capsular bag contracts to enclose and secure the IOL, however, 
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before this contraction occurs there is potentfor rotation (6). To prevent rotation 
immediately after implantation, it is important to maximize the contact between the IOL 
haptic and the capsular bag. A polymethyl methacrylate (PMMA) IOL creates the most 
friction with the bag, followed by acrylic, with silicon causing the least (7). It is believed that 
if the implant rotates by more than 30 degrees postoperatively, the effect of cylindrical 
lenses is lost. The third difference relates to the calculation of the refractive lens, the strength 
and axis cylinder. As a rule, keratometry very carefully set manually, not automatic 
keratometer. Must also be taken into account and astigmatism, which will occur as a 
consequence of the main corneal incision. IOL manufacturers have developed calculators to 
determine the refractive power lens (as spherical and cylindrical components), and 
determine the shaft in which the implant should be placed. The data are entered to the 
calculator are manually specified value keratometry, spherical components required 
strength, where you are planning a major incision. These calculators are easily and freely 
available for use on the Internet (8).  
3. The outcome of intraocular implantation of toric IOL 
When it comes to the outcome of implantation of  toric intraocular lenses, it is essential to 
assess the following parameters:  
3.1 Rotational stability in capsular bag  
3.1.1 Plate haptic IOLs 
Plate haptic IOLs demonstrate excellent long-term stability. In comparison with open-loop 
haptics, plate haptic IOLs are not as susceptible to the effects of compression from the 
capsular bag.  
The first commercially available toric IOL was the STAAR 4203TF (STAAR Surgical, 
Company, California, USA), which achieved FDA approval in 1998. It is a biconvex, 
silicone, plate haptic toric IOL, 10.8 mm in length, with two 1.15-mm positioning holes. 
The lens is available with a torus of either 2.00 or 3.50 D, which corrects levels of corneal 
astigmatism between 1.50 and 3.50 D. The lens demonstrates excellent long-term stability 
once fixation within the capsular bag has been established, 30 however, in the early 
postoperative period, the lens demonstrates a relatively high incidence of rotation. In its 
FDA trial, 24 per cent of the lenses rotated more than 10°, 12 per cent more than 20° and 8 
per cent more than 30° (9). 
The AT-TORBI (Carl Zeiss Meditec, Berlin, Germany) (previously the ACri comfort toric 
IOL) is an acrylic, bi-toric, plate haptic IOL, 11 mm in length, possessing two positioning 
holes on the haptic. It is a microincisional lens, and it can be inserted through a 1.5-mm 
incision. The AT-TORBI has a 6.0-mm optic, and can correct high levels of astigmatism, as 
it is available with a torus of 1.00 to 12.00 D in 0.50-D steps. Large-scale studies are 
required to demonstrate the effectiveness of this lens but early results are very promising. 
In a pilot study involving 21 eyes with 2.00 to 9.00 D of corneal astigmatism, only one lens 
rotated more than 5° between day one and six months post-operatively, with 76.1 per cent 
of these subjects achieving a postoperative uncorrected vision of 20/40 or better (10). 
 






Fig. 3. Slit-lamp retroillumination photographs of a Staar toric intraocular lens with a 
superimposed digital protractor before (left) and after (right) a circular neodymium–






Fig. 4. The ACri comfort toric IOL (10). 
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Fig. 5. The ACri comfort toric IOL in situ 3 months postoperatively (10). 
3.1.2 Open loop haptic lenses 
Open loop haptic lenses compared with previous models (plate haptic IOLs) demonstrate 
excellent early rotational stability in comparison to plate haptics. The longer loop haptics 
ensure immediate contact between haptic and capsular bag, maximizing friction in the early 
postoperative period, however, they are susceptible to late rotation caused by the 
compression of the capsular bag  (11). 
The AcrySof toric IOL (Alcon, Fort Worth, USA) is a single-piece acrylic toric IOL with open 
loop L-shaped haptics. It has a posterior toric surface with three available toric powers 1.50, 
2.25 and 3.00 D. It is a 13mm in length with a 6.0mm optic. The AcrySof toric has 
demonstrated excellent rotational stability results. During its FDA trial, 81.9% of lenses 
rotated less than 5° and only 2.9%  rotated over 10° and only 0.8% of these lenses were 
repositioned (2,8). 
The Torica S (Human Optics, Erlangen, Germany) otherwise known as the Microcyl Toric 
6116 (Human Optics), is a three-piece, silicon, Z-shaped open loop haptic toric IOL. It is 
11.6mm in length with a 6.0mm optic. The Torica S has a novel haptic design with 
undulations designed to increase the friction between lens and bag. It has been reported that 
these undulations maintain the IOLs position but make it difficult to rotate the lens within 
the bag. To prevent the haptic undulations from causing trauma when rotating the lens, it is 
recommended that they are compressed against the optic and held away from the capsular 
bag until the lens is in the required position. In a study of 21 eyes (14 subjects) no lens 
rotated more than 5°(12). 
 




Fig. 6. AcrySof toric IOL. 
 
 
Fig. 7. The Torica-S IOL. 
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3.1.3 Closed loop haptics  IOLs 
Closed-loop haptics are a relatively new addition to the toric IOL market. These lenses are 
typically longer than the plate haptics, which should give good initial contact. The loops 
have a second insertion on the IOL that may resist capsular compression. 
The T-flex toric (Rayner, Hove, UK) is a single-piece, acrylic, closed-loop haptic with anti-
vaulting haptic technology. It is available in two sizes; the 573T has a 5.75-mm optic and 12 
mm haptics, and the 623T has a 6.25-mm optic and 12.5 mm haptic. The anterior surface of 
the optic houses the toric surface, which is available with a torus of one to 11 D. The anti-
vaulting haptic technology is designed to reduce the effect of compression using a lock and 
key system. Compression will push the outside of the haptic against the inner haptic, 
locking it into place. It has been reported that in a group of 10 subjects no lens rotated more 
than 5° between one week and two years after implantation (13). 
 
 
Fig. 8. Rayner T-flex® Aspheric Toric IOL. 
The Akreos (Bausch & Lomb, Rochester, USA) aspheric platform is a single piece acrylic, 
closed loop haptic IOL. It has a 6.0-mm optic and is 11 mm in length with a 360° square 
edge. The IOL is currently being assessed for its viability as a platform for housing a toric 
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3.1.3 Closed loop haptics  IOLs 
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3.2 The reduction of absolute residual astigmatism 
The average absolute residual astigmatism after implantation of toric intraocular lenses is 
less than 0.55D. In patients who have significant astigmatism, and implanted them classic 
spherical lenses residual astigmatism is an average of 1.22D (1). 
3.3 Uncorrected visual acuity at distance 
Ninety-four percent of patients achieve visual acuity ≥ 0.5 with no correction, which is a 
remarkable result. Also, these patients have a greater vision improvement at all levels 
compared with patients who have conventional spherical lens. In 97% of patients whose 
toric lenses implanted in both eyes maximize distance vision without correction (1,2). 
3.3.1 Stability and predictability of outcome 
Patients who have significant astigmatism after cataract surgery have the option for 
correcting glasses or contact lenses. However, for many patients who expect excellent 
postoperative vision this is unacceptable solution. 
Relaxing incisions that had previously been strongly represented in the correction of 
astigmatism now use fewer surgeons (40%) for the following reasons: 
- Unpredictable results in a significant number of cases 
- The problem of regression, astigmatism, especially in patients with severe preoperative 
astigmatism 
- Inability to correct high astigmatism  
- Paracentral incisions can correct high astigmatism, but more complications 
- Healing of incisions can be problematic, since it is predominantly an elderly patient 
- Patients with steep corneas and asymmetriastigmatism are not good candidates (1,16). 
When speaking of the Excimer laser for the correction of astigmatism, the method is 
effective and safe, but laser is expensive and this way the correction is often unavailable for 
most patients (17). 
3.3.2 Economic evaluation of toric intraocular lens 
Pineda and colleagues (18) assessed the economic value of improved uncorrected visual 
acuity among patients with cataract and preexisting astigmatism treated with toric 
intraocular lenses (IOLs) compared with conventional monofocal IOLs. They concluded 
that toric IOLs reduce lifetime economic costs by reducing the need for glasses or  
contact lenses following cataract removal. These results can inform physicians and 
patients regarding the value of toric IOLs in the treatment of cataract and preexisting 
astigmatism.  
Laurendeau and collegues (19) in their study concluded that bilateral toric IOL implants in 
astigmatic patients decreased spectacle dependence for distance vision and the need for 
complex spectacles. The economic consequences for patients depended on the national 
spectacle costs usually incurred after cataract surgery. 
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4. Conclusion  
Toric intraocular lenses are accurate, reliable, predictable, permanently correcting 
astigmatism in cataract patients who are operated, while the flow of the operation is not 
extended, or require special training for surgeons already trained. Rotational stability of an 
IOL is the primary determinant of the refractive outcome. The surgeon should also keep in 
mind that the final outcome is very important and proper selection of patients, including 
patients with irregular astigmatism due to the scar tissue forming of the cornea, 
keratoconus, pellucid marginal degeneration, etc,. New available aspheric toric lens offer a 
better quality of vision postoperatively (reduction of spherical aberration, further improving 
contrast sensitivity, and uncorrected visual acuity at a distance). Toric IOLs reduce lifetime 
economic costs by reducing the need for glasses or contact lenses following cataract 
removal. 
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Amblyopia in Greek is dullness of vision. It is defined as poor unilateral or bilateral visual 
acuity due to poor perception in the presence of normal appearing globe.1 It is caused by 
poor visual perception during the critical postnatal period required for maturation of the 
visual pathways and cortex. Clear and corresponding image is required for visual system 
development in animals including primates.  
1.2 Epidemiology 
The prevalence of amblyopia in the general population is probably between 2 and 2.5%. The 
wider range of 1-4% reflects differences in the degree of amblyopia, the studied population 
and the location. These figures represent the average of the prevalence in the different 
studies. The frequency of disorder has a socioeconomic impact. These patients have a 
greater risk for legal blindness if the fellow eye develops a blinding condition or sustain 
trauma. Indeed, patients with amblyopia as monocular patients are at a greater risk for 
trauma in the fellow eye although their visual field may be full.  
1.3 Development of the visual system 
The postnatal visual system development differs in different animals. In humans, the visual 
acuity improves usually until the age of 5 and this reflects the maturation of both the retina 
and the visual pathways.2 The most critical period for amblyopia is the first 2 to 3 years of 
life.1 The sensitivity of the visual system to abnormal perception is decreasing gradually 
afterwards. One should distinguish between the period when amblyopia may develop, 
which is until 9 years of age (although in most patients, it appears by the age of 5) and the 
period in which it is treatable, probably until the age of 17.3  
1.4 Classification 
Amblyopia is a result of three mechanisms: deprivation (obscuration of the image on its way 
to the retina (i.e., ptosis and media opacities), strabismus and refractive (anisometropic  
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or isoamteropic) all causing blurred or non-corresponding images on the fovea.1 The 
pathophysiology common to all of these is abnormal binocular interaction and/ or vision 
deprivation. Strabismic amblyopia occurs in the non-fixating eye and is always unilateral. It 
occurs in tropia and is more common in esotropia than in exotropia and indeed esotropia is 
neonatal while exotropia may be neonatal or acquired later in life.  It is caused by signaling 
inhibition of the deviating eye to avoid confusion because of different foveal images between 
the eyes. Strabismic amblyopia is applied only to cases where the amblyopia is a result of 
strabismus and not vice versa. In refractive amblyopia, signaling inhibition of the blurred 
image occurs and in deprivation, there is usually no image. Anisometropia of +2.00, -3.00 and 
astigmatism of 1.5D or more are associated with amblyopia. The presence of astigmatism 
causes amblyopia in the astigmatic meridian called meridional amblyopia. Isoametropia of 
+4.00, -8.00 and astigmatism of 2D or more are associated with bilateral amblyopia. Lesser 
amount of hypermetropia than myopia is associated with amblyopia because the inability to 
focus images on the fovea at any distance. While strabismic amblyopia and most of the 
anisometropic amblyopia are unilateral, isoametropic and some of the deprivative amblyopia 
are bilateral. Deprivative amblyopia is usually the most profound and most resistant to 
treatment of all three forms of amblyopia. If it is present in the first 3 months, irreversible 
nystagmus develops. The unilateral cases are usually the worst. 
2. Clinical manifestations 
The visual acuity is poorer in the amblyopic eye than in the fellow eye or than in normal 
eyes and cannot be corrected to full with spectacles or contact lenses. A poorer visual acuity 
is considered if the visual acuity is less in two Snellen lines or more. Differences in one line 
may just be fluctuation and within the normal deviation and this is true not only for 
amblyopia but for all other instances as well. The subject uses the fellow better eye for 
fixation. The patient sees single signs on the Snellen chart better than several signs in a row 
(crowding phenomenon or abnormal contour interaction). This is caused by larger receptive 
fields (larger group of photoreceptors working as a single unit) and lateral inhibition by 
adjacent fields on the fixating field. Under dim light, the visual acuity decreases in both eyes 
but the visual acuity of amblyopic eye becomes similar to the normal eye. Thus the decrease 
in visual acuity is slower in the amblyopic eye than in a normal eye. The use of neutral 
density filters decreases the visual acuity in the amblyopic eye in much lesser extent 
compared with eyes with other diseases. In addition, amblyopic eyes have decreased 
contrast sensitivity, perception of brightness and have longer reaction time.   
Other parameters are normal and similar to normal eyes including light perception (visual 
threshold) and visual field. An afferent pupillary defect is not supposed to occur but is a 
variable finding.  
3. Treatment 
Bilateral amblyopia is treated by eliminating the cause of blurred image (removal of the 
deprivation cause, strabismus surgery or refractive error correction). Unilateral amblyopia is 
treated similarly along with periodical patching or other penalization of the fellow sound 
eye. Penalization of the sound eye is usually performed by instilling once drop of atropine 
sulfate 1% one a day at bedtime. This causes cycloplegia and blurred image in the sound eye 
and forces the visual system of the amblyopic eye to act. Treatment should be initiated 
immediately when the condition is diagnosed. The elimination of the deprivative obstacle 
should be performed as early as possible (usually 2-3 weeks after birth). In strabismic 
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amblyopia, anti-amblyopic treatment is initiated when the condition is diagnosed long 
before the surgery for strabismus. The reasons for this are improving the possibility to gain 
binocular vision if visual acuity is improved, easiness to determine the fixation patters, and 
the strabismus serves as a reminder to the parents on the importance of treatment. Surgery 
is performed only after achieving alternating fixation and equal visual acuity. 
The length of patching or other penalization depends on the severity of the amblyopia. It is 
increased in direct proportion with the degree of the amblyopia. The follow-up frequency is 
also increased as the length of patching increases. Amblyopia is more easily reversible if it 
occurs later (ages 6-9) than earlier in life. Improvement of visual acuity should be both in 
single and multiple signs on Snellen chart and should be permanent. However, regression 
may occur and requires re-treatment. 
Occlusion may be for full-time (all the day) for several days with one day off, or part time 
(several hours per day). Full-time occlusion is preserved for severe amblyopia with no 
binocular vision such as deprivative amblyopia. Full-time occlusion should not exceed one 
week per one year of age. Part-time treatment is preferred according to the Pediatric Eye 
Disease Investigator Group (PEDIG) studies because it has a similar outcome as full-time 
occlusion with less risk for development of amblyopia in the normal fellow eye, especially in 
the presence of binocular vision and mild amblyopia. Six hours per day of occlusion are 
sufficient for severe amblyopia of less than 20/100 and 2-3 hours per day for moderate one 
(better than 20/100). Contact lenses may be employed in anisometropia of more than 3.00D 
to prevent aniseikonia. However, this is more demanding treatment. Bilateral amblyopia in 
isoammteropia is usually not treated with occlusion and improves slowly spontaneously 
once refractive correction has been applied. In all cases, it is essential to rule out the 
development of amblyopia in the sound eye during treatment.  
Obtaining compliance is difficult especially at the beginning of the treatment. The 
compliance becomes better as visual acuity of the amblyopic eye improves. Children try to 
remove or pick through the occluder. Therefore, it is better to use eye drops as penalization 
or a skin sticker rather than a sticker to the eyeglass. A full cooperation is required from the 
parents. They should be insisting on meticulous treatment for the full period. It is best to 
occlude when the child is at home under supervision of the parents and to occlude when the 
child is performing near tasks such as reading or doing homework. A close follow-up is 
required to ascertain improvement in visual acuity of the amblyopic eye and prevention of 
developing amblyopia in the fellow eye. In general, the follow-up intervals are one week per 
each year of life (e.g., a 2-year-old child is followed every 2 weeks). The follow-up includes 
visual acuity in each eye with full cycloplegic correction after refraction. If the visual acuity 
decreases, the reason for it should be disclosed. If the correction is not sufficient, it should be 
adjusted accordingly. If it is sufficient, an adjustment of the anti-amblyopic treatment 
should be performed. The length of occlusion is gradually decreased if the visual acuity 
improves to the desired level and no regression is observed in follow-up visits. Occlusion is 
gradually tapered according to the patient’s response. Gradual decrease in occlusion time 
has been demonstrated to be associated with less recurrence rate than abrupt determination. 
If regression is noted, the treatment is re-initiated and continued over the vulnerable period 
(up to the age of 17). Follow-up until the age of 17 is necessary even if the optimal results 
have been achieved. Recurrence occurs in up to 75% of the patients usually within the first 
13 months.4 If treatment has not been successful after several (usually 6) months, it may be 
abandoned and visual function will not improve thereafter. 
In animal models, L-dopa and bicuculline have been demonstrated to reverse amblyopia. 
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amblyopia, anti-amblyopic treatment is initiated when the condition is diagnosed long 
before the surgery for strabismus. The reasons for this are improving the possibility to gain 
binocular vision if visual acuity is improved, easiness to determine the fixation patters, and 
the strabismus serves as a reminder to the parents on the importance of treatment. Surgery 
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increased in direct proportion with the degree of the amblyopia. The follow-up frequency is 
also increased as the length of patching increases. Amblyopia is more easily reversible if it 
occurs later (ages 6-9) than earlier in life. Improvement of visual acuity should be both in 
single and multiple signs on Snellen chart and should be permanent. However, regression 
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(better than 20/100). Contact lenses may be employed in anisometropia of more than 3.00D 
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each year of life (e.g., a 2-year-old child is followed every 2 weeks). The follow-up includes 
visual acuity in each eye with full cycloplegic correction after refraction. If the visual acuity 
decreases, the reason for it should be disclosed. If the correction is not sufficient, it should be 
adjusted accordingly. If it is sufficient, an adjustment of the anti-amblyopic treatment 
should be performed. The length of occlusion is gradually decreased if the visual acuity 
improves to the desired level and no regression is observed in follow-up visits. Occlusion is 
gradually tapered according to the patient’s response. Gradual decrease in occlusion time 
has been demonstrated to be associated with less recurrence rate than abrupt determination. 
If regression is noted, the treatment is re-initiated and continued over the vulnerable period 
(up to the age of 17). Follow-up until the age of 17 is necessary even if the optimal results 
have been achieved. Recurrence occurs in up to 75% of the patients usually within the first 
13 months.4 If treatment has not been successful after several (usually 6) months, it may be 
abandoned and visual function will not improve thereafter. 
In animal models, L-dopa and bicuculline have been demonstrated to reverse amblyopia. 
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However, they have not been used in humans because the first one showed only a 
temporary effect and the second can cause seizures. 
4. Prevention 
Prevention of amblyopia is of outmost importance. Screening of red reflex at birth should be 
done to all neonates. Screening programs at preschool and school children are also important. 
5. Background 
To date, no changes in gross anatomy of the eye were found in the human amblyopic eye. 
When optical coherence tomography (OCT) was employed to evaluate the overall macular 
thickness, volume and the retinal nerve fiber layer (RNFL) thickness, it was found that all 
were similar in one study between strabismic amblyopic and the fellow eyes in 14 patients.5 
Another study did report thicker RNFL in amblyopic eyes than in normal fellow eyes.6 
When the differences in RNFL thickness were compared between amblyopic eyes and 
normal eyes of other subjects, they were found to be statistically insignificant.7 In this study, 
the foveal thickness in the amblyopic eyes was similar to normal control eyes (p=0.551), but 
the authors did not compare it with the normal fellow eye. It would be expected that any 
differences in the anatomy in vivo between amblyopic and normal eyes would be 
microscopic. One should also consider the reproducibility of the OCT and the normal 
variations between normal eyes at different ages. Therefore, to show differences, a 
comparison should be made first with the fellow normal eye in unilateral amblyopia. 
We compared the foveal thickness of amblyopic eyes with the fellow normal eye by OCT. 
Furthermore, we compared the foveal thickness of amblyopic eyes that underwent 
successful occlusion therapy with amblyopic eyes refractory to treatment. Such a study has 
not been previously reported according to Medline® search. The rationale for the current 
study was that even if the gross anatomy is normal, subtle structural variations such as 
foveal hypoplasia might exist.  
6. Methods 
In a prospective study, we compared the foveal thickness of amblyopic eyes with the fellow 
normal eyes in unilateral strabismic and anisometropic amblyopia by OCT (spectral 
OCT/SLO, OTI, Ophthalmic Technologies, Toronto, Canada). The inclusion criteria included 
best-corrected visual acuity (BCVA) of 20/80 or less in the involved eye, BCVA of 20/25 or 
better of the fellow eye, normal eye exam of each eye and no explanation for the low visual 
acuity except for amblyopia, presence of one of the causes for amblyopia (anisometropia of 
more than –3.00D or more than +1.00D, or strabismus), no other ocular, neurologic or systemic 
disorders, and children between 4 and 10 years of age who can undergo OCT and be treated 
for amblyopia and that followed the treatment orders. All other patients were excluded from 
the study. Ocular and general medical history were obtained and the patients underwent a 
complete ophthalmic examination of each eye including visual acuity by Snellen charts, pupil 
reactions, slit lamp examination, dilated funduscopic examination with a slit lamp 
biomicroscopy and indirect ophthalmoscopy. 
All eyes were analyzed by OCT. Measurement was performed at the thinnest point of the 
macular center, representing the fovea. Several topographic 3D, linear and radial scans were 
 
Amblyopia and Foveal Thickness 
 
283 
obtained. The acceptance criteria of OCT included a central reflex, signal strength of at least 4 and 
standard deviation of the foveal thickness of less than 10% of the mean for each individual.  
Amblyopic patients with refractive errors were treated by refractive full cycloplegic 
correction. Amblyopic patients with strabismus underwent strabismus surgery. All patients 
underwent occlusion (patching) therapy of the sound eye at least 6 for months and were 
followed according to previous recommendations.3,8-10 Successful treatment was defined as 
an improvement in visual acuity in the amblyopic eye in at least 2 Snellen lines. The follow-
up time ranged between 12 and 54 months. 
Statistical analysis was performed with SPSS version 11.5 program (SPSS Inc., Chicago, IL, 
USA). Paired sample T-test was used for samples larger than 15 and Wilcoxon signed rank 
test was employed for smaller samples. Two-tailed p<0.05 was considered as statistically 
significant. Approval by the IRB/Ethics Committee was obtained and the patients’ parents 
received a full explanation about the exam.  
7. Patients 
Nineteen children aged 4-10 with unilateral amblyopia were included. Ten patients had 
anisometropic (refractive) and 9 had strabismic amblyopia. Eight patients had successful 
occlusion therapy, while the other 11 had unsuccessful treatment.  
8. Results 
The foveal thickness in amblyopic eyes was 201±42 µm (average±SD) and in the normal 
fellow eyes 174±27 µm. The fovea was statistically thicker in the amblyopic eyes of whatever 
cause than in the normal fellow eye (p=0.011, paired sample T-test). The foveal thickness in 
eyes with anisometropic amblyopia (n=10) was 194±45 µm and in the fellow eyes of the 
same patients 167±23 µm (p=0.059, Wilcoxon signed rank test). The foveal thickness in eyes 
with strabismic amblyopia (n=9) was 210±39 µm and in the fellow eyes of the same patients 
181± 30 µm (p=0.070, Wilcoxon signed rank test).  
Eight (42%) of the 19 patients experienced improvement in BCVA after occlusion therapy. 
Six of the 8 had anisometropic and 2 had strabismic amblyopia. From the group of 11 (58%) 
patients that did not show improvement in BCVA, 4 had anisometropic and 7 had 
strabismic amblyopia (p=1.000). The foveal thickness in the patients who showed no 
improvement in BCVA after treatment was 216±41 µm and in their fellow eyes 176±31 µm 
(p=0.016, Wilcoxon signed rank test) (Table 1). In those who showed improvement, the 
foveal thickness in the amblyopic eyes was 181±36 µm and in their fellow eyes 171±21 µm 
(p=0.297, Wilcoxon signed rank test). Examples of the topographic 3-dimensional OCT maps 
of an amblyopic and normal fellow eye are seen in figures 1 and 2.  
 
Parameter Amblyopic eye Fellow eye P-value 
Total (n=19) 201±42 174±27 0.011 
Refractive (n=10) 194±45 167±23 0.059 
Strabismic (n=9) 210±39 181±30 0.070 
VA improvement (n=8) 216±41 176±31 0.016 
No VA improvement (n=11) 181±36 171±21 0.297 
Mean±SD in µm 
Table 1. The foveal thickness in µm as measured by optical coherence tomography in 
amblyopic versus the normal fellow eye. 
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Fig. 1. A topographic 3-dimensional OCT image of the right amblyopic eye of a 10-year-old 
boy that was refractory to treatment measured a foveal thickness of 195 µm. 
 




Fig. 2. A topographic 3-dimensional OCT image of the left normal eye of the same patient as 
in figure 1 measured a foveal thickness of 167 µm. The fovea was thinner in this normal eye 
than the amblyopic eye. 
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Fig. 2. A topographic 3-dimensional OCT image of the left normal eye of the same patient as 
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9. Discussion  
Amblyopic eyes are classically considered as having a normal structure.1 The only changes 
that have been found were smaller parvocellular cells in layers II, III and V in the ipsilateral 
lateral geniculate body, layers I, IV and VI of the contralateral lateral geniculate body and 
reduction in the number of cells in the primary (striate) visual cortex V1 receiving input 
from the affected eye.11,12 Reduction was noted in the number of cells receiving binocular 
input. An increase in the number of cortical cells responding to a contour orientation also 
occurs. Positron emission tomography demonstrated a reduced cortical activity under visual 
stimulation of the amblyopic eye.13 
We found that in the amblyopic eyes the fovea was thicker than in the normal fellow eyes. 
This was common both for anisometropic and strabismic eyes. Our finding is supported by 
a recent study in 3,529 children aged 6-12 years that found thicker fovea in amblyopic eyes 
than in the normal fellow eyes by 5µm.14 These and our results differ from a recent 
evaluation of the foveal thickness that did not show statistically significant differences 
(p=0.551) of the foveae in patients with unilateral anisometropic and strabismic amblyopia 
compared with normal subjects.7 Nonetheless, the authors did not compare the amblyopic 
eye with the normal fellow eyes and therefore, did not have an internal control. The 
differences between our study and the previous one probably relate to variability of foveal 
thickness in different individuals and indeed such differences were found between different 
individuals in our study and therefore the standard deviation between different individual 
was quite high. 
Careful review of the OCT images indicated that the foveal thickening was due to either 
thicker outer retinal layers or immature retinal tissue. The structural feature of the foveae in 
amblyopic eyes is hypoplasia similar to albinotic and nanophthalmic eyes.15-18 The fovea is 
thicker and flatter in these eyes. Since there are no histologic preparations of the retina in 
amblyopic eyes, it is impossible to determine the exact composition of the foveal area. 
However, in oculocutaneous albinism the retinal tissue was intact and the Bruch's layer was 
thickened in one specimen.19 
We found that amblyopic eyes refractory to occlusion therapy had thicker fovea than those 
of the normal fellow eyes, while the differences in thickness between amblyopic eyes that 
responded to treatment and the fellow eyes were insignificant. This finding could have been 
different if patients and their parents would not be cooperative. No previous study 
addressed this issue and therefore we cannot compare our data with previous ones. 
In our study, patients with anisometropic amblyopia had not statistical significant success of 
the occlusion therapy compared with patients with strabismic amblyopia. The differences in 
foveal thickness in the amblyopic and the sound fellow eyes in each group were not 
statistically significant although they were marginal in the amblyopic eyes of the 
anisometropic group. The higher number of anisometropic patients that underwent successful 
occlusion therapy might explain this tendency. A larger population will be required to confirm 
if the foveal thickness differs in these two groups and if the type of the amblyopia is the cause 
for different foveal thickness rather than treatment success. The higher success of occlusion 
therapy in anisometropic amblyopia than in strabismic amblyopia might be related to the 
thinner foveae in anisometropic patients. Thicker foveae were found in strabismic than in 
anisometropic amblyopia in another study as well (p=0.046).7 
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In our sample, the foveae of the amblyopic eyes were thicker than in the fellow normal eyes 
except for one in which the thickness was the same and another 3 with thicker normal fovea. 
Two of these patients experienced an improvement in BCVA after occlusion therapy. If in all 
future patients, the fovea of the amblyopic eye will be thicker than in the fellow normal eye, 
the foveal thickness may serve as a prognostic factor for improvement after proper therapy. 
To validate this, more patients should be recruited and a scale should be established for the 
measures that may predict improvement or non-improvement. It is possible that there will 
be patients in whom the fovea in the amblyopic eye would be thinner than in the normal 
fellow eye and would not experience an improvement in BCVA after treatment. In such 
event, it may not be possible to predict the success of a treatment based on the foveal 
thickness at least in those patients. 
In patients with bilateral amblyopia, measurements of each fovea and a comparison with 
normal foveae will be needed. In such cases, the differences might be subtle as after 
comparing unilateral amblyopic eyes with normal controls and prediction of successful 
treatment may be difficult. According to our findings, it might be worthwhile to create a 
database for foveal thickness in the normal population according to age, since the foveal 
thickness may change with age.20 In addition, a correlation between BCVA and foveal 
thickness might be established as well. 
OCT measurements in children are demanding because of inattention, especially in children 
under age 4. In addition, amblyopic eyes tend to fixate less and if nystagmus is present, clear 
images may not be possible to obtain, unless the eye is mechanically fixated. We should also 
consider the accuracy and reproducibility of the OCT. When assessing thin layers as in the 
fovea, if the accuracy and reproducibility are not perfect, subtle differences may not be 
measured accurately, even if the image resolution is of 2µm. For macular thickness, OCT 
was found accurate and reproducible21 and it is expected that with better technologies 
including high-resolution Fourier-domain OCT, this problem will be solved.  
It will be interesting to verify our results in amblyopic adults and to find what is the foveal 
thickness in children that had regression after treatment. The last and the most intriguing 
issue is whether treatment influences the foveal thickness. Since the fovea, as well as other 
structures such as the lateral geniculate body and visual cortex, continue to develop after 
birth (the “critical” period), it is tempting to hypothesize that in successful treatment, the 
foveal thickness might also change. 
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1. Introduction 
In glaucoma, the most commonly used surgical options attempt to establish communication 
between the anterior chamber and the subconjunctival space, either by removing part of the 
trabecular meshwork and thus decreasing resistance to the passage of the aqueous humour 
or by means of drainage tubes that conduct the aqueous humour toward extraocular 
subconjunctival reservoirs. Trabeculectomy is still the most widely performed glaucoma 
procedure worldwide. Nevertheless, it creates an artificial pathway for drainage of aqueous 
that is less optimal than physiologic outflow and is associated with numerous short and 
long-term serious complications. Surgical alternatives, such as deep sclerectomy, are more 
demanding, longer and seem to be surgeon-dependent. Although they achieve a high level 
of hypotensive effect, these forms of surgery are not exempt from potential complications 
and are highly dependent on the inflammatory and healing response of the patient.1 The use 
of antimetabolites to regulate this healing response is also linked to a higher rate of 
complications.2,3,4,5,6 
The interest in new and possibly less invasive surgical techniques to lower intraocular 
pressure is growing. In particular, to avoid the eventual problems linked to surgical trauma to 
the conjunctiva and the ensuing inflammatory response, several new ab interno methods that 
attempt to achieve intraocular pressure control have been developed. Some of these methods 
are aimed at obtaining flow through Schlemm’s canal, whereas others point to the possibility 
of obtaining flow from the anterior chamber to the suprachoroidal space. Gonioscopy is used 
in these ab interno procedures in order to visualize the site of implantation. 
2. Visualizing the trabecular meshwork 
Trabecular bypass surgery can be performed through the same incision used for 
phacoemulsification in cases of combined surgery, or by means of a paracentesis, when it is 
performed as a sole procedure. A temporal incision is warranted because of ease of patient’s 
head positioning. Visualization of the angle using the goniolens should be practiced in cases 
prior to performing surgery, in order to learn the correct techniques. 
In the case of phakic patients, the instillation of a miotic is recommended to minimize the 
risk of lens injury. If the procedure is carried out under topical anaesthesia it is advisable to 
introduce lidocaine 1% into the anterior chamber, because some of the surgical manoeuvres 
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can be uncomfortable for the patient. It is perfectly possible to carry out the surgery under 
topical anaesthesia with intracameral lidocaine; however, when performing the operation 
for the first few times, it may be advisable to use some form of locoregional anaesthetic 
(retrobulbar, peribulbar or sub-Tenon). 
Once the incision has been made in the temporal cornea, the anterior chamber must be filled 
with a cohesive viscoelastic that makes it possible to enlarge the region of the angle where 
surgery is planned. 
A perfect view of the trabecular meshwork and of the angle must be achieved. The most 
common error is failure to position the microscope and/or the patient adequately in order to 
obtain an adequate view of the trabeculum. The patient’s head must be turned 
approximately 45° away from the surgeon. The microscope should be tilted approximately 
30⁰ towards the operating surgeon.  
3. Specific devices and surgical techniques 
3.1 iStent® 
The iStent® trabecular micro-bypass (Glaukos Corporation, Laguna Hills, CA) is made of 
titanium and coated with heparin (Duraflo® powder). It is L-shaped and measures 1 mm x 
0.33 mm, with a nominal snorkel bore diameter of 120 microns (fig.1). The iStent is designed 
to fit into Schlemm´s canal. The distal portion of the stent is bevelled and sharpened to 
facilitate penetration into the tissue of the trabecular meshwork. The external surface 
features three retention arches that impede the movement of the stent once it has been 
implanted. The implant weighs approximately 0.1 mg. It is delivered preloaded on an 
insertion device (fig.2) and it is implanted at the level of the trabecular meshwork with the 
aid of a Swan-Jacob type goniolens (fig.3). Two versions of the iStent are available; one for 
the right eye and one for the left eye. The difference lies in the orientation of the rails, 
designed to facilitate the penetration of the implant into the trabecular meshwork. The distal 
tip of the implant should point towards the patient’s feet at all times. 
 
Fig. 1. iStent® trabecular bypass 
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Fig. 3. Swan-Jacob goniolens 
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In all these techniques the patient is draped as for cataract surgery. Myosis is warranted if 
the surgery is not combined with phaco. Surgical steps are as follows:  
1. A paracentesis is made generally using a 15 degree blade (fig.4).  
2. If needed, the pupil is constricted with intracameral miotics and a cohesive viscoelastic 
is injected in the anterior chamber.  
3. The tip of the stent, with the distal part parallel to the trabecular meshwork, should 
approach the trabecular meshwork at an angle of 15° to facilitate penetration of  
the tissue (fig.5). The stent should be placed parallel to the plane of the iris with the 
inner part covered by the meshwork and the lumen away from the iris. Excessive 
resistance indicates a path that is too perpendicular to the trabeculum or a wrong 
implantation site. Once the trabecular meshwork covers all of the implant, it should 
be released by pressing the applicator button. Only the proximal end of the stent 
should remain visible in the anterior chamber. The stent can be seated in its final 
position by gently tapping the side of the snorkel with the inserter tip. A small reflux 
of blood from Schlemm´s canal is common and reflects adequate positioning of the 
stent. 
4. At the end of surgery, blood and viscoelastic are removed(Fig.6). The corneal incision 






Fig. 4. A paracentesis is performed temporally.  
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Fig. 5. The iStent is already half way within the trabecular meshwork. 
 
Fig. 6. Residual blood and viscoelastic are washed and aspirated by the anterior chamber 
with a coaxial I/A tip - the same can be done using a bimanual technique. 
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The post-operative suggested treatment should be similar to what is commonly used by 
each surgeon for an uncomplicated phacoemulsification procedure. Generally anti-
glaucoma drugs are discontinued post-operatively and reintroduced if the patient does not 
achieve the target pressure. 
iStent inject is a second generation trabecular bypass device that is also designed to restore 
conventional outflow (fig. 7). Two stents come preloaded in a sterile disposable injector that 
is placed on the meshwork.  A stent release button on the injector is used to release the 
stents one at a time into the proper position (approximately 2-3 clock hours apart (fig. 8). 
This new mechanism of implantation allows for implantation of two stents without exiting 
the inserter from the eye. 
 
Fig. 7. iStent® inject (image provided by Glaukos) 
 
Fig. 8. iStent® inject inserter (image provided by Glaukos) 
3.2 Trabectome 
The Trabectome™ (NeoMedix Inc., Tustin, CA, USA) device consists of a disposable 
handpiece tip (19.5-gauge) that will fit through a 1.6mm corneal incision. The handpiece is 
connected to a console with irrigation and aspiration, and also to a simple electrocautery 
generator. The foot pedal controls the irrigation, aspiration and electrocautery ablation via a 
stepwise foot control similar to a phacoemulsification system (fig. 9).  
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Fig. 9. Trabectome probe and tip 
The tip of the handpiece is specially designed with an insulated footplate and is pointed for 
ease of insertion through the trabecular meshwork into Schlemm´s canal. The footplate is 
coated with proprietary multilayered polymer, which provides thermal stability, mechanical 
strength, biocompatibility and chemical resistance in laboratory testing. The aspiration port 
is in close proximity (approximately 0.3 mm) to the cautery electrode and serves to remove 
debris during ablation. The irrigation is 3 mm from the surgical site and serves the dual 
purpose of keeping the eye pressurized and further dissipating heat energy. Although the 
irrigation and aspiration system role is important, the high-frequency electrocautery 
generator system is the pivotal point of this technology. The generator is a modified 800 EU 
unit from Aaron/Bovie (St. Petersburg, FL, USA) and operates at a frequency of 550 kHz 
with adjustable power setting in 0.1-W increment up to 10 W (recommended range 0.5–1.5 
W). The target tissue is disrupted and disintegrated by applying heat energy in bursts with a 
high-peak power and low duty cycle. This ablation approach equates to high-energy bursts, 
which are bunched into small increments with comparably long time intervals in between. 
As a result, disruption and disintegration of tissue is achieved rather than a thermal-cooking 
effect such as that seen in traditional cautery of blood vessels.7,8 
Surgical steps: steps 1 and 2 are equal to the previous procedure, although a specially 
designed blade is provided by the manufacturer to obtain a water-tight paracentesis. A 
small paracentesis is more important with this procedure because during surgery the 
viscoelastic material is washed out by the water flowing through the tip of the instrument. 
2) The tip of the footplate is inserted through the paracentesis aiming at the trabecular 
meshwork and then it is inserted through the trabecular meshwork into Schlemm´s canal . A 
foot switch activates the aspiration and electro-surgical elements that ablate and remove the 
strip of trabecular meshwork and Schlemm´s canal as the surgeon slowly advances the 
instrument along the meshwork in a clockwise and then counter clockwise direction using 
the insertion site as a fulcrum. A strip of trabecular meshwork and Schlemm´s canal 
spanning 80°–100° is ablated and removed under direct gonioscopic visualization. 
Intraoperative reflux of blood through the resulting cleft is desirable in this procedure and 
confirms appropriate ab interno “unroofing” of Schlemm’s canal. 4) At the end of surgery 
any residual viscoelastic or blood present in the anterior chamber is removed. It is generally 
not necessary to hydrate the paracentesis.  
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The post-operative suggested treatment includes: antibiotics used for prophylaxis. 
Pilocarpine 2% qid should be used starting on the first post-operative medication and 
continued for a month. Lotemax is advised for three weeks and then tapered. Directly post-
operative it is advised to continue the previous pre-operative anti-glaucomatous therapy, 
although prostaglandins should possibly be avoided. .Prof. Baerveldt recommends the 
eventual use of Latanoprost rather than other prostaglandins if they are absolutely 
necessary.  Iopidine and Brimonidine can be used and are generally suggested. Anti-
glaucoma medications can be reduced a month after surgery if target pressure is achieved. 
3.3 Other procedures 
Other approaches of gonioscopic surgery include the Ivantis method which simulates a 
short canaloplasty. 
Two additional devices are aimed at improving flow of the aqueous humor from the 
anterior chamber to the suprachoroidal space. These are the Glaukos iStent supra and the 
Transcend Cypass. These devices will not be discussed, because the current data are less 
than one year post-operative. 
4. Results 
4.1 iStent 
Numerous in vitro and in vivo studies support the stability, the effectiveness and the safety 
of the trabecular bypass iStent. 
In 2004, Bahler demonstrated in vitro that the intraocular pressure was lowered after 
placement of a single stent, from 21.4 +/- 3.8 mm Hg to 12.4 +/- 4.2 mm Hg (P < .001).9 This 
corresponded to an 84% increase in facility of outflow. Eyes receiving more than one stent 
had final IOP of 11.9 +/- 3.7 mm Hg. Nine eyes underwent sequential implantation of 
additional stents and seven of these had a further decrease of IOP (13.6 +/- 4.1 to 10.0 +/- 
4.3; P = .02). This work suggested that bypass of the trabecular meshwork lowers IOP in 
cultured human anterior segments. One stent produced the greatest change in pressure. The 
sequential addition of more stents further lowered pressure in seven of nine eyes. Parallel to 
this study the founders/manufacturers of the iStent evaluated the stability of the implant on 
ex vivo eyes confirming that the L shape of the stent could not be moved even with strong 
traction on the stent itself. 
A small clinical case series (n=6) reaffirmed the potential clinical utility of the current 
titanium version inserted ab interno and provided additional confirmation that the device 
stayed in place and continued to function to lower IOP with fewer medications through 
follow-up of one year.10 All patients were seen day one, week one and at 1, 2, 6 and 12 
months post-operatively. The mean pre-operative IOP of 20.2 ±6.3 decreased and stabilized 
at 14 to15 mm Hg with reduced medications out to one year. All devices remained in place 
and no complications were noted. 
A larger prospective, 24-month, uncontrolled, multicenter, multicountry evaluation of 58 
patients with uncontrolled primary open-angle glaucoma (including pseudoexfoliation and 
pigmentary) evaluated the effectiveness of the concurrent phacoemulsification and stent 
implantation.11 Of the 48 patients in the per protocol population, 42 completed the 12 
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months follow-up. At baseline, mean (+/-SD) intraocular pressure (IOP) was 21.7+/-3.98 
mmHg. At 12 months, mean IOP was reduced to 17.4+/-2.99 mmHg, a mean IOP reduction 
of 4.4+/-4.54 mmHg (p<0.001, 18.3%). At baseline, patients were taking a mean 1.6+/-0.8 
medications. By 12 months, the mean number of medications was reduced to 0.4+/-0.62 
(p<0.001). Half the patients achieved an IOP ≤ 18 mmHg and were able to discontinue 
hypotensive medication by the 12 month visit. The most commonly reported device-related 
adverse events were the appearance of stent lumen obstruction (seven eyes) and stent 
malposition (six eyes). None of the adverse events were deemed serious. 
In 2010 Fea compared in a randomized study the results of phacoemulsification alone vs 
combined surgery (i.e. phacoemulsification and stent implantation).12 The baseline IOP was 
similar in the two groups (combined group: 17.9 +/-2.6; control group: 17.3  +/-3.0 mm Hg) 
with a similar number of medications (2.,0 +/- 0.9 in the combined group and 1.9  +/-0.7 in 
the control group). Post-operative mean IOP at 15 months was 14.8 +/-1.2 and 15.7 +/- 1.1 
respectively in the combined and in the control group (p=0.031). The author demonstrated 
that at 15 months the mean number of ocular hypotensive medications was significantly 
lower in the combined group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007). 
Furthermore, after wash-out of ocular hypotensive medications, IOP was significantly lower 
in the combined group (16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg). These results confirm 
the previous observation that IOP reduction could only partially be attributed to 
phacoemulsification and was in fact enhanced further by implantation of the iStent. The 
same author previously published a case report demonstrating the effectiveness of the 
procedure in one pseudophakic patient.13 
More recently the effect of the iStent on flow was further elucidated by a fluorophotometic 
study by Fernandez-Barrientos et al.14 Thirty-three eyes of 33 patients were randomized to 
either two stents and cataract surgery (n = 17, Group 1) or cataract surgery alone (n = 16, 
Group 2). Before surgery, flow and outflow facility were similar between Groups 1 and  
2 (1.78 +/- 0.44 and 1.74 +/- 0.82 microL/min; P = 0.18; 0.12 +/- 0.03 and 0.13 +/-  
0.06 microL/min/mm H; P = 0.71, respectively). At one year, outflow facility was 
significantly higher in the group with two stents (0.45 +/- 0.27 microL/min/mm Hg in 
Group 1 and 0.19 +/- 0.05 microL/min/mm Hg in Group 2; P = 0.02). 
A larger prospective, randomized, open-label, controlled, multicenter clinical trial with a 
total of 240 eyes with mild to moderate open-angle glaucoma with intraocular pressure 
(IOP) ≤ 24 mmHg controlled on one to three medications compared the results of the 
patients who were randomized to undergo cataract surgery with iStent implantation 
(treatment group) or cataract surgery only (control).15 The primary efficacy measure was 
unmedicated IOP ≤ 21 mmHg at one year. A secondary measure was unmedicated IOP 
reduction ≥ 20% at one year. Safety measures included best-corrected visual acuity (BCVA), 
slit-lamp observations, complications and adverse events. The study met the primary 
efficacy endpoint, with 72% of treatment eyes versus 50% of control eyes achieving the 
criterion (P<0.001). At one year, IOP in both treatment groups was statistically lower from 
baseline values. Sixty-six percent of treatment eyes versus 48% of control eyes achieved  
≥ 20% IOP reduction without medication (P = 0.003). The overall incidence of adverse events 
was similar between groups with no unanticipated adverse device effects. This larger series 
not only further demonstrates the efficacy of the iStent in further lowering the intraocular 
pressure in patients undergoing cataract surgery, but also points out the safety of the 
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procedure. A longer post-operative follow-up through two years was reported more 
recently.16 Best-corrected visual acuity of 20/40 or better was reported in 93% of treatment 
vs. 91% of control eyes at two years. Over the two year period, post-operative adverse 
events occurring at a level of 5% or greater included posterior capsular opacification  
(6% treatment vs. 10% control), elevated IOP (4% vs. 7%, respectively), visual disturbance 
(3% vs. 7%, respectively) and iritis (1% vs. 5%, respectively). Furthermore, in the treatment 
group, stent obstruction and malposition occurred in a small percentage of eyes (4% and 3%, 
respectively) and resolved shortly after occurrence (with or without treatment). The authors 
concluded that the overall long-term safety of iStents implanted during cataract surgery was 
similar to that of cataract surgery alone and that the adverse event/complication rate was 
low through the two year post-operative period. 
4.2 Trabectome 
The results obtained by the Trabectome can be summarized by a single paper which reports 
the experience of the Trabectome group. In this retrospective case series the authors 
reported their experience on follow-up through one year on 143 of 1127 Trabectome surgical 
procedures, including 102 through one year from 738 Trabectome-only and 41 through one 
year from 366 Trabectome-phacoemulsification surgeries17. It should be pointed out that 
many eyes at relatively high risk for filtering surgery failure were included after prior failed 
trabeculectomy or other previous surgeries were included in the study. Considering 
glaucoma surgery only: 273 underwent SLT, 170 ALT, 20 aqueous shunt surgery, 104 
trabeculectomy, five prior Trabectome and five laser iridectomy. 
Considering all cases, mean pre-operative IOP of 23.8 +/- 7.7 mm Hg decreased by 39% to 
16.5 +/- 4.0 mm Hg at 24 months (n = 50). Intra-operative reflux bleeding occurred in 77.6%. 
Medications decreased from 2.8 to 1.2 by 24 months. Sixty-five patients (5.8%) had IOP 
elevation > 10 mm Hg above baseline on day one. Failure led to trabeculectomy in 5.9%  
(n = 67) and shunt installation in 1.6% (n = 18). Kaplan-Meier failure was defined across 
groups with at least two weeks follow-up as IOP > 21 mm Hg with or without medications 
and not reduced by 20% below baseline on two consecutive visits or repeat surgery. For 
Trabectome-only cases, mean preoperative IOP of 25.7 +/- 7.7 mm Hg was reduced by 40% 
to 16.6 +/- 4.0 mm Hg at 24 months (n = 46). No prolonged hypotony, choroidal effusion, 
choroidal haemorrhage or infections occurred. Failure led to trabeculectomy in 8.1% (n = 60) 
and shunt installation in 1.9% (n = 14). Medications decreased from 2.93 to 1.2 by 24 months. 
For Trabectome-phacoemulsification cases, baseline IOP of 20.0 +/- 6.2 mm Hg decreased at 
12 months to 15.9 +/- 3.3 mm Hg (18%) (n = 45) and medications decreased from 2.63 +/- 
1.12 to 1.50 +/- 1.36. Sixteen (4.4%) of 365 had prior failed trabeculectomy and 139 of 365 
(38%) had prior laser trabeculoplasty. 
Although the the large number of patients who underwent surgery of the study are very 
impressive, there are major limitations, including the retrospective nature and the fact that a 
very small number of procedures reported had been followed up postoperatively. Of the 738 
patients who underwent only the Trabectome procedure, only 102 had a one year follow-up 
and of the 366 with combined surgery only 41 were followed up to one year. Furthermore, it 
is not clear if the patients with a longer follow-up and with available data include those high 
risk patients who were originally included in the study. If this is the case it would have been 
very important to analyse if there was any difference in terms of efficacy in the high versus 
low risk patients. 
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Recently, Knape and Smith18 presented the case of a patient who had intra-operative blood 
reflux onto peripheral iris during trabeculectomy 11 months after Trabectome surgery. After 
having left the eye firm after surgery, the author did not report any other episode of hyphema 
during the following period. He hypothesizes that the absence of overlying angle structures, 
including the roof of Schlemm’s canal, may have allowed blood to reflux into the angle and 
onto peripheral iris during a sudden decrease in intraocular pressure in trabeculectomy 
surgery. This self-limited episode suggests that the trabeculotomy remained patent, although 
the patient was not compensated and points out that further studies to assess the 
consequences of permanent trabecular meshwork tissue removal may be warranted. 
More recently, Jea19 reported on a cohort of patients and showed that a previously failed 
Trabectome surgery does not seem to impact the effect of subsequent trabeculectomy. 
5. Complications prevention and treatment 
Bleeding: bleeding with iStent, Trabectome or other trabecular bypass procedures is 
generally minimal, although aspiration of the blood in phakic eyes is suggested in order to 
allow proper visualization.. A very rare occurrence of more significant bleeding in the 
anterior chamber is generally due to damage of the iris either because the surgeon did not 
aim at the correct site or because involuntary movements occurred during surgery. The use 
of air or viscoelastics can stop the haemorrhage. It is generally advisable to postpone the 
trabecular bypass procedure if massive bleeding occurred previously because angle 
visualization can be difficult and because the source of bleeding and the effect on the angle 
structures are easier to visualize after the hyphema has cleared.  
Malposition: the iStent may at times appear malpositioned.  This does not preclude the 
implantation of another one provided the angle can be visualized. It is advisable to move at 
least two or three clock hours away from the previous implant to better visualize the 
meshwork. 
Occlusion: occlusion of the Stent by a seemingly fibrinous plug can sometimes be seen 
during the postoperative follow-up. This may sometimes be eliminated by a single YAG 
laser spot. 
Endothelial damage: although possible, it has never been reported with any of the 
procedures described.  
6. Conclusions 
The idea of approaching the surgery site ab interno is certainly appealing. The opportunity to 
perform a more standardized procedure and the opportunity to preserve the conjunctiva 
and the sites of eventual subsequent surgery are attractive. Furthermore, creating a direct 
communication between Schlemm’s canal and the anterior chamber is a more physiological 
approach to IOP reduction with a lower rate of complications and a faster surgery compared 
to any other available approach. 
Several studies pointed out the efficacy of the iStent in the reduction of IOP, although these 
studies were mainly performed in conjunction with cataract surgery. Nevertheless, there is 
strong evidence both in vitro and in vivo that the stent insertion actually facilitates outflow 
independent of the concurrent phacoemulsification. The procedure is safe and complications 
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are mainly limited to a small (and transient) blood reflux into the anterior chamber 
immediately upon insertion into Schlemm’s canal. It should be noted, however, that all 
studies were performed in eyes with relatively low pre-operative IOP. At present there is no 
published evidence of the efficacy in patients with severe glaucoma nor what would be the 
impact in patients with higher baseline IOP. 
Upon casual review of the number of cases reported by the papers on the Trabectome and 
the length of the follow-up, it may appear that the evidence of efficacy of this surgical 
method is more stringent. The net IOP reduction seems higher with the Trabectome 
compared to the iStent and patients at higher risk had been treated with this method. 
However, a more accurate analysis of the literature reveals that a very small number of 
patients have been followed for a reasonable amount of time. Futhermore, the ablation of 
part of the trabecular meshwork is certainly a more destructive procedure, although it seems 
that this fact does not impact upon the results of conventional surgery in the limited series 
followed for an adequate postoperative timeframe. 
IOP outcomes with both approaches are usually in the mid-teens. Although mid-teens IOP 
might be adequate for initial and moderate patients, traditional filtering surgery with anti-
fibrotic enhancement and bleb formation will probably remain the principal surgical 
approach to eyes with advanced glaucomatous optic neuropathy. Eventually more 
advanced patients may benefit from trabecular bypass surgery combined with hypotensive 
medications, but too little data are available at present to sustain this approach. Assuming 
ongoing clinical studies continue to be favourable, a strong argument can be made for use of 
these minimally invasive procedures which do not lead to bleb formation nor require anti-
fibrotics, early in the glaucoma injury process, especially considering the difficulties of 
compliance with medical therapy. Neither of these procedures damages the conjunctiva 
superiorly, leaving surgical alternatives where necessary open. Furthermore, continued 
development of suprachoroidal stents (such as the iStent supra and the newer Transcend 
Cypass) may offer additional IOP lowering and thus serve a broader population of patients 
with more advanced disease. 
Given that glaucoma is typically a chronic disease and that the introduction of these 
methods is relatively new, follow-up of the patients at the moment is limited to two years at 
maximum. 
Trabecular surgery requires some learning curve to visualize the angle using a hand-held 
gonioprims and the diffuse illumination of the microscope gives a different appearance of 
the angle’s structures as compared with slit lamp gonioscopy. Furthermore, the need for 
using a hand to hold the gonioprism makes any trabecular surgery strictly bimanual. 
During surgery, the implantation of the iStent is relatively easier compared with the 
Trabectome, because it does not need a continuous circumferential movement and because 
the chamber is well formed with viscoelastics. After the implantation of the device, the 
blood reflux in the anterior chamber is generally minimal with the iStent. 
On the other hand, the Trabectome allows a visual feeling that the trabecular meshwork is 
ablated, whereas it is sometimes difficult to be sure of the correct iStent placement, 
especially when blood cannot be completely washed from the angle. Compared to 
trabeculectomy, additional costs with any device should also be considered. Furthermore at 
present only the Trabectome has been cleared by the FDA, although U.S. FDA approval of 
the iStent is expected in the near future. 
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are mainly limited to a small (and transient) blood reflux into the anterior chamber 
immediately upon insertion into Schlemm’s canal. It should be noted, however, that all 
studies were performed in eyes with relatively low pre-operative IOP. At present there is no 
published evidence of the efficacy in patients with severe glaucoma nor what would be the 
impact in patients with higher baseline IOP. 
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During surgery, the implantation of the iStent is relatively easier compared with the 
Trabectome, because it does not need a continuous circumferential movement and because 
the chamber is well formed with viscoelastics. After the implantation of the device, the 
blood reflux in the anterior chamber is generally minimal with the iStent. 
On the other hand, the Trabectome allows a visual feeling that the trabecular meshwork is 
ablated, whereas it is sometimes difficult to be sure of the correct iStent placement, 
especially when blood cannot be completely washed from the angle. Compared to 
trabeculectomy, additional costs with any device should also be considered. Furthermore at 
present only the Trabectome has been cleared by the FDA, although U.S. FDA approval of 
the iStent is expected in the near future. 
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1. Introduction 
The natural vitreous is a transparent, gelatinoid structure occupying four-fifths of the 
volume of the eye. It has a thin, membrane-like structure corresponding to the vitreous 
cortex that extends from the ora serrata to the posterior pole.1 It is somewhat spherical but 
slightly flattened meridionally, and it has a cup-shaped depression in its anterior side. It 
consists of about 99% water by weight, collagen fibers (types II, V/XI, VI, and IX), 
hyaluronic acid, opticin, fibrillin, and hyaluronan, which can maintain a certain spatial 
relationship with dipolar water molecules.1,2 However, very few cells are found in the 
vitreous body. These cells are mostly phagocytes that clear useless cellular debris and 
hyalocytes mainly found at the periphery and that produce hyaluronic acid and collagen. In 
human adults, the vitreous body has an approximate weight of 4 g, a density of 1.0053–
1.0089g cm-3, a refractive index of 1.3345–1.3348, and a PH range of 7.0–7.4. 3-5 
The physiological function of the vitreous body involves supporting adjacent posterior 
segment structures, providing an ocular refractive medium, and acting as a cell barrier to 
inhibit cell migration from the retina to the vitreous cavity.6 With age, the natural vitreous 
body gradually shrinks and collapses during the course of syneresis. This phenomenon may 
eventually lead to posterior vitreous detachment and can play a crucial role in the formation 
of retinal breaks which result in rhegmatogenous retinal detachment if untreated.7,8   
The removal of diseased vitreous bodies using pars plana vitrectomy combined with 
artificial vitreous substitutes can restore vision in many patients. These individuals include 
those affected by proliferative diabetic retinopathy, proliferative vitreoretinopathy, and 
endophthalmitis or patients otherwise regarded as hopeless.9-11 
The vitreous body cannot regenerate, so the vitreous cavity must be filled with suitable 
artificial vitreous substitutes that will keep the retina in place and prevent phthisis bulbi. 
Artificial vitreous substitutes are one of the most interesting and challenging topics of 
research in ophthalmology.2 A number of artificial vitreous substitutes, such as gas, silicone 
oil, heavy silicone oil, and hydrogels, have been used.2,12  
There are three major categories of currently available gas vitreous substitutes: air 
substitutes, expansile gas substitutes, and Xenon. Gases are used for pneumatic retinopexy 
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and post-operative endotamponade. However, they are suitable only as short-term vitreous 
substitutes (Table 1).13  
 
 










Air 29 -- 0 5-7 - 
Xenon 131 99.995 0 1 - 
SF6 146 99.9 1.9-2.0 10-14 18 
C2F6  88 99.7 1.9 10-14 - 
C4F8  138 99.9 3.3 30-35 16＋ 
C3F8 188 99.7 4 55-65 14 
Table 1. Physical characteristics of gases as vitreous substitutes 
In 1969, Norton et al. highlighted the advantages of clinical management with intravitreal 
air for the treatment of giant retinal tears.14 However, the intravitreal longevity of air is only 
a few days15 due to diffusion across the retina. The refractive index of the air (1.0008) is also 
incompatible with optically important tissues. Therefore, these issues limit the use of air. To 
date, air is mainly used in liquid–air exchanges during vitrectomy procedures.16 
In 1973, Norton first experimented with sulphur hexafluoride (SF6) and found that the 
persistence of the gas and its expansile characteristics are superior to air. SF6 expands to 
twice its volume by dissolving nitrogen, oxygen, and carbon dioxide from the blood. It also 
stays in the vitreous cavity for about two weeks.17 In 1980, Lincoff et al. proposed the use of 
peruorocarbon gases18. These gases expand after intravitreal injection because of the 
diffusion of other gases from the blood stream. Peruoropropane expands to four times its 
original volume by the fourth day after injection. It is also absorbed at a much slower rate 
than air or sulphur hexauoride. To date, C3F8 is the agent of choice. Expansile gases last 
longer in the vitreous chamber than air, but they are spontaneously absorbed in 6 to 80 days 
and replaced by aqueous humor. Therefore, postsurgical removal is avoided if they cause 
certain concomitant complications.19 However, they may induce lens opacification and 
usually result in a high intraocular pressure (IOP).20,21 As with air, the refractive indices of 
gases are also lower (w1.17).22 
Xenon was tested in rabbit eyes to evaluate its longevity in the vitreous cavity.23 It is 
considered as the most promising gas with successful retinal reattachment in all cases. 
However, the major drawback is its rapid disappearance; almost 90% of Xenon disappears 3 
h after introduction.24 
Silicone oil is hydrophobic, viscous, transparent, and stable. It has a specific gravity of 0.97 
g/mL and a refractive index of 1.4. Its viscosity is measured in centistokes and linearly 
varies with chain lengths and molecular weight. The 1,000 and 5,000 centistoke varieties are 
commonly used in clinics. The surface tension is approximately 40 mN/m. Introduced by 
Cibis in 1962,25 silicone oil has been the most important adjunct for internal tamponade in 
the treatment of complicated retinal or choroidal detachment for the past five decades. It is 
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commonly applied for the treatment of superior retinal detachment through buoyancy force 
and high interfacial tension. It is the only substance currently accepted as a long-term 
vitreous substitute and is the preferred choice in complex retinal detachments, such as long-
standing rhegmatogenous retinal detachment, traction retinal detachment, giant retinal 
tears, proliferative diabetic retinopathy, and severe endoophthalmitis involving the 
posterior segment.  
However, the use of silicone oil has not always been successful. An anatomic success rate of 
around 70% has been reported,19 with complications including cataract, keratopathy, 
anterior chamber oil emulsification, and glaucoma.26 Several reports have demonstrated the 
migration of silicone oil droplets into the retina and the optic nerve. Others have shown the 
widespread loss of myelinated optic nerve fibers due to the oil’s free-fluid characteristics 
within the eye.27, 28  
Heavy oil, a solution of perfluorohexyloctane and silicone oil prepared as internal 
tamponade, has recently been used in retinal detachment surgery. However, it causes 
complications, such as emulsification and inflammatory reaction.29 Some very recent results 
are encouraging,30 but most clinicians are awaiting results from ongoing heavy silicone oil 
trials.12 
Hydrogels and smart hydrogels seem to remain as the best candidates as long-term vitreous 
substitutes because they show excellent transparency and good biocompatibility. They can 
act as viscoelastic shock-absorbing materials, thereby closely mimicking the behavior of 
natural vitreous bodies. Hydrogels are networks of polymer chains that can contain over 
99.9% water so they are hydrophilic and not flowable. Currently, a number of cross-linked 
polymeric hydrogels have been proposed, such as poly (vinyl alcohol) (PVA), poly poly (1-
vinyl-2-pyrrolidone), poly (acrylamide) (PAA), and poly (ethylene glycol) (PEG).2,12,31-34 
Among these, the PVA and PAA hydrogels are the most promising candidates for long-term 
vitreous body replacement and are highly recommended for use. They show excellent 
biocompatibility, are biodegradable, and can closely mimic the physico-mechanical 
properties of natural vitreous bodies.2 PEG is a synthetic water-soluble polymer that has 
been approved by the Food and Drug Administration (FDA) for use in a wide range of 
biomedical applications, including injectable hydrogels.35 However, issues such as retinal 
toxicity, increased IOP, and formation of opacities still need to be addressed.36 
Fragmentation and changes in viscoelastic properties and resiliency after injection through a 
small-gauge needle have also been found in some types of hydrogels.36, 37 
Smart hydrogels are a relatively new class of stimuli-sensitive hydrogels. They possess the 
common properties of conventional hydrogels, and they can respond to a variety of signals, 
including PH, temperature, light, pressure, electric fields, or chemicals.38 Temperature-
sensitive hydrogels, such as poly(N-isopropylacrylamide), the most extensively studied one, 
undergo sharp hydrophilic-hydrophobic transition in aqueous media at a lower critical 
solution temperature of 32 °C, which is close to the body temperature.39 Generally, smart 
hydrogels appear promising, but they are still at an early experimental stage, and their long-
term toxicity is unknown.12 Therefore, despite half a century of research efforts to replace 
the vitreous body of the eye, an ideal and permanent vitreous body replacement has yet to 
be found.40,41 
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Current research on artificial vitreous bodies aims to determine ideal materials that are 
nontoxic and inert, thin and transparent, and have good water and oxygen permeability, 
high compatibility, and good elasticity46 in order to mimic the natural vitreous perfectly. 
The materials must be hydrophilic and can form a gel within the vitreous cavity.35 
However, directly injected vitreous substitutes, like silicon oil and heavy silicon oil, often 
result in severe complications, such as intraocular toxicity, retinal cell proliferation, 
leakage into the anterior chamber, and difficulty of complete removal if emulsified with 
time, among others. 
Inspired by the structure of the natural vitreous, we postulated a novel foldable capsular 
vitreous body (FCVB) to restore the shape and function of the natural vitreous body. The 
FCVB consisted of a capsule, drain tube, and valve. The capsule exactly mimicked the 
vitreous body using a computer. The intra-capsule pressure can be adjusted from the valve 
with a syringe, and there is a slice of anti-penetrating metal in the valve. Figure 1 and Table 
2 show the images and parameters of the FCVB, respectively.50 Silicone rubber elastomer has 
been used for tissue augmentation for many years, 43-45 so it was utilized to manufacture the 
capsule of FCVB. It showed good oxygen permeability, good mechanical and optical 
properties (Shore A hardness: 37.4。, tensile intensity: >5.86 MPa, elongation ratio: >1200%, 
tear intensity: 34KN/m, transmittance: 93%, Hazes<1%),46 and good biocompatibility as 
shown in stable extracts experiment (no significant fever, good genetic safety, and no 
structural abnormality or apoptosis in the cornea, ciliary body, and retina over a six-month 
observation period).50 After pars plana vitrectomy, the seamlessly connected FCVB was 
triple-folded and inserted into the vitreous cavity through a 3 mm × 1 mm scleral incision 
without air fluid exchange. Then an injectable medium, such as balanced salt solution (BSS) 
or silicone oil, can be injected into the capsule and inflated to support the retina. Through 
the tube–valve system, IOP can be adjusted by the volume of the injected medium. Similar 
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Fig. 1. The human foldable capsular vitreous body (FCVB) consists of vitreous-shape high 
molecular capsule, tube, and valve. The intra-capsule pressure can be adjusted from the 
valve with a syringe and there is a slice of anti-penetrating metal in the valve; the designed 
parameters finely mimic the vitreous shape of a human. (A) Illustration of FCVB. (B) Final 
sample of the FCVB (Outside the eye). (C) Side view of varied parameters. (D) Vertical view 
of varied parameters. (E) FCVB inside the eye (Twelve months after implantation). 
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Theoretically, a new artificial vitreous has the following advantages. First, it does not flow 
into the anterior chamber and subretinal regions or other sites. Second, it does not emulsify 
or damage the media over time nor cause it to be isolated in the capsule. Third, it has the 
capability to support discretionary retina using a 360-degree solid arc.  
Developing an irregular vitreous-shaped thin capsule and smoothly connecting it to a very 
thin diameter tube and a pressure-control valve are very difficult. According to this 
hypothesis, a mirror steel mold is specially designed to fabricate FCVB using an injection-
forming technology that would make the capsule, drainage tube, and valve of the FCVB 
seamlessly connected. The mold consists of an upper composite die, a lower composite die, 
and a core.47 The core shape can be manipulated using a computer to match the human 
vitreous parameters. The capsular film is 60 μm thick, only one-third the thickness of the 
retina. In its natural shape, the human FCVB is somewhat spherical, but it is slightly 
flattened meridionally and has a cup-shaped depression anteriorly. 
In the rabbit model of severe retinal detachment, the BSS-filled FCVB was found to mimick 
the morphology of the natural vitreous very closely and to restore its physiological 
functions, such as support, refraction, and cellular barriers, during a three-month 
observation period and without obvious complications. By contrast, the silicone oil control 
group showed obvious lens opacity, significant hyperopic shift, recurrent retinal 
detachment, preretinal membrane formation, and vitreoretinal traction.48 The FCVB capsule 
can provide the detached retina with a platform to form a flat scar and a barrier to block cell 
migration from the retina to the vitreous cavity. 
Interestingly, the BSS-filled FCVB very slightly changes the refraction compared with 
silicone oil and heavy silicone oil based on Gullstrand–Emsley and Liou–Brennan schematic 
eyes.49 Reports from the State FDA in China show that FCVB has suitably mechanical, 
optical, and biocompatibility properties.50 Its optical characteristics indicate that FCVB has 
high light transmission and laser irradiation stability. 
In the early development of breast implants in plastic surgery, similar to current clinical 
vitreous substitutes, directly injectable materials were used. In fact, hydrophilic 
polyacrylamide gel (PAAG) was directly injected into the breast. This procedure was 
practiced widely in China and Eastern Europe in the 1990s. The breast implantation 
procedure was analogous to the use of silicone oil to replace the vitreous body. However, 
the injected PAAG was gradually found to induce severe complications, such as 
inflammation and infection, multiple indurations, hematoma, painful masses, and 
mastalagia. Currently, the direct injection of PAAG is prohibited, and it has been replaced 
with the use of capsule-like implants whose fluid substitute is contained in a thin, elastic 
capsule. This approach to implantation has shown clinical success.51 In case of severe 
complications, as mentioned above, the implant can be completely removed without leaving 
behind residual fluid substitute. Apparently, the development of both artificial vitreous and 
breast substitutes shared a similar path, and both have suffered setbacks from the direct 
injection of the fluid substitute into the organ. Therefore, similar lessons can be learned, and 
the use of a capsule-type implant may be a good replacement for the use of the vitreous 
body.46 
The use of FCVBs in the eyes is not yet a common practice worldwide. Therefore, an 
exploratory study of our new treatment for severe retinal detachment was conducted. The 
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detachment cannot be easily reattached with silicone oil tamponade, such as posterior 
scleral ruptures with large disruptions of the retina or severe scleral ruptures with retinal 
and choroidal detachments. It may also have rigid retinal redetachments or inferior holes 
occurring after silicone or heavy oil tamponade had been attempted. At Zhongshan 
Ophthalmic Center, 11 patients were implanted with FCVBs filled with BSS,52 whereas 3 
patients were implanted with FCVBs filled with silicone oil.53 Patients with serious eye 
inflammation, with only one eye remaining, with silicone oil-filled eyes, with serious heart, 
lung, liver, or kidney dysfunctions, or have other diseases that make them unsuitable for 
inclusion were excluded from the research. Retinal reattachments were found by B-scan in 8 
(73%) of the 11 eyes at the end of the three-month treatment time; leakage of FCVB caused 
failure in three eyes. The production method of FCVB was correspondingly revised, and this 
addressed the problem. No obvious inflammation was observed in any eye after FCVB 
implantation, and UBM showed that the FCVB did not crush the ciliary body. There was no 
obvious difference between the FCVB’s spectral transmittance before implantation and after 
removal.52 Overall, the results showed that FCVB is an effective and safe artificial vitreous 
body for severe retinal detachments. It can help avoid the complications induced by silicone 
oil, such as glaucoma, corneal keratopathy, and silicone oil emulsification during a 12-
month implantation time.53 
Current data have demonstrated the theoretical advantages of using FCVBs, as mentioned 
above. Even if an ideal injectable material can be found, the use of FCVB is necessary to the 
artificial vitreous body. It acts as a transporter that can be injected with media, such as BSS, 
silicone oil, heavy oil, and hydrogels. In the present research, BSS was injected into the 
capsule of FCVB after PPV, and it was demonstrated as a flexible, effective, and safe 
vitreous substitute over a three-month implantation period.52 Further multiple-central 
clinical trials are in progress in China, and the encapsulation of silicone oil, heavy oil, or 
hydrogels in PPV eyes will be attempted. Some common substances are active, such as 
collagen, hyaloronic acid, water, and the natural vitreous that consists of approximately 99% 
water and 1.0% inorganic salts, organic lipids, and hyaluronan1, so these are not 
recommended as encapsulated tamponades in PPV eyes. 
In addition, tiny (300 nm) apertures (Fig.2)54 exist in the capsule, so the FCVB can release 
dexamethasone sodium phosphate and Protein kinase Cα. It can also be used as an 
intravitreal drug delivery system in addition to serving as a vitreous substitute.54,55 
Therefore, without the need to change its chemical properties, FCVB may provide a 
common vehicle for different drug releases, including antibiotics, anti-proliferative agents, 
and vascular endothelial growth factor antagonists.  
The present exploratory clinical study was not large enough to provide a definitive 
conclusion. Further, the effects of FCVB on the lens should be further evaluated because 10 
of 11 eyes were aphakic, and only one eye was phakic.52 Based on this trial, a nine-hospital 
clinical trial is currently in progress in China to ascertain FCVBs’ safety and efficacy as a 
vitreous substitute. The FCVB produced by Guangzhou Vesber Co. Ltd. is still in the stage 
of clinical trial, so it is not commercially available. 
FCVBs have some similarities to thin elastic capsule breast implants and tissue expander 
systems used in plastic surgery. However, they also have differences, which are as follows. 
(1) Production methods: FCVBs are formed by injection forming technology and have a US 
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patent, whereas capsule breast implants and tissue expander systems are made by dip 
forming for large balloons. (2) Sample size: Producing an irregular vitreous-shaped thin 
capsule and smoothly connecting it to a 1.2 mm diameter tube and a pressure-control valve 
are major challenges. However, capsule breast implants and tissue expander systems are 
large and easily made. (3) Implantation site: FCVBs are implanted into the vitreous cavity 
and come into contact with very tender tissues, such as the retina, ciliary body, lens, and 
anterior chamber. However, capsule breast implants and tissue expander systems directly 
come into contact with adipose tissues. Therefore, there are a number of safety issues in the 
use of FCVBs, which have to be addressed.  
(A)   
(B)   
Fig. 2. Scanning electron microscope images of the capsule of the FCVB. Before implantation 
(A) and at the end of the observation time (B) 300-nm-mili apertures in the capsule were 
observed (arrows). 
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In conclusion, a new paradigm for the fabrication of a vitreous body substitute using FCVB 
was proposed in the current work. FCVB was established as an acceptable replacement as it 
closely mimics the morphology and restores the physiological function of the vitreous body. 
This idea provided us with a novel approach in researching on a new therapy strategy 
mimicking the natural vitreous that has been used for nearly half a century. 
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1. Introduction  
Endophthalmitis is an infection of the anterior and posterior segments of the eye resulting 
from the introduction of microorganisms following a surgical procedure (postoperative), 
traumatic penetrating injury (posttraumatic), or metastasis from an infection of a distant site 
in the body (endogenous). Endophthalmitis can develop into panophthalmitis if the 
infectious agent invades the cornea and sclera. The vast majority of cases of endophthalmitis 
result from intraocular surgical procedures, in particular cataract surgery (West et al., 2005). 
Over the past several decades, the number of postoperative endophthalmitis cases has risen 
steadily, owing to the increase in the number of invasive ocular surgeries  performed (West 
et al., 2005).  The etiological agents responsible for endophthalmitis include both Gram-
positive and Gram-negative bacteria and fungi. Cases of post-surgical endophthalmitis are 
usually a result of the introduction of members of the normal microbiota of the eyelid and 
skin surrounding the eye, the most common cause being coagulase-negative staphylococci 
(CNS) (West et al., 2005). Cases of posttraumatic endophthalmitis are more frequently 
caused by environmental bacteria, the most common being Staphylococcus aureus and Bacillus 
cereus (Jonas et al., 2000; Meredith, 1999; O’Brien & Choic, 1995; Thompson et al., 1993). 
Frequent causes of endogenous endophthalmitis (EE) include S. aureus, streptococcal 
species, B. cereus, and Gram-negative bacteria including Klebsiella pneumoniae, Escherichia coli, 
and fungal agents such as Candida albicans (Greenwald et al., 1986; Jackson et al., 2003; 
Okada et al., 1994; Romero et al., 1999; Shammas, 1977; Shrader et al., 1990).  
The clinical hallmarks of endophthalmitis are acute vision loss, severe ocular pain, 
periorbital swelling, hypopyon, proptosis, and the presence of white cells and flare in the 
anterior chamber and vitreous (Lemley and Han, 2007). The visual prognosis can vary 
widely depending on the infectious agent, ranging from mild inflammation and full 
resolution to devastating blindness and loss of the eye. Therapy for endophthalmitis caused 
by avirulent skin microbiota typically results in complete resolution and full vision 
recovery. However, posttraumatic or endogenous endophthalmitis caused by virulent 
pathogens may not respond to therapeutic intervention and result in partial to complete 
vision loss, and in some instances, evisceration or enucleation of the infected eye.  
This chapter will present a summation of the latest findings of epidemiological studies and 
discuss current therapeutic modalities. Moreover, the bacteriology and the current state of 
knowledge regarding the pathogenesis and host/pathogen interactions will be explored. 
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Given that a number of detailed and authoritative reviews of endophthalmitis in general 
have been published in the last ten years, and given the paucity of reviews on endogenous 
bacterial endophthalmitis, this chapter will primarily focus on this route of endophthalmitis.  
2. Endogenous endophthalmitis  
2.1 Historical perspective 
Endogenous or metastatic endophthalmitis results from microorganisms seeding the 
bloodstream from a distant focus of infection and invading the posterior segment of the eye 
via a compromised blood retinal barrier (BRB) (Arevalo et al., 2010; Greenwald et al., 1986; 
Jackson et al., 2003; Okada et al., 1994; Romero et al., 1999; Shammas, 1977; Shrader et al., 
1990). While this form of endophthalmitis is rare, the potential for blindness in one or both 
eyes is high. To date, almost nothing is known about the pathogenesis of endogenous 
endophthalmitis (EE), even though this disease ranks as one of the most devastating infections 
of the eye. In the pre-antibiotic era, the majority of cases of endophthalmitis resulted in poor 
visual outcome. From 1944 to 1966, approximately 73% of endophthalmitis cases resulted in a 
final visual acuity of hand motion vision or worse. The clinical outcome of endophthalmitis 
improved somewhat upon the introduction of intravitreal antibiotics and vitrectomy (Neveu 
and Elliot, 1959; Peyman et al., 1978). Even after the introduction of intravitreal antibiotic 
therapy and vitrectomy, the visual outcome of EE has not improved significantly in over 50 
years (Jackson et al., 2003). Morever, there is a paucity of information on the pathogenic 
mechanisms of this disease from both the causative agent and host perspectives. The majority 
of patients have an underlying condition and are immunocompromised (Jackson et al., 2003). 
The leading predisposing condition of EE is diabetes mellitus type 2, but intravenous drug 
abuse, immunosuppressive agents, malignancies, and AIDS are also underlying conditions 
(Arevalo et al., 2010). Symptoms of EE typically include ocular pain, blurring or loss of vision, 
purulent discharge, and photophobia. EE may present as focal white nodules on the lens 
capsule, iris, retina, or choroid, or as a ubiquitous inflammation of multiple ocular tissues 
resulting in purulent exudate throughout the globe. In addition, inflammation can spread to 
involve the orbital soft tissue (Arevalo et al., 2010).  
EE was first identified and described by the German pathologist Rudolf Ludwig Karl Virchow 
in 1856 (Virchow, 1856). While the causative agent was not identified, it  may have been 
bacterial. In 1894, German ophthalmologist Theodor Axenfeld reported in a treatise on 
endogenous endophthalmitis that the majority of cases involved only one eye and were a 
result of the deposition of septic emboli in the uvea (Axenfeld, 1894). However, in one-third of 
cases, both eyes were affected and infection was selectively localized to the retina. Axenfeld 
postulated that although bacteria were found in all branches of the carotid and ophthalmic 
arteries, the predilection for the retina was probably due to the smaller size of the retinal 
capillaries and „the presence of areas of disease in the capillary walls favoring the lodgment 
there of micro-organisms“ (Tooker, 1938). Collins and Mayou (1925) further speculated that 
„the retina becomes infiltrated with polymorphonuclear leukocyes, which make their way 
inward, collecting in large numbers between the retina and the hyaloid membrane and in the 
neighboring vitreous“. Axenfeld noted in his writings that approximately one-third of patients 
with EE also had endocarditis, and that the vegetations were the likely source of bacteria 
infecting the eye.  In 1916, a case of unilateral EE in a 19 year-old soldier with cerebrospinal 





meningitidis, was cultured from both the cerebrospinal fluid and from the anterior chamber of 
the left eye. The patient was treated with repeated injections of antimeningococcus serum into 
the spinal column, which resulted in complete resolution of the meningitis. Interestingly, 
infection and inflammation of the affected eye was also resolved, leading the case author to 
speculate that the antiserum therapy may have contributed to the rapid clearance of the 
infection. Regardless of whether the antiserum had any effect on clearing the infection, the 
patient retained only perception of light visual acuity (Weakley, 1916). In 1938, Tooker 
described a case of unilateral EE in a patient that was readmitted to the hospital after having 
undergone ear surgery (Tooker, 1938). The left eye was severely inflammed and visual acuity 
was perception of light only. Blood cultures were positive for staphylococci and the patient 
expired from septicemia three days following readmission. An autopsy revealed bronchial 
pneumonia, vegetative endocarditis, and abscesses in the kidneys, spleen, and liver.  
Examination of the left eyeball revealed two primary foci in the retina and ciliary body. Tooker 
concluded that staphylococcal emboli lodged in the retinal and ciliary capillaries, entered the 
vitreous chamber, and induced a robust inflammatory response. Tooker reported that the 
patient had been in excellent condition prior to the ear surgery, blood glucose levels were 
normal, and no other underlying condition was present. It is therefore possible that a systemic 
inflammatory response induced a breakdown in the blood retinal barrier allowing 
staphylococci to invade the vitreous humor.  
Even after the introduction of antibiotic therapy, visual outcomes following EE remained 
poor. Walker and Fenwick (1962) reported a case of fulminate bilateral endophthalmitis 
following streptococcal septicemia. In spite of aggressive treatment with systemic steroids, 
hydrocortisone ointment, and local and systemic antibiotics, vision in the right eye was 
perception of light, and in the left was count fingers. More recently, Jackson et al. (2003) 
reviewed 267 cases of EE and found that the visual prognosis was uniformly poor. These 
authors offered a number of possible explanations for the poor visual outcome of EE, 
including misdiagnosis owing to the fact that EE may mimic other ocular conditions, the 
rapid progression of the disease, and the failure to recognize the overlap between ocular and 
systemic infection (Jackson et al., 2003). Since the earliest reports of EE, little progress has 
been achieved in improving the visual prognosis of this disease. This highlights the 
necessity for studies to characterize the factors that contribute to the pathogenesis of EE, 
both from the host and the bacterial perspectives. 
2.2 Epidemiology and bacteriology 
Current epidemiological studies indicate that EE accounts for approximately 2 to 15% of all 
cases of infectious endophthalmitis (Arevalo et al., 2010; Puliafito et al., 1982). The often 
poor visual outcome and potential for bilateral blindness make EE one of the most 
destructive and devastating ocular infections. In recent reviews of cases of bacterial EE, 41% 
of cases resulted in a final visual acuity of count fingers or better, 26% of infected eyes lost 
all useful vision, and 29% required enucleation or evisceration (Greenwald et al., 1986; 
Jackson et al., 2003; Shammas, 1977). The vast majority of infections are unilateral, with 
disagreement among studies as to whether there is a predilection for the right or left eye 
(Arevalo et al., 2010; Greenwald et al., 1986; Jackson et al., 2003; Okada et al., 1994). Bilateral 
infections occur in approximately 25% of patients with EE (Arevalo et al., 2010). As stated 
earlier, over 50% of EE patients have an underlying medical condition, with diabetes being 
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endogenous endophthalmitis that the majority of cases involved only one eye and were a 
result of the deposition of septic emboli in the uvea (Axenfeld, 1894). However, in one-third of 
cases, both eyes were affected and infection was selectively localized to the retina. Axenfeld 
postulated that although bacteria were found in all branches of the carotid and ophthalmic 
arteries, the predilection for the retina was probably due to the smaller size of the retinal 
capillaries and „the presence of areas of disease in the capillary walls favoring the lodgment 
there of micro-organisms“ (Tooker, 1938). Collins and Mayou (1925) further speculated that 
„the retina becomes infiltrated with polymorphonuclear leukocyes, which make their way 
inward, collecting in large numbers between the retina and the hyaloid membrane and in the 
neighboring vitreous“. Axenfeld noted in his writings that approximately one-third of patients 
with EE also had endocarditis, and that the vegetations were the likely source of bacteria 
infecting the eye.  In 1916, a case of unilateral EE in a 19 year-old soldier with cerebrospinal 





meningitidis, was cultured from both the cerebrospinal fluid and from the anterior chamber of 
the left eye. The patient was treated with repeated injections of antimeningococcus serum into 
the spinal column, which resulted in complete resolution of the meningitis. Interestingly, 
infection and inflammation of the affected eye was also resolved, leading the case author to 
speculate that the antiserum therapy may have contributed to the rapid clearance of the 
infection. Regardless of whether the antiserum had any effect on clearing the infection, the 
patient retained only perception of light visual acuity (Weakley, 1916). In 1938, Tooker 
described a case of unilateral EE in a patient that was readmitted to the hospital after having 
undergone ear surgery (Tooker, 1938). The left eye was severely inflammed and visual acuity 
was perception of light only. Blood cultures were positive for staphylococci and the patient 
expired from septicemia three days following readmission. An autopsy revealed bronchial 
pneumonia, vegetative endocarditis, and abscesses in the kidneys, spleen, and liver.  
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vitreous chamber, and induced a robust inflammatory response. Tooker reported that the 
patient had been in excellent condition prior to the ear surgery, blood glucose levels were 
normal, and no other underlying condition was present. It is therefore possible that a systemic 
inflammatory response induced a breakdown in the blood retinal barrier allowing 
staphylococci to invade the vitreous humor.  
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authors offered a number of possible explanations for the poor visual outcome of EE, 
including misdiagnosis owing to the fact that EE may mimic other ocular conditions, the 
rapid progression of the disease, and the failure to recognize the overlap between ocular and 
systemic infection (Jackson et al., 2003). Since the earliest reports of EE, little progress has 
been achieved in improving the visual prognosis of this disease. This highlights the 
necessity for studies to characterize the factors that contribute to the pathogenesis of EE, 
both from the host and the bacterial perspectives. 
2.2 Epidemiology and bacteriology 
Current epidemiological studies indicate that EE accounts for approximately 2 to 15% of all 
cases of infectious endophthalmitis (Arevalo et al., 2010; Puliafito et al., 1982). The often 
poor visual outcome and potential for bilateral blindness make EE one of the most 
destructive and devastating ocular infections. In recent reviews of cases of bacterial EE, 41% 
of cases resulted in a final visual acuity of count fingers or better, 26% of infected eyes lost 
all useful vision, and 29% required enucleation or evisceration (Greenwald et al., 1986; 
Jackson et al., 2003; Shammas, 1977). The vast majority of infections are unilateral, with 
disagreement among studies as to whether there is a predilection for the right or left eye 
(Arevalo et al., 2010; Greenwald et al., 1986; Jackson et al., 2003; Okada et al., 1994). Bilateral 
infections occur in approximately 25% of patients with EE (Arevalo et al., 2010). As stated 
earlier, over 50% of EE patients have an underlying medical condition, with diabetes being 
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the most prevalent. Additional populations at risk include immunocompromised patients, 
patients with prolonged indwelling devices, and intravenous drug abusers. Sources of 
infection include suppurative liver disease, endocarditis, urinary tract infection, and 
meningitis (Jackson et al., 2003). Virtually any organism that can infect the bloodstream has 
the capability to cause EE, but frequent causes include opportunistic and environmental 
pathogens such as Staphylococcus aureus, Streptococcus sp., Clostridium septicum, coagulase-
negative Staphylococcus, Bacillus cereus, Listeria monogocytogenes, Escherichia coli, Klebsiella 
pneumoniae, Serratia marcescens, Pseudomonas aeruginosa, and Neisseria meningitidis (Arevalo et 
al., 2010). However, S. aureus and K. pneumoniae dominate as bacterial causes of Gram-
positive and Gram-negative cases of EE, respectively.  
S. aureus is a Gram-positive bacterium found as a member of the normal microbiota of skin 
and mucosa, but can cause a variety of systemic, skin, and deep tissue infections and is a 
leading cause of contact lens-associated corneal infections (Callegan et al., 1994; Callegan et 
al., 2002b). The association between S. aureus EE and the prolonged use of indwelling 
prosthetics has been reported in diabetics and patients with other underlying 
immunocompromise with increasing frequency (Jackson et al., 2003; Major et al., 2010; Ness 
and Schneider, 2009; Nixdorff et al., 2009; Okada et al., 1994). S. aureus causes the majority of 
the cases of EE in Western countries and Europe (Ho et al., 2011). The emergence of lineages 
resistant to methicillin in the 1960s has prompted a public health crisis due to the difficulty 
in treating methicillin-resistant S. aureus (MRSA) infections and the increasing trend of 
infection among individuals with fully competent immune systems. MRSA infections may 
be community acquired (CA) or healthcare-associated (HA), with CA-MRSA being easier to 
treat but considerably more virulent. Coinciding with an increase in the prevalence of 
MRSA strains is an increase in MRSA ocular infections (Blomquist, 2006; Major et al., 2010). 
Recently, Ho et al. (2011) described a series of  7 patients (8 eyes) from a single institution 
that were diagnosed with EE caused by MRSA. Treatment of these cases consisted of 
intravitreal tap and injection of vancomycin and ceftazidime, as well as intravenous 
vancomycin. While retinal detachment occurred in 6 of 8 eyes, most of the patients 
experienced improved visual acuity from initial presentation, and only one eye lost all 
vision and required enucleation. Previous reports found that only 23.5% of cases of MRSA 
EE resulted in a visual acuity better than 20/200, whereas these authors found that 37.5% of 
eyes showed a final visual acuity of better than 20/200 (Ho et al., 2011). The authors contend 
that the higher than usual retinal detachment rate observered in their study might have been 
due to the higher than normal time between onset of EE and presentation, generally a mean 
time of 3.5 to 7.1 days versus a mean time of 17 days in their study (Ho et al., 2011).  
K. pneumoniae is responsible for the majority of cases of EE due to Gram-negative bacteria 
and is the leading cause of EE throughout East Asia (Arevalo et al., 2010). Similar to MRSA, 
K. pneumoniae represents a therapeutic challenge due to increasing rates of acquisition of 
antibiotic resistance determinants. Although K. pneumoniae is found in the environment and 
as a commensal member of the gastrointestinal tract microbiota, it is also a frequent cause of 
healthcare-associated infections such as pneumonia, bacteremia, and urinary tract infections 
(Chang et al., 2002; Chuang et al., 2006; Fang et al., 2004; Fung et al., 2002;). K. pneumoniae 
has become the leading cause of pyogenic liver abscess in patients in Taiwan and other 
countries in the Far East (Chang et al., 2000; Wang et al., 1998), and reports of K. pneumoniae 
EE resulting from septicemia following pyogenic liver abscesses in diabetics are increasing 





In a case review of 18 patients with EE in Korea, Chung et al. (2011) also reported a close 
association between diabetes and infection with K. pneumoniae, and these factors were linked 
to a poor visual prognosis. These findings highlight the necessity for increased scrutiny of 
diabetic patients that present with ocular symptoms.  
2.3 Diagnosis and therapeutic modalities 
Early diagnosis and the initiation of treatment are critical to controlling infection and 
improving the visual prognosis of EE. Diagnosis of EE  is difficult to establish based on 
clinical presentation alone because of the nonspecific nature of the symptomology. 
Diagnosis is usually based on clinical presentation and additional methods such as 
fundoscopy, ultrasonography, optical coherence tomography, and magnetic resonance 
imaging (Jackson et al., 2003). When EE is suspected, cultures of blood, vitreous and 
aqueous humor, and Gram stains are criticial for confirmation (Arevalo et al., 2010).  
Symptoms of systemic disease may also be useful in diagnosis, however only 57% of 
patients with EE manifested systemic signs of infection (Okada et al., 1994). Moreover, EE 
might be missed in patients with systemic infection until ocular pain and vision loss are 
experienced. Therapy for diagnosed bacterial EE consists of administration of systemic 
antibiotics such as third generation cephalosporins, vancomycin, and aminoglycosides 
(Lemley and Han, 2007). Fourth generation fluoroquinolones are also used at the discretion 
of the physician (Lemley and Han, 2007). Therapy also consists of intravitreal injection of 1 
mg vancomyin per 0.1 ml for Gram-positive and 2.25 mg ceftazidime per 0.1 ml for Gram-
negative pathogens and/or the aminoglycoside amikacin (0.4 mg). Jackson et al. (2003) 
reported in a literature review that vitrectomy is beneficial in cases of severe EE caused by 
highly virulent organisms and increases the likelihood of a better visual outcome by 
threefold. Vitrectomy is also indicated for cases of EE complicated by retinal detachment 
(Arevalo et al., 2010). As stated earlier, however, the visual outcome of EE has not improved 
in over 50 years. The lack of clinical improvements in EE is likely due to the lack of a 
reproducible animal model in which to study this disease; a disease model would be 
beneficial in terms of therapeutic testing and analysis of pathogenesis. 
2.4 Pathogenesis 
EE is one of the most frequently blinding intraocular infections, however little is known 
about the interplay of host and bacterial factors that contribute to the development of this 
disease. Moreover, the pathogenic mechanisms underlying the migration of bacteria toward 
and into the eye, inflammation, and vision loss have not been addressed. It is also unknown 
as to why diabetes is a common predisposing condition, although there are a number of 
possible explanations. Diabetes compromises the eye both immunologically and 
architecturally, resulting in changes that may weaken the ability of the eye to exclude 
organisms during systemic infection. One of the most serious and common complications 
among diabetics, specifically those with type 2 diabetes, is diabetic retinopathy (Aiello et al., 
1998; Engler et al., 1991). During the progression of diabetic retinopathy, the vasculature, 
glia, and neurons of the retina are affected. The initial changes that occur within the retinal 
vasculature are the death of pericytes and thickening of the basement membrane, which 
lead to capillary leakage and occlusion. These changes ultimately result in macular edema, 
formation of new vessels, and neuroretinal degeneration (Asnaghi et al., 2003; Fong et al., 
2003; Martin et al., 2004; Neely and Gardner, 1998; Qaum et al., 2001; Takeda et al., 2001). 
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the most prevalent. Additional populations at risk include immunocompromised patients, 
patients with prolonged indwelling devices, and intravenous drug abusers. Sources of 
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pathogens such as Staphylococcus aureus, Streptococcus sp., Clostridium septicum, coagulase-
negative Staphylococcus, Bacillus cereus, Listeria monogocytogenes, Escherichia coli, Klebsiella 
pneumoniae, Serratia marcescens, Pseudomonas aeruginosa, and Neisseria meningitidis (Arevalo et 
al., 2010). However, S. aureus and K. pneumoniae dominate as bacterial causes of Gram-
positive and Gram-negative cases of EE, respectively.  
S. aureus is a Gram-positive bacterium found as a member of the normal microbiota of skin 
and mucosa, but can cause a variety of systemic, skin, and deep tissue infections and is a 
leading cause of contact lens-associated corneal infections (Callegan et al., 1994; Callegan et 
al., 2002b). The association between S. aureus EE and the prolonged use of indwelling 
prosthetics has been reported in diabetics and patients with other underlying 
immunocompromise with increasing frequency (Jackson et al., 2003; Major et al., 2010; Ness 
and Schneider, 2009; Nixdorff et al., 2009; Okada et al., 1994). S. aureus causes the majority of 
the cases of EE in Western countries and Europe (Ho et al., 2011). The emergence of lineages 
resistant to methicillin in the 1960s has prompted a public health crisis due to the difficulty 
in treating methicillin-resistant S. aureus (MRSA) infections and the increasing trend of 
infection among individuals with fully competent immune systems. MRSA infections may 
be community acquired (CA) or healthcare-associated (HA), with CA-MRSA being easier to 
treat but considerably more virulent. Coinciding with an increase in the prevalence of 
MRSA strains is an increase in MRSA ocular infections (Blomquist, 2006; Major et al., 2010). 
Recently, Ho et al. (2011) described a series of  7 patients (8 eyes) from a single institution 
that were diagnosed with EE caused by MRSA. Treatment of these cases consisted of 
intravitreal tap and injection of vancomycin and ceftazidime, as well as intravenous 
vancomycin. While retinal detachment occurred in 6 of 8 eyes, most of the patients 
experienced improved visual acuity from initial presentation, and only one eye lost all 
vision and required enucleation. Previous reports found that only 23.5% of cases of MRSA 
EE resulted in a visual acuity better than 20/200, whereas these authors found that 37.5% of 
eyes showed a final visual acuity of better than 20/200 (Ho et al., 2011). The authors contend 
that the higher than usual retinal detachment rate observered in their study might have been 
due to the higher than normal time between onset of EE and presentation, generally a mean 
time of 3.5 to 7.1 days versus a mean time of 17 days in their study (Ho et al., 2011).  
K. pneumoniae is responsible for the majority of cases of EE due to Gram-negative bacteria 
and is the leading cause of EE throughout East Asia (Arevalo et al., 2010). Similar to MRSA, 
K. pneumoniae represents a therapeutic challenge due to increasing rates of acquisition of 
antibiotic resistance determinants. Although K. pneumoniae is found in the environment and 
as a commensal member of the gastrointestinal tract microbiota, it is also a frequent cause of 
healthcare-associated infections such as pneumonia, bacteremia, and urinary tract infections 
(Chang et al., 2002; Chuang et al., 2006; Fang et al., 2004; Fung et al., 2002;). K. pneumoniae 
has become the leading cause of pyogenic liver abscess in patients in Taiwan and other 
countries in the Far East (Chang et al., 2000; Wang et al., 1998), and reports of K. pneumoniae 
EE resulting from septicemia following pyogenic liver abscesses in diabetics are increasing 





In a case review of 18 patients with EE in Korea, Chung et al. (2011) also reported a close 
association between diabetes and infection with K. pneumoniae, and these factors were linked 
to a poor visual prognosis. These findings highlight the necessity for increased scrutiny of 
diabetic patients that present with ocular symptoms.  
2.3 Diagnosis and therapeutic modalities 
Early diagnosis and the initiation of treatment are critical to controlling infection and 
improving the visual prognosis of EE. Diagnosis of EE  is difficult to establish based on 
clinical presentation alone because of the nonspecific nature of the symptomology. 
Diagnosis is usually based on clinical presentation and additional methods such as 
fundoscopy, ultrasonography, optical coherence tomography, and magnetic resonance 
imaging (Jackson et al., 2003). When EE is suspected, cultures of blood, vitreous and 
aqueous humor, and Gram stains are criticial for confirmation (Arevalo et al., 2010).  
Symptoms of systemic disease may also be useful in diagnosis, however only 57% of 
patients with EE manifested systemic signs of infection (Okada et al., 1994). Moreover, EE 
might be missed in patients with systemic infection until ocular pain and vision loss are 
experienced. Therapy for diagnosed bacterial EE consists of administration of systemic 
antibiotics such as third generation cephalosporins, vancomycin, and aminoglycosides 
(Lemley and Han, 2007). Fourth generation fluoroquinolones are also used at the discretion 
of the physician (Lemley and Han, 2007). Therapy also consists of intravitreal injection of 1 
mg vancomyin per 0.1 ml for Gram-positive and 2.25 mg ceftazidime per 0.1 ml for Gram-
negative pathogens and/or the aminoglycoside amikacin (0.4 mg). Jackson et al. (2003) 
reported in a literature review that vitrectomy is beneficial in cases of severe EE caused by 
highly virulent organisms and increases the likelihood of a better visual outcome by 
threefold. Vitrectomy is also indicated for cases of EE complicated by retinal detachment 
(Arevalo et al., 2010). As stated earlier, however, the visual outcome of EE has not improved 
in over 50 years. The lack of clinical improvements in EE is likely due to the lack of a 
reproducible animal model in which to study this disease; a disease model would be 
beneficial in terms of therapeutic testing and analysis of pathogenesis. 
2.4 Pathogenesis 
EE is one of the most frequently blinding intraocular infections, however little is known 
about the interplay of host and bacterial factors that contribute to the development of this 
disease. Moreover, the pathogenic mechanisms underlying the migration of bacteria toward 
and into the eye, inflammation, and vision loss have not been addressed. It is also unknown 
as to why diabetes is a common predisposing condition, although there are a number of 
possible explanations. Diabetes compromises the eye both immunologically and 
architecturally, resulting in changes that may weaken the ability of the eye to exclude 
organisms during systemic infection. One of the most serious and common complications 
among diabetics, specifically those with type 2 diabetes, is diabetic retinopathy (Aiello et al., 
1998; Engler et al., 1991). During the progression of diabetic retinopathy, the vasculature, 
glia, and neurons of the retina are affected. The initial changes that occur within the retinal 
vasculature are the death of pericytes and thickening of the basement membrane, which 
lead to capillary leakage and occlusion. These changes ultimately result in macular edema, 
formation of new vessels, and neuroretinal degeneration (Asnaghi et al., 2003; Fong et al., 
2003; Martin et al., 2004; Neely and Gardner, 1998; Qaum et al., 2001; Takeda et al., 2001). 
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Increases in vascular endothelial growth factor (VEGF) and the cytokines interleukin (IL)-1β, 
IL-6, IL-8, and tumor necrosis factor alpha (TNFα) in diabetic retinas contribute to 
angiogenesis and to breakdown in the BRB, implying an association with inflammation in 
the disease process (Jo et al., 2010). Intercellular adhesion molecule 1 (ICAM-1) and CD18 
are upregulated and contribute to increased leukocyte adhesion to the endothelial wall. This 
is turn results in endothelial cell injury and death (Funatsu et al., 2005; Miyamoto et al., 
1998; Miyamoto et al., 1999; Schroder et al., 1991). Elevated expression of matrix 
metalloproteases in the retina may also facilitate increases in vascular permeability and 
degradation of tight junction complexes, leading to BRB dysfunction (Giebel et al., 2005). 
Retinal pigment epithelia (RPE) and vascular endothelium, barrier cells of the BRB, also 
undergo changes in hyperglycemic environments in vitro and in vivo, including increases in 
VEGF that may contribute to vascular permeability (Amrite et al., 2006; Losso et al., 2010). 
The deterioration of the BRB during the development of diabetic retinopathy may allow 
pathogens to more readily invade the interior of the eye and might partially explain the link 
between diabetes and an  increased risk of acquiring EE. Unfortunately, a clinical link 
between patients with diabetic retinopathy and EE has not been reported, only speculated. 
Retinal vascular permeability is not the only change occurring in a diabetic individual. 
Diabetes also compromises the innate immune response and depresses the ability to clear 
infections in general. Polymorphonuclear leukocytes (PMN) are of critical importance in 
clearing pathogens from the bloodstream and in the eye during acute bacterial 
endophthalmitis (Callegan et al., 1999; Ramadan et al., 2006; Ramadan et al., 2008; Wiskur et 
al., 2008). These important cells are impaired in diabetics. PMN defects in chemotaxis, 
phagocytosis, and bactericidal activity have been reported in the context of diabetes 
(Delamaire et al., 1997; Walrand et al., 2004) and PMN from diabetic mice and humans are 
incapable of phagocytizing and killing both S. aureus and K. pneumoniae (Lin et al., 2006; 
Park et al., 2009). These defects in the ability of PMNs to clear bacteria that are destined  to 
cross a compromised blood retinal barrier may also contribute to the development and 
pathogenesis of EE, but this has not been scientifically analyzed.  
Virtually nothing is known about the bacterial factors that contribute to the pathogenesis of 
EE. S. aureus and K. pneumoniae possess a repertoire of factors with demonstrable roles in the 
virulence of these species in a number of animal models of infection, however it is currently 
unknown if they contribute to the pathogenesis of EE. S. aureus expresses a number of 
adhesins, including the fibronectin binding proteins FnbpA and FnbpB (Green et al., 1995), 
the fibrinogen-binding proteins ClfA and ClfB (McDevitt et al., 1994), and the collagen 
binding protein Cna (Patti et al., 1992) that have been shown to mediate attachment to 
extracellular matrix and plasma proteins, a crucial first step in initiating infections. S. aureus 
synthesizes alpha-toxin, a cytolysin shown to be important in corneal infections (Callegan et 
al., 1994) and endophthalmitis (Booth et al., 1998; Callegan et al., 2002b). S. aureus also 
secretes a host of other secreted cytolytic toxins including the beta-, gamma- and delta-
toxins, and Panton-Valentine leukocidin (Plata et al., 2009) that may contribute to structural 
damage within the eye, or in the case of Panton-Valentine leukocidin (PVL) have either anti- 
or pro-inflammatory effects. PVL lyses neutrophils at higher concentrations but is a potent 
stimulator of the release of proinflammatory cytokines such as IL-8 at lower concentrations 
(Otto, 2010). Some strains of S. aureus are also encapsulated, rendering them resistant to 
phagocytosis and more virulent in animal models of sepsis (Luong and Lee, 2002; Thakker 
et al., 1998). Most clinical isolates of S. aureus produce either Type 5 or Type 8 capsular 





advantage and prevent clearance from the bloodstream as well as the vitreous humor, 
especially in diabetics with impaired clearance mechanisms.  
K. pneumoniae produces at least five major virulence factors that contribute to the 
pathogenesis of infection and include capsular serotype, hypermucoviscosity phenotype 
(HMV), lipopolysaccharide (LPS), siderophores, and pili. However, nothing is known about 
their potential contribution to EE pathogenesis. There are 77 capsular serotypes, however 
serotype K1 predominates among bacteremia, liver abscess, and EE isolates in Taiwan (Fung 
et al., 2002). Capsule production is likely to impede clearance of K. pneumoniae from the 
bloodstream and from the eye. The HMV phenotype is enriched among highly virulent, 
invasive strains of K. pneumoniae, especially those causing EE (Fang et al., 2004; Fang et al., 
2007; Fung et al., 2002; Karama et al., 2008; Keynan and Rubinstein, 2008; Lee et al., 2006). 
Strains that express this phenotype possess a thick, viscous capsule-associated 
mucopolysaccharide web (Wiskur et al., 2008). Two commonly studied genes are associated 
with HMV: magA (mucoviscosity-associated gene A), which encodes a 43 kd outer 
membrane protein that has not been characterized (Fang et al., 2004), and rmpA (regulator of 
the mucoid phenotype A), a regulatory gene that controls the synthesis of the extracapsular 
mucopolysaccharide (Nassif et al., 1989). It has been shown that HMV confers resistance to 
serum killing and phagocytosis, and contributes to virulence in mice (Fang et al., 2004). 
magA- transposon mutants, which lost the HMV phenotype displayed serum sensitivity, 
became phagocytosis susceptible, and were avirulent in a mouse model (Fang et al., 2004). 
magA was located within a 35-kb locus containing 24 open reading frames (ORFs) with 
homologies to genes involved in exopolysaccharide biosynthesis or export and glycosylation 
(Chuang et al., 2006). This locus may represent a novel pathogenicity island responsible for 
the hypervirulence seen with certain K. pneumoniae pathogenic strains (Chuang et al., 2006). 
HMV+ K. pneumoniae are the most common cause of EE in Southeast Asia, with cases of EE 
caused by HMV+ K. pneumoniae on the rise in Western countries (Keynan and Rubinstein, 
2008; Lederman and Crum, 2005). Our laboratory has previously shown that the HMV 
phenotype contributes to the pathogenesis of experimental K. pneumoniae endophthalmitis. 
In this model, an HMV+ strain caused significantly greater inflammation and greater loss of 
visual function than an HMV- strain following direct injection of bacteria into the vitreous 
(Wiskur et al., 2008). Further, the HMV+ strain was not readily cleared from the eye in this 
model (Wiskur et al., 2008). More recently, the magA gene was directly linked to the 
pathogenesis of EE in experimental K. pneumoniae endophthalmitis. Hunt et al. compared a 
wildtype HMV+ K. pneumoniae strain with an isogenic mutant defective in the magA gene, 
and found that mice infected with the magA- strain showed a significantly improved visual 
outcome relative to mice infected with the wildtype strain (Hunt et al., 2011). These results 
clearly demonstrate a role for the HMV phenotype in K. pneumoniae endophthalmitis. As 
this direct injection model circumvents systemic infection, it remains to be seen whether the 
HMV phenotype is important for crossing the BRB and establishing EBE. 
The lipopolysaccharide O side chain has been shown to confer serum resistance to K. 
pneumoniae by preventing the deposition of complement components on the bacterial cell 
membrane and the ensuing complement-mediated cell lysis (Tomas et al., 1986). It is 
therefore possible that K. pneumoniae LPS from cells migrating near the BRB might elicit 
increases in permeability in the retinal vasculature that result in leakiness, facilitating entry 
into the eye. Metrickin et al. (1995), demonstrated that E. coli LPS induced a dose-dependent 
breakdown of the BRB. The siderophores enterobactin and aerobactin could also potentially 
be involved. While enterobactin is synthesized by nearly all isolates of K. pneumoniae, 
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aerobactin is less frequently detected (Podschun et al., 1993). However, only K. pneumoniae 
isolates with capsular serotype K1 or K2 that produced aerobactin were more virulent (LD50 
<103 cfu), and transfer of the genes necessary for synthesis of aerobactin into an avirulent 
strain increased the virulence by 100-fold (Nassif and Sansonetti, 1986). K. pneumoniae 
produce two types of pili or fimbriae, type 1 and type 3, that mediate attachment to 
epithelial cells. The type 1 fimbrial adhesion gene fimH was shown to be enriched among 
blood isolates (Yu et al., 2006), and the type 3 fimbrial adhesion protein MrkD has been 
demonstrated to contribute to virulence by binding to epithelial cells of the urogenital, 
repiratory, and gastrointestinal tracts (Sebghati et al., 1998), and the type 3 fimbrial shaft 
protein MrkA is required for biofilm formation on intravenous and urinary catheters and 
human extracellular matrix (Jagnow and Clegg, 2003; Langstraat et al., 2001). It is 
conceivable that these pili mediate adherence to structures in the eye and aid in the 
establishment of EE. However, as for all of the above discussed factors, no studies have been 
conducted evaluating the importance of these virulence traits to EE pathogenesis due to the 
lack of a well-characterized animal model of this disease. 
3. Postoperative endophthalmitis  
Postoperative endophthalmitis is the most common type of endophthalmitis and most 
frequently occurs following cataract surgery, with 90% of cases occuring following this 
procedure (Lemley and Han, 2007). The rates of postoperative endophthalmitis have been 
increasing over the past several years, owing to increases in the number of cataract surgeries 
and other types of intraocular surgeries performed. This raises concerns due to the ever- 
growing population of the elderly that require cataract surgery. Millions of cataract 
surgeries are performed each year. Fortunately, the rate of occurrence of post-cataract 
endophthalmitis remains low, ranging between 0.06% and 0.25% (O’Brien et al., 2007; West 
et al., 2005). Among the types of cataract surgeries performed, phacoemulsification 
accounted for approximately 48% of the postoperative endophthalmitis cases, while 38.5% 
and 6.6% of cases followed extracapsular or intracapsular extraction, respectively (Ng et al., 
2005). Postoperative endophthalmitis can occur after other types of surgery such as 
secondary intraocular lens placement, pars plana vitrectomy, penetrating keratoplasty, and 
even after corneal suture removal (Lemley and Han, 2007).  
 
Fig. 1. Acute endophthalmitis caused by Staphylococcus aureus in a 43-year-old patient  
3 days following a triple surgical procedure (penetrating keratoplasty, cataract extraction, 
and posterior chamber intraocular lens). Note the hypopion in the anterior chamber.  






Fig. 2. Bleb-associated endophthalmitis due to Streptococcus pneumoniae in the right eye of a 63-
year-old patient, 2 weeks after trabeculectomy.  Note the whitening of the filtering bleb due to 
inflammatory infiltrate. There was also inflammation of the anterior and posterior segment.  
The earliest sign of endophthalmitis is infiltration of the bleb by inflammatory cells, and when 
the anterior and posterior segments are still normal, this is defined as “blebitis”. Reproduced 
with kind permission from Dr. Rumelt 
Preventative measures consist of prophylactic intracameral antibiotics or prophylactic 
subconjunctival antibiotic injection following cataract surgery (Kelkar et al., 2008). Patients 
with acute postoperative endophthalmitis generally present between 1 to 2 weeks following 
surgery. Endophthalmitis has also been reported to occur after intravitreal injection of anti-
VEGF agents for the treatment of age-related macular degeneration (AMD). While the rate 
of endophthalmitis following intravitreal injection of these agents is equivalent to that of 
postoperative endophthalmitis following cataract surgery, approximately 0.16%, the 
increasing number of elderly patients requiring this type of therapy is a significant cause for 
alarm (Gragoudas et al., 2004).  
Endophthalmitis must be distinguished from sterile inflammation following surgery. 
Diagnosis is established by visual acuity measurements, fundoscopy, and ERG, followed by 
microbiological evaluation of aqueous and vitreous samples (Lemley and Han, 2007). Gram-
positive bacteria are the leading cause of postoperative endophthalmitis cases, with 
coagulase-negative staphylococcal (CNS) isolates being the most common, causing 47–70% 
of all postoperative endophthalmitis cases (Han et al., 1996). S. aureus account for 
approximately 10%, Streptococcus species for 9%, Enterococcus species for 2.2%, and Gram-
negative bacteria for approximately 6% (Han et al., 1996). Fortunately, postoperative 
endophthalmitis caused by CNS is relatively mild and is more easily resolved with 
antibiotic and anti-inflammatory therapy (Josephberg, 2006). The visual prognosis is 
generally favorable, with 84% of cases resulting in at least 20/100 visual acuity, and 50% of 
these cases resulted in 20/40 visual acuity (Josephberg, 2006). Less virulent bacteria such as 
Propionibacterium acnes and CNS, and the fungal organism Candida parapsilosis are the most 
common causative agents of chronic endophthalmitis (Lemley and Han, 2007). Patients with 
this form of endophthalmitis typically present several months following surgery (Lemley 
and Han, 2007). Postoperative endophthalmitis caused by S. aureus, species of streptococci, 
enterococci, Bacillus, and Gram-negative bacteria can cause a more explosive and fulminant 
infection. The visual outcome of severe infections is uniformly poor, with only 30% of eyes 
attaining 20/100 visual acuity (Josephberg, 2006). The primary treatment is typically a single 
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intravitreal injection of antibiotics consisting of 1.0 mg vancomycin per 0.1 ml, and 2.25 mg 
ceftazidime per 0.1 ml or 400 µg amikacin per 0.1 ml. Fourth generation fluoroquinolones 
can also be employed because of their broad spectrum of activity and usefulness against 
Gram-negative bacteria. Vitrectomy and corticosteriod therapy are are often advocated as 
adjunct treatment modalities (Lemley and Han, 2007), however corticosteriod treatment is 
still considered controversial. 
4. Posttraumatic endophthalmitis  
Posttraumatic endophthalmitis is a complication of a penetrating injury to the eye and is not 
as frequent as postoperative endophthalmitis. However, the rate of infection is higher and 
the visual prognosis is poorer following penetrating injury to the globe than following 
surgical procedures. The infection rates following traumatic injury to the globe range from 
3% to 17% (Meredith, 1999; O’Brien and Choi, 1995; Thompson et al., 1993). The rates 
increase substantially when a foreign body remains in the globe and range from 11 to 30% 
(Boldt et al., 1989; Brinton et al., 1984; Thompson et al., 1993). Other risk factors include age 
greater than 50 and a more than 24 hour delay prior to presentation (Thompson et al., 1993). 
Those patients who presented for intraocular foregin body removal greater than 24 hours 
following injury were approximately 4-fold more likely to acquire endophthalmitis 
(Thompson et al, 1993), highlighting the necessity of seeking immediate medical attention 
following penetrating injury. Staphylocci and B. cereus rank as the number one and two 
causes, respectively, and together account for 95% of cases (Das et al., 2005; Lemley and 
Han, 2007).  
 
  
Fig. 3. Fundoscopic exam of a patient with Staphylococcus aureus endophthalmitis after a 
penetrating ocular injury. The findings of endophthalmitis in the vitreous may include not 
only flare and cells, but also fibrin in various degrees of organization. Organization to 
fibrotic bands may results in traction retinal detachment due to contraction of such bands. 
Reproduced with kind permission from Dr. Rumelt 
B. cereus is ten times more likely to be the causative agent of posttraumatic than 





intraocular foreign bodies (Das et al., 2005). Other causative agents include CNS, 
streptococcal species, clostridial species, fungi, and protozoa such as acanthamoeba (Lemley 
and Han, 2007; Rumelt et al., 2001).  
 
 
Fig. 4. Gross pathologic specimen of the globe affected by Pseudomonas aeruginosa 
endophthalmitis.  The patient lost his vision in the eye and it became a blind, painful eye 
that underwent enucleation.  Note the massive necrosis of the ocular tissues. Reproduced 
with kind permission from Dr. Rumelt 
 
 
Fig. 5A. Endophthalmitis caused by the gas-forming bacterium Clostridium bifermentans.   
The endophthalmitis was caused following ocular penetrating injury be a soiled-
contaminated foreign body. Note the brownish discoloration of the conjunctiva and a 
subconjunctival gas bubble. The patient was treated with intravenous and intravitreal 
panicillin and clyndamycin, but lost his vision despite the treatment. Reproduced with kind 
permission from Elsevier, Inc., in Rehany U, Dorenboim Y, Lefler E, Schirer E. 
Ophthalmology. 1994;101:839-42. 
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Fig. 5B. The same patient as in 5A a few days later.  Note that the conjunctiva has become 
necrotic, the color became purple, and the gas bubble ruptured. Reproduced with kind 
permission from Elsevier, Inc., in Rehany U, Dorenboim Y, Lefler E, Schirer E. 
Ophthalmology. 1994;101:839-42. 
When penetrating injury occurs, the foreign body should be removed as soon as possible, 
especially when the material is organic or soil contaminated due to the potential for B. cereus 
contamination (Lemley and Han, 2007). In some cases, for example where the foreign body 
is inert glass and is located in a sensitive position such as the retina, it may not be desirable 
to remove the object. Even relatively minor injuries to the eye can result in severe 
endophthalmitis with devastating outcomes. Cases have been described following 
penetrating injury to the eye due to orthodontic headgear (Blum-Hareuveni et al., 2006). 
Diagnosis of posttraumatic endophthalmitis is established by visual acuity tests, slit-lamp 
examination, and ophthalmoscopy, as well as computed tomography and ultrasound 
(Lemley and Han, 2007). For posttraumatic endopthalmitis, treatment consists of 
administration of intravitreal 1 mg vancomycin per 0.1 ml, 2.25 mg ceftazidime per 0.1 ml or 
400 µg amikacin per 0.1 ml (Lemley and Han, 2007). Even with early therapy, the outcomes 
are often poor due to the potential virulence of the infecting bacterium and the explosive 
inflammatory response. 
5. Experimental endophthalmitis and the roles of bacterial and host factors 
A rabbit model of experimental endophthalmitis has been used to assess the contribution of 
both bacterial and host factors to the development of endophthalmitis. This model mimics 
the infection course after introduction of bacteria directly into the posterior segment of the 
eye that would occur following a surgical procedure or penetrating injury, but does not 
allow for the analysis of host immunological status and bacterial factors that contribute to 
the development of EE. This model system allows intravitreal injection across the pars plana 
of low inocula that allow the bacterium under study to adapt to the intraocular environment 
of the eye and replicate (Booth et al., 1995; Booth et al., 1997; Callegan et al., 1999a; Jett et al., 
1992; Sanders et al., 2010; Sanders et al., 2011). Depending on the infecting organisms, 





days, and a number of infection parameters can be repeatedly monitored and quantitative 
data obtained. Parameters that can be monitored include ocular inflammation, fibrin 
deposition, electrophysiologic measurement of retinal function, and bacterial growth and 
distribution. Infiltration of inflammatory cells can be quantified by slit lamp biomicroscopy 
in which progressive inflammation is scored in different anatomical locations within the eye 
(Callegan et al., 1999a). Inflammation and fibrin deposition can be qualitatively assessed by 
analysis of thin-section histopathology. Retinal damage as a result of the production of toxin 
by the bacterium under study or by bystander damage due to PMN activity in the eye can 
be measured by electroretinography (ERG). Using the rabbit model, Callegan et al. (1999a) 
found that supernatants from from B. cereus and S. aureus caused retinal damage and were 
highly inflammogenic, suggesting that secreted toxins are of primary importance to the 
pathogenesis of endophthalmitis.  Callegan and colleagues did not find individual roles for 
the B. cereus membrane damaging toxins hemolysin BL, phosphatidylinositol-specific 
phopholipase C, and phosphatidylcholine-specific phospholipase C in this model, however, 
other toxins controlled by the global regulator plcR were found to contribute to pathogenesis 
of experimental B. cereus endophthalmitis (Callegan et al., 1999b; Callegan et al., 2002a; 
Callegan et al., 2003). The S. aureus alpha- and beta-toxins, but not the gamma-toxin, were 
shown to make an important contribution to endophthalmitis (Booth et al., 1998; Callegan et 
al., 2002b). Isogenic mutants deficient in each of the toxin-encoding genes were compared in 
this model. Injection of rabbit eyes with the gamma-toxin deficient mutant had no impact on 
retinal function when compared with the wildtype strain. However, the alpha- and beta-
toxin deficient mutants were  attenuated when compared with the wildtype. After 2 days, 
rabbit eyes infected with the alpha- or beta-toxin deficient mutant showed 40% and 60% 
retinal function retained, respectively, as compared with 20% retained in rabbits infected 
with the wildtype strain. Moreover, a cumulative effect was observed as a result of 
inactivation of all three toxin loci on retention of retinal function (Callegan et al., 2002b). 
This model has also been used as a sensitive measure of the contribution of enterococcal 
virulence factors to pathogenesis. Jett et al. (1992) demonstrated that the course and severity 
of disease was significantly determined by the E. faecalis biocomponent cytolysin. The 
cytolysin destroyed the neural tissue of the retina and its architecture over a period of 24 – 
72 hours. The toxicity to retinal tissue was not attenuated by either antibiotic and/or anti-
inflammatory therapy when infection involved a cytolytic strain, although an isogenic, non-
cytolytic infection completely resolved when both of these treatments were provided 24 h 
postinfection. These studies showed not only the contribution of the cytolysin to the 
pathogenesis of enterococcal endophthalmitis, but also the importance of inflammatory 
sequelae. Engelbert et al. (2004) demonstrated that the E. faecalis gelatinase and serine 
protease in concert contributed to pathogenesis in this model as double mutants in these 
genes were significantly attenuated when compared to the single mutants.  Callegan et al. 
(1999a) also utilized this model to implicate the contribution of bacterial cell wall 
components in inciting an inflammatory response during endophthalmitis. Injection of 
metabolically inactive bacteria or cell wall sacculi elicited significant intraocular 
inflammation. The rabbit model has also been used to implicate the Streptococcus pneumoniae 
capsule in the pathogenesis of endopthalmitis (Sanders et al., 2011). Infection with an 
isogenic unencapsulated S. pneumoniae mutant strain resulted in significantly lower slit lamp 
examination scores, significantly greater retinal function, and significantly less neutrophil 
infiltration into the eye compared with the wildtype parental strain in this model. Moreover, 
they demonstrated the efficacy of immunizing with the S. pneumoniae pneumolysin in 
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protease in concert contributed to pathogenesis in this model as double mutants in these 
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components in inciting an inflammatory response during endophthalmitis. Injection of 
metabolically inactive bacteria or cell wall sacculi elicited significant intraocular 
inflammation. The rabbit model has also been used to implicate the Streptococcus pneumoniae 
capsule in the pathogenesis of endopthalmitis (Sanders et al., 2011). Infection with an 
isogenic unencapsulated S. pneumoniae mutant strain resulted in significantly lower slit lamp 
examination scores, significantly greater retinal function, and significantly less neutrophil 
infiltration into the eye compared with the wildtype parental strain in this model. Moreover, 
they demonstrated the efficacy of immunizing with the S. pneumoniae pneumolysin in 
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protecting the eye from retinal damage during S. pneumoniae endophthalmitis (Sanders et 
al., 2010). In summary, the rabbit model of experimental endophthalmitis has proven 
invaluable in assessing the role of bacterial virulence factors and identifiying potentially 
new therapeutic targets.  
More recently, a mouse model of experimentally induced endophthalmitis has been 
employed to explore various aspects of disease development, course, and outcome. As with 
the rabbit model, infection parameters can be qualitatively and quantitatively measured 
including bacterial growth, ocular inflammation, and retinal function. Ocular inflammation 
can be qualitatively assessed via thin-section histopathology as well as quantified by slit-
lamp biomicrosopy and indirect measurements of PMN influx by a myeloperoxidase ELISA 
(Ramadan et al., 2006). As stated earlier, Wiskur et al. (2008) implicated the HMV phenotype 
in the persistence of K. pneumoniae in the eye by comparing the bacterial growth of an 
HMV+ to that of an HMV- strain after intravitreal injection of 100 CFU. The HMV- strain 
did not grow to the same level as the HMV+ strain and were cleared with 27 hours. HMV+ 
infected eyes underwent phthisis within 24 hours. This study provided evidence that the 
HMV phenotype makes an important contribution to K. pneumoniae endophthalmitis 
pathogenesis. As discussed above, Hunt et al. (2011) confirmed these findings using a magA- 
mutant of K. pneumoniae in the mouse endophthalmitis model. S. aureus cell wall teichoic 
acids have also been shown to  contribute to the pathogenesis of endophthalmitis and that 
inhibitors of cell wall teichoic acid synthesis might serve as candidates for therapy of S. 
aureus endophthalmitis in this model (Suzuki et al., 2011).  
An important aspect of the murine model of experimental endophthalmitis is that factors of 
the host immune system can be assessed by comparison of the infection course in genetic 
knockout mouse strains with that in wildtype strains of the same genetic background. 
Ramadan and colleagues (2006) showed that as early as 4 hours post-injection with B. cereus, 
significant decline in retinal function and PMN infiltration were observed, which coincided 
with an increase in the proinflammatory cytokine TNF-α. In TNF-α knockout mice, B. cereus 
replicated more rapidly, retinal function declined more sharply, and fewer PMN infiltrated 
the eye. These findings illustrate the power of this model in allowing the repeated 
measurement of multiple infection parameters and showed that damage to the retina 
occurred earlier than was previously thought. Furthermore, the necessity of TNF-α in PMN 
recruitment and control of B. cereus replication was established. Engelbert and Gilmore 
(2005) used C3 and FasL knockout out mice to dissect components of the innate immune 
and ocular immune privilege systems in controlling S. aureus endophthalmitis. The infection 
course in C3 knockout eyes followed a similar course to their wildtype counterparts, 
suggesting that complement does not play a significant role in ocular defense against S. 
aureus infection. On the other hand, the membrane-bound Fas ligand (FasL), which 
functions to maintain the immune privilege status of the eye by inducing apoptosis in 
infiltrating inflammatory cells, was found to be criticial in bacterial clearance. Mice deficient 
in FasL were unable to control S. aureus infection after injection of an inoculum that is 
cleared in wildtype mice (Engelbert and Gilmore, 2005). The host heat shock protein alphaB-
crystallin was shown to be upregulated in the retina and prevent apoptosis and retinal 
damage during murine S. aureus endopthalmitis (Whiston et al., 2008). These authors found 
that mice deficient in the production of this molecular chaperone displayed increased retinal 





protective protein. Finally, Kumar et al. (2010) suggested that the host toll-like receptor 
(TLR) 2 is involved in controlling infection by S. aureus in this model by showing that 
pretreatment of mice with intravitreal injections of the TLR2 ligand Pam3Cys reduced 
bacterial load when compared with mock-injected animals. In summary, the murine model 
of experimental endopthalmitis has proven to be invaluable in analyzing both host and 
bacterial factors that contribute to this disease. The growing number of available genetic 
knockouts in components of the innate and adaptive immune systems and the relative ease 
of use will continue to make the murine model key to understanding the complex interplay 
between host and bacterial factors during the initiation, course, and resolution of 
endophthalmitis.  
6. Conclusions 
Endophthalmitis remains a relatively rare infection, but the potential for vision loss and/or 
blindness is significant. The potential for poor prognosis, which depends on the causative 
organism and the immune status of the patient, remains high despite antibiotic and surgical 
intervention. Research on the contribution of bacterial virulence factors has implicated both 
secreted toxins and proteases, capsules, and the intraocular host response to bacterial cell 
wall components in the pathogenesis of experimental B. cereus, S. aureus, E. faecalis, S. 
pneumoniae, and K. pneumoniae endophthalmitis. Moreover, components of the host 
inflammatory response and mediators of ocular immune privilege have been shown to play 
critical roles in controlling experimental B. cereus and S. aureus endophthalmitis. Virtually 
nothing is known about the contribution of bacterial or host virulence factors to the 
development of EE. The fact that visual prognosis of EE and other types of bacterial 
endophthalmitis caused by pathogenic organisms remains uniformly poor highlights the 
need for continuing research on the interactions between the offending pathogen, the 
internal structures of the eye, underlying disease state and the immune response.  
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Retinal detachment is a potentially blinding condition. It is caused by separation of 
neurosensory retina from the underlying retinal pigment epithelium. Despite treatment 
advances, functional results remain poor (with only 42% achieving 6/12 vision and only 28% if 
the macula is involved). There are three distinct types of retinal detachment: rhegmatogenous 
(RRD), tractional and exudative. For the purpose of this chapter we will focus on RRD.  
RRD demonstrates wide geographical variation with incidence reported between 6.3 and 
17.9 per 100, 000¹ with 7300 new cases estimated annually in the UK²⁹. Risk factors include 
myopia, increasing age and certain vitreoretinal conditions. Horseshoe tears, giant tears and 
round holes have been shown the most common along with lattice degeneration⁷.  
Vitreoretinal traction is responsible for most RRD. As the vitreous becomes syneretic 
(liquefied) with age, a posterior vitreous detachment (PVD) occurs. In most cases, the 
vitreous separates from the retina without any sequelae. However, in certain eyes, strong 
vitreoretinal adhesions are present and the occurrence of a PVD can lead to a retinal tear; 
then, fluid from the liquefied vitreous can enter the sub-retinal space through the tear, 
leading to a retinal detachment.  
Several studies have investigated the epidemiology and risk factors associated with RRD. 
These differ in their methodology making comparison of data difficult ¹,²,⁴,⁶,¹¹,²⁹. RRD 
incidence varies with ethnicity and is strongly associated with increasing age, myopia and 
certain vitreoretinal degenerations including lattice degeneration and round holes. 
Abnormal vitreoretinal adhesions, which may be visible or invisible, are present in many 
eyes. Among the visible ones are lattice degeneration and cystic retinal tufts. When a PVD 
occurs and encounters such an area, a retinal tear may form. Due to changes in cataract 
surgery trends, the proportion of pseudophakic retinal detachment presenting to specialised 
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centres appears to be increasing. The incidence is lower in phacoemulsification than extra 




Fig. 1. Retinal detachment 
Obtaining an accurate estimate of rhegmatogenous retinal detachment incidence in 
England and associated risk factors is essential in understanding the healthcare burden 
related to this disorder. We investigated the epidemiology of rhegmatogenous retinal 
detachment and associated clinical features by analysing routinely collected hospital 
statistics for England, using the Hospital In-patient Enquiry (HIPE) and Hospital Episode 
Statistics (HES) from 1968 to 2004, and for the Oxford National Health Service Region 
using the Oxford Record Linkage Study (ORLS) from 1963 to 2004. A literature review is 
also presented. 
Retinal Detachment – An Update of the Disease and Its Epidemiology – A Discussion  




Fig. 2. Retinal break 
2. Methods 
At the start date for our national analysis, 1968, national hospital statistics for England were 
collected as the HIPE. This system ceased in 1985 and was replaced, though not until 1989 
by HES. Both HIPE and HES are statistical databases of demographic, medical and 
administrative information about each episode of hospital care. HES include data on all 
‘‘day cases’’ or office procedures, as well as patients admitted for overnight stay, whereas 
the HIPE did not include day cases.. The Oxford Record Linkage Study (ORLS) was also 
used for all patients treated in the Oxford Regional Health Authority area. 
The International Classification for Disease (ICD) by the World Health Organisation was 
used to identify rhegmatogenous retinal detachment. The codes included ICD-7 (1955) code 
386, ICD-8 (1965) code 376, ICD-9 (1977) codes 361.0, 361.1, 361.8 and 361.9, ICD-10 (1992) 
codes H33.0, H33.2, H33.4 and H33.5.  
National HES for England were analysed to produce a geographical profile of hospital 
admission for retinal detachment by the Local Authority (LA) between 1998 and 2005. The 
data were used to construct a map showing the person-based admission rate per 100 000 
resident population for each LA, expressed as an average annual rate. The LAs were 
arranged into quintiles: the fifth of LAs with the lowest rates are shown with the lightest 
colour, and the fifth of LAs with the highest rates are shown with the darkest colour. 
The association with affluence was studied using the Index of Multiple Deprivation score 
for 1998-2005 (n= 57,949) as a measure of deprivation levels. The study population was split 
into quintiles from least deprived to the most deprived. Standardised admission ratios and 
95% confidence intervals were calculated to evaluate statistical significance. Seasonal 
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variation by monthly analysis was studied for detachment surgery from 1989-2006 
(n=169,417). 
The datasets were anonymised; approval to analyse them in a programme of research 
undertaken by the Unit and affiliated University, was obtained through the NHS Central 
Office for Research Ethics Committees (reference 04/Q2006/176).  
3. Incidence 
The English National and ORLS admission rates for retinal detachment surgery were just 
over 10 episodes per 100 000 population in the late 1960s. They rose nationally steadily, but 
gradually, to around 22 episodes per 100 000 population by 2004. 
The ORLS data show rates based on the number of people admitted to hospital for retinal 
detachment surgery as well as the number of episodes of care for surgery (episodes of 
separate admission or transfers within an admission, or both). The scale of multiple 
admissions per person was small, although an increase in multiple recording is evident in 
recent years as seen in the recent divergence between the rates for episodes and people 
(figure 3). The figure confirms that the increase in hospital episodes in the 1990s represents 
an increase in the number of people treated (all RRD admissions were operated). It also 
shows more accurately than the English figures (which omit data for 1986–8) that the start of 





































































Fig. 3. Hospital admission rates 1963-2004 for Retinal surgery for ORLS and National data 
measured as episodes and people per year, male and female, all ages, all sources of 
admission, any mention 
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The reported annual incidence of rhegamatogenous retinal detachment in other studies around 
the world varies from 4-17.9 per 100 000 population ¹,²,⁴,⁸,¹⁰,¹²,¹³,³²,³⁸. Studies with small sample size, 
potential for sampling error and varied methodologies underlie these different results.   
4. Geographic variation 
The people rate for the national data is at its peak at 16 per 100,000 in 2004. There is a 
suggestion that the rate has reached its peak as the rate fluctuated between15-16 per 100,000 
from 1998 to 2004. The people rate for the Oxford data continues to show a rise to 20 per 
100,000 in 2004. This can be explained by the fact that Oxford remains a tertiary referral 
centre for retinal detachment and serves patients from outside the region and so the service 
throughput may not represent the local population. Bilaterality was not investigated but 
most series support a bilateral rate of retinal detachment of between 5-15%. 
 
Fig. 4. Vitreo-retinal surgery: males and females indirectly standardised rate per 100 000: 
each local authority in England any mention of operation: 1998/99 to 2004/05 
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Figure 4 shows a geographical profile of the annual rate of retinal detachment surgery by 
LA. LAs showed a wide variation in rates of retinal detachment surgery, ranging from 7 to 
23 people per 100 000 population. This reflects the relative infancy of retinal surgery service 
provision in comparison to cataract surgery for example and highlights the need for more 
service provision for patients in England. 
5. Age distribution 
The prevalence of PVD increases with age; occurring in 11% of 60-69 year olds, 46% of 80-89 
year olds and occurring earlier in myopes. The highest incidence rate of detachment was 
found in the 70-74 age group with rates of 60 per 100,000. The incidence rate in under 20 
year old females was the lowest noted; <3 per 100,000. The bimodal distribution with a 




Fig. 5. Admission rates for retinal detachment per 100,000 population: all sources, males, 
National data 
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Fig. 6. Admission rates for retinal detachment per 100,000 population: all sources, females, 
National data 
6. Gender 
Figures 5 and 6 presents national and ORLS admission rates for retinal detachment surgery 
analysed by age and sex, and over three time periods (1968–1985, 1989–1997 and 1998–2004) 
for men and women separately. Three contrasting time periods were selected: one relatively 
long historical period, when rises in rates were fairly modest, and two more recent periods, 
when rises were more evident. Over these time periods, the rate of retinal detachment 
surgery shows a bi-modal distribution with peaks at the 24-30 and 70-74 age groups for both 
men and women. There was a 6 times higher risk in the 70-74 age group for both males and 
females. The rate of retinal detachment surgery for all age groups shows a 1.5 times male 
preponderance.  
While some reports indicate a sex distribution corresponding with that of the general 
population, most indicate a male preponderance2-6. This may be related to an inherent 
gender risk, though an increased rate of ocular trauma may be contributory. Furthermore, 
the higher proportion of myopia in young males may partly explain this. 
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In a prospective study which involved 1130 cases of RRD in Scotland over a 2-year period 
from 2007-2009, Mitry et al., reported that PVD -associated RRD showed a male 
preponderance of 61.7% male vs. 38.2% female (P<0.001). Notably, 1 in 10 cases were 
associated with a recent history of ocular or head trauma.7 The underlying sex distribution 
could not account for this gender discrepancy but higher rates of traumatic RRD or an 
inherent increased risk in men may be influential.8  
Exclusion of traumatic retinal detachments from analysis may negate or even reverse gender 
differences in RRD incidence. The Beijing Rhegmatogenous Retinal Detachment Study 
Group prospectively reviewed 528 patients diagnosed with RRD from October 1999-
September 2000. It reported a greater incidence of RRD in males (8.98/100000 population; 
95% CI 8.07 – 10.13 in males, and 6.78/100000 population; 95% CI 5.97 – 7.76 in females). 
However, on subgroup analysis, although there was a greater incidence of traumatic RRD in 
males, there was no significant difference between males and females in nontraumatic, 
phakic, aphakic and pseudophakic retinal detachments.11 A Swedish retrospective study of 
590 cases of RRD over a 10-year period from 1971 to 1981 reported a higher incidence of 
non-traumatic RRD in females.12 However in another large retrospective case-control study 
(1032 cases from 1995 to 2001), the male predominance persisted even after excluding 
trauma-related RRD, with a reported 2.15 odds ratio for male gender.13 
The sex difference, that is a higher incidence of RRD in men, also appears to apply to retinal 
detachment incidence after cataract surgery. A small retrospective study from Olmstead 
County, Minnesota, found that men were 2.9 times more likely to have a retinal detachment 
after cataract surgery than women (P<0.001; 95%CI 1,8-4.4).14 
Other possible explanations include increased myopia and axial length in men, as well as 
gender differences in the anatomy of the vitreoretinal base. 15, 16 Myopia is a well-known 
risk factor for retinal detachment and an increase in axial length is significantly associated 
with an increased risk of RRD.17-19 Axial length is related to height and men tend to be 
taller than women.20 Anatomical differences in the vitreoretinal base (with males having 
larger eyes hence longer vitreous chambers as described in 1912 by Salzmann’s Anatomy 
and Histology of the Human Eyeball) can be in the form of greater migration of the 
posterior vitreous base towards the retina in males as reported by Wang et al, in their 
study of donor eyes.21 This may predispose males to retinal breaks after PVD, either from 
greater dynamic vitreoretinal traction and/or an increase in vitreoretinal irregularities of 
the posterior border.  
7. Cataract extraction and other ophthalmic operations 
Cataract operation is the most common ophthalmic surgical procedure worldwide. Even 
with the best technique and in healthy eyes this procedure is associated with an increased 
risk of retinal detachment. There is a higher rate of PVD after cataract extraction and a lower 
hyaluronic acid concentration causing vitreous collapse 5. Increased rates of cataract surgery 
(phacoemulsification, internal and external capsular cataract extraction) and higher life 
expectancy may also contribute to retinal detachment. The cumulated six year risk of 
detachment after cataract surgery is increased by a factor of 6 to 8, increasing linearly for 20 
years22. 
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The risk is increased if there are complications during cataract surgery. There is a 
statistically significant higher incidence of RRD after posterior capsule rupture and 
anterior vitrectomy than after uncomplicated phacoemulsification, 16% versus 0.75% 
according to one study23.The estimated risk of retinal detachment after cataract surgery is 
5 to 16 per 1000 uncomplicated cataract operations24.The risk may be much  higher in 
those who are highly myopic, with a frequency of 7% reported in one study25.Young age 
at cataract removal further increased risk in this study. A vitreo-retinal centre in London 
analysed cases of rhegmatogenous retinal detachment in 1980 and again in 1999 finding 
that pseudophakia rose from 0.8% to 24%. This may explain the steady rise in retinal 
detachment we found as shown in figure 7 in England over the last 4 decades. Most series 
report that about 50% of RRD occur during the first year following cataract surgery. Long 
term risk of retinal detachment after extracapsular and phacoemulsification cataract 
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ORLS data 1963-2004(06) measured as episodes and people per year, all ages, males and 
females, all sources, any mention 
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cataract extraction alters the physiology of the eye. Removal of a larger cataractous lens in 
aphakia or its replacement with a smaller lens implant in pseudophakia is responsible for 
the anterior shift of the iris lens diaphragm resulting in a relative increase in volume of the 
vitreous cavity. The removal of the lens and its anterior capsule also disturbs the diffusion 
barriers and results in a more liquefied vitreous with a reduced hyaluronic acid content . 
This is associated with a higher rate of PVD. Direct evidence between cataract surgery and 
PVD comes from a recently published study from New Zealand ³³. The study showed that 
among 149 patients aged 50 to 60 years who underwent unilateral cataract surgery, the 
incidence of PVD after five years was 51 per cent in the treated eyes, compared to only 21 
per cent in their unoperated fellow eyes. Other possible mechanisms leading to a retinal 
detachment have been implicated to be the inflammatory vitreoretinal adhesions and retinal 
breaks caused by surgical trauma. 
ND:Yag capsulotomy following cataract operation carries a potential to induce PVD, and 
thereby cause a retinal detachment ²³. The risk factors include myopia, lattice degeneration and 
retinal detachment in the fellow eye. No relationship has been established between energy 
application and incidence of retinal detachment. According to one study the incidence of RD 
following Nd:YAG laser capsulotomy was 0.82% , with a mean time of 32 months between 
cataract surgery and capsulotomy and 13.5 months between capsulotomy and RD.²³ 
The incidence of retinal detachment following penetrating keratoplasty is variable, 
dependent on whether the eye is phakic or pseuphakic or whether the procedure has  
involved vitreous  manipulation. Several series report 2.4-6.8% of cases with RRD28 
Intravitreal injections have entered the therapeutic arena recently and remain a potential 
threat to causation of a rhegmatogenous retinal detachment. Iaterogenic retinal tears and 
rips due to misdirected needles can cause retinal detachment, however most studies have 
documented that this risk is low. A consecutive, interventional, multicenter case series 
measured the incidence of RD in patients receiving intravitreal anti-vascular endothelial 
growth factor. During 36 consecutive months the incidence rate of RRD was 0.013% (5/35 
942) (1 per 7188 injections)29. 
8. Affluence 
Socio-economic deprivation plays a major role in health and disease, but its role in retinal 
detachment in England has not been studied. Figure 8 shows the study population being 
split by Index of Multiple Deprivation (IMD) scores into quintiles from the least deprived 
(group 1) to the most deprived (group 5). As shown by the standardised admission ratio 
(with lower and upper 95% CIs) there is a gradient with deprivation score showing a 
significant relationship, though not strong, between affluence (least deprived) and retinal 
detachment surgery. There's about a 10% difference between the least deprived quintile and 
the most deprived (n= 57,949).   
The Scottish Retinal Detachment Study Group, based on 12 months prospective research 
between 1 November 2007 and 31 October 2008, assessed 572 patients diagnosed with 
primary retinal detachment29. They came to the conclusion that retinal detachment is twice 
as common among the more affluent than those living in areas of deprivation. This might be 
as those in poorer areas may present later if at all to medical services and the more affluent 
tend to have greater myopic prevalence. 
Retinal Detachment – An Update of the Disease and Its Epidemiology – A Discussion  
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High myopia is one of the risk factors in patients with retinal detachment. It was 
documented that there is an association of short sightedness with intelligence quotient (IQ) 
and thus higher income and socio-economic status31,32. Saw et al. report the association 
between retinal detachment and educational achievement in a study of 1204 school children 
aged 10 to 12 in Singapore. Using the nonverbal Raven Standard Progressive Matrix test 
Intelligence Quotient they concluded that non-verbal IQ is a strong risk factor for myopia32. 
Higher prevalence of myopia in the most affluent quartile could explain the increased 
incidence in this group. 
However, we cannot exclude the possibility that affluence is associated with some other, 
hitherto undefined, risk factor such as genetic factors. The latest evaluation by the Scottish 
Retinal Detachment Study Group investigated the influence of genetic predilection on 
primary RRD in 2011. They show a doubled risk of the condition in those having an affected 
sibling33. Whilst ethnicity could not be studied we know that the incidence of retinal 
detachment is lower in Asians and in Blacks34. 
As the risk of retinal detachment has direct connection with the most affluent group of 
population, there are implications for service planning, as there is likely to be a greater need 
for vitreoretinal services in wealthier areas. 
9. Seasonality 
Seasonal variation in RRD incidence has been widely reported. Most studies describe a 
summer peak and winter trough; others vice versa and some no seasonal variation at all35-39. 
This is likely attributed to increased sun exposure and outdoor activities in summer³⁶. 
Figure 9 shows that the rate of retinal detachment surgery is higher in summer peaking in July 
with the lowest rates being in January-February. This pattern is most striking in males under 
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40 in whom there is relatively lower presentation in winter (lower incidence in December-
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Fig. 9. Retinal detachment: monthly percentages of all FCEs, National data, male and 
females, any mention 1989-2006 
We found a statistically significant summer peak and winter trough at the level of p=0.01 
(n=115,450). The effect of light and temperature on the vitreous has been implicated. This 
study showed that the seasonal variation was most striking in younger males suggesting 
another association other than the season itself. Could this subgroup of patient be more active 
during the summer months and be more likely to experience trauma and PVD formation? 
In a large retrospective review of 2314 patients with primary RRD in Germany, Thelen et al. 
(1997) reported a significant mid-summer peak incidence (n in July = 228) and winter trough 
(mean n December to January = 161) with a difference of 36% between the two periods.  
They noted a close correlation between seasonal incidence of RRD and seasonal incidence of 
light hours per day and considered a potential role of light-induced changes on vitreoretinal 
adhesion.35 
Mansour et al. (2009) retrospectively reviewed the charts of 211 patients undergoing 
idiopathic RRD repair in one referral centre in Lebanon over a 13-year period. They reported 
a significant (P<0.05) increase in RRD in spring and summer compared to autumn and 
winter (56% vs. 44%). Interestingly, there was a significantly younger age of onset of RRD in 
the warmer months (47 vs. 54, P= 0.007).36 
In contrast, a retrospective evaluation of RRD in Kuwait from 1981 to 1987 reported a peak 
incidence in winter (with the highest level in November) and a trough in the summer 
months.38 These findings have not been replicated elsewhere. 
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Studies reporting no apparent seasonal variation in RRD incidence include the large 
prospective population-based study by the Beijing Rhegmatogenous Retinal Detachment 
Study Group.  There were no seasonal differences in incidence even after further 
classification of retinal detachments into blunt traumatic, aphakic and pseudophakic and 
non-traumatic phakic.39 
Possible explanations for seasonal variation in RRD incidence include: variations in light 
and temperature affecting vitreous structure, and increased outdoor activity and consequent 
trauma during periods of longer daylight hours and warmer weather ³⁵.  
Posterior vitreous detachment (PVD) is widely accepted as a contributory factor in RRD. 
Mitry et al. (2011) found that more than 85% of RRDs are associated with PVD and 
associated tractional retinal tears.40 The influence of climatic variables namely seasonality, 
air temperature, solar radiation and humidity on PVD rates was elegantly evaluated by 
Rahman et al. (2002).41 They retrospectively reviewed 567 patient records diagnostically 
coded as PVD in the Oxford Eye Casualty over a 2-year period. They excluded cases with a 
precipitating cause for PVD such as blunt trauma, retinal vascular disease and diabetes, and 
looked for a correlation between ambient temperatures, humidity and solar radiance and 
PVD incidence.  Interestingly, they found no statistically significant difference in the total 
numbers of new patients attending the Eye casualty over the summer months compared to 
winter (912 from April to September vs. 839 October to March).  They did however note a 
strong association (P= 0.035) between weekly average air temperatures and PVD incidence. 
Air temperatures of the previous week also correlated positively with PVD incidence (P = 
0.028). The higher the average air temperature the higher the weekly rate of PVD. As such, 
increased physical activity and dehydration associated with higher ambient temperatures 
may alter vitreous structure and thereby increase the incidence of PVD and, in turn, RRD. 
Further investigation into the role of increased temperature on the biochemical structure of 
the vitreous and retinal detachment rates is needed. 
10. Conclusion 
The data on overall incidence of RRD worldwide has been inconsistent. The incidence varies 
with the population studied and is limited by study design and inclusion criteria. Few 
recent estimates of incidence have used large samples sizes.  These studies show national 
data and provides longitudinal information, a more inclusive estimate of incidence and its’ 
variation over time. 
The highest annual incidence of RRD in England is in the 70-74 year age group with a 
secondary peak in young myopes and a higher overall incidence in males. Retinal detachment 
is correlated with affluence and season in England and there is geographic variation. This data 
sheds light into understanding the epidemiology of RRD in England. This would be 
particularly useful in designing and developing vitreo-retinal services to meet local needs.  
11. Clinical features and management summary 
Patients perceive flashing lights and floaters acutely. It probably arises from the mechanical 
stimulation of vitreoretinal traction on the retina. Floaters are opacities in the vitreous cavity 
that cast a shadow in the patient's visual field. Cobwebs are caused by condensation of the 
collagen fibers. Floaters can also indicate fresh blood due to the rupture of a retinal vessel 
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during an acute PVD. Patients often describe a black curtain (visual field defect) once the 
subretinal fluid accumalates. When the macula becomes detached (ie, extension of 
subretinal fluid into the macula), the patient experiences a drop in central vision.  
Cell and flare may be seen in the anterior chamber and the intraocular pressure is usually 
lower in the affected eye. Pigment in the anterior vitreous (‘tobacco dusting’ or a Shaffer 
sign) is usually present and this represents release of retinal pigment epithelium through the 
retinal break. Once the retina becomes detached, it assumes a slightly opaque color 
secondary to intraretinal edema. It has a corrugated appearance and undulates freely with 
eye movements unless severe proliferative vitreoretinopathy is present.   
Patients with a RRD should be referred to a vitreoretinal specialist immediately. Regardless of 
the surgical technique chosen, the surgical goals are to identify and close all the breaks with 
minimum iatrogenic damage. Closure of the breaks occurs when the edges of the retinal break 
are brought into contact with the underlying RPE. This is accomplished either by bringing the 
eye wall closer to the detached retina (using a scleral buckle) or by pushing the detached retina 
toward the eye wall (intraocular tamponade with a gas bubble or silicone oil). Sealing of the 
breaks is accomplished by creating a strong chorioretinal adhesion around the breaks; this 
may be completed with cryotherapy or laser photocoagulation.  
Scleral buckles usually are made of solid silicone and silicone sponges. Indirect 
ophthalmoscopy is used to localize all the breaks. Once the breaks are localized, they are 
usually treated with cryotherapy. A buckling element is chosen and sutured over the breaks. 
The drainage of the subretinal fluid is a controversial topic among vitreoretinal specialists. 
The retina can be reattached by either technique and the technical details are outside the 
remit of this chapter. 
Currently, many surgeons use pars plana vitrectomy surgery (PPV) to treat primary 
uncomplicated retinal detachments. A central core vitrectomy and removal of the vitreous from 
the margins of the breaks is the next step. Drainage of subretinal fluid through a break 
internally is then performed. Intraocular tamponade with either gas or silicone oil is chosen 
according to the surgeon's preference. The advantages of gas are that it has a higher surface 
tension than silicone oil and it dissipates on its own. The disadvantage is that it expands with 
changing atmospheric pressure. Patients with an intraocular gas bubble should not fly. 
Transconjunctival and suture-less small-gauge vitrectomy has gained popularity in the past few 
years. 23 and 25 gauge systems have several potential advantages over traditional 20-gauge 
vitrectomy including improved patient comfort, faster wound healing, decreased inflammation, 
less conjunctival scarring, and a decrease in surgical time in opening and closing. 
More than 90% of RRD cases can expect anatomical success with reattachment following one 
operation. Further surgery is required in the failed cases.  
12. References 
[1] Mitry D, Charteris DG, Fleck BW, Campbell H, Singh J. 1The epidemiology of 
rhegmatogenous retinal detachment: geographical variation and clinical 
associations. . Br J Ophthalmol. 2010 Jun;94(6):678-84. Epub 2009 Jun 9. 
[2] Pollinghorne PJ, Craig JP. Northern New Zealand Rhegmatogenous Retinal Detachment 
Study: epidemiology and risk factors. Clin Experiment Ophthalmol. 2004;32:159-63. 
Retinal Detachment – An Update of the Disease and Its Epidemiology – A Discussion  
Based on Research and Clinical Experience at the Prince Charles Eye Unit, Windsor, England 
 
355 
[3] Mowatt L, Shun-Shin G, Price N. Ethnic differences in the demand incidence of retinal 
detachments in two districts in the West Midlands. Eye. 2003;17:63-70. 
[4] Limeira-Soares PH, Lira RP, Arieta CE, et al. Demand incidence of retinal detachment in 
Brazil. Eye. 2007;21:348-52. 
[5] Ivanisevic M, Bojic I, Eterovic D. Epidemiological study of nontraumatic phakic 
rhegmatogenous retinal detachment. Ophthalmic Res. 2000;32:237-9. 
[6] Rosman M, Wong TY, Ong SG et al. Retinal detachment in Chinese, Malay and Indian 
residents in Singapore: a comparative study on risk factors, clinical presentation 
and surgical outcomes. Int Ophthalmol. 2001;24:101-6. 
[7] Mitry D, Singh J, Yorston D, Siddiqui MA, Wright A, Fleck BW, Campbell H, Charteris 
DG. The Predisposing Pathology and Clinical Characteristics in the Scottish Retinal 
Detachment Study. Ophthalmology. 2011 May 9. [Epub ahead of print]. 
[8] Mitry D, Chalmers J, Anderson K, Williams L, Fleck BW, Wright A, Campbell H. 
Temporal trends in retinal detachment incidence in Scotland between 1987 and 
2006. Br J Ophthalmol. 2011;95:365-369 
[9] Wong TY, Tielsch JM. A population-based study on the incidence of severe ocular 
trauma in Singapore. Am J Ophthalmol. 1999;128(3):345-51. 
[10] Wong TY, Tielsch JM, Schein OD. Racial difference in the incidence of retinal 
detachment in Singapore. Arch Ophthalmol. 1999;117(3):379-83. 
[11] Li X; Beijing Rhegmatogenous Retinal Detachment Study Group. Incidence and 
epidemiological characteristics of rhegmatogenous retinal detachment in Beijing, 
China. Ophthalmology. 2003;110(12):2413-7. 
[12] Tornquist R, Stenkula S, Tornquist P. retinal detachment. A study of a population-
based patient material in Sweden 1971-1981. I. Epidemiology. Acta Ophthalmol 
(Copenh). 1987;65(2):213-22. 
[13] Chou SC, Yang CH, Lee CH, Yang CM, Ho TC, Huang JS, Lin CP, Chen MS, Shih YF. 
Characteristics of primary rhegmatogenous retinal detachment in Taiwan. Eye. 
2007;21:1056-1061. 
[14] Rowe JA, Erie JC, Baratz KH, Hodge DO, Gray DT, Butterfield L, Robertson D. Retinal 
Detachment in Olmstead County, Minnesota, 1976 Through 1995. Ophthalmology. 
1999;106(1):154-9. 
[15] Bourne RR, Dineen BP. Ali SM, Noorul Huq DM, Johnson GJ. Prevalence of refractive 
error in Bangladeshi adults: results of the National Blindness and Low Vision 
Survey of Bangladesh. Ophthalmology. 2004;111(8):1150-60. 
[16] Dandona R, Dandona L, Srinivas M, Giridhar P, McCarty CA, Rao GN. Population-
based assessment of refractive error in India: the Andhra Pradesh eye disease 
study. Clin Experiment Ophthalmol. 2002; 30(2):84-93. 
[17] Schepens CLDM. Data on the natural history of retinal detachment. Arch Ophthalmol. 
1961;66:47-58. 
[18] Cambiaggi A. Myopia and Retinal Detachment: statistical study of their relationships. 
Am J Ophthalmol. 1964;58:642-50. 
[19] Sheu SJ, Ger LP, Chen JF. Male sex as a risk factor for pseudophakic retinal detachment 
after cataract extraction in Taiwanese adults. Ophthalmology. 114(10):1898-903. 
[20] Tan CS, Chan YH, Wong TY, Gazzard G, Niti M, Ng TP, Saw SM. Prevalence and risk 
factors for refractive errors and ocular biometry parameters in an elderly Asian 
population: the Singapore Longitudinal Aging Study (SLAS). Eye. 2011 July 1 
[Epub ahead of print]. 
[21] Wang J, McLeod D, Henson DB, Bishop PN. Age-dependent changes in the basal 
retinovitreous adhesion. Invest Ophthalmol Vis Sci. 2003;44(5):1793-800. 
 
Advances in Ophthalmology 
 
354 
during an acute PVD. Patients often describe a black curtain (visual field defect) once the 
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years. 23 and 25 gauge systems have several potential advantages over traditional 20-gauge 
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less conjunctival scarring, and a decrease in surgical time in opening and closing. 
More than 90% of RRD cases can expect anatomical success with reattachment following one 
operation. Further surgery is required in the failed cases.  
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1. Introduction 
Retinal vascular occlusions are serious diseases and significant causes of blindness that 
include arterial and venous obstructions. The causes, pathogenesis, clinical characteristics, 
prognosis, and response to therapy are influenced by the location of the occlusion in the 
retinal vasculature and by the extent of retinal nonperfusion. 
The hallmark of clinical presentation in the retinal occlusive disease is painless loss of 
vision, which can be asymptomatic, gradual with only mildly reduced visual acuity, or 
sudden and reduced to counting fingers depending on the extent of the irrigation area of the 
affected vessel. The clinical presentation aids in distinguishing the type of the occlusion, 
which may be classified according to the anatomical site of the occlusion.  
2. Retinal Artery Occlusion 
Retinal artery occlusion (RAO) represents an ophthalmologic emergency. In 1859, von 
Graefe first described central retinal artery occlusion (von Graefe, 1859). Retinal artery 
obstruction may be classified as follows: central (CRAO), affecting the retinal vessel at the 
optic nerve, hemicentral (occasional, only when one of the two trunks of the CRA is 
occluded) (Akkoyun et al., 2006; Karagoz et al., 2009; Schmidt & Kramer-Zucker, 2011), 
branch (BRAO), obstruction distally to the lamina cribrosa of the optic nerve, cilioretinal 
(CLRAO) and central sparing cilioretinal artery (Hayreh, 2011). Obstructions more proximal 
to the central retinal artery, in the ophthalmic artery, or even in the internal carotid artery, 
may produce visual loss as well. More proximal obstructions usually cause a more chronic 
form of visual problem—the ocular ischemic syndrome often associated with occlusive 
carotid disease (Kearns & Hollenhorst, 1963). 
Central retinal artery occlusion results in sudden visual loss and is therefore one of the most 
important topics in ophthalmology. Branch retinal artery occlusion causes sudden 
segmental visual loss and may recur to involve other branch retinal arterioles. Amaurosis 
fugax is a common transient acute retinal ischemic condition. Acute retinal arterial occlusive 
disorders together comprise one of the major causes of acute visual loss (Hayreh, 2011). 
Only anecdotal reports have described spontaneous recovery of vision, and case series have 
shown only up to 14% of spontaneous recovery (Atebara et al., 1995). 
The majority of retinal arterial obstructions are either thrombotic or embolic in nature (an 
embolus is visible only in 20% of the patients with branch or central retinal artery occlusion) 
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(CLRAO) and central sparing cilioretinal artery (Hayreh, 2011). Obstructions more proximal 
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may produce visual loss as well. More proximal obstructions usually cause a more chronic 
form of visual problem—the ocular ischemic syndrome often associated with occlusive 
carotid disease (Kearns & Hollenhorst, 1963). 
Central retinal artery occlusion results in sudden visual loss and is therefore one of the most 
important topics in ophthalmology. Branch retinal artery occlusion causes sudden 
segmental visual loss and may recur to involve other branch retinal arterioles. Amaurosis 
fugax is a common transient acute retinal ischemic condition. Acute retinal arterial occlusive 
disorders together comprise one of the major causes of acute visual loss (Hayreh, 2011). 
Only anecdotal reports have described spontaneous recovery of vision, and case series have 
shown only up to 14% of spontaneous recovery (Atebara et al., 1995). 
The majority of retinal arterial obstructions are either thrombotic or embolic in nature (an 
embolus is visible only in 20% of the patients with branch or central retinal artery occlusion) 
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(Rumelt & Brown, 2003). Arterial occlusions in the eye are almost always due to 
microembolism and the major source of microemboli is the plaque(s), which may be present 
with or without any significant carotid artery stenosis. Thus, absence of significant stenosis 
of the carotid artery does not necessarily rule out the carotid artery as the source of 
microembolism (Hayreh et al., 2009). 
Immediate intervention improves chances of visual recovery, but even then, the prognosis is 
rather poor, with only 21-35% of eyes retaining useful vision (Jain & Juang, 2009), because it 
dominantly depends on the type of the occlusion (Hayreh & Zimmerman, 2005). Although 
restoration of vision is of immediate concern, retinal artery occlusion is a forerunner for 
other systemic diseases that must be evaluated promptly. Establishing of the cause of 
obstruction is essential. In case of giant cell arteritis causing occlusion immediate treatment 
is urgent. 
2.1 Epidemiology 
Central retinal artery obstruction (CRAO) is a rare event – it has been estimated to account 
for about 0.85 in 100,000 per year (Jain & Juang, 2009). The mean age at onset is about 60 
years, with a range from the first to the ninth decade of life (Duker, 2003). Bilateral 
obstruction occurs in 1-2% of cases (Brown, 1994). CRAOs account for 58% of acute RAOs, 
BRAOs for 38%, and cilioretinal artery occlusions (CLRAOs) (Jain & Juang, 2009). There are 
discrepancies among authors regarding the prevalence of men over women. Some advocate 
the ratio 2:1 (Duker, 2003) whereas the others found slightly more frequent occurrence in 
men (Hayreh et al., 2009). A large case series documented that approximately one fourth of 
patients with CRAO had a form with the cilioretinal sparing (Brown & Shields, 1979). The 
incidence of CLRA occlusion (CLRAO) varies in different studies from none to 32% (Justice 
& Lehmann 1976), which would be the most acceptable data, because the incidence was 
calculated by reviewing stereoscopic color fundus photographs as well as FA; the incidence 
of CLRAO is in direct proportion with the presence of cilioretinal artery in the population. 
FA is the most reliable way to ascertain the true incidence because the CLRA dyes 
concurrently with the filling of the choroid and usually before the start of filling of the CRA. 
The arteries occurred bilaterally in 14.6% (Justice & Lehmann, 1976). 
Multiple studies have shown increased mortality in patients with retinal arterial emboli 
(Bruno et al., 1995; Ho et al., 2008; Lindley et al., 2009). The frequency of retinal emboli 
increases with age and are more common in men than in women. Bilateral are rare, although 
multiple emboli in a single eye may be seen in up to one third of cases. They are associated 
with the presence of carotid artery disease (CAD), hypertension, smoking, and possibly 
diabetes (Wong & Klein, 2002). The large Beaver Dam Eye Study calculated the prevalence 
of retinal arteriolar emboli of 1.3% in the population ranged from 43-86 years, and the 5-year 
incidence of 0.9%, the 10-year incidence of 1.5% for the same population, and also confirmed 
a significantly higher hazard of dying from a stroke in people with retinal emboli (Klein et 
al., 1999; Klein et al., 2003). 
Debate exists in the literature on the prevalence and etiology of neovascularization (NV) 
following CRAO. The reported prevalence varies from 2.5% to 31.6%. Studies have reported 
prevalence of 18.2% of neovascularization and 15.2% of neovascular glaucoma (NVG) 
(Duker et al., 1991; Rudkin et al., 2010). In branch retinal artery occlusion, the incidence is 
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even rarer. Neovascularization is more likely to occur in persons with concurrent diseases 
and not CRAO per se, as with diabetes, severe carotid artery disease or generalized 
atherosclerosis (Hayreh & Podhajsky, 1982). Clinical cases have been reported in which 
neovascular glaucoma developed after branch retinal artery occlusion (Brown & Reber, 
1986); most probably they are a result of later complete CRAO rather than pure BRAO. 
2.2 Pathophysiology and histology 
Visual loss from retinal arterial occlusion (RAO) occurs from the loss of blood supply to the 
inner layer of the retina. Blood supply to the retina originates from the central retinal (CRA) 
and the cilioretinal (CLRA) artery. The primary source of blood supply to both arteries - the 
ophthalmic artery (OA), usually the first intracranial branch of the internal carotid artery 
(ICA), does not always originate from the ICA; the most common abnormal origin is the 
middle meningeal artery (Hayreh, 2011; Morandi et al., 1998). The central retinal artery 
arises independently in 37.5% from the ophthalmic artery, in 59.5% by a common trunk with 
one or another posterior ciliary artery (PCA), and extremely rarely with other branches of 
the OA. Numerous anastomoses are established by the branches of the CRA with other 
branches of the OA, mostly pial. The study showed that these pial anastomoses were 
usually large enough to establish a variable amount of collateral circulation in the eye 
having an occlusion of the CRA. This was also demonstrated by fluorescein fundus 
angiography (FA) (Hayreh, 2011; Hayreh & Weingeist, 1980). The central retinal artery 
supplies the retina as it branches into smaller segments upon leaving the optic disc. The so-
called “branch retinal arteries” are in fact arterioles after the first branching in the retina 
which don’t have either an internal elastic lamina or a continuous muscular layer (Hayreh, 
2011). A retinal vascular bed does not own any anastomoses; it is end-arterial system. The 
cilioretinal artery belongs to the PCA system; it usually originates from the peripapillary 
choroid or directly from one of the PCAs and supplies the part of the macular retina. The 
CLRA has a characteristic hook-like appearance at its site of entry into the retina at the optic 
disc margin, usually on the temporal side. Branch retinal artery occlusion (BRAO) occurs 
when the embolus lodges in a more distal branch of the retinal artery. BRAO typically 
involves the temporal retinal vessels and usually does not require treatment, unless 
perifoveolar vessels are threatened (Ho et al., 2008). 
Acutely, obstruction of the central retinal artery results in inner retinal layer edema and 
pyknosis of the ganglion cell nuclei. Ischemic necrosis results and the retina become 
opacified and yellow-white in appearance. The opacity is most dense in the posterior pole as 
a result of the increased thickness of the nerve fiber layer and ganglion cells in this region. 
The opacification takes as little as 15 minutes to several hours before becoming evident and 
resolves in 4-6 weeks. Furthermore, the foveola assumes a cherry-red spot because of a 
combination of 3 factors: (i) the intact retinal pigment epithelium and choroid underlying 
the fovea, (ii) the foveolar retina is nourished by the choriocapillaris, and (iii) the thinnest 
NFL at this location. The late stage shows a homogenous scar replacing the inner layer of the 
retina. Pigmentary changes are typically absent since the retinal pigment epithelium 
remains unaffected (Kearns & Hollenhorst, 1963).  
It has been shown experimentally on animal studies that the retinal damage is irreversible 
after 105 minutes of completely occluded circulation, but may recover at 97 minutes 
(Hayreh et al., 2004), and the treatment instituted at any time beyond 4h after the onset of 
 
Advances in Ophthalmology 
 
358 
(Rumelt & Brown, 2003). Arterial occlusions in the eye are almost always due to 
microembolism and the major source of microemboli is the plaque(s), which may be present 
with or without any significant carotid artery stenosis. Thus, absence of significant stenosis 
of the carotid artery does not necessarily rule out the carotid artery as the source of 
microembolism (Hayreh et al., 2009). 
Immediate intervention improves chances of visual recovery, but even then, the prognosis is 
rather poor, with only 21-35% of eyes retaining useful vision (Jain & Juang, 2009), because it 
dominantly depends on the type of the occlusion (Hayreh & Zimmerman, 2005). Although 
restoration of vision is of immediate concern, retinal artery occlusion is a forerunner for 
other systemic diseases that must be evaluated promptly. Establishing of the cause of 
obstruction is essential. In case of giant cell arteritis causing occlusion immediate treatment 
is urgent. 
2.1 Epidemiology 
Central retinal artery obstruction (CRAO) is a rare event – it has been estimated to account 
for about 0.85 in 100,000 per year (Jain & Juang, 2009). The mean age at onset is about 60 
years, with a range from the first to the ninth decade of life (Duker, 2003). Bilateral 
obstruction occurs in 1-2% of cases (Brown, 1994). CRAOs account for 58% of acute RAOs, 
BRAOs for 38%, and cilioretinal artery occlusions (CLRAOs) (Jain & Juang, 2009). There are 
discrepancies among authors regarding the prevalence of men over women. Some advocate 
the ratio 2:1 (Duker, 2003) whereas the others found slightly more frequent occurrence in 
men (Hayreh et al., 2009). A large case series documented that approximately one fourth of 
patients with CRAO had a form with the cilioretinal sparing (Brown & Shields, 1979). The 
incidence of CLRA occlusion (CLRAO) varies in different studies from none to 32% (Justice 
& Lehmann 1976), which would be the most acceptable data, because the incidence was 
calculated by reviewing stereoscopic color fundus photographs as well as FA; the incidence 
of CLRAO is in direct proportion with the presence of cilioretinal artery in the population. 
FA is the most reliable way to ascertain the true incidence because the CLRA dyes 
concurrently with the filling of the choroid and usually before the start of filling of the CRA. 
The arteries occurred bilaterally in 14.6% (Justice & Lehmann, 1976). 
Multiple studies have shown increased mortality in patients with retinal arterial emboli 
(Bruno et al., 1995; Ho et al., 2008; Lindley et al., 2009). The frequency of retinal emboli 
increases with age and are more common in men than in women. Bilateral are rare, although 
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al., 1999; Klein et al., 2003). 
Debate exists in the literature on the prevalence and etiology of neovascularization (NV) 
following CRAO. The reported prevalence varies from 2.5% to 31.6%. Studies have reported 
prevalence of 18.2% of neovascularization and 15.2% of neovascular glaucoma (NVG) 
(Duker et al., 1991; Rudkin et al., 2010). In branch retinal artery occlusion, the incidence is 
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even rarer. Neovascularization is more likely to occur in persons with concurrent diseases 
and not CRAO per se, as with diabetes, severe carotid artery disease or generalized 
atherosclerosis (Hayreh & Podhajsky, 1982). Clinical cases have been reported in which 
neovascular glaucoma developed after branch retinal artery occlusion (Brown & Reber, 
1986); most probably they are a result of later complete CRAO rather than pure BRAO. 
2.2 Pathophysiology and histology 
Visual loss from retinal arterial occlusion (RAO) occurs from the loss of blood supply to the 
inner layer of the retina. Blood supply to the retina originates from the central retinal (CRA) 
and the cilioretinal (CLRA) artery. The primary source of blood supply to both arteries - the 
ophthalmic artery (OA), usually the first intracranial branch of the internal carotid artery 
(ICA), does not always originate from the ICA; the most common abnormal origin is the 
middle meningeal artery (Hayreh, 2011; Morandi et al., 1998). The central retinal artery 
arises independently in 37.5% from the ophthalmic artery, in 59.5% by a common trunk with 
one or another posterior ciliary artery (PCA), and extremely rarely with other branches of 
the OA. Numerous anastomoses are established by the branches of the CRA with other 
branches of the OA, mostly pial. The study showed that these pial anastomoses were 
usually large enough to establish a variable amount of collateral circulation in the eye 
having an occlusion of the CRA. This was also demonstrated by fluorescein fundus 
angiography (FA) (Hayreh, 2011; Hayreh & Weingeist, 1980). The central retinal artery 
supplies the retina as it branches into smaller segments upon leaving the optic disc. The so-
called “branch retinal arteries” are in fact arterioles after the first branching in the retina 
which don’t have either an internal elastic lamina or a continuous muscular layer (Hayreh, 
2011). A retinal vascular bed does not own any anastomoses; it is end-arterial system. The 
cilioretinal artery belongs to the PCA system; it usually originates from the peripapillary 
choroid or directly from one of the PCAs and supplies the part of the macular retina. The 
CLRA has a characteristic hook-like appearance at its site of entry into the retina at the optic 
disc margin, usually on the temporal side. Branch retinal artery occlusion (BRAO) occurs 
when the embolus lodges in a more distal branch of the retinal artery. BRAO typically 
involves the temporal retinal vessels and usually does not require treatment, unless 
perifoveolar vessels are threatened (Ho et al., 2008). 
Acutely, obstruction of the central retinal artery results in inner retinal layer edema and 
pyknosis of the ganglion cell nuclei. Ischemic necrosis results and the retina become 
opacified and yellow-white in appearance. The opacity is most dense in the posterior pole as 
a result of the increased thickness of the nerve fiber layer and ganglion cells in this region. 
The opacification takes as little as 15 minutes to several hours before becoming evident and 
resolves in 4-6 weeks. Furthermore, the foveola assumes a cherry-red spot because of a 
combination of 3 factors: (i) the intact retinal pigment epithelium and choroid underlying 
the fovea, (ii) the foveolar retina is nourished by the choriocapillaris, and (iii) the thinnest 
NFL at this location. The late stage shows a homogenous scar replacing the inner layer of the 
retina. Pigmentary changes are typically absent since the retinal pigment epithelium 
remains unaffected (Kearns & Hollenhorst, 1963).  
It has been shown experimentally on animal studies that the retinal damage is irreversible 
after 105 minutes of completely occluded circulation, but may recover at 97 minutes 
(Hayreh et al., 2004), and the treatment instituted at any time beyond 4h after the onset of 
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CRAO cannot have any scientific rationale for improvement of vision. However, complete 
occlusion or retinal artery circulation in humans is rare with retinal artery disease; thus, 
retinal recovery is possible even after days of ischemia (Brown & Magargal, 1988). 
Controversy exists regarding the optimal window of treatment in humans, but the 
conservative approach involves treatment up to 24 hours (Kearns & Hollenhorst, 1963).  
The retinal artery could be occluded due to embolism, vasoobliteration (atherosclerotic 
plaques, giant-cell arteritis and other types of vasculitis) and vascular compression (a 
retrobulbar mass - hematoma, neoplasm, retrobulbar injections may lead to an optic nerve 
and central retinal artery compression) (Korner-Stiefbold, 2001), angiospasm, hemodynamic 
or hydrostatic arterial occlusion (Hayreh, 2011). By far the most common cause of 
nonarteritic RAO is the embolism. Emboli are usually of three types: cholesterol - 
Hollenhorst plaque, platelet-fibrin, calcified, and occasionally myxomatous, or bacterial. The 
incidence is 74%, 15.5% and 10.5% for the first 3 types, respectively (Arruga & Sanders, 
1982). They are mostly of carotid and/or cardiac origin (Korner-Stiefbold, 2001). The major 
source of embolism in the carotid arteries is plaque (66%), whereas a significant carotid 
stenosis (>50%) accounts for only 30% of cases (Hayreh et al., 2009; Korner-Stiefbold, 2001; 
Younge, 1989). Statistically, Caucasians, when compared to African Americans, have 
significantly different incidence of ICA stenosis, which is 41% and 3.4% for the each group, 
respectively (Ahuja et al., 1999). A significant stenosis of the extracranial internal carotid 
artery is the most common identified condition associated with retinal and ocular ischemia 
(Biousse, 1997; Mizener et al., 1997; Sharma et al., 1998). It represents the hemodynamic 
cause, and, especially if associated with nocturnal arterial hypotension, can lead to transient 
CRAO (Hayreh & Zimmerman, 2005). The sources of emboli in heart are valvular lesions, 
patent foramen ovale, myxoma and endocarditis (Mangat, 1995; Reese & Shafer, 1978; 
Schmidt et al., 2005; Sharma et al., 1997). It must be remembered though, that the absence of 
any abnormality on color Doppler ultrasound or echocardiography does not exclude carotid 
artery or the heart as the source of microembolism, because of the test-resolution and 
location of the plaque/stenosis. 
Animal studies have shown that, serotonin in atherosclerotic vessels produces vasospasm of 
the central retinal artery (CRA) and/or posterior ciliary artery (PCA) in various 
combinations (but not vasospasm of the arterioles in the retina). It is postulated that in some 
atherosclerotic individuals this mechanism may play an important role in the development 
of ischemic disorders of the retina and optic nerve head (ONH), including amaurosis fugax, 
CRA occlusion and anterior ischemic optic neuropathy, and possibly also glaucomatous 
optic neuropathy, particularly in normal tension glaucoma (Hayreh, 1999). 
Central retinal arterial occlusions could be divided into permanent or transient; arteritic 
(usually gigantocellular arteritis) or nonarteritic occlusion. The transient is the nonarteritic 
and could occur due to (i) transient impaction of an embolus, (ii) fall of perfusion pressure 
in the retinal vascular bed below the critical level (night arterial hypotension, hypovolemic 
shock, hemodialysis, spasm of CRA, marked carotid artery disease, ocular ischemia, or a rise 
of intraocular pressure because of orbital swelling, acute angle-closure glaucoma, 
neovascular glaucoma (NVG) with ocular ischemia), and (iii) vasospasm of the 
atherosclerotic lesions (induced by the platelet-aggregation plaque secreting serotonin) 
(Hayreh, 2011). 
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Branch arterial occlusion is usually due to embolism and occasionally vasculitis. It could be 
recurrent (Barak et al., 1997; Beiran et al., 1995; Beversdorf et al., 1997; Johnson et al., 1994). 
Most of these cases probably have Susac’s syndrome (autoimmune endotheliopathy leading to 
encephalopathy, BRAO and hearing loss) (Susac et al., 2007). The etiology of this syndrome is 
still unknown, but the prognosis is good in most cases. Spontaneous resolution usually occurs, 
but early treatment minimizes the risk of sequelae (Van Winden & Salu, 2010). 
2.3 Causes 
Embolism of the carotid artery and the heart are the most common causes of retinal artery 
obstruction. Carotid artery disease causes retinal arterial occlusion by three mechanisms: 
embolism, hemodynamic changes in significantly stenosed carotid artery, and arterial 
spasm. The major source of emboli is plaques in the carotid arteries, and much less 
frequently stenosis. According to some studies, hemodynamically significant carotid artery 
stenosis was found in about 18%of patients with acute RAO (Sharma et al., 1998) and as 
previously mentioned, Hayreh et al. suggest that the presence of plaques on Doppler color 
imaging is of more value in determining the cause of acute occlusive event rather than the 
embolus itself (Hayreh, 2005). The probable cause is the microembolism, which may not 
produce hemodynamically significant stenosis recordable on Doppler color imaging but 
may indeed account for the retinal artery occlusion. As shown in the study, carotid Doppler 
and/or angiography showed the presence of plaques in 71% in CRAO and 66% in BRAO 
(Hayreh et al., 2009). The fluctuation of hemodynamic factors, especially drops in blood 
pressure in nocturnal hypotension along with significant stenosis of the carotid artery may 
be responsible for transient retinal artery occlusion (Hayreh & Zimmerman, 2005; 
McCullough et al., 2004). Based on experimental studies on animals, the investigators have 
introduced the possible role of serotonin, released by platelet aggregation on atherosclerotic 
plaques in the carotid artery, causing transient vasospasm of the central retinal artery and 
thus potentially inducing retinal artery occlusion and retinal ischemic disorders. 
Systemic cardiovascular diseases have a well known association with retinal arterial 
occlusive disease in elderly people (Sharma, 1998). Therefore, a careful history should 
include identifying the possible underlying causes such as arterial hypertension, diabetes 
mellitus, hyperlipidemia, carotid artery disease, coronary artery disease, cerebrovascular 
disease and symptoms suggestive of temporal arteritis. Cigarette smoking has been 
described significantly more common among these patients than in the general population. 
In patients with no obvious systemic risk factors and especially in subjects under the age of 
40, the other causative options should be considered, which include systemic vasculitis, 
blood dyscrasias, drug abuse, hypercoagulabile states, infective diseases, migraine and 
prolonged direct pressure to the globe in unconscious patients (Brown et al., 1981; Graham, 
1990; Greven et al., 1995).  
Coagulopathies from sickle cell anemia or antiphospholipid antibodies are more common 
etiologies for CRAO in patients younger than 30 years of age and the proposed mechanisms 
involve increase in coagulation factor or platelet activity, thrombocytosis, interaction of lupus 
anticoagulant and anticardiolipin antibodies with phospholipids as well as the deficiencies of 
protein C and S and resistance to activated protein C (Comp & Esmon, 1984; Love & Santoro, 
1990; Palmowski-Wolfe et al., 2007; Vignes et al., 1996). Increased levels of homocysteine have 
been linked with higher incidence of occlusive vascular incidents damaging the vascular 
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CRAO cannot have any scientific rationale for improvement of vision. However, complete 
occlusion or retinal artery circulation in humans is rare with retinal artery disease; thus, 
retinal recovery is possible even after days of ischemia (Brown & Magargal, 1988). 
Controversy exists regarding the optimal window of treatment in humans, but the 
conservative approach involves treatment up to 24 hours (Kearns & Hollenhorst, 1963).  
The retinal artery could be occluded due to embolism, vasoobliteration (atherosclerotic 
plaques, giant-cell arteritis and other types of vasculitis) and vascular compression (a 
retrobulbar mass - hematoma, neoplasm, retrobulbar injections may lead to an optic nerve 
and central retinal artery compression) (Korner-Stiefbold, 2001), angiospasm, hemodynamic 
or hydrostatic arterial occlusion (Hayreh, 2011). By far the most common cause of 
nonarteritic RAO is the embolism. Emboli are usually of three types: cholesterol - 
Hollenhorst plaque, platelet-fibrin, calcified, and occasionally myxomatous, or bacterial. The 
incidence is 74%, 15.5% and 10.5% for the first 3 types, respectively (Arruga & Sanders, 
1982). They are mostly of carotid and/or cardiac origin (Korner-Stiefbold, 2001). The major 
source of embolism in the carotid arteries is plaque (66%), whereas a significant carotid 
stenosis (>50%) accounts for only 30% of cases (Hayreh et al., 2009; Korner-Stiefbold, 2001; 
Younge, 1989). Statistically, Caucasians, when compared to African Americans, have 
significantly different incidence of ICA stenosis, which is 41% and 3.4% for the each group, 
respectively (Ahuja et al., 1999). A significant stenosis of the extracranial internal carotid 
artery is the most common identified condition associated with retinal and ocular ischemia 
(Biousse, 1997; Mizener et al., 1997; Sharma et al., 1998). It represents the hemodynamic 
cause, and, especially if associated with nocturnal arterial hypotension, can lead to transient 
CRAO (Hayreh & Zimmerman, 2005). The sources of emboli in heart are valvular lesions, 
patent foramen ovale, myxoma and endocarditis (Mangat, 1995; Reese & Shafer, 1978; 
Schmidt et al., 2005; Sharma et al., 1997). It must be remembered though, that the absence of 
any abnormality on color Doppler ultrasound or echocardiography does not exclude carotid 
artery or the heart as the source of microembolism, because of the test-resolution and 
location of the plaque/stenosis. 
Animal studies have shown that, serotonin in atherosclerotic vessels produces vasospasm of 
the central retinal artery (CRA) and/or posterior ciliary artery (PCA) in various 
combinations (but not vasospasm of the arterioles in the retina). It is postulated that in some 
atherosclerotic individuals this mechanism may play an important role in the development 
of ischemic disorders of the retina and optic nerve head (ONH), including amaurosis fugax, 
CRA occlusion and anterior ischemic optic neuropathy, and possibly also glaucomatous 
optic neuropathy, particularly in normal tension glaucoma (Hayreh, 1999). 
Central retinal arterial occlusions could be divided into permanent or transient; arteritic 
(usually gigantocellular arteritis) or nonarteritic occlusion. The transient is the nonarteritic 
and could occur due to (i) transient impaction of an embolus, (ii) fall of perfusion pressure 
in the retinal vascular bed below the critical level (night arterial hypotension, hypovolemic 
shock, hemodialysis, spasm of CRA, marked carotid artery disease, ocular ischemia, or a rise 
of intraocular pressure because of orbital swelling, acute angle-closure glaucoma, 
neovascular glaucoma (NVG) with ocular ischemia), and (iii) vasospasm of the 
atherosclerotic lesions (induced by the platelet-aggregation plaque secreting serotonin) 
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Branch arterial occlusion is usually due to embolism and occasionally vasculitis. It could be 
recurrent (Barak et al., 1997; Beiran et al., 1995; Beversdorf et al., 1997; Johnson et al., 1994). 
Most of these cases probably have Susac’s syndrome (autoimmune endotheliopathy leading to 
encephalopathy, BRAO and hearing loss) (Susac et al., 2007). The etiology of this syndrome is 
still unknown, but the prognosis is good in most cases. Spontaneous resolution usually occurs, 
but early treatment minimizes the risk of sequelae (Van Winden & Salu, 2010). 
2.3 Causes 
Embolism of the carotid artery and the heart are the most common causes of retinal artery 
obstruction. Carotid artery disease causes retinal arterial occlusion by three mechanisms: 
embolism, hemodynamic changes in significantly stenosed carotid artery, and arterial 
spasm. The major source of emboli is plaques in the carotid arteries, and much less 
frequently stenosis. According to some studies, hemodynamically significant carotid artery 
stenosis was found in about 18%of patients with acute RAO (Sharma et al., 1998) and as 
previously mentioned, Hayreh et al. suggest that the presence of plaques on Doppler color 
imaging is of more value in determining the cause of acute occlusive event rather than the 
embolus itself (Hayreh, 2005). The probable cause is the microembolism, which may not 
produce hemodynamically significant stenosis recordable on Doppler color imaging but 
may indeed account for the retinal artery occlusion. As shown in the study, carotid Doppler 
and/or angiography showed the presence of plaques in 71% in CRAO and 66% in BRAO 
(Hayreh et al., 2009). The fluctuation of hemodynamic factors, especially drops in blood 
pressure in nocturnal hypotension along with significant stenosis of the carotid artery may 
be responsible for transient retinal artery occlusion (Hayreh & Zimmerman, 2005; 
McCullough et al., 2004). Based on experimental studies on animals, the investigators have 
introduced the possible role of serotonin, released by platelet aggregation on atherosclerotic 
plaques in the carotid artery, causing transient vasospasm of the central retinal artery and 
thus potentially inducing retinal artery occlusion and retinal ischemic disorders. 
Systemic cardiovascular diseases have a well known association with retinal arterial 
occlusive disease in elderly people (Sharma, 1998). Therefore, a careful history should 
include identifying the possible underlying causes such as arterial hypertension, diabetes 
mellitus, hyperlipidemia, carotid artery disease, coronary artery disease, cerebrovascular 
disease and symptoms suggestive of temporal arteritis. Cigarette smoking has been 
described significantly more common among these patients than in the general population. 
In patients with no obvious systemic risk factors and especially in subjects under the age of 
40, the other causative options should be considered, which include systemic vasculitis, 
blood dyscrasias, drug abuse, hypercoagulabile states, infective diseases, migraine and 
prolonged direct pressure to the globe in unconscious patients (Brown et al., 1981; Graham, 
1990; Greven et al., 1995).  
Coagulopathies from sickle cell anemia or antiphospholipid antibodies are more common 
etiologies for CRAO in patients younger than 30 years of age and the proposed mechanisms 
involve increase in coagulation factor or platelet activity, thrombocytosis, interaction of lupus 
anticoagulant and anticardiolipin antibodies with phospholipids as well as the deficiencies of 
protein C and S and resistance to activated protein C (Comp & Esmon, 1984; Love & Santoro, 
1990; Palmowski-Wolfe et al., 2007; Vignes et al., 1996). Increased levels of homocysteine have 
been linked with higher incidence of occlusive vascular incidents damaging the vascular 
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endothelium and thus increasing atherosclerotic changes and the formation of blood cloths. 
Therefore, in cases of suspected homocystinuria or heterozygosity for homocystinuria an oral 
methionine loading test may be performed since this state may be preventable by taking 
appropriate vitamin supplements (Boers et al., 1985; Weger et al., 2002; Wenzler et al., 1993). In 
cases of clinical suspicion, the HIV testing may be indicated since there have been case reports 
of CRAO or BRAO associated with HIV infection (Conway et al., 1995). A variety of other 
diseases, including systemic lupus erythematosus, polyarteritis nodosa, dengue fever, West 
Nile virus, sickle cell disease, Takayasu’s arteritis, after smallpox vaccination, Churg-Strauss 
syndrome, ocular Behçet’s disease, Fabry’s disease, Susac'c syndrome, and head injury may 
present with retinal occlusive disorders. It is necessary to exclude these states if there is a 
young person with sudden loss of vision, fundoscopic findings of arterial occlusion, central or 
branch, and no obvious identifiable systemic risk factors as above mentioned. In conclusion, 
arterial occlusive disease of the retina is the result of either arteriosclerotic thrombosis, embolic 
impaction (predominantly atheromatous plaques of carotid bifurcation, or the internal carotid 
artery, but also consisting of different material – fat, parasites, talc, air), vasculitis, vasospasm 
or systemic hypotension. These numerous potential causes mandate often time-consuming 
and expensive lab tests, and sometimes a causative management of the underlying disease. 
The possible causes and underlying states associated with retinal arterial occlusion are 
incorporated in Table 1.  
2.4 Clinical presentation 
2.4.1 Symptoms 
The main presenting symptom of the arterial occlusive disease is loss of vision, usually 
monocular, which may be sudden (seconds to minutes) blurring, decrease or total loss of 
vision. The extent of visual loss depends on the type of the occlusion. In central artery 
occlusions, visual loss is central and dense. In branch artery occlusions, visual loss may go 
unnoticed if only a section of the peripheral visual field space is affected. Various types of 
the retinal artery occlusion have different degree of visual acuity (VA) drop; CRAO 
characterizes severely decreased VA (counting fingers to light perception); BRAO has VA 
20/20 to counting fingers; VA in cilioretinal occlusion ranges from 20/30-20/60; CRAO with 
cilioretinal sparing has VA 20/30 to hand motion, depending on the amount of the 
papillomacular bundle supplied by the patent vessel; combined CRAO and CRVO have VA 
counting fingers to light perception (Rumelt S, Brown GC, 2004). The patients with CRAO 
without cilioretinal sparing rarely regained any useful vision (Brown & Shields, 1979). 
Pain accompanying the visual loss is unusual and usually denotes associated ocular 
ischemic syndrome (Werner et al. 1994). Rarely, in cases associated with arterial spasm, a 
relapsing and remitting course of visual loss precedes central retinal artery obstruction. 
Amaurosis fugax precedes visual loss in about 10% of patients involving transient loss of 
vision lasting seconds to minutes, but which may last up to 2 hours (Brown, 1999). The 
vision usually returns to baseline after an episode of amaurosis fugax. 
2.4.2 Signs 
In CRAO, the first signs are afferent pupillary defect on the affected side and segmental 
arterial blood flow (“box- carring”), which appear immediately at the occlusion and are 
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accompanied by the various degree of diminished visual acuity. Later signs are retinal 
opacification and cherry-red spot and optic disc pallor, attenuation of the retinal arteries, 
arterio-arteriolar collaterals or neovascular glaucoma (as a complication). Von Graefe was 
the first one who described typical fundoscopic findings associated with occlusion of the 
central retinal artery: whitish, edematous retina attributable to infarction, especially at the 
posterior pole where the nerve fibre layer and ganglion cell layer are the thickest (Beatty & 
Au Eong, 2000). As these layers are absent in the fovea, the underlying choroidal vascular 
bed can be seen in this area, thus giving rise to the classic cherry-red spot (Fig. 1.). In the 
presence of a patent cilioretinal artery, the retinal region served by the unobstructed vessel 
is not involved (Fig. 2.). Disc pallor and retinal vascular narrowing are characteristic of the 
late stage of CRAO. The characteristic of BRAO is retinal edema in the distribution of the 
affected vessel only (Fig. 3.). Obstruction of a cilioretinal artery, or even a macular branch 
arteriole, gives cloudy, edematous appearance of the macula and affects central vision. In 
acute stage, the arteries appear thin and attenuated while cherry red spot and ground glass 
appearance may take hours to develop. In severe blockages, both veins and arteries may 
manifest “box-carring” or segmentation of the blood flow. 
 
Fig. 1. Central retinal artery occlusion, note foveal cherry red spot and ground glass 
appearance of the macula (arrow) 
 
Fig. 2. Cilioretinal sparing central artery occlusion; sparing between the disc and fovea 
(arrows), representing irrigation area of the cilioretinal artery  
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endothelium and thus increasing atherosclerotic changes and the formation of blood cloths. 
Therefore, in cases of suspected homocystinuria or heterozygosity for homocystinuria an oral 
methionine loading test may be performed since this state may be preventable by taking 
appropriate vitamin supplements (Boers et al., 1985; Weger et al., 2002; Wenzler et al., 1993). In 
cases of clinical suspicion, the HIV testing may be indicated since there have been case reports 
of CRAO or BRAO associated with HIV infection (Conway et al., 1995). A variety of other 
diseases, including systemic lupus erythematosus, polyarteritis nodosa, dengue fever, West 
Nile virus, sickle cell disease, Takayasu’s arteritis, after smallpox vaccination, Churg-Strauss 
syndrome, ocular Behçet’s disease, Fabry’s disease, Susac'c syndrome, and head injury may 
present with retinal occlusive disorders. It is necessary to exclude these states if there is a 
young person with sudden loss of vision, fundoscopic findings of arterial occlusion, central or 
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accompanied by the various degree of diminished visual acuity. Later signs are retinal 
opacification and cherry-red spot and optic disc pallor, attenuation of the retinal arteries, 
arterio-arteriolar collaterals or neovascular glaucoma (as a complication). Von Graefe was 
the first one who described typical fundoscopic findings associated with occlusion of the 
central retinal artery: whitish, edematous retina attributable to infarction, especially at the 
posterior pole where the nerve fibre layer and ganglion cell layer are the thickest (Beatty & 
Au Eong, 2000). As these layers are absent in the fovea, the underlying choroidal vascular 
bed can be seen in this area, thus giving rise to the classic cherry-red spot (Fig. 1.). In the 
presence of a patent cilioretinal artery, the retinal region served by the unobstructed vessel 
is not involved (Fig. 2.). Disc pallor and retinal vascular narrowing are characteristic of the 
late stage of CRAO. The characteristic of BRAO is retinal edema in the distribution of the 
affected vessel only (Fig. 3.). Obstruction of a cilioretinal artery, or even a macular branch 
arteriole, gives cloudy, edematous appearance of the macula and affects central vision. In 
acute stage, the arteries appear thin and attenuated while cherry red spot and ground glass 
appearance may take hours to develop. In severe blockages, both veins and arteries may 
manifest “box-carring” or segmentation of the blood flow. 
 
Fig. 1. Central retinal artery occlusion, note foveal cherry red spot and ground glass 
appearance of the macula (arrow) 
 
Fig. 2. Cilioretinal sparing central artery occlusion; sparing between the disc and fovea 
(arrows), representing irrigation area of the cilioretinal artery  
 




Fig. 3. Branch retinal artery occlusion; note pale, edematous retina in the area of affected 
vessel (arrows) 
Late complication of CRAO is a neovascularization which indicates severe retinal ischemia 
and is more common at the far periphery and not at the optic disc or the posterior pole, and 
may complicate with vitreous or preretinal hemorrhage (Duker & Brown, 1989). This is why, 
in most cases, they are not observed clinically or angiographically with standard angle 
fundus camera. Only ischemia is usually seen by fluorescein angiography. The typical 
angiographic finding of neovascularization is the leakage of dye, whereas collateral 
shunting vessels do not present with such a feature. The fundoscopic findings typically 
resolve within days to weeks of the acute event, and residual optic atrophy may be the only 
physical finding. This feature also explains why it is crucial to treat the far periphery of the 
retina by cryo in addition to treatment by photocoagulation, in cases that the retinal 
periphery cannot be treated by photocoagulation. 
Acute simultaneous obstruction of both the retinal and choroidal circulations is referred to 
as an ophthalmic artery obstruction. It can be differentiated clinically from central retinal 
artery obstruction by the following features: severe visual loss—bare or no light perception; 
intense ischemic retinal whitening that extends beyond the macular area; little to no cherry-
red spot; pronounced choroidal perfusion defects on fluorescein angiography; 
nonrecordable electroretinogram; and late retinal pigment epithelium alterations (Brown et 
al., 1986). Cases of ophthalmic artery obstruction usually have associated local orbital or 
systemic diseases: orbital mucormycosis, orbital trauma, retrobulbar anesthesia, depot 
corticosteroid injection, atrial myxoma, or carotid artery disease (Sullivan et al., 1983). In 
conjunction with ipsilateral ischemic optic neuropathy, temporal arteritis may produce 
ophthalmic artery obstruction. 
2.5 Evaluation and imaging 
To summarize and to choose a rational approach in the workup, it is our opinion that the 
evaluation should be related to the age group. We recommend the following procedures to 
be undertaken in the persons over 50 years: the physical examination with complete 
cardiovascular assessment, ECG, the lab tests including full blood count, erythrocyte 
sedimentation rate, C reactive protein, fasting blood glucose, lipidogram, urine analysis, 
Doppler color imaging of the carotid arteries, and transthoracic echocardiography in 
patients with cardioembolic risk factors.  
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In the younger patients and those with unidentifiable systemic risk factors these are the 
proposed investigations: fluorescein angiography, vasculitis screen including anticardiolipin 
antibodies, antinuclear antibodies, anti-double stranded DNA antibodies, routine 
coagulation tests (prothrombin time, partial thromboplastin time), specialized clotting factor 
and platelet activity studies (levels of protein S, protein C, antithrombin III, plasminogen 
activator, plasminogen activator inhibitor, fibrinogen and resistance to activated protein C) 
and homocysteine.  
 
Systemic cardiovascular disease 
 Hypertension, Diabetes mellitus, Atheromatous disease, Cardiac-valvular 
 disease, bacterial endocarditis, myxoma, arrhythmias  
Coagulopathies 
 Antiphospholipid antibodies, Protein C deficiency, Protein S deficiency, 
 Antithrombin III deficiency, Elevation of platelet factor 4, Sickle cell anemia, 
 Homocysteine 
Systemic vasculitis 
 Polyarteritis nodosa, Temporal arteritis, Kawasaki's syndrome, Wegener's 
 granulomatosis, Susac's disease, Systemic lupus erythematosus 
Oncologic 
 Metastatic tumors, Leukemia, Lymphoma  
Infective diseases 
 Syphilis, HIV  
Trauma 
 Direct ocular compression, Penetrating injury, Retrobulbar injection, Orbital 
 trauma, Purtscher's disease 
Ocular conditions 
 Preretinal arterial loops, Optic nerve drusen, Necrotizing herpetic retinitis, 
 Toxoplasmosis 
Other causes 
 Oral contraceptives, Pregnancy, Drug abuse, Migraine 
Table 1. Systemic and ocular conditions related to retinal arterial occlusion 
It is important to exclude temporal arteritis in older patients, since it follows different 
clinical course and mandates the prompt administration of systemic corticosteroids. Giant 
cell arteritis is concerned as approved clinically if two of the three symptoms or signs exist: 
headache, tenderness over the temple and high sedimentation rate. Biopsy only approves it 
and treatment should not be deferred for biopsy result. It should be immediately initiated if 
two or more of the above are present. The purpose of the treatment is to prevent visual loss 
of the fellow eye, which usually occurs within 10 days of the event in one eye. Apart from 
the sudden, painless, nonprogressive vision loss in one eye, the patients may have 
headaches, jaw claudication, scalp tenderness, proximal muscle and joint aches, anorexia, 
weight loss, or fever. 
All patients with acute retinal arterial occlusion must be evaluated for the source of 
embolism, which is the commonest cause for its development. The imaging techniques are 
used to confirm the diagnosis in uncertain cases and these are fluorescein angiography, 
visual field testing, optical coherence tomography and electroretinography.  
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2.5.1 Fluorescein angiography 
Fluorescein angiography is not routinely indicated in the acute phase of arterial occlusive 
disease. The angiographic findings in both types, CRAO and BRAO (Fig. 4.), include 
delayed arm-to-retina time which is over 12 seconds (Richard G. et al., 1998), reduced 
arterial caliber and “cattle-trucking” of the blood column in the branch arteries. Sometimes, 
it may be minutes before the retinal arterial tree fills with fluorescein. Arteriovenous transit 
is also delayed, and late staining of the disc is common. 
The CLRA dyes concurrently with the filling of the choroid and usually before the start of 




Fig. 4. Superior branch retinal artery occlusion of the right eye. Note the delayed filling of 
the dye in the superior quadrant of retina 
2.5.2 Visual field testing 
Visual fields show a remaining temporal island of peripheral vision. In cases of a patent 
cilioretinal artery, a small intact central island is found as well. 
2.5.3 Electroretinography 
Electroretinography characteristically shows a decreased to absent b-wave with intact a-
wave.  
2.5.4 Optical Coherence Tomography (OCT) 
Optical coherence findings depend on the duration of the ischemia. Acute stages show 
increased reflectivity in the inner retinal layers and decreased reflectivity of the 
photoreceptor layer due to the shadowing effect (Fig. 4.). If involved, the macular region 
shows cystoid changes with loss of the foveolar contour. Old cases of arterial occlusion are 
presented with macular thinning with increased reflectivity of the retinal structure denoting 
ischemia. 
 




Fig. 5. CRAO – OCT changes, retinal edema in the inner layers (white arrows) denoting 
ischemia and the shadowing effect in the photoreceptor layer (black arrows) 
2.5.5 Color Doppler imaging 
Color Doppler imaging is an ultrasonographic evaluation of the blood flow characteristics of 
the retrobulbar circulation. Color Doppler studies of acute central retinal artery obstruction 
show diminished to absent blood flow velocity in the central retinal artery, generally with 
intact flow in the ophthalmic and choroidal branches (Sharma, 1998). Color Doppler 
imaging can be used to detect calcific emboli at the lamina cribrosa and also may be used to 
monitor blood flow changes induced by therapy. In addition, carotid artery studies may be 
carried out concurrently with ocular blood flow determinations to evaluate the possible 
causes of the central retinal artery obstruction. It is, however, important to determine the 
presence of plaques in the inspected vessels that are often the source of microemboli 
responsible for the occlusive event. In doubtful cases, the above-mentioned physical 
examination and laboratory testing should be carried out, especially in subjects younger 
than 40 years of age (Table 2). 
2.6 Differential diagnosis 
Ocular ischemic syndrome 
Purtscher’s retinopathy 
Severe commotio retinae 
Inflammatory or infectious retinitis 
2.7 Management 
Due to the poor prognosis of retinal artery occlusions, several treatment approaches have 
been attempted. These can be divided into two major categories: (1) conservative treatment, 
including mechanical (ocular massage and paracentesis), pharmacologic, and other means; 
and (2) invasive treatment, including catheterization of the proximal ophthalmic artery, 
usually through the femoral artery with infusion of thrombolytic agents. Any treatment that 
results in a statistically higher percentage of visual recovery compared with the spontaneous 
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recovery rate and has a low risk for morbidity and mortality could be considered the 
treatment of choice (Rumelt & Brown, 2003). 
2.7.1 Management of central retinal artery occlusion 
Conservative treatment 
 First step is arterial vasodilatation using sublingval isosorbid dinitrat, or CO2 
rebreathing in the bag; 
 Reduction of intraocular pressure (IOP) and improvement of perfusion by means of 
antiglaucomatous treatment topically (timolol, etc), systemically (manitol), or surgically 
by paracenthesis; 
 Ocular massage to move embolus further downstream through artery circulation in 
distant arterioles. Begin ocular massage with 3-mirror contact lens. Press the lens 
repeatedly for 10 seconds until the appearance of pulsation; or in the absence of 
pulsation, until collapse of the retinal blood flow. Observation for improvement of 
retinal blood flow is made through the lens during the ocular massage. If blood 
supply improves, ocular massage can be stopped and no further steps are required. 
If the blood flow does not improve, ocular massage should be continued 
meticulously for approximately 20 minutes. In addition, treatment prior to 24 hours 
is more highly to be successful and the success depends on the type of the embolus 
(calcified are the resistant ones). No light perception is also indication to start 
treatment. Our experience supports the statement  of others that even patients with 
no light perception may recover (this was also seen in cases of orbital compartment 
syndrome) (Rumelt et al, 1999); 
 During the ocular massage, administer acetazolamide 500 mg IV; 
 During the ocular massage, administer mannitol 20% 1 mg/kg IV or glycerol  
1ml/kg PO; 
 Scleral paracenthesis or anterior chamber paracenthesis – anesthetize the limbus 
with q-tip soaked with lidocaine 4%, and perform anterior chamber paracentesis 
with 25-G needle withdrawing  0.2 ml of aqueous humor; 
 Antiplatelet therapy (streptokinase 750 000 I.U. IV, urokinase), heparin therapy, 
isovolemic haemodilution, which basically make no sense if there is no circulation in 
the occluded artery and agents cannot reach the embolus (Hayreh, 2011); 
 Pentoxyfilline injection intravenously to reduce red blood cell rigidity; 
 Systemic steroids, in case where CRAO is caused by giant cell arteritis; 
 yperbaric oxygenation is one of the promising ways of treatment (Weinberger et al., 
2002; Bradvica et al., 2009), which can override the time to artery recanalization. 
However, there is still need for further evaluation because of the lack of greater 
randomized studies. 
Invasive treatment 
 Nd:Yag laser arteriotomy and embolectomy (Opremcak et al., 2008), although this 
rather invasive treatment frequently caused vitreous hemorrhage and need for 
vitrectomy, so it requires further evaluation; 
 Local intraarterial trombolysis, one of the very enthusiastically announced approaches 
in CRAO therapy, which is suspended due to a high adverse reactions incidence as 
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reported by the last European Assessment Group for Lysis in the Eye Study (EAGLE) 
(Schumacher et al., 2010). Probable reason for the high complication rate was the 
inexperience of some of the participating physicians. The results and complications 
were much lower when the procedure was performed by one group (Schmidt et al., 
1992; Schumacher et al., 1993). 
Since the outcome of invasive treatment depends on the experience of the physician and 
therefore is not applicable to most centers, the best treatment so far is the conservative 
multi-step treatment that requires the persistence of the physician (Rumelt et al, 1999). 
2.7.2 Management of branch retinal artery occlusion 
Management of BRAO depends on the type of occlusion; either it is permanent or transient. 
In permanent BRAO, like in CRAO there are a lot of advocated treatments but none of them 
has proven efficient. Transient BRAO does not require any treatment at all except a 
thorough diagnostics to establish the cause of the occlusion and possibly prevent permanent 
BRAO from occurring. Nonarteritic cilioretinal artery occlusion (CLRAO) can be treated 
with any of the procedures described in CRAO treatment. Only arteritic CLRAO associated 
with giant cell arteritis (GCA) has to be treated with a high dose of steroids, i.e. treat GCA to 
prevent affecting the other eye and total blindness. 
It is important that CRAO and BRAO are both emergencies and any procedures leading to 
recanalization, or improving the outflow, have to be done urgently inside 97 min from the 
onset of occlusion (Hayreh et al., 2004), and certainly not after 240 min, because after that 
time the most part of the retinal tissue function is probably destroyed. It has to be 
emphasized though that these results are valid for experimental models in primates and for 
complete occlusion and not for humans that usually have partial obstruction. That is 
probably the reason why the treatment may be successful even more than 24 hours after the 
occlusion and the onset of symptoms. Therefore, prevention and education of patients to 
present immediately to an ophthalmologist or emergency care unit may be the one of the 
measures of improving the chances of treatment in such patients. 
3. Retinal Vein Occlusion 
Retinal vein occlusion (RVO) has been recognized as an entity since 1855 (Liebreich, 1855) 
and is one of the most common causes of acquired retinal vascular abnormality in adults as 
well as the frequent cause of visual loss. However, the pathogenesis and management of this 
disorder remains somewhat of an enigma. Current treatments for RVO and its sequelae are 
still evolving. 
CRVO and HCRVO are commonly subdivided into nonischemic and ischemic (hemorrhagic) 
types according to the degree of obstruction. Ischemic type occurs in more severe (complete) 
obstruction. Such a distinction is relevant to the clinician, since these two types have very 
different clinical features, visual outcomes, complications, prognosis and management. 
Nonischemic RVO is a comparatively benign disease, with central scotoma, essentially due to 
macular edema, as its major complication, with no risk of ocular neovascularization. Ischemic 
RVO, by contrast, is a seriously blinding disease, since up to two thirds of patients develop the 
devastating complications of ischemia, and neovascularization that lead to neovascular 
glaucoma which causes blindness (Hayreh, 1994). 
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Retinal vein obstruction is divided into central (CRVO), an occlusion of the central retinal 
vein resulting in four quadrants of retinal involvement; hemi-central retinal vein occlusion 
(HCRVO) and branch (BRVO) which consists of major BRVO, an occlusion of either a major 
branch retinal vein draining one quadrant of the retina, macular BRVO (Hayreh, 1994), an 
occlusion of a macular branch vein draining a portion of the macula, and peripheral BRVO, 
an occlusion of a branch retinal vein draining a portion of the retinal periphery. According 
to the most study data, hemicentral (HCRVO) is an anatomic variant of central retinal vein 
occlusion (CRVO). Thus, HCRVO acts more like CRVO in terms of risk factors, visual 
outcome, risk of neovascularization, and response to laser treatment (Appiah & Trempe, 
1989). CRVO and BRVO have both differences and similarities in pathophysiology, 
underlying systemic associations, average age of onset, clinical presentation, prognosis 
(natural history, complication rate) and treatment. 
Furthermore, central and hemi-central occlusion are divided into ischemic and nonischemic 
subtypes each having different clinical implications and ischemic carrying the risk of 
developing macular edema and devastating consequences regarding the visual function.  
3.1 Epidemiology 
The worldwide RVO prevalence, according to the meta-analysis which used pooled data 
from 15 different international studies involving over than 50,000 participants, ranged from 
30 to 101 years, has been calculated per 1000 as follows: 5.20 for any RVO, 4.42 for BRVO, 
and 0.80 for CRVO. On the basis of these rates, projected to the world population, 16.4 
million adults are affected by RVO (Rogers et al., 2010). For comparison, more than 171 
million adults with diabetes worldwide either have diabetic retinopathy or are at risk of 
developing this potentially blinding disease, according to a 2005 World Health Organization 
report (Wild et al., 2004). An estimated 13.9 million people globally are affected by BRVO 
and 2.5 million by CRVO. Prevalence varied by race/ethnicity and increased with age, but 
did not have a sex predilection. The age- and sex-standardized prevalence of any RVO was 
3.7 per 1000 in whites, 3.9 per 1000 in blacks, 5.7 per 1000 in Asians, and 6.9 per 1000 in 
Hispanics. Prevalence of CRVO was lower than BRVO in all ethnic populations. Although 
BRVO prevalence appears to be highest in Asians and Hispanics and lowest in whites, the 
authors assume this may reflect differences in the prevalence of RVO risk factors, varying 
methodologies or definitions among reviewed studies (Rogers et al., 2010). Ischemic central 
retinal vein obstructions account for 20–25% of all central retinal vein obstructions (Klein et 
al., 2000). 
3.2 Pathophysiology 
All types of RVO are multifactorial in origin. A whole host of local and systemic factors 
acting in different combinations and to different extent may produce the vascular occlusion. 
The role of the various factors may vary, with some as predisposing factors and other as 
precipitating ones in one group and vice versa in another. Most investigators accept that 
BRVO and CRVO represent varying degrees of the same underlying disease process. Yet, 
other clinicians and researchers argue that ischemic and nonischemic types are distinct 
clinical entities. It is also essential to understand that CRVO and HCRVO are very different 
from BRVO pathogenetically. In conclusion, it is a mistake to try to explain all types of RVO 
by one common pathogenetic mechanism (Hayreh, 1994). 
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3.2.1 Central Retinal Vein Occlusion 
The pathogenesis of CRVO is not fully understood and there are marked controversies on 
the pathogenesis of ischemic and especially nonischemic CRVO. A combination of vascular, 
anatomic, and inflammatory factors contributes to its pathophysiology.  
The occlusive mechanisms in CRVO are mostly these: (i) external mechanical compression 
of the vein (i.e. by sclerotic adjacent central retinal artery and common adventitia, especially 
in elderly persons, structural changes in lamina cribrosa, e.g., glaucomatous cupping, 
inflammatory swelling in optic nerve and orbital disorders) followed by secondary 
endothelial proliferation; (ii) primary venous wall disease (degenerative or inflammatory); 
and (iii) hemodynamic disturbances produced by a variety of factors (e.g., hyperdynamic or 
sluggish circulation, blood dyscrasias, disturbances on the arterial side, etc.). Consequently, 
a stagnation of the vein flow occurs and a thrombus formation ensues (Hayreh, 1994; 
Williamson, 1997). 
There are multiple anatomic variations of the branching pattern to the central retinal vein. In 
20% of eyes there are, as a congenital abnormality, two trunks of the central retinal vein 
(CRV) in the optic nerve (instead of the usual one), and the merging of the trunks occurs 
posterior to the lamina cribrosa (Chopdar, 1984; S. S. Hayreh & M. S. Hayreh, 1980). If one of 
these trunks is occluded, the result is a nonperfusion to superior or inferior retina. 
Additionally, the venous outflow from the nasal retina may occur via a branch of one of the 
temporal branches, rather than an independent nasal vein. In an eye with such a branching 
pattern, an inferior or superior HCRVO may occur if one the venous branches that drain the 
nasal and temporal retina is occluded (Sanborn & Magargal, 1984). So, considering the 
various possible scenarios that can result in a HCRVO, a consensus as to whether HCRVO is 
a variant of BRVO or CRVO still has not been reached. 
CRVO is significantly more common in patients with raised intraocular pressure (IOP) and 
glaucoma (up to 5- to 10-fold increased risk) (Risk factors for central retinal vein occlusion. 
The Eye Disease Case-Control Study Group, 1996). To maintain the blood flow, the pressure 
in the CRV at the optic disc has to be higher than the IOP, otherwise a retinal venous stasis 
and sluggish venous outflow occur (Hayreh, 2005). 
There is much more congruence of the data on the pathogenesis of the ischemic CRVO. Most 
probably ischemic CRVO represents a more extensive (or complete) obstruction while non-
ischemic RCVO represents a milder (partial) obstruction. A conception suggests that the 
vessels are in a tight compartment within limited space for displacement, because of a 
common adventitial sheath as CRA and CRV exit the optic nerve head and pass through a 
narrow opening in the lamina cribrosa. This anatomical position per se predisposes to 
thrombus formation in the central retinal vein. But, CRV has multiple tributaries during its 
course in the optic nerve, pial outside the optic nerve, none in the lamina cribrosa, and only 
a small one in the prelaminar region. These tributaries establish anastomoses with the 
surrounding veins. Since the severity of retinal venous stasis depends upon the site of 
occlusion in the CRV, and the number of available tributaries anterior to it, the site of the 
occlusion is likely to be much posteriorly to the lamina cribrosa in nonischemic CRVO than 
in ischemic CRVO (Hayreh, 2005). There is a possibility of changing nonischemic CRVO to 
ischemic in some patients, probably due to a further precipitous gradual or sudden fall of 
perfusion pressure (Hayreh, 1994). 
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Occlusion of the central retinal vein leads to the retention of the blood in the retinal venous 
system, and increased resistance to venous blood flow subsequently causes a stagnation of 
the blood and ischemic damage to the retina. It has been postulated that ischemic damage to 
the retina stimulates increased production of vascular endothelial growth factor (VEGF) in 
the vitreous cavity. Increased levels of VEGF stimulate neovascularization of the posterior 
and anterior segment (responsible for secondary complications due to CRVO). Also, it has 
been shown that VEGF causes capillary leakage leading to macular edema (which is the 
leading cause of visual loss in both ischemic CRVO and nonischemic CRVO) (Boyd et al., 
2002; Noma et al., 2008; Pe'er et al., 1998). 
The prognosis of CRVO depends upon the reestablishment of patency of the venous system 
by recanalization, dissolution of clot, or formation of optociliary shunt vessels. 
3.2.2 Combined Retinal Vein and Artery Occlusion 
A central retinal artery obstruction combined with central retinal vein obstruction can occur 
rarely (Richards, 1979), and the mechanism is probably increased pressure on both central 
retinal artery and vein. The most common cause for combined CRAO and CRVO is 
retrobulbar anesthetic injection, caused probably by inadvertent injection into the optic 
nerve sheath (Torres, 2005). If no CRV tributaries are available anterior to the site of 
occlusion in the CRVO, it converts the circulation into a closed loop and this results in 
complete hemodynamic block of the retinal circulation, and secondary CRAO. This 
condition is invariably diagnosed as simultaneous occlusion of CRA and CRV (Hayreh, 
2005). Nonischemic CRVO associated with cilioretinal artery occlusion (CLRAO) is usually a 
result of transient rise i.e. a functional obstruction of the blood pressure in the entire retinal 
capillary bed due to a sudden blockage of blood flow by a thrombus in the CRV, which, in 
turn, results in a physiologic block in the CLRA circulation (Theoulakis et al., 2010). Within a 
day or two, with the development of venous collaterals by the CRV, the blood pressure in 
the retinal vascular bed falls, and normal cilioretinal filling occurs. However, the severity of 
retinal ischemia and associated visual loss depends upon the length of time elapsed before 
the circulation was re-established (Hayreh, 1994). 
3.2.3 Branch Retinal Vein Occlusion 
Branch retinal vein occlusion is defined as a focal occlusion of a retinal vein at an arterio-
venous crossing site. In all but a few rare cases, the BRVO occurs at crossing sites where the 
artery is passing anteriorly (superficially) to the vein (Duker & Brown, 1989; Weinberg et al., 
1990). The upper temporal vascular arcade is more often involved than the lower temporal 
vascular arcade. Most BRVOs involve the area inside the temporal vascular arcades 
(macular BRVO), whereas peripheral BRVOs are more rarely seen, partly because they tend 
to be asymptomatic (Christoffersen & Larsen, 1999). 
The arterio-venous crossing plays an important role in the pathogenesis of BRVO, and the 
anterior position of the arteriole at the crossing somehow renders the underlying vein 
vulnerable to occlusion. It seems logical to assume that sclerotic retinal arteriole probably 
compresses the accompanying vein because of a common thickened, adventitial and glial 
sheath; however, histopathological studies failed to confirm this view. In addition, turbulent 
flow may injure the vessel wall exposing it for thrombus formation (Hayreh, 1994; 
Williamson, 1997). 
 




Retinal vascular occlusions all have overlapping clinical presentation as well as the similar 
underlying causes. They are all multifactorial in origin and each patient may have a unique 
combination of systemic and local factors leading to the occlusive event (Hayreh, 1994). 
Since the systemic vascular disease is a possible underlying pathophysiological cause, it is 
important to ask about history of hypertension, diabetes mellitus, any condition 
predisposing embolic events (endocarditis, atrial fibrillation, atherosclerotic disease, drug 
and alcohol abuse, hypercoagulabile states) (Klein et al., 2003; Schmidt et al., 2007). Also, the 
questions regarding possible trauma as well as the undertaken surgical procedures should 
not be omitted from the medical history since the prolonged pressure to the globe may lead 
to the ischemic event.  
The well-known risk factors contributing to retinal vein occlusions are systemic vascular 
diseases. The most recognized risk factors for retinal vein occlusion are hypertension, 
diabetes mellitus, arteriosclerosis and hyperlipidemia. Also, cigarette smoking has been 
related to increased risk of RVO. They predominately affect the older age group of patients 
but the younger patients may also develop this type of retinal occlusive disorder and they 
account for 10-15% of patients with RVO. Mild central retinal vein obstructions in patients 
younger than 50 years have been referred to as papillophlebitis or optic disc vasculitis. An 
inflammatory optic neuritis or vasculitis is hypothesized as the cause (Fong, 1992).  
According to the recent studies by Hayreh et al. there may be some difference in the risk 
factors between CRVO and BRVO, with higher prevalence of hypertension, venous disease, 
peripheral vascular disease and peptic ulcer in the latter (Hayreh et al., 2001). This suggests 
that it may not be correct to generalize about these underlying causes for the entire group of 
retinal vein occlusions.  
In addition to well-recognized risk factors, new thrombophilic factors have been 
investigated in these patients. The role of thrombophilic risk factors in RVO is controversial 
and the studies are showing conflicting results. Hyperhomocysteinemia as well as low levels 
of vitamin B6 and folic acid have been identified as independent risk factors (Sofi et al., 2008; 
Taubert, 2008). Other potential risk factors include elevated factor V Leiden, protein C or S 
deficiency, anti-cardiolipin antibodies or lupus anticoagulant. Blood dyscrasias and 
dysproteinemias result in hyperviscosity syndromes, which may appear similar to central 
retinal vein obstruction but possibly represent curable disease. Hyperviscosity syndromes 
may produce a bilateral retinopathy similar to central retinal vein obstruction and may, in 
fact, induce a true central retinal vein obstruction with thrombus formation (Bandello et al., 
1994). Simultaneous bilateral disease is an unusual finding in central retinal vein 
obstructions but occurs more commonly in hypercoagulabile and hyperviscous states. 
Diseases such as sickle cell disease, polycythemia vera, leukemia, and multiple myeloma are 
but a few of the possibilities. When there is a patient with bilateral central retinal vein 
obstructions, especially simultaneous, the medical and laboratory evaluation should include 
a search for evidence of hyperviscous and hypercoagulabile syndromes (Marcucci et al., 
2001) Severe anemia with thrombocytopenia can masquerade as a central retinal vein 
obstruction, and it is differentiated from a central retinal vein obstruction by a complete 
blood count with platelets. 
In combined central retinal vein occlusion with branch retinal artery occlusion systemic 
associations other than hypertension and diabetes have not been confirmed. In combination 
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with central retinal artery occlusion associated systemic or local disease is the rule—collagen 
vascular disorders, leukemia, orbital trauma, retrobulbar injections, and mucormycosis have 
been implicated (Jorizzo, 1987). 
Oral contraceptive use in women may be associated with both thromboembolic disease and 
central retinal vein obstruction (Stowe et al., 1978). In addition, acute hypertensive 
retinopathy with disc edema may resemble bilateral central retinal vein obstruction. 
Obstructive sleep apnea affects more patients with retinal vein obstruction than other 
disorders and treatment of the sleep apnea may help prevent central vein obstruction 
(Glacet-Bernard et al., 2010). Other rare associations include closed-head trauma, optic disc 
drusen, and arteriovenous malformations of retina.  
The Eye Disease Case-Control Study Group reported that the risk of CRVO is decreased in 
men with increased levels of physical activity and increased alcohol consumption (Risk 
factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group, 1996). 
The same study group reported a decreased risk of CRVO with the use of postmenopausal 
estrogens and an increased risk with higher erythrocyte sedimentation rates in women. 
An ocular risk factor for the development of central retinal vein occlusion is raised 
intraocular pressure; the risk of central retinal vein occlusion in glaucoma patients is 5-fold 
to 10-fold increase (Risk factors for central retinal vein occlusion. The Eye Disease Case-
Control Study Group, 1996). Unlike CRVO and HCRVO, glaucoma plays no role in the 
pathogenesis of BRVO (Hayreh, 1994). 
In ischemic CRVO, for example, neovascular glaucoma develops in about 45%. The chronic 
hypoxia of the retinal tissue induces ocular neovascularization by producing the 
vasoproliferative factor, which is the proposed mechanism in CRVO whereas in CRAO, 
there is acute retinal ischemia and infarction responsible for the occlusive event. Also a 
surprisingly small proportion of patients (2.5%) have the course of illness complicated with 
neovascular glaucoma (Hayreh, 2011). 
3.4 Clinical presentation 
3.4.1 Symptoms 
Retinal vein occlusion is characterized by painless unilateral loss of vision. It may be subtle 
in character, with intermittent episodes of blurred vision. In other cases, it may be sudden 
and dramatic. The nonischemic type is often the more subtle of the two, while the ischemic 
type is prone to the more acute clinical presentations and may be accompanied by pain. 
Ischemic CRVO Acute, markedly decreased visual acuity ranged from 20/200 (6/60) to 
hand-motion is the usual initial complaint. A prominent afferent pupillary defect is typical. 
Pain at the time of evaluation may occur if neovascular glaucoma already had developed. 
Nonischemic CRVO The majority of patients with central retinal vein obstruction (75–80%) 
fall into nonischemic form. Patients usually have mild to moderate decreased visual acuity, 
although this can vary from normal to as poor as the finger counting. Transient visual 
obscuration may also be a complaint. 
Branch retinal vein occlusion is characterized by painless decrease in vision on the affected 
eye and some patients may have a scotoma. 
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Combined Retinal Vein and Artery Occlusion Such patients present with acute, severe loss 
of vision, usually to bare or no light perception. The visual prognosis is generally poor. 
3.4.2 Signs 
The distinction between the ischemic and nonischemic type is important, because they carry 
a totally different prognosis regarding visual recovery and potential complication, which 
may result in permanent visual deterioration. 
Both types of central retinal vein obstruction, ischemic and nonischemic, have similar 
fundoscopic findings—dilated, tortuous retinal veins and retinal hemorrhages in all four 
quadrants, optic disc swelling, cotton wool spots and macular edema (Fig. 5). Hemorrhages can 
be superficial, dot and blot, and/or deep. They may vary in severity, covering the whole fundus 
and sometimes even obscuring retinal and choroidal details, or can be limited to the peripheral 
fundus only. Vitreous hemorrhage may ensue when bleeding breaks through the internal 
limiting membrane. The optic disc is usually edematous during the early-stage disease, but the 
edema may persist in chronic cases (Ehlers & Fekrat, 2011). Many or all of the pathological 
retinal findings may resolve over the 6–12 months following diagnosis. The resolution of retinal 
hemorrhages may be complete whereas the optic nerve may appear normal, but optociliary 
collateral vessels are common finding. In spite the resolution of macular edema, a persistent 
cystoid macular edema can linger and result in permanent visual loss, often leading to 
pigmentary changes, epiretinal membrane formation, or subretinal fibrosis.  
Ischemic CRVO The presence of cotton-wool spots located around the posterior pole is 
characteristic of and more common with ischemic CRVO (Fig. 6.). In ischemic CRVO, the 
ganglion cells in the macular retina are irreversibly damaged by ischemia during the initial 
stages of the disease; therefore, there is little chance of improvement of visual acuity in such 
an eye. The distinction between the two types of vein obstructions remains somewhat 
arbitrary and is based on the total area of nonperfusion on fluorescein angiography. 
However, dense intraretinal hemorrhage in acute stages may block retinal fluorescence and 
renders it impossible to determine the extent of retinal nonperfusion. Therefore, it is 
important to take into account other clinical features such as poor initial visual acuity, the 
presence of an afferent pupillary defect, neovascularization as well as the functional tests – 
visual field testing (Goldmann) and electroretinography (ERG) to establish the perfusion 
status of the retina (Hayreh et al., 2011). In central retinal vein obstruction, perfusion of the 
inner retina is affected, so that the amplitude of the b-wave is decreased relative to the a-
wave; the b-to-a ratio has been shown to be reduced. Some studies indicate that a b-to-a 
ratio of less than 1 suggests an ischemic central retinal vein obstruction (Matsui et al., 1994). 
It is only the ischemic CRVO eye which is at risk of developing ocular neovascularization 
(Hayreh et al., 1983; Natural history and clinical management of central retinal vein 
occlusion. The Central Vein Occlusion Study Group, 1997). The incidence of anterior 
segment neovascularization in ischemic central retinal vein obstruction is 60% or higher and 
has been documented as early as 9 weeks after onset of an occlusive event. The greatest risk 
of developing anterior segment neovascularization is during the first 7 months, after which 
the risk of dreaded complication of neovascular glaucoma falls dramatically to minimal. 
Neovascularization of the optic disc and retinal neovascularization may be seen as well, but 
they are less common. As with nonischemic central retinal vein obstruction, the findings 
may decrease or resolve 6–12 months after diagnosis. The anterior segment structures may 
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with central retinal artery occlusion associated systemic or local disease is the rule—collagen 
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surprisingly small proportion of patients (2.5%) have the course of illness complicated with 
neovascular glaucoma (Hayreh, 2011). 
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ganglion cells in the macular retina are irreversibly damaged by ischemia during the initial 
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has been documented as early as 9 weeks after onset of an occlusive event. The greatest risk 
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they are less common. As with nonischemic central retinal vein obstruction, the findings 
may decrease or resolve 6–12 months after diagnosis. The anterior segment structures may 
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show signs of ischemia: congestion of the conjunctival and ciliary vessels, corneal edema, 
iris and anterior chamber angle neovascularization with development of synechial changes 
predisposing the development of secondary glaucoma.  
 
Fig. 6. Central retinal vein occlusion; dilated, tortuous retinal veins and retinal hemorrhages 
in all four quadrants, optic disc swelling (arrows), cotton wool spots and macular edema 
Nonischemic CRVO Neovascularization of either the anterior or posterior segment is rare in a 
true nonischemic central retinal vein obstruction (less than 2% incidence), although conversion 
from an initially nonischemic vein obstruction to the ischemic variety is fairly common. The 
Central Vein Occlusion Study Group noted that 34% of nonischemic central retinal vein 
occlusions (CRVOs) progressed to become ischemic within 3 years and 15% of the study group 
converted within the first 4 months (Natural history and clinical management of central retinal 
vein occlusion. The Central Vein Occlusion Study Group, 1997).  
Hemicentral RVO In hemicentral retinal vein obstruction venous outflow from the superior 
or inferior parts of retina is impaired. Although they involve half of the retina, in terms of 
visual outcome, the risk of neovascularization, and response to the laser treatment, they 
resemble the ischemic variant of the disease. 
Branch retinal vein occlusion (Fig. 7.) Intraretinal hemorrhages (usually flame shaped), 
retinal edema, and cotton-wool spots are seen in the distribution of a retinal vessel. 
Papillophlebitis The characteristic finding is optic disc edema out of proportion to the 
retinal findings, cotton-wool spots that ring the optic disc, and occasionally cilioretinal 
artery obstructions or even partial central retinal artery obstructions. Although spontaneous 
improvement occurs, the course is not always benign. Approximately 30% of these patients 
may develop the ischemic type of occlusion, a final visual acuity of 20/200 in nearly 40% of 
these subjects, and neovascular glaucoma has been reported (Fong, 1992). 
Combined Retinal Vein and Artery Occlusion Examination shows a cherry-red spot 
combined with features of a central retinal vein obstruction, which include dilated, tortuous 
veins that have retinal hemorrhages in all four quadrants (Fig. 8.). The risk of 
neovascularization of the iris is about 75%. Exceptionally, a patient may manifest 
spontaneous improvement (Jorizzo, 1987). Branch retinal artery obstruction combined with 
simultaneous central retinal vein obstruction has also been reported. This rare entity 
behaves as a central retinal vein obstruction. Neovascularization of the iris is possible. 
 











Fig. 8. Combined branch retinal artery occlusion (BRAO) and central retinal vein occlusion 
(CRVO) of the right eye, ischemia involving superior macular branches (arrows), optic disc 
swelling, tortuous veins and dot and blot hemorrhages 
3.5 Evaluation and imaging 
3.5.1 Systemic evaluation 
Given the heterogenity of risk factors and their possible interaction in these subjects, the 
following algorithm of patients with RVO is proposed in the Table 2. As for the arterial 
occlusive retinal disease, these tests should be performed in younger patients and in 
doubtful cases. 
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Fig. 8. Combined branch retinal artery occlusion (BRAO) and central retinal vein occlusion 
(CRVO) of the right eye, ischemia involving superior macular branches (arrows), optic disc 
swelling, tortuous veins and dot and blot hemorrhages 
3.5 Evaluation and imaging 
3.5.1 Systemic evaluation 
Given the heterogenity of risk factors and their possible interaction in these subjects, the 
following algorithm of patients with RVO is proposed in the Table 2. As for the arterial 
occlusive retinal disease, these tests should be performed in younger patients and in 
doubtful cases. 
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We feel that, as with the arterial occlusive disease, the stepwise approach to each patient 
should be tailored, taking into account the age of the patient. Therefore the investigations in 
the patients older than 50 years of age should consist of: cardiovascular risk assessment, 
ECG, carotid and vertebral artery Doppler color imaging, echocardiogram; the lab tests 
including full blood count, erythrocyte sedimentation rate, C reactive protein, fasting blood 
glucose, lipidogram. The younger patients should be evaluated for thrombophilia, 
hyperviscosity syndromes, screening for autoimmune diseases and women should be asked 
about the use of oral contraceptives. Of course, other possible causes of retinal vein 
occlusions should be considered in cases of normal findings and the investigations should 
be expanded in stepwise approach, since each case may have a unique combination of risk 
factors and underlying causes. 
 
  
 Cardiovascular risk factors assessment  
 (diabetes, hypertension, smoking  habitus, dyslipidemia, BMI)  
 ECG 
 Carotid and vertebral artery Doppler color imaging 
 Echocardiogram  
 (transthoracic, transesophageal in selected cases) 
 Lab tests  
 (complete blood count, fasting glucose, lipidogram, autoimmune screen in 
 selected cases: ANA, anti ENA, anti DNA; homocysteine level, folic acid, 
 vitamin B12 and B6, antiphospholipid antibodies) 
 Thrombophilia assessment in subjects younger than 50 years (factor V Leiden, 
 antithrombin, protein C, protein S) 
Table 2. Proposed systemic work-up in RVO patients 
Although most cases are diagnosed straightforward from the fundus appearance, the 
following ancillary tests may be undertaken to distinguish between ischemic or milder, 
nonischemic form, which is very important in terms of the treatment options as well as the 
natural course and visual prognosis of the patients.  
3.5.2 Fluorescein angiography 
Arteriolar filling is usually normal, but venous filling in the affected vessel is usually 
delayed in the acute phase. Hypofluorescence caused by hemorrhage and capillary 
nonperfusion are common findings, and dilated, tortuous veins are seen (Fig. 9a.). The 
retinal vessels, particularly the vein walls, may stain with fluorescein, especially at the site 
of the occlusion (Fig.10.). The very important distinction should be made between 
neovascular fronds, which may show profuse leakage of dye, vs. collateral vessels, which do 
not leak fluorescein. Cystoid macular edema (Fig. 9b.) appears in the late stage of the 
angoigram shows typically petaloid pattern and may involve the entire fovea or just several 
clock hours, depending on the distribution of the obstruction. It is, however, important to 
emphasize that in early stages the retinal angiograms may be misleading because of the 
masking by abundant hemorrhages and the fact that retinal capillary obliteration is a 
progressive phenomenon which takes at least 3-4 weeks or even longer to develop after the 
occurrence of ischemic CRVO (Hayreh, 1994). 
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Fig. 9. Fluorescein angiogram of the left eye with central retinal vein occlusion a and b. a) 
staining of blood vessel walls, disc hyperfluorescence and blockage from intraretinal 
hemorrhage b) the late stages of angiogram shows leakage of dye in cystoid macular edema, 
with characteristic “petaloid” appearance. 
   
Fig. 10. Fluorescein angiogram of the right eye with superior branch retinal vein occlusion a 
and b. a) blockage of dye with hemorrhages, mottled areas of intraretinal leakage and 
microaneurysm formation with vascular teleangiectasia in the upper parts b) the late stages 
of angiogram shows further diffuse leakage of dye, through all layers of the retina, affecting 
the macular region as well. 
3.5.3 Optical coherence tomography 
The optical coherence tomograms show increase in the retinal thickness, which is seen as a 
loss of macular contour. In the area of edematous retina the presence of cystoids spaces 
denotes the existence of cystoid macular edema (Fig. 11.). The retinal hemorrhages, 
subretinal fluid accumulation, cotton wool spots and optic disc edema may also be 
visualized on OCT. OCT is useful in the management and treatment of the macular edema; 
it also offers certain advantages over angiograms because it quantifies the macular thickness 
useful in monitoring the response to treatment and gives valuable data on distribution of the 
fluid, is not invasive and has no potentially serious side effects. There have been some 
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loss of macular contour. In the area of edematous retina the presence of cystoids spaces 
denotes the existence of cystoid macular edema (Fig. 11.). The retinal hemorrhages, 
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disputes whether the macular thickness correlates significantly with visual acuity 
(Nussenblatt et al., 1987). What counts is the improvement in visual functions and not the 
anatomy. Several factors were predictive of better visual acuity outcomes and more 
favorable OCT outcomes, including younger age and shorter duration of macular edema, 
respectively. These factors may assist clinicians in predicting disease course for patients 
with CRVO and BRVO (Scott et al., 2011). Loss of foveal IS/OS junction line and absence of 
inner retinal layers in late stage significantly correlated with poorer visual outcome. 
Macular ischemia by fluorescein angiography shows significant correlation with thinner 
central subfield thickness, loss of inner retinal layers (Lima, 2011). 
 
  
Fig. 11 a and b. Optical coherence tomography (OCT) changes of eye with central retinal 
vein occlusion a) Cystoid macular edema prior to anti-VEGF injection; b) Cystoid macular 
edema after anti-VEGF injection treatment Cross-section goes through inferior retina to 
superior retina, capturing the abnormally thickened retina associated with intracellular 
edema. 
3.6 Differential diagnosis 
Hypertensive retinopathy 
Diabetic retinopathy 
Ocular ischemic syndrome 
Juxtafoveal retinal telangiectasia 
Radiation retinopathy 




Some treatments have addressed the venous outflow and the majority the sequelae of the 
venous occlusion (i.e. cystoid macular edema, neovascularization). In the following text the 
advocated treatment options are discussed. 
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3.7.1 Management of branch retinal vein occlusion 
Etiology treatment 
 Isovolemic hemodilution, used to lower plasma viscosity and to improve retinal 
perfusion. However, the true benefit of hemodilution has not been established because 
the published reports have used a combination therapy in the hemodilution groups ; 
 Laser chorioretinal venous anastomosis, performed to bypass the occluded site by 
inducing a communication between the involved branch vein and the choroidal 
circulation by placing a laser burn directly on the vein and then on the adjacent Bruch’s 
membrane. During the healing process, a chorioretinal anastomosis may form. The 
technique is studied on CRVO patient, but the small number of BRVO case series were 
reported (Bavbek et al., 2005; Fekrat et al., 1998); 
 Pars plana vitrectomy and arteriovenous sheathotomy. Arteriovenous sheathotomy, in 
which the retinal vein and artery are surgically separated at the arteriovenous crossing 
by cutting the common adventitial sheath bare the same idea of improving perfusion. 
Several small, uncontrolled series have shown good results in improving macular 
edema and macular perfusion. However, others have reported a lack of efficacy of this 
procedure (Le Rouic et al., 2001; Cahill et al., 2003). 
Sequelae treatment 
 Grid laser photocoagulation. The Branch Vein Occlusion Study (BVOS) demonstrated 
the efficacy of grid laser photocoagulation in the treatment of BRVO-related macular 
edema. According to the study, grid photocoagulation performed in the first 12 months 
of onset of the occlusion can, compared to the natural course, improved the response 
almost twice (Argon laser photocoagulation for macular edema in branch vein 
occlusion. The Branch Vein Occlusion Study Group, 1984) Argon laser grid or sector 
treatment result in resolution of the edema but do not improve visual acuity; 
 Sector Scatter Retinal Laser Photocoagulation. This treatment was also evaluated during 
the BVOS study in the ability of preventing the development of neovascularization and 
vitreous hemorrhage in the BRVO. It is recommended that scatter photocoagulation should 
be used in BRVO, if and when neovascularization occurs (Argon laser scatter 
photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch 
vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group, 1986); 
 Intravitreal corticosteroids, using a long lasting corticosteroid such as triamcinolone 
(IVTA), or biodegradable carrier containing dexamethasone to manage macular edema. 
SCORE study was conducted to compare IVTA versus standard of care, i.e. grid-pattern 
macular photocoagulation (Scott et al., 2009). The results of this study suggest that both 
procedures have a similar effect on resolving macular edema and improving visual acuity, 
but IVTA has more side effects (increasing IOP, cataract progression). In a randomized 
pilot study of subjects with cystoid macular edema (CME) secondary to BRVO, the 
increase in visual acuity was significantly greater in those treated with combination of 
IVTA and grid-pattern laser photocoagulation than in the eyes treated with grid-pattern 
laser alone, suggesting that IVTA can be effective as an adjunctive treatment to laser 
(Parodi et al., 2008). Allergan conducted an international study at 167 centers in 24 
countries on the effect of intravitreal dexamethasone sustained release delivery system 
(Ozurdex). The data for the first 6 months was released (Haller et al., 2010). It appears that 
visual acuity was significantly better in the group of patients who received 0.7 mg 
dexamethasone implant than in the control group after 60 and 90 days, but is similar 180 
days after the treatment. Ozurdex received FDA approval for treatment of macular edema 
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Hypertensive retinopathy 
Diabetic retinopathy 
Ocular ischemic syndrome 
Juxtafoveal retinal telangiectasia 
Radiation retinopathy 




Some treatments have addressed the venous outflow and the majority the sequelae of the 
venous occlusion (i.e. cystoid macular edema, neovascularization). In the following text the 
advocated treatment options are discussed. 
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3.7.1 Management of branch retinal vein occlusion 
Etiology treatment 
 Isovolemic hemodilution, used to lower plasma viscosity and to improve retinal 
perfusion. However, the true benefit of hemodilution has not been established because 
the published reports have used a combination therapy in the hemodilution groups ; 
 Laser chorioretinal venous anastomosis, performed to bypass the occluded site by 
inducing a communication between the involved branch vein and the choroidal 
circulation by placing a laser burn directly on the vein and then on the adjacent Bruch’s 
membrane. During the healing process, a chorioretinal anastomosis may form. The 
technique is studied on CRVO patient, but the small number of BRVO case series were 
reported (Bavbek et al., 2005; Fekrat et al., 1998); 
 Pars plana vitrectomy and arteriovenous sheathotomy. Arteriovenous sheathotomy, in 
which the retinal vein and artery are surgically separated at the arteriovenous crossing 
by cutting the common adventitial sheath bare the same idea of improving perfusion. 
Several small, uncontrolled series have shown good results in improving macular 
edema and macular perfusion. However, others have reported a lack of efficacy of this 
procedure (Le Rouic et al., 2001; Cahill et al., 2003). 
Sequelae treatment 
 Grid laser photocoagulation. The Branch Vein Occlusion Study (BVOS) demonstrated 
the efficacy of grid laser photocoagulation in the treatment of BRVO-related macular 
edema. According to the study, grid photocoagulation performed in the first 12 months 
of onset of the occlusion can, compared to the natural course, improved the response 
almost twice (Argon laser photocoagulation for macular edema in branch vein 
occlusion. The Branch Vein Occlusion Study Group, 1984) Argon laser grid or sector 
treatment result in resolution of the edema but do not improve visual acuity; 
 Sector Scatter Retinal Laser Photocoagulation. This treatment was also evaluated during 
the BVOS study in the ability of preventing the development of neovascularization and 
vitreous hemorrhage in the BRVO. It is recommended that scatter photocoagulation should 
be used in BRVO, if and when neovascularization occurs (Argon laser scatter 
photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch 
vein occlusion. A randomized clinical trial. Branch Vein Occlusion Study Group, 1986); 
 Intravitreal corticosteroids, using a long lasting corticosteroid such as triamcinolone 
(IVTA), or biodegradable carrier containing dexamethasone to manage macular edema. 
SCORE study was conducted to compare IVTA versus standard of care, i.e. grid-pattern 
macular photocoagulation (Scott et al., 2009). The results of this study suggest that both 
procedures have a similar effect on resolving macular edema and improving visual acuity, 
but IVTA has more side effects (increasing IOP, cataract progression). In a randomized 
pilot study of subjects with cystoid macular edema (CME) secondary to BRVO, the 
increase in visual acuity was significantly greater in those treated with combination of 
IVTA and grid-pattern laser photocoagulation than in the eyes treated with grid-pattern 
laser alone, suggesting that IVTA can be effective as an adjunctive treatment to laser 
(Parodi et al., 2008). Allergan conducted an international study at 167 centers in 24 
countries on the effect of intravitreal dexamethasone sustained release delivery system 
(Ozurdex). The data for the first 6 months was released (Haller et al., 2010). It appears that 
visual acuity was significantly better in the group of patients who received 0.7 mg 
dexamethasone implant than in the control group after 60 and 90 days, but is similar 180 
days after the treatment. Ozurdex received FDA approval for treatment of macular edema 
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secondary to BRVO in 2009. An implantable fluocinolone acetonide (Retisert, Bausch and 
Lomb, Rochester, NY), at present being registered for the intravitreal treatment of chronic 
non-infectious uveitis, is also being evaluated for the treatment of BRVO and CRVO. The 
beneficial effect of intravitreal corticosteroids is limited in time and repeated treatment is 
associated with the accumulation of the complications including steroid-induced 
glaucoma, cataract, endophthalmitis and retinal detachment. IOP sparing corticosteroids 
may only prevent glaucoma but not the other side-effects; 
 Intravitreal Anti-Vascular Endothelial Growth Factor. It was noticed that VEGF plays a 
substantial role in the development of CME and neovascular complication in RVO 
patients. The first intravitreally used drug was bevacizumab, originally developed for 
the intravenous treatment of colorectal carcinoma metastases, but widely used for 
treating RVO complications and other retinal disorders (e.g. diabetic macular edema, 
age related macular degeneration). Several studies have reported a decrease in retinal 
thickness and improved visual acuity after receiving bevacizumab (Kreutzer et al., 2008; 
Kriechbaum et al., 2008; Pai et al., 2007). Visual acuity usually increased to maximum in 
3-6 weeks after the injections (Stahl et al., 2007). A subsequent decrease in visual acuity 
appeared to be closely related to an increase in CME. Early recurrence of CME should 
prompt consideration for retreatment. The most appropriate timing interval between 
injections is still unclear. The other anti-VEGF agents on the market are pegaptanib, the 
first FDA approved intravitreal agent (for the treatment of neovascular age-related 
macular degeneration - ARMD) and ranibizumab, the first FDA approved agent for the 
treatment of not only ARMD but also macular edema caused by BRVO, based on the 
results of BRAVO study. Results of phase III BRAVO study show us that after six 
monthly intravitreal injections of ranibizumab 55% (0.3mg group), and 61% (0.5mg 
group) gain more than 15 letters, compared to 28.8% in the control group. Also a central 
foveal thickness decreased by 158 microns in the control group versus 337 microns in 
the 0.3 mg group and by 345 microns in the 0.5 mg group. Adverse events are rare - one 
retinal detachment in the 0.3 mg group, one endophthalmitis and one myocardial 
infarction in 0.5 mg group, and one stroke in the control group. According to our 
experience as well as numerous other authorities it is doubtfull that myocardial 
infarction and stroke are caused by the local treatment with anti-VEGF, since they are 
most prominent in the older population which is prone to these conditions (Rosenfeld, 
2006). After six months the control group received intravitreal ranibizumab on as 
needed basis; i.e. if macular edema occurs. Therefore, the long-term results remain 
unknown. We can say that, according to this data, the use of anti-VEGF agents become 
an important option in macular edema treatment secondary to BRVO; 
 Pars plana vitrectomy with removal of the posterior hyaloid is effective in resolving 
CME (only if the traction is the cause of retinal edema and usually if the duration of the 
edema is less than 6 months) and improving visual acuity (Figueroa et al., 2004). Due to 
complications associated with these procedures, such as vitreous hemorrhage, 
intraoperative retinal tears, rhegmatogenous retinal detachment and cataract 
development, they are not often in use. 
3.7.2 Management of central retinal vein occlusion 
Etiology treatment 
 Isovolemic hemodilution. Several studies have suggested the presence of abnormal 
blood viscosity in CRVO patients. Based on that assumption, some authors have 
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advocated the use of hemodilution in CRVO, but other (Hayreh, 2003) claim that there 
is little scientifically valid evidence of beneficial effects of this therapy; 
 Anticoagulant and antiplatelet therapy. Although no clear ocular benefit of antithrombotic 
drugs has been demonstrated, antiplatelet drugs (e.g. aspirin) are prescribed for many 
patients, including CRVO patients. Hayreh (Hayreh, 2002) claims that this therapy as well 
as the anticoagulant therapy, such as recombinant tissue plasminogen activator (rt-PA), is 
contraindicated and even harmful for CRVO patients. Some authors have tried local 
application of rt-PA into retinal branch vein but the results are controversial and 
complication rate (haemophtalmus, neovascular glaucoma, retinal detachment, eye 
phthysis) is unacceptably high;  rt-PA should penetrate the retina to exert its activity  
 Chorioretinal venous anastomosis. The techniques explained earlier may create an 
anastomosis, but also carry significant risks. Given the variable success rate, these 
techniques are rarely employed; 
 Surgical decompression of the retinal vein. Proposed procedures can be divided into 
two mayor types; the first is the vitrectomy with radial optic neurotomy, in which a 
surgeon’s approach is from inside the globe, and the second is optic nerve sheet 
decompression using orbital “outer” approach. Because of the danger and invasiveness 
of the procedures and the lack of scientific explanation (Hayreh et al., 2002), there is a 
need for a larger study to eventually find a place for these procedures in the 
management of CRVO. 
Treatment directed at sequelae 
 When speaking of sequelae treatment, we have to add an antiglaucomatous treatment 
as needed if increase of IOP occurs. Local medical therapy such as, β-blocker (timolol 
0,5%), α-2 agonists (brimonidine 0’1-0,2%), carbonic anhydrase inhibitor 
(acetazolamide, dorzolamide) and panretinal photocoagulation. If failed, the other 
method of treatment has to be applied such as (i) trabeculectomy with antimetabolites 
as a first step when there is potential to improve state, (ii) aqueous shunt implants as a 
second step, and (iii) diode laser cyclophotocoagulation or retinal cryoablation , and in 
the worst case, with no vision and the patient suffering from great pain, (iv) 
evisceration or enucleation should be considered (Sivak-Callcott et al., 2001); 
 Grid-pattern laser photocoagulation. According to CVOS study, these procedures have 
no beneficial effect on the visual outcome in macular edema due to CRVO, either 
ischemic or non-ischemic; 
 Scatter panretinal laser photocoagulation. It has been almost universally accepted that 
prophylactic panretinal photocoagulation (PRP) is the treatment of choice to prevent 
neovascular glaucoma or treat neovascular glaucoma itself in ischemic CRVO. CVOS 
study revealed that there is no benefit of the prophylactic PRP in the eyes with ischemic 
CRVO. These results have led to the recommendation that PRP should be applied 
promptly after the identification of intraocular neovascularization in eyes with ischemic 
CRVO to minimize the risk of the development of neovascular glaucoma; 
 Corticosteroids. Steroids reduce vascular permeability and stabilize the blood-retina 
barrier. The mechanism for these effects involves inhibition of the production of 
inflammatory mediators and vascular permeability factors (e.g. VEGF) as well as the 
stabilization of the vascular endothelial cell tight junctions. The inhibition of VEGF 
production may further help prevent neovascular sequelae. Some authors have 
proposed for some patients the systemic use of corticosteroids (Hayreh, 2010) in high 
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advocated the use of hemodilution in CRVO, but other (Hayreh, 2003) claim that there 
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complication rate (haemophtalmus, neovascular glaucoma, retinal detachment, eye 
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 Chorioretinal venous anastomosis. The techniques explained earlier may create an 
anastomosis, but also carry significant risks. Given the variable success rate, these 
techniques are rarely employed; 
 Surgical decompression of the retinal vein. Proposed procedures can be divided into 
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need for a larger study to eventually find a place for these procedures in the 
management of CRVO. 
Treatment directed at sequelae 
 When speaking of sequelae treatment, we have to add an antiglaucomatous treatment 
as needed if increase of IOP occurs. Local medical therapy such as, β-blocker (timolol 
0,5%), α-2 agonists (brimonidine 0’1-0,2%), carbonic anhydrase inhibitor 
(acetazolamide, dorzolamide) and panretinal photocoagulation. If failed, the other 
method of treatment has to be applied such as (i) trabeculectomy with antimetabolites 
as a first step when there is potential to improve state, (ii) aqueous shunt implants as a 
second step, and (iii) diode laser cyclophotocoagulation or retinal cryoablation , and in 
the worst case, with no vision and the patient suffering from great pain, (iv) 
evisceration or enucleation should be considered (Sivak-Callcott et al., 2001); 
 Grid-pattern laser photocoagulation. According to CVOS study, these procedures have 
no beneficial effect on the visual outcome in macular edema due to CRVO, either 
ischemic or non-ischemic; 
 Scatter panretinal laser photocoagulation. It has been almost universally accepted that 
prophylactic panretinal photocoagulation (PRP) is the treatment of choice to prevent 
neovascular glaucoma or treat neovascular glaucoma itself in ischemic CRVO. CVOS 
study revealed that there is no benefit of the prophylactic PRP in the eyes with ischemic 
CRVO. These results have led to the recommendation that PRP should be applied 
promptly after the identification of intraocular neovascularization in eyes with ischemic 
CRVO to minimize the risk of the development of neovascular glaucoma; 
 Corticosteroids. Steroids reduce vascular permeability and stabilize the blood-retina 
barrier. The mechanism for these effects involves inhibition of the production of 
inflammatory mediators and vascular permeability factors (e.g. VEGF) as well as the 
stabilization of the vascular endothelial cell tight junctions. The inhibition of VEGF 
production may further help prevent neovascular sequelae. Some authors have 
proposed for some patients the systemic use of corticosteroids (Hayreh, 2010) in high 
 
Advances in Ophthalmology 
 
384 
oral doses of about 80 mg of prednisone to control macular edema, which is the main 
cause of visual loss. Most of the patients with CRVO according to the SCORE study 
respond to intravitreal triamcinolone application of either 1 or 4 mg doses compared to 
the standard care in terms of improving visual acuity of more than 15 letters. As far as 
the safety is concerned, there are more complications such as cataract formation and 
IOP elevation in the triamcinolone group. Complications rate is higher in the group 
with higher dose (4 mg) (Ip et al., 2009). Although triamcinolone is a long lasting 
corticosteroid, it appears that it is not enough and it leads to the development of 
sustained corticosteroid delivery devices, which release the drug longer. One of them is 
Retisert which has good results in chronic refractory CME (Ramchandran et al., 2008), 
with the best results 12 month after injection. However, the complication rates are very 
high - all phakic eyes developed visually significant cataracts, and 92% have had an 
elevation of IOP that needed intervention. Allergan conducted an international study 
on dexamethasone sustained delivery devices (Ozurdex) and the six month results have 
been published. In CRVO subgroup of patients a significantly better result in gaining 
visual acuity (more than 15 letters) has been recorded in the group which received 0.7 
mg implant compared with control group at 30 and 60 days control point, and not 
significantly better at 90 and 180 days point. There were no significant differences in 
cataract formation between groups and ocular hypertension occurred in only 4% of 
patients receiving an implant. In 2009 FDA gave approval for the Ozurdex in the 
treatment of macular edema secondary to CRVO; 
 Intravitreal anti vascular endothelial growth factor (anti-VEGF). As VEGF plays a key role 
in the pathophysiology of CRVO, several anti-VEGF treatments have been developed to 
decrease VEGF and block vascular permeability and angiogenic activity (bevacizumab, 
ranibizumab, pegaptanib). According to the results of CRUISE study, FDA released 
approval of intravitreal ranibizumab for the treatment of CRVO (Brown et al., 2010); 
 In cases of refractory CME secondary to CRVO with no resolution after bevacizumab or 
IVTA individually, a combination treatment with both agents may result in resolution 
of CME and significant recovery of visual acuity (Ehlers & Fekrat, 2011; Ekdawi & 
Bakri, 2007). These results suggest that for some patients, the complementary actions of 
bevacizumab and IVTA on VEGF and inflammation may be more effective than either 
therapy used alone in the treatment of RVO. Further studies examining multi-modal 
therapy are needed to answer these questions regarding optimal therapy. Probably a 
combined treatment or new drugs will have a better efficacy. 
4. Ocular Ischemic Syndrome 
Obstructions more proximal to the central retinal artery usually cause a more chronic form of 
visual problem – the ocular ischemic syndrome. Ocular ischemic syndrome (OIS) is a 
condition that has a variable spectrum of signs and symptoms that result from chronic ocular 
insufficiency, usually secondary to severe carotid artery disease (CAD). Moreover, they may 
be the first manifestations of CAD (Dugan & Green, 1991). OIS was firstly described in 1963 
and named venous stasis retinopathy (Hedges, 1963; Kearns & Hollenhorst, 1963). 
4.1 Epidemiology 
The OIS occurs at a mean age of 65 years and generally does not develop before 50 years of 
age. Men outnumber women by a ratio of 2:1, because of the higher incidence of 
 
Retinal Vascular Occlusions 
 
385 
atherosclerosis in men (Brown & Magargal, 1988). No racial predilection exists. Bilaterally OIS 
occurs up to 22% of cases (Mendrinos et al., 2010). The incidence of OIS is not known precisely, 
but is estimated at 7.5 cases per million people annually (Sturrock & Mueller, 1984).  
Different studies found various incidence of OIS development in patients with 
hemodynamically significant CAD, which is 4%, 18%, and 1.5% respectively (Kearns & 
Hollenhorst, 1963; Kearns et al., 1978; Klijn et al., 2002). Ipsilateral transient monocular 
visual loss is the hallmark of carotid insufficiency and occurs in 30-40% of patients with 
CAD. CAD on the one common (CCA) or internal carotid artery (ICA) is often accompanied 
by occlusion or stenosis of the opposite carotid artery (Mendrinos et al., 2010). 
4.2 Pathophysiology and causes 
Both stenosis and occlusion of the common or internal carotid arteries are responsible for 
ipsilateral ocular signs and symptoms that may herald a devastating cerebral infarction 
(Biousse, 1997). The decreased vascular perfusion results in tissue hypoxia and increased 
ocular ischemia, leading to neovascularization (Leibovitch et al., 2009; Kahn et al., 1986; 
Takaki et al., 2008). 
Patients who develop OIS show decreased blood flow in the retrobulbar vessels and reversal 
of blood flow in the ophthalmic artery (OA) (Mendrinos et al., 2010). OA shunts blood flow 
away from the eye to the low-resistance intracranial circuit. This blood steal leads to further 
reduction of retrobulbar blood flow, hypoperfusion, and subsequently ocular ischemia.  
OIS develops especially in patients with poor collateral circulation between the internal and 
external arterial systems or between the two ICAs. The occurrence of cerebral infarctions 
and poor neurologic prognosis could also be explained by the insufficient collateral 
circulation.  
4.3 Clinical presentation 
Ocular ischemic syndrome encompasses a spectrum of ocular signs and symptoms that are 
the result of ocular hypoperfusion caused by severe carotid artery obstruction.  
4.3.1 Symptoms 
The presenting symptom is a variable degree of visual loss often accompanied by pain 
caused either by ischemia of the globe or elevated intraocular pressure in neovascular 
glaucoma. The natural course of the ischemic syndrome is generally poor, although there is 
certain proportion of cases with milder clinical picture retaining the visual function. 
4.3.2 Signs 
The anterior segment signs are often present: neovascularization of the iris in approximately 
two thirds of eyes at the time of initial examination; corneal edema and striae usually 
concurrent with increased pressure from neovascular glaucoma. Although the iris 
neovascularization is the presenting sign in large percentage of patients with ischemic 
syndrome, only one third of cases develop secondary neovascular glaucoma. This may be 
due to a lower arterial supply of the ciliary body causing hypotony or normal pressure in 
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spite neovascular changes in the iridocorneal angle. There may be signs of mild anterior 
chamber reaction in 20% of these eyes with flare being a more prominent feature than the 
cellular response (Kahn et al., 1986). Advanced lens opacification may also be present in the 
late stages of this syndrome. The fundoscopic findings may mimic other vascular retinal 
disorders and involutive changes seen in elderly population: constriction, straightening and 
narrowing of the arteries, dilated retinal veins, but without accentuated tortuosity 
commonly seen in vein occlusions. Venous beading may resemble features of proliferative 
diabetic retinopathy. In the majority of cases there are dot and blot retinal hemorrhages 
distributed diffusely around the periphery, but they can spread onto the posterior pole. The 
other features of retinal ischemia may also be present: cherry red spot appearance, cotton 
wool exudates, optic atrophy and edema. 
4.4 Evaluation and imaging 
A careful clinical examination and lab tests (ESR, CRP) must be undertaken to exclude 
possible temporal arteritis, which may resemble this clinical entity and mandates different 
diagnostic and therapeutic approach, which may prevent further visual loss and potentially 
blindness. 
4.4.1 Fluorescein and indocyanine green angiography 
Besides clinical examination, fluorescein angiography (FA) can help to establish the diagnosis 
of ocular ischemic syndrome. Prolonged choroidal filling time is the most specific 
angiographic sign of ocular ischemic syndrome (Mendrinos et al., 2010). Patchy filling of the 
choroid that lasts more than 5 seconds is seen in about 60% of eyes affected by ocular ischemic 
syndrome (Brown & Margargal, 1998). Staining of the retinal vessels, both the major vessels 
and its branches, is another sign seen in 85% of eyes with ocular ischemic syndrome. 
Demonstration of a well-demarcated leading edge of fluorescein dye within a retinal artery is a 
typical sign of OIS. Other findings on fluorescein angiography include an increased 
arteriovenous transit time (over 11 seconds), macular edema, retinal capillary nonperfusion, 
and evidence of microaneurysms (especially in the periphery) (Richard et al., 1998). 
Indocyanine green angiography (ICG) shows signs of choroidal hypoperfusion – occlusion 
of choriocapillaries with filling defects in the posterior pole or the mid-periphery. There is 
also prolonged arm to choroid (over 10 seconds) and intrachoroidal circulation time (over 5-
6 seconds). Another characteristic finding is slow filling of the watershed zones of the 
choroids) (Richard et al., 1998). 
4.4.2 Electroretinography 
Electroretinography demonstrates a decrease in both a and b waves in these eyes, which is 
in contrast to the sparing of the a wave found in central retinal artery occlusions (Brown et 
al., 1982). 
It is of paramount role to assess the carotid artery function since the endarterectomy procedure 
reduces the risk of stroke as life threatening consequence and there is some evidence of 
improvement in retinal function viewed through the improvement of a and b waves in 
electroretinography, as well as the normalization of preoperative retrograde ophthalmic artery 
flow shown on Doppler color imaging (Kawaguchi et al., 2001; Story et al., 1995). 
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4.4.3 Duplex carotid ultrasonography 
Duplex carotid ultrasonography combines B-mode ultrasound and Doppler ultrasound 
providing the morphologic imaging and flow velocity data. It is the most commonly used 
noninvasive method in evaluation of carotid artery obstruction. 
Color Doppler imaging is a noninvasive tool for assessing the velocity of blood flow in the 
retrobulbar circulation. Diminished velocities of the blood flow in the central retinal artery, 
choroidal vessels, and ophthalmic artery are typical. There may be a reversal of flow in the 
ophthalmic artery, as well. Color Doppler imaging may assess the carotid arteries 
simultaneously.  
4.4.4 Invasive diagnostics 
If noninvasive carotid artery evaluation is unremarkable in an eye that shows signs 
suggestive of ocular ischemia, conventional carotid arteriography or digital subtraction 
angiography may be required to detect possible chronic obstruction of the ophthalmic artery 
(Wardlaw et al., 2006).  
The new minimally invasive methods, magnetic resonance angiography and computed 
tomographic angiography are evolving and improving as adjunctive diagnostic tests in 
evaluating the patients with carotid occlusive disease.  
4.5 Differential diagnostic 
Diabetic retinopathy 
Nonischemic central retinal venous occlusions 
Giant cell arteritis 
Takayasu arteritis 
Ischemic optic neuropathy 
Retinal artery occlusion 
Neovascular glaucoma 
4.6 Management 
Management of OIS is basically multidisciplinary and the task of the ophthalmologist is to 
treat ocular condition, recognize the possible cause of OIS and refer the patient to a 
cardiologist, neurologist or other specialists, where they can get proper treatment of the 
cause of OIS. 
Ophthalmology treatment consists of increased IOP control, management of 
neovascularization and control of anterior segment inflammation. 
 Anterior segment inflammation is usually treated with topical steroids and long acting 
cycloplegic agents; 
 Increased IOP, usually controlled with topical β-adrenergics blockers, ά-agonists and 
topical or oral carbonic anhydrase inhibitors to reduce aqueous production; 
prostaglandins (could increase ocular inflammation) and pilocarpin should be avoided; 
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 Ocular neovascularization following carotid occlusive disease is usually managed with 
panretinal photocoagulation and can prevent neovascular glaucoma (Carter, 1984; Chen 
et al., 2001). If PRP is not possible due to media opacities or refractory miosis, other 
modalities such as transconjunctival cryotherapy of peripheral retina or transscleral 
diode laser retinopexy should be considered to prevent neovascularization. In any case, 
PRP works effectively and reduces the iris neovascularization in only 36% of patients 
with OIS (Sivalingam et al., 1991). In other cases it can even get worse (Turut & 
Malthieu, 1986), which suggests that uveal ischemia can induce neovascularization, as it 
is shown on animal model (Hayreh & Baines, 1973). Therefore, in the cases where there 
is retinal ischemia, prophylactic PRP is advisable. Neovascularization and macular 
edema caused by OIS can be also treated with intravitreal bevacizumab (Amselem et al., 
2007). In this case report neovascularization regressed, but there was no improvement 
in VA or IOP. Macular edema can also be treated with triamcinolone intravitreally, 
reducing macular edema and improving visual acuity (Klais & Spaide, 2004). Further 
investigation with a more reliable sample is needed to establish the role of this therapy 
in IOS patient. Additionally, we have to mention that when neovascular glaucoma 
occurs it is usually refractory to medical therapy and if panretinal photocoagulation 
failed the other method of treatment has to be applied, such as (i) trabeculectomy with 
antimetabolites as a first step when there is potential to improve state, (ii) aqueous 
shunt implants as a second step, and (iii) diode laser cyclophotocoagulation or retinal 
cryoablation, and in the worst case, with no vision and the patient suffering from great 
pain (iv) evisceration or enucleation should be considered (Sivak-Callcott et al., 2001). 
Medical treatment includes conservative treatment by other specialists in order to manage 
associated systemic diseases or states such as coronary artery disease, hiperlipidemia, 
hypertension, diabetes mellitus etc. 
Some of the surgical treatment is advocated to manage carotid stenosis and to improve ocular 
ischemia (Costa et al. 1999; Chaer & Makaroun, 2008; Sivalingam et al., 1991), such as carotid 
artery endarterectomy (CEA), carotid artery stenting (CAS) or extracranial-intracranial arterial 
bypass surgery (EC-IC), but without sufficient evidence to claim improvement of the ocular 
state with this treatment, except for CEA, where studies show some beneficial effect on the 
patient who has mild ocular ischemia and less effect on the patient with a greater degree of 
ocular ischemia, where retinal damage has probably become irreversible. 
In conclusion, we can say that the ocular ischemic syndrome is a rare, vision-threatening 
condition and since the ophthalmologists may be the first to deal with such patients, they 
should be aware of the clinical presentation of OIS and recognize it early enough to start 
treating the condition when visual acuity is preserved enough and when prognosis is better. 
The continuing improvements in the diagnostic techniques, medical management and surgical 
treatment of carotid artery occlusive disease make the role of ophthalmologists increasingly 
important in the early detection and management of the OIS and its comorbidity. 
5. Conclusion 
Retinal vascular occlusions are an important cause of visual loss, particularly in elderly patients 
with multifactorial pathophysiological arms uniquely intertwined in each patient. They are 
often referred to as a „stroke“in the eye due to symptoms and clinical picture, often dramatic in 
its presentation. It also emphasizes the tremendous influence on patient's quality of life. 
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Apart from the similar clinical symptoms of visual loss there are some distinctive features 
that direct the clinician towards the diagnosis of arterial or venous occlusion. A thorough 
examination should assess the degree of vision loss by testing visual acuity, the presence of 
afferent pupillary defect, visual field testing, slit lamp examination of both anterior and 
posterior segments of the eye as well as ERG, which along with afferent pupillary defect and 
visual field testing provides the most sensitive diagnostic test in distinguishing between 
ischemic and non ischemic types of the occlusive disease (Hayreh, 2005). Visual acuity alone 
is not sufficient to validate peripheral retinal function but solely central vision. Therefore, it 
has been advocated by some authors to combine morphologic and functional tests in order 
to establish the type of the occlusion which has tremendous impact on the clinical course, 
prognosis and management of each case. The oxymetry (Gehlert et al., 2010) offers new 
possible tool in evaluating the perfusion status of the retina as this is extremely important 
prognostic factor when deciding which diagnostic and therapeutic algorithm should be 
undertaken in patient with occlusive disorder. 
In conclusion we can say that retinal vascular occlusions are very common ocular diseases 
and the causes of visual loss with poor perspectives in the past, but recent studies on 
various medications and treatment modalities raise hope between a patient and 
ophthalmologist for establishing the proper treatment. Although we still cannot foresee, 
prevent, or causatively and successfully treat occlusive diseases of the retina, there are 
promising, recently introduced novel options focused on the management of visually 
deteriorating complications. Intravitreal agents, especially anti-VEGF medications and 
intravitreal corticosteroid implants have drastically changed the visual outcome for the 
affected patients. The perspective looks brighter as the development of the most effective 
treatment regimens and their combinations is evolving. Probably a combined therapy will 
better act than a single one. Developing new drugs is warranted. 
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1. Introduction 
Branch retinal vein occlusion (BRVO) is a common vascular disorder that is frequently 
associated with severe vision loss due to its complications. There are two forms of BRVO, the 
ischaemic and the non-ischemic, both leading to loss of visual acuity. About 20-30% of the 
BRVOS are ischemic and the majority of them develop secondary glaucoma and rubeosis. [1] 
Although this disorder was first reported by J. von Michel in 1878, its pathogenesis has still not 
been fully understood, and no effective therapy has been developed for this disorder [1-3]. 
Comparative research on this disorder is based on clinical models of BRVO.  
The pathological features of BRVO can be more accurately reproduced by a photodynamic 
method to induce thrombosis in retinal vessels[4–14] than by using other methods such as laser 
coagulation[15–17], electrocoagulation of the retinal vein via the vitreous body[18], intravenous 
thrombin instillation[19–21] and endothelin-I injection into the posterior vitreous body[22, 23]. In 
the photodynamic method, a photosensitizing agent, namely, rose Bengal, is injected 
intravenously. This dye absorbs light maximally at a specific wavelength of 550 nm. Dye 
activation in the presence of molecular oxygen leads to the generation of singlet oxygen, which 
in turn acts locally to injure or destroy the vascular endothelium. The altered endothelium 
provides a surface for platelet aggregation and subsequent thrombosis. By using this method, 
thrombi can be produced in vessels. Because relatively low light intensities are required to 
initiate this process, the thermal effects on the surrounding tissues are minimized.  
In this investigation, we used a Xenon arc lamp as the light source, and visible light was 
transmitted through an intraocular fiber to induce BRVO in pigmented rabbits. The 
characteristics of BRVO were evaluated quantitatively, and histological studies were 
performed to support the clinical findings. The results provided  a framework for future 
applications of this technique. 
2. Materials and methods  
2.1 Animals and husbandry 
Thirty-two male Standard Chinchilla rabbits were purchased from the Experimental Animal 
Center of Tianjin Medical University (Tianjin, China) and allowed to acclimate upon arrival 
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Advances in Ophthalmology 
 
400 
for 10 d before the initiation of the experiment. At the beginning of the study, the animals 
were aged 3–4 months and weighed 2.5–3.5 kg. All experimental animals were housed in 
individual cages under stable environmental conditions: diet, commercial pellet diet 
(Lushifu, Beijing, China) and tap water ad libitum; relative humidity, 45–55%; temperature, 
18°C; and light-dark cycle, 12/12 h (intensity, 300 lux).  
The study was approved by the Ethics Committee of Tianjin medical university. All animal 
experiments were performed in accordance with the conventions of the Association for 
Research in Vision and Ophthalmology (ARVO) for ethics in animal experimentation.  
2.2 Experimental design 
The 32 rabbits (32 eyes, 32 vessels) were randomly divided into 15 treatment groups (n = 2) 
and 1 control group (n = 2). The treatment groups were administered 5 different rose Bengal 
doses (3, 6, 9, 12 and 15 mg/kg) and exposed to light of 3 different intensities (600, 1000 and 
1400 lux) 1 min later. In the control group rabbits, the vessels were exposed to a light 
intensity of 1400 lux for 20 min without injection of the rose Bengal dye. 
2.3 Experimental procedure 
In preparation for the treatment and follow-up examinations, the rabbits were fully 
anesthetized with an intramuscular injection of 60 mg/kg ketamine (Beijing Shuanghe 
Pharmaceuticals, Beijing, China) and 8 mg/kg xylazine (Beijing Shuanghe Pharmaceuticals, 
Beijing, China). The pupils were dilated using 0.5% tropicamide eye drops (Beijing 
Shuanghe Pharmaceuticals, Beijing, China).  
Rose Bengal (tetrachloro-tetraiodo-fluorescein sodium; certified purity, 90%; Sigma, St. 
Louis, MO) was dissolved in normal saline (30 mg/ml), sterilized by passage through a 0.22-
µm filter and injected intravenously in doses of 3, 6, 9, 12 or 15 mg/kg before the light 
treatment. A Xenon arc lamp (Anshijia Instrument Co. Ltd., Beijing, China) was used as a 
light source, and light was transmitted by using a 0.2-mm intraocular illumination fiber 
(Alcon (China) Ophthalmic Product Co. Ltd., Shanghai, China). Light intensity was 
measured using a digital lux meter (LX-9621; Landtek Instrument Co. Ltd., Guangzhou, 
China). Average values of 600, 1000 and 1400 lux, for the low, medium and high settings, 
respectively, were obtained with less than 3% variation in repeated measurements 
throughout the study. 
According to the treatment protocol, the rabbits were placed on a stage under a surgical 
microscope (OPTON Universal S3; Germany). 2% methylcellulose solution (Zhengda Co. Ltd., 
Shandong, China) is dropped on the cornea to couple the input light into the 30-degree prism 
lens (Anshijia Instrument Co. Ltd., Beijing, China). The operations were observed by using a 
contact lens and a surgical microscope. A 25-gauge trocar (Alcon (China) Ophthalmic Product 
Co. Ltd., Shanghai, China) was used to make an incisions in the conjunctiva and sclera at the 
projection holes located supratemporally 3 mm from the corneal limbus, then the needle was 
removed and the intraocular fiber was inserted through the incision and its direction was 
toward optic disc, the depth was 10 mm. Rose Bengal was injected intravenously through the 
marginal ear vein. After 1 min, the trunk vessels adjacent to the optic disc of 1~ 3 mm were 
exposed to a beam of white light. The duration of continuous exposure to light did not exceed 
20 min, and the exposure time was recorded if complete vascular occlusion was observed. The 
fiber finally was then taken out and the sclera was finally sutured. 
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Fundus fluorescein angiography (FFA) was performed using a fundus camera (Zeiss FF450IR; 
Carl Zeiss Far East Co. Ltd., Beijing, China) before the treatment and everyday after the 
treatment until the occluded vein reopened. The 5 mg aqueous fluorescein sodium (100 
mg/ml, Baiyunshan Pharmaceuticals Co. Ltd., Guangzhou, China) was injected into ear veins 
immediately prior to FFA under anesthesia and pupil dilation those were as same as the prior. 
2.4 Experimental observation  
The rate and duration of vessel occlusion are confirmed with an ophthalmoscope and by 
FFA. The blood flow was confirmed by a scleral depressor transiently applied pressure on 
the equator of the eyeball, thereby the higher intraocular pressure (IOP) reduced the flow 
rate until freely moving red blood cells were seen. Once the scleral depressor was removed, 
a rapid uninterrupted column of blood flow passed through without the presence of 
stagnant red blood cells. [9] These dynamic phenomenons were monitored by an 
ophthalmoscope and it was the character of reperfused vessels. 
When reperfusion was noted on post-treatment day 1, the number of days of occlusion was 
defined as 0. When the vessel was observed to be occluded on day 1 but not on day 2, the 
number of days of occlusion was defined as 1 and so on. 
Two rabbits in the control group and 1 rabbit in the treatment groups in whom BRVO was 
confirmed by FFA were euthanized using intravenous overdose of pentobarbital sodium 
(Beijing Shuanghe Pharmaceuticals, Beijing, China). Their eyes were enucleated and 
prepared for light microscopic examination by using standard techniques. Sections (5-µm-
thick) were stained with haematoxylin/eosin. The remaining rabbits were euthanized by 
administering an overdose of pentobarbital sodium at the end of the experiment.  
2.5 Statistical analysis  
A partial correlation coefficient was used to analyze the relationship between the time of 
thrombosis, the drug dose, and light intensity. A P value of 0.05 or less was considered 
statistically significant. All data were analysed with the SPSS 11.5 software. 
3. Results 
3.1 Evaluation of BRVO animal model 
BRVO models were developed in 22 of the 30 rabbits in the treatment group. The fundus 
could be observed in detail by using a surgical microscope (please see supplemental video 
1). In the site exposed to light, photodynamic injury resulted in white debris (plaque-like 
thrombi) and the stagnation of blood flow. FFA showed the engorged distal ends of the 
venules proximal to the occlusion site and peripheral retinal oedema in the BRVO area 
(Figure 1).  
Histological sections were studied to confirm the presence and extent of the photodynamic 
lesions. Retinal vein damage was confined to the area of direct light exposure in the treatment 
groups. Histological examination revealed thrombi consisting of platelet aggregates, stagnant 
red blood cells and a few white blood cells. Occluded retinal vein histological section indicated 
that compact thrombus filled the entire vein cavity and occlusion is evident. (Figure 2).  
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Fig. 1. Photodynamic thrombosis of a branch retinal vein in a pigmented rabbit eye. Initial 
formation of a thrombosis in the target vein (A) and complete obliteration of the vessel 
lumen (B). FFA showed a delay in the time required for angiosclerosis in the distal end of 
the vein and discontinuous intravenous blood flow in the vicinity of the optic disc (C). 
Arrows indicate the occlusion site and peripheral retinal oedema. 
 





Fig. 2. Histological findings. Two hours after thrombosis, the thrombus filled the entire 
vein cavity (long arrow), and the artery was normal (short arrow). The thrombus consisted 
of platelet aggregates, stagnant red blood cells and a few white blood cells. Magnification, 
200×. 
The control vessels and the blood flow through them were as same as those in healthy 
animals. The histological sections from the rabbits that were not injected with rose Bengal 
showed no evidence of photochemical or thermal retinal damage in the site that was 
exposed to a light intensity of 1400 lux (maximum light intensity) for 20 min. 
3.2 Dose- and light-response studies 
Vein occlusion in the pigmented rabbits was considered as the end point for determining 
dose- and light-response relationships. In 22 successful BRVO models, the time required to 
produce an occlusion decreased with an increase in the dose of rose Bengal administered 
and the light intensity. Rose Bengal at doses of more than 9 mg/kg was effective in 
producing BRVO; a dose of 6 mg/kg was ineffective in producing BRVO at a light intensity 
of 600 lux. At a dose of 3 mg/kg, small plaques also developed in the target vessel; however, 
they did not progress to vascular occlusions in 20 min even if the light intensity was as high 
as 1400 lux. The total light energy required to produce an occlusion increased from an 
average of 600 lux with 9 mg/kg of rose Bengal to 1000 lux with 6 mg/kg of rose Bengal. 
The time of occurrence of thrombosis showed a negative correlation with the drug dose and  
light intensity. A decrease in the time required for the development of BRVO corresponded 
to a higher drug dose (partial r = –0.7895; P < 0.001) and a higher light intensity (partial  
r = –0.9060; P < 0.001) (Figure 3).  
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Bengal and the light intensity. The mean value of the time required for thrombosis was 
determined (n = 2). Complete BRVO formation did not occur when a dose of 3 mg/kg rose 
Bengal was used, and a dose of 6 mg/kg rose Bengal was ineffective in producing BRVO at 
a light intensity of 600 lux.  
3.3 Duration of occlusion 
In the early period of BRVO in the animal models, FFA and fundus photography 
documented the blood along the circuitous expanded vein, and retinal oedema that was 
similar to the lesion in humans. The area of the white thrombus gradually decreased with 
time, and the angiostenosis in the distal end of the retinal vein also gradually decreased. In 
21 cases, the minimum duration record for the reopening of an occlusion was 3 d and the 
maximum, 10 d (Figure 4).  
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from 3 to 10 d. The data correspond to a Gaussian distribution (P < 0.01); the 95% confidence 
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method used to induce experimental thrombosis.  
The animal species that are usually selected for the development of BRVO animal models 
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availability and breeding management. Further, these models enable easy identification of 
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investigative surgical procedures. The structure of the retina in pigs[12, 15], cats[8] or dogs[4] is 
similar to that in humans except that it does not have a macular region. The retinal blood 
supply in rhesus monkeys[16, 17] is similar to that in human; however, the sources of these 
animals are limited, and they are difficult to breed and manage. Compared with the eyeballs 
of other animal species, the rabbit eyeball is sufficiently large to operate[19–23]. Further, 
rabbits are inexpensive, can be easily bred and the FFA of the rabbit eye is stable. Therefore, 
we selected pigmented rabbits for our study.  
The combination of intraocular fibre illumination with the administration of rose Bengal 
should be classified as a photodynamic method of inducing BRVO because the wavelength 
of visible light include 550 nm. These findings correspond to Virchow’s hypothesis of 
thrombosis in humans. Compared with the photodynamic method, laser coagulation[15–17] 
requires higher energy and a longer exposure time, which would inevitably result in heat 
injury and disruption of the vessel wall, and subsequently, frequent bleeding. 
Electrocoagulation of the retinal vein via the vitreous body[18] utilizes electrothermal energy 
to destroy the vascular endothelium and block the vessels, which is different from the 
process of thrombosis. In intravitreous thrombin instillation method[19–21], the location of the 
retinal thrombus could not be determined; thus, the thrombus may occlude other regions 
but not the target vessels. The injection of endothelin-I into the posterior vitreous body[22, 23] 
caused complete occlusion of the temporal retinal vessels, but this vasospastic mechanism is 
also unsuitable for application in the experimental induction of thrombosis because actual 
clinical BRVO was occluded at one or some spots in vein.  
Presently, an argon (Ar) laser is often used as the excitation light source in the 
photodynamic method because its wavelength of 514 nm is similar to the light absorption 
peak of rose Bengal. However, heat injury from laser-coagulation to the retinal tissue and its 
vessels is observed. Moreover, due to the pulsed excitation of the laser, continuous exposure 
of the vessel to the laser beam is impossible. Consequently, it is difficult to adjust the level of 
energy used in this procedure: if the energy level is too low, no thrombus formation occurs 
and if it is too high, vessel hemorrhage occurs[8]. Some researchers utilize common light 
sources such as slit lamps and Xenon lamps to develop BRVO animal models. However, the 
use of these light sources resulted in an extensive arteriovenous obstruction caused due to 
the exposure of a large area to the light source, therefore, these light sources are not suitable 
for studying a typical BRVO[9, 10, 13]. In a previous study, we use a microsurgical illumination 
system, which comprised a 0.9-mm intraocular fibre that served as an endoilluminator to 
produce RVO in pigs[11]; the intraocular fibre illuminated the nearby retinal vascular target 
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and by localizing energy, it is able to produce a thrombus as effectively as laser irradiation. 
However, the diameter of the retinal trunk vein in rabbits was only 150–200 µm, and the 
microsurgical system was too wide to the rabbit. Therefore, in this study, we used a Xenon 
arc lamp as a light source and designed a 0.2 mm fiber for illumination to ensure that the 
light beam irradiate the trunk vein and not the accompanying artery. We find that this is a 
simple and reliable system for developing BRVO models in rabbits.  
The process of formation of BRVO in our rabbit model can be visualized and photographed 
using a surgical microscope. At the site exposed to light, the following course of 
thrombogenesis is recognized: photodynamic injury resulted in a decrease in the rate of 
venous blood flow; this is followed by the appearance of stagnant red blood cells in the 
vessel, the gradual accumulation of white debris (plaque-like thrombi) and the development 
of a vascular occlusion. The distal ends of the venules are engorged proximal to the 
occlusion site. The morphological and histopathological changes are similar to Kohner’s 
results[24]. No changes were observe in the light microscopic images of the control vessels; 
this confirmes that illumination do not produce heat injury in the retinal vessels and tissue.  
The dose- and light-response studies show that the time of occurrence of thrombosis 
correlate negatively with the drug dose and light intensity; further, the basic set of 
parameters require to produce an occlusion is an average light intensity of 600 lux, a rose 
Bengal dose of 9 mg/kg and an exposure time of 11.5 min or an average light intensity of 
1000 lux, a rose Bengal dose of 6 mg/kg and an exposure time of 6.75 min. Thus, we suggest 
that the optimum parameters should be 1000 lux, 9 mg/kg of rose Bengal and an exposure 
time of 3–5 min. This suggestion is based on the following considerations: the experimental 
dose of rose Bengal in this model is maintained as low as possible to prevent the leakage of 
rose Bengal into the vitreous humour and the anterior chamber[12]; the energy level of the 
light used to induce thrombosis is higher than that in the breeding conditions (300 lux); this 
ensures that thrombosis occur only in the area exposed to the light and not in other vessels. 
On the other hand, the exposure time of 3–5 min was suitable for operation. The 
optimization of this method may aid investigators in controlling thrombus formation more 
precisely. 
Clinical BRVO is a disease of long duration and various types [1-3]; however, the 
experimental occlusion is maintained for 3 to 10 d (average, 5.38 d) in our model. This may 
be attributed to the use of young and healthy experimental animals, the sudden generation 
of an obstruction in the normal vascular bed and the activation of an autochthonous repair 
mechanism; all these factors result in rapid thrombolysis. Therefore, this BRVO model is 
very suitable for observation of immediate therapy experiment, for example, surgery; and 
not suitable for long-term drug treatment studies.  
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1. Introduction 
The sense of vision has utmost significance and the loss of vision leads to the impairment of 
active human behavior as evident in pathological disorders that affect vision. Among 
different pathological visual disorders, Age Related Macular Degeneration (AMD/ARMD) 
is of serious concern as a leading cause of blindness, observed with aging globally. The 
clinical manifestation of AMD includes retinal damage with the degeneration of macula, 
leading to the partial or complete loss of acuity in vision. One form of pathologic AMD 
named, “wet form of AMD”, involves the growth of new blood vessels from the choroid 
which lies underneath the retina, leading to the pathological blood vessel growth termed as 
Choroidal Neovascularization (CNV), with subsequent damage to the retina. Thus, 
choroidal neovascularization reflects a pathological angiogenic condition, where the loss of 
regulation over angiogenesis leads to the retinal damage. It also indicates that, the 
regulation of pathological angiogenesis can be an efficient strategy in preventing CNV of 
AMD. Though, some genetic disposition and aging factors are identified as peculiar 
etiological factors causing AMD; recent studies have shown that different cellular 
mechanisms regulating angiogenesis are common in different angiogenic scenarios 
including CNV. Further, the role of different endogenous angiogenesis 
inhibitors/angioinhibitors conferring the tissues with angiogenic regulation has been 
deciphered, which can be applied for regulation of CNV in AMD through inhibition of 
angiogenic signaling mechanisms. The present chapter provides an overview of the role of 
factors leading to choroidal neovascularization, the mechanisms underlying such 
angiogenesis and also the scope for endogenous angioinhibitors in regulation of CNV of 
AMD.  
1.1 Retina and choroid   
Retina is the inner most layer of the eye, which possesses anatomically ten distinct layers 
that are broadly categorized into two layers. The inner neural layer comprising of extensive 
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nervous tissue towards the vitreous chamber and the outer retinal pigmented epithelium 
(RPE) adhering to the choroid. Some of the functions of the RPE include the phagocytosis of 
outer retinal segmental discs, maintenance of chorio-capillaries, fluid and electrolyte balance 
in subretinal space. Choroid is the highly vascular and pigmented tissue of the eye lying 
between the retina and the sclera. It consists of lamina suprachoroidea adhering to sclera, 
followed by lamina vesculosa, chorio-capillaries, stroma and Bruch membrane adhering to 
the RPE. Choroid is rich in vasculature and the extracellular matrix (ECM) components, 
including collagen and elastin fibers. It provides nutrient, metabolite and gaseous exchange 
to the retina by diffusion through chorio-capillaries.  
1.2 Choroidal neovascularization in age related macular degeneration 
The histological proximity between retinal pigmented epithelium and choroid confers not 
only physiological but also pathological effect on RPE. The mechanical barrier that separates 
the RPE from choroid is the Bruch membrane, which in turn consists of basement membrane 
secreted by RPE, inner collagenous layer, elastic layer, outer collagenous zone and the 
basement membrane of chorio-capillaries acting as a mechanical barrier for the underlying 
chorio-capillaries, but facilitating diffusion of metabolites and gaseous exchange for RPE. In 
cases of CNV the Bruch membrane is distorted with initial deposition of lipid and 
protienaceous component called ‘drusen’ followed by the growth and penetration of blood 
capillaries from choroid into Bruch membrane, finally leading to the leakage of fluid into 
sub-retinal spaces and retinal or retinal pigmented epithelial damage (Green, 1999; Green 
and Enger, 1993; Jager et al., 2008).  
1.3 Factors for choroidal neovascularization in age related macular degeneration 
Pathological neovascularization in CNV of AMD is considered to be contributed by both the 
angiogenesis and vasculogenesis, which are the processes of de-novo blood vessel formation 
(Chan-Ling et al., 2011; Jager et al., 2008). Angiogenesis is the process of formation of new 
blood vessels from the pre-existing ones, which involves the role of different cell types and 
remodeling of ECM. The inception of different cell types involved in the angiogenesis, such 
as, the endothelial cells (ECs) of RPE and choroid involved in CNV, mural cells and 
inflammatory cells occurs through vasculogenesis, by the differentiation of endothelial 
progenitor cells (EPCs). The EPCs found in the normal circulation are recruited into 
angiogenic sites, where they differentiate into different cell types leading to angiogenesis 
(Chan-Ling et al., 2011; Jager et al., 2008). However, the salient feature of neovascularization 
involves the common sequential events of angiogenesis including the proliferation of ECs, 
degradation of ECM or vascular basement membrane (VBM) by ECs through secretion of 
proteases, migration and differentiation of ECs into tip and stalk cells, lumen development, 
ECM reorganization and finally vessel anastomosing into functional capillaries (Carmeliet 
and Jain, 2000). These sequential steps of angiogenesis are considered to be common for 
CNV, which are initiated by the release of angiogenic factors by the RPE and other cell types 
differentiated from EPCs or infiltrating through the leaky capillaries in response to aging 
evoked stress (Alon et al., 1995; Grossniklaus et al., 2002). The initiating cellular and 
physiological factors that lead to the secretion of angiogenic factors by ECs and other cell 
types have been identified in different studies, which can be systematically framed for 
synergistic interpretation of etiological factors leading to CNV.  
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The normal function of phagocytosis and degradation of phagocytosed membranes is 
impaired with aging in RPE, leading to the accumulation of lipofuscin in these cells, with 
senescence (Marshall, 1987; Young and Bok, 1969). Ischemia and hypoxia evident in the 
ocular tissues of CNV are identified as factors promoting free radical generation in RPE and 
also the release of cellular lipids and proteinaceous deposits into the Bruch membrane 
(Spaide et al., 2003). Thus, impairing Bruch membrane’s barrier function and in turn leading 
to the secretion of different angiogenic factors like vascular endothelial growth factor 
(VEGF), transforming growth factor-β (TGF- β), basic fibroblast growth factor (bFGF), 
insulin-like growth factor-1 and platelet derived growth factor (PDGF) by the RPE and the 
macrophages and stromal cells that are recruited by the differentiation of EPCs (Alon et al., 
1995; Grossniklaus et al., 2002; Lu and Adamis, 2006; Penn et al., 2008; Young and Bok, 
1969). Damage to the Bruch membrane is considered to enhance the diffusion of the growth 
factors, which elicit angiogenic signaling in the ECs (Lu and Adamis, 2006; Marshall, 1987; 
Penn et al., 2008).  
 
 
Fig. 1. The angiogenic balance between endogenous angioactivators and angioinhibitors 
regulate vascular homeostasis. Angiogenesis under physiological and pathological 
conditions is associated with up-regulation of endogenous angioactivators and/or down-
regulation of endogenous angioinhibitors. Up-regulation of angioinhibitors and/or down-
regulation of angioactivators may be associated with impaired neovascularization capacity 
in the choroidal neovascularization in age related macular degeneration (CNV of AMD). 
VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; IGF-I, 
insulin-like growth factor-I; IL-8, interleukin-8; PDGF, platelet-derived growth factor; PlGF, 
placental growth factor; TGF-and , transforming growth factor- and  
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nervous tissue towards the vitreous chamber and the outer retinal pigmented epithelium 
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cases of CNV the Bruch membrane is distorted with initial deposition of lipid and 
protienaceous component called ‘drusen’ followed by the growth and penetration of blood 
capillaries from choroid into Bruch membrane, finally leading to the leakage of fluid into 
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and Enger, 1993; Jager et al., 2008).  
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angiogenesis and vasculogenesis, which are the processes of de-novo blood vessel formation 
(Chan-Ling et al., 2011; Jager et al., 2008). Angiogenesis is the process of formation of new 
blood vessels from the pre-existing ones, which involves the role of different cell types and 
remodeling of ECM. The inception of different cell types involved in the angiogenesis, such 
as, the endothelial cells (ECs) of RPE and choroid involved in CNV, mural cells and 
inflammatory cells occurs through vasculogenesis, by the differentiation of endothelial 
progenitor cells (EPCs). The EPCs found in the normal circulation are recruited into 
angiogenic sites, where they differentiate into different cell types leading to angiogenesis 
(Chan-Ling et al., 2011; Jager et al., 2008). However, the salient feature of neovascularization 
involves the common sequential events of angiogenesis including the proliferation of ECs, 
degradation of ECM or vascular basement membrane (VBM) by ECs through secretion of 
proteases, migration and differentiation of ECs into tip and stalk cells, lumen development, 
ECM reorganization and finally vessel anastomosing into functional capillaries (Carmeliet 
and Jain, 2000). These sequential steps of angiogenesis are considered to be common for 
CNV, which are initiated by the release of angiogenic factors by the RPE and other cell types 
differentiated from EPCs or infiltrating through the leaky capillaries in response to aging 
evoked stress (Alon et al., 1995; Grossniklaus et al., 2002). The initiating cellular and 
physiological factors that lead to the secretion of angiogenic factors by ECs and other cell 
types have been identified in different studies, which can be systematically framed for 
synergistic interpretation of etiological factors leading to CNV.  
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conditions is associated with up-regulation of endogenous angioactivators and/or down-
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regulation of angioactivators may be associated with impaired neovascularization capacity 
in the choroidal neovascularization in age related macular degeneration (CNV of AMD). 
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Table 1. Endogenous activators, their receptors and angiogenic activities (EC: endothelial 
cell, ECM: extracellular matrix, FGFRs: Fibroblast growth factor receptors, Flk-1: Fetal liver 
kinase-1, Flt-1, 4: fms-related tyrosine kinase, GPCRs: G-protein coupled receptors, HSPG: 
Heparan sulfate proteoglycan, KDR: kinase insert domain receptor, MMP: matrix metallo 
proteinase, NO: nitric oxide, Pak: p21 protein activated kinase, PDGF: platelet derived 
growth factor, Tie: tyrosine kinase with immunoglobulin-like and EGF-like domains, 
VEGFRs: vascular endothelial growth factor receptors) 
The integrins and other ECM binding receptors present on ECs are essential in maintaining 
the ECM promoted survival and migration in angiogenesis (Avraamides et al., 2008; 
Mettouchi and Meneguzzi, 2006). The synergistic activation of integrins and other ECM 
binding receptors on ECs by the growth factors and cytokines leads to the activation of 
different signaling cascades mediated by the kinases, secondary messengers, transcription 
factors such as, nuclear factor kappa β (NF-κβ), hypoxia inducible factor-1 (HIF-1), and 
other enzymes such as, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) 
and metalloproteinases (MMPs) (Avraamides et al., 2008; Boosani et al., 2007; Egeblad and 
Werb, 2002; Mettouchi and Meneguzzi, 2006; Oklu et al., 2010). The transcription factors that 
are stabilized, up-regulated or expressed under hypoxia also lead to activation of different 
signaling cascades that promote effective survival and proliferation of ECs. The secretion of 
proteases such as matrix metallo-proteinases (MMPs) including collagenases and elastases, 
which degrade the collagen and elastin of vascular basement membrane (VBM) promote the 
migration of ECs. The urokinase is another proteinase, which binds to its receptors (urikanse 
binding receptor, uPAR) and activates signaling cascades leading to the secretion of MMPs, 
which promote migration of ECs and angiogenesis. The organization and differentiation of 
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migrating ECs into tip and stalk cells is further enumerated to be regulated by Wingless 
type (Wnt)/Frizzled-Notch signaling that provides an insight about formation of functional 
capillaries in neovascular vessels (Dejana, 2010; Zerlin et al., 2008).  
The inflammatory cells that are recruited through the expression of cytokines such as 
monocyte chemo-attractant protein-1 (Ccl2/MCP-1), Chemokine (C-X-C motif) liagnd 1 
(CXCL1), macrophage inflammatory protein-1/-2 (MIP-1, MIP-2) are also considered to play 
role in CNV progression (Hendricks, 2006). Further, the intriguing stimulative role of Bruch 
membrane in promoting AMD is also being deciphered by identifying the complement 
components 3a and 5a (C3a and C5a), which lead to the up-regulation of VEGF-A (Nozaki et 
al., 2006). Thus, the orchestration of various signaling events at different stages of 
angiogenesis leads to the neovascularization. The angiogenic ECs lining the neovascular 
vessels arising due to the above factors in CNV are found to possess fenestrations and also 
organize into defective capillaries leading to the leakage of macromolecules as well as 
vascular cells into the Bruch membrane and sub-retinal spaces leading to the degeneration 
of macula of retina (Dvorak et al., 1995; Roberts and Palade, 1995).  
2. Endogenous angioinhibitors 
In addition to the angiogenic factors, which activate angiogenesis, tissues and ECM also 
possess angioinhibitors, which have the potency to inhibit the angiogenesis and thus, 
regulating the pathological angiogenesis by inhibiting the signaling mechanisms activated 
by angiogenic factors (Boosani et al., 2010; Sudhakar and Kalluri, 2010, Zhang and Ma, 
2007). Nearly, 40 endogenous angioinhibitors have been characterized and some of them are 
found in the ocular tissues or secreted into vasculature and released into ocular tissues, 
where they exhibit angio-inhibition and finally regulation of CNV (Boosani et al., 2011; 
Sudhakar and Kalluri, 2010). The significance of imbalance in the levels of endogenous 
angioinhibitors and angioactivators in regulation of vascular homeostasis can be 
summarized as in Figure 1. This significance was also ascertained by the evaluations 
showing the correlation between the decrease in specific angioinhibitors and the progression 
of CNV (Bhutto et al., 2008).  
2.1 Mechanisms of regulation of CNV by endogenous angioinhibitors 
2.1.1 Vasoinhibins 
The vasoinhibins (14-18 kDa) are antiangiogenic peptides found in the pituitary, retina and 
extrapituitary tissues. They constitute the amino terminal regions of three different 
precursors; prolactin, growth hormone and placental lactogen. Though their precursors do 
not exhibit angioinhibitory activities; vasoinhibins found in the tissues or those expressed 
using recombinant methods exhibit antiangiogenic properties (Clapp et al., 2008).  
The therapeutic potential of vasoinhibins in regulating angiogenesis in CNV and tumor 
growth was evaluated and studies indicate that adenovirus mediated expression of 
vasoinhibins inhibits CNV, in-vivo and also angiogenesis (Zhou et al., 2010). Mechanisms of 
regulation of EC survival, proliferation and migration by the vasoinhibins have been 
deciphered in different studies; nevertheless, the receptors through which the mechanisms 
are mediated still remain enigmatic. Vasoinhibins regulate the EC migration and survival 
through inhibition of VEGF and bFGF stimulated MAPK activation (D'Angelo et al., 1995).  
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Mettouchi and Meneguzzi, 2006). The synergistic activation of integrins and other ECM 
binding receptors on ECs by the growth factors and cytokines leads to the activation of 
different signaling cascades mediated by the kinases, secondary messengers, transcription 
factors such as, nuclear factor kappa β (NF-κβ), hypoxia inducible factor-1 (HIF-1), and 
other enzymes such as, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) 
and metalloproteinases (MMPs) (Avraamides et al., 2008; Boosani et al., 2007; Egeblad and 
Werb, 2002; Mettouchi and Meneguzzi, 2006; Oklu et al., 2010). The transcription factors that 
are stabilized, up-regulated or expressed under hypoxia also lead to activation of different 
signaling cascades that promote effective survival and proliferation of ECs. The secretion of 
proteases such as matrix metallo-proteinases (MMPs) including collagenases and elastases, 
which degrade the collagen and elastin of vascular basement membrane (VBM) promote the 
migration of ECs. The urokinase is another proteinase, which binds to its receptors (urikanse 
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migrating ECs into tip and stalk cells is further enumerated to be regulated by Wingless 
type (Wnt)/Frizzled-Notch signaling that provides an insight about formation of functional 
capillaries in neovascular vessels (Dejana, 2010; Zerlin et al., 2008).  
The inflammatory cells that are recruited through the expression of cytokines such as 
monocyte chemo-attractant protein-1 (Ccl2/MCP-1), Chemokine (C-X-C motif) liagnd 1 
(CXCL1), macrophage inflammatory protein-1/-2 (MIP-1, MIP-2) are also considered to play 
role in CNV progression (Hendricks, 2006). Further, the intriguing stimulative role of Bruch 
membrane in promoting AMD is also being deciphered by identifying the complement 
components 3a and 5a (C3a and C5a), which lead to the up-regulation of VEGF-A (Nozaki et 
al., 2006). Thus, the orchestration of various signaling events at different stages of 
angiogenesis leads to the neovascularization. The angiogenic ECs lining the neovascular 
vessels arising due to the above factors in CNV are found to possess fenestrations and also 
organize into defective capillaries leading to the leakage of macromolecules as well as 
vascular cells into the Bruch membrane and sub-retinal spaces leading to the degeneration 
of macula of retina (Dvorak et al., 1995; Roberts and Palade, 1995).  
2. Endogenous angioinhibitors 
In addition to the angiogenic factors, which activate angiogenesis, tissues and ECM also 
possess angioinhibitors, which have the potency to inhibit the angiogenesis and thus, 
regulating the pathological angiogenesis by inhibiting the signaling mechanisms activated 
by angiogenic factors (Boosani et al., 2010; Sudhakar and Kalluri, 2010, Zhang and Ma, 
2007). Nearly, 40 endogenous angioinhibitors have been characterized and some of them are 
found in the ocular tissues or secreted into vasculature and released into ocular tissues, 
where they exhibit angio-inhibition and finally regulation of CNV (Boosani et al., 2011; 
Sudhakar and Kalluri, 2010). The significance of imbalance in the levels of endogenous 
angioinhibitors and angioactivators in regulation of vascular homeostasis can be 
summarized as in Figure 1. This significance was also ascertained by the evaluations 
showing the correlation between the decrease in specific angioinhibitors and the progression 
of CNV (Bhutto et al., 2008).  
2.1 Mechanisms of regulation of CNV by endogenous angioinhibitors 
2.1.1 Vasoinhibins 
The vasoinhibins (14-18 kDa) are antiangiogenic peptides found in the pituitary, retina and 
extrapituitary tissues. They constitute the amino terminal regions of three different 
precursors; prolactin, growth hormone and placental lactogen. Though their precursors do 
not exhibit angioinhibitory activities; vasoinhibins found in the tissues or those expressed 
using recombinant methods exhibit antiangiogenic properties (Clapp et al., 2008).  
The therapeutic potential of vasoinhibins in regulating angiogenesis in CNV and tumor 
growth was evaluated and studies indicate that adenovirus mediated expression of 
vasoinhibins inhibits CNV, in-vivo and also angiogenesis (Zhou et al., 2010). Mechanisms of 
regulation of EC survival, proliferation and migration by the vasoinhibins have been 
deciphered in different studies; nevertheless, the receptors through which the mechanisms 
are mediated still remain enigmatic. Vasoinhibins regulate the EC migration and survival 
through inhibition of VEGF and bFGF stimulated MAPK activation (D'Angelo et al., 1995).  
 





Angioinhibitor Parent molecule Receptors 
Mode of action/ Inhibition 
pathways 
Vasoinhibins Prolactin,  growth hormone Not known 
Sos/Ras/MAPK or eNOS 
/Raf/MAPK, Ca2+/ eNOS/protein 
phosphatase 2, Ras/Tiam-
1/Rac1/Pak1, Bcl-XL, NF-kβ, 
caspases  
PEDF PEDF Not known Possible apoptosis 
Arresten Collagen  IV,  
1 NC1 11 integrin, HSPG 
Raf/MEK/ERK1/2/p38-MAPK, 
HIF-1MMPs 
Canstatin Collagen IV,  2 NC1 
V3, V5 
integrins, Fas 
procaspse-8 and -9, Akt/ 
FAK/mToR, eIF-4EBP-1, 
Ribosomal S6-kinase  





eIF-4EBP1/NFB,  COX-2 signaling 
Endostatin Collagen  XVIII-NC1 
V1/51 
integrins, 






Angiostatin Plasminogen ATP synthases, αVβ3 integrin,  angiomotin 
αVβ3 integrin mediated apoptotis, 
ATP synthase 
Thrombospondins TSP 
CD36, IAP, CD47,  





Endorepellin Perlecan α2β1 integrins, lipid rafts, caveolin 
cAMP-PKA/FAK/p38-
MAPK/Hsp27, 
SHP-1, Ca2+ signaling 
Table 2. Endogenous angioinhibitors, their precursors, cell surface receptors and mode of 
action AMD/ARMD: Age related macular degeneration, Akt: protein kinase B, Bcl-XL: B-cell 
lymphoma-extra large, bFGF: basic fibroblast growth factor, Ccl2/MCP-1: chemoattractant 
protein-1, CD(CD47, CD36): cluster of differentiation, CNV: choroidal neovascularization, 
COX-2: cyclooxygenase-2, eIF-4EBP-1: eukaryotic translation initiation factor-4E binding 
protein-1, eNOS: endothelial nitric oxide synthase, ECs: endothelial cells, ECM: extracellular 
matrix, EPCs: endothelail progenitor cells, ERK1/2: extracellular signal-regulated kinase1/2, 
FAK: focal adhesion kinase, Flk-1: fetal liver kinase-1, HIF-1 hypoxia inducible factor-
1Hsp: heat shock protein, HSPG: Heparan sulfate proteoglycan, IAP: integrin associated 
protein, KDR: kinase insert domain receptor, MAPK: Mitogen activated protein kinase,  
MEK: MAPK-ERK kinase, MMPs: matrix metallo proteinases, mToR: mammalian target of 
rapamycin, NF-kβ: nuclear factor kappa β, Pak: p21 protein activated kinase, PDGF: platelet 
derived growth factor, PEDF: Pigment epithelium derived factor, PEX: noncatalytic Carboxy-
terminal hemopexin-like domain of MMP, PI3K: phosphatidyl inositol 3-kinase,  
Rac: Ras-related C3 botulinin toxin susbtrate 1, Raf: Ras activated factor, Ras: Rat sarcoma, 
RPE: retinal pigmented epithelium, SHP: Src homology region 2 domain-conatining 
phopshatase, Sos: Son of sevenless, Src: Schmidt-Ruppin A-2 sarcoma viral oncogene  
homolog, Tiam: T-lymphoma invasion and metastasis-inducing protein,  
TGF-β: transforming growth factor β, TNF: tumor necrosis factorTSP: thrombospondin, 
VBM:  vascular basement membrane, VEGF: vascular endothelial growth factor,  
Wnt: wingless-type 
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VEGF activated Sos/Ras/MAPK or eNOS/Raf/MAPK-mediated proliferative signaling and 
Ca2+/eNOS/protein phosphatase-2 mediated vascular permeability and vasodilatation 
were shown to be inhibited by the vasoinhibins (Gonzalez et al., 2004; Ziche and Morbidelli, 
2000). In addition vasoinhibins also inhibit the migration of EC stimulated by IL-1β through 
Ras/Tiam-1/Rac-1/Pak1 and promote apoptosis through conversion of Bcl-XL to 
proapoptoctic Bcl-Xs and NF-kβ mediated activation of initiator and effector caspases 
(Martini et al., 2000; Tabruyn et al., 2003).  
2.1.2 Pigment Epithelium Derived Factor (PEDF) 
Pigment epithelium derived factor (PEDF) is a 50 kDa, secreted, serpin family 
glycoprotein, first identified from the cultured fetal RPE conditioned media (Tombran-
Tink et al., 1991). PEDF accumulates in the vitreous humor and is also expressed in 
different adult tissues (Tombran-Tink et al., 1991). Addition of PEDF to the cultured 
HUVECs increased the number of TUNEL positive cells suggesting apoptotic mode of 
action of PEDF and thus, possibly preventing EC response to ischemia in-vivo (Ho et al., 
2007). The levels of PEDF were found to be decreased in Bruch membrane with 
progression of AMD and concomitant increase in VEGF levels were also identified with 
decrease in PEDF levels (Bhutto et al., 2008). Different methods of PEDF upregulation 
have been applied to investigate the effect of PEDF on CNV. Intravitreous injections of 
adenovirus expressing the PEDF and ultrasound-microbubble technique of noninvasive 
gene transfer of PEDF gene in rats exhibited significant decrease in the CNV (Gehlbach et 
al., 2003; Zhou et al., 2009). However, studies also demonstrate that PEDF at lower doses 
(90μg/ml) has negative effect on CNV whereas; higher doses (2-4 fold) can augment CNV; 
thus, indicating a strategic approach to be developed during clinical trials for CNV 
treatment with PEDF (Apte et al., 2004).  
2.1.3 Angiostatin 
Angiostatins are 38-45 kDa kringle domains derived by the protease activity of parent 
molecule plasminogen, which itself has significant role in activation of fibrinogen and blood 
clotting (Hayashi et al., 2008). Some of the angiostatin peptide derivates exhibit anti-
angiogenic properties including inhibition of EC proliferation, tube formation and 
migration. The application of angiostatins in regulating CNV of AMD was evaluated by the 
expression of the angiostatins in-vivo, using viral vectors (Lai et al., 2001). Angiostatins bind 
to ATP synthases on the surface of ECs leading to their apoptotic death (Burwick et al., 2005; 
Tarui et al., 2001). Further V3 integrin and angiomotin are also shown to bind angiostatin 
and induce apoptosis (Burwick et al., 2005; Tarui et al., 2001).  
2.1.4 Thrombospondins 
Thrombospondins (TSPs) are secreted ECM glycoproteins playing key role in the cellular 
and ECM interactions (Bornstein, 2001; Lawler, 2000). The NH2-terminal peptides derived 
from the TSPs, by the action of different proteases are identified to possess angioinhibitory 
properties. TSP-1 and TSP-2 are trimeric globular domain subunits (145 kDa) categorized 
into subgroup-A and subgroup-B consists of TSP’s 3-5, which are pentameric subunits (110 
kDa) (Bornstein, 2009). TSP-1 was the first identified ECM derived endogenous 
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PEDF PEDF Not known Possible apoptosis 
Arresten Collagen  IV,  
1 NC1 11 integrin, HSPG 
Raf/MEK/ERK1/2/p38-MAPK, 
HIF-1MMPs 
Canstatin Collagen IV,  2 NC1 
V3, V5 
integrins, Fas 
procaspse-8 and -9, Akt/ 
FAK/mToR, eIF-4EBP-1, 
Ribosomal S6-kinase  





eIF-4EBP1/NFB,  COX-2 signaling 
Endostatin Collagen  XVIII-NC1 
V1/51 
integrins, 






Angiostatin Plasminogen ATP synthases, αVβ3 integrin,  angiomotin 
αVβ3 integrin mediated apoptotis, 
ATP synthase 
Thrombospondins TSP 
CD36, IAP, CD47,  





Endorepellin Perlecan α2β1 integrins, lipid rafts, caveolin 
cAMP-PKA/FAK/p38-
MAPK/Hsp27, 
SHP-1, Ca2+ signaling 
Table 2. Endogenous angioinhibitors, their precursors, cell surface receptors and mode of 
action AMD/ARMD: Age related macular degeneration, Akt: protein kinase B, Bcl-XL: B-cell 
lymphoma-extra large, bFGF: basic fibroblast growth factor, Ccl2/MCP-1: chemoattractant 
protein-1, CD(CD47, CD36): cluster of differentiation, CNV: choroidal neovascularization, 
COX-2: cyclooxygenase-2, eIF-4EBP-1: eukaryotic translation initiation factor-4E binding 
protein-1, eNOS: endothelial nitric oxide synthase, ECs: endothelial cells, ECM: extracellular 
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derived growth factor, PEDF: Pigment epithelium derived factor, PEX: noncatalytic Carboxy-
terminal hemopexin-like domain of MMP, PI3K: phosphatidyl inositol 3-kinase,  
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RPE: retinal pigmented epithelium, SHP: Src homology region 2 domain-conatining 
phopshatase, Sos: Son of sevenless, Src: Schmidt-Ruppin A-2 sarcoma viral oncogene  
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VBM:  vascular basement membrane, VEGF: vascular endothelial growth factor,  
Wnt: wingless-type 
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VEGF activated Sos/Ras/MAPK or eNOS/Raf/MAPK-mediated proliferative signaling and 
Ca2+/eNOS/protein phosphatase-2 mediated vascular permeability and vasodilatation 
were shown to be inhibited by the vasoinhibins (Gonzalez et al., 2004; Ziche and Morbidelli, 
2000). In addition vasoinhibins also inhibit the migration of EC stimulated by IL-1β through 
Ras/Tiam-1/Rac-1/Pak1 and promote apoptosis through conversion of Bcl-XL to 
proapoptoctic Bcl-Xs and NF-kβ mediated activation of initiator and effector caspases 
(Martini et al., 2000; Tabruyn et al., 2003).  
2.1.2 Pigment Epithelium Derived Factor (PEDF) 
Pigment epithelium derived factor (PEDF) is a 50 kDa, secreted, serpin family 
glycoprotein, first identified from the cultured fetal RPE conditioned media (Tombran-
Tink et al., 1991). PEDF accumulates in the vitreous humor and is also expressed in 
different adult tissues (Tombran-Tink et al., 1991). Addition of PEDF to the cultured 
HUVECs increased the number of TUNEL positive cells suggesting apoptotic mode of 
action of PEDF and thus, possibly preventing EC response to ischemia in-vivo (Ho et al., 
2007). The levels of PEDF were found to be decreased in Bruch membrane with 
progression of AMD and concomitant increase in VEGF levels were also identified with 
decrease in PEDF levels (Bhutto et al., 2008). Different methods of PEDF upregulation 
have been applied to investigate the effect of PEDF on CNV. Intravitreous injections of 
adenovirus expressing the PEDF and ultrasound-microbubble technique of noninvasive 
gene transfer of PEDF gene in rats exhibited significant decrease in the CNV (Gehlbach et 
al., 2003; Zhou et al., 2009). However, studies also demonstrate that PEDF at lower doses 
(90μg/ml) has negative effect on CNV whereas; higher doses (2-4 fold) can augment CNV; 
thus, indicating a strategic approach to be developed during clinical trials for CNV 
treatment with PEDF (Apte et al., 2004).  
2.1.3 Angiostatin 
Angiostatins are 38-45 kDa kringle domains derived by the protease activity of parent 
molecule plasminogen, which itself has significant role in activation of fibrinogen and blood 
clotting (Hayashi et al., 2008). Some of the angiostatin peptide derivates exhibit anti-
angiogenic properties including inhibition of EC proliferation, tube formation and 
migration. The application of angiostatins in regulating CNV of AMD was evaluated by the 
expression of the angiostatins in-vivo, using viral vectors (Lai et al., 2001). Angiostatins bind 
to ATP synthases on the surface of ECs leading to their apoptotic death (Burwick et al., 2005; 
Tarui et al., 2001). Further V3 integrin and angiomotin are also shown to bind angiostatin 
and induce apoptosis (Burwick et al., 2005; Tarui et al., 2001).  
2.1.4 Thrombospondins 
Thrombospondins (TSPs) are secreted ECM glycoproteins playing key role in the cellular 
and ECM interactions (Bornstein, 2001; Lawler, 2000). The NH2-terminal peptides derived 
from the TSPs, by the action of different proteases are identified to possess angioinhibitory 
properties. TSP-1 and TSP-2 are trimeric globular domain subunits (145 kDa) categorized 
into subgroup-A and subgroup-B consists of TSP’s 3-5, which are pentameric subunits (110 
kDa) (Bornstein, 2009). TSP-1 was the first identified ECM derived endogenous 
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angioinhibitor from many normal tissues and produced by a variety of cells including 
platelets, megakaryocytes, epithelial, endothelial and stromal cells (Bornstein, 2009). TSP-1 
is secreted by the retinal-pigmented epithelium (RPE) and regulates angiogenesis in normal 
eye (Miyajima-Uchida et al., 2000). Immunolocalization studies showed decrease in the 
levels of TSP in the chorio-capillaries and the Bruch membrane of AMD samples (Bhutto et 
al., 2008). Wispostatin-1 (WISP-1) repeat derived peptide from TSP-1 was shown to inhibit 
the CNV in LASER induced CNV mice models (Cano Mdel et al., 2009). TSP-1 induces 
apoptosis in ECs through CD36 and integrin associated protein (IAP)/Src-family protein 
kinases/Caspase-3/p38 MAPK signaling (Dawson et al., 1997). In addition TSP-1 can also 
bind to different integrins, including CD47 and heparin sulfated proteoglycans (Kaur et al., 
2011). Thus the significance of TSPs in regulation of CNV have been evaluated through 
detection of endogenous levels in pathological tissues and also by evaluating the effects of 
TSPs both in vitro and in vivo. 
2.1.5 Arresten   
Arresten [1(IV)NC1], is the 26 kDa collagen type IV, 1 chain derived non-collagenous 
domain, which functions via binding to α1β1 integrin and heparan sulfate proteolgycans, 
regulating bFGF and VEGF stimulated activation of ECs (Boosani and Sudhakar, 2006; 
Colorado et al., 2000; Sudhakar et al., 2005). It inhibits the survival of mouse lung 
endothelial cells through inhibition of FAK phopshorylation in AKT independent manner 
(Sudhakar et al., 2005). FAK inhibition by arresten via 11 integrin leads to inhibition of 
downstream Raf/MEK/ERK1/2/p38 MAPK signaling and HIF-1 expression (Figure 2). 
Inhibition of HIF-1 by arresten is critical in preventing hypoxic survival of ECs through 
VEGF regulation (Sudhakar et al., 2005). Arresten inhibited VEGF-mediated angiogenesis by 
promoting apoptosis, caspase-3/PARP activation and negatively impacting FAK/p38-
MAPK phosphorylation, Bcl-2 and Bcl-xL expressions leading to mouse retinal endothelial 
cell (MREC) death (Boosani et al., 2009). In addition angioinhibitory activity of arresten was 
found to inhibit bFGF induced proliferation of MREC in-vitro in a dose dependent manner. 
It also inhibited the bFGF-induced migration of MREC mediated by MMP-2 activity but not 
the expression levels of MMP-2 (Boosani et al., 2010). Thus, arresten was shown to effect the 
proliferation and migration of choroidal endothelial cells and regulate CNV of AMD. The 
endothelial specific inhibitory actions of arresten may be of benefit in the treatment of a 
variety of eye diseases with a neovascular component. 
2.1.6 Canstatin 
It is the 24 kDa collagen type IV, 2 derived non-collagenous domain [2(IV)NC1], which 
binds to the V3 and V5 integrins and  inhibits EC proliferation, migration  and tube 
formation by enhancing apoptosis in these cells (Magnon et al., 2005; Magnon et al., 2007; 
Petitclerc et al., 2000; Roth et al., 2005). The antiangiogenic efficacy of canstatin in regulating 
the neovascularization of cornea was also evaluated using the recombinant canstatin in 
alkali burn induced neovascularization study (Lima et al., 2006; Wang et al., 2011). Cantstain 
was shown to induce apoptosis through the induction of Fas-ligand, activation of procaspse-
8 and -9 cleavage, reduction in membrane potential, inhibition of Akt, FAK, mToR, eIF-
4E/4E-BP1 and ribosomal S6-kinase phosphorylations, in cultured HUVECs (Figure 2) 
(Panka and Mier, 2003).  
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Fig. 2. Schematic illustration of distinct angioinhibitory signaling mediated by different 
extracellular matrix (ECM) reloaded molecules. Tumstatin, arresten, canstatin and 
endostatin interact with V3/31, 11, V3/V5 and 51 integrins respectively, to 
inhibit the phosphorylation of focal adhesion kinase (FAK). Tumstatin: It binds to V3 and 
31 integrins and inhibits the pathway that includes phosphorylation of FAK, PI3-K, Akt, 
mTOR, 4E-BP1 and eIF4E to decrease endothelial cell protein synthesis and proliferation. In 
addition tumstatin also inhibits NFB mediated signaling in hypoxic conditions leading to 
the inhibition of COX-2, VEGF and bFGF expressions, resulting in inhibition of hypoxic 
tumor angiogenesis. Arresten: It binds to 11 integrin and inhibit phosphorylation FAK, 
causes inhibition of Ras, Raf, extra cellular signal related kinase 1 (ERK1) and p38 MAPK 
pathways that leads to inhibition of HIF-1and VEGF expression resulting in inhibition of 
endothelial cell migration, proliferation and tube formation. In addition arresten initiates 
two apoptotic pathways, involving activation of caspase-9 and -8, leading to activation of 
caspase-3 and PARP cleavage. (a) Arresten activates caspase-3 directly through inhibition of 
FAK/p38-MAPK/Bcl-2/Bcl-xL and activation of caspase-9; (b) Integrin 11 cross talk with 
Fas-L through mitochondrial pathway and leads to activation of caspase-8 and-3 in 
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proliferating endothelial cells. Canstatin: It binds to V3/V5 integrins and inhibits two 
apoptotic pathways, involving activation of caspase-8 and casoase-9, leading to activation of 
caspase-3. Canstatin activates procaspase-9 not only through inhibition of the 
FAK/PI3K/AKT pathways but also by integrins cross talking mitochondrial pathway 
through Fas-L dependent caspase-8 activation leads to endothelial cell apoptosis. CM 
represents cell membrane. Endostatin: It binds to 51 integrin and inhibit phosphorylation 
FAK, causes inhibition of Ras, Raf, extra cellular signal related kinase-1 (ERK1) and p38 
MAPK pathways that leads to inhibition of endothelial cell migration and tube formation.  
2.1.7 Tumstatin 
Tumstatin [3(IV)NC1], is a 28 kDa collagen type IV, 3 chain derived non-collagenous 
domain with anti-angiogenic and proapoptotic activities. It binds to the CD47/IAP, V3, 
31 and 61 integrins and inhibits the signaling cascade mediated by FAK, Akt, 
PI3K/mTOR/eIF-4E/4E-BP1 and NFκB/COX-2 (Boosani et al., 2007; Hamano et al., 2003; 
Maeshima et al., 2002; Monboisse et al., 1994; Sudhakar et al., 2003). Inhibition of eIF-4E/4E-
BP1 by tumstatin leads to the regulation of cap dependent translational level of genes, 
whereas inhibition of transcriptional factor signaling such as NFκB leads to regulation of 
genes such as COX-2 at transcriptional level (Figure 2) (Boosani et al., 2007). Thus, tumstatin 
exhibits gene regulation in endothelail cell-specific and integrin-dependent manner. 
Angioinhibitory effect of tumstatin has been evaluated in regulation of CNV in mice 
(Boosani et al., 2011). Recombinant tumstatin regulated tube formation by mouse corneal 
endothelial cells (MCECs) in-vitro and adenoviral mediated expression of tumstatin in-vivo 
in mice has shown reduction in CNV (Boosani et al., 2011; Gunda et al., 2011). 
2.1.8 Endostatin 
Endostatin is the partial 20-kDa fragment of collagen type XVIII, carboxy terminal non- 
collagenous domain, derived from the parent collagen by proteolytic cleavage activities of 
elastase and cathepsin-L (Felbor et al., 2000). Endostatin is found in normal circulation 
enabling it to be utilized as an effective angioinhibitor without toxic effects (Fukai et al., 
2002). Lower levels of endostatin have been recorded in CNV samples compared to the 
healthy donor eyes and within the tissues of progressive AMD (Bhutto et al., 2008; Fukai et 
al., 2002). Deletion of endostatin or collagen type XVIII massively up-regulates LASER 
induced CNV; where as administration of physiological concentrations of endostatin was 
able to inhibit such CNV in these mice (Marneros et al., 2007). Endostatin also down 
regulates the expression of VEGF in experimental CNV rat models (Takahashi et al., 2003). 
These observations along with the evidence of inhibition of CNV with intravenous injection 
of adenoviral vectors that express secretable endostatin, confirm the significance of 
endostatin in regulation of CNV (Mori et al., 2001; Wickstrom et al., 2003).  
Endostatin elicits the anti-proliferative and anti-migratory effects by binding to different EC 
surface molecules and regulating the signaling cascades (Faye et al., 2009). Recombinant 
endostatin binds to V integrin as shown in human endothelial cells (Rehn et al., 2001). 
Further studies have also shown localization of endostatin in the lipid rafts and association 
with caveolae (Wickstrom et al., 2002; Wickstrom et al., 2003). Surface plasmon resonance 
assays characterized the binding of endostatin to both V1 integrins and the heparin 
Regulation of Angiogenesis in Choroidal  
Neovascularization of Age Related Macular Degeneration by Endogenous Angioinhibitors 
 
419 
sulfates and also localization to the lipid rafts (Ricard-Blum et al., 2004). In-vitro assays using 
ECs also showed the co-localization of endostatin with 51 integrin, actin stress fibers, 
membrane anchor protein and caveolin-1, which enumerates the interaction of endostatin 
with caveolae, inhibiting EC migration through the disassembly of actin stress fibers/focal 
adhesions, activation of Src and impaired fibronectin deposition by ECs in response to bFGF 
(Wickstrom et al., 2002; Wickstrom et al., 2003; Sudhakar et al., 2003). Binding of endostatin 
with integrins also down-regulates the activity of RhoA-GTPase and inhibits signaling 
pathways mediated by small kinases of the Ras and Raf families (Ricard-Blum et al., 2004). 
In addition, binding to the KDR/Flk-1, endostatin inhibits the VEGF-induced tyrosine 
phosphorylation of KDR/Flk-1 and activation of ERK, p38 MAPK, and p125FAK in 
HUVECs (Kim et al., 2002; Sudhakar et al., 2003). Further signaling cascades regulated by 
the endostatin are being identified, which are mediated by activator protein 1 (Id), HIF1, 
ephrin, tumor necrosis factor- (TNF), nuclear factor-B (NFB), coagulation cascades, 
adhesion molecules and Wnt, which indicate the potential role of endostatin as an 
endogenous angioinhibitor (Nyberg et al., 2005) (Figure 2).  
2.2 Scope for endogenous angioinhibitors in CNV treatment 
Current modalities of treatment for the CNV in AMD include the regulation of angiogenesis 
as angiogenesis being one of the pathological factors of neovascularization. The therapies 
such as LASER photocoagulation, photodynamic therapy and anti-VEGF therapies using 
Macugen or Lucentis, that are currently being applied to regulate the CNV have their own 
constraints such as development of lesions, loss of acuity in vision and frequent 
administration, respectively (Gallemore and Boyer, 2006). Alternative strategies for the 
treatment of CNV in AMD are therefore being developed in which the specific targeting on 
angiogenesis can be possible. Endogenous angioinhibitors are considered as one of the area 
to be explored in this arena to include them in regimens of complementary treatments for 
the regulation of CNV (Chappelow and Kaiser, 2008; Do, 2009). The signaling cascades 
regulated by some of endogenous angioinhibitors have been identified (Table 2 and Figure 
2), which enabled the application of those inhibitors in CNV. 
3. Conclusions  
The cellular, extracellular milieu and genetic factors responsible for the neovascularization 
arising in AMD are being deciphered with emphasis on identifying those factors that play a 
key role in the inception and progression of CNV. In this scenario, different etiological 
factors have been identified which regulate angiogenesis, effecting both extracellular milieu 
and intracellular angiogenic signaling pathways. Identification of the signaling cascades 
leading to the pathological angiogenesis in CNV has further lead to the possibility of 
regulating CNV, by focusing on signaling pathways as one of the targets. Application of 
endogenous angioinhibitors has proven as a promising strategy in this scenario of inhibiting 
angiogeneic pathways that are identified in CNV. The inhibitors such as vasoinhibins, 
PEDF, angiostatin, endostatin, tumstatin, canstatin and arresten that have been so far 
evaluated for regulation of CNV have not only shown promising evidence of CNV 
regulation, but also provided new strategies for inhibiting CNV through differential mode 
of actions. Such variation exhibited by different endogenous angioinhibitors can be 
beneficial in targeting CNV using different combinations of these inhibitors. It can be 
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HUVECs (Kim et al., 2002; Sudhakar et al., 2003). Further signaling cascades regulated by 
the endostatin are being identified, which are mediated by activator protein 1 (Id), HIF1, 
ephrin, tumor necrosis factor- (TNF), nuclear factor-B (NFB), coagulation cascades, 
adhesion molecules and Wnt, which indicate the potential role of endostatin as an 
endogenous angioinhibitor (Nyberg et al., 2005) (Figure 2).  
2.2 Scope for endogenous angioinhibitors in CNV treatment 
Current modalities of treatment for the CNV in AMD include the regulation of angiogenesis 
as angiogenesis being one of the pathological factors of neovascularization. The therapies 
such as LASER photocoagulation, photodynamic therapy and anti-VEGF therapies using 
Macugen or Lucentis, that are currently being applied to regulate the CNV have their own 
constraints such as development of lesions, loss of acuity in vision and frequent 
administration, respectively (Gallemore and Boyer, 2006). Alternative strategies for the 
treatment of CNV in AMD are therefore being developed in which the specific targeting on 
angiogenesis can be possible. Endogenous angioinhibitors are considered as one of the area 
to be explored in this arena to include them in regimens of complementary treatments for 
the regulation of CNV (Chappelow and Kaiser, 2008; Do, 2009). The signaling cascades 
regulated by some of endogenous angioinhibitors have been identified (Table 2 and Figure 
2), which enabled the application of those inhibitors in CNV. 
3. Conclusions  
The cellular, extracellular milieu and genetic factors responsible for the neovascularization 
arising in AMD are being deciphered with emphasis on identifying those factors that play a 
key role in the inception and progression of CNV. In this scenario, different etiological 
factors have been identified which regulate angiogenesis, effecting both extracellular milieu 
and intracellular angiogenic signaling pathways. Identification of the signaling cascades 
leading to the pathological angiogenesis in CNV has further lead to the possibility of 
regulating CNV, by focusing on signaling pathways as one of the targets. Application of 
endogenous angioinhibitors has proven as a promising strategy in this scenario of inhibiting 
angiogeneic pathways that are identified in CNV. The inhibitors such as vasoinhibins, 
PEDF, angiostatin, endostatin, tumstatin, canstatin and arresten that have been so far 
evaluated for regulation of CNV have not only shown promising evidence of CNV 
regulation, but also provided new strategies for inhibiting CNV through differential mode 
of actions. Such variation exhibited by different endogenous angioinhibitors can be 
beneficial in targeting CNV using different combinations of these inhibitors. It can be 
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realized that these naturally occurring inhibitors can pose low immune reactions and thus, 
an efficient way of regulating diseases. Further, clinical studies using individual and 
combinations of endogenous angioinhibitors, included in different regimens along with 
current therapies of CNV would elaborate the application of endogenous angioinhibitors for 
regulating CNV of AMD.  
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1. Introduction  
Retinal pigment epithelium (RPE) is a single layer of epithelial cells lined between the 
neurosensory retina and choriocapillaris. It is part of the blood-retinal barrier and is a 
central component of the visual phototransduction pathway. RPE cells regenerate 11-cis-
retinal by RPE65 isomerase and its related enzymes and chaperones (Moiseyev et al., 2006; 
Xue et al., 2004). They are professional phagocytes and are responsible for the clearance of 
daily shed photoreceptor outer segments (POS) (Young, 1967; Young & Bok, 1969). The 
multi-step process of phagocytosis includes receptor-mediated binding of POS to the RPE 
(Finnemann et al., 1997), internalization (Feng et al., 2002; Finnemann & Silverstein, 2001), 
transport to lysosome and degradation. The importance of RPE phagocytosis has been 
clearly illustrated by the Royal College of Surgeons (RCS) rats, which carry a mutation in 
Mertk gene (D'Cruz et al., 2000). MERTK is a membrane-associated receptor tyrosine kinase 
and is activated upon binding of POS to the RPE (Feng et al. 2002). In RCS rats, loss-of-
function mutation of Mertk causes defects in phagocytosis and consequently these animals 
develop inherited retinal dystrophy and photoreceptor apoptosis (Tso et al., 1994). In 
addition to their roles in the visual cycle, RPE cells provide vital support for the structure 
and function of the outer retina. They transport ions, water and nutrients between choroidal 
blood supply and the retina, and synthesize melanin which absorbs light and shields the 
retina. RPE-produced growth factors, such as vascular endothelial growth factor (VEGF), are 
indispensable for the choroidal vasculature (Saint-Geniez et al., 2009). 
Degeneration of the RPE with aging is an initiating event in age-related macular 
degeneration (AMD), a major cause of blindness in elderly people. Approximately 11% of 
persons between ages 65 and 74 have AMD, with prevalence rates rising to 30% in 
individuals at age 75 or older (Lee et al., 2003). Vision loss in AMD occurs through 
photoreceptor loss in the macula, the central area of the retina, and results either from a 
gradual “geographic atrophy” of the RPE (dry or atrophic disease) or from leakage and/or 
bleeding from choroidal neovascularization (CNV) (wet or neovascular disease). During 
CNV, blood vessels break through Bruch’s membrane, leading to rapid loss of central vision 
in many cases. In recent years anti-VEGF agents have achieved unprecedented success in 
preserving visual acuity in patients with CNV (Brown et al., 2006; Rosenfeld et al., 2006; 
Galbinur et al., 2009). Detailed clinical aspects of wet AMD and anti-VEGF therapy are 
covered by other chapters of this book. 
 
Advances in Ophthalmology 
 
426 
Zhou, S. Y., Xie, Z. L., Xiao, O., Yang, X. R., Heng, B. C., and Sato, Y. (2010). Inhibition of 
mouse alkali burn induced-corneal neovascularization by recombinant adenovirus 
encoding human vasohibin-1. Mol Vis 16, 1389-1398. 
Zhou, X. Y., Liao, Q., Pu, Y. M., Tang, Y. Q., Gong, X., Li, J., Xu, Y., and Wang, Z. G. (2009). 
Ultrasound-mediated microbubble delivery of pigment epithelium-derived factor 
gene into retina inhibits choroidal neovascularization. Chin Med J (Engl) 122, 2711-
2717. 
Ziche, M., and Morbidelli, L. (2000). Nitric oxide and angiogenesis. J Neurooncol 50, 139-148. 
24 
NRF2 and Age-Dependent RPE Degeneration 
Yan Chen, Zhenyang Zhao,  
Paul Sternberg and Jiyang Cai  
Vanderbilt Eye Institute,  
Vanderbilt University Medical Center, Nashville, TN,  
USA 
1. Introduction  
Retinal pigment epithelium (RPE) is a single layer of epithelial cells lined between the 
neurosensory retina and choriocapillaris. It is part of the blood-retinal barrier and is a 
central component of the visual phototransduction pathway. RPE cells regenerate 11-cis-
retinal by RPE65 isomerase and its related enzymes and chaperones (Moiseyev et al., 2006; 
Xue et al., 2004). They are professional phagocytes and are responsible for the clearance of 
daily shed photoreceptor outer segments (POS) (Young, 1967; Young & Bok, 1969). The 
multi-step process of phagocytosis includes receptor-mediated binding of POS to the RPE 
(Finnemann et al., 1997), internalization (Feng et al., 2002; Finnemann & Silverstein, 2001), 
transport to lysosome and degradation. The importance of RPE phagocytosis has been 
clearly illustrated by the Royal College of Surgeons (RCS) rats, which carry a mutation in 
Mertk gene (D'Cruz et al., 2000). MERTK is a membrane-associated receptor tyrosine kinase 
and is activated upon binding of POS to the RPE (Feng et al. 2002). In RCS rats, loss-of-
function mutation of Mertk causes defects in phagocytosis and consequently these animals 
develop inherited retinal dystrophy and photoreceptor apoptosis (Tso et al., 1994). In 
addition to their roles in the visual cycle, RPE cells provide vital support for the structure 
and function of the outer retina. They transport ions, water and nutrients between choroidal 
blood supply and the retina, and synthesize melanin which absorbs light and shields the 
retina. RPE-produced growth factors, such as vascular endothelial growth factor (VEGF), are 
indispensable for the choroidal vasculature (Saint-Geniez et al., 2009). 
Degeneration of the RPE with aging is an initiating event in age-related macular 
degeneration (AMD), a major cause of blindness in elderly people. Approximately 11% of 
persons between ages 65 and 74 have AMD, with prevalence rates rising to 30% in 
individuals at age 75 or older (Lee et al., 2003). Vision loss in AMD occurs through 
photoreceptor loss in the macula, the central area of the retina, and results either from a 
gradual “geographic atrophy” of the RPE (dry or atrophic disease) or from leakage and/or 
bleeding from choroidal neovascularization (CNV) (wet or neovascular disease). During 
CNV, blood vessels break through Bruch’s membrane, leading to rapid loss of central vision 
in many cases. In recent years anti-VEGF agents have achieved unprecedented success in 
preserving visual acuity in patients with CNV (Brown et al., 2006; Rosenfeld et al., 2006; 
Galbinur et al., 2009). Detailed clinical aspects of wet AMD and anti-VEGF therapy are 
covered by other chapters of this book. 
 
Advances in Ophthalmology 
 
428 
The genetic and biochemical mechanisms of RPE degeneration in dry AMD, however, 
remain largely unknown. Several hypothetical models have been proposed, including 
accumulation of lipofuscin and its bisretinoid fluorophore (Sparrow et al., 2003; Zhou et al., 
2006), iron overload (Dunaief, 2006; Hahn et al., 2004), autoimmune response (Hollyfield et 
al., 2008) and exposure to double strand RNA (Ambati, 2011; Kaneko et al., 2011). All of 
them have suggested clinical associations with AMD and their causal relationships to the 
disease have been demonstrated by respective animal models (Ramkumar et al., 2010). 
Oxidative stress is a common mechanism underlying these diversified pathological 
processes. Photooxidation of the bisretinoids can produce singlet oxygen and release 
methylglyoxal to form advanced glycation end product (Wu et al., 2010). Iron overload 
increased isoprostane, a marker of lipid peroxidation, in the RPE/choroid 
(Hadziahmetovic et al., 2008). Mice immunized with serum albumin conjugated with 
carboxyethylpyrrole, an oxidation product of docosahexaenoic acid, developed signs of 
RPE degeneration and deposition of complement proteins in the Bruch’s membrane 
(Hollyfield et al., 2008). Oxidative stress can downregulate DICER1, a RNA processing 
enzyme whose deficiency was shown to cause Alu RNA-induced cytotoxicity and RPE 
apoptosis (Kaneko et al., 2011). 
Results from earlier clinical and laboratory studies also support the contributing roles of 
oxidative stress to AMD. Smoking is the strongest environmental risk factor of AMD (Cano 
et al., 2010; Smith et al., 2001) and has been clearly associated with oxidative stress (DeBlack, 
2003; Mitchell et al., 2002; Pryor et al., 1983; Smith et al., 2001). A number of interventional 
studies showed that antioxidant supplementation had protective effects against 
development of AMD or limiting its progression. Experimental animals fed with diets 
supplemented with antioxidants demonstrated an increased resistance to retinal 
degeneration (Ham et al., 1984; Organisciak et al., 1985; Tso et al., 1984). Results from the 
Age-Related Eye Disease Study (AREDS) showed that supplemental antioxidants (vitamin 
C, vitamin E and beta carotene) and zinc can decrease the risk of progression from 
intermediate AMD to advanced AMD by 25% (AREDS 2000 & 2001). Taken together, the 
findings from the research of the past two decades suggest that AMD is a multifactorial 
disease, with oxidative stress viewed as a common mechanism involved in the gene-
environmental interaction of its etiololgy. 
Oxidative stress is due to an imbalance between the generation of reactive oxygen species 
and their clearance by antioxidant systems. The RPE has powerful endogenous antioxidant 
capacity to overcome the high level of oxidative stress, which is caused by both focal light 
exposure and high metabolic rate of the retina. In addition to utilizing direct radical 
scavengers such as -carotene, ascorbic acid and -tocopherol, RPE cells have an elaborate 
enzymatic antioxidant system that can prevent and repair oxidative injury. Nuclear factor 
erythroid 2-related factor 2 (NRF2) is a master regulator of cellular antioxidant and 
detoxification responses (Kensler et al., 2007). We and others have shown previously that 
elevating the transcriptional activity of NRF2 can protect against oxidative injury to the RPE; 
while mice that are deficient of NRF2 developed pathological features similar to human 
AMD (Zhao et al., 2011; Cano et al., 2010). Oral zinc supplementation, which was used in the 
AREDS to slow AMD progression, can activate NRF2-dependent antioxidant system in the 
RPE (Ha et al., 2006). More recently, a newer class of NRF2 inducers, which are based on 
synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) and its 
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derivatives, have achieved potent protection in various models of retinal damage (Pitha-
Rowe et al. 2009). In this chapter we will review past and recent literature reports, based on 
cell culture, animal models and human clinical studies, to address how NRF2 regulates RPE 
function both in vitro and in vivo. 
2. NRF2-dependent antioxidant defense 
NRF2 is a transcription factor that controls the expression of phase 2 detoxification genes. It 
heterodimerizes with members of the Maf family of transcription factors and binds to the 
cis-acting antioxidant response element in the promoter regions of various phase 2 genes 
(Katsuoka et al., 2005; Motohashi et al., 2004). The latter encode a group of enzymes, such as 
glutamate-cysteine ligase, glutathione S-transferase, glutathione peroxidase, heme 
oxygenase, NAD(P)H:quinone reductase and glutamate-cysteine exchanger, which are 
essential for detoxification of xenobiotics and endogenous reactive intermediates (Kensler et 
al., 2007; Wakabayashi et al. 2010). NRF2-deficient mice showed increased sensitivity to a 
variety of pharmacological and environmental toxicants (Kensler et al., 2007; Rangasamy et 
al., 2004). The protective effects of NRF2 inducers have been tested in a number of models of 
human diseases, including cancer, neurodegeneration, cardiovascular disease, and liver and 
lung injury (Kensler et al., 2007; Wakabayashi et al., 2010). 
Activation of NRF2 is subjected to multiple levels of regulation. Under basal conditions, 
NRF2 is sequestered by its inhibitor protein, Keap1, and is targeted for Cullin 3/Rbx1-
mediated ubiquitination and degradation (Cullinan et al., 2004; Furukawa & Xiong, 2005; 
Kobayashi et al., 2004). Upon conditions of oxidative stress or exposure to electrophilic 
compounds, NRF2 protein can be liberated from Keap1 and will translocate into nucleus to 
mediate gene trasncription. As illustrated in Fig. 1, there are six Neh (NRF2 ECH homology) 
domains that are responsible for most of the functions of NRF2. The Neh domains show 
amino acid sequence homology conserved between different species including human, 
rodents and chicken (McMahon et al., 2004; Zhang et al., 2007). 
 
 
Fig. 1. Illustration of the Neh domains of the NRF2 protein. Human NRF2 is a polypeptide 
of 605 amino acids and contains 6 Neh domains. The relative positions of each domain and 
their putative functions are listed. Neh1 contains the signature cap-n-collar motif which is a 
highly conserved basic leucine zipper domain for DNA binding. The nuclear localization 
and export signals are present in both Neh6 and Neh1. 
3. NRF2-mediated protection in cultured RPE cells 
Compounds that promote the nuclear translocation of Nrf2 and elevate its transcriptional 
activity can protect against oxidative injury in cultured RPE cells. In 2001, Talalay and 
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colleagues first reported that sulforaphane could prevent RPE cell death caused by 
treatments with menadione, t-butyl hydroperoxide, 4-hydroxynonenal and peroxynitrite 
(Gao et al., 2001). Since then numerous other studies reported the protective effects of a wide 
range of structurally-different NRF2 inducers including isothiocyanates (sulforaphane) (Gao 
& Talalay, 2004), polyphenols (curcumin, resveratrol and flavonoids) (Alex et al., 2010; 
Johnson et al., 2009; Mandal et al., 2009), 1,2,dithiole-3-thiones (oltipraz) (Nelson et al., 2002), 
zinc (Ha et al., 2006) or triterpenoids (Pitha-Rowe et al., 2009). Many of them are naturally 
occurring compounds present in fruits and vegetables, making them ideal for dietary 
supplementation. Some of the compounds have either gone through human clinical trials or 
are currently used for other applications. For instances, zinc was used in the AREDS 
supplementation either alone or with antioxidant vitamins. Oltipraz, a dithiole derivate, is 
used in treating schistosomiasis and cancer chemoprevention (Jacobson et al., 1997). A 
common mechanism underlying the antioxidant and detoxification functions of NRF2 is to 




Fig. 2. Structure of glutathione. The -glutamylcysteine is formed by a peptide bond between 
the carboxylate group of glutamate and animo group of cysteine. The sulfhydryl group of 
cysteine is responsible for the antioxidant function of the tripeptide. 
GSH is a tripeptide consisted of glutamate, cysteine and glycine. It contains a unique 
peptide bond between the amine group of cysteine and the carboxyl group of the glutamate 
side chain so that it is much more resistant to degradation by peptidase (Fig. 2). The 
sulfhydryl group of cysteine of GSH can be used by glutathione S-transferase to conjugate 
electrophilic centers on a wide variety of substrates (Pool-Zobel et al., 2005). GSH is also 
used by glutathione peroxidase to reduce lipid hydroperoxides and hydrogen peroxide to 
alcohols and water, respectively. The glutamate cysteine ligase (GCL) is the rate-limiting 
enzyme of GSH synthesis. It generates -glutamylcysteine from glutamate and cysteine. 
NRF2 inducers can elevate the mRNA levels of the catalytic and modulatory subunits of 
GCL. Cystine uptake by the RPE is mediated by a sodium independent, cystine/glutamate 
exchanger (Bridges et al., 2001; Ishii et al., 1992). The transporter is consisted of two 
subunits, xCT as the light chain and 4F2hc as the heavy chain (Wagner et al., 2001). NRF2 
controls the expression of xCT gene (Sato et al., 1999). In xCT knock out mice, the plasma 
cystine concentration almost doubled, resulted from decreased tissue uptake (Sasaki et al., 
2002). The xCT-/- mice showed more several renal injury caused by ischemia-reperfusion 
(Shibasaki et al., 2009). Thus, NRF2 inducers can increase both the rate of GSH synthesis and 
cellular concentration of its amino acid precursor. 
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Monitoring the RPE glutathione content is a reliable assay for initial screening of model 
compounds designed to activate NRF2. For instance, RPE cells pretreated with oltipraz 
showed increased total and mitochondrial GSH. At 50 M, oltipraz increased total cellular 
GSH by 18% and mitochondrial GSH by 50%, and achieved significant protection against 
tert-butylhydroperoxide-induced RPE cell death (Nelson et al., 2002). Similar results were 
obtained from cells pretreated with dimethylfumarate (DMF) for 24 hours (Nelson et al., 
1999). However, when the time course of the DMF was evaluated, a transient decrease in 
GSH levels was found that preceded the increase noted at later time points. Compared to 
vehicle-treated control cells, cells pretreated with DMF for 3 hours showed a significant 
reduction in viability when further challenged by peroxide (Nelson et al, 1999). Thus, the 
initial decrease of GSH after DMF treatment rendered the RPE cells more sensitive to 
oxidative injury, although it can subsequently lead to a feedback increase of GSH synthesis 
and a more robust antioxidant response (Nelson et al., 1999). Many of the NRF2 inducers are 
thiol-reacting compounds and may cause a similar initial depletion of cellular GSH. 
Therefore, although the in vitro culture system does not present the complexity of the retinal 
microenvironment and cell-cell interaction in vivo, it is a valuable tool for assessing both the 
pharmacological properties of new NRF2 inducers and their potential toxicities. For 
treatment of a chronic disease like AMD, the RPE cells are already stressed by oxidative 
burden and may not tolerate transient GSH depletion after repeated administration of 
agents that react with cellular thiols with low selectivity. 
4. Ocular pathology of Nrf2 knockout mice 
Nrf2 knockout mice have normal embryonic development (Chan et al., 1996) and their basal 
level of antioxidant status in many tissues is not different from age-matched wild type mice. 
However, the Nrf2 null mice show increased sensitivity to a variety of pharmacological and 
environmental toxicants (Cano et al., 2010; Kensler et al., 2007; Osburn & Kensler, 2008). 
Depending upon the stimuli, injuries occur in different organs and tissues. The phenotypes 
vary, but commonly involve oxidative and inflammatory stress. For ocular pathology, 
neonatal Nrf2 knockout mice develop more severe retinal vaso-obliteration at early phase 
after hyperoxia exposure (Uno et al., 2010). NRF2 also modulates the innate immune 
response in the retina and iris-ciliary body in a mouse model of uveitis induced by 
intraperitoneal injection of lipopolysaccaride (Nagai et al., 2009).  
Aging and smoking are the major demographic and environmental risk factor of AMD, 
respectively. Cano and colleagues (2010) reported that NRF2-deficient mice were more 
susceptible to smoking-induced retinal injury. At 8 months, Nrf2 null mice showed a mild 
degree of ultrastructural change in the RPE. Comparing to age-matched wild type mice, RPE 
of the knockout mice exposed to cigarette smoking for 6 months (starting at 2 months) 
displayed markedly increased staining of 8-hydroxydeoxyguanosine, an indicator of 
accumulated oxidative DNA damage (Cano et al., 2010). On electron microscopy, Nrf2-/- 
smoking mice displayed abnormal RPE basal infoldings and vacuoles, without apparent 
changes of the choroidal endothelium or sub-RPE deposit formation (Cano et al., 2010). 
Thickening and deposits in the outer collagenous layer of Bruch’s membrane were often 
observed in smoking mice. The data suggest that NRF2-mediated protection to the RPE is 
important against chronic environmental toxicities associated with AMD. 
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Fig. 3. Accelerated aging in Nrf2-/- mice. (A) and (B) Growth curves of male and female  
Nrf2-/- mice and their age-matched littermates. Knockout animals showed a lower body 
weight after the first year. (C) and (D) Hair loss in Nrf2-/- mice. A representative picture  
of a 12-month-old alopecic Nrf2-/- mice is shown in (C). Hair loss was often first observed 
between 5 to 6 months of age (D). 
We recently reported that Nrf2-/- mice developed age-related RPE and choroidal 
degeneration resembling cardinal features of human AMD (Zhao et al., 2011). The Nrf2-/- 
mice have accelerated aging. Some of the animals exhibited extensive hair loss (alopecia), 
which began as early as 4 months and peaked at 8 months (Fig. 3). Interestingly, more 
female Nrf2-/- mice suffered from hair loss than male ones; this could possibly be attributed 
to the higher susceptibility of female mice to autoimmune diseases as reported by Takahashi 
and colleagues (Yoh et al., 2001). After 12 months, the Nrf2-/- mice started to show lower 
body weight than the age-matched wild type littermates (Fig. 3). The life expectancy of Nrf2-
/- mice is about 20 months which is only 60% of wild type mice with the same genetic 
background (Pearson et al., 2008). 
 







Fig. 4. Fundus examinations of Nrf2-/- mice. (A) Normal fundus image taken from a 12-
month-old wild type mouse. (B) Drusen like deposits developed in the peripheral retina of 
an 8-month-old Nrf2-/- mouse. (C) Yellowish patchy lesions found in a 14-month-old  
Nrf2-/- mouse. (D-F) A 16-month-old knockout mouse developed extensive RPE lesions (D), 
one of which showed hyperfluorescence in both early (E) and late (F) phase of fluorescein 
angiography. Arrowheads in D and E indicate the same lesion. 
Drusen-like deposits were noted in around 70% of eyes from Nrf2-/- mice, as examined by 
funduscopy between 8 to 11 months (Fig. 4B). With aging, these small, dome-shaped whitish 
spots in the fundus tended to become confluent yellowish lesions, gradually increasing in 
area (Fig. 4C). Atrophic RPE lesions were frequently seen in Nrf2-/- mice after the first year 
(Fig 4C and 4D). Some of these lesions would eventually develop into sites of CNV, which 
were identified by both fundus fluorescein angiography (Fig 4E and 4F) and histopathology 
(Zhao et al., 2011). Moderate but statistically significant decreases in both a- and b-wave 
amplitudes on ERG were observed between the Nrf2-/- and wild-type mice at 12 months of 
age (Zhao et al., 2011), indicating compromised visual function in knockout mice. 
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The fundus phenotype in aged Nrf2-/- mice was further confirmed by histology (Fig. 5 and 
Zhao et al., 2011), which showed drusen formation, extensive RPE atrophy with numerous 
vacuoles, increased autofluorescence inside the RPE layer and CNV. Thickening of the 
Bruch’s membrane with age and basal laminar and basal linear deposit were found 
exclusively in Nrf2-/- mice by electron microscopy (Zhao et al., 2011). Immunostaining of eye 
sections revealed increased deposition of proteins that are related to innate immunity (i.e., 
C3d, vitronectin and serum amyloid P) and marker of oxidative injury (nitrotyrosine) 
between the RPE and Bruch’s membrane in Nrf2-/- mice (Zhao et al., 2011). The same 
proteins have been found in drusen and Bruch’s membrane of human AMD eyes (Crabb et 














Fig. 5. Histology examination of retina of Nrf2-/- mice. (A) A 14-month-old wild type mouse 
showed normal structure of the outer retina. (B) Representative image of RPE degeneration 
with big vacuoles, taken from a 14-month-old Nrf2-/- mouse. (C-D) Semi-thin sections from a 
12-month-old wild-type mouse (C) and an age-matched Nrf2-/- mouse (D). Bruch’s 
membranes of the two were aligned at the same level (red line). Note that the RPE layer was 
elevated due to heterogeneous deposits (under the dotted line) in the sub-RPE space. (A and 
B: Paraffin section with hematoxylin and eosin staining. C and D: Plastic section with 
toluidine blue staining. ONL: outer nuclear layer; POS: photoreceptor outer segment; CC: 
choriocapillaris) 
The accelerated degeneration after middle age and the typical pathology of the RPE/choroid 
indicate that the Nrf2-/- model shares many features of human AMD. At advanced age, the 
retinal pathology progressed from atrophic form to neovascularization and about 15% of the 
Nrf2-/-mice developed spontaneous CNV (Zhao et al., 2011). Photoreceptor degeneration 
was moderate and was probably secondary to RPE dysfunction. Rodents do not have 
macula and, therefore, cannot be used to generate ideal models of AMD. On the other hand, 
mechanistic studies exploring the molecular and biochemical mechanisms of age-related 
RPE degeneration and CNV can greatly benefit from animal models that at least partially 
reproduce representative lesions commonly seen in human AMD eyes. Animal models, such 
as the Nrf2-/- mice, will display the dynamic process of the disease and offer windows of 
intervention that can either slow down or accelerate the progression. Similar experiments 
will be difficult if not impossible to perform with human eyes mainly at late stages of AMD. 
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5. Pharmacological interventions that activate NRF2 in vivo 
A number of in vivo studies have investigated the protective roles of NRF2 inducers in 
models of retinal injury and inflammation. A study by Yodoi and colleagues (Tanito et al., 
2005) showed that sulforaphane, a prototypic NRF2 inducer, could upregulate thioredoxin 
in both the RPE and neural retina, and was effective in protecting photoreceptors from 
photo-oxidative damage. Compared to vehicle-treated controls, mice received sulforaphane 
showed fewer apoptotic cells in the outer nuclear layer and RPE, and had moderate but 
statistically significant improvement of both a- and b-wave amplitudes. At four days after 
light exposure, the ONL was significantly thicker in sulforaphane-treated mice (Tanito et al., 
2005). Sulforaphane also delayed photoreceptor cell death in tubby mouse, a model of Usher 
syndrome (Kong et al., 2007). Homozygous tubby mice develop progressive photoreceptor 
degeneration shortly after birth. Sulforaphane-treated tub/tub mice showed significantly 
increased ONL thickness and b-wave amplitude at P28 and P34, as compared to vehicle-
treated animals (Kong et al., 2007). 
For human clinical studies, AREDS reported (2001) that supplementation with zinc alone, or 
antioxidants plus zinc, decreased the risk of progression towards advanced AMD by 20%. 
We showed that zinc could activate NRF2 both in cultured RPE cells and in RPE of NRF2 
reporter mice (Chen et al., data not shown). In an ancillary study of AREDS, we analyzed 
the effects of long-term zinc supplementation on plasma thiol metabolites and their redox 
status (Moriarty-Craige et al., 2007). There was a significant decrease in plasma cystine 
concentration in the zinc-supplemented group. The systemic effects may be due to increased 
tissue uptake of cystine, as NRF2 regulates the transporter protein xCT (Sasaki et al., 2002). 
These results prove the concept that long term dietary supplementation of an NRF2 inducer 
is a feasible approach for treating early stage AMD patients. 
A new class of synthetic triterpenoids derivatives of oleanolic acid have been tested both in 
cultured RPE cells and in vivo. These agents exerted highly potent activity at concentration as 
low as 10 nM. They reacted with a broad range of accessible protein thiols and activate NRF2 
about 10 times more potently (by the ARE reporter assay) than previously used compounds 
(Pitha-Rowe et al., 2009). The in vivo protection against light-induced retinal toxicity has been 
demonstrated. Mice receiving 200 mg/kg CDDO-trifluoroethylamide (-TFEA) showed 
significantly increased ONL thickness after light-induced retinal degeneration (Pitha-Rowe et 
al., 2009). CDDO-imidazolide decreased mouse leukocyte adherence to retinal vasculature 
after lipopolysaccaride treatment, and reduced expression of inflammatory mediators 
including ICAM-1, IL-6, COX-2, TNF- and MCP-1 (Nagai et al., 2009; Cano et al., 2010). 
CDDO-methyl ester inhibited neutrophil infiltration in vitreous and internal limiting 
membrane after retinal ischemia-reperfusion induced by high intraocular pressure, and 
inhibited degeneration of retinal capillary (Wei et al., 2011). The CDDO compounds are 
currently under clinical trials for chronic kidney disease and type 2 diabetes. Their potential 
applications in treating dry AMD can be explored in human studies in the near future. 
6. Signaling pathways that regulate NRF2 activation 
The interaction between Keap1 and NRF2 is considered as a major determinant of the 
stability and function of NRF2 (Dinkova-Kostova et al., 2002; Hong et al., 2005). Electrophilic 
compounds, such as sulforaphane, can directly react with various cysteine residues of Keap1 
and consequently cause dissociation and activation of NRF2 (Eggler et al., 2005). Keap1-
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deficient hepatocytes had increased NRF2 activity and were more resistant to 
acetaminophen (Okawa et al., 2006). In addition to thiol modification and redox regulation, 
it is well established that there are cross-talk between the protein kinase pathways and 
NRF2-dependent antioxidant system (Sherratt et al., 2004). 
Several phosphorylation sites of NRF2 protein have been mapped out and associated to its 
activity (Fig. 6). Phosphorylation of NRF2 at Serine 40 by protein kinase C promotes its 
dissociation from Keap1 and translocation into the nucleus (Bloom and Jaiswal, 2003; Huang 
et al., 2002). Phosphorylation at Tyrosine 568 by a Src subfamily kinase Fyn controls the 
export and inactivation of NRF2 at the late phase of induction (Jain and Jaiswal, 2006; 
Salazar et al., 2006). Other Src subfamily kinases, Src, Yes and Fgr, can also function as 
negative regulators of NRF2 by phosphorylating the protein at Tyr568 (Niture et al., 2011). A 
recent study by Rada et al (2011) demonstrated that a serine cluster in the Neh6 domain 
(Ser335, 338, 342, 347, 351, and 355) (Fig. 1) of NRF2 can be phosphorylated by glycogen 
synthase kinase-3 (GSK-3). The phosphorylation enhanced the association between Nrf2 
and SCF/-TrCP, which is an adaptor protein for ubiquitin ligase and targets NRF2 for 
cullin-1/Rbx1-mediated degradation (Rada et al., 2011). Thus, phosphorylation of NRF2 by 
GSK-3 will facilitate it proteosomal degradation and inhibit its transactivation function. 
GSK-3 may also act upstream of Src family kinases (Jain and Jaiswal, 2006; Kaspar and 
Jaiswal, 2011). It remains elusive whether those two mechanisms work independently or 
additively. Mitogen-activated protein kinases (MAPKs) have been shown to phosphorylate 
NRF2 at Ser215, 408, 558, 577 and Tyr559; however, impacts on NRF2 location and activity 
were marginal after phosphorylation at those residues (Sun et al., 2009). 
Results from the functional studies consistently showed that inhibition of the PI3K/Akt 
pathway decreased NRF2 activation induced by a variety of stimuli in different cell lines, 
while expression of a constitutive active mutant of Akt increased NRF2 activity, indicating 
that PI3K/Akt signalling is a positive regulator of NRF2 (Chen et al., 2009; Jain and Jaiswal, 
2006; Kang et al., 2000; Lee et al., 2001; Wang et al., 2008). PI3K/Akt controls NRF2 via 
multiple indirect mechanisms. They can facilitate translocation of NRF2 into the nucleus via 
rearrangement of cytoskeletal actin (Kang et al., 2002). They are upstream kinases of GSK-
3. Akt phosphorylates GSK-3 at Ser9 and inhibits its kinase activity, which in turn will 
potentiate NRF2 activation because GSK-3 is its negative regulator (Jain and Jaiswal, 2006; 
Niture et al., 2011; Rada et al., 2011; Salazar et al., 2006).  
There are other kinases that can be positive regulators of NRF2. PKR-like endoplasmic 
reticulum kinase phosphorylates and activates NRF2 under conditions of ER stress 
(Cullinan and Diehl, 2004; Cullinan et al., 2003). Casein kinase 2 phosphorylates endogenous 
NRF2 and regulates its activity and degradation (Pi et al., 2007). MAPK family proteins, 
extracellular signal-regulated protein kinases (ERKs) and the c-Jun N-terminal kinases 
(JNK), also play positive roles in NRF2-signaling pathway (Shen et al., 2004; Yu et al., 2000a; 
Zipper and Mulcahy, 2003). However, the positive regulation by ERKs and JNK may not 
through direct phosphorylation of NRF2 (Shen et al., 2004; Zipper and Mulcahy, 2003). 
Instead, they may upregulate NRF2 activity by phosphorylating and activating Nrf2 binding 
partner, such as the nuclear transcriptional coactivator CBP (Shen et al., 2004; Yu et al., 
2000a). The p38 kinase may either stimulate or inhibit NRF2 activity, depending on the 
different type of cells and the pharmacological agents used for the studies (Yu et al., 2000b; 
Zipper and Mulcahy, 2000). 
 



























Fig. 6. Regulation of NRF2 activity by protein phosphorylation. There are positive and 
negative regulators of upstream kinases that function at various steps of the signalling 
pathway. Phosphorylation can leads to either its activation or degradation/inactivation. 
Because of the multiple putative phosphorylation sites of NRF2, and its dual regulation by 
cellular redox status and protein phosphorylation, it is difficult to clearly define its upstream 
signalling network both at basal level and in response to oxidative stress. Identification of 
authentic phosphorylation sites and development of antibodies specific for phosphorylated 
NRF2 can greatly advance our knowledge in this area. More importantly, most of the works 
on signal transduction of NRF2 have been performed in transformed cancer cells, which 
harbour genetic and biochemical variations and function quite differently from the RPE. 
Future mechanistic studies of NRF2 will be needed to address cell type-specific signalling 
mechanisms involved in RPE aging and degeneration. 
7. Potential mechanisms linking NRF2 to AMD 
A unique pathology of AMD is that RPE degeneration occurs before severe loss of 
photoreceptors, a retinal phenotype also seen in NRF2-deficient mice. In contrast, in model 
systems of retinal toxicities, animals exposed to excessive levels of oxidative stress often 
showed much more severe retinal degeneration than the RPE damage. Compared to 
epithelial cells, neurons are less efficiently protected by the endogenous antioxidant system. 
The outer segments of rods and cones have very low GSH (Winkler 2008). As shown in both 
the SOD1- and SOD2-deficient mice, severe loss of neurons occurred before or at the same 
time of RPE degeneration (Imamura et al. 2006; Justilien et al., 2007). In Vldlr-/- mice, 
antioxidant supplementation protected retinal degeneration and improved the retinal 
electrophysiology (Dorrell et al., 2009). The fact that Nrf2-/- mice showed preferential loss of 
RPE suggests that NRF2 can have functions other than antioxidant protection. 
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It is noteworthy that the retinal ultrastructure of aged Nrf2-/- mice showed signs of 
dysregulated autophagy (Zhao et al., 2011). Autophagy is a major self-renewal process 
which is essential for organelle turnover and removal of aggregated proteins that cannot be 
processed by proteasome (Klionsky 2007). During autophagy, unwanted proteins and 
organelles are sorted to double-membrane autophagosomes, which are further delivered to 
and fused with lysosomes to degrade the sequestered cargos. The accumulation of various 
intermediate forms of autophagic vacuoles and multivesicular bodies in the RPE and 
Bruch’s membrane was evident on EM images of aged Nrf2-/- mice (Zhao et al. 2011). This 
can be caused by either increased autophagic flux or decreased final degradation by 
lysosome. Similar findings of dysregulated autophagy were reported in another study using 
human AMD eyes (Wang et al., 2009).  
Autophagy is of particular importance in non-dividing cells like neurons and RPE which, 
unlike proliferating cells, are incapable of diluting the waste products by mitosis. 
Dysregulated autophagy is considered as pathogenic in various neurodegenerative diseases; 
and the underlying mechanisms are disease-specific. In Alzheimer’s disease, mutations in 
presenilin-1 impairs lysosomal targeting of v-ATPase V0a1, which is essential for lysosome 
acidification and protease activation (Lee et al., 2010). In Parkinson’s disease, mutated -
synuclein cannot be efficiently degraded by autophagy (Cuervo et al., 2004). In Huntington’s 
disease, mutant huntingtin may impair the initial cargo assembly of autophagic vesicles 
(Martinez-Vicente et al., 2010). It has been hypothesized that dysregulated autophagy is also 
involved in AMD (Wang et al., 2009; Kaarniranta 2010). 
NRF2 can be an important regulator of RPE autophagy via multiple mechanisms. In normal 
RPE cells, autophagy is responsible for the removal of ubiquitinated and/or aggregated 
proteins. Cargos inside autophagosomes will be delivered to lysosome for degradation and 
recycled for catabolism. NRF2 is likely involved in autophagosome formation. Several 
previous studies reported that p62, which is a receptor protein of ubiquitinated proteins and 
essential for the initial assembly of autophagosome, is transcriptionally regulated by NRF2 
(Komatsu et al., 2010). Whether NRF2 controls other specific molecular components of the 
autophagy pathway remains to be characterized by future studies. Accelerated 
accumulation of lipofuscin was observed in Nrf2-/- RPE (Zhao et al., 2011). Reactive 
metabolites from bisretinoids inhibit lysosome-mediated autophagic degradation. NRF2-
dependent detoxification can be protective in both formation and elimination of lipofuscin-
related metabolic waste products. Thus, compromised NRF2 signalling can impact both the 
early and late stages of RPE autophagy.  
NRF2 may also be involved in the innate immune response that amplifies the initial RPE 
lesions in AMD. As shown in the uveitis model, NRF2-deficient retina had higher number of 
infiltrated leukocytes and increased production of pro-inflammatory cytokines (Cano et al., 
2010). Thioredoxin 1, a downstream protein of NRF2, can interact with complement factor H 
and regulate its activation (Inomata et al., 2008). Autophagy can be a possible mechanistic 
link between oxidative stress and inflammation (Levine et al., 2011). Elevated cellular stress 
will cause increased damage to proteins and organelles and overwhelm the degradation 
capacity of RPE autophagy. Consequently, the undigested wastes could be exported into 
Bruch’s membrane via exocytosis and deposited in the sub-RPE space (Wang et al., 2009). 
The exported proteins, possibly in oxidatively modified forms, may further promote drusen 
formation and cause local inflammation mediated by complement proteins and 
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macrophages. Loss of endothelial fenestration was observed in choriocapillaris of aged Nrf2-
/- mice (Zhao et al., 2011). In human AMD eyes, choroidal vascular degeneration occurs in 
areas of geographic atrophy (McLeod et al., 2009; Mullins et al. 2011). Decreased transport 
function of choroidal vessels can facilitate the accumulation of damaged proteins in the sub-
RPE space and Bruch’s membrane. 
Single nucleotide polymorphisms (SNPs) in the coding region of NRF2 gene have been 
detected in human cancerous tissues (Shibata et al. 2008). Functional polymorphisms in the 
promoter region of NRF2 have been reported (Marzec et al., 2007). However, according to 
the GWAS data (Chen et al., 2010), NRF2 is not a major risk allele of AMD and SNPs of 
NRF2 are unlikely to be a major genetic factor. A recent study showed that age-dependent 
decline of NRF2 function could be caused by upstream regulatory mechanisms, such as 
GSK-3, that control its localization and activity (Tomobe et al., 2011). Defining these 
mechanisms will open up new revenues of intervention to prevent oxidative injury and RPE 
loss during dry AMD. Unlike the inherited genetic variations, the biochemical changes 
associated with RPE aging are likely treatable.  
8. Conclusion 
NRF2 is a protein that has been extensively studied in cancer and other chronic human 
diseases. Accumulating evidence suggests that NRF2-mediated signalling pathways have 
central roles in protecting the RPE cells from aging and age-related degeneration. The Nrf2-/- 
mice represent a new model for translational and mechanistic studies of AMD. Agents that 
activate Nrf2 are potential candidates for treating AMD and other retinal diseases involving 
oxidative and inflammatory stress. 
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It is noteworthy that the retinal ultrastructure of aged Nrf2-/- mice showed signs of 
dysregulated autophagy (Zhao et al., 2011). Autophagy is a major self-renewal process 
which is essential for organelle turnover and removal of aggregated proteins that cannot be 
processed by proteasome (Klionsky 2007). During autophagy, unwanted proteins and 
organelles are sorted to double-membrane autophagosomes, which are further delivered to 
and fused with lysosomes to degrade the sequestered cargos. The accumulation of various 
intermediate forms of autophagic vacuoles and multivesicular bodies in the RPE and 
Bruch’s membrane was evident on EM images of aged Nrf2-/- mice (Zhao et al. 2011). This 
can be caused by either increased autophagic flux or decreased final degradation by 
lysosome. Similar findings of dysregulated autophagy were reported in another study using 
human AMD eyes (Wang et al., 2009).  
Autophagy is of particular importance in non-dividing cells like neurons and RPE which, 
unlike proliferating cells, are incapable of diluting the waste products by mitosis. 
Dysregulated autophagy is considered as pathogenic in various neurodegenerative diseases; 
and the underlying mechanisms are disease-specific. In Alzheimer’s disease, mutations in 
presenilin-1 impairs lysosomal targeting of v-ATPase V0a1, which is essential for lysosome 
acidification and protease activation (Lee et al., 2010). In Parkinson’s disease, mutated -
synuclein cannot be efficiently degraded by autophagy (Cuervo et al., 2004). In Huntington’s 
disease, mutant huntingtin may impair the initial cargo assembly of autophagic vesicles 
(Martinez-Vicente et al., 2010). It has been hypothesized that dysregulated autophagy is also 
involved in AMD (Wang et al., 2009; Kaarniranta 2010). 
NRF2 can be an important regulator of RPE autophagy via multiple mechanisms. In normal 
RPE cells, autophagy is responsible for the removal of ubiquitinated and/or aggregated 
proteins. Cargos inside autophagosomes will be delivered to lysosome for degradation and 
recycled for catabolism. NRF2 is likely involved in autophagosome formation. Several 
previous studies reported that p62, which is a receptor protein of ubiquitinated proteins and 
essential for the initial assembly of autophagosome, is transcriptionally regulated by NRF2 
(Komatsu et al., 2010). Whether NRF2 controls other specific molecular components of the 
autophagy pathway remains to be characterized by future studies. Accelerated 
accumulation of lipofuscin was observed in Nrf2-/- RPE (Zhao et al., 2011). Reactive 
metabolites from bisretinoids inhibit lysosome-mediated autophagic degradation. NRF2-
dependent detoxification can be protective in both formation and elimination of lipofuscin-
related metabolic waste products. Thus, compromised NRF2 signalling can impact both the 
early and late stages of RPE autophagy.  
NRF2 may also be involved in the innate immune response that amplifies the initial RPE 
lesions in AMD. As shown in the uveitis model, NRF2-deficient retina had higher number of 
infiltrated leukocytes and increased production of pro-inflammatory cytokines (Cano et al., 
2010). Thioredoxin 1, a downstream protein of NRF2, can interact with complement factor H 
and regulate its activation (Inomata et al., 2008). Autophagy can be a possible mechanistic 
link between oxidative stress and inflammation (Levine et al., 2011). Elevated cellular stress 
will cause increased damage to proteins and organelles and overwhelm the degradation 
capacity of RPE autophagy. Consequently, the undigested wastes could be exported into 
Bruch’s membrane via exocytosis and deposited in the sub-RPE space (Wang et al., 2009). 
The exported proteins, possibly in oxidatively modified forms, may further promote drusen 
formation and cause local inflammation mediated by complement proteins and 
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macrophages. Loss of endothelial fenestration was observed in choriocapillaris of aged Nrf2-
/- mice (Zhao et al., 2011). In human AMD eyes, choroidal vascular degeneration occurs in 
areas of geographic atrophy (McLeod et al., 2009; Mullins et al. 2011). Decreased transport 
function of choroidal vessels can facilitate the accumulation of damaged proteins in the sub-
RPE space and Bruch’s membrane. 
Single nucleotide polymorphisms (SNPs) in the coding region of NRF2 gene have been 
detected in human cancerous tissues (Shibata et al. 2008). Functional polymorphisms in the 
promoter region of NRF2 have been reported (Marzec et al., 2007). However, according to 
the GWAS data (Chen et al., 2010), NRF2 is not a major risk allele of AMD and SNPs of 
NRF2 are unlikely to be a major genetic factor. A recent study showed that age-dependent 
decline of NRF2 function could be caused by upstream regulatory mechanisms, such as 
GSK-3, that control its localization and activity (Tomobe et al., 2011). Defining these 
mechanisms will open up new revenues of intervention to prevent oxidative injury and RPE 
loss during dry AMD. Unlike the inherited genetic variations, the biochemical changes 
associated with RPE aging are likely treatable.  
8. Conclusion 
NRF2 is a protein that has been extensively studied in cancer and other chronic human 
diseases. Accumulating evidence suggests that NRF2-mediated signalling pathways have 
central roles in protecting the RPE cells from aging and age-related degeneration. The Nrf2-/- 
mice represent a new model for translational and mechanistic studies of AMD. Agents that 
activate Nrf2 are potential candidates for treating AMD and other retinal diseases involving 
oxidative and inflammatory stress. 
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1. Introduction 
Blindness is a loss of vision resulting in the inability to continue with a normal lifestyle. The 
prevalence of blindness varies from country to country and from region to region within the 
same country. An average estimate of the number of blind people in industrialized countries 
is 1–2 per 2000, compared to 5–10 per 1000 in developing countries. According to World 
Health Organisation estimates, there are between 27 and 35 million blind people in the 
world today. 
Retinal dystrophies and degenerations represent a heterogeneous group of disorders 
affecting the function of the retina. They are characterized by degeneration of 
photoreceptors or adjacent cells such as retinal pigment epithelium or Müller cells. Retinitis 
pigmentosa (RP), hereditary maculopathies, and age-related macular degeneration (AMD) 
are representative of these diseases. RP as well as macular degeneration can be part of 
syndromes with symptoms from other organs or organ systems, for example, Usher 
syndrome with RP and deafness. More than 190 loci for different retinal diseases have been 
localized, and 140 genes have been identified (http://www.sph.uth.tmc.edu/Retnet/). 
In northern Sweden the presence of all hereditary disorders is higher than in the southern 
part of the country. Explanations offered include a low migration rate in the sixteenth to 
nineteenth centuries and a certain number of marriages among relatives, which influenced 
the presence of autosomal recessive disorders. Furthermore, a disposition to a genetic 
abnormality in a geographically restricted area gave rise to a ‘founder’ effect, which 
influenced the presence of autosomal dominant disorders. These factors are taken into 
consideration in studies of all hereditary disorders, including those affecting vision. 
2. Retinitis pigmentosa 
Retinitis pigmentosa is a genetically and clinically heterogeneous group of hereditary 
retinopathies characterized by a degeneration of photoreceptors (rods primary) with a 
progressive loss of peripheral vision. This leads to night blindness, ‘tunnel vision’, and 
eventually, complete blindness. Typical signs of the disease, except for night blindness and 
progressive loss of the peripheral visual field, are typical pigment deposition in the retina, 
attenuation of the retinal blood vessels, and optic disc pallor. The diagnosis is confirmed by 
an abnormal or extinguished electroretinogram (ERG). RP can be nonsyndromic, syndromic, 
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or systemic, when multiple tissues are affected. Nonsyndromic RP can be inherited in 
autosomal dominant (15–25%), autosomal recessive (5–20%), and X-linked (5–15%) manners 
(Daiger & Pagon, 2000). However, an inheritance pattern is still unknown in many cases. So-
called simplex usually represents an isolated case without any family history. Due to 
different degrees of penetrance and expressivity of RP genes, the phenotype can vary 
between families and even within the same family (Shintani et al., 2009). 
The prevalence in the United States and Europe is approximately 1/3500 to 1/4000, and the 
disorder is the most common cause of blindness among young adults. In Denmark the 
lifetime risk of developing RP is 1/2500 (Haim et al., 2002), and in Sweden it is 1/2000 
(Burstedt et al., 1999). Similar frequencies can be expected in other populations, but they 
have not been well documented. Frequency of RP in certain isolated or consanguineous 
populations might be higher due to mutations in particular genes (Daiger & Pagon, 2000). 
Among known loci and genes there are 57 identified for autosomal dominant RP and 
autosomal recessive RP. Many genes associated with RP encode proteins functioning as 
photoreceptor transcription factors; others are involved in phototransduction and the visual 
cycle or photoreceptor structure (Phelan & Bok, 2000; Fig. 1). Despite many retinal diseases 
having been mapped to specific chromosomal regions, the genes and their functions still 
have not been identified in all cases. 
 
 
Fig. 1. Visual cycle proteins cause retinal degenerations. CRBP = cellular retinol binding 
protein, RPE65 = retinal pigment epithelium-specific protein 65kDa, LRAT = lecithin retinol 
acyltransferase, IRBP = interphotoreceptor retinoid-binding protein, RPE = retinal pigment 
epithelium, IPM = interphotoreceptor matrix, ROS = rod outer segment, ABCR = retina-
specific ATP-binding cassette transporter, CRALBP = retinaldehyde-binding protein 1,  
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In Västerbotten County of northern Sweden 160 RP cases were identified and genetic defects 
were found in 66%, representing 79 patients with autosomal recessive RP of Bothnia type 
and 27 patients with autosomal dominant RP. However, genetic mechanisms of RP are still 
unknown in patients from other counties of northern Sweden. In this chapter we will focus 
on a disease with characteristic phenotype common in northern Sweden form of autosomal 
recessive RP, Bothnia dystrophy. 
2.1 Autosomal recessive RP, Bothnia Dystrophy (BD) 
Examination of medical records for patients with RP in Västerbotten County in northern 
Sweden has shown an accumulation of cases with a unique phenotype of RP called Bothnia 
dystrophy. Bothnia is the region in northern Sweden west of the Gulf of Bothnia, historically 
known as Bothnia Occidentalis (Fig. 2). Affected individuals showed night blindness with 
onset in early childhood, retinitis punctata albescens (RPA) at some stage of the disease, 
macular degeneration, and markedly elevated dark adaptation (DA) thresholds. 
 
Fig. 2. The map shows the location of Västerbotten County in Scandinavia. 
2.1.1 Genetic cause of BD 
Initially, twenty patients from seven families originating from the same geographic area 
were included in the linkage analysis study aimed at identifying a disease-causing gene 
(Burstedt et al., 1999). All affected individuals had a nonsyndromic type of retinal 
degeneration inherited in an autosomal recessive way (Fig. 3). By statistical two-point lod 
(logarithm [base 10] of odds) score analysis, which is used to determine the linkage between 
trait and a chromosome marker, BD was mapped between the markers D15S526 and FES on 
chromosome 15q26.1. The D15S116, located near the RLBP1 gene showed a maximum lod 
score of 7.79. Since lod score greater than 3 is considered evidence for linkage, the RLBP1 
gene was a strong candidate to cause the BD. Mutation analysis showed that all patients 
were homozygous for a cytosine (C) to thymine (T) change in exon 7 of the RLBP1 gene, 







Advances in Ophthalmology 
 
452 
or systemic, when multiple tissues are affected. Nonsyndromic RP can be inherited in 
autosomal dominant (15–25%), autosomal recessive (5–20%), and X-linked (5–15%) manners 
(Daiger & Pagon, 2000). However, an inheritance pattern is still unknown in many cases. So-
called simplex usually represents an isolated case without any family history. Due to 
different degrees of penetrance and expressivity of RP genes, the phenotype can vary 
between families and even within the same family (Shintani et al., 2009). 
The prevalence in the United States and Europe is approximately 1/3500 to 1/4000, and the 
disorder is the most common cause of blindness among young adults. In Denmark the 
lifetime risk of developing RP is 1/2500 (Haim et al., 2002), and in Sweden it is 1/2000 
(Burstedt et al., 1999). Similar frequencies can be expected in other populations, but they 
have not been well documented. Frequency of RP in certain isolated or consanguineous 
populations might be higher due to mutations in particular genes (Daiger & Pagon, 2000). 
Among known loci and genes there are 57 identified for autosomal dominant RP and 
autosomal recessive RP. Many genes associated with RP encode proteins functioning as 
photoreceptor transcription factors; others are involved in phototransduction and the visual 
cycle or photoreceptor structure (Phelan & Bok, 2000; Fig. 1). Despite many retinal diseases 
having been mapped to specific chromosomal regions, the genes and their functions still 
have not been identified in all cases. 
 
 
Fig. 1. Visual cycle proteins cause retinal degenerations. CRBP = cellular retinol binding 
protein, RPE65 = retinal pigment epithelium-specific protein 65kDa, LRAT = lecithin retinol 
acyltransferase, IRBP = interphotoreceptor retinoid-binding protein, RPE = retinal pigment 
epithelium, IPM = interphotoreceptor matrix, ROS = rod outer segment, ABCR = retina-
specific ATP-binding cassette transporter, CRALBP = retinaldehyde-binding protein 1,  





Leber´s congenital amaurosis 
Early-onset 
retinal degeneration  

























Retinitis Pigmentosa in Northern Sweden – From Gene to Treatment 
 
453 
In Västerbotten County of northern Sweden 160 RP cases were identified and genetic defects 
were found in 66%, representing 79 patients with autosomal recessive RP of Bothnia type 
and 27 patients with autosomal dominant RP. However, genetic mechanisms of RP are still 
unknown in patients from other counties of northern Sweden. In this chapter we will focus 
on a disease with characteristic phenotype common in northern Sweden form of autosomal 
recessive RP, Bothnia dystrophy. 
2.1 Autosomal recessive RP, Bothnia Dystrophy (BD) 
Examination of medical records for patients with RP in Västerbotten County in northern 
Sweden has shown an accumulation of cases with a unique phenotype of RP called Bothnia 
dystrophy. Bothnia is the region in northern Sweden west of the Gulf of Bothnia, historically 
known as Bothnia Occidentalis (Fig. 2). Affected individuals showed night blindness with 
onset in early childhood, retinitis punctata albescens (RPA) at some stage of the disease, 
macular degeneration, and markedly elevated dark adaptation (DA) thresholds. 
 
Fig. 2. The map shows the location of Västerbotten County in Scandinavia. 
2.1.1 Genetic cause of BD 
Initially, twenty patients from seven families originating from the same geographic area 
were included in the linkage analysis study aimed at identifying a disease-causing gene 
(Burstedt et al., 1999). All affected individuals had a nonsyndromic type of retinal 
degeneration inherited in an autosomal recessive way (Fig. 3). By statistical two-point lod 
(logarithm [base 10] of odds) score analysis, which is used to determine the linkage between 
trait and a chromosome marker, BD was mapped between the markers D15S526 and FES on 
chromosome 15q26.1. The D15S116, located near the RLBP1 gene showed a maximum lod 
score of 7.79. Since lod score greater than 3 is considered evidence for linkage, the RLBP1 
gene was a strong candidate to cause the BD. Mutation analysis showed that all patients 
were homozygous for a cytosine (C) to thymine (T) change in exon 7 of the RLBP1 gene, 







Advances in Ophthalmology 
 
454 
(c.700C>T, p.R234W) in encoded cellular retinaldehyde-binding protein (Burstedt et al., 
1999). No homozygotes for the c.700C>T mutation were found among 33 unaffected control 
subjects who underwent ophthalmologic examinations or 92 anonymous blood donors. 
 
Fig. 3. A pedigree demonstrating autosomal recessive inheritance of BD in one of the 
families used for linkage analysis study. 
2.1.2 Compound heterozygosity in BD 
Sixty-nine BD cases homozygous for the c.700C>T were identified amongst patients with 
retinal dystrophies. In addition, 10 patients with similar to BD phenotype were heterozygous. 
Further screening for known mutations causing autosomal recessive RP revealed a second 
RLBP1 mutation, a thymine (T) to adenine (A) change, resulting in a substitution of a 
methionine to lysine, c.677 T>A, p.M226K (Köhn et al., 2008). R234W and M226K were shown 
to be allelic and the patients were compound heterozygotes, c.[677T>A]+[700C>T] (Fig. 4). 
 
Fig. 4. Pedigrees of compound heterozygotes (A) and segregation analysis of RLBP1 c.700C>T 
(B) and c.677T>A (C) performed by polymerase chain reaction and restriction fragment length 
polymorphism. (Figure published in Invest Ophthal Vis Sci, 2008;49(7):3172–3177). 
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Frequency of c.677 T>A allele in a matched control population was 0.0021. Among RP 
patients from northern Sweden two were homozygotes for p.M226K mutation. Based on 
allele frequency of R234W (3/250) and M226K (1/466), we believe that R234W was the first 
mutation to appear in northern Sweden, resulting in expected disease incidence of 1.5 per 
10,000 in a population of 257,000 inhabitants. 
Notably, one RLBP1 compound heterozygote BD patient tested for 848 mutations in 29 
genes causing autosomal dominant RP was shown to be a carrier of a mutation in carbonic 
anhydrase IV (CAIV), known to be associated with autosomal dominant retinitis 
pigmentosa RP17 (Rebello et al., 2004; Yang et al., 2005). Presence of this sequence variant in 
6 out of 143 blood donors from a control Swedish population (4%) and phenotype 
undistinguishable from the other BD patients casts doubt on the pathogenic role of the 
CAIV (Köhn et al., 2008), though modifier genes switching off the mutant CAIV protein or 
other factors resisting its function in carriers of Swedish origin remain to be investigated. 
2.1.3 RLBP1 mutations in RP 
To date, at least 12 mutations representing single nucleotide changes, in addition to small 
and one gross deletion have been reported (http://www.hgmd.cf.ac.uk). First homozygous 
RLBP1 mutation was found in a consanguineous family of Indian origin and in one of 
consanguineous kindred from Saudi Arabia, both diagnosed with retinitis punctata 
albescens (Maw et al., 1997; Katsanis et al., 2001). Three additional mutations in the RLBP1 
gene were identified in the patients of European ancestry with recessively inherited RPA 
(Morimura et al., 1999), and in patients of Newfoundland origin with a severe rod cone 
dystrophy two splice junction mutations were detected (Eichers et al., 2002). The reported 
cases of retinal degeneration associated with RLBP1 mutations were either homozygous or 
compound heterozygous (Demirci et al., 2004; Eichers et al., 2002; Fishman et al., 2004; 
Morimura et al., 1999; Nakamura et al., 2005). One of the compound heterozygotes, a 
Japanese patient with RPA, carried the c.700C>T mutation on one allele (Nakamura et al., 
2005). Finally, changes involving single nucleotides are not the only type of mutation that 
affects the RLBP1 gene. A large homozygous deletion was described in a RPA patient 
(Humbert et al., 2006). 
2.1.4 Cellular retinaldehyde-binding protein (CRALBP) 
RLBP1 gene mapped to chromosome 15q26 (Rosenfeld & Dryja, 1995) encodes the human 
cellular retinaldehyde-binding protein (CRALBP) expressing in outer epithelium of the iris, 
ciliary body pigment epithelium, cornea, optic nerve, pineal gland, Müller cells of the retina, 
and retinal pigment epithelium (RPE) (Bridges et al., 1987; Bunt-Milan & Saari, 1983; 
Eisenfeldt et al., 1985; Futterman & Saari, 1977; Saari et al., 1997; Sarthy, 1996). In the RPE, 
CRALBP functions as a carrier protein for endogenous retinoids, such as 11-cis-retinol, 
participating in the visual cycle. 11-cis-retinol can either be stored as an ester in the RPE or 
become oxidized to 11-cis-retinal by 11-cis-retinol dehydrogenase for visual pigment 
regeneration, and consecutively recycled back to the outer segment of photoreceptor cells of 
the retina (Saari, 1990). In vitro studies indicate that the presence of CRALBP diminishes the 
esterification and enhances oxidation of 11-cis-retinol (Saari et al., 1994). 
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A missense mutation of a conserved residue arginine at position 150 of CRALBP abolished 
binding to 11-cis-retinaldehyde. The mutation was shown to be associated with an atypical 
form of autosomal recessive RP in a small consanguineous Indian family (Maw et al., 1997). 
We evaluated binding activities for two recombinant mutant proteins causing BD 
(Golovleva et al., 2003). M226K mutation completely abolished binding of the recombinant 
protein with 11-cis retinaldehyde, while the R234W, in contrast, increased binding activity 
of the recombinant CRALBP (Fig. 5). Double mutant M226K + R234W showed less solubility 
than the wild type rCRALBP (Köhn et al., 2008). 
 
Fig. 5. Retinoid binding analysis of CRALBP mutants R234W (A) and M226K (B). UV-visible 
absorption spectra are shown before and after exposure to bleaching illumination following 
retinoid labelling with either 11-cis- or 9-cis-retinal. Spectra from wild-type rCRALBP  
(black line) and mutant R234W (red line) are indistinguishable and reflect stoichiometric 
binding of 11-cis- and 9-cis-retinal. The absorption spectra from mutant M226K show no 
chromophore absorbance at 425 nm or 400 nm, indicating no bound retinoid  
(Figure published in J Biol Chem, 2001;278:14,12397–12402). 
We also analysed RLBP1 promoter by sequencing 4kb in the upstream region in two BD 
compound heterozygotes. Seven single nucleotide polymorphisms (SNP) were identified; 
six had been reported previously and one was unique (cytosine to thymine change at 
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were both associated with BD phenotype. In experiments with reporter gene expression, 
decrease of expression level was shown when using either the entire ‘affected’ promoter 
haplotype or only C2614T (Golovleva, personal communication). 
Thus, M226K mutation resulted in loss of functional CRALBP, which is true even for R234W 
mutant, since gene expression was decreased due to sequence variant in promoter. 
2.2 Phenotype of retinitis pigmentosa of Bothnia type 
All 79 patients originating from Västerbotten County, with a population of 257,000 
inhabitants, present the phenotype caused by loss of CRALBP function. 
2.2.1 Clinical findings and effects of age 
The BD phenotype is characterized by central and peripheral degeneration of the retina with 
a unique expression of retinitis pigmentosa. All BD patients from the north of Sweden being 
homozygous for either the c.700C>T (p.R234W) (n = 67) or for the c.677T>A (p.M226K) (n = 
2), and compound heterozygous [c.677T>A]+[c.700C>T] (p.M226K+p.R234W) (n = 10), have 
a clinical expression of the disease with a progression of retinal degeneration. The 
progressive maculopathy in BD presents an overall decrease of the visual acuity (VA) with 




















Fig. 6. Scatterplot of BD patients showing the relation of weighted distance logMAR visual 
acuity (WVA) with age. (●) Single observations of WVA vs. age in homozygotes c.700C>T 
(p.R234W); n = 49, (y = 0.035 × -0.53). (□) Retrospective recordings of WVA vs. age in 
compound heterozygotes [c.677T>A] + [c.700C>T] (p.M226K + p.R234W); n = 10  
(y = 0.04 × −0.7), and homozygotes c.677T>A (p.M226K) (■); n = 2 (y = 0.03 × -0.32). 
Trendlines are drawn. 
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Notably, testing of monocular low-contrast VA using Sloan letter logarithmic translucent 
contrast charts (10% and 2.5%, Precision Vision®) allowed recording of measurable results, 
predominantly in the younger patients (Burstedt et al., 2005). 
The retinal findings in BD patients show distinct maculopathy with central pigment 
deposits in the teens, and areolar maculopathy is observed in the younger adults (Burstedt 
et al., 1999, 2001, 2010). In the peripheral retina the pigmentations are similar to a ‘salt and 
pepper’ pattern and round retinal atrophies develop paracentrally and/or peripherally with 
age. The areolar atrophies are the most common peripheral findings in BD fundus as the 
degeneration progresses, though discrete pigmentations with an appearance similar to bone 
spicules may occasionally be found. No premature cataract of significance is observed in 
BD, and in advanced cases narrowing of the retinal vessels and pale optic disc are not 
typical findings (Fig. 7). 
 
Fig. 7. Fundus photography. (A) 16-year-old girl, discrete central maculopathy and 
peripheral mottling, (WVA, weighted visual acuity, 0.00 logMAR). (B) 25-year-old woman 
with maculopathy and peripheral areolar atrophies (WVA 0.5 logMAR). (C) 41-year-old 
woman with central maculopathy and central RPA changes (WVA 0.3 logMAR).  
(D) 52-year-old woman with maculopathy, pigmentary changes (WVA 1.2 logMAR),  
and advanced retinal degeneration with retinal atrophies. 
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2.2.2 Morphological changes in BD found with ocular computed tomography 
A generalized early decrease of the central foveal thickness (Ø 1 mm) and the inner ring of 
the retina (Ø 3 mm) are shown with optical coherence tomography (Burstedt et al., 2010). In 
the outer ring (Ø 6 mm), the generalized thinning is seen predominately in the inferior 
regions of the OCT measurement and a trend of more preserved areas of the retinal 
thickness of the superior and nasal regions are observed. The total macular volumes in all 
ages of BD patients are low compared with those of controls. Comparisons of macular 



















Fig. 8. Optical coherence tomography (OCT) macular thickness measurements of 9 areas in 
young BD patients (age 9–34 years, n = 8) and controls (in bold), using a Stratus OCT, model 
3000 (Carl Zeiss Meditec AG, Jena, Germany): the central foveal, the foveal (Ø 1mm), the 
inner ring (Ø 3mm), and the outer ring (Ø 6 mm) with Superior area (S), Inferior area (I), 
Temporal area (T), and Nasal areas (N). The controls are presented with standard deviation 
shown on the graph. (Figure was published in Arch Ophthalmol. 2010;128(8); 989–995).  
The cross-sectional morphology visualized by OCT presents a general thinning of cell layers 
and a reduced outer nuclear layer (ONL) in the youngest BD patients (9–34 years). Also, a 
third high-reflectance band, (3rd HRB), found in the younger cases, diminished in younger 
adults with BD, possibly representing the loss of the outer segment length of 
photoreceptors, predominately the cones in the fovea measured with OCT (Burstedt et al., 
2010; Costa et al., 2004; Sandberg et al., 2005). This finding probably indicates an affection of 
the cone photoreceptors, and a possible degeneration of the outer segments of cones early in 
the course of the BD disease. The decreased retinal thickness and degenerative signs in the 
outer retinal layer were detected early in the course of the disease reported in a compound 
heterozygous patient with mutations in the RLBP1 gene (R103W/R234W) (Nakamura et al., 
2005). Similar to BD, prominent photoreceptor loss in the foveal and extrafoveal retina even 
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superior–temporal and temporal pericentral retina and the ONL, were demonstrated in the 
patients with Leber congenital amaurosis, another retinal degenerative disease caused by 
mutations in RPE65 gene encoding for a protein active in the visual cycle (Jacobson et al., 
2008). How can an early foveal thinning, suggesting early degeneration of cone 
photoreceptors in BD patients possibly be explained? Studies show that not only the rods 
but the cones also incorporate 11-cis retinoids, derived from the rod and cone visual cycles, 
in their visual pigments, and when examining the visual cycle in the RPE-65 and LRAT 
knock-out mice, diseases affecting the visual cycle, a key role for cell survival, was found to 
be 11-cis-retinal bound to cone opsins, important for retinal protein sorting, transport, and 
targeting (Collery et al., 2008; Zhang et al., 2008). 
2.2.3 Morphological findings of retinitis punctata albescens (RPA) 
The subretinal white lesions, retinitis punctata albescens, were initially observed in the teens 
with BD phenotype (Burstedt et al., 1999, 2001, 2010). The RPA spots often dominate in the 
macula area and adjacent to the arcades, varying from single to multiple generalized white 
lesions scattered over the posterior pole of the retina. Notably, these changes fade as the 
progressive retinal degeneration advances (Fig. 9). 
 
 
Fig. 9. Colour fundus photo and OCT. Top: 23-year-old man; below: 30-year-old woman. 
The vertical line of the binocular fundus photo with multiple generalized RPA traversing 
the retina at the temporal area of the macula between the arcades represents the scan lines of 
the corresponding OCT image presenting cross-sectional, visualized RPA (marked with 
arrows). (Figure published in Arch Ophthalmol. 2010;128(8);989–995). 
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RPA or subtle white lesions of the fundus have previously been described in several 
autosomal recessive RP cases with RLBP1 mutations, and also in other progressive 
degenerative diseases, for example, the rhodopsin-related RP (Demirci et al., 2004; Eichers et 
al., 2002; Fishman et al., 2004; Katsanis et al., 2001; Nakamura et al., 2005; Souied et al., 1996). 
The localization of RPA lesions and their appearance may resemble more commonly known 
retinal lesions like drusen in age-related macular degeneration. However, the RPA lesions in 
BD do not present elevation, disruption, or detachment of RPE. Another finding in AMD is 
an accumulation of drusen between the retina and choriocapillaris that is shown to interfere 
with the exchange of nutrients and products close to the drusen, inducing RPE or neural 
retinal damage with overlaying photoreceptor cell layer thinning, predominately the 
photoreceptor outer segment affection (Holz et al., 2004; Pauleikhoff et al., 1990; Schumann 
et al., 2009). Since similar thinning or compression of the ONL overlaying the RPA lesions is 
observed in BD, a possible cause could be an accumulation of products in the RPE, possibly 
due to the higher affinity and impaired 11-cis-retinal release in the visual cycle in the BD 



























Fig. 10. Progression of visual field defects in a BD case. (A) Small central scotoma is noted in 
one eye at the age of 18. (B, C) Deeper and larger central-paracentral scotomas develop in 
young adulthood. (D) In middle age absolute central-paracentral scotomas are present and 
expanded, finally affecting the peripheral border. (Figure published in Arch Ophthalmol. 
2001;119(2):260–267). 
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2.2.4 Psychophysical findings 
Significant foveal depression was found early in BD by testing foveal threshold with 
Humphrey SITA standard 24-2. The mean deviations in all younger cases show significant 
loss, indicating an overall depression and/or loss of the central parts of the visual field in 
BD. Goldmann perimetries are unaffected in the BD cases under the age of 10, and relative 
parafoveal scotoma and/or ring scotoma is found in the teens, with additional large, deep to 
absolute central scotomas in both eyes, accompanied by a decrease in visual acuity in 
adulthood. The visual fields and the development of defects, registered over a time period 
of 23 years, are presented in Fig. 10. 
In the fifth decade, extensive scotomas are present and only peripheral islets of the visual 
fields remain in middle age. 
2.2.5 Angiographic findings 
The fundus fluorescein angiograms in the early arteriovenous phase show a diffuse 
hyperfluorescence in the anatomic macular area, and locally, in the centre of the fovea, also 
presenting an early retinal thinning. As well as outside the arcades, corresponding to the 
atrophic areas in the colour fundus photograph, a general hyperfluorescence of granular 
type appears, indicating a gross atrophy of the pigment epithelium of the entire retina as a 
common clinical finding in this retinal degeneration (Burstedt et al., 2001). 
2.3 Dark adaptometry and electrophysiological findings 
2.3.1 Dark adaptometry and electrophysiological findings during standard dark-
adapted conditions 































































Fig. 11. Results of dark adaptometry in 14 cases aged 8–59 years. The grey area indicates  
the normal range of recovery of cone and rod sensitivity during dark adaptation for 
corresponding ages. (Figure published in Arch Ophthalmol. 2001;119(2):260–267). 
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In the younger patients the rod function is severely affected or absent and the cone 
adaptation often shows an extremely high, elevated final threshold, with the final dark-
adapted sensitivity about four log units higher than a normal range. In elderly affected cases 
an even more pronounced cone dysfunction is found (Burstedt et al., 2001, 2003). 
Full-field, single flash, and flicker electroretinograms (ERGs), including the oscillatory 
potentials (OPs) are recorded (UTAS-E 2000 LKC Technologies Inc., Gaithersburg, MD) 
using Burian-Allen bipolar electrodes during standard dark-adapted conditions, according 
to the recommendations of ISCEV (International Society for Clinical Electrophysiology of 
Vision). The outcome of the ERGs in all BD cases is subnormal or with non-recordable 
amplitudes of the rod-isolated b-waves with peak times either within the normal range or 
prolonged compared to controls (Burstedt et al., 2001, 2003, 2008). Representative full-field 
ERGs from five individuals from one family are presented in Fig. 12. The mixed rod-cone b-
waves amplitudes are subnormal/non-recordable with comparatively short peak times in 
the younger cases. The amplitudes of the mixed rod-cone a-waves are found to be within the 
normal range in younger patients and subnormal to non-recordable with a prolonged peak 
time in adulthood. The amplitudes of the cone b-waves are better preserved and are within 
the normal range at the very young age, with peak times within the normal range, but 
prolonged in young adulthood and thereafter. Most of the younger patients had normal 
amplitudes and implicit times of the 30-Hz flicker ERGs that are within the normal limits, 
but already in early adulthood subnormal and delayed. The summed amplitudes of the 
individual oscillatory peaks, representing the Ops, show subnormal values at young age, 





















































































Fig. 12. Full-field ERG responses of the nonaffected individual (above) and BD patients, two 
elderly, and two younger women (52, 42, 23, and 8 years of age, respectively) from the same 
family. (Figure published in Arch Ophthalmol. 2001;119(2):260–267). 
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individual oscillatory peaks, representing the Ops, show subnormal values at young age, 





















































































Fig. 12. Full-field ERG responses of the nonaffected individual (above) and BD patients, two 
elderly, and two younger women (52, 42, 23, and 8 years of age, respectively) from the same 
family. (Figure published in Arch Ophthalmol. 2001;119(2):260–267). 
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The ERGs recorded under standard conditions show that the rod and mixed rod-cone b-
wave responses are relatively more affected than the mixed a-wave. The cone b-wave and 
the 30 Hz flicker amplitudes are significantly better preserved than the b-wave amplitudes 
of the rod and mixed rod-cone responses as well as the a-wave amplitude of the mixed rod-
cone response, indicating later disturbance of the cones compared with the rods. At the 
same time the glial and inner retinal cell types seem to be affected at a relatively early stage 
in retinal degenerative disease (Burstedt et al., 2003). 
2.3.2 Dark adaptometry and electrophysiology findings during 24 h prolonged dark-
adaptation conditions 
It has been shown that after illumination, the rhodopsin regeneration, 11-cis-retinal 
production, and dark adaptation are delayed by >10-fold in the visual cycle in RLBP1 
knockout mice (Saari et al., 2001). This could also be observed in humans, in six younger 
adults with BD, examined with a standardized Goldmann-Weekers adaptometer during an 
extremely prolonged dark adaptation of 24 hours (Burstedt et al., 2003). The extremely slow 
DA reaches steady state within 5 to 12 hours (Fig. 13); however, the final visual sensory 
thresholds do not return to normal levels after 24 hours of DA in most of the cases studied, 
probably affected by the disturbance in the normal function of CRALBP and lack of 
regeneration of 11-cis retinal in the RPE. An apparent plateau of recovery in the dark is 
observed, and duration for about 1 to 4 hours possibly represents a removal of bleached 
pigments, which has been suggested to occur in other retinal diseases affecting visual cycle 
function (Cideciyan et al., 1997). The 11-cis-retinal has been estimated to range from about 
3.5% to 8% of that in normal subjects (Lamb & Pugh, 2004), with an average level of about 
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Fig. 13. Results of extremely prolonged (24 h) dark-adaptometry examinations in single eyes 
in BD patients, n = 6 (age 12–47 years). The final thresholds after 24 h were measured in both 
the patched single eye and in the unpatched contralateral eye. The values of the unpatched 
contralateral eye are indicated as filled symbols (•). The shaded area indicates normal range 
for corresponding age groups. (Figure published in Vision Research 2003:43(24):2559–2571). 
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Full-field ERGs after 24 hours of extremely prolonged DA were performed to evaluate the 
capacity of recovery of the whole retinal area and different cell types in BD disease. Six 
young cases (age 15–30 years) underwent full-field ERGs after 24 hours of DA in one eye 
and standard DA in the fellow eye. The results could be compared with the effect of the 
ERG after 10 hours’ prolonged DA from a previous study (Burstedt et al., 2003, 2008). 
Enhanced rod-isolated b-wave after extremely prolonged DA (24 h) shows a sufficient 
number of rods able to function, generating responses of normal amplitudes even in young 
BD patients, although still with prolonged peak times (Fig. 14). Since the b-wave of the ERG 
is a glial response reflecting a depolarization of the Müller cells (Miller & Dowling, 1970), 
these findings may be correlated to an affected CRALBP function in the Müller cells of the 
retina or possibly a reversible effect on the second-order ON-bipolar cell function, as a 
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Fig. 14. Full-field electroretinograms of one eye, recorded after prolonged DA (10 h) and 
after extremely prolonged DA (24 h) in two BD patients (both 21 years old). A ‘second’, 
comparatively slowly rising positivity was observed in the mixed rod-cone response 
(arrows). For comparison, recordings of a normal subject are shown. (Figure published in 
Doc Ophthalmol. 2008;116(3):193–205). 
The mixed rod-cone b-wave amplitude created by depolarization of the Müller and ON-
bipolar cells in the inner retina is increased but still subnormal in the majority of patients. 
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Fig. 13. Results of extremely prolonged (24 h) dark-adaptometry examinations in single eyes 
in BD patients, n = 6 (age 12–47 years). The final thresholds after 24 h were measured in both 
the patched single eye and in the unpatched contralateral eye. The values of the unpatched 
contralateral eye are indicated as filled symbols (•). The shaded area indicates normal range 
for corresponding age groups. (Figure published in Vision Research 2003:43(24):2559–2571). 
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Fig. 14. Full-field electroretinograms of one eye, recorded after prolonged DA (10 h) and 
after extremely prolonged DA (24 h) in two BD patients (both 21 years old). A ‘second’, 
comparatively slowly rising positivity was observed in the mixed rod-cone response 
(arrows). For comparison, recordings of a normal subject are shown. (Figure published in 
Doc Ophthalmol. 2008;116(3):193–205). 
The mixed rod-cone b-wave amplitude created by depolarization of the Müller and ON-
bipolar cells in the inner retina is increased but still subnormal in the majority of patients. 
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After extended (24 h) DA, the mixed rod-cone a-wave response increases in amplitude to 
normal values in 4/5 cases with normal or somewhat delayed peak times. As the mixed a-
wave shows normalized responses in the majority of the young BD cases examined, and the 
leading edge of the a-wave mainly represents a light-evoked hyperpolarization of the 
photoreceptors (Brown, 1968; Jamison et al., 2001; Robson et al., 2003; Tomita, 1965), these 
data suggest an additional, extremely slow regeneration of photopigments occurring even 
after 10 h DA. No obvious recovery of the cone b-wave is noted after the extremely 
prolonged DA (24 h); therefore, a relatively early damage to the cone system in BD patients 
cannot be excluded. Even though regeneration of opsin photopigments has been 
demonstrated in cone-dominant retinas, suggesting an interaction between Müller cells and 
cones in the recycling of visual chromophore (Mata et al., 2002), these electrophysiological 
results cannot confirm these findings. 
In three younger BD patients a late evolvement in the mixed rod-cone response is observed 
(Fig. 14, arrows). The amplitudes are within the normal range of a mixed rod-cone b-wave, 
but the peak is extremely delayed (115 ms) compared to normal. This can be related to an 
enhanced scotopic activity associated with the slow and disturbed regeneration of 
photopigments. However, the exact origin of this late positive potential observed in BD 
patients is not known. 
In summary, the continuous but slow regeneration of rod photopigments in RLBP1 mutants 
presents an additional capacity for recovery of rod function and gain in activity in the inner 
retinal layers with extremely prolonged dark adaptation, possibly as a consequence of a 
change in photoreceptor function (Burstedt et al., 2003, 2008). 
2.4 Outcome of visual function 
Visual loss is an early sign of the BD disease, and individuals of working age may 
experience important socioeconomic consequences and interference with education as a 
result of their visual impairment. To provide insight into the perceived visual function of 
retinitis pigmentosa of Bothnia type, measurements of visual function were associated with 
the patients’ self-assessment of their total self-reported visual function and health-related 
quality of life, measured with a questionnaire in 49 BD cases (Burstedt et al., 2010). 
Significant correlation was found between objective visual functions studied, and the 
subjective visual function. Almost 70% of the variability of the composite score could be 
explained by WVA and age alone. BD patients’ responses to a majority of the questionnaire 
subscales significantly correlated with several of the clinical vision measures, especially 
those depending on central vision. Notably, the progressive declines in visual field area did 
not seem to affect significantly the self-perceived quality of life in patients with this 
phenotype. This finding might be an indication of ability to adapt to this type of gradual 
progressive visual field area loss, probably due to use of paracentral preserved areas. The 
expression of the disease has a significant impact on multiple domains of daily living, but 
there are no signs of worsening depression related to the increasing visual impairment. 
2.5 Tinted contact lenses in BD 
Could visual function be improved in BD? With the knowledge of an extremely prolonged 
dark adaptation (5–12 h) and even further gain of the ERG responses up to more than 12 h in 
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this phenotype, outcome of wearing of tinted contact lenses during daylight was tested 
(Jonsson et al., 2007). 
Twelve patients with BD were fitted with soft contact lenses tinted dark brown. Outcome of 
visual parameters, and visual-function questionnaire, were tested before the contact lens 
fitting and after one month. Visual function was improved by dark-tinted contact lenses, 
and it was observed that the BD cases with the lowest visual acuity described the most 
obvious improvement of their visual function and preferred the darker tinted contact lenses; 
the majority of BD cases from this study have also chosen to continue wearing the brown-
tinted contact lenses for several years following the study, possibly indicating a continuous 
benefit in their daily life over time (authors’ comments). 
Absorbance 50%   70%     90%
 
Fig. 15. Contact lenses with clear and different grades of tint were evaluated in retinitis 
pigmentosa of Bothnia type. 
3. Conclusions 
The RP population of northern Sweden has given us a unique opportunity to evaluate and 
compare the phenotypical expression of different RLBP1 mutations over time. Despite 
genetic heterogeneity, the clinical expression of different RLBP1 mutations in northern 
Sweden presents a unique phenotype of the retinal disease, clearly directing the molecular 
diagnosis and search for RLBP1 mutations. It became possible to offer genetic testing among 
the families related to BD patients and also to the patients with a hereditary form of the 
recessive form of RP. In BD families we can offer risk assessment to future generations, 
providing genetic counselling based on molecular testing and clinical findings. There are 
several approaches to treatment of RP patients, although there are no established standards. 
Several drugs and nutritional supplements such as vitamin A palmitate, ascorbic acid, 
docosahexaenoic acid and others were evaluated with contradictory outcomes in different 
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studies. Vitamin A palmitate, the most-used nutritional supplement, is shown to slow the 
rate of retinal degeneration, but this type therapy is not without controversy (Shintani et al., 
2009). Gene therapy, which replaces or turns off the mutant disease-causing gene, represents 
another option for treatment. Several years of basic research of RPE65-Lebers congenital 
amaurosis, a retinal disease affecting the visual cycle, by several independent research 
groups, resulted in clinical trials of human gene therapies during recent years, 
demonstrating short-term evidence of visual gain (Jacobson & Cideciyan, 2010; Musarella & 
MacDonald, 2011). Therefore, we suggest that for treatment of BD patients, gene therapy is 
the most promising option among other concepts in the treatment of retinitis pigmentosa. 
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To Finley: You made this work very special to us. 
1. Introduction 
Retinal dystrophies are characterized by the degeneration of vision-supporting 
photoreceptor cells of the retina, leading to irreversible blindness. It is a heterogeneous 
group of diseases that can be caused by mutations on more than 150 identified genes with 
diverse functions (http://www.sph.uth.tmc.edu/Retnet/home.htm). Retinal dystrophies 
can be classified based on whether the rod or the cone photoreceptor cells are affected first, 
and based on the onset and progression of vision loss [1]. Leber congenital amaurosis (LCA) 
is in clear contrast with other inherited retinal dystrophies in that both rod and cone 
photoreceptor cells are affected from the onset of the disease [1]. The second major 
characteristic of LCA is that the progression to complete blindness is fast, making it the most 
devastating form of inherited retinal dystrophies [1]. In most cases, visual handicap is 
diagnosed before one year of age and progresses to legal blindness in early adulthood [2]. 
Other signs of the disease are an extinguished or severely reduced scotopic and photopic 
electroretinogram, absent or diminished pupillary response to light, and nystagmus 
(roaming eye movements) [3]. It is a rare disease, affecting approximately 1:30,000 people 
worldwide but it is the first cause of inherited blindness in children [2]. 
During the past 15 years, our understanding of the genetic basis of LCA has greatly 
progressed [1]. Today, 14 different genes causing LCA have been identified [1]. Together 
they are responsible for approximately 75% of LCA cases, the remaining 25% of LCA cases 
being caused by mutations in unidentified genes. The identified LCA-causing genes are 
expressed in various cell types of the retina and are involved in a wide variety of 
developmental and physiological pathways [1]. Because the disease is induced by mutation 
on a single gene, LCA patients are potentially good candidates for gene replacement 
therapy. In recent years, exciting results have been obtained in clinical trials for LCA caused 
by mutations on the RPE65 gene (LCA2), representing 3 to 16% of LCA cases [4]. Several 
other LCA-causing genes have received proof-of-concept validation for gene therapy in 
animal models [1]. We can anticipate that in the following years, patients with LCA induced 
by mutations on these genes will undergo clinical trials for gene replacement therapy. 
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In this chapter, we will concentrate on LCA13 caused by mutations in the RDH12 gene. 
This gene encodes for an enzyme of the short-chain dehydrogenase/reductase 
superfamily. It was named retinol dehydrogenase 12 (RDH12) based on its similarity with 
the RDH11 enzyme (Figure 1) [5]. Gene replacement therapy is not currently available for 
LCA13 patients and may not be for several years. Thus, any alternative therapeutic 
approach would be beneficial. We will review our and other’s findings regarding the 
function of RDH12, providing new insight into the mechanism of RDH12-induced LCA. 
We will discuss how understanding the role of RDH12 is allowing the development of 
alternative therapeutic strategies to gene replacement therapy for patients with LCA13. 
Finally, we will describe our encouraging preliminary results obtained in a mouse line 
with disrupted Rdh12 gene, using an imidazole-containing peptide derivative, which 
could be rapidly developed into an effective therapeutic strategy to preserve retinal 





Fig. 1. Alignment of human RDH12 and RDH11 sequences. Residue numbers are  
shown on the right. Identical residues are boxed. Overbars denote the two signature 
sequences for the superfamily of short-chain dehydrogenase/reductases [6].  
GenBank™ accession numbers for human RDH12 and RDH11 are NP_689656 and 
CAG33461, respectively. Stretches of NH2-terminal hydrophobic residues predicted  
to be inserted in the membrane are underlined. 
2. RDH12 and Leber Congenital Amaurosis 
In 2004, mutations in the RDH12 gene were found in a subset of LCA patients [7, 8]. Since 
then, more than 30 RDH12 mutations have been found in the homozygous or compound 
heterozygous state in LCA13 patients [7-11]. LCA13 is inherited in an autosomal recessive 
manner and represents about 4% of all LCA cases [2]. LCA13 appears to share  a common 
clinical picture with other types of LCA characterized by a poor visual function in early 
life, followed by a progressive decline due to both rods and cones degeneration [9]. 
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Interestingly, when compared with the RPE65-mutant retina that has a relatively well 
preserved structure with a disproportionate loss of photoreceptor function (as measured 
in 4 LCA2 patients; ages 17, 19, 19 and 23), the structure of RDH12-mutant retina appears 
disrupted at much younger ages (measured in 4 LCA13 patients; ages 8, 11, 13 and 21) 
[12]. 
A number of RDH12 mutations leading to LCA have been biochemically evaluated by 
expressing the mutants in cultured cells and by measuring the enzymatic activities of the 
recombinant enzymes [7-11]. These studies have shown that mutations in RDH12 result in 
decreased or abolished enzymatic activity due to a lower affinity for the substrate or a lower 
affinity for the coenzyme and/or to a decreased specific activity. In addition, most of 
RDH12 mutations resulted in low steady-state levels of the mutant proteins in cells [11, 13]. 
It was hypothesized that these mutants could be recognized as misfolded and targeted for 
accelerated degradation by the ubiquitin-proteasome system [13]. These studies strongly 
suggest that the loss of RDH12 function is the primary event causing the development of 
LCA13 phenotype (i.e. rapid loss of photoreceptor function and disruption of retinal 
structure). Thus, to determine the triggering event in LCA13 pathogenesis, and because 
RDH12 is an enzyme, the fundamental question is: what is the nature of the RDH12 
substrate?  
3. Enzymatic activity of RDH12 
RDH12 is an oxidoreductase enzyme of the short-chain dehydrogenase/reductase 
superfamily [5]. Its substrate and coenzyme specificities have been elucidated in vitro [5, 
14]. RDH12 was found to reduce all-trans retinal and other retinaldehydes (in cis 
configurations) to corresponding retinols, using the reduced form of nicotinamide 
adenine dinucleotide phosphate as cofactor [5, 14]. In addition, various aldehyde-
containing molecules, including 4-hydroxynonenal (4-HNE), were found to be reduced by 
RDH12 to corresponding alcohols [14]. Thus, RDH12 has a double substrate specificity for 
all-trans retinal (and other retinaldehydes) and for 4-HNE (and other toxic aldehydes). In 
addition, the possibility that RDH12 could have other -yet unknown- substrates cannot be 
ruled out. 
The existence of two groups of substrates for RDH12 suggests that this enzyme could 
have two distinct physiological functions in vivo. As mentioned, mutations of RDH12 
associated with LCA resulted in a decreased enzymatic activity of RDH12, inhibiting the 
reduction of all-trans retinal and 4-HNE to the corresponding alcohols in vitro [7, 10, 11, 
15].  
4. Possible RDH12 function(s) in the retina 
RDH12 is abundantly expressed in rod and possibly cone photoreceptor cells in the retina 
[16-19]. These cells are photosensitive; they detect the presence of photons through the 11-cis 
retinal chromophore bound to opsin protein (forming the photosensitive rhodopsin). When 
photobleaching of rhodopsin occurs, light isomerizes 11-cis retinal to all-trans retinal, which 
then dissociates from opsin. This photoisomerization is the initial event that triggers the 
visual transduction pathway, activation of second order neurons, and eventually 
transmission of the signal to the brain. Under constant illumination, 11-cis retinal has to be 
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RDH12 mutations resulted in low steady-state levels of the mutant proteins in cells [11, 13]. 
It was hypothesized that these mutants could be recognized as misfolded and targeted for 
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suggest that the loss of RDH12 function is the primary event causing the development of 
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substrate?  
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RDH12 is an oxidoreductase enzyme of the short-chain dehydrogenase/reductase 
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visual transduction pathway, activation of second order neurons, and eventually 
transmission of the signal to the brain. Under constant illumination, 11-cis retinal has to be 
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replaced (recycled) and all-trans retinal has to be removed from the surrounding of opsin so 
that photoreceptor cells continue to have an optimum sensitivity to light. The retinoid or 
visual cycle is the multi-step biochemical pathway that allows the recycling of 11-cis-retinal. 
The retinol dehydrogenases RDH8 (expressed in photoreceptor cells) and RDH5 (located in 
retinal pigment epithelium cells) were shown to directly participate in this essential 
pathway for maintenance of normal vision [20]. A possible function for RDH12 could thus 
be to reduce all-trans retinal, duplicating the RDH8 function, to keep photoreceptor cells in a 
state of high sensitivity to light.  
We proposed another possible function for RDH12 in photoreceptor cells, in relation with its 
ability to reduce 4-HNE [15]. Reactive oxygen species formed within the mitochondria as 
byproducts of the electron transport chain can directly attack polyunsaturated fatty acids 
and initiate an auto-amplified chain reaction of lipid oxidation in cellular membranes. This 
causes the degradation of polyunsaturated fatty acids into a variety of oxidized products, 
including short- and medium-chain reactive aldehydes such as malondialdehyde, 4-
hydroxyhexenal, and 4-HNE [21]. 4-HNE is the oxidation product of -6 arachidonic and 
linoleic fatty acids and is the most abundant and toxic end-product of lipid oxidation found 
in tissues [21-23]. It reacts readily with histidine, cysteine, and lysine to form Michael’s 
adduct with these residues [24]. Oxidative modification of protein by 4-HNE leads to a 
variety of effects including inhibition of enzymatic activities; inhibition of protein functions; 
targeting of modified proteins for degradation; inhibition of protein, RNA, and DNA 
synthesis; cell cycle arrest; and apoptosis [21, 22, 25, 26]. When 4-HNE is reduced to the 
corresponding alcohol dihydroxynonene, its ability to form toxic adduct with proteins is 
abolished. Thus, we proposed that a possible function for RDH12 in the retina could be to 
detoxify 4-HNE by reducing it to dihydroxynonene [15].  
When there is a loss of enzymatic function in cells, the substrate of the inactivated enzyme 
accumulates while the product of the reaction decreases. The next question is then 
whether it is the accumulation of substrate(s) or the disappearance of product(s), or both, 
that triggers the LCA13 phenotype. All-trans retinol, the product of all-trans retinal 
reduction, is not absolutely required for visual function because it is constantly supplied 
to the retinal pigment epithelium cells from the circulating blood. Therefore the most 
probable hypothesis is that accumulation of the substrate (all-trans retinal) rather than 
lack of product (all-trans retinol) might cause the retinal phenotype in LCA13 patients. 
Dihydroxynonene, the product of 4-HNE reduction, is not known to mediate any crucial 
biological function therefore in this scenario also, it seems that accumulation of the toxic 
substrate (4-HNE) rather than lack of product (dihydroxynonene) would cause the LCA13 
phenotype. 
5. Utilization of the Rdh12 knockout mouse to determine the physiological 
substrate of RDH12 
Identifying possible substrates for an enzyme in vitro is not enough to demonstrate that they 
are physiological substrates. In vivo, other considerations such as the localization and 
concentration of substrate relative to that of the enzyme are very important. Locations of the 
enzyme and substrate have to overlap and the substrate concentration has to be within a 
specific range for the enzymatic reaction to take place in vivo. The next step is thus to 
determine if there is accumulation of all-trans retinal and/or 4-HNE in the retina, in absence 
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of RDH12. Mice with disrupted Rdh12 gene have been generated [16, 19] and they have been 
useful to determine what substrate of RDH12 accumulates in the retina.  
After bleaching of rhodopsin, a moderate delay in all-trans retinal clearance was found in 
the Rdh12 knockout retina [19, 27, 28]. To explain the existing but surprisingly small delay 
in all-trans retinal clearance, it has been argued that RDH12 is located only in the inner 
segment of photoreceptor cells, while rhodopsin is located only in the outer segment. 
Thus, it was proposed that instead of participating directly (with RDH8) to the reduction 
of all-trans retinal released in the outer segment, RDH12 could reduce only a small 
portion of all-trans retinal overflowing to the inner segment after bleaching of rhodopsin 
[27, 28].  
In our study, we found that retinas of  both albino [15] and pigmented Rdh12 knockout mice 
(Figure 2)  accumulated more 4-HNE-modified proteins than the corresponding wild-type 
animals on the same genetic background. As shown in Figure 2, pigmented knockout mice 
have significantly more retinal 4-HNE-protein adduct than the wild-type when exposed to 
bright light, a condition that induces oxidative damage. Similarly, in the BALB/c albino 
mice, 4-HNE-protein adduct was 60% higher in Rdh12 knockout than in wild-type retinas in 
2-month old animals raised under dim cyclic light [15]. These results support the hypothesis 
that 4-HNE is a physiological substrate of RDH12 in rod inner segments. 
 
 
Fig. 2. RDH12 protects against light-induced adduct formation in pigmented mouse 
retina. Graph shows results for 6 mice per group. Littermates of wild-type and Rdh12 
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knockout mice were raised under dim (5-10 lux) cyclic light for 8 weeks. Control wild-type 
(WT) and knockout (KO) mice were killed 5 h after the (dim) light started. Light damaged 
(WT LD and KO LD) mice were killed after 48 h exposure to bright light (3,000 lux), without 
prior dilation of the pupils. Dissected retinas were homogenized in T-PER buffer (Pierce), 
according to the manufacturer's instructions. Protein concentrations were measured and dot 
blot analyses were carried out as described to quantify retinal adduct [15]. Equal aliquots  
(5 g) of retinal protein were applied to a 96-well dot blot apparatus (Bio-Rad) and then 
transferred to a nitrocellulose membrane by vacuum filtration. Sample loading was 
monitored by staining the membrane with Ponceau red (Sigma). Membranes were blotted 
over night with a 1:1000 dilution of anti-HNE antibody coupled with horseradish 
peroxidase (abcam). Signals were quantified using SuperSignal West Femto 
Chemiluminescent Substrate (Pierce) and the digital Kodak Image Station 4000R.  
Error bars denote SEM and Student’s t test was used for significance.  
NS, not significant (p>0.05); ***, p<0.0001. 
The conclusion of these studies is that at least two physiological substrates of RDH12 coexist 
in photoreceptor cells; namely all-trans retinal and 4-HNE. The clearance of both of these 
substrates is delayed in the Rdh12 knockout retina and it is now of crucial importance to 
determine which one, or if they can both, trigger the LCA13 phenotype. 
6. Limitations of the Rdh12 knockout mouse model to determine what 
substrate mediates photoreceptor damage 
The main limitation to further determine whether accumulation of all-trans retinal or 
accumulation of 4-HNE is the triggering event in LCA13 is that, unlike LCA13 patients, the 
Rdh12 knockout mouse does not develop a retinal phenotype [16, 19]. Thus the Rdh12 
knockout mouse is not an appropriate model for LCA13. We propose two possible 
explanations for the differences between mouse and human phenotypes. 
6.1 Perhaps in mouse -but not in human- another enzyme is compensating for the 
loss of RDH12 
In addition to RDH12, RDH11 and RDH13 are located in the inner segment of mouse 
photoreceptors. RDH11 and 12 are integral membrane proteins. Both enzymes are inserted in 
the membrane through a stretch of ~20 NH2-terminal hydrophobic residues (Figure 1) [5, 29]. 
RDH13 does not contain this stretch of hydrophobic residues and is a peripheral membrane 
protein. In previous studies, we showed that RDH11 is localized in the Golgi apparatus in 
spermatocytes [29] and in various cultured cells (unpublished observation). We performed a 
subcellular fractionation of mouse retinal tissues through ultracentrifugation on sucrose 
gradient [30]. RDH12 was found in Golgi- and endoplasmic reticulum-enriched fractions and 
RDH11 was detected only in the Golgi-enriched fractions [31]. Another study showed that 
RDH13 is a mitochondrial enzyme, localized within the intermembrane space, and associated 
with the inner mitochondrial membrane [32]. These different subcellular localizations suggest 
a specific role for RDH13 in the mitochondria, another specific role for RDH12 in the 
endoplasmic reticulum, but a possible redundant function for RDH11 and RDH12 in the Golgi. 
In the Rdh12 knockout mouse photoreceptors, RDH11 may functionally compensate for 
RDH12 because these enzymes have overlapping localization and they have similar enzymatic 
activities and substrate specificities [17]. In humans on the other hand, RDH11 may not be 
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expressed in photoreceptor cells [5] and thus may not compensate for the loss of RDH12 
activity, possibly explaining the more dramatic phenotype in LCA13 patients.  
6.2 Perhaps bright light is triggering the phenotype resulting from disruption of 
RDH12 enzymatic activity 
Patients with LCA13 show an early disruption of their retinal structure [12]. The distorted 
laminar architecture of RDH12-mutant retinas seems to be a specific feature of some 
subtypes of LCA [12]. It has been suggested that such dysplastic retinal response could be 
triggered by some forms of photoreceptor damage induced by environmental conditions 
[12]. For example, light exacerbates the retinal dysplasia in a mouse model of LCA caused 
by CRB1 mutations (LCA8) [33, 34]. Interestingly, the Rdh12 knockout mice do not have a 
retinal phenotype when they are raised under a controlled dim (5-10 lux) cyclic light 
environment [15, 16, 19]. However, when they are challenged by exposure to bright light 
(3,000 lux for the Rdh12 knockout mice under the BALB/c background), the Rdh12-null 
photoreceptors appear significantly more sensitive than the wild-type cells to light-induced 
apoptosis [15, 19]. Since Rdh12 knockout photoreceptors degenerate only after exposure to 
bright light but do not have a spontaneous degeneration when raised under controlled dim 
cyclic light, it is possible that similarly, the LCA13 patients have retinal degeneration 
because they are regularly exposed to very bright light intensities (i.e. outdoor light during a 
sunny day). Anticipation of dysplastic retinal response and greater understanding of the 
pathway that triggers it could lead to specific therapy to prevent this process in LCA13 
patients. Without such prevention, the amount of salvageable retina might quickly become 
so low that any gene replacement therapy would not be worth attempting. 
It is likely that the compensation by other RDHs combined with the controlled lighting 
environment, and anatomical differences between mouse and human retinas explain the 
absence of retinal phenotype in the Rdh12 knockout mouse, as opposed to the dramatic 
phenotype in LCA13 patients. In any case, it is difficult to use the Rdh12 knockout mice to 
determine what substrate of RDH12 accumulating in absence of enzyme induces a retinal 
phenotype, because there is no phenotype. Retinal damage can be induced by exposure to 
bright light but this treatment exacerbates the production of both substrates of RDH12 
simultaneously so it is impossible to distinguish which one triggers the hypersensitivity of 
Rdh12-null photoreceptor cells to light-induced damage. In addition, we cannot exclude the 
alternative possibility that the hypersensitivity to light of the Rdh12-null photoreceptors is 
not the specific result of accumulation of RDH12 substrate(s) but rather due to a non-specific 
effect of the gene inactivation. 
7. Alternative strategy to determine what substrate mediates photoreceptor 
damage 
An alternative strategy is to experimentally induce the production of all-trans retinal and 4-
HNE simultaneously by exposure of the Rdh12 knockout mice to bright light, while at the 
same time decreasing the level of 4-HNE using a molecule that can specifically scavenge 4-
HNE and lower its concentration in the retina (Figure 3). This strategy allowed us to 
distinguish the relative participation of each substrate to the photoreceptor hypersensitivity 
to light. 
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Fig. 3. Experimental strategy to determine what substrate of RDH12 mediates  
photoreceptor hypersensitivity to light-induced damage. Exposure to bright light 
exacerbates the production of both substrates (all-trans retinal and 4-HNE)  
simultaneously. In absence of RDH12, both substrates accumulate so it is impossible  
to distinguish which one triggers the hypersensitivity of photoreceptor cells to  
light-induced damage. Carcinine scavenges 4-HNE, forming 4-HNE-carcinine adduct,  
and thus can be used to lower 4-HNE independently of all-trans retinal. This allowed  
us to dissociate the effects of 4-HNE and all-trans retinal in the Rdh12 knockout mouse 
retina.  
Carcinine (-alanyl-L-histamine) is a natural imidazole-containing peptide derivative that 
has antioxidant properties and can scavenge reactive aldehydes produced by lipid 
peroxidation [35, 36], thus preventing them from reacting with cellular proteins (manuscript 
submitted for publication). We have shown that intravitreal injection and systemic 
administration of carcinine protect wild-type photoreceptors from light-induced damage 
(manuscript submitted for publication). Photoreceptors are the first retinal cell type to show 
signs of damage after exposure to bright light. Light-induced apoptosis of photoreceptor 
cells is preceded by an increase of oxidative modification of retinal proteins [17, 37] and can 
be blocked by various types of antioxidants [38-40] including carcinine (manuscript 
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We used carcinine to lower 4-HNE independently of all-trans retinal and dissociate the 
effects of these two molecules in mouse retina. Incubation of carcinine with all-trans retinal 
in vitro does not lead to any modification of the all-trans retinal molecule as determined by 
high-performance liquid chromatography analysis (unpublished observation) but 
incubation with 4-HNE leads to the formation of an adduct between carcinine and 4-HNE as 
determined by high-performance liquid chromatography and mass spectrometry 
(manuscript submitted for publication). Thus, carcinine is not expected to lower the retinal 
level of all-trans retinal or other retinoids under normal conditions or during exposure to 
bright light.  
As shown in Figure 4A, without carcinine treatment (phospate buffered saline-injected eye), 
exposure of wild-type mice to bright light induces a decrease of rod-mediated visual 
function by approximately 50% for both a- and b-waves (black bars). As expected, the Rdh12 
knockout mice are more sensitive than the wild-type to light-induced damage, as shown by 
the 80 to 90% decrease of rod-mediated visual function for both a- and b-waves under the 
same conditions of light exposure (white bars). This result is consistent with previously 
published studies showing hypersensitivity of these knockout mice to light-induced damage 
[15].   
Carcinine is expected to prevent light-induced damage mediated by oxidative stress and 
lipid peroxidation in photoreceptors. As shown in Figure 4A, with carcinine treatment 
(carcinine-injected eye), exposure of wild-type mice to bright light induce the decrease of 
rod-mediated visual function to about 25% loss instead of 50% loss without carcinine. In 
the Rdh12 knockout mice, carcinine completely prevents the decrease of rod-mediated 
visual function. The remaining rod-mediated visual function after light damage goes from 
10% without carcinine to 100% with carcinine, demonstrating a considerably beneficial 
effect of carcinine in these mice. The reason(s) why carcinine seems to protect more 
efficiently Rdh12 knockout than wild-type photoreceptors is unknown. However, we can 
speculate that the disruption of Rdh12 creates a “mild stress” in photoreceptors, inducing 
maybe some alternative protective mechanisms. The combination of enhanced 
compensatory protection and carcinine protection could be a possible explanation for this 
apparent higher efficiency of carcinine in the knockout than in the wild-type 
photoreceptors. 
As shown in Figure 4B, cone-mediated visual function is more affected in the knockout than 
in the wild-type mouse by exposure to bright light (in phospate buffered saline -injected 
eye), and complete protection was provided by carcinine in both wild-type and knockout 
mice (carcinine-injected eye). 
The fact that carcinine completely prevents light-induced damage in the Rdh12 knockout 
mouse photoreceptors strongly suggests that the damage induced by light is mostly -if not 
only- mediated by oxidative stress and lipid peroxidation products accumulating in the 
Rdh12 knockout photoreceptor cells. However, a mirror experiment in which all-trans 
retinal is specifically lowered independently of 4-HNE would further confirm our 
conclusion, if there was no protection. To specifically lower all-trans retinal independently 
of 4-HNE, a possible approach could be to overexpress the RDH8 enzyme in the Rdh12 
knockout photoreceptors because, as we have shown before, 4-HNE is not a substrate of 
RDH8 [29]. 
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Rdh12 knockout photoreceptor cells. However, a mirror experiment in which all-trans 
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conclusion, if there was no protection. To specifically lower all-trans retinal independently 
of 4-HNE, a possible approach could be to overexpress the RDH8 enzyme in the Rdh12 
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Fig. 4. Carcinine protects visual function against light-induced damage in wild-type and 
Rdh12 knockout mice. BALB/c mice were raised in dim cyclic light for 8 weeks. Each 
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mouse was injected intravitreally in one eye with 1 l phospate buffered saline (PBS) and in 
the other eye with 1 l of 2 M carcinine diluted in PBS. Mice were returned in dim cyclic 
light for 48 h before light damage was initiated. Light damage was then induced in mice by 
5 h exposure to 4,000 lux of white fluorescent light. After light exposure, mice are returned 
in dim cyclic light for 7 days to allow the retina to clear all dead cells. A. Scotopic 
electroretinographies were performed using saturating flash intensity. The a- and b-wave 
amplitudes of wild-type (black bars) and Rdh12 knockout (white bars) are plotted to 
quantify rod-mediated visual function. B. Photopic ERGs were then performed to measure 
cone-mediated visual function. The a- and b-wave amplitudes are plotted to quantify cone-
mediated visual function. Graphs show averaged results from 7 mice and error bars indicate 
SEM. Grey boxes show normal a- and b-waves recorded from PBS-injected eyes in mice that 
were not exposed to bright light. 
8. Could decrease clearance of 4-HNE have toxic effects in photoreceptors?  
Effects of 4-HNE in cells and its association with disease states have been increasingly well 
documented [23, 41]. Studies have shown that low, basal levels of the lipid aldehyde are 
present in cells (<5 M), and at these concentrations, 4-HNE acts as a signaling molecule [42, 
43]. It can activate cell growth and survival as well as stress response mechanisms, such as 
mitogen activated protein kinases, detoxification mechanisms, and inflammatory response, 
and by this way prepare the cells to overcome acute stress (protective effects) [41]. Under 
conditions of oxidative stress, 4-HNE concentrations increase above physiological levels; in 
membranes it accumulates at concentrations of 10 M to 5 mM in response to oxidative 
insult [22, 23]. At such concentrations, the protective effect is lost; 4-HNE forms adduct with 
proteins inactivating their physiological functions, and activates intra cellular pathways 
promoting cell death [22, 23, 41]. 
The presence of 4-HNE-derived epitopes, including 4-HNE-protein adduct, has been 
reported in a growing number of diseases, including diabetes, cardiovascular, autoimmune, 
and neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and 
amyotrophic lateral sclerosis [23]. The consistently growing evidence of increased 4-HNE 
tissue/blood levels in a great variety of human diseases certainly suggests a pathogenetic 
involvement of the aldehyde in their clinical expression and possible progression [41]. 
Recent studies have implicated 4-HNE in the pathogenesis of atherosclerosis and 
Alzheimer’s disease [22, 41]. 
Oxidative stress, which induces lipid peroxidation and 4-HNE production, has been 
abundantly described to induce photoreceptor cell death [44-47]. Whether toxicity is 
mediated by 4-HNE and other lipid peroxidation products is unknown. We hypothesize 
that 4-HNE-mediated toxicity is inducing the rapid loss of vision in LCA13 patients. This 
hypothesis is based on the following evidences: (1) in cell culture, enzymatically active 
RDH12 protects against 4-HNE-induced cell death, while enzymatically inactive RDH12 
does not [15, 37]. (2) Photoreceptor cells are particularly predisposed to oxidative stress 
because the retina has a high oxygen consumption, is chronically exposed to light, and 
contains several photosensitizers. This leads to an active production of reactive oxygen 
species. Furthermore, photoreceptors have a high content in polyunsaturated fatty acids, 
making their membranes particularly susceptible to lipid oxidation induced by reactive 
oxygen species. (3) In photoreceptor cells, 4-HNE production is induced by exposure to 
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bright light, specifically in the inner segment, the compartment where RDH12 is located [15, 
37]. (4) Disruption of RDH12 induces accumulation of 4-HNE-modified proteins in mouse 
retina, correlated with a hypersensitivity to acute light damage [15]. 
Taken together these results show a correlation between accumulation of 4-HNE in 
photoreceptor inner segments and loss of visual function, suggesting a possible cause-effect 
relationship. The cause-effect relationship has not been demonstrated but the mechanisms of 
4-HNE toxicity have been abundantly documented in other cells types and disease states.  
In LCA13 patients, it is likely that the loss of retinal structure and function is triggered by 
accumulation of RDH12 substrate(s). Two physiological substrates of RDH12 have been 
identified in vitro and in vivo. In absence of RDH12, accumulation of each of these substrates 
could theoretically mediate unwanted effects in photoreceptor cells.  
9. Carcinine – A possible therapeutic agent for LCA13? 
If 4-HNE is indeed involved in the LCA13 disease mechanism, then carcinine would clearly be 
beneficial based on its antioxidant and 4-HNE scavenging activities. Additionally, we recently 
found that carcinine has another effect that might be of significant interest for LCA13.  
9.1 Carcinine protects RDH12 from degradation 
In a previous study, we have shown that exposure to bright light induces a specific decrease 
of RDH12 protein level in the mouse retina while the closely related RDH11 protein remains 
stable [17]. This effect is not accompanied by a decrease of the Rdh12 mRNA level so we 
hypothesized that the protein reduction was due to increased degradation rather than 
decreased production of RDH12 [17]. We further hypothesized that RDH12, like any other 
protein could be modified by 4-HNE (or maybe even more so because it has specific affinity 
for this molecule) and targeted for degradation [17]. Bright light would increase the 
endogenous production of 4-HNE and modification of RDH12, and the adduct would be 
quickly degraded. If not compensated by an increase in RDH12 synthesis, this would result 
in a net decrease of RDH12. 
We used mouse retinal explants to test this hypothesis (Figure 5). Incubation of mouse 
retinas in a media containing 4-HNE leads to a 40% decrease of RDH12 in 4 h, while RDH12 
level remains stable in retinas incubated in the same media without 4-HNE (Figure 5A). 
Total 4-HNE-modified proteins were then immunoprecipitated with anti-HNE antibody and 
immunoblotted using an RDH12 antibody. RDH12 was immunoprecipitated by the anti-
HNE antibody (Figure 5B), demonstrating the modification of RDH12 by 4-HNE. The 4-
HNE-RDH12 adduct accumulates first (at 1 and 2 h incubation with 4-HNE) and then 
decreases (at 4 and 6 h incubation with 4-HNE), supporting the hypothesis that the adduct is 
targeted for degradation. When compared with the total amount of 4-HNE-modified 
protein, the modification of RDH12 does not seem to happen significantly faster than the 
modification of the other proteins (Figure 5C). This result invalidates the idea that the 
specific affinity of RDH12 for 4-HNE would increase the rate of adduct formation. By 
contrast, the decrease of 4-HNE-RDH12 adduct is significantly faster than the decrease of 
the total amount of 4-HNE-modified protein (Figure 5C). This result suggests that RDH12 is 
particularly unstable (compared with other proteins) when subjected to oxidative 
modification. 
 
Mechanisms of RDH12-Induced Leber Congenital Amaurosis and Therapeutic Approaches 485 
 
Fig. 5. 4-HNE modifies RDH12 and induces its degradation in retinal explants. Retinas 
were dissected from 4- to 6-weeks-old pigmented wild-type mice. Retinas were incubated  
in Dulbecco's modified Eagle's medium, with or without 200 M 4-HNE, at 37C under 5% CO2. 
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immunoblotted using an RDH12 antibody. RDH12 was immunoprecipitated by the anti-
HNE antibody (Figure 5B), demonstrating the modification of RDH12 by 4-HNE. The 4-
HNE-RDH12 adduct accumulates first (at 1 and 2 h incubation with 4-HNE) and then 
decreases (at 4 and 6 h incubation with 4-HNE), supporting the hypothesis that the adduct is 
targeted for degradation. When compared with the total amount of 4-HNE-modified 
protein, the modification of RDH12 does not seem to happen significantly faster than the 
modification of the other proteins (Figure 5C). This result invalidates the idea that the 
specific affinity of RDH12 for 4-HNE would increase the rate of adduct formation. By 
contrast, the decrease of 4-HNE-RDH12 adduct is significantly faster than the decrease of 
the total amount of 4-HNE-modified protein (Figure 5C). This result suggests that RDH12 is 
particularly unstable (compared with other proteins) when subjected to oxidative 
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Fig. 5. 4-HNE modifies RDH12 and induces its degradation in retinal explants. Retinas 
were dissected from 4- to 6-weeks-old pigmented wild-type mice. Retinas were incubated  
in Dulbecco's modified Eagle's medium, with or without 200 M 4-HNE, at 37C under 5% CO2. 
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At indicated times, 6 retinas were removed from incubation, immediately washed in 
phosphate buffered saline, and frozen in liquid nitrogen for subsequent protein preparation. 
Frozen retinas were homogenized in T-PER buffer (Pierce), according to the manufacturer's 
instructions. A. Protein concentrations were measured and immunoblot analysis using anti-
RDH12 antibody was performed using 30 g of protein. The levels of RDH12 in retinal 
explants incubated with 4-HNE were expressed relative to those of RDH12 in retinal 
explants incubated without 4-HNE, arbitrarily defined as 1.0. B. Immunoprecipitation of 4-
HNE-modified proteins was carried out as follow: equal amounts of protein were pooled 
from 6 retinas. 100 g of pooled protein were incubated with 5 l of anti-HNE antibody 
coupled with biotin (abcam) over night at 4oC, in a volume of 100 l T-PER. 50 l of 
streptavidin agarose resin (Pierce) was then added to each sample and incubated for 1 h at 
4oC. After 3 washes with 1 ml T-PER, proteins were eluted in 50 l Laemmli buffer and 
immunoblot analysis of supernatant and immunoprecipitated proteins were carried out 
with the anti-RDH12 antibody. C. Dot blot quantification of total 4-HNE-protein adduct was 
carried out as described in Fig. 2. with 2.5 g of protein. The results from B were quantified 
and plotted on the same graph. At each time point the amounts of adducts are expressed 
relative to the highest level of adduct, arbitrarily defined as 1.0. Signals were detected using 
SuperSignal West Pico chemiluminescent or West Femto Maximum Signal Substrate (Pierce) 
and quantified using Kodak Molecular Imaging Software.  
Interestingly, following intravitreal injection (Figure 6A) or systemic administration of 
carcinine (Figure 6B), the RDH12 protein level in mouse retina is stabilized and completely 
resistant to light-induced degradation. In vivo, the amount of 4-HNE-RDH12 adduct was 
undetectable (unpublished observation) so we could not determine whether carcinine was 
protecting RDH12 because it was opposing the 4-HNE-modification of RDH12 or through 
another mechanism. Absence of detectable 4-HNE-RDH12 adduct in vivo might be 
explained by the fact that endogenous production of 4-HNE as well as formation and 
degradation of adduct is an ongoing process, by contrast with the single dose of 4-HNE 
applied to the retinal explants creating a detectable “pulse” of 4-HNE-RDH12 adduct. 
The stabilization of RDH12 protein by carcinine could enhance its therapeutic benefits for 
LCA13 patients. As discussed before, the RDH12 mutants associated with LCA are not only 
poorly active, but are also particularly unstable. The stabilizing effect of carcinine could 
keep the level of mutant RDH12 high enough to allow residual RDH12 enzymatic activity in 
photoreceptor cells. This, in addition with 4-HNE scavenging and antioxidant properties, 
could preserve the retinal structure and function in LCA13 patients. 
9.2 Carcinine can be administered topically for chronic treatment 
Treatment with carcinine would have to be started at the time of diagnosis and applied 
chronically to protect against 4-HNE and oxidative damage, which are ongoing processes in 
cells. We have investigated various modes of administration that could be compatible with a 
chronic treatment and measured the resulting level of carcinine in the retina (manuscript 
submitted for publication and unpublished results). Interestingly, topical administration 
through eye drop leads to detectable levels of carcinine in the retina (Figure 7). This result 
suggests that carcinine migrates from the cornea to the retina, following topical administration. 
The mechanisms of migration (simple diffusion versus transport) as well as the routes of 
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migration (trans-corneal versus trans-conjonctival penetration, migration through the vitreous 
humor or by lateral diffusion through the sclera, etc) are currently under investigation. The 
possibility to administer carcinine through eye drops is promising because it is a non-invasive 
and particularly easy route of administration, compatible with chronic treatment. 
 
Fig. 6. Carcinine protects RDH12 from light-induced degradation in mouse retina. BALB/c 
mice were raised in dim cyclic light for 8 weeks before carcinine treatment. A. Mice were 
injected with carcinine or PBS and exposed to bright light as described in Fig. 4. For each 
group, 10 g protein extract from 6 mice were pooled (60 μg final) and immunoblotted with 
anti-RDH12 antibody. B. Carcinine was administered through gavage (0 or 20 mg / mouse/ 
day) once a day for 5 days before light exposure. Mice were then exposed to bright white 
fluorescent light (3,000 lux) for 4h. Retinas were immediately frozen and proteins were 
extracted from one retina from each mouse (4 mice per group) using T-PER reagent. Protein 
 
Advances in Ophthalmology 486 
At indicated times, 6 retinas were removed from incubation, immediately washed in 
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protecting RDH12 because it was opposing the 4-HNE-modification of RDH12 or through 
another mechanism. Absence of detectable 4-HNE-RDH12 adduct in vivo might be 
explained by the fact that endogenous production of 4-HNE as well as formation and 
degradation of adduct is an ongoing process, by contrast with the single dose of 4-HNE 
applied to the retinal explants creating a detectable “pulse” of 4-HNE-RDH12 adduct. 
The stabilization of RDH12 protein by carcinine could enhance its therapeutic benefits for 
LCA13 patients. As discussed before, the RDH12 mutants associated with LCA are not only 
poorly active, but are also particularly unstable. The stabilizing effect of carcinine could 
keep the level of mutant RDH12 high enough to allow residual RDH12 enzymatic activity in 
photoreceptor cells. This, in addition with 4-HNE scavenging and antioxidant properties, 
could preserve the retinal structure and function in LCA13 patients. 
9.2 Carcinine can be administered topically for chronic treatment 
Treatment with carcinine would have to be started at the time of diagnosis and applied 
chronically to protect against 4-HNE and oxidative damage, which are ongoing processes in 
cells. We have investigated various modes of administration that could be compatible with a 
chronic treatment and measured the resulting level of carcinine in the retina (manuscript 
submitted for publication and unpublished results). Interestingly, topical administration 
through eye drop leads to detectable levels of carcinine in the retina (Figure 7). This result 
suggests that carcinine migrates from the cornea to the retina, following topical administration. 
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migration (trans-corneal versus trans-conjonctival penetration, migration through the vitreous 
humor or by lateral diffusion through the sclera, etc) are currently under investigation. The 
possibility to administer carcinine through eye drops is promising because it is a non-invasive 
and particularly easy route of administration, compatible with chronic treatment. 
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mice were raised in dim cyclic light for 8 weeks before carcinine treatment. A. Mice were 
injected with carcinine or PBS and exposed to bright light as described in Fig. 4. For each 
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extracts from each mouse were individually quantified by immunoblot. RDH12 levels were 
normalized to -actin first and expressed relative to the level of RDH12 in retinas of dim 
untreated mice,  defined as 100%. Graph shows average and SEM values for 4 mice per group. 
Student’s t test was used for significance; NS, not significant (>0.05); **=p<0.001. 
 
Fig. 7. Topical administration of carcinine leads to detectable levels in the retina.  
Mice received carcinine (0.2 M) dissolved in Can-C eye drop solution (Innovative Vision 
Products, Inc). To analyze and quantify retinal carcinine, 2 retinas were homogenized in 1ml of 
cold 0.01M HCl with polytron. One g of internal standard anserine was added to the samples. 
Samples were extracted with acetonitrile and derivatized with phenylisothiocyanate (PITC). 
Samples were analyzed by high-performance liquid chromatography / mass spectrometry 
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(Michrom Bioresources Paradigm MSRB capillary HPLC, Bruker Daltonics HCT Ultra Ion trap 
MS). High-performance liquid chromatography was run on column Magic MS C18, 5m, 200 A, 
0.5 x 150 mm with Solvent A (0.09% formic acid, 0.01% TFA, 2% acetonitrile, 97.9% water) and 
Solvent B (0.09% formic acid, 0.0085% TFA, 95% acetonitrile, 4.9% water). An isocratic 
program (15% B for 10 min) was used. The flow rate was 20 ml/min and detection wavelength 
was 215 nm. An ion trap mass spectrometer (HCT Ultra PTM discovery system, Bruker 
Daltonics) equipped with an electrospray ion source and operating under an Esquire data 
analysis system was used. The spray voltage was set at 4 kV in the positive mode. The heater 
temperature was maintained at 300 o C. A, 0.2 M carcinine was administered in Can-C eye 
drop solution at 0 min and mice were killed 30 min later to collect retinas. B, Another set of 
mice received 0.2 M carcinine at 0 and 60 min (indicated by arrows) and were killed 30 min 
following the second administration (at 90 min) to collect retinas.  
 
Fig. 8. Carcinine decreases total 4-HNE-modified protein in mouse retina. BALB/c mice 
were raised in dim cyclic light for 8 weeks before carcinine treatment. 0.2 M carcinine was 
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Fig. 8. Carcinine decreases total 4-HNE-modified protein in mouse retina. BALB/c mice 
were raised in dim cyclic light for 8 weeks before carcinine treatment. 0.2 M carcinine was 
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administered in Can-C eye drop solution (1 drop each 60 min, for 6 h) and mice were kept in 
dim light (A) or exposed to bright light (3,000 lux) for 4 h, starting right after administration 
of the second drop (B). Immediately after exposure to bright light, retinas were collected. 
Whole retinal homogenates were prepared and equal aliquots (10 g) of retinal 
homogenates were analyzed by dot blot using anti-HNE coupled with HRP to quantify total 
4-HNE-protein adduct. Five mice were used in each group, and the mean and SEM are 
plotted. Values were compared using Student’s t test for significance; *=p<0.05; **=p<0.001.  
9.3 Carcinine decreases the amount of 4-HNE-protein adduct in the retina 
After administration of carcinine through eye drop, we found that the total amount of 
protein modified by 4-HNE in mouse retina is significantly decreased, both under dim and 
bright light (Figure 8). This result suggests that carcinine can scavenge 4-HNE in vivo after 
topical administration through eye drop. This implies that carcinine levels within the retina 
are adequate and that carcinine can enter the retinal cells to scavenge 4-HNE produced 
endogenously. Thus, carcinine could prevent the accumulation of toxic 4-HNE in RDH12-
mutant retinas. We predict that carcinine, administered through eye drops, will prevent 
light-induced retinal damage in the wild-type and Rdh12 knockout but these experiments 
have not been completed at this time. 
10. Future directions 
10.1 Developing therapeutic strategies 
As shown by our preliminary experiments with carcinine, it is possible to start developing 
appropriate therapeutic strategies from the information already available on the function of 
RDH12. As discussed, exposure to bright light, as well as increased all-trans retinal levels, 
and increased oxidative damage particularly through 4-HNE modification are suspected to 
play a role in the disease mechanism. Accordingly, protection against these triggers can be 
developed with the goal to protect the retinal structure at least long enough to allow LCA13 
patients to be eligible for gene replacement therapy.  
10.1.1 Protection from light-induced damage 
As discussed, the Rdh12 knockout photoreceptors are more sensitive than the wild-type 
photoreceptors to light damage in mouse and exposure to bright light might be a trigger for 
the early dysplastic retinal response in LCA13 patients. Therefore, protection against light-
induced retinal damage is an appropriate strategy. 
Physical protection from bright light by wearing sun glasses should be encouraged for 
patients with LCA13. Compounds such as retinoid-like small molecules that provide 
chemical protection against light-induced retinal damage could also be beneficial [48, 49]. A 
number of studies have identified that photobleaching of rhodopsin is the essential trigger 
for retinal light damage [50, 51]. Genetically-modified mice that lack the opsin apoprotein or 
that have the opsin apoprotein but lack the ability to generate 11-cis-retinal are both 
protected against light damage [50-52]. A steady state rhodopsin level is achieved by the 
balance between its bleaching and regeneration. Therefore, the rate of rhodopsin 
regeneration is an important factor in light damage susceptibility. Fast regeneration of 
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functional rhodopsin after bleaching increases retinal sensitivity to light damage, whereas 
slowing the flux of retinoids through the visual cycle increases the resistance of 
photoreceptors to light-induced insult. For example, slowing rhodopsin regeneration and 
inhibiting the visual cycle with 13-cis-retinoic acid prevents light damage in albino rats [53]. 
More recently, it has been shown that retinylamine provides efficient protection from light 
damage through a similar mechanism [48].  
Most of the small molecules inhibiting the visual cycle are structurally similar to retinoids 
[49]. However, we recently identified α-phenyl-N-tert-butyl nitrone, a commonly used free 
radical spin trap, as another type of compound with no structural similarity with retinoids 
that interferes with rhodopsin regeneration during continuous illumination and protects 
against light-induced retinal degeneration [54]. The advantage that α-phenyl-N-tert-butyl 
nitrone may have over these retinol-related compounds is that it is not structurally similar 
nor a derivative of any of the visual cycle components and therefore may not have adverse 
effect by interacting with retinoid receptors and other components of the visual cycle.  
10.1.2 Protection from oxidative damage 
Because oxidative damage is likely to contribute to the LCA13 disease mechanism, 
compounds that inhibit oxidative damage or enhance endogenous protection against 
oxidative damage would be appropriate candidates for LCA13 treatment.  
A wide variety of antioxidants are available as oral supplementations. Specific advantages 
of carcinine would be to combine antioxidant and 4-HNE scavenging activities. Thus, 
carcinine can offer an additional line of defense against oxidative damage by decreasing 4-
HNE, a secondary product of oxidative stress that mediates and amplify the oxidative 
damage triggered by reactive oxygen species and that was shown to accumulate in mouse 
retina in absence of RDH12.  
In addition, the main limitation for therapeutic utilization of antioxidants in retinal diseases 
is usually the poor targeting of the posterior segment of the eye (choroid, retinal pigmented 
epithelium, and retina) due to anatomical and physiological barriers that normally protect 
the eye. Most molecules cannot reach the posterior segment tissues upon topical 
administration in the form of eye drops. Periocular or intravitreal injections are more 
efficient routes of administration but they are invasive procedures, which are not 
compatible with a chronic preventive treatment. Oral supplementation of antioxidants is 
usually preferred but oral bioavailability and the necessity to cross the blood-retinal barrier 
limits the amount of compound reaching the target tissues, and therefore limits the 
prevention of oxidative damage in these tissues.  
Carcinine is one of the very few compounds that can reach posterior segment tissues upon 
topical administration (less than 10 of such compounds have been reported to date) [55]. 
This method of administration represents the great advantages of being non-invasive, safer 
because it is used locally no systemic side effects are expected, and cheaper because it is 
used locally the amount needed is smaller than with systemic administration than any other 
methods. It is also compatible with a chronic treatment that could be administered by the 
patients themselves, or by their parents. 
Drugs that upregulate the body’s natural defense against oxidative stress would also be 
appropriate. Reactive oxygen species are constantly generated in cells as unwanted by-
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administered in Can-C eye drop solution (1 drop each 60 min, for 6 h) and mice were kept in 
dim light (A) or exposed to bright light (3,000 lux) for 4 h, starting right after administration 
of the second drop (B). Immediately after exposure to bright light, retinas were collected. 
Whole retinal homogenates were prepared and equal aliquots (10 g) of retinal 
homogenates were analyzed by dot blot using anti-HNE coupled with HRP to quantify total 
4-HNE-protein adduct. Five mice were used in each group, and the mean and SEM are 
plotted. Values were compared using Student’s t test for significance; *=p<0.05; **=p<0.001.  
9.3 Carcinine decreases the amount of 4-HNE-protein adduct in the retina 
After administration of carcinine through eye drop, we found that the total amount of 
protein modified by 4-HNE in mouse retina is significantly decreased, both under dim and 
bright light (Figure 8). This result suggests that carcinine can scavenge 4-HNE in vivo after 
topical administration through eye drop. This implies that carcinine levels within the retina 
are adequate and that carcinine can enter the retinal cells to scavenge 4-HNE produced 
endogenously. Thus, carcinine could prevent the accumulation of toxic 4-HNE in RDH12-
mutant retinas. We predict that carcinine, administered through eye drops, will prevent 
light-induced retinal damage in the wild-type and Rdh12 knockout but these experiments 
have not been completed at this time. 
10. Future directions 
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As shown by our preliminary experiments with carcinine, it is possible to start developing 
appropriate therapeutic strategies from the information already available on the function of 
RDH12. As discussed, exposure to bright light, as well as increased all-trans retinal levels, 
and increased oxidative damage particularly through 4-HNE modification are suspected to 
play a role in the disease mechanism. Accordingly, protection against these triggers can be 
developed with the goal to protect the retinal structure at least long enough to allow LCA13 
patients to be eligible for gene replacement therapy.  
10.1.1 Protection from light-induced damage 
As discussed, the Rdh12 knockout photoreceptors are more sensitive than the wild-type 
photoreceptors to light damage in mouse and exposure to bright light might be a trigger for 
the early dysplastic retinal response in LCA13 patients. Therefore, protection against light-
induced retinal damage is an appropriate strategy. 
Physical protection from bright light by wearing sun glasses should be encouraged for 
patients with LCA13. Compounds such as retinoid-like small molecules that provide 
chemical protection against light-induced retinal damage could also be beneficial [48, 49]. A 
number of studies have identified that photobleaching of rhodopsin is the essential trigger 
for retinal light damage [50, 51]. Genetically-modified mice that lack the opsin apoprotein or 
that have the opsin apoprotein but lack the ability to generate 11-cis-retinal are both 
protected against light damage [50-52]. A steady state rhodopsin level is achieved by the 
balance between its bleaching and regeneration. Therefore, the rate of rhodopsin 
regeneration is an important factor in light damage susceptibility. Fast regeneration of 
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functional rhodopsin after bleaching increases retinal sensitivity to light damage, whereas 
slowing the flux of retinoids through the visual cycle increases the resistance of 
photoreceptors to light-induced insult. For example, slowing rhodopsin regeneration and 
inhibiting the visual cycle with 13-cis-retinoic acid prevents light damage in albino rats [53]. 
More recently, it has been shown that retinylamine provides efficient protection from light 
damage through a similar mechanism [48].  
Most of the small molecules inhibiting the visual cycle are structurally similar to retinoids 
[49]. However, we recently identified α-phenyl-N-tert-butyl nitrone, a commonly used free 
radical spin trap, as another type of compound with no structural similarity with retinoids 
that interferes with rhodopsin regeneration during continuous illumination and protects 
against light-induced retinal degeneration [54]. The advantage that α-phenyl-N-tert-butyl 
nitrone may have over these retinol-related compounds is that it is not structurally similar 
nor a derivative of any of the visual cycle components and therefore may not have adverse 
effect by interacting with retinoid receptors and other components of the visual cycle.  
10.1.2 Protection from oxidative damage 
Because oxidative damage is likely to contribute to the LCA13 disease mechanism, 
compounds that inhibit oxidative damage or enhance endogenous protection against 
oxidative damage would be appropriate candidates for LCA13 treatment.  
A wide variety of antioxidants are available as oral supplementations. Specific advantages 
of carcinine would be to combine antioxidant and 4-HNE scavenging activities. Thus, 
carcinine can offer an additional line of defense against oxidative damage by decreasing 4-
HNE, a secondary product of oxidative stress that mediates and amplify the oxidative 
damage triggered by reactive oxygen species and that was shown to accumulate in mouse 
retina in absence of RDH12.  
In addition, the main limitation for therapeutic utilization of antioxidants in retinal diseases 
is usually the poor targeting of the posterior segment of the eye (choroid, retinal pigmented 
epithelium, and retina) due to anatomical and physiological barriers that normally protect 
the eye. Most molecules cannot reach the posterior segment tissues upon topical 
administration in the form of eye drops. Periocular or intravitreal injections are more 
efficient routes of administration but they are invasive procedures, which are not 
compatible with a chronic preventive treatment. Oral supplementation of antioxidants is 
usually preferred but oral bioavailability and the necessity to cross the blood-retinal barrier 
limits the amount of compound reaching the target tissues, and therefore limits the 
prevention of oxidative damage in these tissues.  
Carcinine is one of the very few compounds that can reach posterior segment tissues upon 
topical administration (less than 10 of such compounds have been reported to date) [55]. 
This method of administration represents the great advantages of being non-invasive, safer 
because it is used locally no systemic side effects are expected, and cheaper because it is 
used locally the amount needed is smaller than with systemic administration than any other 
methods. It is also compatible with a chronic treatment that could be administered by the 
patients themselves, or by their parents. 
Drugs that upregulate the body’s natural defense against oxidative stress would also be 
appropriate. Reactive oxygen species are constantly generated in cells as unwanted by-
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products of aerobic metabolism. A wide variety of enzymatic as well as non-enzymatic 
cellular defense systems prevents and repair reactive oxygen species-induced damage to 
tolerable levels. Under ideal circumstances, the rate of production of oxidative damage 
should be comparable to that of its removal or repair. In LCA13, absence of the cellular 
defense mediated by RDH12 could perhaps be compensated by the enhancement of other 
cellular cytoprotective mechanisms through dietary or pharmaceutical manipulations. A 
wide variety of dietary polyphenols and other classes of phytochemicals have been reported 
to induce the expression of enzymes involved in cellular antioxidant defenses and 
detoxification mechanisms [56]. Such compounds would be appropriate candidates for 
LCA13 treatment as well. 
11. Conclusion 
Although generally described in the literature as an enzyme involved in all-trans retinal 
reduction, in this chapter we presented evidences for an additional detoxification role of 
RDH12 in photoreceptor inner segments, reducing the 4-HNE produced by lipid oxidation 
that takes place constantly in mouse retina. Loss of this function in patients with inherited 
retinal dystrophy due to mutations in RDH12 might contribute to the dramatic and early 
onset loss of retinal structure and function in these individuals. Our preliminary 
experiments with carcinine show that this compound might be beneficial in LCA13 because 
it has antioxidant, 4-HNE scavenging, and RDH12 stabilizing effects in the retina. In 
addition, we showed that carcinine can be conveniently administered through eye drops to 
target the retina. Additional therapeutic strategies are developed for protection against 
bright light and all-trans retinal toxicity. Finally, the recent impressive clinical 
accomplishment of gene therapy for LCA2 patients laid the ground for using similar 
approaches to treat various types of LCA, including LCA13. 
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products of aerobic metabolism. A wide variety of enzymatic as well as non-enzymatic 
cellular defense systems prevents and repair reactive oxygen species-induced damage to 
tolerable levels. Under ideal circumstances, the rate of production of oxidative damage 
should be comparable to that of its removal or repair. In LCA13, absence of the cellular 
defense mediated by RDH12 could perhaps be compensated by the enhancement of other 
cellular cytoprotective mechanisms through dietary or pharmaceutical manipulations. A 
wide variety of dietary polyphenols and other classes of phytochemicals have been reported 
to induce the expression of enzymes involved in cellular antioxidant defenses and 
detoxification mechanisms [56]. Such compounds would be appropriate candidates for 
LCA13 treatment as well. 
11. Conclusion 
Although generally described in the literature as an enzyme involved in all-trans retinal 
reduction, in this chapter we presented evidences for an additional detoxification role of 
RDH12 in photoreceptor inner segments, reducing the 4-HNE produced by lipid oxidation 
that takes place constantly in mouse retina. Loss of this function in patients with inherited 
retinal dystrophy due to mutations in RDH12 might contribute to the dramatic and early 
onset loss of retinal structure and function in these individuals. Our preliminary 
experiments with carcinine show that this compound might be beneficial in LCA13 because 
it has antioxidant, 4-HNE scavenging, and RDH12 stabilizing effects in the retina. In 
addition, we showed that carcinine can be conveniently administered through eye drops to 
target the retina. Additional therapeutic strategies are developed for protection against 
bright light and all-trans retinal toxicity. Finally, the recent impressive clinical 
accomplishment of gene therapy for LCA2 patients laid the ground for using similar 
approaches to treat various types of LCA, including LCA13. 
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1. Introduction 
The major infections of the ocular adnexal and orbital tissues are preseptal cellulitis and 
orbital cellulitis. They occur more frequently in children than in adults. In Schramm's series 
of 303 cases of orbital cellulitis, 68% of the patients were younger than 9 years old and only 
17% were older than 15 years old.  
Orbital cellulitis is less common, but more serious than preseptal. Both conditions happen 
more commonly in the winter months when the incidence of paranasal sinus infections is 
increased. There are specific causes for each of these types of cellulitis, and each may be 
associated with serious complications, including vision loss, intracranial infection and 
death. Studies of orbital cellulitis and its complication report mortality in 1- 2% and vision 
loss in 3-11%. In contrast, mortality and vision loss are extremely rare in preseptal cellulitis. 
1.1 Definitions 
Preseptal and orbital cellulites are the most common causes of acute orbital inflammation. 
Preseptal cellulitis is an infection of the soft tissue of the eyelids and periocular region that is 
localized anterior to the orbital septum outside the bony orbit. Orbital cellulitis ( 3.5 per 
100,00 ) is an infection of the soft tissues of the orbit that is localized posterior to the orbital 
septum and involves the fat and muscles contained within the bony orbit. Both types are 
normally distinguished clinically by anatomic location.  
1.2 Pathophysiology 
The soft tissues of the eyelids, adnexa and orbit are sterile. Infection usually originates from 
adjacent non-sterile sites but may also expand hematogenously from distant infected sites 
when septicemia occurs. Preseptal cellulitis usually originates from skin infection with or 
without local trauma. It may also originate from structures inside the eyelid that are 
connected to the surface and become infected such as external and internal hordeolom. 
Chalazion is an example of internal hordeolom and these are all infected glands with surface 
connections. Glands with even partial preseptal location such as the lacrimal gland, in which 
the palpebral lobe is located preseptally, may also cause preseptal cellulitis.  
Orbital cellulitis occurs in the following three situations:  
 Spreading of an infection from the periorbital structures, usually from the paranasal 
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 Direct inoculation of the orbit from surgical trauma. 
 Hematogenous spread from distant sites (bacteremia). 
In case of local cutaneous infection, preseptal cellulitis can arise from the spread of a 
contiguous anterior eyelid infection such as a chalazion, local trauma resulting in infection 
such as insect bite, or a foreign body. The skin and, in some instances, the sinuses and 
lacremal mucosa, are colonized by various microorganisms. Orbital cellulitis following 
trauma is the consequence of a direct exposure of the orbital contents to these 
microorganisms. Open periorbital fractures, as well as closed fractures involving the sinuses 
or the nasal bone, may be a risk factor for orbital infections. 
Orbital cellulitis, in contrast, usually arises from spread of infection from the paranasal 
sinuses. The ethmoid sinus is the most common source that extends to the orbit in children. 
In adults, pansinusitis is often accompanied by orbital cellulitis and its spread is believed to 
be caused through the ethmoid or frontal sinuses. The ethmoid sinus separeated from the 
orbit medially by the thinnest orbital bone – lamina papyracea. Often, the lamina contains 
congenital dehiscences through which sinus infections can easily spread into the orbit. This 
may support the frequency of orbital cellulitis secondary to ethmoiditis. The anterior and 
posterior ethmoidal foramina may also serve as potential passages for infection. 
The orbital roof borders the frontal sinus. It is a diploeic bone and is thicker than the lamina 
papiracea. Infection may spread more easily through the valveless facial veins. Since the 
frontal sinus is adjacent to the anterior cranial fossa, it may serve as an intermediary for the 
spread of infection. 
The orbital floor that borders the maxillary antrum also contain congenital dehiscences 
through which infection from the maxillary sinus can enter and facilitate infection spreading. 
The posterior medial wall of the orbit borders the sphenoid sinus. Isolated sphenoiditis is rare. 
The sphenoid may be involved secondary to ethmoiditis. Sphenoethmoidal sinusitis has 
distinct clinical characteristics. Marked visual loss with or without ophthalmoplegia usually 
precedes the findings of proptosis and inflammatory orbital signs. This condition is rare due to 
the thick bony barrier and firm attachment of periorbita to the posterior orbital wall. 
One dehiscence or more is often present in orbital walls, particularly in the thin-walled 
lamina papyracea and this facilitates the spread of infection to the orbit. Posteriorly, the 
optic nerve within the optic canal is adjacent to the lateral wall of the sphenoidal sinus. 
Dehiscence can also be found in the lateral wall of the sphenoidal sinus adjacent to the optic 
canal. The free valveless venous communication between the orbit and the sinus is another 
reason predisposing the orbit to the spread of adjacent sinus infection.  
However, not all orbital cellulitis infections caused by sinus disease are secondary to acute 
sinusitis. Orbital fracture involving sinuses may allow spreading of an existing chronic sinus 
infection. Open fractures may also result in orbital cellulitis due to direct contact with the 
environment. Foreign bodies, such as a glass, wood or orbital floor implants, can cause 
orbital cellulitis. Infection can extend to the orbit from the eye, teeth, middle ear, or in 
neglected cases of preseptal cellulitis, from the eyelids and face.  
Uncomplicated eyelid, strabismus, cataract surgery, glaucoma valve and retinal surgery may 
all expose the orbit to infection. Orbital implants that are imbedded and other foreign bodies, 
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such as Molteno valve implant, may carry a risk for infection, especially if they are colonized 
or exposed. Orbital cellulitis secondary to keratitis may develop after radial keratotomy.  
Advanced carries with secondary infection, poor dental work or an infected root or dental 
cyst can cause orbital cellulitis. Extraction of maxillary premolars, molars or canines exposes 
the patient to orbital infection. The most common pathway for odontico-orbital infections is 
through the paranasal sinuses. The apices of maxillary molars and premolars are in close 
proximity to the floor of the maxillary sinus and are, in fact, in direct contact with the 
maxillary mucosa. Direct fistula to the antrum may be caused by a floor fracture during 
dental extraction or maxillary mucosa disruption. Infection spreading from the sinus to the 
orbit can occur through congenital dehiscences in the medial orbital wall or through 
communication between the venous plexus of the maxillary mucosa and the ophthalmic 
veins, thereby causing thrombophlebitis. 
Another pathway for the spread of infection is the thin buccal cortical plate of the alveolar 
processes. 
Finally orbital cellulitis can occur secondarily from embolic spread in subacute bacterial 
endocarditis and from other distant organs.  
 
Pathway for odontico-orbital infections 
 
 
Dental abscess.Predisposing factors:poor dental care, advanced caries, root treatment, 
following dental extraction. 
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In 1970, chandler described a spectrum of progressive infectious changes in orbital cellulitis. 
Chandler's Classification: 
Stage I – Preseptal cellulitis  
Ocasionally, edema may spread secondarily to preseptal cellulitis posterior to the septum 
without infection. In these cases chemosis may be present, but the extraocular movements 
and visual acuity remain intact.  
  
Stage II – Orbital cellulitis 
Diffuse edema of orbital contents, with leukocytosis, fever, proptosis and impaired 
extraocular motility without discrete abscess formation.  
Examples are shown in the images below: 
 
A male with left orbital cellulitis presented with proptosis, ophthalmoplegia, and edema 
and erythema of the eyelids. The patient also exhibited pain on eye movement, fever, 
headache, and malaise. 
 




A male with left orbital cellulitis with proptosis, ophthalmoplegia, and edema and erythema of 
the eyelids. The patient also exhibited chemosis and resistance to retropulsion of the globe. 
Stage III - Subperiosteal abscess  
The globe is often displaced and limited in the field of gaze of the abscess. 
 
An axial computed tomography scan in a patient with a right orbital infection caused by 
streptococcus pneumoniae and a right superior orbital subperiosteal abscess that resulted in 
blindness. 
 
A coronal computed tomography scan of a child with pansinusitis as well as a left orbital 
and subperiosteal abscess. 
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A coronal computed tomography scan of a child with pansinusitis as well as a left orbital 
and subperiosteal abscess. 
 




A coronal computed tomography scan in a patient with sickle cell disease. In this image, the 
patient has a left subperiosteal bleeding that mimiced the appearance of an infectious 
subperiosteal abscess. 
Stage IV – Intraorbital abscess, purulent collection: 
These patients have severe proptosis, chemosis, ophthalmoplegia and often visual loss.  
 
Frontal view of the patient with a right orbital abscess showing periorbital redness, swelling 
and proptosis. 
 
Coronal computed tomography scan in a pediatric patient with pansinusitis sinusitis and 
left orbital abscess. 
 




Axial computerized tomography scan shows a right classic proptosis associated with an 
abscess of the orbit, as well as displacement of the medial orbital tissues and tenting of the 
posterior. 
Stage V – Cavernous sinus thrombosis (septic abscess)  
In these instances, the orbital signs evolve in the fellow eye (bilateral) and other central 




A T1 weighted coronal MRI demonstrating asymmetry between the caverenous sinuses 
with obliteration of the right cavernous sinus. 
2. Preseptal cellulitis  
Preseptal cellulitis is more common than orbital cellulitis. It can present with swelling and 
erythema of tissues surrounding the orbit, with or without fever. Preseptal cellulitis most 
commonly occurs from a contiguous infection of the soft tissues of the face and eyelids 
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secondary to local trauma, foreign bodies or insect or animal bites. It is rare for untreated 
preseptal cellulitis to progress to orbital cellulitis by local extension. Defining the exact 
location of inflammation is essential for proper diagnosis and treatment. 
2.1 Symptoms and signs  
Patients with preseptal cellulitis often have a short history (days) of painless swelling of the 
eyelids. A history of early upper respiratory tract infection, trauma, insect or animal bite, 
conjunctivitis, or chalazion may be disclosed. Fever is an inconstant feature. The eyelid 
characteristically is erythematous, edematous, tender and warm. Vision and pupillary 
response are always unaffected and proptosis, globe displacement and limitation in ocular 
motility are never present. Concurrent preseptal cellulitis was discovered in the presence of 
many systemic diseases including, varicella, asthma, nasal polyposis and neutropenia. 
Preseptal cellulitis is more common among children than in adults. 
                                      
 
Preseptal cellulitis is more 
common in children than in 
adults.  
swelling and erythema of 
soft tissues surrounding the 
orbit. 
Eyelid swelling, erythema, 
local warmth, 
tenderness.no proptosis, 
limited ocular motility or 
optic nerve involvement. 
2.2 Microbiology  
The most common inciting microorganisms include Streptococcus pneumoniae, Staphylococcus 
aureus, other Streptococcus species and anaerobes. Haemophilus infuenzae type B was the 
most common cause in children under four years old. However, routine vaccination with 
conjugate Haemophilus influenzae vaccines since 1985 has dramatically decreased this 
infection in young children. Less commonly implicated microorganisms include 
Acinetobacter spp., Nocardia brasiliensis, Bacillus anthracis, Pseudomonas aeruginosa, Neisseria 
gonorrhoea, Proteus spp., Pasteurella multocida, Mycobacterium tuberculosis and Trichophyton 
spp.  
2.3 Differential diagnosis 
Conditions that might masquerade as preseptal cellulitis include allergic edema 
(anaphylactoid reaction) of the eyelids, severe blepharitis with scruffs (seborrheic), 
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collarets(staphylococcal), sleeves(demodex) with or without erythema but no local warmth. 
The meibomianitis is characterised with eyelid swelling, pouting of meibomian gland 
orisices and discharge from orifices but no local warmth. 
In addition dacryoadenitis, blunt trauma, thyroid eye disease, leukemic infiltrates, 
blepharochalasis syndrome and autoimmune inflammatory disorder such as lupus. Other 
disorders of less resemblance include orbital tumors/pseudotumours (, orbital vasculitis, 
necrotising fascitis and others.  
2.4 Management  
Treatment regimens cover the most likely organisms to cause infection in this setting and 
according to case series. Outpatient treatment should include broad-spectrum oral antibiotics 
and close observation. The author came to a conclusion that most cases of preseptal cellulitis 
can be safely managed as outpatients with oral antibiotics and follow-up until improvement is 
documented. If the condition does not improve or deteriorates 48 hours or more after oral 
antibiotic treatment, the patients should be admitted for intravenous antibiotic treatment and 
close observation. The average time of hospitalization is four days. 
The appropriate antibiotics in adults include Amoxicillin–clavulinate ( Augmentin ) 875 mg 
every 12 h, and in children 90 mg/kg/day amoxicillin and 6.4 mg/Kg/day of clavulanate 
divided to two doses. Another option includes Cefpodoxime ( Vantin ) 200 mg every 12 h in 
adults, and 10 mg/kg/d divided every 12 h in children with maximum daily dose of 400 
mg. Cefdinir ( Omnicef ) 600 mg daily in adults, and 14 mg/kg/d divided every 12 h in 
children with maximum daily dose 600 mg is another option. 
Pediatric patients under 1 year of age and all more severe cases require the same approach 
as patients with orbital cellulitis, namely, intravenous broad-spectrum antibiotics and 
hospital observation .Blood cultures should be obtained if the systemic fever increases. The 
recommended duration of antimicrobial therapy is for 7-10 days. Occasionally, patients will 
continue to have local signs of cellulitis at end of treatment. Oral antibiotic therapy is 
recommended to be continued in these patients until resolution of the erythema. Children 
with preseptal cellulitis, no orbital involvement, and who do not appear toxic can be treated 
with intramuscular or oral antibiotics on a daily basis as outpatients. Preseptal cellulitis in 
adults can be managed on outpatient basis with oral antibiotics with frequent monitoring 
for progression.  
3. Orbital cellulitis  
Orbital cellulitis occurs in three settings: 
i. Extension of infection from periorbital structures, such as the face, lacrimal sac and 
globe, but particularly from the paranasal sinuses. Acute sinusitis is complicated by 
orbital cellulitis in 1-3% of cases and the coexisting sinusitis is present in 73-94% of 
patients with orbital cellulitis. Ethmoid sinusitis and pansinusitis are most likely to 
progress to orbital cellulitis. The first ocular sign of sinusitis may be preseptal 
inflammation only. This can then quickly progress to the classic clinical picture of 
orbital cellulitis. Other causes include – orbital trauma, with fracture or a foreign body, 
dacryocystitis, and infection of teeth, middle ear or face.  
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ii. Direct inoculation from accidental trauma or from surgery. Orbital cellulitis is 
uncommon complication of ophthalmic surgery, being reported after strabismus 
surgery, blepharoplasty, radial keratotomy, retinal surgery and following peribulbar 
anesthesia. A special case is fungal orbital cellulitis, a relatively rare condition occurring 
in two principal forms – 1. Subacute infection due to genera of Zygomacetes 
(mucormycosis). 2. A more chronic orbital infection caused by species of Aspergillus. 
The distinction between these two may be difficult on clinical observation alone.  
iii. Hematogenous spread (endogenous from bacteremia). The microorganisms responsible 
for most cases are aerobic non-spore forming bacteria.  
3.1 Symptoms and signs 
Orbital cellulitis as preseptal cellulitis can present with swelling and erythema. The cardinal 
signs and symptoms are proptosis, ophthalmoplegia and globe displacement. Pain on eye 
movement, vision loss (indicates orbital apex involvement), diplopia, conjunctival chemosis 
and elevated intraocular pressure are common but variable accompanying signs.  
3.2 Microbiology 
S. aureus and Streptococci are the most commonly identified organisms in culture-positive 
orbital cellulitis. Less common causes are H. influenza and non-spore forming anaerobes. 
However, many other common and rare bacterial pathogens include Eikenella corrodens, 
Aeromonas hydrophilia, P. aeroginosa, fungal and mycobacterial pathogens, including 
Scedosporium apospermum, M. tuberculosis and Mycobacterium avium complex. The prognosis 
of aspergillosis is poor. More than 80% of reported patients have died from this causative.  
3.3 Differential diagnosis 
Conditions that may mimic orbital cellulitis include: 
 Anaphylactoid reaction can be characterised with eyelid swelling and erythema but no 
local warmthand no proptosis, limited ocular motility or optic nerve involvement.  
  Cavernous sinus syndrome that is characterised by proptosis, complete 
ophthalmoplegia, optic nerve involvement, V2 involvement, evolve to bilateral 
condition and usually in debilitated patients (diabetics, drug abusers, HIV). 
 The orbital apex syndrome is characterised with complete external ophthalmoplegia, 
optic nerve and V1 involvement with/without proptosis. 
 Superior orbital fissure syndrome is a condition that is characterised with complete 
external ophlmoplegia, V1 involvement with or without proptosis. 
 The orbital compartment syndrome and the orbital tumors can present with proptosis, 
limited ocular motility, optic nerve involvement and increased intraocular pressure but 
no local warmth. 
3.4 Diagnosis 
There have been no controlled trials examining the utility of radiologic studies (e.g. 
computed tomography scanning, orbital ultrasound, or magnetic resonance imaging) in the 
diagnosis of orbital cellulitis or in distinguishing preseptal from orbital cellulitis.  
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Computed Tomography scanning (CT) 
CT can confirm extension of inflammation into the orbit, detect coexisting sinus disease, and 
identify an orbital or subperiosteal abscess. Whether every patient with suspected orbital 
cellulitis needs a CT scan is controversial. Some experts suggest that a CT scan be performed 
only in those patients who deteriorate or fail to respond to 48 hours of IV antibiotics, as the 
majority of patients with orbital cellulitis do well with conservative medical management. It 
is suggested that patients with suspected orbital cellulitis – those with proptosis, globe 
displacement, limitation of eye movements, double vision, vision loss, and those patients in 
whom the physician cannot accurately assess vision – usually patients less than one year of 
age, at presentation have a baseline CT scan.  
Orbital Ultrasunography(US) 
US provides higher-resolution details of orbital contents and is useful when sequential 
follow-up of an abscess or drained abscess is required. However, orbital sonography is not 
widely available and is dependent on the expertise of the sonographer. 
Magnetic Resonance Imaging (MRI) 
MRI is superior to CT in the resolution of soft tissue disease. However, it is not usually 
performed because of the need for sedation in pediatric patients and because MRI is rarely 
immediately available.  
Microbiologic studies 
The causative microorganism in orbital cellulitis may be difficult to identify due to normal 
flora contaminants, mixed infection, and prior antibiotic therapy. Cultures for aerobic and 
anaerobic organisms may be obtained from blood, sinus aspirates, and abscess. Because 
blood cultures are usually negative, some clinicians obtain cultures of eye secretions or 
pharyngeal culture. However, these cultures are likely to be contaminated with normal 
oropharyngeal flora and should not guide the choice of antibiotic therapy. Microbiologic 
data limited to microorganisms recovered by surgical drainage from orbital abscesses or 
involved sinuses and/or positive blood culture are the most reliable information. It is 
recommended that in patients with suspected orbital cellulitis, blood cultures should be 
obtained before the initiation of antibiotic treatment. If surgery is performed, culture of 
abscess material or sinus contents should be sent for aerobic, anaerobic and fungal cultures.  
3.5 Complications  
The complications of bacterial orbital cellulitis may be orbital or intracranial. Orbital 
complications of orbital cellulitis include subperiosteal or orbital abscess formation in 7-9%, 
permanent globe displacement, limited ocular motility that may cause diplopia, and vision 
loss in 1%. Orbital abscess may be clinically indistinguishable from orbital cellulitis. 
Proptosis and globe displacement tends to be more severe with orbital abscess than in 
orbital cellulitis, and patients are more likely to be systemically ill. The diagnosis of orbital 
abscess is confirmed by imaging or at surgery. The identification of an orbital abscess on the 
baseline CT scan is important since these patients almost always require surgery. 
Intracranial complications, which are encountered in 4% of orbital cellulitis secondary to 
sinusitis include meningitis in 2%, cavernous sinus thrombosis in 1%, intracranial abscess 
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uncommon complication of ophthalmic surgery, being reported after strabismus 
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oropharyngeal flora and should not guide the choice of antibiotic therapy. Microbiologic 
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sinusitis include meningitis in 2%, cavernous sinus thrombosis in 1%, intracranial abscess 
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formation, epidural or subdural abscess or parenchymal brain abscess in 1%, and carotid 
artery occlusion. Intracranial involvement may be heralded by ophthalmoplegia, changes in 
mental status, contralateral cranial nerve palsy, or bilateral orbital cellulitis. Cavernous sinus 
thrombosis has become relatively rare in developed countries because of prompt and 
adequate treatment of most cases of acute sinusitis, but it still poses a major threat. The 
mortality rate of cavernous sinus thrombosis may exceed 50%.  
Permanent vision loss may occur because of: 
1. Corneal ulcer and perforation secondary to exposure or neurotrophic keratitis.  
2. Destruction of intraocular tissues following neovascular or inflammatory glaucoma, 
endophthalmitis, septic uveitis or retinitis and exudative retinal detachment.  
3. Various other mechanisms affecting the globe or posterior orbit, such as secondary 
glaucoma due to elevated orbital pressure, infectious optic neuritis or inflammatory 
optic neuritis , pressure effects the optic nerve, thrombophlebitis of ocular veins and 
central retinal artery occlusion.  
Blindness can result from elevated intraorbital pressure causing optic neuropathy or 
extension of the infection to the optic nerve from the sphenoid sinus.  
3.6 Management  
Prompt administration of appropriate antibiotics is the key for successful treatment of 
orbital cellulitis. After appropriate workup, all periorbital and orbital infections should be 
treated with broad-spectrum antimicrobial agents. There have been no controlled trials 
examining the required duration of antimicrobial therapy in orbital cellulitis. Treatment 
regimens are based upon coverage of the most likely organisms to cause infection in this 
setting and treatment of case series. The initial empiric antibiotic treatment should consist of 
parenteral broad-spectrum therapy. Infection due to methicillin-resistant S. aureus is best 
treated with vancomycin, clindamycin and cefotaxime.  
Fungal orbital cellulitis occurs and is primarily due to mucor and aspergillums species. It 
requires antifungals, such as amphotericin. Corticosteroids may be helpful in bacterial 
infections, but they should not be started before surgery and until the patient has been on 
appropriate antibiotics for 2-3 days to ascertain eradication of the microbial agents. 
If secondary glaucoma develops, ocular anti-hypertensive agents should be initiated 
promptly. Prompt diagnosis and therapy are important since delayed intervention can 
result in sustained vision loss. 
3.6.1 Antibiotic treatment 
Due to increasing incidence of Methicillin-resistant S. Aureus, empiric therapy with 
Vancomycin (Vancocin) (15 mg/kg IV every 12 hours in adults, 10 to 15 mg/kg IV every 6 
hours in children, maximum daily dose of 4gr) is recommended. If susceptibility testing 
reveals Methicillin-sensitive S. aureus, Vancomycin should be replaced with Nafcilin 
(Unipen), or Oxacillin ( Bactocill ) - (both agents are dosed at 2gr IV every 4 hours in adults, 
and 200 mg/kg per day IV in 4-6 divided doses in children, maximum daily dose of 12gr) 
since these agents have better CNS penetration than vancomycin. 
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One of the following should be added: 
1. Ampicillin-sulbactam ( Unasyn ) 3gr IV every 6 hours in adults, 300 mg/kg per day in 4 
divided doses in children, maximum daily dose of 12 gr.  
2. Ticarcillin-clavulanate (Ticar), which covers most of the Gram-negative bacteria as well 
as Gram-positive organisms, including atypical H. influenza, and has also excellent 
anaerobic coverage. The dosage is 3.1gr IV every 4 hours in adults, 200-300 mg of 
ticarcillin component per kg per day in 4-6 divided doses in children of less than  
60 kg. The maximum daily dose of ticarcillin component is 18 gr. 
3. Piperacillin-Tazobactam 4.5gr IV every 6 hours in adults, 240 mg/kg per day in 3 
divided doses in children, with a maximum daily dose of 16gr of piperacillin 
component. 
4. Ceftriaxone (Rocephin ) is effective agpenicillinase-producing S. aureus, most Gram–
positive organisms, and most Gram-negative organisms except for Pseudomonas. 
Ceftriaxone also crosses the blood-brain barrier; therefore, it is an excellent choice if 
there is a suspicion of concurrent intracranial infection. 2gr IV every 12 hours in adults, 
80-100 mg/kg per day in 2 divided doses in children, maximum dose of 4gr daily may 
be given. 
5. Cefotaxime (Claforan), a third-generation cephalosporin that covers most of the 
common sinus pathogens with the exception of Clostridium difficile, may be given 2gr IV 
every 4 hours in adults, 150-200 mg/kg per day in 3-4 equally divided doses in 
children, with a maximum daily dose of 12gr. 
Patients allergic to penicillin and/or cephalosporins may be treated with a combination of 
vancomycin and a flouroquinolon. For patients over 17 years of age, ciprofloxacin 500 mg 
twice a day or levofloxacin 500 mg daily may be prescribed. Flouroquinilones are not 
recommended for use in pediatric patients as first-line therapy for any infection because of 
the musculoskeletal side effects - The mildest side effects include muscle pain, called 
fibromyalgia. A more serious side effect, though also less common, is tendon damage. 
Fluoroquinolones can, in high doses, cause tendon damage, which can ultimately lead to 
rupture of the Achilles tendon ( in addition gastrointestinal effects predominating (nausea, 
vomiting, diarrhea, or abdominal pain in 1.0%–5.0% of thepatients), followed byeffects 
onthecentral nervous system (dizziness, headache, and/or insomnia in 0.1%–0.3% of the 
patients) and skin (0.5%–2.2% of the patients). Elevation in levels of hepatic enzymes 
occurred in 1.8%–2.5% of thepatients, azotemia in 0.2%–1.3%, and eosinophilia in 0.2%–
2.0%. Initial antibiotic therapy should be administered IV under hospitalization. Generally 
switching to oral therapy is done after the patient is afebrile and skin findings have begun to 
resolve, which usually take 3-5 days. 
The duration of treatment depends on the response. Patients should be treated with 
parenteral antibiotics until they show clear evidence of clinical improvement as manifested 
by decrease in orbital congestive signs such as proptosis, gaze limitation, cellulitis and 
edema. Intravenous therapy should continue for a minimum of 3 days. Then oral antibiotic 
therapy may be instituted for a total course of 10 days to 3 weeks, depending on the severity 
of infection. Associated bacteremia, however, should be treated with 7-10 days of IV 
therapy.  
As aforesaid, the oral regimen should be tailored based upon the results of the cultures. If 
the results are not available, reasonable empiric oral antibiotic choices include 1. amoxicillin 
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formation, epidural or subdural abscess or parenchymal brain abscess in 1%, and carotid 
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endophthalmitis, septic uveitis or retinitis and exudative retinal detachment.  
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glaucoma due to elevated orbital pressure, infectious optic neuritis or inflammatory 
optic neuritis , pressure effects the optic nerve, thrombophlebitis of ocular veins and 
central retinal artery occlusion.  
Blindness can result from elevated intraorbital pressure causing optic neuropathy or 
extension of the infection to the optic nerve from the sphenoid sinus.  
3.6 Management  
Prompt administration of appropriate antibiotics is the key for successful treatment of 
orbital cellulitis. After appropriate workup, all periorbital and orbital infections should be 
treated with broad-spectrum antimicrobial agents. There have been no controlled trials 
examining the required duration of antimicrobial therapy in orbital cellulitis. Treatment 
regimens are based upon coverage of the most likely organisms to cause infection in this 
setting and treatment of case series. The initial empiric antibiotic treatment should consist of 
parenteral broad-spectrum therapy. Infection due to methicillin-resistant S. aureus is best 
treated with vancomycin, clindamycin and cefotaxime.  
Fungal orbital cellulitis occurs and is primarily due to mucor and aspergillums species. It 
requires antifungals, such as amphotericin. Corticosteroids may be helpful in bacterial 
infections, but they should not be started before surgery and until the patient has been on 
appropriate antibiotics for 2-3 days to ascertain eradication of the microbial agents. 
If secondary glaucoma develops, ocular anti-hypertensive agents should be initiated 
promptly. Prompt diagnosis and therapy are important since delayed intervention can 
result in sustained vision loss. 
3.6.1 Antibiotic treatment 
Due to increasing incidence of Methicillin-resistant S. Aureus, empiric therapy with 
Vancomycin (Vancocin) (15 mg/kg IV every 12 hours in adults, 10 to 15 mg/kg IV every 6 
hours in children, maximum daily dose of 4gr) is recommended. If susceptibility testing 
reveals Methicillin-sensitive S. aureus, Vancomycin should be replaced with Nafcilin 
(Unipen), or Oxacillin ( Bactocill ) - (both agents are dosed at 2gr IV every 4 hours in adults, 
and 200 mg/kg per day IV in 4-6 divided doses in children, maximum daily dose of 12gr) 
since these agents have better CNS penetration than vancomycin. 
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as Gram-positive organisms, including atypical H. influenza, and has also excellent 
anaerobic coverage. The dosage is 3.1gr IV every 4 hours in adults, 200-300 mg of 
ticarcillin component per kg per day in 4-6 divided doses in children of less than  
60 kg. The maximum daily dose of ticarcillin component is 18 gr. 
3. Piperacillin-Tazobactam 4.5gr IV every 6 hours in adults, 240 mg/kg per day in 3 
divided doses in children, with a maximum daily dose of 16gr of piperacillin 
component. 
4. Ceftriaxone (Rocephin ) is effective agpenicillinase-producing S. aureus, most Gram–
positive organisms, and most Gram-negative organisms except for Pseudomonas. 
Ceftriaxone also crosses the blood-brain barrier; therefore, it is an excellent choice if 
there is a suspicion of concurrent intracranial infection. 2gr IV every 12 hours in adults, 
80-100 mg/kg per day in 2 divided doses in children, maximum dose of 4gr daily may 
be given. 
5. Cefotaxime (Claforan), a third-generation cephalosporin that covers most of the 
common sinus pathogens with the exception of Clostridium difficile, may be given 2gr IV 
every 4 hours in adults, 150-200 mg/kg per day in 3-4 equally divided doses in 
children, with a maximum daily dose of 12gr. 
Patients allergic to penicillin and/or cephalosporins may be treated with a combination of 
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twice a day or levofloxacin 500 mg daily may be prescribed. Flouroquinilones are not 
recommended for use in pediatric patients as first-line therapy for any infection because of 
the musculoskeletal side effects - The mildest side effects include muscle pain, called 
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switching to oral therapy is done after the patient is afebrile and skin findings have begun to 
resolve, which usually take 3-5 days. 
The duration of treatment depends on the response. Patients should be treated with 
parenteral antibiotics until they show clear evidence of clinical improvement as manifested 
by decrease in orbital congestive signs such as proptosis, gaze limitation, cellulitis and 
edema. Intravenous therapy should continue for a minimum of 3 days. Then oral antibiotic 
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– clavulinate – 875 mg twice daily for adults or children over 40 kg, and 45 mg/kg/day 
divided every 12 hours for children over 3 moths and under 40 kg or 2. fluoroquinolone – 
(levofloxacin 750 mg once daily in adults). Linezolid (ZYVOX) - (600 mg twice daily in 
adults and children over 12 years of age, 10 mg/kg three times daily for children under 11 
years) should be added if MRSA is suspected. 
Careful follow-up is indicated in all patients who present with orbital cellulitis. This should 
include twice-daily examinations with attention to visual acuity, confrontation visual fields, 
exophthalmometry, motility and pupillary examination.  
3.6.2 Antifungals 
(Amphotericin B- Ambisome) 1 mg/kg IV q24h or Voriconazole ( VFEND, Pfizer ) 6 mg/kg 
IV q12h for 2 doses, then 4 mg/kg IV q12h or Voriconazole 200-300 mg PO q12h 
Antifungal is the treatment of choice for fungal orbital cellulitis. It is administered IV and 
may be appropriately administered before laboratory confirmation of fungal infection in 
cases of severe infection and debilitated patients (diabetes mellitus, drug abusers, human 
immunodeficiency disease, metastatic cancer, prolonged administration of antibiotics and/ 
or corticosteroids). 
3.6.3 Surgery  
The timing for surgical intervention is critical. In cases of orbital cellulitis without abscess 
formation, in which visual acuity is 20/60 (Snellen notation), 6/15 (metric equivalent) or 
less, or declines with appropriate medical management, orbital exploration should be 
emergent. In cases in which the acuity is better than 20/60, the patient should be followed, 
expectantly, and frequently while more conservative management is initiated. 
Orbital surgery is indicated if the patient: 
1. Fails to respond 
2. Deteriorates clinically despite treatment 
3. Has worsening visual acuity or develops afferent pupillary defect 
4. Develops an abscess, except selected pediatric cases with medial subperiosteal abscess, 
which may be successfully treated medically. 
In patients older than 14 years of age, the author favours the latter approach because the 
risks of surgery are negligible compared with the visual and life-threatening risks of no 
intervention. In patients 9 years of age or younger, 25% of the subperiosteal abscesses are 
likely to resolve with antibiotic therapy alone. Several indications have been suggested for 
drainage of subperiosteal abscesses. These include age of 9 years or older, large abscess, 
frontal sinusitis, non-medial abscesschronic sinusitis, dental infection, optic nerve 
involvement, suspicion of anaerobic infection and recurrence after drainage. All other cases 
may be managed conservatively by intravenous antibiotics. 
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1. Introduction 
There has been significant evolution over time from external headlight sinus surgery to 
endoscopic sinus surgery(ESS). ESS was pioneered by Messenklinger, who discovered that 
the sinuses had a predetermined mucociliary clearance pattern towards the natural ostium 
irrespective of additional openings into the sinuses. This philosophy of opening the natural 
ostium of the diseased sinus was then popularized by Stammberger and Kennedy. ESS is 
now accepted as the surgical management of choice for chronic sinusitis. Furthermore, as 
our knowledge of the anatomy of the sinuses has improved, other anciliary surgeries such 
as endoscopic lacrimal surgery, orbital decompression, applications to the pterygopalatine 
and infratemporal fossa, approaches from the sphenoid/sella extending to the cribriform, 
parasellar and clival region have evolved. Moreover, innovation in instrumentation has led 
to the acceptance of endoscopic management of benign endonasal tumors and more 
recently, on endoscopic management of malignant tumors of the nose and sinuses.  
The current interest in ESS stems from several developments. The first is the advent of 
compact, multi-angled telescopes that allow excellent visualization of the nasal cavity for 
examination and of the sinuses during procedures, including such areas as the maxillary 
ostia and the frontal recess. Secondly, is the acceptance and appreciation of the great work 
of Messerklinger(1967) demonstrating that the anterior ethmoids are usually the key to 
persistent sinusitis. Thirdly, is the advent in radiological imaging. Endoscopic diagnostic 
examinations in conjunction with modern imaging methods, particularly CT scan, have 
proven to be an ideal combination and have been accepted as the “Standard of Care’ for 
sinus disease. The CT scan can clearly identify anterior ethmoids disease which can easily be 
missed on a plain paranasal sinus X-ray. These developments make it possible to diagnose 
more accurately and treat sinusitis refractory to non-invasive therapy. 
The technique of ESS was developed in Europe by Messerklinger and Wigand, who had two 
different goals designed for extremes of disease. The Messerklinger technique advocated in 
1985 is an anterior to posterior approach which involves only the anterior ethmoids and the 
maxillary sinus ostium and can be extended into the posterior ethmoids, sphenoid and the 
frontal sinus anteriorly if necessary. Thus, the Messerklinger technique is ideal for patient 
with anterior ethmoid disease with or without maxillary or frontal sinus disease. On the 
contrary, the Wigand approach advocated in 1978 is posterior-to-anterior and routinely 
involves all the sinuses on the ipsilateral side and is ideal for patient with pan-sinusitis who 
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has or is apt to fail the more limited Messerklinger approach. Both techniques are based on 
the assumption that the sinus mucosa is most likely reversibly diseased and will return to 
normal once ventilation has been established. No attempt is made to eradicate the sinus 
mucous membrane, as in the Caldwell-Luc procedure, but rather to reestablish drainage so 
the mucosa can return to normal and restore its proper function. 
Although telescopes give the surgeon a clearer and magnified view of the nose and sinuses, 
the picture on the video monitor is not three-dimentional  and depth perception and 
orientation can be difficult. Consequently there is a risk of getting lost and this may result in 
an injury to the orbit, its contents, the optic nerve and the intracranial cavity. To reduce this 
risk, surgeons should ensure that they are thoroughly familiar with the anatomy and the 
anatomical variations that can occur in the nose and sinuses. Therefore, radiological imaging 
is essential prior to surgical intervention. 
A significant development for soft-tissue removal was the development of “through-
cutting” instrumentation. Powered instrumentation using soft tissue shavers (Metronic, 
Xomed, USA) offer another significant advancement to the endoscopic sinus surgeon but 
with some risk to the orbit and cranium in inexperienced hands (Fig 1). Setliff and Parsons 
were the first to report the use of soft-tissue shavers in endoscopic sinus surgery (Setliff , 
1994). ESS with its minimally invasive technique often reduces pain, bleeding and length of 
hospital stay and avoids external incision and thus reduces surgical cost compared to 
conventional techniques. Endoscopic surgery cannot replace every conventional external 
approach and we should never be embarrassed to employ or convert to these conventional 
approaches when necessary (Gendeh et al, 2007). However, not all cases are suitable for an 
endoscopic approach and the surgeon must be experienced in the full range of surgical 
options, the patho-physiology and natural history of disease processes, if optimum results 
are to be achieved. This is particularly true in the controversial area of sinonasal neoplasia.  
 
Fig. 1. Diagrammatic coronal section of paranasal sinuses showing the anatomical proximity 
of orbit and cranium to the nasal cavity in utilization of powered instrumentation and the 
risk involved. 
 
Extended Applications of Endoscopic Sinus Surgery to the Orbit and Pituitary Fossa 
 
523 
This chapter will briefly outline the future trends in endoscopic skull base surgery. The 
Expanded Endonasal Approach(EEA) is a an extended endoscopic transnasal approach, 
providing access to the entire skull base from the epicenter, the sphenoid sinus.  
It is important to define the word “endoneurosurgery” (Kassam et al, 2007). This is a new 
and emerging field and represents the use of the endoscope as the sole and only tool used 
to visualize the entire neural axis. In the case of EEA, only the endoscope is used to access 
the ventral skull via a completely transnasal route. As a joint team effort, this extended 
applications beyond the sphenoid sinus/sella needs a lot of surgical skills, planning and 
coordination for proper patient selection and optimal care. The EEA provides surgical 
access to the ventral skull base to resect a wide variety of intra-dural and extra-dural 
pathologies and allows the reconstruction of the resulting defect using a naso-septal flap. 
The evolution of these techniques has been enabled by technological advances including 
the design of specific endonasal instrumentation, surgical navigation technology and the 
development of new biomaterials for reconstruction. The incidence of tumor recurrence 
will be very much reduced with this minimally invasive ventral skull base technique. The 
use of powered instruments with navigational fusion imaging is most beneficial especially 
in revision cases.  
2. Endoscopic dacryocystorhinostomy 
Dacryocystorhinostomy(DCR)  involves the formation of a bypass from the lacrimal sac into 
the nose. It is essential that with proper history and examination including syringing and 
probing, a correct diagnosis is made. Syringing and probing is performed only in congenital 
and acquired nasolacrimal duct obstruction (NLDO) and are indications for the procedure. 
They are not performed in acute and chronic dacryocystitis.  
2.1 Indications (Table 1) 
The main indication is when there is distal outflow obstruction to the nasolacrimal system 
which can  clearly be demonstrated on a dacrocystogram. Endoscopic surgery is not 
indicated for obstruction of a punctum or a canaliculus for which there are other 
procedures. Often distal obstruction is mixed with varying degree of proximal obstruction 
and this need to be explained when counseling the patient. Syringing and probing is helpful 
in defining the site of obstruction. It is expected that in congenital and acquired NLDO, the 
epiphora  would resolve and in  acute and chronic dacryocysitis, the infection  would be 
resolved without recurrences. 
 
1. Primary acquired NLDO 
2. Secondary acquired NLDO 
a. Infectious causes of secondary acquired lacrimal duct obstruction 
b. Inflammatory causes of secondary lacrimal obstruction 
c. Neoplastic causes of lacrimal obstruction 
d. Traumatic causes of lacrimal obstruction 
e. Mechanical causes of lacrimal obstruction 
Table 1. Indications for Endonasal DCR(EDCR) 
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A dacrocystogram (Fig 2) is indicated if there is any mass within the sac and scintigraphy 
helps to define a functional problem. A functional problem  is one issue for which a 
dacryocystogram  is helpful. Lacrimal sac mass is another indication for dacryocystogram. A 
bloody discharge from the punctum is a symptom that needs investigating to exclude 
malignancy in the sac. The common symptoms are epiphora, recurrent dacryocystitis or 
swelling from a mucocele. It is unusual for intranasal pathology like Wegener 
granulomatosis and sarcoidosis to be the causative factor. Nasolacrimal duct obstruction can 
occur following a middle-third facial fracture. Distal nasolacrimal obstruction can be 
secondary to endoscopic sinus surgery if the Stammberger Rhinoforce Antrum Punch 
(Stortz, Germany) used to remove the uncinate process is placed too far forward. 
 
Fig. 2. A dacrocystogram showing distal obstruction of right nasolacrimal system on failure of 
penetration of dye into the inferior meatus in a patient with unilateral unresolving tearing. 
2.2 Contraindications (Table 2) 
A contraindication to DCR is the presence of a benign or malignant lesion in the lacrimal system 
or the surrounding tissues and active Wegener granulomatosis. Other causes are lacrimal sac 
diverticulum,, canalicular stenosis, lacrimal calculi and extensive midfacial trauma. 
 
1. Known or suspected lacrimal system neoplasm 
2. Large lateral lacrimal sac diverticulum 
3. Common canalicular stenosis 
4. Lacrimal system stones 
5. Extensive midfacial trauma 
Table 2. Contraindications for Endonasal DCR(EDCR) 
2.3 Anatomy and pre-operative assessment 
The lacrimal system comprises the lacrimal gland and its drainage system which 
commences with a punctum in each eyelid for 1mm at right angles to the lid margin. It 
continues as the upper and lower canaliculus which run parallel to the lid margin and then 
join to form a common canaliculus that drains into the lacrimal sac (Fig 3). Inferiorly the sac 
forms the nasolacrimal duct, which drains into the inferior meatus about 1cm posterior to 
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the anterior end of the inferior turbinate (Fig 4). The lacrimal  sac sits in the lacrimal fossa 
which is a very thin bone. Unlike its anterior margin, the anterior lacrimal crest, is made of 
very dense bone. In about 8% of patients, an anterior ethmoidal air cell lies medial to the 
lacrimal fossa which needs to be transverse before a rhinostomy can be created.  
Topical anesthetic drops such as amethocaine are placed in the eye followed by dilatation of 
the upper and lower puncta performed with punctual dilator. The puncta are initially 
dilated with the instrument perpendicular to the lid margin, rotating it for the first 1 mm 
with the lid margin taut, before turning it medially parallel to the lid. Upon dilatation of the 
punctum, a “0” Bowman probe is passed through the dilated punctum and angled medially. 
As the probe enters the common canaliculus, a slight resistance may be felt as a “soft stop” 
and as it touches the medial wall of the sac, there is a “hard stop”. The probe is then angled 
vertically down to feel whether there is any sac pathology or distal obstruction. This is a 
description for probing in children, which is preferably performed under general 
anaesthesia. It is avoided in adults because of the intolerable pain. Rigid 0.7 mm 
dacryocystoscopes can be used to inspect the fine obstructing membranes that can be found 
at the medial aspect of the upper and lower canaliculi (Wormald, 2002). These proximal 
membranes are the main cause of proximal obstruction, and a DCR is not indicated if this is 
the site of the obstruction. For surgeons becoming familiar with intranasal anatomy or a 
history of previous sinonasal surgery, it may be helpful to introduce a 20-gauge fiberoptic 
endoilluminator(Stortz, Germany) through the superior or inferior canaliculus after 
punctual dilator. The endoilluminator is then advanced gently until a hard stop signifying 
the lacrimal bone is identified (Woog, 2004). The location of the lacrimal sac may then be 
visualized endoscopically by transillumination (Fig 5 a, b). 
 
Fig. 3. Diagrammatic anatomical picture of nasolacrimal drainage system 
 
Fig. 4. Endoscopic view of a right nasolacrimal duct opening into an inferior meatus 
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Distal obstruction is diagnosed by probing and then syringing to see whether the fluid can 
initially pass through the canaliculi into the nose. If it refluxes through the other punctum, it 
indicates that there is distal obstruction. On the contrary, if there is reflux through the same 
punctum, then there is canalicular or common canalicular stenosis and this can be confirmed 
by gentle probing. There are  many causes of dysfunction that requires a different treatment 
than DCR. The most common site of distal obstruction is where the sac becomes the duct. 
Some surgeons will offer a DCR to patients with a functional blockage where there is free 
flow on syringing but on scintigraphy the pump system does not work. Only  70-75% of the 
tears are drained through the inferior canaliculus. Lester-Jones Pyrex tube is required only 
in bi-canalicular extensive obstruction that cannot be managed by other procedures such as 
forced probing and silicone intubation. 
  
(a)     (b) 
Fig. 5. A picture showing a fiber-optic endoilluminator being introduced via the left inferior 
cannaliculus to illuminate the nasolacrimal sac(a) and a zero degree endoscopic view 
identifying  the location of the illuminated  lacrimal sac(b) in the same patient. 
2.4 Surgical technique 
Upon nasal decongestion with neuropatties and infilteration with lidocaine and adrenaline, 
a 15 scalpel blade is used for initial mucosal incisions. The first incision is made horizontally 
1 cm above the axilla of the middle turbinate, commencing 3 mm posterior to the axilla and 
coming forward 1 cm onto the frontal process of the maxilla. The blade is then turned 
vertically and incision made about two thirds of the vertical height of middle turbinate, 
stopping just above the insertion of the inferior turbinate into the lateral nasal wall. The 
blade is then turned horizontally and the inferior insertion commenced at the insertion of 
the uncinate process and brought forward to meet the vertical incision. 
A suction Freer’s dissector (Stortz, Germany) is used to elevate the mucosal flap, ensuring that 
the tip of the sucker always maintains contact with the bone. Meanwhile the bone should be 
palpable so that the junction of the soft lacrimal bone and hard bone of the frontal process can 
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be identified. The thin lacrimal bone is 2 to 5 mm wide before the insertion of the uncinate 
process is reached. The dissection stops at the uncinate. A round knife (Stortz, Germany) is 
used to flake the soft lacrimal bone away from the postero-inferior region of the sac.  
A forward-bitting Hajek Koeffler punch (Stortz,  Germany) is used to remove the lower 
portion of the frontal process of the maxilla (Fig 6). The tip of the punch is used to push the 
lacrimal sac away where the lacrimal bone has to be removed. The punch is engaged in the 
hard bone of the frontal process and this bone is removed. Care should be taken not to   
grasp the sac as the punch is closed during bone removal. Removal of the frontal process of 
the maxilla uncovers the antero-inferior portion of the lacrimal sac. Bony removal with 
punch is continued as far superiorly as possible until the bone becomes too thick for the 
punch to engage. At this juncture the 15 degree curved 2.9 mm rough diamond 
burr(Medtronic Xomed, Jacksonville, Florida, USA) is attached to the micro-debrider and 
used to remove the rest of the bone up to the superior mucosal incision (Jones,1998). Often, 
an agger nasi cell is present and the mucosa of this cell will be exposed as the sac is followed 
superiorly above the axilla of the middle turbinate thus exposing the frontal recess (Fig 7). 
The diamond burr can be brought into light contact with the lacrimal sac lining without 
damaging the sac. A cutting burr will remove the bone faster but may cause significant 
damage to the sac wall with development of hole in the sac wall.  
 
Fig. 6. Intraoperative endoscope view showing right dacrocystorhinostomy with initial 
removal of the thin lacrimal bone with Hajek Koffler sphenoid punch and subsequently the 
hard frontal process of maxilla with a microdrill 
 
Fig. 7. Intraoperative endoscopic view showing a right dacrocystorhinostomy with wide 
exposure of the nasolacrimal sac with visible end of eye probe and removal of agger nasi cell 
exposing the frontal recess 
 
Advances in Ophthalmology 
 
526 
Distal obstruction is diagnosed by probing and then syringing to see whether the fluid can 
initially pass through the canaliculi into the nose. If it refluxes through the other punctum, it 
indicates that there is distal obstruction. On the contrary, if there is reflux through the same 
punctum, then there is canalicular or common canalicular stenosis and this can be confirmed 
by gentle probing. There are  many causes of dysfunction that requires a different treatment 
than DCR. The most common site of distal obstruction is where the sac becomes the duct. 
Some surgeons will offer a DCR to patients with a functional blockage where there is free 
flow on syringing but on scintigraphy the pump system does not work. Only  70-75% of the 
tears are drained through the inferior canaliculus. Lester-Jones Pyrex tube is required only 
in bi-canalicular extensive obstruction that cannot be managed by other procedures such as 
forced probing and silicone intubation. 
  
(a)     (b) 
Fig. 5. A picture showing a fiber-optic endoilluminator being introduced via the left inferior 
cannaliculus to illuminate the nasolacrimal sac(a) and a zero degree endoscopic view 
identifying  the location of the illuminated  lacrimal sac(b) in the same patient. 
2.4 Surgical technique 
Upon nasal decongestion with neuropatties and infilteration with lidocaine and adrenaline, 
a 15 scalpel blade is used for initial mucosal incisions. The first incision is made horizontally 
1 cm above the axilla of the middle turbinate, commencing 3 mm posterior to the axilla and 
coming forward 1 cm onto the frontal process of the maxilla. The blade is then turned 
vertically and incision made about two thirds of the vertical height of middle turbinate, 
stopping just above the insertion of the inferior turbinate into the lateral nasal wall. The 
blade is then turned horizontally and the inferior insertion commenced at the insertion of 
the uncinate process and brought forward to meet the vertical incision. 
A suction Freer’s dissector (Stortz, Germany) is used to elevate the mucosal flap, ensuring that 
the tip of the sucker always maintains contact with the bone. Meanwhile the bone should be 
palpable so that the junction of the soft lacrimal bone and hard bone of the frontal process can 
 
Extended Applications of Endoscopic Sinus Surgery to the Orbit and Pituitary Fossa 
 
527 
be identified. The thin lacrimal bone is 2 to 5 mm wide before the insertion of the uncinate 
process is reached. The dissection stops at the uncinate. A round knife (Stortz, Germany) is 
used to flake the soft lacrimal bone away from the postero-inferior region of the sac.  
A forward-bitting Hajek Koeffler punch (Stortz,  Germany) is used to remove the lower 
portion of the frontal process of the maxilla (Fig 6). The tip of the punch is used to push the 
lacrimal sac away where the lacrimal bone has to be removed. The punch is engaged in the 
hard bone of the frontal process and this bone is removed. Care should be taken not to   
grasp the sac as the punch is closed during bone removal. Removal of the frontal process of 
the maxilla uncovers the antero-inferior portion of the lacrimal sac. Bony removal with 
punch is continued as far superiorly as possible until the bone becomes too thick for the 
punch to engage. At this juncture the 15 degree curved 2.9 mm rough diamond 
burr(Medtronic Xomed, Jacksonville, Florida, USA) is attached to the micro-debrider and 
used to remove the rest of the bone up to the superior mucosal incision (Jones,1998). Often, 
an agger nasi cell is present and the mucosa of this cell will be exposed as the sac is followed 
superiorly above the axilla of the middle turbinate thus exposing the frontal recess (Fig 7). 
The diamond burr can be brought into light contact with the lacrimal sac lining without 
damaging the sac. A cutting burr will remove the bone faster but may cause significant 
damage to the sac wall with development of hole in the sac wall.  
 
Fig. 6. Intraoperative endoscope view showing right dacrocystorhinostomy with initial 
removal of the thin lacrimal bone with Hajek Koffler sphenoid punch and subsequently the 
hard frontal process of maxilla with a microdrill 
 
Fig. 7. Intraoperative endoscopic view showing a right dacrocystorhinostomy with wide 
exposure of the nasolacrimal sac with visible end of eye probe and removal of agger nasi cell 
exposing the frontal recess 
 
Advances in Ophthalmology 
 
528 
Next, the inferior punctum is dilated with a punctum dilator and a Bowman’s canalicular 
probe is passed into the sac. If the tip of the probe is not seen to move behind the thin sac 
wall, the probe is not in the lumen. The exposed sac is incised vertically with a DCR 
minisickle knife (Metronic Xomed, USA). Belucci scissors (Stortz, Germany) are used to 
make upper and lower releasing incisions in the posterior flap which is rolled out on the 
lateral nasal wall. The sac should now be completely marsupialized and lie flat on the lateral 
nasal wall. Approximating the lacrimal and nasal mucosa should result in a first intention 
healing rather than a secondary intention healing and should reduce the formation of 
granulation tissue and scarring. The puncta are dilated and Silastic lacrimal intubation 
tubes(O’Donoghue tubes) are placed through the upper and lower puncta and retrieved 
endonasally. Ligar clips are placed to secure the tubes in place (Fig 8). Before placing the 
clips ensure  a loop of tubing is pulled in the medial canthus of the eye so that the tubes are 
not tight. If the loop is tight the tubes can cheese-wire through the punctum (Khairullah and 
Gendeh, 2011). A square of Gelfoam(Pharmacia NSW, Sydney, Australia) or Merogel 
(Metronic Xomed) is slid up the tubing and placed over the flaps to hold them in position.  
 
Fig. 8. Intraoperative endoscope view showing right dacrocystorhinostomy with stent  
in situ an adult patient presenting with unresolving right tearing. 
Saline irrigation is started within 3 to 4 hours of surgery. The patient is commenced on 
broad spectrum antibiotics for 5 days and eye drops are used for 3 weeks. The O’Donoghue 
tubes are removed in the clinic after 4 weeks. It is rare to see any granulation tissue but if 
they are present they should be removed. The patient is reviewed for a further 18 months 
before discharge. 
2.5 Laser assisted DCR 
For osteotomy, laser was used exclusively in the early part of the series in 1992 and 1993. 
The preferred site for osteotomy was the thinnest bone located in the infero-posterior parts 
of the lacrimal fossa, which corresponds to the brightest area in the nasal cavity as 
demonstrated by the transilluminator. The authors concluded that the success rate of laser-
assisted DCR was around 78%, which was much lower than that of conventional DCR. 
Beginning in 1999 and 2000, osteotomy was performed with either a drill, a punch, or both, 
which enabled removal of thicker bone. The site of the osteotomy was moved to the level of 
medial canthus, which was anterior and superior to that of previous surgeries. When the 
osteotomy was completed, the common internal punctum was visible on endoscopy. With 
this approach, the success rate improved to 92%(Lee et al, 2004). 
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In another interesting study in 65 patients with a mean follow-up of 74 months, the authors 
found the success rate of endoscopic laser assisted DCR has gradually declined over the 
years to 56%. The authors do not advocate the use of laser in endonasal DCR with epiphora 
(Umapathy et al, 2006). 
3. Endoscopic applications in orbital surgery 
3.1 Endoscopic blow out fracture repair 
Fractures of the roof of the maxillary sinus with herniation of the orbital content (blow-out 
fracture), often produce strangulation of the inferior rectus or inferior oblique muscles and 
thereby impairing movement of eyeball (Fig 9). They can present with periorbital 
ecchymosis and subconjunctival hemorrhage. Those with fracture of medial wall of orbit 
without prior surgical intervention can present with enopthalmos. 
 
Fig. 9. Coronal CT scan of the paranasal sinuses showing a ‘tear drop’ sign resulting  
from a blunt trauma  to the left eye in a patient presenting with diplopia 
Passage of the endoscope through the intranasal maxillary antrostomy may provide superb 
visualization of the posterior orbital floor which is the most difficult area to view by 
transconjunctival or subciliary approach. Anatomically, this area of the orbital floor 
commonly lies behind the middle half of the globe on axial view. This posterior view may 
furthermore be obscured because the orbital floor angulates 15 degrees superiorly as one 
proceeds from the orbital rim toward the orbital apex. Therefore, the endoscope is an 
extremely useful means of safely and definitely identifying the posterior edge of the defect 
and ensuring that the posterior edge of the orbital implant do not compromise the optic 
nerve or other structures at the orbital apex (Hartstein et al, 2004). In many small fractures 
for which an implant is not required, endoscopic examination and reduction may be 
sufficient, thus avoiding an external incisional approach. 
It is doubtful that endoscopy alone will replace standard CT scanning in the evaluation of 
orbital fractures. Thus, combining forced duction testing with endoscopic visualization of a 
fracture may prove to be useful diagnostic tool. 
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Next, the inferior punctum is dilated with a punctum dilator and a Bowman’s canalicular 
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(Metronic Xomed) is slid up the tubing and placed over the flaps to hold them in position.  
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This include fractures with extension to the middle and posterior portions of the orbital 
floor, in delayed or secondary fracture repair. 
3.1.2 Surgical technique 
Orbital fracture repair is normally performed using general anaesthesia. Some author’s  
have reported the use of purely endoscopic approach for the repair of orbital floor fracture 
(Ikeda et al, 1999). The procedure is commenced by enlarging the maxillary ostium and then 
introducing an angled endoscope. Bony fragmenst in the fracture site are removed 
endoscopically until an improvement in forced duction testing is noted. Subsequently, a 
uretheral balloon catheter is introduced through the ostium into the maxillary sinus. In 
some patients with trap-door-type fractures, successful fracture repair may be possible with 
endoscopic approach alone, with removal of the displaced bony fragment and relieve of the 
entrapment. Saline is used to inflate the balloon which elevates the contents out of the 
fracture site. The balloon is removed approximately two weeks after surgery. 
Tips for successful surgery 
Endoscopic visualization of fractures of the posterior aspect of the orbital floor and medial 
orbit may facilitate safe and secure implant placement and ensures that no residual orbital 
soft tissue is entrapped within the fracture site or beneath the implant. The endoscopic 
technique minimizers the uncertainty of implant placement posteriorly in both primary and 
secondary repairs. It may help to minimize the number of additional incisions required in 
the medial orbit, maxillary sinus and even the eyelid. The increased accuracy of implant 
placement may help to reduce the risks of residual exopthalmos postoperatively. This 
technique is useful in the more complex fractures involving the posterior orbital floor and 
medial wall.  
3.2 Endoscopic orbital decompression of complications of thyroid-related orbitopathy 
Graves’ disease is an autoimmune disorder affecting the thyroid, orbit and skin. 
Approximately 50% of patients with this disorder develop orbital manifestation of 
dysthyroid orbitopathy. Fewer than 5% of such patients have disease that is severe enough 
to require surgical decompression of the orbit (Metson and Samaha, 2004). The extensive 
muscle enlargement limits globe movement in extremes of gaze which will cause diplopia. 
Visual loss in Grave’s disease is uncommon, occurring in only 2 to 7% of patients 
(Kountantakis et al, 2000; Kuppersmith et al, 1997). Exopthalmos in Grave’s disease is 
thought to result from the deposition of immune complexes in the intraocular mucles and 
fat which in turn leads to edema and fibrosis (Tandon et al, 1994). The resultant increase in 
intraorbital pressure pushes the globe forward causing proptosis. If this proptosis become 
severe enough, the eyelids cannot close properly and chemosis with or without exposure 
keratitis of the cornea may occur. Furthermore, the crowding of the orbital apex by the 
obviously enlarged extraocular muscles places pressure on the optic nerve. Stretching of the 
optic nerve by increasing proptosis may result in the development of optic neuropathy and 
visual loss. If medical treatment fails (high dose steroids with or without low-dose 
radiotherapy) , surgical decompression of eyelid is indicated(Cook et al, 1996).  
 
Extended Applications of Endoscopic Sinus Surgery to the Orbit and Pituitary Fossa 
 
531 
Removing one or more of the bony walls can decompress the contents of the orbit. The least 
amount of decompression  would be achieved with medial wall removal , but the most 
physiologic and least to cause complications like globe displacement and diplopia. 
Endoscopic orbital decompression affords maximal orbital decompression at the orbital 
apex, an area that is not fully accessible via the external or transantral routes (Metson et al, 
1994). Many techniques have been described for decompressing the orbit  but the order of 
the procedures is that orbital decompression first, then strabismus and lastly the  eyelid.  
3.2.1 Indications and contraindications 
The primary indication for the surgery is exopthalmos, either for cosmetic reasons or when 
vision is deteriorating and steroids and radiotherapy treatment has failed. The most 
common indications for such surgery are exposure keratopathy and optic neuropathy that 
have been refractory to conservative measures. Patients with diplopia from dysthyroid 
orbitopathy may require decompression before strabismus surgery to reaccess the globe and 
improve the predictability of muscle adjustments. Some surgeons who consider aesthetically 
undesirable proptosis to be an indication for orbital decompression have performed such 
surgery for its cosmetic benefits. 
Contraindications to endoscopic orbital decompression include acute sinusitis and anatomic 
abnormalities of the maxillary bone. Endoscopic decompression may be technically difficult 
in patients with very small maxillay sinuses or thick orbital walls. These features are easily 
identified on computed tomography(CT) scan of the orbit and sinuses, which should be 
obtained on all patients before surgery.  
3.2.2 Useful instruments 
- A long-shanked drill with a course diamond burr (Medtronic Xomed, Jacksonville, 
Florida, USA) and good irrigation system to keep the bone cool. 
- Image guided surgery 
3.2.3 Endoscopic technique 
The patient is placed in a supine position with head slightly elevated. Packing that has been 
soaked in a 4% cocaine solution is placed in the nasal cavity to initiate mucosal 
vasoconstriction. Both eyes are exposed in the surgical field. If general anaesthesia is used, 
the corneas are covered with protective shells. Under endoscopic visualization, submucosal 
injections of 1% lidocaine with epinephrine are administered along the lateral nasal wall and 
middle turbinate. If a septal deviation precludes endoscopic access to the middle meatus 
region, a septoplasty is performed before orbital decompression. 
The bones removed in endoscopic decompression include the medial wall of the orbit and 
the portion of the floor that is medial to the infraorbital canal. The procedure is initiated 
with an incision through the uncinate process. This incision is made just posterior to the 
maxillary line, a bony eminence that extends from the anterior attachment of the middle 
turbinate to the root  of the inferior turbinate(Fig 10). The maxillary sinus ostium is then 
generously enlarged to provide optimal exposure of the orbital floor to prevent obstruction 
of the maxillary sinus by the decompressed globe. Bone is removed in the posterior 
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direction to the level of the back wall of the sinus. Anterior removal is terminated at the 
thick bone of the frontal process of the maxilla, which protects the nasolacrimal duct. The 
ostium is enlarged superiorly to the level of the orbital floor and inferiorly to the root of the 
inferior turbinate. A 30-degree endoscope is used to identify the infraorbital nerve along the 
roof of the sinus (Fig 11).  
 
Fig. 10. A zero degree endoscopic view of left lateral nasal wall showing the maxillary line 
and uncinate process 
 
Fig. 11. A 30 degree endoscopic view showing  evidence of wide right middle meatal 
antrostomy with infraorbital indentation in the roof of the maxillary sinus 
An endoscopic sphenoethmoidectomy is then completed as described by Stammberger 
(1991) and Kennedy (1985). The degree of pneumatization of the sphenoid determines 
whether the optic nerve indents or even dehiscent in its lateral wall. Similarly, if the 
posterior ethmoid sinuses envelop the optic nerve before it reaches the sphenoid sinus, am 
Onodi cell may be present (Fig 12).The anterior and posterior ethmoid arteries are identified 
along the ethmoid roof. The middle turbinate that serves as a landmark during the 
sphenoethmoidectomy is removed before opening the lamina papyracea to optimize 
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exposure to the medial orbital wall and facilitate postoperative cleaning. The skeletonized 
lamina papyracea is gently penetrated with a small spoon curette. Bony fragments of lamina 
papyracea is lifted in a medial direction to avoid perforation of the underlying periorbita. 
This elevation may also be performed with a periosteal elevator or delicate Blakesley 
forceps(Stortz, Germany). If surgery is performed using local anaesthesia, additional 
injections may be necessary to desensitize the medial orbital wall. Anaesthetic agent is 
injected just deep to the periorbita through the bony opening in the lamina. 
  
(a)     (b) 
Fig. 12. An intra-operative endoscopic view (a) and coronal CT scan view (b) showing  an 
Onodi cell  
Bone of the lamina papyracea is removed in a superior direction toward the level of the 
ethmoid roof. The frontal recess is the most anterior superior portion of the ethmoid sinus, 
which communicates with the frontal sinus. Removal of the lamina papyracea in this region 
can cause postoperative obstruction of the frontal sinus by herniated fat. As dissection 
continous in a posterior direction toward orbital apex, thicker bone and underlying 
periorbita are generally encounterd within 2 mm of the sphenoid face. This thickening 
represents the annulus of Zinn, from which the extra ocular muscles(EOMs) originate and 
through which the optic nerve passes (Fig 13). This landmark represents the posterior limit 
of dissection and does not need to be removed. In cases of neuropathy, bone removal 
proceeds more posteriorly and may extend to the lateral wall of the sphenoid sinus. 
Fragments of bone are cleared from the anterior end of lamina papyracea where it joins the 
lacrimal bone. Dissection in this region may be facilitated by use of an angled spoon curette 
and 30-degree endoscope (Stortz, Germany). The thick white fascia of the lacrimal sac may 
be uncovered but should not be opened. Firm bone anterior to the maxillary line protects 
most of the sac, so it should not be removed. Removal of the bone along the medial orbital 
floor can be most technically challenging aspect of this surgery. A spoon curette is used to 
fracture the bone in a downward direction. This bone may break apart in several small 
fragments with a natural cleavage plane along the infraorbital canal. Use of a 30-degree 
endoscope may facilitate visualization within the maxillary sinus and aid in the 
identification of the infraorbital nerve which serves as the lateral limit of bone removal. 
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Fig. 13. A diagrammatic sagittal section of left sphenoid and posterior ethmoids showing the 
thick bone at the annulus of Zinn at the junction of the orbital apex and sphenoid sinus 
After the periorbita has been fully exposed and cleared of bony fragments, it is opened with a 
sickle knife(Stortz, Germany). The incision is usually commenced in front of the sphenoid 
sinus. Care is taken to keep the tip of the blade superficial to avoid injury of the underlying 
orbital contents especially the medial rectus muscle, which may be enlarged secondary to 
dysthyroid orbitopathy. Incision of the periorbita is extended along the ethmoid roof and the 
orbital floor. A horizontal strip of periorbita overlying the medial rectus muscle is preserved 
(Fig 14). This fascial sling serves to decrease prolapsed of the muscle and is thought to reduce 
the incidence of postoperative diplopia (Metson and Samaha, 2002). However, in patients with 
optic neuropathy, maximal decompression is needed and the fascial sling is sacrificed to allow 
for wider excision of the periorbita which is removed eventually with angled Blakesley 
forceps. At the completion of the procedure, the generous prolapsed of the orbital fat into the 
opened ethmoid and maxillary sinuses should be observed(Fig 15) 
 
Fig. 14. A 70 degree endoscopic view showing  an emergency horizontal orbital 
decompression incisions of the periorbita extending from the ethmoidal roof to the orbital 
floor for thyroid related orbitopathy 
 




Fig. 15. A 30 degree endoscopic view showing prolapsed of orbital fat into the nasal cavity 
on balloting the right eye  
A lateral orbital decompression may be performed at this time, depending on the extent of 
patient’s disease and the degree of additional decompression desired. Due to the prior 
medial decompression, the orbital contents are easily retracted in a medial direction to 
provide excellent exposure of the lateral bony wall, which is removed or contoured. 
Concurrent excision of excess intraconal fat may also be performed if necessary. Bilateral 
orbital decompressions may be performed concurrently or as a staged procedure. 
Nasal packing is avoided in order to prevent compression of the optic nerve, which is 
rendered increasingly vulnerable by the decompression. The patient is discharged the 
morning after surgery with a prescription for oral antibiotics and instructions to begin 
twice-daily nasal saline irrigations with a bulb syringe. During postoperative visit a week 
later, residual debri is cleared from the nasal cavity under endoscopic guidance. 
In some cases, local anaesthesia may be preferred to general anaesthesia. These situations 
include patients who have an only-seeing eye, significant medical comorbidity, or a strong 
preference for local anesthesia.  
The use of local anesthetic enables the surgeon to monitor the patient’s vision on a 
continuous basis during the surgery and reduces the likelihood of occult injury to the optic 
nerve (Metson et al, 1994). Ideal sedation is achieved with intravenous bolus of propofol, 0.4 
to 0.8mg/kg, administred before local injection, followed by maintenance infusion of 95 to 
75 ug/kg during the procedure. Submucosal infilteration of 1% lidocaine with epinephrine 
1:100,000 is performed exactly as described for the procedure utilizing general anaesthesia. 
Patients may report discomfort during removal of the lamina papyracea, and this may 
require a small additional infiltration of anaesthetic solution into the periorbita. 
3.2.4 Complications 
Diplopia is a relatively common sequela of endoscopic orbital decompression reported in 15 
to 30 % of postoperative patients. This complication can be the result of change in the vector 
of pull of the EOMs. Diplopia that is present preoperatively is usually not improved by this 
surgery. Patients with preexisting or new-onset post-operative diplopia frequently require 
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twice-daily nasal saline irrigations with a bulb syringe. During postoperative visit a week 
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continuous basis during the surgery and reduces the likelihood of occult injury to the optic 
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to 0.8mg/kg, administred before local injection, followed by maintenance infusion of 95 to 
75 ug/kg during the procedure. Submucosal infilteration of 1% lidocaine with epinephrine 
1:100,000 is performed exactly as described for the procedure utilizing general anaesthesia. 
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of pull of the EOMs. Diplopia that is present preoperatively is usually not improved by this 
surgery. Patients with preexisting or new-onset post-operative diplopia frequently require 
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strabismus surgery. It is essential that all patients be informed of the possibility of 
postoperative double vision before undergoing orbital decompression. 
Techniques to decrease the incidence of new-onset postoperative diplopia, including the 
preservation of the fascial sling of periorbita to prevent prolapsed of the medial rectus 
muscle, have been mentioned (Metson and Samaha, 2002). To decrease the incidence of 
postoperative diplopia, the use of balanced decompression technique is advocated. This 
technique involves performing external lateral wall decompression at the time of endoscopic 
medial wall decompression to reduce pressure on the medial rectus muscle while 
simultaneously increasing the degree of ocular recession. 
Postoperative bleeding after endoscopic orbital decompression is managed by direct 
caurterization of the bleeding site. Nasal packing is avoided in these patients to avoid 
pressure in the region of the optic nerve. The incidence of sinonasal infection post-surgery is 
minimized with the routine use of postoperative antistaphylococcal antibiotics. 
Postoperative epiphora may occur if the nasolacrimal duct is transected during the 
maxillary antrostomy. This complication is readily treated with an endoscopic DCR. 
Blindness and cerebrospinal fluid rhinorrhea are also potentially serious complications of 
orbital decompression but rare. 
Endoscopic orbital decompression should be performed only by surgeons with extensive 
experience in endoscopic intranasal techniques. A team approach, which uses the skills of 
both an Otolaryngologist and an Opthalmologist during the performance of this procedure 
is highly recommended.  
Tips for successful surgery 
Orbital decompression for thyroid-related orbitopathy is an effective method for reduction 
of proptosis for cosmetic proptosis, eye complications from exposure of the cornea and 
visual loss. The amount of regression of proptosis is related to the number of walls removed 
during surgery. It is believed that three-walled decompression may give a more balanced 
decompression with less likelihood of postoperative diplopia. 
3.3 Endoscopic orbital decompression for acute orbital hemorrhage 
The procedure of choice is lateral canthotomy and inferior cantholysis with of course cold 
dry compresses as tolerable. This is performed for ‘orbital compartment syndrome’ due to 
orbital bleeding, emphysema or tumor. For orbital decompression, lateral canthotomy alone 
is not sufficient and the inferior eyelid should be completely free to allow anterior 
displacement of the globe. Drainage  of any kind is only indicated if this is not helpful. The 
problem with drainage is that the bleeding is diffuse and not confined to one compartment. 
Endoscopic drainage is actually performed to remove adjacent orbital wall and open the 
periosteum to allow decompression of orbital soft tissues. It is important to note that the 
same can be achieved with the faster canthotomy and inferior cantholysis. 
Invariably the anterior ethmoidal artery(AEA) can be located one cell behind the frontal 
recess(Fig 16 a, b). The size of the so called supra-orbital cell (Bolger & Mann, 2001) varies: it 
can be small or large. The AEA can often be seen on CT scan, (Fig 10) particularly as it enters 
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the orbit where it produces a fluted defect in the lamina papyracea(LP). The more 
pneumatized the supra-orbital recess, the more vulnerable it is to damage. Often the 
ethmoidal bulla (EB) attaches to the skull base and the AEA lies within the roof  and is 1-2 
mm behind the attachment of the anterior wall of the EB to skull base. If the frontal recess 
(FR) does require opening, it is best approached anteriorly, away from AEA if the 
landmarks are poor owing to previous surgery or bleeding. As the AEA is sometimes 
dehiscent, it is advisable not to grasp polyps in this area if one is unable to identify the 
anatomy clearly. Often the FR can be found by following the intact anterior wall of the 
ethmoidal bulla superiorly. 
  
(a)      (b) 
Fig. 16. A coronal CT imaging showing an indentation of right anterior ethmoidal artery at 
the region of frontal recess (a) and a 70 degree endoscopic view showing indentation of the 
artery in the same patient(b).  
The AEA is dehiscent at some point in the majority of patients (Lang, 1989). It is essential to 
avoid   tearing it for it can cause marked bleeding. If it is transected and retracts into the 
orbit, a marked increase in pressure in the posterior compartment of the eye can occur and 
place the retinal artery and its supply to the retina at risk. If it is torn, gentle bipolar 
diathermy will arrest the bleeding but this should be performed with great care to avoid 
transecting the remaining segment of the artery. 
3.3.1 Bleeding 
If there is obvious bleeding into the posterior compartment of the eye, the eye will prop out, 
the orbit will become very firm and within a few minutes the swinging flash light test will 
reveal an afferent defect. An  awake patient will complaint of discomfort and loss of vision. 
An orbital tourniquet should be tried on immediate recognition. This involves  placing a 
cotton wool over the closed eyelid and applying an orbital tourniquet over the cotton wool 
and around the head and then inflating it to systolic pressure. This is performed for one 
minute and then it should be removed and the pupil reflexes and/or the vision checked. If 
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strabismus surgery. It is essential that all patients be informed of the possibility of 
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orbit, a marked increase in pressure in the posterior compartment of the eye can occur and 
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diathermy will arrest the bleeding but this should be performed with great care to avoid 
transecting the remaining segment of the artery. 
3.3.1 Bleeding 
If there is obvious bleeding into the posterior compartment of the eye, the eye will prop out, 
the orbit will become very firm and within a few minutes the swinging flash light test will 
reveal an afferent defect. An  awake patient will complaint of discomfort and loss of vision. 
An orbital tourniquet should be tried on immediate recognition. This involves  placing a 
cotton wool over the closed eyelid and applying an orbital tourniquet over the cotton wool 
and around the head and then inflating it to systolic pressure. This is performed for one 
minute and then it should be removed and the pupil reflexes and/or the vision checked. If 
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the vision or pupil reflex has improved, the orbital tourniquet should be reapplied and the 
process repeated every minute for up to 5 minutes. If this is performed soon after injury, it 
may be sufficient to stop bleeding into the orbit and it can arrest the process.  
It is advisable to monitor vision for 6 hours postsurgery to ensure that no further bleeding 
occurs into the posterior compartment. If this maneuver fails then the orbit must be 
decompressed. A lateral canthotomy and inferior cantholysis is quick and efficient 
technique for up to one hour and it is best to decompress the orbit as early as possible 
(Jones, 1997). Moreover, one should not wait for an opthalmological colleague to arrive 
unless they do so within an hour. Assessing the vascular supply of the retinal vessels with 
an opthalmoscope is inadequate. 
3.3.2 Lateral canthotomy and inferior cantholysis  
Local anesthetic is placed around the lateral canthus of eye and it is divided using small 
straight scissors down to the bone of the orbital rim and to the depth of the lateral sulcus of the 
conjunctiva. A corneal abrasion or conjuctival damage can be avoided by protecting the globe. 
The lower lid is then retracted downward for good expose. The scissors is angled at 45 degree 
to the horizontal axis and the lateral ligament and septum is divided and the globe and 
contents of the orbit will then prolapse forward (Fig 17). The pupil reflexes, the pressure of the 
orbit and vision should all be checked. The orbit will retract to its normal position over the 
next 2-3 days. Suturing is usually performed a week or so after the procedure. 
    
(a)     (b) 
Fig. 17. Picture showing an emergency left lateral canthotomy (a) and subsequent 
cantholysis (b) being performed in the same patient for iatrogenic orbital hemorrhage  
This procedure is normally sufficient to decompress the posterior compartment of the eye. If 
inadequate a surgical decompression should be undertaken. It can be done either 
endoscopically by removing the LP widely and incising the orbital periosteum or externally 
via a Lynch-Howarth incision. Preserving vision takes priority over producing an external 
scar. If the orbit is decompressed by an external approach, the AEA will not be found as it 
will have retracted into substance of the orbit. 
3.3.3 Medial rectus damage 
Medial rectus damage occurs when there is disinsertion of the muscle, damage to the 
muscle nerve or intramuscular bleeding. In damage encountered during enscopic sinus 
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surgery,  a vigilant  assistant should look out for movement of the globe which occurs 
unintentionally. As a precautionary measure, the assistant should repeatedly ballot the 
eye when the surgeon is operating on the lateral nasal wall. Anatomically the medial 
rectus muscle is located closer to LP posteriorly then anteriorly (Fig 18). The suction port 
of the powered shaver should preferably be directed medially away from the LP to 
minimize the risk of damaging the structures in the lateral nasal wall. Damage to medial 
rectus occurs through deeper penetration into the orbit. Unfortunately, it is very difficult 
to prevent the scarring and diplopia that are likely to occur if recognized then. Moreover, 
expert strabismus surgeons have difficulty in correcting the problems caused by damage 




Fig. 18. Axial section of the relationship of  right medial rectus and optic nerve to the lamina 
papyracea 
3.3.4 Optic nerve damage 
The optic nerve can be damaged by penetration of the orbit through the lamina papyracea. 
Therefore, it is important for the assistant to look for eye movements when the surgeon is 
operating on the lateral nasal wall. Moreover, the optic nerve can be damaged if it is 
exposed in a sphenoethmoid air cell(Onodi cell)(Fig 19). An Onodi cell should be identified 
on routine pre-operative imaging and care taken in removing polyps lateral to the sagittal 
plane of the medial wall of the maxillary sinus. It is advisable to identify the sphenoid sinus 
ostia medially and then work forward. The optic nerve indentation can be prominent in 20% 
of patients in the upper half of lateral wall of sphenoid sinus but is rarely dehiscent (Fig 20). 
The carotid artery lies in the lateral and inferior aspect of the sphenoid sinus. Therefore, it is 
advisable to avoid the lateral wall of sphenoid sinus by directing the suction port of the 
powered shaver medially away from the lateral wall of sphenoid sinus to minimize the risk 
of damaging the structures present there. 
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surgery,  a vigilant  assistant should look out for movement of the globe which occurs 
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of the powered shaver should preferably be directed medially away from the LP to 
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to prevent the scarring and diplopia that are likely to occur if recognized then. Moreover, 
expert strabismus surgeons have difficulty in correcting the problems caused by damage 
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The optic nerve can be damaged by penetration of the orbit through the lamina papyracea. 
Therefore, it is important for the assistant to look for eye movements when the surgeon is 
operating on the lateral nasal wall. Moreover, the optic nerve can be damaged if it is 
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The carotid artery lies in the lateral and inferior aspect of the sphenoid sinus. Therefore, it is 
advisable to avoid the lateral wall of sphenoid sinus by directing the suction port of the 
powered shaver medially away from the lateral wall of sphenoid sinus to minimize the risk 
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Fig. 19. A diagrammatic axial view of the paranasal sinuses showing a rare bilateral Onodi 
cell 
     
Fig. 20. Diagrammatic sagittal section  and endoscopic view of the sphenoid sinus showing  
indentations of the lateral wall by internal carotid artery inferiorly and optic nerve 
superiorly 
3.3.5 Post-operative complications 
3.3.5.1 Bleeding 
Sitting the patient 30% head up at end of procedure is often adequate for minor general 
ooze. Coughing during extubation will result in temporarily more bleeding due to increase 
in venous pressure. A nasal pack soaked in 1:10,000 epinephrine is helpful for more than 
minor ooze and removed in the recovery or left in position for 12 hours if oozing continues. 
Prophylactic antibiotics are advocated for nasal packs left in position for more than 24 
hours. Rarely, torrential reactionary bleeding can occur in the first 12 hours due to these 
vessels initially going into spasm intra-operatively when the platelet plug and clotting 
factors block them but with due time either due to relaxation of artery or fibrinolysis 
reverses this process and bleeding commences. Usually it is impossible to locate the 
bleeding site. If a local nasal pack with vasoconstrictor and local anesthetic is not helpful to 
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control the bleeding, then bipolar caurtery of the offending vessel may be helpful. If this too 
fails, then reinserting a nasal pack and/or balloon may be necessary to tamponade the 
bleeding until the spheno-palatine artery(SPA) can be ligated under general anesthesia. If a 
large sphenoidotomy has been performed, the bleeding could be due to the damaged septal 
branch as it crosses the anterior wall of the sphenoid (Fig 21). 
 
Fig. 21. Intraoperative Endoscopic view showing a right low sphenoidotomy with evidence 
of sphenopalatine bleed 
3.3.5.2 Adhesions 
Mucosal damage to adjacent surfaces can result in adhesions (Fig 22). Adhesions can be 
minimized by topical and local corticosteroids application. If adhesions are present pre-
operatively, they need removal with a through-cutting punch followed by douching and 
debridement at one week. 
 
Fig. 22. Endoscopic view showing adhesions between left septum and inferior turbinate 
after nasal surgery 
3.3.5.3 Epiphora 
The lacrimal sac or naso-lacriminal duct can be damaged if the middle meatal 
antrostomy(MMA) is extended too far anteriorly. If middle meatus needs to be enlarged 
anteriorly to allow improved access or drainage, then the uncinate process (UP) is removed 
retrograde with Stammberger Rhinoforce antrum punch (Stortz, Germany). If patient 
complaints of watery eyes post surgery, it is best not to intervene as it will often resolve on 
its own. If the epiphora is persistent, an endo-nasal DCR will be helpful.  
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3.3.5.4 Periorbital emphysema  
Peri-orbital emphysema or air in the soft tissues around the eye is due to intra-operative 
breach of the LP and the patient unknowingly blown their nose(Fig 23).The anesthetist 
should be advice to take care on extubating the patient and not to use too much force if 
patient needs to be ventilated with face mask. The emphysema will resolve in due time 
provided the patient does not blow any more air into the area. Prophylactic antibiotics are 
administered for active sinusitis or history of sinusitis. 
 
Fig. 23. Left periorbital  emphysema post powered endoscopic sinus surgery which resolved 
spontaneously 
3.3.5.5 Anosmia 
Smell is a precious sense and every effort should be made to preserve or improve it. The 
olfactory mucosa extends from the cribriform plate to cover almost all the medial side of 
middle turbinate and the same area on the septum with a little inferior extension. 
Pre-operative oral steroids are helpful in preventing damage to the mucosa, especially if 
polyps are medial to the middle turbinate (MT) when assessed as an outpatient. If the 
polyps remain medial to middle turbinate at surgery, perform an ethmoidectomy and then 
gently lateralize the MT to open the olfactory cleft which allows better access to topical 
steroid spray. If the patient has hyposmia or anosmia post-surgery and the MT is adherent 
to the septum, it is worth resecting and lateralizing the MT as an elective procedure when 
mucosal edema has settled down. 
3.3.5.6 Frontal recess stenosis 
The frontal sinus is often opaque on CT scan in nasal polyposis and it is normally due to 
retained secretions. It is rare to find polyps within the frontal sinus. Often opening the 
middle meatus and de-bulking polyps in region below the frontal recess with a shaver or 
through-cutting forceps (Stortz, Germany) followed by washing and topical nasal steroids 
may be adequate to allow the patients disease to be controlled. 
It is essential not to denude the frontal recess of its mucosa since this may predispose to 
stenosis. If there is purulent disease within the frontal sinus causing symptoms, then it is 
advisable to open the recess, preserving as much mucosa as possible. This is ideally 
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performed by dissecting the mucosa off the agger nasi cells with a ball probe and pulling it 
down on the shell of the cell and removing the fragments of bone and carefully preserving 
the mucosa. Any loose fragments of mucosa are best left alone. Large fragments of 
redundant mucosa around the frontal recess can be trimmed using a shaver or through-
cutting forceps (Stortz, Germany). If there is a bony partition between the supra-orbital cell 
and frontal recess or a high frontal cell, the partition between them should be removed sub-
mucosally. 
3.3.5.7 Crusting 
Crust results from mucosal damage. If there is full thickness mucosal damage, the mucus 
produced stagnates because there is no functioning cilia to clear it and it may take up to a 
year for the cilia to start to function synchronously again. Therefore, mucosal damage 
should be minimized and a full thickness defect should be avoided at all cost. 
3.3.5.8 Infection 
Superficial infection of stagnant mucus is common and usually resolves with douching. 
Sometimes, staphylococci multiply in a sump of mucus that collects in the maxillary sinus 
and may be slow to clear with douching alone. Topical nasal mupirocin ointment sniffed 
liberally after douching 6 times a day for 3 weeks can be very helpful. 
3.3.5.9 Osteitis 
Local osteitis due to exposure of bone is a rare complication resulting in severe pain. It 
produces a very dull, severe crippling nagging ache that causes tears to the patient. This 
condition is very distressing to the patient and worrying for the surgeon. Major analgesics 
are required and local treatment appears to provide little relief. Patients undergoing surgery 
for inverted papilloma where mucosal preservation is not practiced are at risk.  
Tips for successful surgery 
Intraobital hemorrhage should be managed with lateral canthotomy and cantholysis 
followed by orbital decompression with removal of the medial orbital wall. Orbital 
decompression can be performed without canthotomy and cantholysis if the complication is 
notice intraoperatively 
3.4 Endoscopic orbital decompression for orbital sub-periosteal abscess 
Rhinosinusitis in children is not a surgical disease, and therefore the treatment is medical 
with systemic antibiotics such as clavulinic acid and ampicillin(Augmentin). The priority 
should be safety in any treatment as the problem usually resolves with time without 
intervention. Growth and maturation of the immunological response to pathogens play a 
major role in resolution of the disease (Jones, 1999; Howe & Jones, 2004).  
Patients presenting with orbital complications of sinusitis commonly have a degree of 
cellulitis and edema (chemosis) around the eye with associated proptosis (Fig 24). This may 
be associated with some restriction of eye movement. Patients typically present with history 
of nasal obstruction, purulent rhinorrhea and facial pressure or pain. Nasal endoscopy 
reveals an inflammed and oedematous nasal mucosa with usually presence of pus in the 
middle meatus.  
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3.3.5.4 Periorbital emphysema  
Peri-orbital emphysema or air in the soft tissues around the eye is due to intra-operative 
breach of the LP and the patient unknowingly blown their nose(Fig 23).The anesthetist 
should be advice to take care on extubating the patient and not to use too much force if 
patient needs to be ventilated with face mask. The emphysema will resolve in due time 
provided the patient does not blow any more air into the area. Prophylactic antibiotics are 
administered for active sinusitis or history of sinusitis. 
 
Fig. 23. Left periorbital  emphysema post powered endoscopic sinus surgery which resolved 
spontaneously 
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performed by dissecting the mucosa off the agger nasi cells with a ball probe and pulling it 
down on the shell of the cell and removing the fragments of bone and carefully preserving 
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Rhinosinusitis in children is not a surgical disease, and therefore the treatment is medical 
with systemic antibiotics such as clavulinic acid and ampicillin(Augmentin). The priority 
should be safety in any treatment as the problem usually resolves with time without 
intervention. Growth and maturation of the immunological response to pathogens play a 
major role in resolution of the disease (Jones, 1999; Howe & Jones, 2004).  
Patients presenting with orbital complications of sinusitis commonly have a degree of 
cellulitis and edema (chemosis) around the eye with associated proptosis (Fig 24). This may 
be associated with some restriction of eye movement. Patients typically present with history 
of nasal obstruction, purulent rhinorrhea and facial pressure or pain. Nasal endoscopy 
reveals an inflammed and oedematous nasal mucosa with usually presence of pus in the 
middle meatus.  
 




Fig. 24. Picture of a child with a left orbital cellulitis 
If a subperiostal abcess is suspected, a CT scan of the parananasal sinuses with contrast will 
present a mass located on the lamina papyracea or in relation to the frontal sinus. The rim of 
the mass will enhance with the contrast. Moreover, the proptosis will be visible on the axial 
scans. 
The external approach is quick and easy and the abscesss can usually be rapid and safely 
drained. If the surgeon  is a skilled and experienced endoscopic sinus surgeon, endoscopic 
drainage of the subperiosteal abscess can be performed. The problem with this procedure is 
the significant vascularity that is associated with acute sinusitis. If the mucosal surface is 
touched with an instrument or endoscope, it will usually bleed and an inexperienced 
surgeon may lose orientation and complications may occur as a result of poor visibility 
during the surgery. Frequent packing with decongested soaked neuropatties throughout the 
procedure helps to minimize the bleeding but will not control it entirely. In a patient with 
acute sinusitis, the anaesthetist needs to optimize the patient’s  hemodynamics parameters 
to create an optimal surgical field.  
The surgical approach is to perform an uncinectomy and enlarge the maxillary ostium to a 
moderate degree. Uncinectomy alone  without antrostomy carries the risk of postoperative 
closure of the maxillary sinus because the inflammation and edema predisposes to scarring 
and adhesion formation. Clearance of the frontal sinus depends on whether the frontal sinus 
is thought to be the origin of the subperiosteal abscess. If the abscess is located adjacent to 
the ethmoidal sinuses, clearance of the bulla ethmoidalis and posterior ethmoids is 
performed with identification of the lamina papyracea. The lamina papyracea over the 
subperiosteal abscess is widely exposed and removed. If the abscess is related to the floor of 
the frontal sinus, it can still be drained endoscopically. A minitrephine is usually placed in 
the frontal sinus before dissection of the frontal recess. This aids in identification of the 
frontal outflow tract. The frontal recess is cleared and the frontal ostium identified. The 
lamina papyracea directly behind the the lacrimal sac is removed and using a curette,  the 
orbital periostium is kept intact and gently pushed laterally while the curette advances into 
the subperiosteal abscess and the abscess drained (Wormald PJ, 2005). 
A malleable suction (Medtronic Xomed, Jacksonville, Florida, USA) is introduced into the 
cavity and any fibrin within the cavity is removed. A corrugated Pendrose drain is slid into 
the abscess cavity and left in place, draining the abscess cavity into the ethmoid sinuses for 1 
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to 2 days before being endoscopically removed. Endoscopic removal of the subperiosteal 
abscess remains highly effective but it must be emphasized that the surgeon should be very 
experienced. 
Although endoscopic drainage of subperiosteal and other orbital abcesses is becoming more 
common, the efficiency of narrow surgical drainage via an endoscopic approach has not 
been thoroughly been evaluated (Page and Wiatrak, 1996). Similarly, although endoscopic 
treatment of frontal sinus is less invasive than open frontal surgery, it also has a lower 
reported success rate (Metson and Gliklich, 1998). 
Indications for CT scan 
- Unable to accurately assess vision, gross proptosis, opthalmoplegia, deteriorating visual 
acuity or colour vision, bilateral edema, no improvement or deterioration at 24 hours or 
a swinging pyrexia that does not resolve within 36 hours 
Tips for successful surgery 
Endoscopic decompression of a subperiosteal abscess should only be performed by very 
experienced endoscopic sinus surgeons because the surgical field can be very bloody, which 
can significantly increase the degree of difficulty and the likelihood of complications. If the 
surgeon is not experienced, then the abscess should be drained via an external incision. 
3.5 Endoscopic optic canal decompression 
The most common indication for endoscopic optic canal decompression is traumatic optic 
nerve neuropathy(TON). Currently it is thought that 5% of severe head injuries will have 
concomitant injury to the optic nerve, optic tract or optic cortex (Tandon et al, 1994; 
Kountantakis et al, 2000; Kuppersmith et al, 1997). Since major brain injury takes precedence 
over traumatic optic neuropathy, it may result in the optic nerve injury being diagnosed 
somewhat later then the brain injury. Some authors feel that early diagnosis and treatment 
of traumatic optic neuropathy may be of greater benefit to the patient(Lubben et al, 2001, 
Sofferman, 1995) and advocate diagnosis of optic nerve deficit by the presence of an 
absolute or relative afferent pupillary defect supported by disc edema and congestion of the 
vessel walls. These findings in addition to CT scan and possibly MRI scan and visual evoked 
potentials are sufficient to undertake optic canal decompression. Currently there is no 
properly conducted randomized controlled trials comparing high-dose steroid therapy, 
surgical decompression and observation (Steinsapir et al, 2002).  
Traumatic optic neuropathy is believed to result from two distinct injuries to the nerve. The 
primary injury is the result of either a direct contusive force on the optic canal and nerve or 
elastic deformation of the sphenoid, with transfer of the force on the intra-canalicular optic 
nerve disrupting the axons and blood vessels (Steinsapir & Goldberg, 1994). This primary 
injury may result in compression of the nerve by bony fragments or in hemorrhage into the 
nerve sheath. A secondary injury may occur if the primary injury is not treated in due time. 
Compression of the blood vessels occur if there is bleeding into the dura resulting in 
ischaemia and continued axon loss (Sofferman, 1995; Steinsapir & Goldberg, 1994).  
We have adopted a conservative approach to traumatic neuropathy with all patients 
undergoing high-dose steroid treatment before being offered surgical intervention. The 
exception is when bony fragments are found to impinge on the optic nerve. 
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orbital periostium is kept intact and gently pushed laterally while the curette advances into 
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to 2 days before being endoscopically removed. Endoscopic removal of the subperiosteal 
abscess remains highly effective but it must be emphasized that the surgeon should be very 
experienced. 
Although endoscopic drainage of subperiosteal and other orbital abcesses is becoming more 
common, the efficiency of narrow surgical drainage via an endoscopic approach has not 
been thoroughly been evaluated (Page and Wiatrak, 1996). Similarly, although endoscopic 
treatment of frontal sinus is less invasive than open frontal surgery, it also has a lower 
reported success rate (Metson and Gliklich, 1998). 
Indications for CT scan 
- Unable to accurately assess vision, gross proptosis, opthalmoplegia, deteriorating visual 
acuity or colour vision, bilateral edema, no improvement or deterioration at 24 hours or 
a swinging pyrexia that does not resolve within 36 hours 
Tips for successful surgery 
Endoscopic decompression of a subperiosteal abscess should only be performed by very 
experienced endoscopic sinus surgeons because the surgical field can be very bloody, which 
can significantly increase the degree of difficulty and the likelihood of complications. If the 
surgeon is not experienced, then the abscess should be drained via an external incision. 
3.5 Endoscopic optic canal decompression 
The most common indication for endoscopic optic canal decompression is traumatic optic 
nerve neuropathy(TON). Currently it is thought that 5% of severe head injuries will have 
concomitant injury to the optic nerve, optic tract or optic cortex (Tandon et al, 1994; 
Kountantakis et al, 2000; Kuppersmith et al, 1997). Since major brain injury takes precedence 
over traumatic optic neuropathy, it may result in the optic nerve injury being diagnosed 
somewhat later then the brain injury. Some authors feel that early diagnosis and treatment 
of traumatic optic neuropathy may be of greater benefit to the patient(Lubben et al, 2001, 
Sofferman, 1995) and advocate diagnosis of optic nerve deficit by the presence of an 
absolute or relative afferent pupillary defect supported by disc edema and congestion of the 
vessel walls. These findings in addition to CT scan and possibly MRI scan and visual evoked 
potentials are sufficient to undertake optic canal decompression. Currently there is no 
properly conducted randomized controlled trials comparing high-dose steroid therapy, 
surgical decompression and observation (Steinsapir et al, 2002).  
Traumatic optic neuropathy is believed to result from two distinct injuries to the nerve. The 
primary injury is the result of either a direct contusive force on the optic canal and nerve or 
elastic deformation of the sphenoid, with transfer of the force on the intra-canalicular optic 
nerve disrupting the axons and blood vessels (Steinsapir & Goldberg, 1994). This primary 
injury may result in compression of the nerve by bony fragments or in hemorrhage into the 
nerve sheath. A secondary injury may occur if the primary injury is not treated in due time. 
Compression of the blood vessels occur if there is bleeding into the dura resulting in 
ischaemia and continued axon loss (Sofferman, 1995; Steinsapir & Goldberg, 1994).  
We have adopted a conservative approach to traumatic neuropathy with all patients 
undergoing high-dose steroid treatment before being offered surgical intervention. The 
exception is when bony fragments are found to impinge on the optic nerve. 
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A randomized clinical trial demonstrated no benefit of either high-dose corticosteroids nor 
optic nerve decompression. Both are still employed because the alternative may be 
irreversible blindness. However, at the initial presentation, the visual performance of visual 
fields is correlated to the final outcome.  
3.5.1 Medical therapy for traumatic optic neuropathy 
Presently megadose intravenous methylprednisolone is helpful. Methylprednisolone 
30mg/kg IV loading dose is given followed by 5.4 mg/kg/hr thereafter (Cook et al, 1996). 
The patient’s visual acuity is monitored hourly and surgical intervention is considered if the 
patient shows or fails any of the criteria below: 
 A dilated optic nerve on CT scan 
 Fracture of optic canal on CT scan with vision less than 6/60 
 Fracture of optic canal with vision more than 6/60 but the patient’s vision deteriorates 
on steroids 
 Vision is less than 6/60 after 48 hours of steroids with likely canal injury (indicated by 
the presence of fluid levels in the posterior ethmoids and sphenoids and/or the 
presence of fractures of the ethmoids, orbital apex and sphenoid). 
3.5.2 Surgical therapy for traumatic optic neuropathy 
Optic nerve decompression (OND) is an extension of orbital decompression when the optic 
nerve in the lateral wall of the sphenoid is decompressed.  
3.5.3 Indications 
Optic nerve injury is usually and should be recognized immediately by the existence of relative 
afferent papillary defect (RAPD) or inverse RAPD. It always appears in optic nerve injury even 
if visual acuity is relatively preserved initially. If it occurs in traumatic setting, the visual acuity 
will always deteriorate to no light perception. One should suspect this injury whether the ocular 
media are clear or opaque. It may be inappropriate for the patient to undergo surgery if they 
have a Glasgow coma scale of less than eight (Jones et al, 1997). Several studies suggest that 
with retro-orbital hemorrhage, decompression of the orbit needs to be done in less than one 
hour (Mason et al, 1998). However, where there is no hemorrhage, it is less understood under 
what circumstances it is beneficial to decompress the nerve pathway. If there is an anatomical 
constriction on CT scans affecting the course of the optic nerve and the patient is fit for 
anesthesia, then it seems reasonable to remove bone pressing on the nerve. 
3.5.4 Useful instruments 
- A long-shank drill with a course diamond burr and good irrigation system (Medtronic 
Xomed) to keep the bone cool. 
- Image guided surgery 
3.5.5 Surgical technique 
The standard preparation of the nose is performed with decongestants and infilteration. An 
uncinectomy with exposure of the maxillary ostium is performed (Fig 25). An axillary flap is 
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performed and the agger nasi cell removed for acess to skull base. The fovea ethmoidalis is 
exposed in the region above the bulla ethmoidalis. If there is disruption of the cells of the 
frontal recess, then this will be cleared. In some patients with severe sinus fracture, the 
entire skull base may be mobile. 
 
Fig. 25. A zero degree endoscopic view showing a left uncinectomy being performed 
In majority of patients, the posterior ethmoid cells will be full of blood and when combined 
with mobility of lamina papyracea, the skull base surgeon can become disorientated. Thus, 
this surgery should be undertaken only by highly experienced endoscopic sinus surgeons. A 
posterior ethmoidectomy and sphenoidotomy should be performed. In the posterior 
ethmoids, the posterior lamina papyracea and fovea ethmoidalis should be identified. If 
significant disruption of the posterior ethmoids and lamina papyracea has occurred, then a 
large middle meatus antrostomy provides an extra reference point and lessens the 
likelihood of the surgeon becoming disorientated. The natural ostium of the sphenoid sinus 
should be identified and anterior face of the sphenoid widely opened.  
The anterior face of the sphenoid needs to be taken as high as possible so that the roof of the 
sphenoid and the posterior ethmoids is continuous (Kuppersmith et al, 1997; Luxenberger et 
al, 1998; Chow and Stankiewicz, 1997). The sphenoid should be inspected and the optic 
nerve, carotid artery and pituitary fossa identified (Luxenberger et al, 1998; Chow and 
Stankiewicz, 1997). If there is significant disruption of the orbital apex or the lateral wall of 
the sphenoid, the identification of these basic structures can be difficult and image guidance 
may be helpful here. 
The thick bone overlying the junction of the orbital apex and sphenoid sinus is known as the 
optic tubercle. This bone is normally too thick to flake off and an irrigated 15 degree angled 
diamond burr(Medtronic Xomed, Jacksonville, Florida, USA) is used to thin this bone down 
until it is almost transparent (Luxenberger et al, 1998; Chow and Stankiewicz, 1997). A blunt 
Free’s elevator is pushed through the lamina papyracea 1.5 cm anterior to the junction of the 
posterior ethmoids air cell(s) and the sphenoid. While performing, care should be taken to 
keep the orbital periosteum intact, otherwise prolapsed of the orbital fat can severely 
obstruct the dissection of the optic nerve. The bone of the posterior orbital apex is flaxed off 
the underlying orbital periosteum  (Luxenberger et al, 1998; Chow and Stankiewicz, 1997). 
The bone over the optic canal is approached once the bone over the orbital apex is removed. 
This bone is usually quite thin and in majority of the cases can simply be flaked off the 
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performed and the agger nasi cell removed for acess to skull base. The fovea ethmoidalis is 
exposed in the region above the bulla ethmoidalis. If there is disruption of the cells of the 
frontal recess, then this will be cleared. In some patients with severe sinus fracture, the 
entire skull base may be mobile. 
 
Fig. 25. A zero degree endoscopic view showing a left uncinectomy being performed 
In majority of patients, the posterior ethmoid cells will be full of blood and when combined 
with mobility of lamina papyracea, the skull base surgeon can become disorientated. Thus, 
this surgery should be undertaken only by highly experienced endoscopic sinus surgeons. A 
posterior ethmoidectomy and sphenoidotomy should be performed. In the posterior 
ethmoids, the posterior lamina papyracea and fovea ethmoidalis should be identified. If 
significant disruption of the posterior ethmoids and lamina papyracea has occurred, then a 
large middle meatus antrostomy provides an extra reference point and lessens the 
likelihood of the surgeon becoming disorientated. The natural ostium of the sphenoid sinus 
should be identified and anterior face of the sphenoid widely opened.  
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obstruct the dissection of the optic nerve. The bone of the posterior orbital apex is flaxed off 
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This bone is usually quite thin and in majority of the cases can simply be flaked off the 
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underlying nerve (Fig 26). Sometimes, the bone over the nerve can be too thick and will 
need to be thinned with diamond burr prior to removal. When the bone is thin enough to be 
flaked off the underlying nerve, suitable instruments like the Beale’s elevator and the House 
curette, both from the ear tray should be used.  
 
Fig. 26. A 45 degree endoscopic view showing bone being cleared off the optic canal with 
underlying optic nerve sheath clearly visible in a patient with traumatic optic neuropathy 
When all the bone has been cleared off the optic canal and underlying optic nerve sheath is 
clearly visible, the sheath should be incised (Luxenberger et al, 1998; Chow and Stankiewicz, 
1997). The location of the ophthalmic artery should be noted for it usually runs in the 
posteriorinferior quadrant of the nerve. Occassionally, this artery can migrate around the 
lower edge of the nerve and potentially into the surgical field (Steinsapir et al, 2002). However, 
if the nerve is incised in the upper medial quadrant, the risk to this artery should be 
minimal(Luxenberger et al, 1998; Chow et al, 1995). A sharp sickle knife is used to incise the 
sheath of the optic nerve. Usually the swollen nerve is under pressure and the sheath splits as 
it is incised and nerve will protrude through the incision.. The incision is continued onto the 
orbital periosteum of the posterior orbital apex with resultant protrusion of orbital fat. The 
orbital fat covering this area of the medial rectus muscle is thin and care should be taken to 
avoid injuring this muscle (Fig 27). No packs are placed on the nerve or in the sinuses. 
 
Fig. 27. A diagrammatic axial section of the paranasal sinuses and the orbit showing the 
anatomical relationship of the medial rectus muscle to fat and periorbita 
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It is vital to monitor the vision post-operatively quarter-hourly for one hour and then hourly 
for 4 hours. The immediate or early results of decompression are frequently extremely 
gratifying. The patient should be instructed not to blow their nose or sniffle sneezes for 4 
days to avoid surgical emphysema.  
Tips for successful surgery 
Optic nerve decompression is a highly complex procedure  and should be undertaken by 
endoscopic sinus surgeon with significant experience and skill. Potential injury to the skull 
base with a resultant CSF leak may occur and in addition an associated injury to the internal 
carotid artery may be present. Injudicious manipulation of bony fragments may have 
catastrophic consequences for the patient. A trial of medical therapy should be advocated 
before surgery is contemplated unless there is an obvious bony fragment impinging on the 
optic nerve. Literature review suggests that patients should be operated upon if medical 
therapy fails to improve the vision within 24 to 48 hours. Significant delays would seem to 
lessen the potential for success of the surgery. Great care should be considered in exposing 
the optic nerve especially when flaking the bone from the nerve. Injudicious use of 
inappropriate instruments has the potential to worsen the vision. In the hands of an 
experienced endoscopic sinus surgeon, this procedure is relatively safe with low morbidity 
and has the potential to improve and in some cases restore lost vision, especially after blunt 
trauma. 
4. Endoscopic applications to the pterygopalatine and infratemporal fossa for 
resection of benign pathological lesions 
The most common benign tumor involving the pterygo-palatine  and infra-temporal fossa is 
the juvenile angiofibroma(Fig 28). These tumors originate in the region of spheno-palatine 
foramen and expand into pterygo-palatine fossa. Large tumors may extend into infra-
temporal fossa and usually have a large intranasal component that may extend into nearby 
sinuses especially the sphenoid sinus. Other benign tumors in this region are inverting 
papilloma extending from the nasal cavity  or rare tumors arising from the nerve sheath 
(schwannomas)(Fig 29), cartilage or muscle. Meningoceles extending into this area from the 
middle cranial fossa are rare. 
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Fig. 27. A diagrammatic axial section of the paranasal sinuses and the orbit showing the 
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Fig. 29. A coronal(a) and axial(b) MRI view of the paranasal sinuses showing a left maxillary 
nerve schwanomma 
4.1 Surgical technique for endoscopic modified medial maxillectomy  
The nasal cavity is prepared by placing cocaine and adrenaline-soaked neuropatties in the 
nasal cavity. The lateral nasal wall and septum are infiltrated with 2% lidocaine and 1:80,000 
adrenaline. Using 2 ml of lidocaine and adrenaline, a pterygo-palatine fossa block is placed 
via the greater palatine canal which greatly helps to reduce vascularity during dissection of 
medial wall of the maxilla and pterygo-palatine fossa.  
The initial step in endoscopic modified medial maxillectomy is to remove the uncinate 
process and perform a large middle meatal antrostomy. Moreover, the maxillary antrum is 
enlarged posteriorly up to posterior wall of maxillary sinus. This provides visualization of 
the medial orbital wall and aids in removal of residual medial maxilla without endangering 
the orbit. Majority of tumors of maxillary sinus and pterygo-palatine fossa will involve the 
posterior ethmoids and sphenoid. The bulla ethmoidalis is removed and a posterior 
ethmoidectomy and sphenoidotomy are performed. The inferior turbinate is medialized and 
its posterior two-thirds removed. A right angled phako-knife is used to make mucosal 
incisions from just below the orbit, through the anterior one third of the inferior turbinate 
onto the floor of the nasal cavity. The incision is continued along the floor of the nose to the 
posterior region of the inferior turbinate and on to the maxillary sinus. A sharp chisel is 
used to cut the bone under the mucosal incisions 
If the bone forming the medial maxillary wall is mobilized, the naso-lacrimal duct will tether 
the bone anteriorly and the duct will be visualized which can be transected with a scalpel (Fig 
30). Subsequently, a DCR spear knife (Metronic Xomed) is used to open the lower half of the 
sac, creating an anterior and posterior flaps and rolling these out (Wormald et al, 2003; 
Wormald & van Hasselt, 2003; Vrabac, 1994). This prevents stenosis of the sac postoperatively 
(Wormald et al, 2003; Wormald & van Hasselt, 2003). The edges of the resected maxilla are 
cleaned with micro-debrider (Metronic Xomed). Using a 70 degree endoscope the entire 
maxillary sinus can be visualized including the anterior wall and floor. The tumor can now be 
removed from the maxillary sinus under direct vision. A canine fossa puncture can be 
performed, if additional access is required which can be useful to access areas within the sinus 
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that may otherwise be difficult to access. Malleable suction dissector’s are useful because these 
instruments can be bent to the required angle for dissection in difficult areas like the anterior 
wall or antero-lateral region of the lateral wall of maxillary sinus. 
 
Fig. 30. A 30- degree endoscopic view showing  evidence of right modified medial 
maxillectomy performed for an inverted papilloma. 
4.2 Exposure of the pterygo-palatine fossa 
Exposure of the pterygo-palatine fossa via a wide medial maxillary antrostomy is necessary 
for tumors the occupy the ptergo-palatine fossa and extending into the infra-temporal fossa. 
The mucosa from the posterior wall of the maxillary sinus is elevated and preserved and the 
exposed bone removed to access the pterygo-palatine fossa. A 45 degree through-bitting 
Blakesley forceps is used to remove the bone anterior to the spheno-palatine artery and 
continued to the posterior wall  of the maxillary sinus exposing the contents of the pterygo-
palatine fossa. Traction is vital for tumors that extend into the infra-temporal fossa because 
it allows the surgeon to identify the areas of attachment of the tumor to the surrounding 
tissues and to dissect these free with suction dissector. Thus the entire tumor can be 
mobilized and its pedicle identified.  
Tumors that extend into the infra-temporal fossa will usually be closely associated with the 
maxillary nerve in the pterygo-palatine fossa. This nerve should be identified both distally 
and proximally early in the dissection and preserved. Suction dissection instruments are 
used to separate the nerve from the tumor. Fibrous tissue is easily divided  with endoscopic 
soft tissue scissors.  
Feeding blood vessels can either be caurterized with suction bipolar diathermy forceps or 
clipped and cut. Once the tumor is removed, the tumor bed can be closely inspected to 
ensure no tumor remnant remains. Once hemostasis  is achieved with suction bipolar 
forceps, the preserved mucosa from the posterior wall of the maxillary sinus is replaced. 
Surgicel can be placed in the cavity if required. Finally, ensure that the lacrimal sac is 
adequately exposed to prevent postoperative stenosis and epiphora. The incidence of 
postoperative epiphora has been described as high as 30% (Bolger et al, 1992).  
Endoscopic two-surgeon technique for tumors of the pterygo-palatine  
and infra-temporal fossa 
The key to successful endoscopic removal of large tumors in this region is  having two 
surgeons operating at the same time. This can be achieved by providing access to the tumor 
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bed for the second surgeon through the septum from the opposite nasal cavity. A hemi-
transfixation(Freer’s) incision is made on the opposite site of tumor. Using standard 
septoplasty techniques, the mucosa is elevated off the cartilage of the septum which is 
preserved but most of posterior bony septum is resected. A horizontal incision is made in 
the opposite septal mucosa to allow instruments placed through the opposite nostril and 
into the Freer’s incision to cross the septum and access the tumor on the contra-lateral side 
of the nose. 
During tumor removal, the second surgeon can provide significant traction on the tumor 
and when the feeding vessel from the maxillary artery is cut, large volume suction in the 
field can allow the suction bipolar cautery to be used to identify and cauterize the large 
bleeding vessel. 
4.3 Juvenile angiofibroma with pterygo-palatine and infra-temporal fossa extension 
Angiofibromas that significantly extend into pterygopa-latine fossa can be removed after 
endonasal endoscopic medial maxillectomy (Kennedy et al, 1990) and embolization within 
the preceding 24 hours. This reduces the vascularity of the tumor and allows dissection 
around the tumor without major hemorrhage. The second surgeon can keep the surgical 
field clear using a large suction in the area of dissection while the other surgeon holds the 
telescope and suction dissection instrument.  
4.4 Schwannoma involving the pterygo-palatine and infra-temporal fossa 
Endoscoopic medial maxillectomy also provides access to other tumors that may involve the 
pterygo-palatine and infra-temporal fossa. Schwannoma of the maxillary nerve involves the 
entire ptrygo-palatine fossa and extends significantly into the infra-temporal fossa. 
Endoscopic medial maxillectomy allows access to the entire posterior wall of the maxillary 
sinus and after its removal, to the tumor. 
4.5 Post-operative care 
Douching of the nose with saline is started immediately postoperatively. Local and systemic 
antibiotics and corticosteroids are usually helpful. Crusting will usually continue for a few 
weeks until the cavity epithelializers but has not proved to be problematic in the long run. 
Benign tumors do not usually need any adjuvant treatment but malignant tumors may 
require postoperative radiotherapy. 
5. Endoscopic resection of benign pathological lesions of paranasal sinuses 
5.1 Mucoceles 
Mucocele is a chronic, expansile, benign cystic lesion limited by the mucosa of the paranasal 
sinus, with thick, translucent mucous secretions (Fig 31). The most common are the 
frontoethmoidal mucoceles which presents with headaches and orbital symptoms. The 
expansile character of the mucocele promotes slow erosion of the adjacent bone via 
compression and consequent bone absorption. This disease is usually secondary to 
obstruction to sinus drainage, leading to stagnation of the secretion within the cavity. The 
predisposing factors can be fractures, mucosal edema, polyps, tumors, surgical trauma and 
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chronic sinusitis. Mucoceles are classified according to the sinus of origin. The frontal  sinus 
being the most common site, followed by the ethmoid, maxillary and sphenoid sinuses.  
 
Fig. 31. Coronal CT imaging of the right frontal sinus with evidence of a right mucocele 
showing expansile erosion of right orbital floor with lateral extension 
Fronto-ethmoidal sphenoidal and the rare maxillary sinus mucoceles are ideal cases for 
endoscopic approach provided wide marsupilization can be achieved (Hehar & Jones, 1997). 
Mucoceles accessible with the endoscope should be opened as widely as possible using 
through-cutting forceps in order to minimize the amount of scar tissue that forms around 
the edges and which might lead to recurrence. Coronal CT scan is helpful to show whether 
the lesion can be approached via the nasal cavity and whether it is unilocular or 
multilocular. In the frontal sinus, a small mucocele may be drained via the endoscopic 
approach (Fig 32) but mucoceles with lateral extension may be difficult to access via the 
nose. Therefore, an external and endoscopic approach can be usefully combined, preserving 
lateral support of the frontal recess and avoiding a stent.  
 
Fig. 32. Coronal CT imaging showing a right iatrogenic frontoethmoid mucocele and 
intraoperative endoscopic drainage and follow up a 3 months post surgery showing a patent 
frontal sinustomy in an adult presenting with frequent right headaches and heavy eyes 
Preoperative evaluation of patients with frontal mucoceles should include careful evaluation 
of the lesion relative to the skull base. Endoscopic decompression is probably the best initial 
therapy for these lesions. It is particularly true of mucoceles that have eroded the posterior 
table of the frontal sinus and become adherent to the dura.An uncinectomy is performed 
with an axillary flap as advocated by Wormald PJ(2005). Often in surgery of these lesions, 
the skull base is identified within the posterior ethmoids and then followed anteriorly until 
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the bone of the lesion is identified. The mucosal covered mass at the frontal recess area is 
opened with Blackesley’s straight forceps (Stortz, Germany). As the lesion is approached or 
entered, mucoid or mucopurulent  material is sucked out. The frontal sinustomy is enlarged 
upto about 2cm and the edges of exposed mucosa marsupilized. It is essential to remove all 
osteitic intersinus septa if recurrence of disease is to be avoided. If the bony margins are not 
flushed with the surrounding wall, narrowing of the opening, due to scarring and closure 
may occur (Kennedy et al, 1989). Once a frontal and/or ethmoid mucocele has been 
marsupilized, the expanded “shell” of bone that remains can be pushed manually to correct 
any bony swelling that may cause a cosmetic defect or displacement of the orbit 
intraoperatively. Sometimes a posteriorly placed mucocele may leave the orbit displaced 
even after marsupilization and then the orbit may need to be decompressed by removing its 
lateral wall (Conboy & Jones, 2003). 
The majority of mucocels can be marsupilized endoscopically with minimal morbidity and 
long-term results as compared to other techniques. The wider the mococele is marsupilized, 
the better the result. Majority of mucoceles can be marsupilized well with the endoscope 
except those lying in the lateral aspect of the frontal sinus, those that are secondary to 
malignancy(require an en-bloc and a craniofacial resection) and those secondary to pathology 
like Paget disease of fibrous dysplasia (Kennedy et al, 1989; Beasley & Jones, 1995). 
In the postoperative period, the mucosal lining the mucocele cavity may undergo significant 
hypertrophy and secretions may accumulate, necessitating suction from time to time. 
However, mucociliary clearance becomes reestablished, typically in a few weeks and the 
mucosal hypertrophy resolves over time (Kennedy et al, 1989). Hospitalization usually is 
less than 24 hours. As with other endoscopic sinus surgery, meticulous postoperative care is 
essential.  
Relative contraindications for endoscopic marsupilization 
- Abnormally thick bone ( Paget’s disease (Fig 33), fibrous dysplasia (Fig 34)). 
- Revision surgery where an external fronto-ethmoidectomy was performed and if the 
recurrence is located lateral to area accessible via a median drainage procedure 
- A laterally placed frontal mucocele 
- Malignancy associated with a mucocele 
 
Fig. 33. A coronal CT scan view of paranasal sinuses and skull showing evidence of Pagets 
disease 
 




Fig. 34. A coronal CT scan of the paranasal sinuses showing evidence of fibrous dysplasia 
involving the sphenoid sinus 
6. Endoscopic applications to the sellar, parasellar and clival for resection of 
benign pathological lesions 
6.1 Endoscopic pituitary micro-adenoma and macro-adenoma surgery  
6.1.1 The various approaches to the pituitary include 
 Trans-septal, trans-sphenoidal 
 Trans-nasal 
 Transcolumellar approach(Fig 35) 
 Via an external ethmoidectomy approach 
 Through the upper buccal sulcus of the mouth and then trans-septal, trans-sphenoidal 
 Via a craniotomy eg an anterolateral or a frontal approach 
 
 
Fig. 35. A picture of transcolumella approach as an access route to the pituitary  
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Pituitary tumors occur in 9 in 10,000 pupulation and comprise 10% of intracranial tumors. 
The commonest pituitary tumors in patients under 35 years secrete prolactin and 
adrenocorticotropin whereas after 35 to 50 years they generally secrete growth hormone. In 
the latter, non-secreting tumors are more common. Symptoms can be caused by pressure on 
the anterior pituitary and hypo-pituitarism or by extra-sellar growth that can produce 
headaches, pressure on the optic chiasma or brain (Fig 36). Surgery is usually the treatment 
of choice. Surgery is the first-line treatment in acromegaly, where up to 90% of micro-
adenomas are cured but the outcome is not as good as in large tumors. 
 
 
Fig. 36. A coronal MRI of the paranasal sinuses showing a suprasellar extension of a 
pituitary adenoma presenting with headaches and visual symptoms 
Surgery for pituitary disease must be based on an assessment of the patient by a 
multidisciplinary team (Gendeh, 2006). The medical management of many pituitary tumors 
has reduced the frequency of the need for surgery in many patients. Medical management is 
rarely indicated in tumors that extend into the supra-sellar region and extending above the 
diaphragma sellae.  
The endoscope gives excellent visibility within the sphenoid sinus and with a 45 degree 
endoscope it is possible to see more detail within the pituitary fossa than with the 
microscope. The advantages of the trans-nasal, trans-septal or lower buccal approach is that 
it avoids an external scar and by removing the posterior part of the septum, vomer and 
anterior wall of sphenoid, this approach allows wide access. In the endoscopic trans-nasal 
technique, mucosal preservation is an added advantage and allows the surgeon to work 
bimanually if necessary. The advantage of the two nostril technique is when there is 
moderate or severe  bleeding, it can be controlled more readily. An external ethmoidectomy 
approach produces a scar and has the potential to cause stenosis of the frontal recess. 
Pituitary surgery has been routinely been performed with endoscopic endonasal approach 
at our referral center since 1990. (Gendeh, 2010)   
 
Extended Applications of Endoscopic Sinus Surgery to the Orbit and Pituitary Fossa 
 
557 
6.1.3 Surgical anatomy 
The vomer consistently joins the sphenoid in the mid-line and this is a very reliable 
landmark. The sphenoid inter-sinus septum is often asymmetric(more than 75%) and its 
essential to review the CT scans pre-operatively. The degree of pneumatization of the 
sphenoid sinus also varies greatly (Lang, 1989). A chonchal sinus is small and confined to 
the anterior aspect of the sphenoid in 5% of cases. A pre-sellar sinus extends to the coronal 
plane level with the anterior wall of the sphenoid in 28% of cases. In 67% of cases it is sellar 
type(Fig 37). Agenesis of the sphenoid sinus occurs in 0.7% of patients. The carotid artery 
bulges into its lateral wall and it can be dehiscent in up to 30% of patients. Axillary imaging 
cuts complement coronal sections and sagittal reconstruction helps. The natural sphenoid 
sinus is relatively high in the posterior wall of the sphenoid and is often placed at the level 
of the superior turbinate which may be readily visible after gentle lateralization of the 
middle turbinate. The bony anterior wall of the sphenoid sinus is often thin or deficient 1 to 
1.5 cm above the posterior choana. The lateral wall of the sphenoid sinus has indentations 
from various structures (Fig 38): 
 The optic nerve can indent its surface in the upper third  
 The maxillary nerve can form an almost horizontal semicircular intrusion that may be 
mistaken for optic nerve in its medial third 
 The degree of pneumatization of the sinus varies and influences how prominent 
structures are in its lateral wall. Pneumatization can extend to the clivus, the lesser wing 
and the root of the pterygoid process ).  
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complete block of bone 
2. Presellar (28%)
• Posterior limit of air 
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Fig. 38. A diagrammatic coronal section of the sphenoid sinus showing the anatomical 
indentaions of vital structures in its roof, lateral wall and floor. 
6.1.4 Useful instruments 
 Hajek-Koffler punch (Stortz, Germany)  to remove thick bone. The rotating sleeve 
allows its jaws to be pointed in any direction and for the handle to be in a comfortable 
position for the operator 
 A Kerrison punch (Stortz, Germany) allows fine controlled removal of small segments 
of bone and the slight reversed angle of its jaws help to remove the back of the vomer 
 A long-shanked drill with a coarse diamond (Metronic Xomed) to remove any bone in 
the roof of the sphenoid bone in a controlled way 
 A computer guided systems  
6.1.5 Surgical technique 
The trans-nasal endoscopic approach commences by making a sphenoidotomy on the side 
of the tumor or when it is in the midline opening, the side where the sinus is larger. The 
sphenoidotomy is opened up to the level of the skull base using a sphenoid punch. Suction 
diathermy will be needed to stop the bleeding from the posterior branch of spheno-palatine 
artery when opening the sphenoidotomy inferiorly. Any vomerine spur should be removed. 
After careful CT examination and endoscopically inspecting the sphenoid sinus to check on 
the proximity of the lateral structures, the lateral aspect of the anterior wall can be removed 
if necessary. A Kerrison antrum punch (Stortz, Germany) is useful for performing this as its 
small diameter means that the bone can be removed in small pieces with good visibility. If 
more space is required across the midline, the vomer can be fractured across or it can be 
incised 1cm in front of the sphenoid and removed. The vomer can be very thick where it 
joins the sphenoid but it rarely needs drilling (Fig 39). The pituitary often bulges into the 
roof of the sphenoid and the bone may be very thin (Fig 40). If the bone is thick, a course 
diamond burr (Metronic Xomed) should be used to thin it. A diathermy point is useful to 
open the dura by making a cross-shaped incision through it. A 45 degree endoscope gives 
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excellent visibility and helps to avoid going through the diaphragm sellae. A Hajek punch 
(Stortz, Germany)  helps to remove the bone over the pituitary. The tumor is often grey in 
colour, but occasional it can be vascular and ooze moderately. The pituitary  fossa can be 
closed at the end of the procedure with raised naso-septal flap placed onto the bony defect. 
If there is a CSF leak, in addition an underlay duragen(collagen matrix graft) is placed 
before a naso-septal flap is placed as overlay flap and secured in position by Tisseel and gel-
foam over it. 
 
Fig. 39. Intraoperative endoscopic view showing a transseptal transsphenoidal approach to 
pituitary adenoma exposing the sphenoid rostrum 
 
 
Fig. 40. A 45 degree endoscopic view of exposed sphenoid sinus showing a intersinus 
septum and an enlarged sella 
It is possible to approach the pituitary via a limited sphenoidotomy, although it reduces 
access and visibility. It may be useful to trim the middle turbinate on one side for better 
access and visibility utilizing a four hand technique. 
7. Endoscopic repair of skull base CSF fistula 
CSF leak  results from a breach in the dura, which may be spontaneous, secondary to a 
fracture, related to a surgical trauma or associated with pathology of the skull base and/or 
secondary to a high-pressure system (Fig 41). 
 





Fig. 38. A diagrammatic coronal section of the sphenoid sinus showing the anatomical 
indentaions of vital structures in its roof, lateral wall and floor. 
6.1.4 Useful instruments 
 Hajek-Koffler punch (Stortz, Germany)  to remove thick bone. The rotating sleeve 
allows its jaws to be pointed in any direction and for the handle to be in a comfortable 
position for the operator 
 A Kerrison punch (Stortz, Germany) allows fine controlled removal of small segments 
of bone and the slight reversed angle of its jaws help to remove the back of the vomer 
 A long-shanked drill with a coarse diamond (Metronic Xomed) to remove any bone in 
the roof of the sphenoid bone in a controlled way 
 A computer guided systems  
6.1.5 Surgical technique 
The trans-nasal endoscopic approach commences by making a sphenoidotomy on the side 
of the tumor or when it is in the midline opening, the side where the sinus is larger. The 
sphenoidotomy is opened up to the level of the skull base using a sphenoid punch. Suction 
diathermy will be needed to stop the bleeding from the posterior branch of spheno-palatine 
artery when opening the sphenoidotomy inferiorly. Any vomerine spur should be removed. 
After careful CT examination and endoscopically inspecting the sphenoid sinus to check on 
the proximity of the lateral structures, the lateral aspect of the anterior wall can be removed 
if necessary. A Kerrison antrum punch (Stortz, Germany) is useful for performing this as its 
small diameter means that the bone can be removed in small pieces with good visibility. If 
more space is required across the midline, the vomer can be fractured across or it can be 
incised 1cm in front of the sphenoid and removed. The vomer can be very thick where it 
joins the sphenoid but it rarely needs drilling (Fig 39). The pituitary often bulges into the 
roof of the sphenoid and the bone may be very thin (Fig 40). If the bone is thick, a course 
diamond burr (Metronic Xomed) should be used to thin it. A diathermy point is useful to 
open the dura by making a cross-shaped incision through it. A 45 degree endoscope gives 
 
Extended Applications of Endoscopic Sinus Surgery to the Orbit and Pituitary Fossa 
 
559 
excellent visibility and helps to avoid going through the diaphragm sellae. A Hajek punch 
(Stortz, Germany)  helps to remove the bone over the pituitary. The tumor is often grey in 
colour, but occasional it can be vascular and ooze moderately. The pituitary  fossa can be 
closed at the end of the procedure with raised naso-septal flap placed onto the bony defect. 
If there is a CSF leak, in addition an underlay duragen(collagen matrix graft) is placed 
before a naso-septal flap is placed as overlay flap and secured in position by Tisseel and gel-
foam over it. 
 
Fig. 39. Intraoperative endoscopic view showing a transseptal transsphenoidal approach to 
pituitary adenoma exposing the sphenoid rostrum 
 
 
Fig. 40. A 45 degree endoscopic view of exposed sphenoid sinus showing a intersinus 
septum and an enlarged sella 
It is possible to approach the pituitary via a limited sphenoidotomy, although it reduces 
access and visibility. It may be useful to trim the middle turbinate on one side for better 
access and visibility utilizing a four hand technique. 
7. Endoscopic repair of skull base CSF fistula 
CSF leak  results from a breach in the dura, which may be spontaneous, secondary to a 
fracture, related to a surgical trauma or associated with pathology of the skull base and/or 
secondary to a high-pressure system (Fig 41). 
 




Fig. 41. Picture of an adult obese female presenting with unilateral clear watery spontaneous 
CSF rhinorrhoea on exertion 
7.1 Indications  
The main indications for repairing a CSF leak is its association with a 10% risk per year of 
developing meningitis (Gendeh et al, 1998). Those who have a leak from a fracture of the 
anterior skull base repaired still have a slightly increased risk of developing meningitis in 
the future but this is less than those whose leak stops spontaneously. Therefore, active leaks 
should probably be repaired at any stage.  
7.2 Surgical anatomy 
The skull base is made up anteriorly  of the posterior wall of the frontal sinus, which is a thick 
frontal bone that extends posteriorly to form roof of ethmoid sinuses(fovea ethmoidalis) on 
either side of the cribriform plate. The cribriform plate joins the fovea through the lateral 
lamella and can be almost non-existent when the cribriform plate and fovea ethmoidalis are on 
the same plane or it can form the thin vertical bone connecting them, depending on how far 
the cribriform plate dips into the nose (Fig 42). Posteriorly, the sphenoid sinus and posterior 
ethmoidal air cells form the inferior relationship of the skull base. 
 
Fig. 42. Keros classification of the anatomy of the cribriform plate which may lie at different 
level in relation to the anterior skull base 
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The commonest site of a spontaneous CSF leak is the area of the cribriform plate where dura 
around the olfactory nerves appears to have extended through the cribriform plate and 
ruptured (Fig 43). The next most commonest leak is from a very well-pneumatized sphenoid 
sinus (Fig 44). A high-pressure system may be a contributing factor in these cases and a 
shunt or venrticulostomy may be required. 
 
Fig. 43. Intraoperative endoscopic view showing arachnoid granulations arising from the 
left cribriform area in an obese female presenting with spontaneous cerebro-spina fluid 
rhinorrhea 
 
Fig. 44. A coronal CT scan showing a well pneumatized sphenoid sinus 
Iatrogenic CSF leaks are often found around the lamina lateralis (the vertical thin bone 
joining the cribriform plate to the fovea ethmoidalis) near the anterior ethmoidal artery. Post 
neurosurgical procedure leaks most commonly follow pituitary surgery, come from the 
posterior wall of frontal sinus when it has not been cranialized and more likely if a peri-
cranial flap has not been used to repair any dural defect. 
7.3 Diagnosis 
 It is vital to localize the site of a leak (Marshall et al, 2001) 
 Fluid collected should be tested for immune-fixation of beta-2-transferrin 
 Rule out any high- pressure system leak 
 Successful closure depends on localizing the exact site of the fistula 
It is essential  to confirm the diagnosis with immune-fixation of beta-2-transferrin which is 
extremely specific and sensitive test (Eljamel, 1993). Unilateral autonomic rhinitis is unusual  
but can mimic CSF rhinorrhea. 
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Site of any defect should be defined using high-resolution coronal CT (Lloyd et al, 1994). If 
CT fails to define the site of the defect, T2-weighted MRI may help which has superseded 
CT cisternography (Stafford et al, 1996). In a few post-trauma patients the site of leak is 
uncertain or it could be that there is more than one leak. In dural defects less than 15mm, the 
‘bath plug’ technique is encouraged which consists of introducing a fat plug with vicryl 
suture into the intra-dural space (Wormald & McDonough, 1997) It is believed that this 
technique would prevent high pressure from pushing the graft away from the defect 
(Gendeh et al, 2002). The fat pug can be harvested from the ear lobule. A 4 0 vicryl suture is 
knotted through one end of the fat plug and the suture is passed down the length of the fat 
plug. A free mucosal graft about 3 x 3 cm is harvested anterior to the middle turbinate from 
the contralateral lateral nasal wall. The fat plug is placed below the defect and the malleable 
frontal sinus probe (Metronic Xomed, Jacksonville, Florida, USA) is used gently to introduce 
the fat plug through the defect (Wormald and McDonough, 1997). Once the fat plug has 
been safely introduced through the defect, the plug is stabilized with the probe and the 
vicryl suture is gently pulled. The seal is tested by placing the patient head down and asking 
the anaesthetist to perform a forced-inspiration maneuver. No Fluorescein-stained CSF 
should be seen. The patient is placed head-up (15 degrees) and the free mucosal graft is slid 
up the vicryl suture until it covers the defect (Fig 45). Ensure that the graft is correctly 
orientated with the mucosal surface facing the nasal cavity. Fibrin glue is applied and the 
vicryl suture cut. Gelfoam is placed over the free mucosal graft and fibrin glue is reapplied. 
No other nasal packing is used. 
 
 
Fig. 45. A diagrammatic sagittal section of the nose showing the a free mucosal graft being 
slid up the vicry suture to cover the protruding fat plug and skull base defect. Adapted with 
permission from Wormald and McDonough. Americal J Rhinol 2003; 17:299-305 
A diagnostic or pre-operative sodium fluorescein lumbar puncture will help define the 
source of leak(Fig 46 a). It is vital to ensure that there is a free flow of CSF before proceeding 
to inject any sodium fluorescein. The patient was skin tested with 2% sodium flourescein 
eye drops one day before surgery. A lumbar drain was inserted on the day of surgery and 
intrathecal sodium fluorescein 10%(0.1% of sodium flourescein is diluted with 10ml of 
withdrawn CSF) was given in a slow bolus over 10 minutes to identify site of fistula 
(Gendeh et al, 2005). The ideal time for the sodium fluorescein to be injected is one hour 
beforehand. It is a great help to place the patient in a 10 degree head-down position. The 
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fluid will appear bright yellow, unless a blue filter is used when it appears fluorescent green 
(Fig 46 b). The systemic clearance of fluorescein is essentially complete by 48 to 72 hours 
from the patient’s body.  
 
   
(a)     (b) 
Fig. 46. A 30 degrees endoscopic view showing a spontaneous CSF leak from the anterior 
cribriform plate using intrathecal sodium fluorescein(a) and highlighted using blue blue 
filter(b) in the same patient 
The adverse reactions of intrathecal fluorescein administration are  nausea, vomiting, 
gastrointestinal distress, headache, syncome and hypotention. Cardiac arrest, basilar artery 
ischaemia, severe shock, convultions, thrombophlebitis at the injection site and rare cases of 
death have been reported. 
7.4 Surgical technique 
Initially the repair of CSF fistula involved the use of multi-layered barrier comprised of free 
tissue grafts  harvested from the nasal perichondrium or temporalis fascia. On top of the on 
lay graft, an abdominal fat graft was used as a bolster and a biological dressing. A fibrin 
sealant was applied to help fixate the fat graft. Sponge packing (Merocel tampons) were 
placed intra-nasally to support the fat graft and provide some compression. 
We adopted the use of collagen matrix graft (duragen, Intra Life Sciences, USA), which was 
easy to maneuver, is soft and pliable, thus decreasing the risk of injuring any critical 
structures as we tuck the graft to overlap the surrounding dural edges  of the defect. 
Duragen  is an absorbable and sutureless collagen onlay indicated as dura substitute for the 
repair of dura mater. We eliminated the routine use of lumbar drains and reserved them for 
high-risk situations or secondary repairs. 
The latest intervention to decrease CSF leaks employs vascularized mucosal flaps  which 
hastens the healing process, especially in patients with prior radiation therapy and make 
patients more suitable for early postoperative radiation therapy. Hadad and Bassagasteguy 
from Argentina developed the nasoseptal flap, supplied by the posterior nasoseptal arteries 
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The latest intervention to decrease CSF leaks employs vascularized mucosal flaps  which 
hastens the healing process, especially in patients with prior radiation therapy and make 
patients more suitable for early postoperative radiation therapy. Hadad and Bassagasteguy 
from Argentina developed the nasoseptal flap, supplied by the posterior nasoseptal arteries 
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which are branches of the posterior nasal artery. A mucoperichondrial/mucoperiosteal flap 
pedicle on the posterior nasal arteries provides a long flap that has a wide arc of rotation 
and a potential for area of coverage that is superior to any other flap previously 
described(Fig 47). The flap may be harvested to cover the entire anterior skull base from 
the frontal sinus to the sella or cover a clival defect from the sella to second cervical 
vertebra (C2). Use of this flap has to be anticipated in advance, since a posterior 
septectomy and a wide large slphenoidotomy removes the vascular pedicle. This flap is 
very reliable and is typically positioned over a fascial graft or fat graft and held in place 
with fibrin glue and a balloon catheter. We have not observed any significant donor site 
morbidity with the use of this flap and the septum becomes remucosalized within several 
months of surgery 
 
 
Fig. 47. Endoscopic view of a healed nasoseptal flap repair at 3 months post surgery for a 
pituitary macroadenoma with evidence of CSF fistula 
8. Recent advances in technology and its application to anterior and ventral 
skull base lesions 
There is an ongoing revolution in multiple surgical specialties with the introduction of 
minimally invasive techniques. A natural extension of ESS has been the application of 
endoscopic techniques for the surgical treatment of pathologic conditions of the cranial base. 
This has been driven by the ongoing development of endoscopic technology increasing 
consumer demand. Furthermore, as the limits of  ESS is tested, the possibilities for cranial 
base surgery are expanded. Truly, it is a maximally invasive endoscopic surgery than 
minimally invasive surgery. 
The Expanded Endo-nasal Approach(EEA) to the ventral skull base provides endoscopic 
access from the frontal sinus to C2 in the sagittal plane and from the midline to the jugular 
foramen, internal acoustic canal(IAC) and lateral mass of C2 in the coronal plane (Fig 48). 
Potential advantages of the EEA not only include improved cosmesis but more importantly, 
the potential for much less neurovascular manipulation in well selected cases. In pediatric 
patients, preservation of facial skeleton avoids disruption of growth centers and 
development of facial asymmetry with further growth. In contrast to an intracranial 
approach, an endo-nasal approach avoids the need for any brain retraction and may result 
in less damage to brain tissue. Improved visualization and better access to difficult sites may 
result in improved oncological outcomes. 
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Fig. 48. Expanded endonasal approaches to base of skull 
Advances in cranial base surgery over the last two decades have only been possible with the 
collaboration of multiple surgical specialities  (Kassam et al, 2007). This is more obvious 
with endoscopic skull base surgery. Rather than working sequentially as is often done with 
open approaches, surgeons from different speciality work together simultaneously as a 
team: one person maintaining a view with the endoscope and the other working bimanually 
to dissect the tissues. The benefits of the two team surgery include improved visualization, 
increased efficiency and the ability to deal with a crisis such as vascular injury. There is 
added value of having a ‘co-pilot’ for problem solving, avoiding complications and 
modulating enthusiasm. 
The primary advantage of the endoscope compared to other methods is improved 
visualization which accounts for an increased access to difficult to reach areas and may 
facilitate complete tumor resection and avoidance of complications due to poor 
visualization. Other potential benefits of endoscopic surgery include improved cosmesis 
and decreased morbidity from tissue trauma and manipulation of vessels and nerves. The 
consequences of decreased morbidity are a faster recovery, shortened hospitalization and 
decreased cost of medical care (Gendeh, 2009).  
Familiarity with endoscopic anatomy, proper instrumentation, an experienced surgical team 
and adherence to endoscopic surgical principles are essential ingrediants for avoiding 
severe complications. The basic principle of endoscopic cranial base surgery is internal 
debulking of tumor to allow extra-capsular dissection of tumor margin with early 
identification of neural and vascular structures. This principle is the same for open 
neurosurgical procedures and sharp dissection of tumor margins is performed without 
pulling on tumor. Adherence to these fundamental principles  minimizes the risk of neural 
or vascular injury. 
In the late 1970s and early 1980s, the combined effort between the Otolaryngologist and 
neurosurgeons worldwide, made significant strides in the surgical removal of tumors at the 
base of the skull and brain. These procedures were however disfiguring and painful for the 
patient. Furthermore, patients encountered long recovery periods and significant risk of 
complications because the procedures involved large incisions in the face and scalp and 
removal of parts of the skull to reach the abnormality at the cranial base. 
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In 1998, a group of Otolaryngologist and neurosurgeons at UPMC in Pittsburgh, USA 
initiated the first systemic approach to using the nose as a minimally invasive passageway 
to the brain. They began the extensive process of mapping anatomy and in collaboration 
with the medical device manufacturers, designed new instruments to make this idea a 
reality. 
By 2000, the Pittsburgh team of doctors had developed the necessary tools and techniques to 
access tumors located inside the skull by the way of the nose known as EEA. In EEA, the 
surgeons use endoscopes with light source as well as other instruments especially designed, 
to treat various types of brain and spinal abnormality. Hence, today surgeons can take out 
baseball-sized growths without pulling on the brain or touching the normal tissue. This 
continued refinement of EEA now allows access to an expanded region of the brain, skull 
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Snyderman CH.2007. Acquisation of surgical skills for endonasal skull base surgery: a training 
program. Laryngoscope  117(4): 699-705 
Table 3. Classification of endoscopic approaches to cranial base 
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The collaborative effort has put the Otolaryngologist and the neurosurgeon to work closely 
via the nose using the two-nostril and four hand technique was first advocated by Prof. Dr 
Heinz Stammberger from Graz, Austria for endoscopic cranial base surgery.  
Standardization of training and the adoption of modular, incremental training program are 
expected to facilitate the gradual training of endo-nasal surgeons in Otolaryngology and 
Neurosurgical disciplines. Stages of training are established for both surgical speciality 
based on level of technical difficulty, potential risk of vascular and neural injury and 
unfamiliar endoscopic anatomy. Mastery of each level is recommended before attempting 
procedures at higher level. Adherence to such a program during the growth phase  of 
endoscopic skull base surgery may decrease the risk of complications as the surgeon’s  
knowledge and surgical expertise develop (Snyderman et al, 2007). 
Complications of EEA are the same as open approaches: neural and vascular injury, 
infection and CSF leak. Literature report of  neural and vascular injury are fortunately rare 
accounting for 1% incidence. These can be avoided with attention to anatomical landmarks 
and proper dissection techniques. An experienced team can effectively control venous 
bleeding from the cavernous sinus or basilar plexus. Peri-operative antibiotic prophylaxis, 
multilayered repair of dural defects and aggressive management of postoperative CSF leaks 
are contributing factors. One of the biggest remaining challenges is repair of large dural 
defects and prevention of post-operative leaks. With the advent of the septal mucosal flap, 
the Pittsburgh group suggest an incidence of 6% of CSF leak. Developments that have 
decreased the incidence of postoperative CSF leaks include a multilayered closure, direct 
suturing of grafts to dural edges, use of biological glues, coverage with vascularized septal 
mucosal flap and supporting the reconstruction with an intranasal balloon catheter. 
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